--
-- PostgreSQL database dump
--

-- Dumped from database version 14.9
-- Dumped by pg_dump version 14.9

SET statement_timeout = 0;
SET lock_timeout = 0;
SET idle_in_transaction_session_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SELECT pg_catalog.set_config('search_path', '', false);
SET check_function_bodies = false;
SET xmloption = content;
SET client_min_messages = warning;
SET row_security = off;

--
-- Name: PublicationStatus; Type: TYPE; Schema: public; Owner: tim
--

CREATE TYPE public."PublicationStatus" AS ENUM (
    'UNKNOWN',
    'PUBLISHED',
    'CT_RESULTS',
    'NO_PUBLICATION_FOUND'
);


ALTER TYPE public."PublicationStatus" OWNER TO tim;

SET default_tablespace = '';

SET default_table_access_method = heap;

--
-- Name: ConditionMeshTermOnEntries; Type: TABLE; Schema: public; Owner: tim
--

CREATE TABLE public."ConditionMeshTermOnEntries" (
    id integer NOT NULL,
    "createdAt" timestamp(3) without time zone DEFAULT CURRENT_TIMESTAMP NOT NULL,
    "updatedAt" timestamp(3) without time zone NOT NULL,
    "meshId" integer NOT NULL,
    "entryId" integer NOT NULL
);


ALTER TABLE public."ConditionMeshTermOnEntries" OWNER TO tim;

--
-- Name: ConditionMeshTermOnEntries_id_seq; Type: SEQUENCE; Schema: public; Owner: tim
--

CREATE SEQUENCE public."ConditionMeshTermOnEntries_id_seq"
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public."ConditionMeshTermOnEntries_id_seq" OWNER TO tim;

--
-- Name: ConditionMeshTermOnEntries_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: tim
--

ALTER SEQUENCE public."ConditionMeshTermOnEntries_id_seq" OWNED BY public."ConditionMeshTermOnEntries".id;


--
-- Name: Entry; Type: TABLE; Schema: public; Owner: tim
--

CREATE TABLE public."Entry" (
    id integer NOT NULL,
    "createdAt" timestamp(3) without time zone DEFAULT CURRENT_TIMESTAMP NOT NULL,
    "updatedAt" timestamp(3) without time zone NOT NULL,
    "NCTId" text NOT NULL,
    "OfficialTitle" text,
    "BriefTitle" text NOT NULL,
    "OverallStatus" text NOT NULL,
    "BriefSummary" text NOT NULL,
    "DesignInterventionModel" text,
    "LeadSponsorName" text,
    "LeadSponsorClass" text,
    "Gender" text,
    "MaximumAge" double precision,
    "MinimumAge" double precision,
    "EnrollmentCount" integer,
    "EnrollmentType" text,
    "OrgClass" text NOT NULL,
    "OrgFullName" text NOT NULL,
    "DesignAllocation" text,
    "DesignInterventionModelDescription" text,
    "DesignMasking" text,
    "DesignMaskingDescription" text,
    "DesignObservationalModel" text,
    "DesignPrimaryPurpose" text,
    "DesignTimePerspective" text,
    "DetailedDescription" text,
    "StartDate" text,
    "PrimaryCompletionDate" text,
    "CompletionDate" text,
    "StudyFirstPostDate" text,
    "ResultsFirstPostDate" text,
    "LastUpdatePostDate" text,
    "PointOfContactOrganization" text,
    "ResponsiblePartyInvestigatorAffiliation" text,
    "ResponsiblePartyInvestigatorFullName" text,
    "ResponsiblePartyInvestigatorTitle" text,
    "ResponsiblePartyOldNameTitle" text,
    "ResponsiblePartyOldOrganization" text,
    "ResponsiblePartyType" text,
    "WhyStopped" text,
    "StudyType" text NOT NULL,
    "AgeCategories" text[],
    "Phases" text[],
    conditions text[],
    drug_role text,
    legacy_search_term text,
    notes text,
    repurpose boolean DEFAULT false,
    usecase text,
    legacy_import_date timestamp(3) without time zone,
    "ReferenceCitation" text[],
    "publicationStatus" public."PublicationStatus" DEFAULT 'UNKNOWN'::public."PublicationStatus" NOT NULL,
    "publicationUrl" text,
    drug_name text
);


ALTER TABLE public."Entry" OWNER TO tim;

--
-- Name: EntryView; Type: VIEW; Schema: public; Owner: tim
--

CREATE VIEW public."EntryView" AS
 SELECT e.id,
    e."NCTId",
    e."BriefTitle",
    e."OverallStatus",
    e."BriefSummary",
    e.conditions,
    e."LeadSponsorName",
    e."Gender",
    e."AgeCategories",
    e."Phases",
    e."EnrollmentCount",
    e."EnrollmentType",
    e."StudyType",
    e."StartDate",
    e."PrimaryCompletionDate",
    e."CompletionDate",
    e."StudyFirstPostDate",
    e."LastUpdatePostDate",
    e.legacy_import_date,
    e.legacy_search_term,
    e.usecase,
    e.repurpose,
    e.drug_role,
    e."MinimumAge",
    e."MaximumAge",
    e."DesignAllocation",
    e."DesignInterventionModel",
    e."DesignMasking",
    e."publicationStatus",
    e."publicationUrl"
   FROM public."Entry" e
  ORDER BY e.id;


ALTER TABLE public."EntryView" OWNER TO tim;

--
-- Name: Entry_id_seq; Type: SEQUENCE; Schema: public; Owner: tim
--

CREATE SEQUENCE public."Entry_id_seq"
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public."Entry_id_seq" OWNER TO tim;

--
-- Name: Entry_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: tim
--

ALTER SEQUENCE public."Entry_id_seq" OWNED BY public."Entry".id;


--
-- Name: InterventionMeshTermOnEntries; Type: TABLE; Schema: public; Owner: tim
--

CREATE TABLE public."InterventionMeshTermOnEntries" (
    id integer NOT NULL,
    "createdAt" timestamp(3) without time zone DEFAULT CURRENT_TIMESTAMP NOT NULL,
    "updatedAt" timestamp(3) without time zone NOT NULL,
    "meshId" integer NOT NULL,
    "entryId" integer NOT NULL,
    description text
);


ALTER TABLE public."InterventionMeshTermOnEntries" OWNER TO tim;

--
-- Name: InterventionMeshTermOnEntries_id_seq; Type: SEQUENCE; Schema: public; Owner: tim
--

CREATE SEQUENCE public."InterventionMeshTermOnEntries_id_seq"
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public."InterventionMeshTermOnEntries_id_seq" OWNER TO tim;

--
-- Name: InterventionMeshTermOnEntries_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: tim
--

ALTER SEQUENCE public."InterventionMeshTermOnEntries_id_seq" OWNED BY public."InterventionMeshTermOnEntries".id;


--
-- Name: Location; Type: TABLE; Schema: public; Owner: tim
--

CREATE TABLE public."Location" (
    id integer NOT NULL,
    "createdAt" timestamp(3) without time zone DEFAULT CURRENT_TIMESTAMP NOT NULL,
    "updatedAt" timestamp(3) without time zone NOT NULL,
    city text NOT NULL,
    country text NOT NULL,
    facility text
);


ALTER TABLE public."Location" OWNER TO tim;

--
-- Name: LocationOnEntries; Type: TABLE; Schema: public; Owner: tim
--

CREATE TABLE public."LocationOnEntries" (
    id integer NOT NULL,
    "createdAt" timestamp(3) without time zone DEFAULT CURRENT_TIMESTAMP NOT NULL,
    "updatedAt" timestamp(3) without time zone NOT NULL,
    "locationId" integer NOT NULL,
    "entryId" integer NOT NULL
);


ALTER TABLE public."LocationOnEntries" OWNER TO tim;

--
-- Name: LocationOnEntries_id_seq; Type: SEQUENCE; Schema: public; Owner: tim
--

CREATE SEQUENCE public."LocationOnEntries_id_seq"
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public."LocationOnEntries_id_seq" OWNER TO tim;

--
-- Name: LocationOnEntries_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: tim
--

ALTER SEQUENCE public."LocationOnEntries_id_seq" OWNED BY public."LocationOnEntries".id;


--
-- Name: Location_id_seq; Type: SEQUENCE; Schema: public; Owner: tim
--

CREATE SEQUENCE public."Location_id_seq"
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public."Location_id_seq" OWNER TO tim;

--
-- Name: Location_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: tim
--

ALTER SEQUENCE public."Location_id_seq" OWNED BY public."Location".id;


--
-- Name: MeshTerm; Type: TABLE; Schema: public; Owner: tim
--

CREATE TABLE public."MeshTerm" (
    id integer NOT NULL,
    "createdAt" timestamp(3) without time zone DEFAULT CURRENT_TIMESTAMP NOT NULL,
    "updatedAt" timestamp(3) without time zone NOT NULL,
    term text NOT NULL
);


ALTER TABLE public."MeshTerm" OWNER TO tim;

--
-- Name: MeshTerm_id_seq; Type: SEQUENCE; Schema: public; Owner: tim
--

CREATE SEQUENCE public."MeshTerm_id_seq"
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public."MeshTerm_id_seq" OWNER TO tim;

--
-- Name: MeshTerm_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: tim
--

ALTER SEQUENCE public."MeshTerm_id_seq" OWNED BY public."MeshTerm".id;


--
-- Name: _prisma_migrations; Type: TABLE; Schema: public; Owner: tim
--

CREATE TABLE public._prisma_migrations (
    id character varying(36) NOT NULL,
    checksum character varying(64) NOT NULL,
    finished_at timestamp with time zone,
    migration_name character varying(255) NOT NULL,
    logs text,
    rolled_back_at timestamp with time zone,
    started_at timestamp with time zone DEFAULT now() NOT NULL,
    applied_steps_count integer DEFAULT 0 NOT NULL
);


ALTER TABLE public._prisma_migrations OWNER TO tim;

--
-- Name: ConditionMeshTermOnEntries id; Type: DEFAULT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."ConditionMeshTermOnEntries" ALTER COLUMN id SET DEFAULT nextval('public."ConditionMeshTermOnEntries_id_seq"'::regclass);


--
-- Name: Entry id; Type: DEFAULT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."Entry" ALTER COLUMN id SET DEFAULT nextval('public."Entry_id_seq"'::regclass);


--
-- Name: InterventionMeshTermOnEntries id; Type: DEFAULT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."InterventionMeshTermOnEntries" ALTER COLUMN id SET DEFAULT nextval('public."InterventionMeshTermOnEntries_id_seq"'::regclass);


--
-- Name: Location id; Type: DEFAULT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."Location" ALTER COLUMN id SET DEFAULT nextval('public."Location_id_seq"'::regclass);


--
-- Name: LocationOnEntries id; Type: DEFAULT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."LocationOnEntries" ALTER COLUMN id SET DEFAULT nextval('public."LocationOnEntries_id_seq"'::regclass);


--
-- Name: MeshTerm id; Type: DEFAULT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."MeshTerm" ALTER COLUMN id SET DEFAULT nextval('public."MeshTerm_id_seq"'::regclass);


--
-- Data for Name: ConditionMeshTermOnEntries; Type: TABLE DATA; Schema: public; Owner: tim
--

COPY public."ConditionMeshTermOnEntries" (id, "createdAt", "updatedAt", "meshId", "entryId") FROM stdin;
1	2023-01-02 15:22:35.751	2023-01-02 15:22:35.751	0	1
2	2023-01-02 15:22:35.751	2023-01-02 15:22:35.751	1	1
3	2023-01-02 15:22:35.753	2023-01-02 15:22:35.753	14	2
4	2023-01-02 15:22:35.753	2023-01-02 15:22:35.753	15	2
5	2023-01-02 15:22:35.757	2023-01-02 15:22:35.757	1	3
6	2023-01-02 15:22:35.757	2023-01-02 15:22:35.757	0	3
7	2023-01-02 15:22:35.761	2023-01-02 15:22:35.761	1	5
8	2023-01-02 15:22:35.761	2023-01-02 15:22:35.761	0	5
9	2023-01-02 15:22:35.766	2023-01-02 15:22:35.766	15	6
10	2023-01-02 15:22:35.766	2023-01-02 15:22:35.766	14	6
11	2023-01-02 15:22:35.769	2023-01-02 15:22:35.769	0	7
12	2023-01-02 15:22:35.769	2023-01-02 15:22:35.769	1	7
13	2023-01-02 15:22:35.77	2023-01-02 15:22:35.77	1	10
14	2023-01-02 15:22:35.768	2023-01-02 15:22:35.768	10	8
15	2023-01-02 15:22:35.77	2023-01-02 15:22:35.77	0	10
16	2023-01-02 15:22:35.769	2023-01-02 15:22:35.769	7	7
17	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	14	11
18	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	15	11
19	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	1	15
20	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	0	15
21	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	17	15
22	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	15	15
23	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	1	13
24	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	0	13
25	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	1	17
26	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	0	17
27	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	15	18
28	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	6	13
29	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	6	17
30	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	14	18
31	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	14	15
32	2023-01-02 15:22:35.777	2023-01-02 15:22:35.777	18	22
33	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	18	23
34	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	19	24
35	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	20	26
36	2023-01-02 15:22:35.781	2023-01-02 15:22:35.781	1	25
37	2023-01-02 15:22:35.782	2023-01-02 15:22:35.782	7	27
38	2023-01-02 15:22:35.782	2023-01-02 15:22:35.782	0	27
39	2023-01-02 15:22:35.782	2023-01-02 15:22:35.782	18	28
40	2023-01-02 15:22:35.782	2023-01-02 15:22:35.782	1	27
41	2023-01-02 15:22:35.783	2023-01-02 15:22:35.783	14	32
42	2023-01-02 15:22:35.783	2023-01-02 15:22:35.783	15	32
43	2023-01-02 15:22:35.781	2023-01-02 15:22:35.781	0	25
44	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	0	33
45	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	0	31
46	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	1	33
47	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	6	33
48	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	14	31
49	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	0	35
50	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	1	35
51	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	6	35
52	2023-01-02 15:22:35.785	2023-01-02 15:22:35.785	15	37
53	2023-01-02 15:22:35.785	2023-01-02 15:22:35.785	14	36
54	2023-01-02 15:22:35.785	2023-01-02 15:22:35.785	14	37
55	2023-01-02 15:22:35.785	2023-01-02 15:22:35.785	0	39
56	2023-01-02 15:22:35.785	2023-01-02 15:22:35.785	1	39
57	2023-01-02 15:22:35.785	2023-01-02 15:22:35.785	15	36
58	2023-01-02 15:22:35.785	2023-01-02 15:22:35.785	7	39
59	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	0	41
60	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	26	38
61	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	18	40
62	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	18	42
63	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	27	68
64	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	10	68
65	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	1	55
66	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	0	55
67	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	7	55
68	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	15	65
69	2023-01-02 15:22:35.789	2023-01-02 15:22:35.789	0	63
70	2023-01-02 15:22:35.789	2023-01-02 15:22:35.789	1	63
71	2023-01-02 15:22:35.789	2023-01-02 15:22:35.789	7	63
72	2023-01-02 15:22:35.79	2023-01-02 15:22:35.79	28	81
73	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	14	65
74	2023-01-02 15:22:35.79	2023-01-02 15:22:35.79	1	69
75	2023-01-02 15:22:35.79	2023-01-02 15:22:35.79	0	69
76	2023-01-02 15:22:35.79	2023-01-02 15:22:35.79	0	70
77	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	1	70
78	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	30	70
79	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	1	75
80	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	7	75
81	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	6	75
82	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	0	75
83	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	14	75
84	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	1	67
85	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	30	67
86	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	0	67
87	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	7	67
88	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	1	71
89	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	0	71
90	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	7	71
91	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	0	76
92	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	0	72
93	2023-01-02 15:22:35.792	2023-01-02 15:22:35.792	18	86
94	2023-01-02 15:22:35.792	2023-01-02 15:22:35.792	6	72
95	2023-01-02 15:22:35.792	2023-01-02 15:22:35.792	1	72
96	2023-01-02 15:22:35.792	2023-01-02 15:22:35.792	32	77
97	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	32	79
98	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	0	73
99	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	33	78
100	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	1	73
101	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	0	84
102	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	1	84
103	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	36	80
104	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	37	80
105	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	1	85
106	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	0	85
107	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	1	83
108	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	0	83
109	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	14	83
110	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	15	83
111	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	0	90
112	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	1	90
113	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	15	90
114	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	14	90
115	2023-01-02 15:22:35.803	2023-01-02 15:22:35.803	10	87
116	2023-01-02 15:22:35.803	2023-01-02 15:22:35.803	27	87
117	2023-01-02 15:22:35.803	2023-01-02 15:22:35.803	17	87
118	2023-01-02 15:22:35.803	2023-01-02 15:22:35.803	11	87
119	2023-01-02 15:22:35.805	2023-01-02 15:22:35.805	39	91
120	2023-01-02 15:22:35.805	2023-01-02 15:22:35.805	38	91
121	2023-01-02 15:22:35.805	2023-01-02 15:22:35.805	1	93
122	2023-01-02 15:22:35.805	2023-01-02 15:22:35.805	42	93
123	2023-01-02 15:22:35.806	2023-01-02 15:22:35.806	0	95
124	2023-01-02 15:22:35.805	2023-01-02 15:22:35.805	0	93
125	2023-01-02 15:22:35.806	2023-01-02 15:22:35.806	1	95
126	2023-01-02 15:22:35.807	2023-01-02 15:22:35.807	0	94
127	2023-01-02 15:22:35.807	2023-01-02 15:22:35.807	1	94
128	2023-01-02 15:22:35.807	2023-01-02 15:22:35.807	7	94
129	2023-01-02 15:22:35.809	2023-01-02 15:22:35.809	30	104
130	2023-01-02 15:22:35.808	2023-01-02 15:22:35.808	18	97
131	2023-01-02 15:22:35.809	2023-01-02 15:22:35.809	10	104
132	2023-01-02 15:22:35.809	2023-01-02 15:22:35.809	1	105
133	2023-01-02 15:22:35.809	2023-01-02 15:22:35.809	7	105
134	2023-01-02 15:22:35.809	2023-01-02 15:22:35.809	6	105
135	2023-01-02 15:22:35.809	2023-01-02 15:22:35.809	14	105
136	2023-01-02 15:22:35.809	2023-01-02 15:22:35.809	0	105
139	2023-01-02 15:22:35.81	2023-01-02 15:22:35.81	38	102
138	2023-01-02 15:22:35.809	2023-01-02 15:22:35.809	27	104
168	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	0	120
188	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	0	130
193	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	30	136
204	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	0	143
211	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	14	174
218	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	0	152
231	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	1	160
232	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	1	156
244	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	15	161
245	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	1	164
254	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	2	172
269	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	1	176
272	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	0	178
283	2023-01-02 15:22:35.858	2023-01-02 15:22:35.858	75	181
298	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	0	195
321	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	10	209
331	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	0	213
336	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	101	215
339	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	1	217
344	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	0	218
348	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	1	222
351	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	7	223
357	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	104	224
366	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	76	229
368	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	75	229
379	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	0	235
390	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	1	252
413	2023-01-02 15:22:35.898	2023-01-02 15:22:35.898	7	253
423	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	1	264
434	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	7	267
457	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	1	278
468	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	124	285
476	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	7	284
480	2023-01-02 15:22:35.914	2023-01-02 15:22:35.914	136	287
495	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	1	297
497	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	149	294
529	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	0	311
539	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	6	320
582	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	218	346
592	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	0	349
599	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	30	374
601	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	245	356
602	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	1	355
626	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	6	378
629	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	14	373
639	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	278	380
662	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	287	386
683	2023-01-02 15:22:35.973	2023-01-02 15:22:35.973	315	395
701	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	329	403
705	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	317	404
715	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	1	408
735	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	342	423
736	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	343	422
743	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	348	424
748	2023-01-02 15:22:35.998	2023-01-02 15:22:35.998	1	48
762	2023-01-02 15:22:36.002	2023-01-02 15:22:36.002	7	54
778	2023-01-02 15:22:36.008	2023-01-02 15:22:36.008	0	60
779	2023-01-02 15:22:36.008	2023-01-02 15:22:36.008	6	60
140	2023-01-02 15:22:35.81	2023-01-02 15:22:35.81	39	102
148	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	0	109
158	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	15	116
166	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	1	120
178	2023-01-02 15:22:35.82	2023-01-02 15:22:35.82	20	125
187	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	1	130
199	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	1	142
247	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	14	162
255	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	6	172
263	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	82	182
310	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	6	204
322	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	61	209
337	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	7	216
371	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	76	233
387	2023-01-02 15:22:35.887	2023-01-02 15:22:35.887	43	243
422	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	0	264
442	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	0	271
455	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	0	312
475	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	0	284
485	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	1	288
513	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	7	307
518	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	1	308
535	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	76	338
544	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	176	319
574	2023-01-02 15:22:35.941	2023-01-02 15:22:35.941	1	336
616	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	15	363
618	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	43	369
632	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	267	376
655	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	287	389
674	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	234	401
678	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	301	398
687	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	320	394
689	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	317	418
696	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	319	403
708	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	0	405
759	2023-01-02 15:22:36.002	2023-01-02 15:22:36.002	1	54
771	2023-01-02 15:22:36.005	2023-01-02 15:22:36.005	6	47
785	2023-01-02 15:22:36.009	2023-01-02 15:22:36.009	0	50
141	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	43	101
153	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	7	109
159	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	0	117
220	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	71	157
226	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	7	155
237	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	73	158
257	2023-01-02 15:22:35.852	2023-01-02 15:22:35.852	0	171
277	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	7	197
328	2023-01-02 15:22:35.878	2023-01-02 15:22:35.878	0	219
367	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	76	230
375	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	7	234
403	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	0	249
433	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	0	267
459	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	7	278
474	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	130	283
505	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	157	299
516	2023-01-02 15:22:35.925	2023-01-02 15:22:35.925	14	316
546	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	0	323
552	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	15	332
558	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	1	330
566	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	11	342
575	2023-01-02 15:22:35.942	2023-01-02 15:22:35.942	10	337
613	2023-01-02 15:22:35.954	2023-01-02 15:22:35.954	253	367
627	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	1	378
633	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	58	376
648	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	10	393
668	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	26	391
669	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	0	388
711	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	0	411
721	2023-01-02 15:22:35.982	2023-01-02 15:22:35.982	1	414
728	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	0	417
769	2023-01-02 15:22:36.004	2023-01-02 15:22:36.004	1	49
142	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	14	96
155	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	32	115
164	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	7	140
219	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	70	157
236	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	7	160
266	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	7	177
278	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	75	180
290	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	6	191
300	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	86	200
332	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	75	220
401	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	27	251
414	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	15	292
424	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	0	261
431	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	1	266
436	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	116	268
439	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	7	271
449	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	7	272
464	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	120	282
498	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	149	298
506	2023-01-02 15:22:35.92	2023-01-02 15:22:35.92	15	302
517	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	0	308
527	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	86	322
560	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	7	330
591	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	1	348
608	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	248	370
628	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	0	378
644	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	32	380
658	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	10	387
722	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	7	412
729	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	0	421
754	2023-01-02 15:22:36	2023-01-02 15:22:36	7	56
787	2023-01-02 15:22:36.01	2023-01-02 15:22:36.01	0	59
793	2023-01-02 15:22:36.013	2023-01-02 15:22:36.013	0	34
145	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	1	100
154	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	6	111
169	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	0	124
185	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	7	131
234	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	1	153
261	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	80	173
285	2023-01-02 15:22:35.859	2023-01-02 15:22:35.859	1	183
313	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	71	205
330	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	76	220
341	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	6	217
370	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	75	233
381	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	15	240
385	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	0	239
393	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	80	244
410	2023-01-02 15:22:35.898	2023-01-02 15:22:35.898	0	258
425	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	1	261
470	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	125	285
487	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	14	290
493	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	7	297
540	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	1	320
549	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	26	324
553	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	184	327
557	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	14	329
590	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	0	348
594	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	232	350
607	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	89	360
635	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	0	377
667	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	43	390
719	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	337	409
731	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	75	417
767	2023-01-02 15:22:36.004	2023-01-02 15:22:36.004	0	49
788	2023-01-02 15:22:36.01	2023-01-02 15:22:36.01	1	59
144	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	0	100
209	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	64	146
222	2023-01-02 15:22:35.838	2023-01-02 15:22:35.838	1	154
248	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	0	163
256	2023-01-02 15:22:35.852	2023-01-02 15:22:35.852	1	171
273	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	1	178
308	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	1	204
329	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	1	213
338	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	100	215
347	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	6	222
383	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	0	238
396	2023-01-02 15:22:35.895	2023-01-02 15:22:35.895	14	250
404	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	6	249
412	2023-01-02 15:22:35.898	2023-01-02 15:22:35.898	1	253
418	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	1	259
451	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	0	276
524	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	109	310
532	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	1	315
650	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	11	393
698	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	318	403
749	2023-01-02 15:22:35.999	2023-01-02 15:22:35.999	0	9
773	2023-01-02 15:22:36.005	2023-01-02 15:22:36.005	7	47
792	2023-01-02 15:22:36.013	2023-01-02 15:22:36.013	7	34
146	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	0	107
162	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	0	140
175	2023-01-02 15:22:35.816	2023-01-02 15:22:35.816	6	121
189	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	15	134
194	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	61	137
205	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	6	143
212	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	0	148
252	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	1	172
286	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	7	193
295	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	14	187
304	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	17	202
362	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	1	232
374	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	1	241
407	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	7	248
421	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	7	264
430	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	112	266
437	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	30	269
446	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	7	274
456	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	7	312
465	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	121	282
503	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	70	299
510	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	0	307
555	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	186	327
564	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	64	334
580	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	204	340
611	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	251	361
624	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	264	371
654	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	185	389
699	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	320	403
718	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	1	409
725	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	340	413
757	2023-01-02 15:22:36	2023-01-02 15:22:36	0	57
772	2023-01-02 15:22:36.005	2023-01-02 15:22:36.005	0	47
789	2023-01-02 15:22:36.013	2023-01-02 15:22:36.013	0	30
147	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	1	107
157	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	1	114
180	2023-01-02 15:22:35.821	2023-01-02 15:22:35.821	0	128
183	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	30	129
206	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	1	143
267	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	0	176
293	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	0	186
324	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	0	207
343	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	7	218
352	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	0	223
398	2023-01-02 15:22:35.895	2023-01-02 15:22:35.895	1	246
427	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	1	262
432	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	1	267
445	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	1	274
458	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	0	278
463	2023-01-02 15:22:35.91	2023-01-02 15:22:35.91	0	279
477	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	1	284
482	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	14	291
502	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	158	299
520	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	0	314
526	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	43	310
533	2023-01-02 15:22:35.928	2023-01-02 15:22:35.928	7	315
548	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	180	326
576	2023-01-02 15:22:35.943	2023-01-02 15:22:35.943	14	341
609	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	249	370
653	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	33	382
680	2023-01-02 15:22:35.973	2023-01-02 15:22:35.973	311	420
692	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	0	410
706	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	320	404
712	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	0	408
765	2023-01-02 15:22:36.003	2023-01-02 15:22:36.003	7	46
776	2023-01-02 15:22:36.007	2023-01-02 15:22:36.007	0	14
786	2023-01-02 15:22:36.01	2023-01-02 15:22:36.01	7	59
790	2023-01-02 15:22:36.013	2023-01-02 15:22:36.013	7	30
149	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	0	111
161	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	14	116
177	2023-01-02 15:22:35.82	2023-01-02 15:22:35.82	53	125
198	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	1	138
260	2023-01-02 15:22:35.852	2023-01-02 15:22:35.852	7	171
275	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	61	176
288	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	0	191
296	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	15	187
305	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	30	221
323	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	15	209
333	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	0	214
342	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	1	218
350	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	1	223
377	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	6	241
397	2023-01-02 15:22:35.895	2023-01-02 15:22:35.895	0	246
406	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	0	248
467	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	126	285
484	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	0	288
491	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	146	296
542	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	174	321
554	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	185	327
573	2023-01-02 15:22:35.941	2023-01-02 15:22:35.941	7	336
577	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	202	340
598	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	109	357
640	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	274	380
649	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	27	393
652	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	283	381
661	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	185	386
691	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	320	418
703	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	318	404
713	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	337	408
738	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	344	422
745	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	342	425
753	2023-01-02 15:22:36	2023-01-02 15:22:36	0	56
766	2023-01-02 15:22:36.003	2023-01-02 15:22:36.003	0	46
794	2023-01-02 15:22:36.013	2023-01-02 15:22:36.013	1	34
150	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	1	109
172	2023-01-02 15:22:35.816	2023-01-02 15:22:35.816	0	121
225	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	1	155
235	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	0	156
359	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	7	228
389	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	0	252
440	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	1	271
450	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	1	272
460	2023-01-02 15:22:35.905	2023-01-02 15:22:35.905	14	280
509	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	17	304
536	2023-01-02 15:22:35.929	2023-01-02 15:22:35.929	0	318
551	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	14	332
559	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	0	330
585	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	32	345
588	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	230	347
604	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	149	359
610	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	88	360
615	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	14	363
619	2023-01-02 15:22:35.959	2023-01-02 15:22:35.959	109	369
642	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	276	380
666	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	109	390
672	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	109	401
677	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	298	396
681	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	1	399
710	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	26	411
744	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	350	425
751	2023-01-02 15:22:35.999	2023-01-02 15:22:35.999	6	9
760	2023-01-02 15:22:36.003	2023-01-02 15:22:36.003	1	12
783	2023-01-02 15:22:36.009	2023-01-02 15:22:36.009	10	45
151	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	6	109
190	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	7	130
196	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	0	138
207	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	1	141
216	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	15	174
251	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	6	163
274	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	0	197
279	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	76	180
292	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	1	186
303	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	30	203
309	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	0	204
319	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	11	209
335	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	1	216
361	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	1	236
395	2023-01-02 15:22:35.895	2023-01-02 15:22:35.895	6	246
399	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	10	251
405	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	1	248
441	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	0	275
454	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	1	312
462	2023-01-02 15:22:35.91	2023-01-02 15:22:35.91	7	279
472	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	129	283
479	2023-01-02 15:22:35.914	2023-01-02 15:22:35.914	135	287
490	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	1	290
507	2023-01-02 15:22:35.92	2023-01-02 15:22:35.92	158	302
515	2023-01-02 15:22:35.923	2023-01-02 15:22:35.923	7	305
534	2023-01-02 15:22:35.929	2023-01-02 15:22:35.929	75	318
593	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	1	349
620	2023-01-02 15:22:35.959	2023-01-02 15:22:35.959	0	372
663	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	185	384
671	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	6	388
682	2023-01-02 15:22:35.973	2023-01-02 15:22:35.973	314	395
707	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	1	405
717	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	6	409
764	2023-01-02 15:22:36.003	2023-01-02 15:22:36.003	1	46
775	2023-01-02 15:22:36.007	2023-01-02 15:22:36.007	6	14
784	2023-01-02 15:22:36.009	2023-01-02 15:22:36.009	1	50
152	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	1	111
160	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	1	117
202	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	0	141
210	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	0	147
215	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	14	152
240	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	74	158
262	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	17	182
271	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	1	192
282	2023-01-02 15:22:35.858	2023-01-02 15:22:35.858	76	181
326	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	26	208
382	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	1	238
444	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	1	275
453	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	1	276
461	2023-01-02 15:22:35.91	2023-01-02 15:22:35.91	1	279
478	2023-01-02 15:22:35.914	2023-01-02 15:22:35.914	134	287
489	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	15	290
500	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	154	303
512	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	0	305
568	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	0	333
583	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	219	346
634	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	268	376
641	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	275	380
670	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1	388
688	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	318	418
156	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	0	114
174	2023-01-02 15:22:35.816	2023-01-02 15:22:35.816	1	121
191	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	58	135
213	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	1	148
229	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	6	155
239	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	17	159
249	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	1	163
258	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	75	168
280	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	30	179
302	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	88	198
318	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	0	206
334	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	0	216
345	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	27	226
355	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	103	224
365	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	0	232
386	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	26	237
392	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	112	260
411	2023-01-02 15:22:35.898	2023-01-02 15:22:35.898	0	253
471	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	33	281
481	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	138	291
521	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	17	317
528	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	1	311
695	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	146	402
704	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	319	404
733	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1	421
747	2023-01-02 15:22:35.998	2023-01-02 15:22:35.998	2	48
755	2023-01-02 15:22:36	2023-01-02 15:22:36	7	57
163	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	1	140
200	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	0	142
214	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	66	149
228	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	0	153
238	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	10	159
250	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	76	168
259	2023-01-02 15:22:35.852	2023-01-02 15:22:35.852	77	171
264	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	1	177
276	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	1	197
312	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	70	205
349	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	0	222
358	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	1	228
369	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	75	230
376	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	0	241
394	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	113	244
402	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	1	249
419	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	17	257
447	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	0	274
466	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	122	285
486	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	0	290
496	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	17	295
530	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	167	315
541	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	172	321
547	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	179	326
603	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	0	355
625	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	263	371
638	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	273	379
659	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	27	387
686	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	318	394
690	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	319	418
739	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	347	422
742	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	349	424
750	2023-01-02 15:22:35.999	2023-01-02 15:22:35.999	1	9
768	2023-01-02 15:22:36.004	2023-01-02 15:22:36.004	7	49
777	2023-01-02 15:22:36.007	2023-01-02 15:22:36.007	1	14
165	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	18	118
181	2023-01-02 15:22:35.821	2023-01-02 15:22:35.821	6	128
203	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	6	142
243	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	0	164
284	2023-01-02 15:22:35.859	2023-01-02 15:22:35.859	0	183
289	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	0	193
294	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	18	190
320	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	14	209
327	2023-01-02 15:22:35.878	2023-01-02 15:22:35.878	1	219
354	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	0	225
363	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	7	232
373	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	1	234
384	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	1	239
408	2023-01-02 15:22:35.898	2023-01-02 15:22:35.898	1	258
426	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	0	262
435	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	115	268
443	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	7	275
501	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	155	303
514	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	1	305
537	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	75	338
545	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	175	319
556	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	15	329
563	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	193	334
569	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	27	335
587	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	0	343
623	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	262	371
630	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	265	392
643	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	280	380
656	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	286	389
664	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	288	384
665	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	163	390
675	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	296	396
702	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	185	406
714	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	7	408
724	2023-01-02 15:22:35.984	2023-01-02 15:22:35.984	1	412
761	2023-01-02 15:22:36.002	2023-01-02 15:22:36.002	0	12
780	2023-01-02 15:22:36.008	2023-01-02 15:22:36.008	1	60
167	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	47	122
176	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	48	127
197	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	7	138
241	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	11	159
316	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	97	209
340	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	0	217
346	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	10	226
356	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	0	228
415	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	14	292
420	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	30	256
429	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	0	266
448	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	0	272
504	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	156	299
511	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	1	307
523	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	97	313
531	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	0	315
538	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	0	320
543	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	173	321
567	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	75	333
581	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	146	339
597	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	163	357
636	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	1	377
647	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	281	380
673	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	43	401
684	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	317	394
730	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	7	417
756	2023-01-02 15:22:36	2023-01-02 15:22:36	1	57
770	2023-01-02 15:22:36.005	2023-01-02 15:22:36.005	1	47
782	2023-01-02 15:22:36.009	2023-01-02 15:22:36.009	11	45
795	2023-01-02 15:22:36.014	2023-01-02 15:22:36.014	22	74
170	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	46	122
182	2023-01-02 15:22:35.821	2023-01-02 15:22:35.821	1	128
201	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	7	141
217	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	1	147
230	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	7	153
242	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	14	161
265	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	0	177
301	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	89	198
315	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	27	209
353	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	1	225
360	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	0	236
380	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	14	240
473	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	128	283
562	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	191	334
570	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	11	335
586	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	226	345
596	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	234	357
621	2023-01-02 15:22:35.959	2023-01-02 15:22:35.959	1	372
637	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	6	377
646	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	277	380
660	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	286	386
709	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	7	411
734	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	7	415
758	2023-01-02 15:22:36.001	2023-01-02 15:22:36.001	0	54
791	2023-01-02 15:22:36.013	2023-01-02 15:22:36.013	1	30
171	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	1	124
195	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	62	137
208	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	18	145
221	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	14	150
227	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	0	155
246	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	6	164
281	2023-01-02 15:22:35.856	2023-01-02 15:22:35.856	30	185
291	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	1	193
299	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	7	195
314	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	17	209
364	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	6	236
378	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	1	235
428	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	0	263
492	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	147	296
499	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	153	301
522	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	1	314
550	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	181	324
565	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	33	328
572	2023-01-02 15:22:35.941	2023-01-02 15:22:35.941	0	336
578	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	201	340
589	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	75	343
600	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	14	351
622	2023-01-02 15:22:35.959	2023-01-02 15:22:35.959	7	372
631	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	86	392
676	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	297	396
720	2023-01-02 15:22:35.982	2023-01-02 15:22:35.982	0	414
740	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	345	422
752	2023-01-02 15:22:36	2023-01-02 15:22:36	1	56
763	2023-01-02 15:22:36.003	2023-01-02 15:22:36.003	7	12
781	2023-01-02 15:22:36.008	2023-01-02 15:22:36.008	7	60
173	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	6	124
186	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	1	131
224	2023-01-02 15:22:35.838	2023-01-02 15:22:35.838	7	154
253	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	0	172
270	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	0	192
306	2023-01-02 15:22:35.874	2023-01-02 15:22:35.874	93	210
311	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	1	206
317	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	98	209
372	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	0	234
391	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	0	260
409	2023-01-02 15:22:35.898	2023-01-02 15:22:35.898	7	258
416	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	17	255
438	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	17	270
488	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	7	288
494	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	0	297
584	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	225	345
606	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	247	375
612	2023-01-02 15:22:35.954	2023-01-02 15:22:35.954	252	367
617	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	73	365
645	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	279	380
651	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	282	381
657	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	11	387
693	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1	410
700	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	334	406
723	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	0	412
727	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1	417
737	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	346	422
741	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	172	424
746	2023-01-02 15:22:35.998	2023-01-02 15:22:35.998	0	48
774	2023-01-02 15:22:36.007	2023-01-02 15:22:36.007	7	14
137	2023-01-02 15:22:35.809	2023-01-02 15:22:35.809	17	105
143	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	6	100
179	2023-01-02 15:22:35.82	2023-01-02 15:22:35.82	17	125
184	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	0	131
192	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	14	134
223	2023-01-02 15:22:35.838	2023-01-02 15:22:35.838	0	154
233	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	0	160
268	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	7	176
287	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	1	191
297	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	1	195
307	2023-01-02 15:22:35.874	2023-01-02 15:22:35.874	94	210
325	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	1	207
388	2023-01-02 15:22:35.887	2023-01-02 15:22:35.887	109	243
400	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	11	251
417	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	0	259
452	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	6	276
469	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	123	285
483	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	139	291
508	2023-01-02 15:22:35.92	2023-01-02 15:22:35.92	14	302
519	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	6	308
525	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	163	310
561	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	192	334
571	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	10	335
579	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	203	340
595	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	43	357
605	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	149	358
614	2023-01-02 15:22:35.954	2023-01-02 15:22:35.954	26	364
679	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	0	399
685	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	319	394
694	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	7	410
697	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	317	403
716	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	0	409
726	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	339	413
732	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	7	421
\.


--
-- Data for Name: Entry; Type: TABLE DATA; Schema: public; Owner: tim
--

COPY public."Entry" (id, "createdAt", "updatedAt", "NCTId", "OfficialTitle", "BriefTitle", "OverallStatus", "BriefSummary", "DesignInterventionModel", "LeadSponsorName", "LeadSponsorClass", "Gender", "MaximumAge", "MinimumAge", "EnrollmentCount", "EnrollmentType", "OrgClass", "OrgFullName", "DesignAllocation", "DesignInterventionModelDescription", "DesignMasking", "DesignMaskingDescription", "DesignObservationalModel", "DesignPrimaryPurpose", "DesignTimePerspective", "DetailedDescription", "StartDate", "PrimaryCompletionDate", "CompletionDate", "StudyFirstPostDate", "ResultsFirstPostDate", "LastUpdatePostDate", "PointOfContactOrganization", "ResponsiblePartyInvestigatorAffiliation", "ResponsiblePartyInvestigatorFullName", "ResponsiblePartyInvestigatorTitle", "ResponsiblePartyOldNameTitle", "ResponsiblePartyOldOrganization", "ResponsiblePartyType", "WhyStopped", "StudyType", "AgeCategories", "Phases", conditions, drug_role, legacy_search_term, notes, repurpose, usecase, legacy_import_date, "ReferenceCitation", "publicationStatus", "publicationUrl", drug_name) FROM stdin;
115	2023-01-02 15:22:35.728	2023-03-20 16:39:49.777	NCT00776282	An Open Label, Balanced, Randomized, Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover, Bioavailability Study on Loratadine Formulations Comparing Loratadine 10 mg Orally Disintegrating Tablets of Ohm Laboratories, Inc. (A Subsidiary of Ranbaxy Pharmaceuticals Inc) With Claritin Reditabs 10 mg Tablet (Containing Loratadine 10 mg) of Schering- Plough Healthcare Product Inc, in Healthy, Adult, Male, Human Subjects Under Fed Condition	Bioequivalence Study of Loratadine Orally Disintegrating Tablets 10 mg Under Fed Conditions	Completed	To compare the single-dose oral bioavailability of loratadine 10 mg orally disintegrating tablets of Ohm Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals, Inc. USA) with Claritin Reditabs (containing loratadine 10 mg) of Schering-Plough Healthcare Product Inc., USA in healthy, adult, human male subjects under fed condition.	Crossover Assignment	Ranbaxy Laboratories Limited	INDUSTRY	Male	45	18	80	Actual	INDUSTRY	Ranbaxy Inc.	Randomized	\N	None (Open Label)	\N	\N	\N	\N	The study was conducted as an open label, balanced, randomized, two-treatment, two-sequence,two-period, single-dose, crossover, bioavailability study on loratadine formulation comparing loratadine 10 mg orally disintegrating tablets of Ohm Laboratories, Inc. (A subsidiary of Ranbaxy pharmaceuticals Inc. USA) with Claritin Reditabs 10 mg Tablet (containing loratadine 10 mg) of Schering- Plough Healthcare Product Inc, USA. in healthy, adult, male, human subjects under fed condition.\n\nA single oral dose of loratadine 10 mg orally disintegrating tablets was administered under low light condition during each period of the study under supervision of a trained medical officer.\n\nSubjects were instructed to completely dissolve the tablet on the tongue before swallowing the saliva and then, 240 mL of water was administered 30 seconds after drug administration.\n\nDuring the course of the study safety parameters assessed were vital signs, clinical examination, medical history and clinical laboratory safety tests (hematology, biochemical, serology parameters and urine analysis) at base line. Laboratory parameters of hematology and biochemistry were repeated at the end of the study.\n\nA total of 80 subjects were randomized to receive single oral dose of Loratadine 10mg and Subjects were admitted in two groups of equal size. Group I: 1-40 Group II: 41-80 70 subjects completed both the periods of the study.	2006-07-01	2006-08-01	2006-09-01	2008-10-21	\N	2008-10-21	\N	\N	\N	\N	Dr. tausif monif	Ranbaxy Research Laboratories	\N	\N	Interventional	{Adult}	{"Not Applicable"}	{Healthy}	main	loratadine	\N	f	Bioequivalence	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
118	2023-01-02 15:22:35.728	2023-03-20 16:44:56.507	NCT01567501	A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Levocetirizine Dihydrochloride 5 mg Tablets With Xyzal 5 mg Tablets in Normal, Healthy, Adult, Human Subjects Under Fed Condition	Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition	Completed	This is a single-dose, Randomized, two-period,cross over pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fed condition in normal, healthy, adult, human subjects.	Crossover Assignment	IPCA Laboratories Ltd.	INDUSTRY	All	45	18	28	Actual	INDUSTRY	IPCA Laboratories Ltd.	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	Primary Objective of this pivotal study was to assess the bioequivalence between Test Product: Levocetirizine Dihydrochloride 5 mg Tablets of M/s Ipca Laboratories Limited, India and the corresponding Reference Product: Xyzal (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA, under fed condition in normal, healthy, adult, human subjects in a randomized crossover study.\n\nSecondary Objective was to monitor the safety and tolerability of a single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets in normal,healthy, adult, human subjects.\n\nThe study was conducted with 28 healthy adult subjects. In each study period, a single 5 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position.\n\nThe duration of the clinical phase was approximately 11 days including washout period of at least 7 days between administrations of study drug in each study period.	2012-02-01	2012-03-01	2012-03-01	2012-03-30	\N	2012-12-03	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Fed}	main	cetirizine	\N	f	Bioequivalence	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
120	2023-01-02 15:22:35.728	2023-03-20 16:46:09.264	NCT02513290	Quality of Life in Patients With Allergic Rhinitis: a Clinical Trial Comparing the Use of Bilastine Versus Loratadine	Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine	Completed	The purpose of this study was to verify whether there were differences in health-related quality of life of patients with allergic rhinitis treated with bilastine 20 mg compared to those treated with loratadine 10 mg.	Parallel Assignment	Universidade do Sul de Santa Catarina	OTHER_GOV	All	65	18	73	Actual	OTHER_GOV	Universidade do Sul de Santa Catarina	Randomized	\N	Triple	\N	\N	Treatment	\N	This was a prospective randomized double-blinded study, in which patients were recruited from august 2013 until august 2014. Outpatients attended in 4 otolaryngology clinics from Cricima, state of Santa Catarina, Brazil were invited to participate of the study. They were aged between 18 and 63 years. Seventy-three patient were included, of whom 36 were treated with loratadine 10 mg and 37 with bilastine 20 mg with medication administered once a day for ten days. The primary outcome was quality of life, assessed by the modified Rhinoconjunctivitis Quality of Life Questionnaire (RQLQm), which was applied at baseline and after 10 days of treatment.	2013-08-01	2014-08-01	2014-08-01	2015-07-31	\N	2018-05-07	\N	Universidade do Sul de Santa Catarina	Jane da Silva	PhD	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Allergic Rhinitis"}	comparison	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):364-9. doi: 10.1016/s0091-6749(99)70380-5.","Carter NJ. Bilastine: in allergic rhinitis and urticaria. Drugs. 2012 Jun 18;72(9):1257-69. doi: 10.2165/11209310-000000000-00000.","Nascimento Silva M, Naspitz C, Sole D. Evaluation of quality of life in children and teenagers with allergic rhinitis: adaptation and validation of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Allergol Immunopathol (Madr). 2001 Jul-Aug;29(4):111-8. doi: 10.1016/s0301-0546(01)79042-8.","Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, van de Heyning P, Loureiro A; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009 Jan;64(1):158-65. doi: 10.1111/j.1398-9995.2008.01813.x.","Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000 Jun;30(6):891-9. doi: 10.1046/j.1365-2222.2000.00914.x."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/27385478/	loratadine
3	2023-01-02 15:22:35.721	2023-03-19 21:58:10.304	NCT00794378	A Single-Center, Pediatric, Comparative Taste Test of Desloratadine and Cetirizine Antihistamine Syrup Medications	Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)	Completed	This study was conducted to compare the taste acceptability of Zyrtec syrup with desloratadine syrup in children. Children between 6 and 11 years of age received 5 mL of each syrup, separated by 15 to 20 minutes on a single day.	Crossover Assignment	Organon and Co	INDUSTRY	All	11	6	202	Actual	INDUSTRY	Organon and Co	Randomized	\N	Quadruple	\N	\N	Other	\N	This study is a cross-over study design.	2004-11-01	2004-11-01	2004-11-01	2008-11-20	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Allergic Rhinitis"}	comparison	cetirizine	\N	f	Taste, Form, Preference	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	desloratadine|cetirizine
6	2023-01-02 15:22:35.722	2023-03-19 22:01:27.887	NCT00751218	A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU)	A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)	Completed	This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (cetirizine) and a placebo control to evaluate desloratadine 5 mg once daily during a 28-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.	Parallel Assignment	Organon and Co	INDUSTRY	All	70	12	174	Actual	INDUSTRY	Organon and Co	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2004-05-06	2005-05-24	2005-05-24	2008-09-11	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{Urticaria}	comparison	cetirizine	\N	f	Urticaria	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	desloratadine|cetirizine
8	2023-01-02 15:22:35.723	2023-03-19 22:03:20.83	NCT02447393	A Single Blind, Randomized, Single Oral Dose Study to Compare the Oral Disposition of Levocetirizine When Given Alone (5mg) or as the Racemate (Cetirizine 10mg), and to Investigate the Safety and Tolerability and the Pharmacokinetics of Levocetirizine and Cetirizine, Following a Single Dose in Healthy Japanese Male Subjects	Phase 1 Study of Levocetirizine	Completed	This is a single center, single blind, single dose, randomized, partial cross-over study to confirm bioequivalence between levocetirizine and cetirizine.	Crossover Assignment	GlaxoSmithKline	INDUSTRY	Male	64	20	20	Actual	INDUSTRY	GlaxoSmithKline	Randomized	\N	Single	\N	\N	Prevention	\N	\N	2008-03-18	2008-04-30	2008-04-30	2015-05-18	\N	2017-08-03	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Dermatitis}	main	cetirizine	\N	f	Bioequivalence	2022-08-17 13:39:16	{"Hiroko Ino, Shigeru Nohda, Shuji Miki, Kastutoshi Hara, Toshiyasu Hirama. Comparison of levocetirizine pharmacokinetics, following a single dose of levocetirizine alone or as cetirizine in Japanese healthy male volunteers . [Jpn J Clin Pharmacol Therapeut]. 2010;41(6):309."}	UNKNOWN	\N	levocetirizine
18	2023-01-02 15:22:35.723	2023-03-19 22:16:50.578	NCT00525382	A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Chronic Idiopathic Urticaria (CIU)	Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria	Completed	Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria.	Parallel Assignment	UCB Pharma	INDUSTRY	All	60	18	134	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Single	\N	\N	Treatment	\N	\N	2003-08-01	2004-03-01	2004-03-01	2007-09-05	\N	2013-12-12	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult}	{"Phase 3"}	{Urticaria}	comparison	loratadine	\N	f	Urticaria	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	levocetirizine|loratadine
13	2023-01-02 15:22:35.723	2023-03-19 22:07:04.451	NCT00160589	A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR)	LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)	Completed	Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)	Parallel Assignment	UCB Pharma	INDUSTRY	All	\N	18	729	\N	INDUSTRY	UCB Pharma	Randomized	\N	Double	\N	\N	\N	\N	\N	2005-04-01	2005-09-01	2005-09-01	2005-09-12	\N	2013-12-16	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Rhinitis, Allergic, Perennial"}	combination	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine|desloratadine
20	2023-01-02 15:22:35.723	2023-03-19 22:19:58.418	NCT01064102	Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Cetirizine Hydrochloride Tablets 10 mg in Healthy Adult Human Male Subjects Under Fasting Conditions.	Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition	Completed	A Two Way, Open Label, Single Dose, Cross Over, Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys laboratories with Zyrtec 10 mg of Pfizer labs in Healthy Adult Human Male Subjects Under Fasting Conditions.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	Male	45	18	30	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Cross Over, and Comparative Oral Bioavailability study in healthy, adult, human, male subjects under Fasting Conditions.	2006-01-01	2006-01-01	2006-02-01	2010-02-08	\N	2010-02-08	\N	\N	\N	\N	Senior Manager - Research & Development	Dr. Reddy's Laboratories Limited	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	main	cetirizine	\N	f	Bioequivalence	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
337	2023-01-02 15:22:35.741	2023-03-21 09:22:32.314	NCT00721331	A Phase I, Single-Center, Randomized, Vehicle-Controlled Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers	A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers	Completed	This will be a phase I, single center, randomized, vehicle-controlled, blinded study comparing two dosage strengths of CRx-197 cream, nortriptyline, an active comparator (0.1% mometasone) and placebo (the active ingredient free vehicle cream of CRx-197)in healthy volunteers.	Factorial Assignment	Zalicus	INDUSTRY	All	60	18	20	Anticipated	INDUSTRY	Zalicus	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2008-07-01	2008-09-01	2008-09-01	2008-07-24	\N	2008-09-26	\N	\N	\N	\N	James Keane, Sr. Clinical Project Manager	CombinatoRx, Inc.	\N	\N	Interventional	{Adult}	{"Phase 1"}	{"Atopic Dermatitis"}	combination	loratadine	\N	f	Dermatitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
132	2023-01-02 15:22:35.729	2023-03-20 16:58:25.922	NCT01298505	A Phase 1 Double-blind (3rd Party Open), Randomized, Placebo-controlled Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of Pf-03654764 In Combination With Fexofenadine In Healthy Subjects	A Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects	Terminated	The purpose of this study in heathy people is to investigate the safety, toleration and time course of PF-03654764 in the blood, following multiple doses given by mouth together with fexofenadine.	Parallel Assignment	Pfizer	INDUSTRY	All	55	21	36	Actual	INDUSTRY	Pfizer	Randomized	\N	Double	\N	\N	Basic Science	\N	\N	2010-06-04	2010-06-04	2010-06-04	2011-02-17	\N	2019-02-11	\N	\N	\N	\N	\N	\N	Sponsor	This study was stopped due to lack of evidence for clinical efficacy.	Interventional	{Adult}	{"Phase 1"}	{Healthy}	combination	fexofenadine	TODO usecase, not really listed what it does PF-03....	f	Safety Evaluation	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
133	2023-01-02 15:22:35.729	2023-03-20 16:58:36.413	NCT01557439	A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Levocetirizine Dihydrochloride 5 mg Tablets With Xyzal 5 mg Tablets in Normal, Healthy, Adult, Human Subjects Under Fasting Condition	Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fasting Condition	Completed	This is a single-dose, Randomized, two-period,cross over pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in normal, healthy, adult, human subjects.	Crossover Assignment	IPCA Laboratories Ltd.	INDUSTRY	All	45	18	28	Actual	INDUSTRY	IPCA Laboratories Ltd.	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	Primary Objective of this pivotal study was to assess the bioequivalence between Test Product: Levocetirizine Dihydrochloride 5 mg Tablets of M/s Ipca Laboratories Limited, India and the corresponding Reference Product: Xyzal (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA, under fasting condition in normal, healthy, adult, human subjects in a randomized crossover study.\n\nSecondary Objective was to monitor the safety and tolerability of a single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets in normal,healthy, adult, human subjects.\n\nThe study was conducted with 28 healthy adult subjects. In each study period, a single 5 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position.\n\nThe duration of the clinical phase was approximately 11 days including washout period of at least 7 days between administrations of study drug in each study period.	2012-02-01	2012-03-01	2012-03-01	2012-03-19	\N	2012-12-03	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{"Fasting State"}	main	levocetirizine	\N	f	Bioequivalence	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
10	2023-01-02 15:22:35.723	2023-03-19 22:04:32.065	NCT02551536	Comparison of Efficacy, Safety and Cost Effectiveness of Montelukast and Levocetirizine Versus Montelukast and Fexofenadine in Patients of Allergic Rhinitis: a Randomized, Double-blind Clinical Trial	Montelukast and Fexofenadine Versus Montelukast and Levocetrizine Combination in Allergic Rhinitis	Completed	Objectives: Allergic Rhinitis (AR) is a global health problem. 10-25% of population worldwide is affected by AR. Oral/intranasal H1-antihistamine, decongestants, leukotriene receptor antagonists, intranasal corticosteroids are the pillars in the management of AR.Materials and methods: Seventy patients with allergic rhinitis participated in a prospective, randomized, double-blind, parallel, active controlled, comparative 4 week trial. The patients between age group of 18-65 years of either gender having moderate-severe intermittent or mild persistent allergic rhinitis were included. The study inclusion criteria required the subjects with Total Nasal Symptom Score (TNSS) of 5 or higher. The patients were randomly divided into two treatment groups with montelukast-levocetrizine (10 mg and 5 mg) in one group and montelukast-fexofenadine (10 mg and 120 mg) in another group. TNSS parameter was the main effectiveness parameter.	Parallel Assignment	Indira Gandhi Medical College, Shimla	OTHER	All	65	18	70	Actual	OTHER	Indira Gandhi Medical College, Shimla	Randomized	\N	Double	\N	\N	Treatment	\N	Allergic Rhinitis (AR) is a global health problem. It is the cause of major illness and disability worldwide. Estimates indicate that 10-25% of population worldwide is affected by AR. The main symptoms of AR include nasal congestion, rhinorrhea, itching, sneezing and non-nasal symptoms like burning, itching and watery eyes or itching ears and palate. These symptoms can have a considerable toll on patient's quality of life by interfering with cognitive and emotional functioning. The estimated annual cost attributable to AR in United States ranges from $1.4 billion to nearly $ 6 billion in direct cost annually. Today's antiallergic therapy is based on avoidance of the causative allergen, symptomatic pharmacotherapy, specific immunotherapy and education. Oral/intranasal H1-antihistaminics, decongestants, leukotrienes receptor antagonists, intranasal corticosteroids are the pillars in the management of allergic rhinitis. Second generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to first generation counterparts. Levocetirizine, a potent second generation histamine (H1) receptor antagonist, is effective against persistent allergic rhinitis and thus improves quality of life and reduces co-morbidities and societal costs. Fexofenadine, is a selective, non sedating, second generation H1 receptor antagonist which have an additional impact on the inflammatory mediators. Monteleukast is a highly selective type I receptor antagonist of leukotriene D4. The leukotrienes modifiers have both anti-inflammatory and bronchodilator properties.\n\nThe literature search establishes that addition of an antihistamine to montelukast has added benefit. The combination therapy of montelukast with antihistamine provide enhancing and complimentary effects thereby reducing the symptoms effectively. The results with concomitant levocetirizine and montelukast treatment are better as compared to monotherapy with levocetirizine on symptoms and quality of life in allergic rhinitis. Fexofenadine along with montelukast is more effective than antihistaminic alone in control of allergic rhinitis symptoms. There is literature available for the comparisons of concomitant levocetirizine and montelukast with monotherapy or placebo and comparisons of concomitant fexofenadine and montelukast with monotherapy or placebo. But scanty data is available regarding comparisons of concomitant montelukast-levocetirizine with montelukast-fexofenadine.	2014-04-01	2015-04-01	2015-06-01	2015-09-16	\N	2015-09-16	\N	Indira Gandhi Medical College, Shimla	DR.MOHINI MAHATME	ASSOCIATE PROFESSOR	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Allergic Rhinitis"}	comparison	fexofenadine	also combination	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	CT_RESULTS	\N	fexofenadine|levocetirizine
17	2023-01-02 15:22:35.723	2023-03-19 22:15:23.808	NCT00524836	A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Perennial Allergic Rhinitis.	Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis	Completed	Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis.	Parallel Assignment	UCB Pharma	INDUSTRY	All	60	18	71	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Single	\N	\N	Treatment	\N	\N	2003-09-01	2004-02-01	2004-02-01	2007-09-05	\N	2013-12-16	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult}	{"Phase 3"}	{Rhinitis,Allergic,Perennial}	comparison	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	levocetirizine|loratadine
44	2023-01-02 15:22:35.725	2023-03-20 09:28:58.889	NCT01133470	An Open Label, Balanced, Randomized, Two-way, Single Dose, Crossover Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tabs of Dr. Reddy's and Allegra-D 24 hr ER Tabs of Aventis, in Healthy Subjects Under Fasting Conditions	Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra D 24 Hour ER Tablets Under Fasting Conditions	Completed	The purpose of this study is to\n\nCompare and evaluate the single dose, crossover, bioequivalence study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets and Allegra-D 24 hr tablets.\nMonitor the adverse events and ensure the safety of subjects.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	All	45	18	54	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover bioequivalence study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals Inc., USA in healthy, adult, human subjects under fasting conditions.	2007-02-01	2007-02-01	2007-04-01	2010-05-28	\N	2010-06-14	\N	\N	\N	\N	Mr. Indu Bhushan / Senior Director	Dr. Reddy's Laboratories Limited	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	combination	fexofenadine	\N	f	Bioequivalence	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
134	2023-01-02 15:22:35.729	2023-03-20 17:00:32.876	NCT00598611	An Exploratory Phase III, Randomised, Double-blind, Therapeutic Single Dose-related Effect, Parallel Group Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)	Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)	Completed	The purpose of this study is to compare urticaria lesions (size, kinetics) by thermography, volumetry and digital time lapse photography in CU patients treated with desloratadine 5 mg or desloratadine 20 mg. Hypothesis: Updosing of desloratadine (20mg) is more efficient in the treatment of urticarial lesions as compared to standard dosing (5 mg desloratadine).	Parallel Assignment	Charite University, Berlin, Germany	OTHER	All	75	18	29	Actual	OTHER	Charite University, Berlin, Germany	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2007-09-01	2009-08-01	2009-08-01	2008-01-22	\N	2012-05-31	\N	Charite University, Berlin, Germany	K. Weller	Dr. Karsten Weller	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Chronic Urticaria"}	main	loratadine	\N	f	Urticaria	2022-08-17 18:44:47	{"Weller K, Ardelean E, Scholz E, Martus P, Zuberbier T, Maurer M. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol. 2013 Mar 27;93(2):168-74. doi: 10.2340/00015555-1434."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/23053062/	desloratadine
12	2023-01-02 15:22:35.721	2023-03-19 22:05:55.81	NCT00783133	Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis	Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)	Completed	This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex or Allegra. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.	Crossover Assignment	Organon and Co	INDUSTRY	All	\N	18	131	Actual	INDUSTRY	Organon and Co	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2002-11-01	2003-06-01	2003-06-01	2008-10-31	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	comparison	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	UNKNOWN	\N	desloratadine|fexofenadine
25	2023-01-02 15:22:35.724	2023-03-19 22:22:55.097	NCT00637585	A Comparison of Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine	Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine	Completed	To examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (ALLEGRA) and desloratadine 5 mg (CLARINEX) as compared to placebo on skin wheals and flares induced by histamine.	Crossover Assignment	Sanofi	INDUSTRY	All	55	12	42	Actual	INDUSTRY	Sanofi	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2002-12-01	\N	2003-07-01	2008-03-18	\N	2011-01-11	\N	\N	\N	\N	Study Director	sanofi-aventis	\N	\N	Interventional	{Child,Adult}	{"Phase 4"}	{"Allergic Rhinitis"}	comparison	fexofenadine	intervention table in study description only lists fex	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine|desloratadine
14	2023-01-02 15:22:35.722	2023-03-19 22:07:35.177	NCT00794599	Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis	Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)	Completed	This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex or Zyrtec. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.	Crossover Assignment	Organon and Co	INDUSTRY	All	\N	18	118	Actual	INDUSTRY	Organon and Co	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2002-12-01	2003-08-01	2003-08-01	2008-11-20	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis","Perennial Allergic Rhinitis"}	comparison	cetirizine	\N	f	Taste, Form, Preference	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	desloratadine|cetirizine
30	2023-01-02 15:22:35.723	2023-03-19 22:27:03.179	NCT00525278	Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Seasonal Allergic Rhinitis (SAR)	To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis	Completed	To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis	Parallel Assignment	UCB Pharma	INDUSTRY	All	60	18	67	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Single	\N	\N	Treatment	\N	\N	2003-08-01	2003-10-01	2003-10-01	2007-09-05	\N	2013-12-16	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult}	{"Phase 3"}	{Rhinitis,Allergic,Seasonal}	comparison	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	levocetirizine|loratadine
142	2023-01-02 15:22:35.73	2023-03-20 17:03:12.256	NCT00639587	A Double-blind, Parallel, Active Comparator Controlled, Randomized Trial; Comparison of the Efficacy and Safety in Children With Perennial Allergic Rhinitis of Cetirizine Tablets Versus Ketotifen Dry Syrup	Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis	Completed	Ketotifen is an established antihistamine drug, widely used in pediatric clinical practice in Japan. The objective of the study was to compare the efficacy and safety of cetirizine hydrochloride versus ketotifen dry syrup on children 7 years and older with perennial allergic rhinitis.	Parallel Assignment	UCB Pharma	INDUSTRY	All	14	7	149	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2002-08-01	2003-03-01	2003-03-01	2008-03-20	\N	2009-09-04	\N	\N	\N	\N	Study Director	UCB	\N	\N	Interventional	{Child}	{"Phase 3"}	{"Rhinitis, Allergic, Perennial"}	comparison	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
341	2023-01-02 15:22:35.741	2023-03-21 09:29:12.062	NCT03250143	A Randomised Study to Assess and Compare the Efficacy of Cyclosporine Versus Azathioprine in the Treatment of Chronic Refractory Urticaria	To Assess and Compare the Efficacy of Cyclosporine Versus Azathioprine in the Treatment of Chronic Refractory Urticaria	Completed	Fifty six patients of CRU attending the urticaria clinic in the department of Dermatology, Venereology and Leprology at the Post Graduate Institute of Medical Education and Research, Chandigarh will be recruited in the study calculated by using equivalence analysis assuming power of 90%, significance level of 5% and standard deviation of 1 and adjusting 5% of expected drop-outs after taking written informed consent. This study is undertaken with an intention to treat the patients of chronic refractory urticaria completely. Patients will be randomized into two groups A and B using computer generated random number tables, group A will receive Cyclosporine and group B will receive Azathioprine; wherein, 28 random single and double-digit numbers from 1-56 will be selected before recruitment, and patients coming on these numbers will be randomized in a particular group. Random number generation, recruitment and randomization, were all done by the same investigator..	Parallel Assignment	Postgraduate Institute of Medical Education and Research	OTHER_GOV	All	60	18	56	Actual	OTHER_GOV	Postgraduate Institute of Medical Education and Research	Randomized	Randomized prospective study	None (Open Label)	\N	\N	Treatment	\N	Available definition for chronic refractory urticaria (CRU) is chronic spontaneous urticaria, with disease duration of at least 6 months or above, which is not controlled with four fold increased dosage of antihistamines (as per EAACI guidelines), given for at least three consecutive months and requiring repeated courses of oral corticosteroids. There is no strict number of oral corticosteroids intake courses before the patient can be labeled as chronic refractory urticaria.\n\nStudy end- points\n\nPrimary end-point :\n\nChange in urticaria activity score (UAS7) i.e decrease more than 75% from baseline to week 12 (at end of treatment) within group A and B and comparison between corresponding groups.\n\nSecondary end-points :\n\nChange in outcome scoring scale (OSS) from baseline to week 12 within group A and B.\nChange in UAS7 and OSS from baseline to week 24 (end of follow-up) within group A and B.\nChange in ASST, APST, IgE levels from baseline to week 12 within group A and B.\n\nComparison for the above mentioned parameters between group A and B. Treatment sessions will be for three months, daily oral cyclosporine and daily oral azathioprine and after completion, patients will be additionally followed for three more months.\n\nOral cyclosporine 3mg/kg/day (200mg/day) will be started and given for one week, if patient shows improvement, the same dose will be continued for the total study period ( three months) ,after physical examination and various laboratory testing most importantly renal function tests, blood pressure monitoring, hemogram and if no symptomatic improvement then dose of cyclosporine will be increased slowly till 5 mg/kg /day.\n\nOral azathioprine will be started at 1mg/kg/day ( 50mg/day) for one week , if patient demonstrates improvement, same dose is continued for the total study period ( 3months), after physical examination and various laboratory testing i.e LFTs, Hemogram, if no symptomatic improvement then dose of azathioprine will be increased to 2mg/kg/day (100mg/day).\n\nAll the patients will be uniformly started on levocetrizine 10mg/day, which will continue daily for one month in all patients followed by stopping the drug and adding only if the patient is symptomatic.\n\nAfter three months both the drugs will be stopped and levocetrizine (10mg/day) will be continued for three months of follow up period.\n\nClinical assessment of patients will be done before the starting of cyclosporine and azathioprine, and every fortnightly during three months of treatment and during three months of follow up period. Assessment will be done using UAS7and OSS as devised by Berroeta et al.\n\nURTICARIA ACTIVITY SCORE Table-2 SCORE WEALS PRURITUS\n\n0 None None\n\n1 Mild (<20 weals / 24 hours) Mild (present but not troublesome)\n\n2 Moderate (20-50 weals / 24 hours) Moderate (troublesome but does not interfere with sleep)\n\n3 Severe (>50 weals / 24 hours) Severe (sufficiently troublesome to interfere with normal daily activity and sleep)\n\nScores of both parameters i.e. number of weals and severity of the pruritus per day are to be added to get UAS of that day and average UAS over 7 days is calculated which will range between 0 to 6. Patients will be instructed to write down number of weals and severity of itching in their daily urticaria diary. UAS7 will be calculated every fortnightly by calculating average of weal and itch score of the previous seven days after taking detailed history from patient.\n\nUAS7 SCORES71 HEALTH STATE\n\n0 Urticaria free\n\n1-6 Well controlled urticaria\n\n7-15 Mild urticaria\n\n16-27 Moderate urticaria\n\n26-42 Severe urticaria\n\nOUTCOME SCORING SCALE Another assessment scale i.e.Outcome scoring scale devised by Berroeta et al 22 for cyclosporine and azathioprine treatment of CU will also be used for clinical assessment of subjects.\n\n1- No change 2 - Minimal improvement (no change in frequency or extent, symptomatic improvement ) 3- Moderate improvement (less frequent or extensive, symptomatic improvement +) 4- Marked improvement (occasional episodes and less extensive, symptomatic improvement ++) 5- Clearance\n\nIn addition, ASST , APST and IgE levels will be done before starting cyclosporine and azathioprine and at the completion of the treatment after three months.\n\nFOLLOW UP After completion of oral cyclosporine and oral azathioprine for three months, patients will be followed up for a period of three more months, every fortnightly in urticaria clinic. At each visit, clinical assessment will be done using UAS7 and OSS. Urticaria being a type 1 hypersensitivity reaction, will relapse immediately as soon as the treatment is withheld. So, a follow up period of three months will be sufficient enough to study the effect of cyclosporine and azathioprine on long term remission of urticaria. Patients developing angioedema and having uncontrolled excessive exacerbation during treatment will be removed from study and will be treated accordingly.\n\nPatients who will fail to take the treatment for  one week will be defined as defaulters and removed from the study. Those with no improvement even after one month of regular treatment will be labelled as non responders.	2016-12-06	2017-11-01	2017-11-01	2017-08-15	\N	2018-01-11	\N	Postgraduate Institute of Medical Education and Research	Davinder Parsad	DParsad(professor)	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Phase 1","Phase 2"}	{"Chronic Refractory Urticaria"}	not included	levocetirizine	Other name for treatment is levocetirzine but that does not make any sense in this context	f	Urticaria	2022-09-15 18:58:14	{}	UNKNOWN	\N	levocetirizine
28	2023-01-02 15:22:35.724	2023-03-19 22:25:57.952	NCT01506063	An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg With XYZAL Tablets 5 mg in Healthy Subjects Under Fed Conditions	Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fed Conditions	Completed	The purpose of this study is to assess the Bioequivalence of Levocetirizine DiHCl Tablets 5mg with XYZAL tablets 5 mg and to monitor clinical status, adverse events and laboratory investigations and assess relative safety and tolerance, under fed conditions.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	All	45	18	31	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	A pivotal study to compare the Bioequivalence of Levocetirizine DiHCl Tablets 5 mg of Dr.Reddy's Laboratories Limited with XYZAL Tablets 5 mg of UCB Farchim S.A. in healthy, human subjects under fed conditions.	2008-01-01	2008-01-01	2008-01-01	2012-01-09	\N	2012-01-11	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	main	levocetirizine	\N	f	Bioequivalence	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
21	2023-01-02 15:22:35.723	2023-03-19 22:20:25.132	NCT01066754	Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg Tablets and Allegra 180 mg Tablets Administered as 1 x 180 mg Tablet in Healthy Subjects Under Fasting Conditions	Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions	Completed	Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg Tablets of Dr.Reddy's Laboratories Limited, and Allegra 180 mg Tablets, Aventis Administered as 1 x 180 mg Tablet in Healthy Subjects under Fasting Conditions	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	All	\N	18	44	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	The objective of this study is to compare the rate and extent of absorption of fexofenadine hydrochloride 180 mg tablets (test) versus Allegra (reference) administered as 1 x 180 mg tablet under fasting conditions. Single oral dose (1 x 180 mg) in each period with a washout of at least 7 days between doses.	2002-04-01	2002-05-01	2002-05-01	2010-02-10	\N	2010-02-10	\N	\N	\N	\N	Assistant Manager	Dr. Reddy's Laboratories Limited	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{Healthy}	main	fexofenadine	\N	f	Bioequivalence	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
29	2023-01-02 15:22:35.724	2023-03-19 22:26:34.045	NCT02593747	A Single-dose, Single-center, Randomized, Open-label, Two-way Crossover Study in Healthy Adults to Assess the Bioequivalence of Loratadine Oral Solution/Syrup 1mg/mL (GPLA Formula) Versus Claritin Peach Syrup 1mg/mL (ANNA Formula)	To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup	Completed	To assess the bioequivalence of Loratadine Oral Solution/Syrup 1mg/mL (GPLA Formula) versus Claritin Peach Syrup 1mg/mL (ANNA Formula)	Crossover Assignment	Bayer	INDUSTRY	All	55	18	54	Actual	INDUSTRY	Bayer	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2015-12-01	2016-01-01	2016-03-01	2015-11-01	\N	2017-02-13	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{"Histamine H1 Antagonists, Non-Sedating"}	comparison	loratadine	\N	f	Bioequivalence	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
144	2023-01-02 15:22:35.73	2023-03-20 17:04:35.023	NCT01526213	Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?	Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?	Completed	Purpose: Grapefruit juice is one of the most extensively studied dietary/natural substances shown to interact with a variety of medications. However, unanswered questions remain regarding the causative ingredients and mechanisms underlying such drug-grapefruit juice interactions. Compounds in grapefruit juice called furanocoumarins have been established as major causative ingredients, which act by inhibiting the elimination (metabolism) of drugs, leading to increased circulating drug concentrations. Increased drug concentrations can in turn lead to increased drug potency or even toxicity. Grapefruit juice also has been shown, paradoxically, to decrease circulating concentrations of some drugs, including the non-sedating antihistamine agent, fexofenadine (Allegra), which undergoes negligible metabolism. Whether or not furanocoumarins mediate the decrease in fexofenadine concentrations is unknown. The purpose of the proposed study is to compare the effects of a "furanocoumarin-free" grapefruit juice with grapefruit juice on circulating concentrations of fexofenadine.	Crossover Assignment	University of North Carolina, Chapel Hill	OTHER	All	65	18	18	Actual	OTHER	University of North Carolina, Chapel Hill	Randomized	\N	None (Open Label)	\N	\N	Other	\N	Participants: Healthy volunteers of any race/ethnicity, ranging in age from 18 to 65 years, will be enrolled.\n\nProcedures (methods): Procedures will include administration of water, furanocoumarin-free grapefruit juice, or grapefruit juice with fexofenadine; placement of an intravenous (IV) line; and collection of blood over 72 hours.	2009-09-01	2010-04-01	2011-04-01	2012-02-03	2013-02-04	2017-05-30	UNC-Chapel Hill	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{"Food-drug Interaction"}	combination	fexofenadine	combination with grape juice	f	Pharmacokinetics	2022-08-18 16:54:53	{}	CT_RESULTS	\N	fexofenadine
345	2023-01-02 15:22:35.741	2023-03-21 09:35:20.571	NCT04990388	A Phase 1/2 First-in-human, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Repeat Doses of UX053 in Patients With GSD III	Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)	Recruiting	The primary objective of the study is to evaluate the safety of UX053 in adults with Glycogen Storage Disease Type III (GSD III).	Sequential Assignment	Ultragenyx Pharmaceutical Inc	INDUSTRY	All	\N	18	18	Anticipated	INDUSTRY	Ultragenyx Pharmaceutical Inc	Randomized	\N	Quadruple	The SAD and OL-RD cohorts will be open-label, while the DB-RD dose cohorts will be randomized, double-blind, and placebo-controlled.	\N	Treatment	\N	This study is a phase 1/2 first-in-human (FIH), study to evaluate the safety, tolerability, and pharmacokinetic (PK) of a single ascending dose (SAD) and repeat doses (RD) of UX053 in patients with GSD III. The SAD cohorts will be open-label (OL). There will be two types of RD cohorts, an open-label (OL-RD) and a randomized, double-blind (DB), and placebo-controlled (DB-RD).	2021-10-18	2024-06-01	2024-06-01	2021-08-04	\N	2022-10-24	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1","Phase 2"}	{"Glycogen Storage Disease Type III"}	pre-medication	cetirizine	Drug: H1 Blocker\nparticipants will receive oral premedication prior to infusion\nOther Name: cetirizine	f	Infusion Reaction	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	\N
27	2023-01-02 15:22:35.724	2023-03-19 22:25:31.158	NCT00542607	Trial to Compare the Efficacy and Safety of Levocetirizine 5 mg od and Fexofenadine 120 mg od in Reducing Symptoms of Seasonal Allergic Rhinitis in Grass Pollen Sensitized Adults	Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis	Completed	No information was yet available over the effect of levocetirizine in children under 12 years. The aim of this double-blind, placebo-controlled study was to assess the efficacy and safety of levocetirizine in children from 6 to 12 years old with perennial allergic rhinitis due to house dust mites.	Crossover Assignment	UCB Pharma	INDUSTRY	All	55	18	94	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2002-09-01	2002-12-01	2002-12-01	2007-10-11	\N	2013-12-12	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult}	{"Phase 4"}	{"Rhinitis, Allergic, Seasonal"}	comparison	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	levocetirizine|fexofenadine
43	2023-01-02 15:22:35.725	2023-03-20 09:28:38.077	NCT01314339	A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Healthy Subjects Under Fasting Conditions	Bioavailability Study of Dr. Reddy's Desloratadine Tablets, 5 mg Under Fasting Conditions.	Completed	The purpose of this study is to compare the rate and extent of absorption of Dr. Reddy's Desloratadine 5 mg tablet to that of Clarinex 5 mg tablet in healthy subjects under fasting conditions.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	All	45	18	28	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Fasted Normal,Healthy subjects.	2005-12-01	2005-12-01	2006-02-01	2011-03-14	\N	2012-02-20	\N	\N	\N	\N	Dr. M.S. Mohan	Dr. Reddy's Laboratories Limited	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Fasting}	main	desloratadine	\N	f	Bioavailability	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
34	2023-01-02 15:22:35.723	2023-03-19 22:29:52.276	NCT00544388	Trial to Compare the Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects Exposed to Pollen Challenge in an Environmental Exposure Unit (EEU).	Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects	Completed	Controlled conditions of the EEU allow a reliable assessment of the efficacy and a determination of the action onset, action intensity and duration of effect of levocetirizine and cetirizine in order to establish the relative efficacy of these two drugs available for the treatment of SAR.	Parallel Assignment	UCB Pharma	INDUSTRY	All	\N	16	570	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2004-04-01	2004-07-01	2004-07-01	2007-10-16	\N	2013-12-16	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Rhinitis, Allergic, Seasonal"}	main	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	levocetirizine|cetirizine
64	2023-01-02 15:22:35.725	2023-03-20 15:01:08.306	NCT01506037	Randomized, Single Dose, 2-Way Crossover, Relative Bioavailability Study of Desloratadine Orally Disintegrating Tablet Fed Conditions	Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fed Condition	Completed	This is an open label, randomised, single dose, 2-way crossover, comparative bioequivalence study.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	All	45	18	36	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Laboratories Ltd., India, desloratadine ODT 5 mg and Schering Corporation, U.S.A.(Clarinex 5 mg), desloratadine ODT 5 mg under fed conditions. The treatment phases were separated by a washout period of 14 days. 38 subjects were dosed and were enrolled in the study; 36 of these enrolled subjects completed the study.	2006-01-01	\N	2006-02-01	2012-01-09	\N	2012-01-11	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	main	desloratadine	\N	f	Bioequivalence	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
145	2023-01-02 15:22:35.73	2023-03-20 17:05:32.032	NCT03517943	A Randomized, Crossover Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet (Loratadine 5mg/Pseudoephedrine Sulfate 120 mg, Manufacturer-SAG) to a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet (Loratadine 5 mg/Pseudoephedrine Sulfate 120 mg, Manufacturer-Heist) Under Fed Conditions in Healthy Adult Subjects	A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects	Completed	To evaluate the bioequivalence of one extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer HealthCare LLC by SAG Manufacturing, S.L.U. Madrid, Spain (test treatment) to the extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer SA-NV by Schering- Plough Labo NV Heist (reference treatment) which is currently marketed in Europe.	Crossover Assignment	Bayer	INDUSTRY	All	55	18	29	Actual	INDUSTRY	Bayer	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2018-04-24	2018-08-30	2018-08-30	2018-05-08	\N	2018-09-13	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{"Clinical Pharmacology"}	main	loratadine	\N	f	Bioequivalence	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
35	2023-01-02 15:22:35.724	2023-03-20 08:41:39.33	NCT01228630	Randomized Clinical Study for Efficacy Assessment Between Cloratadd-D, Loratadine + Pseudoephedrine (Coated Pill), Produced by EMS S/A Laboratories and Allegra-D , Produced by Sanofi-Aventis for Patients With Perennial Allergic Rhinitis.	Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.	Completed	The loratadine-pseudoephedrine combination has proven to be more effective than the use of these individual components. This prospective, randomized, double-blind and paralel study, in which patients with perennial allergic rhinitis receive one of loratadine + pseudoephedrine association drug for treatment of signs and symptoms during 4 weeks.	Parallel Assignment	Azidus Brasil	INDUSTRY	All	\N	12	156	Actual	INDUSTRY	Azidus Brasil	Randomized	\N	Double	\N	\N	Treatment	\N	The effectiveness of treatment in each drug group will be evaluate by global improvement of signs (nasal mucous edema, ocular hyperemia, nasal secretion) and symptoms (itching eye, tearing,itching nose, itching on the palate) of perennial allergic rhinitis, after 4 weeks of treatment. Symptoms as rhinorrhea, nasal congestion, itching nose, sneezing and itching eye were considered as secondary efficacy endpoint, along with the questionnaire of quality of life SF-36. Safety evaluation data will include report of all adverse events (including type, frequency, instensity, seriousness, severity and action taken related to investigational product) reported by patients, parents or legal responsible, ou observed by Investigator.	2011-08-01	2012-04-01	2012-05-01	2010-10-26	\N	2016-04-11	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Perennial Allergic Rhinitis"}	combination	loratadine	compare to ctz, there was also a combination with Pseudoephedrine	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
352	2023-01-02 15:22:35.741	2023-08-01 18:29:02.346	NCT02535416	A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 at Varying Infusion Rates in Normal Adult Volunteers	A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers	Completed	Single doses of ARC-520 will be evaluated at varying infusion rates and by slow bolus push.	Single Group Assignment	Arrowhead Pharmaceuticals	INDUSTRY	All	55	18	40	Actual	INDUSTRY	Arrowhead Pharmaceuticals	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	This is a single-center, open-label, sequential cohort, single-dose study of ARC-520 administered intravenously to healthy adult volunteers. Eligible subjects will receive a single intravenous injection of ARC-520. Up to 8 cohorts (a total of approximately 40 subjects) may be enrolled. ARC-520 (4.0 mg/kg) will be administered at increasing infusion rates up to a bolus push in cohort 5. In addition dose levels at 5.0 mg/kg and 6.0 mg/kg will be evaluated at an infusion rate of 0.9 mL/min. For each subject the duration of the study clinic visits is approximately 6 weeks; maximum study duration is approximately 17 weeks including follow-up telephone calls at Days 30, 60 and 90.\n\nParticipants will undergo the following evaluations at regular intervals: medical history, physical examinations, bee venom allergy blood test, vital signs measurements, weight, adverse event monitoring, electrocardiograms (ECGs), telemetry, pregnancy test (females), concurrent medication, blood sample collection for hematology, coagulation, chemistry, pharmacokinetics, pharmacodynamics, and drug screens, and urinalysis.	2015-09-01	2016-08-01	2016-08-01	2015-08-28	2018-02-26	2018-02-26	Arrowhead Pharmaceuticals, Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	combination	cetirizine	Prev usecase was allergic rhinitis\nRepurpose?	f	Infusion Reaction	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
151	2023-01-02 15:22:35.73	2023-03-20 17:09:43.778	NCT03517930	A Randomized, Crossover Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet (Loratadine 5mg/Pseudoephedrine Sulfate 120 mg, Manufacturer-SAG) to a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet (Loratadine 5 mg/Pseudoephedrine Sulfate 120 mg, Manufacturer-Heist) Under Fasted Conditions in Healthy Adult Subjects	A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects	Completed	To evaluate the bioequivalence of one extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer HealthCare LLC by SAG Manufacturing, S.L.U. Madrid, Spain (test treatment) to the extended release combination (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer SA-NV by Schering-Plough Labo NV Heist (reference treatment) which is currently marketed in Europe.	Crossover Assignment	Bayer	INDUSTRY	All	55	18	52	Actual	INDUSTRY	Bayer	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2018-04-17	2018-07-20	2018-07-20	2018-05-08	\N	2018-09-19	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{"Clinical Pharmacology"}	main	loratadine	\N	f	Bioequivalence	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
152	2023-01-02 15:22:35.73	2023-03-20 17:10:14.383	NCT00724698	Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Tablet Among Filipino Patients	Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria	Completed	Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.	\N	Organon and Co	INDUSTRY	All	\N	12	3011	Actual	INDUSTRY	Organon and Co	\N	\N	\N	\N	Cohort	\N	Prospective	\N	2005-10-01	2007-12-01	2007-12-01	2008-07-29	2009-07-17	2022-02-09	Schering-Plough	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Child,Adult,"Older Adult"}	{}	{Rhinitis,Urticaria}	main	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{}	CT_RESULTS	\N	desloratadine
33	2023-01-02 15:22:35.724	2023-03-19 22:29:02.523	NCT00730912	Protocol for Post-approval Commitment Study of Loratadine for PPK Analysis in Japanese Pediatric and Adults Patients	Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)	Completed	This is a post marketing study to confirm the appropriate dose of loratadine in children by obtaining drug concentration data at multiple time points per child and adult patient, after the patient receives repeated administrations of the approved dose of loratadine.	Parallel Assignment	Merck Sharp & Dohme LLC	INDUSTRY	All	64	3	261	Actual	INDUSTRY	Merck Sharp & Dohme LLC	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2008-06-01	2008-12-01	2008-12-01	2008-08-08	2010-07-05	2017-04-13	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult}	{"Phase 4"}	{"Perennial Allergic Rhinitis"}	main	loratadine	\N	f	Pharmacokinetics	2022-08-17 18:44:47	{}	CT_RESULTS	\N	loratadine
103	2023-01-02 15:22:35.727	2023-02-14 20:06:43.455	NCT05421416	Loratadine for the Prevention of Bone Pain Caused by Granulocyte Colony Stimulating Factor (G-CSF) During Stem Cell Mobilization	Loratadine for the Prevention of G-CSF-related Bone Pain	Not yet recruiting	The research question for the current study is: Is loratadine more effective than placebo in preventing G-CSF-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma? The hypothesis is that prophylaxis with loratadine will help prevent or reduce the severity of bone pain in this setting.	Parallel Assignment	AHS Cancer Control Alberta	OTHER	All	\N	18	78	Anticipated	OTHER	AHS Cancer Control Alberta	Randomized	\N	Triple	\N	\N	Prevention	\N	\N	2022-11-01	2024-11-01	2025-11-01	2022-06-16	\N	2022-06-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Stem Cell Transplant Complications"}	main	loratadine	\N	t	Bone Pain	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
63	2023-01-02 15:22:35.725	2023-03-20 15:00:06.182	NCT00160537	A Monocenter, Double-blind, Randomized Trial, With Two Parallel Groups Comparing the Clinical Efficacy of Levocetirizine 5 mg Capsules and Desloratadine 5 mg Capsules Taken Once a Day Over 3 Weeks of Treatment in Adult Subjects Suffering From Seasonal Allergic Rhinitis (SAR) Due to Grass Pollen	POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)	Completed	Comparative study on clinical efficacy and safety of levocetirizine and desloratadine as measured by the subject's satisfaction/dissatisfaction after one week of treatment	Parallel Assignment	UCB Pharma	INDUSTRY	All	\N	18	200	\N	INDUSTRY	UCB Pharma	Randomized	\N	Double	\N	\N	\N	\N	\N	2005-05-01	2005-07-01	2005-07-01	2005-09-12	\N	2013-12-16	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	comparison	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine|desloratadine
156	2023-01-02 15:22:35.731	2023-03-20 17:46:53.224	NCT00637884	A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms	A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms	Completed	This is a single-center, prospective, randomized, double-blind, placebo-controlled, two-way crossover study. A live cat challenge model will be used for exposing subjects to Fel d1. Subjects who test positive for cat allergy symptoms during a priming cat exposure challenge will be eligible to enter the treatment phase of the study. Baseline efficacy measures will be obtained prior to the dispensing of study medication during both treatment periods. Cat challenges will be initiated 1.5 hours following treatment with study medication.	Crossover Assignment	Sanofi	INDUSTRY	All	\N	12	70	Actual	INDUSTRY	Sanofi	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2003-11-01	\N	2004-02-01	2008-03-18	\N	2011-01-11	\N	\N	\N	\N	Study Director	sanofi-aventis	\N	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{"Cat Induced Allergic Rhinitis"}	main	fexofenadine	cat	f	Allergy	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
94	2023-01-02 15:22:35.727	2023-03-20 16:27:05.516	NCT00637611	Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit (Study I)	Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit	Completed	The primary objective of this study is to determine the efficacy and onsets of action of single-dose fexofenadine hydrochloride 180 mg and montelukast sodium 10 mg relative to placebo. Secondary objectives are to compare the safety and efficacy of fexofenadine hydrochloride 180 mg, montelukast sodium 10 mg, and placebo	Parallel Assignment	Sanofi	INDUSTRY	All	\N	15	1010	Actual	INDUSTRY	Sanofi	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2003-02-01	\N	2003-04-01	2008-03-18	\N	2011-01-12	\N	\N	\N	\N	Study Director	sanofi-aventis	\N	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	comparison	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
356	2023-01-02 15:22:35.742	2023-03-21 09:47:04.287	NCT04762082	A Single Dose Randomized Five-Way Crossover Pharmacokinetics (PK) Study of Tadalafil Semi-Chewable (Gummy) Formulations in Healthy Volunteers	A Single Dose Randomized Five-Way Crossover Pharmacokinetics (PK) Study of Tadalafil Semi-Chewable (Gummy) Formulations in Healthy Volunteers	Not yet recruiting	This is a randomized, open-label, single-dose, five-period crossover, relative bioavailability study to evaluate tadalafil gummy 10mg and tadalafil oral tablets 10mg in healthy volunteers	Crossover Assignment	Seattle Gummy Company	INDUSTRY	Male	65	19	30	Anticipated	INDUSTRY	Seattle Gummy Company	Randomized	Eligible subjects will receive a single oral dose of one of five treatments (Treatments A, B, C, D or E) in five separate periods in a randomly assigned sequence, with each treatment separated by an approximate 5-day washout period. In each study period, dosing will occur in the morning after an overnight fast of at least 10 hours.\n\nAll doses will be administered under fasted conditions except for Treatment C, when tadalafil gummy 10 mg will be administered after consumption of a high-calorie, high-fat breakfast.\n\nAll doses will be administered with approximately 240 mL of room temperature water except for Treatment D, when tadalafil gummy 10 mg dose will be administered without water.\n\nAll doses of tadalafil gummy 10 mg will be chewed before swallowing except for Treatment E, when subjects will be instructed to swallow the dose whole.	None (Open Label)	\N	\N	Treatment	\N	This is an open-label, single dose, randomized, five-period, crossover design study to evaluate the relative bioavailability of a single oral dose of tadalafil gummy 10 mg (Test) and tadalafil oral tablets 10 mg (Reference) under fasted conditions in healthy adult male and female subjects, and the impact on the bioavailability of tadalafil gummy sugar free 10 mg when administered with food, when administered with or without water, and when chewed or swallowed whole.\n\nEach subject will receive tadalafil gummy (10 mg) or tadalafil tablet and thereby will be his/hers own control.	2023-03-01	2023-06-30	2023-09-30	2021-02-21	\N	2022-05-19	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Erectile Dysfunction"}	not included	cetirizine	Certizine not included what so ever!\nError in study description? ""maximum plasma cetirizine concentration (Cmax)	f	Erectile Dysfunction	2022-08-17 13:39:16	{}	UNKNOWN	\N	cetirizine
165	2023-01-02 15:22:35.731	2023-03-20 19:14:41.694	NCT00647985	Single-Dose Food In Vivo Bioequivalence Study of Fexofenadine Tablets (180 mg; Mylan) and Allegra Tablets (180 mg; Aventis) in Healthy Adult Volunteers	Food Study of Fexofenadine Tablets 180 mg and Allegra Tablets 180 mg	Completed	The objective of this study was to investigate the bioequivalence of Mylan's fexofenadine 180 mg tablets to Aventis' Allegra 180 mg tablets following a single, oral 180 mg (1 x 180 mg) dose administered under fed conditions.	Crossover Assignment	Mylan Pharmaceuticals Inc	INDUSTRY	All	\N	18	28	Actual	UNKNOWN	MylanPharma	Randomized	\N	None (Open Label)	\N	\N	\N	\N	\N	2003-11-01	2003-11-01	2003-11-01	2008-04-01	\N	2008-04-01	\N	\N	\N	\N	Will Sullvan, Global Head of Product Risk and Safety Management	Mylan Inc.	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{Healthy}	main	fexofenadine		f	Bioequivalence	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
360	2023-01-02 15:22:35.743	2023-03-21 09:48:46.044	NCT01390441	A Two-Part, Phase I Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of MK-8808 and to Compare the Pharmacokinetics of MK-8808 With EU-approved MabThera and US-licensed Rituxan in Patients With Rheumatoid Arthritis (RA)	A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)	Terminated	This is a study of the overall safety, tolerability, and pharmacokinetics (PK) of MK-8808 versus rituximab (MabThera and Rituxan) in participants with moderate to severe RA with an inadequate response or intolerance to methotrexate.	Parallel Assignment	Merck Sharp & Dohme LLC	INDUSTRY	All	65	18	100	Actual	INDUSTRY	Merck Sharp & Dohme LLC	Randomized	\N	Quadruple	\N	\N	Treatment	\N	In Part A of the base study, participants are randomized to either MK-8808 or MabThera. In Part B of the base study, participants are randomized to either MK-8808, MabThera, or Rituxan. Participants enrolled in Part A are not eligible to participate in Part B. In both Parts A and B, participants will receive one or two courses of therapy, with each course including two infusions of the study drugs.\n\nThe extension portion of the study (Part C) will sequentially follow the base study beginning at Week 52 and continue for an additional 54 weeks. All participants who meet eligibility criteria and continue into the study extension will be treated with open-label MK-8808. Participants randomized to MK-8808 in the base study will remain on the same therapy. Participants randomized to rituximab (MabThera or Rituxan) in the base study will be switched to MK-8808 for the extension study.	2011-07-01	2014-04-01	2014-04-01	2011-07-11	2016-07-20	2016-07-20	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	The study was terminated early by the Sponsor for business reasons.	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Rheumatoid Arthritis"}	pre-medication	loratadine	\N	f	Infusion Reaction	2022-08-17 18:44:47	{}	CT_RESULTS	\N	loratadine
361	2023-01-02 15:22:35.743	2023-03-21 09:48:53.983	NCT00606957	The Effect of Vitamin D Repletion on Insulin Resistance	The Effect of Vitamin D Repletion on Insulin Resistance	Completed	The reason for doing this study is to learn whether raising a person's vitamin D level from below normal to normal levels will improve his or her body's ability to use sugar. Vitamin D is well known to be an important vitamin for the development and maintenance of bones. Recently, scientists have learned that vitamin D may have a role in the prevention of cancer, diabetes, and autoimmune diseases. The investigators are specifically interested in studying this question in the overweight/obese population as they are at greater risk for both vitamin D deficiency and impaired ability to metabolize sugar (glucose intolerance).\n\nPrimary Hypotheses:\n\nVitamin D repletion (increasing the serum 25(OH)D level from  20 ng/ml to  30 ng/ml) will improve insulin sensitivity in individuals who are overweight/obese and insulin resistant.\n\nSecondary Hypotheses:\n\n1.Vitamin D repletion will improve biomarkers of cardiovascular risk and inflammation (directly altering macrophage cytokine production and/or indirectly as a result of improvement in insulin sensitivity.) 2.30,000 IU (0.25 mg) weekly of cholecalciferol (vitamin D3) will raise serum 25(OH)D levels from  20 ng/ml to  30 ng/ml overweight/obese population.	Single Group Assignment	Rockefeller University	OTHER	All	65	18	10	Anticipated	OTHER	Rockefeller University	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2008-01-01	2009-05-01	2009-05-01	2008-02-05	\N	2011-10-13	\N	\N	\N	\N	Allegra Grossman, MD	The Rockefeller University	\N	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{Obesity}	not included	fexofenadine	Name of responsible party is Allegra, fex is not included in study itself	f	Obesity	2022-08-18 16:54:53	{}	UNKNOWN	\N	fexofenadine
37	2023-01-02 15:22:35.724	2023-03-20 09:22:59.284	NCT00536380	A Study of the Efficacy, Safety, and Quality of Life (QOL) in Patients With Chronic Idiopathic Urticaria Dosed With AERIUS Tablets (Desloratadine 5 mg, 10 mg, or 20 mg Once Daily)	Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)	Completed	This study will investigate the effectiveness of desloratadine at doses higher (10 mg and 20 mg) than currently approved (5 mg) for the treatment of chronic idiopathic urticaria. Subjects with chronic urticaria who are currently taking a second generation antihistamine will be treated with desloratadine (5, 10, or 20 mg) for 28 days.	Parallel Assignment	Organon and Co	INDUSTRY	All	75	18	314	Actual	INDUSTRY	Organon and Co	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2007-09-01	2009-04-01	2009-04-01	2007-09-27	2010-05-03	2022-02-22	Merck, Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Chronic Idiopathic Urticaria"}	main	loratadine	\N	f	Urticaria	2022-08-17 18:44:47	{}	CT_RESULTS	\N	desloratadine
107	2023-01-02 15:22:35.728	2023-03-20 16:36:01.591	NCT00405964	Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Persistent Allergic Rhinitis (PER)	Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)	Completed	This study will investigate the effectiveness of desloratadine in treating subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis (PER)	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	12	716	Actual	INDUSTRY	Organon and Co	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2006-09-01	2008-04-01	2008-04-01	2006-12-04	2010-11-19	2022-02-15	Merck Sharp & Dohme Corp	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Allergic Rhinitis"}	main	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{"Bousquet J, Bachert C, Canonica GW, Mullol J, Van Cauwenberge P, Jensen CB, Fokkens WJ, Ring J, Keith P, Gopalan G, Lorber R, Zuberbier T; ACCEPT-2 Study Group. Efficacy of desloratadine in persistent allergic rhinitis - a GA(2)LEN study. Int Arch Allergy Immunol. 2010;153(4):395-402. doi: 10.1159/000316351. Epub 2010 Jun 18.","Bousquet J, Zuberbier T, Canonica GW, Fokkens WJ, Gopalan G, Shekar T. Randomized controlled trial of desloratadine for persistent allergic rhinitis: correlations between symptom improvement and quality of life. Allergy Asthma Proc. 2013 May-Jun;34(3):274-82. doi: 10.2500/aap.2013.34.3668."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/20559006/	desloratadine
260	2023-01-02 15:22:35.736	2023-03-20 21:18:34.465	NCT01509209	Efficacy and Safety of Cossac L Tablet in Vasomotor Rhinitis Patients : A Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial	Efficacy/Safety of Pseudoephedrine Plus Levocetirizine Versus Placebo in Patients With Vasomotor Rhinitis	Completed	The purpose of this study is to evaluate efficacy and safety of Cossac L tablet in the treatment of vasomotor rhinitis	Parallel Assignment	Hanmi Pharmaceutical Company Limited	INDUSTRY	All	75	12	137	Actual	INDUSTRY	Hanmi Pharmaceutical Company Limited	Randomized	\N	Quadruple	\N	\N	Treatment	\N	randomized, double-blind, placebo-controlled, phase 3	2011-05-01	2013-04-01	2013-04-01	2012-01-12	\N	2013-05-23	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Vasomotor Rhinitis"}	combination	levocetirizine	\N	f	Vasomotor Rhinitis	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
128	2023-01-02 15:22:35.729	2023-03-20 16:53:03.043	NCT01640535	Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial	Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients	Completed	The purpose of this study is to demonstrate that the efficacy of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride is superior to that of Levocetirizine and Montelukast monotherapies and to compare the safety and tolerability of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride to those of Levocetirizine and Montelukast monotherapies in Perennial Allergic Rhinitis (PAR) patients.	Parallel Assignment	Hanmi Pharmaceutical Company Limited	INDUSTRY	All	\N	15	283	Actual	INDUSTRY	Hanmi Pharmaceutical Company Limited	Randomized	\N	Quadruple	\N	\N	Treatment	\N	randomized, double-blind, active-controlled, multicenter, phase 3 trial	2012-06-01	2013-02-01	2013-02-01	2012-07-13	\N	2013-04-08	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Perennial Allergic Rhinitis"}	combination	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
61	2023-01-02 15:22:35.725	2023-03-20 14:57:14.595	NCT03078777	The Effect Dialysis on the Pharmacokinetics of Fexofenadine	The Effect Dialysis on the Pharmacokinetics of Fexofenadine	Unknown status	The Investigators recently completed and published a study that demonstrated that fexofenadine pharmacokinetics are significantly altered in dialysis patients (Thomson et al. (2015) American Journal of Kidney Diseases 65(4):574-582). In this study, patients were studied directly before routine dialysis treatment. Other published literature suggests the timing of the dose of some drugs (before or after dialysis) may have a profound impact on the drug pharmacokinetics (Nolin et al (2006) 17(9):2363-7). The hypothesis is that compounds that accumulate in the blood of patients with kidney failure impact the pharmacokinetics such that dosing before or after dialysis produces significantly different blood levels of the drug.	Crossover Assignment	Lawson Health Research Institute	OTHER	All	\N	18	30	Anticipated	OTHER	Lawson Health Research Institute	Randomized	\N	None (Open Label)	\N	\N	Basic Science	\N	This will be an open, randomized pharmacokinetic study in 30 patients treated by dialysis. Patients will be asked to spend an additional 3 hours at the hospital on each of two study days separated by at least a week. At the first study visit, the patient will be randomized to receive the drug fexofenadine (120 mg, orally) either 3 hour prior to, OR at the conclusion of their regularly scheduled dialysis treatment. Three hours following fexofenadine administration, a single 4 mL (approximately 1 teaspoon) blood sample will be drawn. One week or more after the first study day, the patient will have the study repeated but with the timing of the dose altered to match the randomization. For example, if at the first study visit the patient received fexofenadine after their dialysis session, they will now receive the drug 3 hours prior to their dialysis session. The blood sample will be centrifuged immediately and plasma stored at -80 celsius until analysis. Fexofenadine concentration will be determine by liquid chromatography coupled to mass spectrometry.	2017-11-29	2020-08-01	2020-08-01	2017-03-13	\N	2017-11-27	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Hemodialysis}	main	fexofenadine	This is mainly about dialysis not about fex\nIt is about the pharmacokinetics when dialysis is required	f	Pharmacokinetics	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
90	2023-01-02 15:22:35.726	2023-03-20 16:24:26.957	NCT00628108	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With Symptoms of Allergic Rhinitis or Chronic Urticaria.	Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months	Completed	To determine the safety of levocetirizine in children ages 6-11 months with symptoms of allergic rhinitis or chronic idiopathic urticaria.	Parallel Assignment	UCB Pharma	INDUSTRY	All	0.9166666666666666	0.5	69	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2008-03-01	2008-09-01	2008-09-01	2008-03-04	2009-10-14	2015-03-06	UCB	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Allergic Rhinitis","Chronic Urticaria"}	main	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{"Hampel F, Ratner P, Haeusler JM. Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Allergy Asthma Proc. 2010 Jul-Aug;31(4):290-5. doi: 10.2500/aap.2010.31.3349."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/20819318/	levocetirizine
46	2023-01-02 15:22:35.721	2023-07-31 19:14:11.261	NCT00783146	A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR)	Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)	Completed	This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (fexofenadine) and a placebo control to evaluate desloratadine 5 mg once daily during a 15-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	12	728	Actual	INDUSTRY	Organon and Co	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2004-08-01	2004-10-01	2004-10-01	2008-10-31	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	comparison	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{"Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc. 2006 May-Jun;27(3):214-23. doi: 10.2500/aap.2006.27.2851."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/16913264/	desloratadine|fexofenadine
48	2023-01-02 15:22:35.721	2023-03-20 09:33:31.051	NCT00789152	The Effects of Desloratadine and Levocetirizine on Nasal Obstruction in Subjects With Induced Allergic Rhinitis in the VCC Assessed Clinically and With Nasal Rhinomanometry and Nasal Flowmetry	The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)	Completed	This was a study to measure the ability of desloratadine and levocetirizine to decrease nasal obstruction in subjects who had study-induced allergic rhinitis. Study participants had allergic rhinitis symptoms induced in a Vienna Challenge Chamber and then received desloratadine or levocetirizine for 8 days. After at least a 10 to 35-day washout period (time when no drug is given), subjects received the opposite treatment for 8 days. Subjects had their total nasal symptom measured.on the 8th day of each treatment period.	Crossover Assignment	Organon and Co	INDUSTRY	All	45	18	81	Actual	INDUSTRY	Organon and Co	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2003-12-01	2004-05-01	2004-05-01	2008-11-11	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 3"}	{"Allergic Rhinitis"}	combination	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	desloratadine|levocetirizine
45	2023-01-02 15:22:35.722	2023-03-20 09:29:35.227	NCT00375713	A Multi-centre, Double-blind, Double-dummy, Randomized, Active-controlled Phase III Study to Evaluate the Efficacy and Safety of Xyzal 5mg od vs Zyrtec 10mg od in Subjects Aged 15 Years and Above With Dermatitis and Eczema	Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal (Levocetirizine) vs Zyrtec (Cetirizine) in Subjects With Dermatitis and Eczema	Completed	Korean double-blind non-inferiority study to asses the efficacy (as measured by the responder rate of pruritus severity score by the patient at visit 4 or end-of-treatment visit over the 2 weeks treatment period) and safety of Xyzal to Zyrtec in subjects suffering from dermatitis and eczema with pruritus symptoms	Parallel Assignment	UCB Pharma	INDUSTRY	All	\N	15	466	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2005-10-01	2006-05-01	2006-05-01	2006-09-13	2009-10-14	2011-08-31	UCB Pharma	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{Dermatitis,Eczema}	comparison	cetirizine	\N	f	Dermatitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	levocetirizine|cetirizine
47	2023-01-02 15:22:35.722	2023-03-20 09:32:05.357	NCT00794846	Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis	Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)	Completed	This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex or Zyrtec. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.	Crossover Assignment	Organon and Co	INDUSTRY	All	\N	18	124	Actual	INDUSTRY	Organon and Co	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2002-12-01	2003-05-01	2003-05-01	2008-11-20	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis","Perennial Allergic Rhinitis"}	comparison	cetirizine	\N	f	Taste, Form, Preference	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	desloratadine|cetirizine
49	2023-01-02 15:22:35.721	2023-03-20 09:39:07.775	NCT00783211	A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR)	Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)	Completed	This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (fexofenadine) and a placebo control to evaluate desloratadine 5 mg once daily during a 15-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	12	722	Actual	INDUSTRY	Organon and Co	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2004-08-01	2004-10-01	2004-10-01	2008-10-31	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	comparison	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	desloratadine|fexofenadine
167	2023-01-02 15:22:35.727	2023-03-20 19:15:10.332	NCT04071821	A Randomized, Open-Label, Single-Dose, Five-Period Crossover, Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg Administered in Healthy Adult Male and Female Subjects	Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg	Not yet recruiting	A Randomized, Open-Label, Single-Dose, Five-Period Crossover, Relative Bioavailability Study to Evaluate Cetirizine HCl Gummy 10 mg and Cetirizine HCl Oral Tablets 10 mg Administered in Healthy Adult Male and Female Subjects	Crossover Assignment	Seattle Gummy Company	INDUSTRY	All	55	18	30	Anticipated	INDUSTRY	Seattle Gummy Company	Randomized	Randomized, Open-Label, Single-Dose, Five-Period Crossover	None (Open Label)	\N	\N	Other	\N	Primary:\n\n To determine the relative bioavailability of a single oral dose of cetirizine HCl Gummy 10 mg and cetirizine HCl oral tablets 10 mg administered under fasted conditions in healthy adult male and female subjects.\n\nSecondary:\n\nTo determine the relative bioavailability of a single oral dose of cetirizine HCl Gummy 10 mg administered under fasted and fed conditions in healthy adult male and female subjects;\nTo determine the relative bioavailability of a single oral dose of cetirizine HCl Gummy 10 mg administered under fasted conditions with and without water in healthy adult male and female subjects;\nTo determine the relative bioavailability of a single oral dose of cetirizine HCl Gummy 10 mg administered under fasted conditions and chewed or swallowed whole in healthy adult male and female subjects.	2022-09-01	2022-12-15	2023-04-30	2019-08-28	\N	2022-05-19	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Allergy}	main	cetirizine	\N	f	Bioavailability	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
54	2023-01-02 15:22:35.721	2023-03-20 14:44:58.006	NCT00794768	Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis	Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178)	Completed	This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex or Allegra. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.	Crossover Assignment	Organon and Co	INDUSTRY	All	\N	18	118	Actual	INDUSTRY	Organon and Co	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2002-11-01	2003-07-01	2003-07-01	2008-11-20	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	comparison	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	desloratadine|fexofenadine
50	2023-01-02 15:22:35.722	2023-03-20 09:40:13.566	NCT00636870	A Randomized, Double-blind, Repeat-dose, Crossover Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Desloratadine (Clarinex) Compared to Fexofenadine (Allegra) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine.	Fexofenadine (Allegra) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine	Completed	To evaluate the single-dose and steady-state pharmacokinetics of desloratadine and fexofenadine in desloratadine slow metabolizers. To evaluate the safety and tolerability of desloratadine compared to fexofenadine following single and multiple oral doses administered to desloratadine slow metabolizers.	Crossover Assignment	Sanofi	INDUSTRY	All	55	18	220	Actual	INDUSTRY	Sanofi	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2003-02-01	\N	2004-01-01	2008-03-17	\N	2011-01-11	\N	\N	\N	\N	Study Director	sanofi-aventis	\N	\N	Interventional	{Adult}	{"Phase 4"}	{"Allergic Rhinitis"}	comparison	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
69	2023-01-02 15:22:35.725	2023-03-20 15:04:35.129	NCT05214911	Multicenter, Randomized, Parallel, Double-blind, Comparative Study of the Superiority of the FDC of Desloratadine 0.5 mg/mL and Prednisolone 4 mg/mL Versus Desloratadine 0.5 mg/mL in the Treat. of Persistent Allergic Rhinitis in Children	Fixed Dose Combination of DESloratadine / PREDnisolone in the Treat. of Moderate - Severe Allergic Rhinitis in Children	Not yet recruiting	Multicenter, randomized, parallel-group, double-blind, comparative clinical trial of the superiority of the fixed-dose combination of desloratadine 0.5 mg/mL and prednisolone 4 mg/mL from Eurofarma Laboratrios SA versus desloratadine 0.5 mg/mL (Leg) in the treatment of moderate to severe persistent allergic rhinitis in children aged 6 to 12 years.\n\nStudy will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).	Parallel Assignment	Eurofarma Laboratorios S.A.	INDUSTRY	All	12	6	248	Anticipated	INDUSTRY	Eurofarma Laboratorios S.A.	Randomized	\N	Double	Double-blind	\N	Treatment	\N	Desloratadine and prednisolone are active pharmaceutical ingredients (APIs) already registered in the country as monodrugs. These products are widely used and their efficacy and safety are well known in daily clinical practice in the approved indications.\n\nOnce confirmed the absence of pharmacokinetic interaction between desloratadine and prednisolone in relative bioavailability studies, this phase 3 study will be conducted with the objective of demonstrating the superiority of the new FDC containing desloratadine and prednisolone over the isolated administration of desloratadine in treatment from moderate to severe allergic rhinitis in children. The aim is to provide a new effective, safe and well-tolerated therapeutic option for dealing with these cases.\n\nMulticenter, randomized, parallel group, double blind, superiority comparative clinical trial.\n\nChildren aged  6 years and < 12 years with moderate to severe persistent allergic rhinitis unresponsive to optimal treatment, including daily use of intranasal corticosteroids, will be randomized in a 1:1 ratio to receive FDC desloratadine 0.5mg/mL/prednisolone 4mg/mL - gel for oral administration by Eurofarma Laboratrios SA (experimental drug) or desloratadine 0.5mg/mL - syrup (Leg - Eurofarma Laboratrios SA), for five (05) days.\n\nStudy will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).	2023-10-01	2024-10-01	2025-04-01	2022-01-31	\N	2022-12-02	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Allergic Rhinitis"}	combination	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	desloratadine
79	2023-01-02 15:22:35.726	2023-03-20 16:15:27.673	NCT00776022	An Open Label, Randomized, Single-center, Single-dose, Two-treatment, Two-period, Crossover Bioavailability Study Comparing Cetirizine Hydrochloride 10 mg Tablet of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy, Inc) With Zyrtec Cetirizine Hydrochloride, 10 mg Tablet of Pfizer Labs (Division of Pfizer Inc.) in Healthy, Adult, Human Subjects Under Fed Condition	Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions	Completed	An open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability study comparing Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) with Zyrtec Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs (Division of Pfizer Inc.) in healthy, adult, human subjects under fed condition	Crossover Assignment	Ranbaxy Laboratories Limited	INDUSTRY	\N	50	18	32	Actual	INDUSTRY	Ranbaxy Inc.	Randomized	\N	None (Open Label)	\N	\N	\N	\N	The study was conducted as an open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability of the test formulation of cetirizine hydrochloride tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) containing 10 mg cetirizine hydrochloride study comparing to the marketed product, Zyrtec, containing 10 mg of cetirizine hydrochloride of Pfizer Labs (Division of Pfizer Inc.), in healthy, adult, human, subjects under fed condition.\n\nSafety measures were performed throughout the study and included a physical examination, laboratory evaluation, and measurement of vital signs.\n\nA total of 32 subjects were randomized to receive single oral dose of cetirizine hydrochloride 10 mg tablet and 29 subjects completed both the periods of the study.	2005-04-01	2005-04-01	2005-06-01	2008-10-20	\N	2010-03-02	\N	\N	\N	\N	Dr. Tausif Monif	Ranbaxy Laboratories Limited	\N	\N	Interventional	{Adult}	{"Not Applicable"}	{Healthy}	main	cetirizine		f	Bioequivalence	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
58	2023-01-02 15:22:35.725	2023-03-20 14:51:38.53	NCT00863902	Single Dose Two-Way Crossover Fed Bioequivalence Study of Cetirizine Hydrochloride 10 mg Tablets in Healthy Volunteers	A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fasting Conditions	Completed	To determine the pharmacokinetics and bioequivalence of cetirizine hydrochloride formulations after administration of single doses to normal healthy subjects under fed conditions. These data were to be evaluated statistically to determine if the products meet bioequivalence criteria.	Crossover Assignment	Actavis Inc.	INDUSTRY	All	\N	18	26	Actual	INDUSTRY	Actavis Inc.	Randomized	\N	None (Open Label)	\N	\N	\N	\N	Study Type: Interventional Study Design: Single-dose two-way, crossover bioequivalence study with an adequate washout period (7 days) between the two periods of the study and with an equal number of subjects randomly assigned to receive the study test (Treatment A) and study reference (Treatment B).\n\nOfficial Title: Single Dose Two-Way Crossover Fed Bioequivalence Study of Cetirizine Hydrochloride 10 mg Tablets in Healthy Volunteers\n\nFurther study details as provided by Actavis Elizabeth LLC:\n\nPrimary Outcome Measures:\n\nRate and Extend of Absorption	2006-08-01	2006-09-01	2006-09-01	2009-03-18	\N	2010-08-16	\N	\N	\N	\N	Meena Venugopal, Director, Clinical R&D	Actavis Inc	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{Healthy}	main	cetirizine	\N	f	Bioavailability	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
60	2023-01-02 15:22:35.722	2023-03-20 14:53:11.091	NCT00794495	Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis	Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)	Completed	This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex or Zyrtec. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.	Crossover Assignment	Organon and Co	INDUSTRY	All	\N	18	122	Actual	INDUSTRY	Organon and Co	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2002-12-01	2003-07-01	2003-07-01	2008-11-20	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis","Perennial Allergic Rhinitis"}	comparison	cetirizine	\N	f	Taste, Form, Preference	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	desloratadine|cetirizine
59	2023-01-02 15:22:35.722	2023-03-20 14:52:36.426	NCT01469234	A Double-Blind, Parallel, Randomized, Placebo Controlled Trial to Evaluate Onset of Action of Loratadine and Fexofenadine in Subjects With Seasonal Allergic Rhinitis in a Pollen Challenge Chamber	A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)	Completed	The purpose of this study is to determine the onset of action of two commercially available over-the-counter antihistamines (Loratadine and\n\nFexofenadine) in a model of seasonal allergic rhinitis (SAR). Participants undergo sensitization exposures to Mountain Cedar (juniperus ashei) pollen in a Biogenics Research Chamber; those who demonstrate an adequate allergic response determined by the Major Symptom Complex (MSC) score will then receive drug.	Parallel Assignment	Bayer	INDUSTRY	All	\N	18	255	Actual	INDUSTRY	Bayer	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2011-10-01	2011-11-01	2011-11-01	2011-11-10	2013-03-22	2015-03-11	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Rhinitis}	comparison	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	CT_RESULTS	\N	loratadine|fexofenadine
168	2023-01-02 15:22:35.731	2023-03-20 19:21:55.834	NCT02132169	A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)	A Multi-Center Study Evaluating the Safety of AC-170 0.24%	Completed	The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).	Parallel Assignment	Aciex Therapeutics, Inc.	INDUSTRY	All	\N	2	512	Actual	INDUSTRY	Aciex Therapeutics, Inc.	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2014-05-01	2014-10-01	2014-10-01	2014-05-07	2017-07-26	2017-09-11	Nicox Ophthalmics Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Atopic Disease (Including Allergic Conjunctivitis)"}	main	cetirizine	\N	f	Safety Evaluation	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
176	2023-01-02 15:22:35.732	2023-03-20 19:27:55.904	NCT00488176	Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation Measured by Exhaled Nitric Oxide Concentration in Children With Seasonal Allergic Rhinitis	Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis	Unknown status	The aim of this study is to compare the effect of montelukast and cetirizine on allergic inflammation measured by exhaled nitric oxide concentration in children with seasonal allergic rhinitis.	Parallel Assignment	Medical University of Lodz	OTHER	All	18	6	116	Anticipated	OTHER	Medical University of Lodz	Randomized	\N	Triple	\N	\N	Treatment	\N	During the pollen season children with seasonal allergic rhinitis without concomitant asthma are at risk of having allergic inflammation in the lower respiratory tract. About 60% of children with seasonal allergic rhinitis present bronchial hyperresponsiveness and signs and symptoms of asthma.\n\nThe aim of this study is to compare the effect of montelukast and cetirizine on allergic inflammation measured by exhaled nitric oxide concentration in children with seasonal allergic rhinitis.	2007-04-01	2013-11-01	2013-12-01	2007-06-20	\N	2013-02-07	\N	Medical University of Lodz	Iwona Stelmach	MD, PhD, Professor	\N	\N	Principal Investigator	\N	Interventional	{Child,Adult}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	comparison	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
183	2023-01-02 15:22:35.732	2023-03-20 19:33:14.691	NCT00679250	A Placebo Controlled Trial to Evaluate The Effects of Levocetirizine on Nasal Allergen Challenge And Adenosine Monophosphate Challenge In Patients With Intermittent and Persistent Allergic Rhinitis	To Evaluate Adenosine Monophosphate and Allergen Challenge in Allergic Rhinitis	Completed	Allergic rhinitis is a common condition characterize by inflammation of the upper airways. Third generation antihistamines have been demonstrated effective in the treatment of this condition. Allergen challenge can be use to assess the effects of drugs in allergic rhinitis, adenosine monophosphate may also be used as a means to investigate these effects but as yet its effects have yet to be compared to allergen challenge. We intend to compare the effects of levocetirizine at a single dose of 5mg on allergen and AMP challenge compared to placebo in a double blind cross-over study. The study will include 20 patients with allergic rhinitis. Each patient will have allergen and AMP challenge on placebo and active treatment. The primary outcome variable will be the change in concentration of AMP/Allergen required to produce a 20% drop in nasal flow as manifest by peak nasal inspiratory flow. A 1 doubling dose change in concentration of challenge medium to cause a 20% drop in nasal flow will be deemed significant. We will also measure time to recovery after both challenges. AMP challenge is a safe alternative to allergen challenge and does not have the risk of anaphylaxis.	Crossover Assignment	Brian J Lipworth	OTHER	All	75	16	25	Actual	OTHER	University of Dundee	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2005-11-01	2006-12-01	2006-12-01	2008-05-16	\N	2019-04-12	\N	University of Dundee	Brian J Lipworth	Professor (Clinical) Airway allergy and COPD	\N	\N	Sponsor-Investigator	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{"Allergic Rhinitis"}	main	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol. 2003 Jun;111(6):1171-83; quiz 1184. doi: 10.1067/mai.2003.1592.","Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001 Nov;108(5 Suppl):S147-334. doi: 10.1067/mai.2001.118891. No abstract available.","Clough GF, Boutsiouki P, Church MK. Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy. 2001 Oct;56(10):985-8. doi: 10.1034/j.1398-9995.2001.00204.x.","Wang DY, Hanotte F, De Vos C, Clement P. Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy. 2001 Apr;56(4):339-43. doi: 10.1034/j.1398-9995.2001.00775.x.","Lee DK, Gray RD, Wilson AM, Robb FM, Soutar PC, Lipworth BJ. Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. Br J Clin Pharmacol. 2004 Jul;58(1):34-9. doi: 10.1111/j.1365-2125.2004.02110.x.","Terada N, Hamano N, Kim WJ, Hirai K, Nakajima T, Yamada H, Kawasaki H, Yamashita T, Kishi H, Nomura T, Numata T, Yoshie O, Konno A. The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. Am J Respir Crit Care Med. 2001 Aug 15;164(4):575-9. doi: 10.1164/ajrccm.164.4.2009046.","Wilson AM, Sims EJ, Orr LC, Robb F, Lipworth BJ. An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge. Br J Clin Pharmacol. 2003 Apr;55(4):354-9. doi: 10.1046/j.1365-2125.2003.01776.x.","Vaidyanathan S, Nair A, Barnes ML, Meldrum K, Lipworth BJ. Effect of levocetirizine on nasal provocation testing with adenosine monophosphate compared with allergen challenge in allergic rhinitis. Clin Exp Allergy. 2009 Mar;39(3):409-16. doi: 10.1111/j.1365-2222.2008.03166.x."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19187327/	levocetirizine
131	2023-01-02 15:22:35.729	2023-03-20 16:57:19.214	NCT00315523	Double-blind, 3 Parallel Randomized Groups, Therapeutic Confirmatory. Clinical Trial to Compare the Efficacy of Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing SAR Symptoms in Ragweed Sensitive Subjects in an EEC.	Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen	Completed	To compare the clinical efficacy of levocetirizine 5 mg and montelukast 10 mg, administered once daily during two consecutive days, on symptoms of seasonal allergic rhinitis occurring in subjects exposed to ragweed pollen in an environmental exposure unit.	Parallel Assignment	UCB Pharma	INDUSTRY	All	\N	18	403	\N	INDUSTRY	UCB Pharma	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2006-07-01	2006-10-01	2006-10-01	2006-04-18	\N	2013-12-16	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Rhinitis, Allergic, Seasonal"}	comparison	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{"Patel P, Patel D. Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients. Ann Allergy Asthma Immunol. 2008 Sep;101(3):287-94. doi: 10.1016/S1081-1206(10)60494-2."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/18387222/	levocetirizine
143	2023-01-02 15:22:35.73	2023-03-20 17:03:56.238	NCT00521131	Evaluation of Efficacy, Using the Number of Comfortable Days and the Safety of Levocetirizine Dihydrochloride, Administered Once Daily in the Evening for 30 Days, to Subjects Suffering From Perennial Allergic Rhinitis to House Dust Mites	Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites	Completed	Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites	Parallel Assignment	UCB Pharma	INDUSTRY	All	\N	12	453	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2002-09-01	2003-05-01	2003-05-01	2007-08-27	\N	2013-12-16	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{Rhinitis,Allergic,Perennial}	main	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
68	2023-01-02 15:22:35.725	2023-03-20 15:03:49.699	NCT00817076	Evaluation of the Efficacy and Safety of Desloratadine Syrup in Childhood Atopic Dermatitis	Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Allergic Skin Inflammation (P03475)	Completed	The purpose of this study was to test the effectiveness and safety of desloratadine (Aerius) syrup in children with allergic skin inflammation. Patients took desloratadine syrup once a day for 28 days. Once a week, the doctor measured the patient's symptoms. This measurement is called SCORAD. The doctor also rated how much relief the patient got from treatment and recorded any side effects.	Single Group Assignment	Organon and Co	INDUSTRY	All	12	6	40	Actual	INDUSTRY	Organon and Co	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2003-03-01	2003-07-01	2003-07-01	2009-01-06	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Dermatitis, Atopic"}	main	desloratadine	\N	f	Dermatitis	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
363	2023-01-02 15:22:35.743	2023-03-21 09:50:31.666	NCT02873364	High Dose Vitamin D Supplementation in Treatment of Chronic Spontaneous Urticaria	High Dose Vitamin D Supplementation in Chronic Spontaneous Urticaria	Unknown status	Chronic spontaneous urticaria is an inflammatory disease which is characterized with intermittent or daily urticaria. This diseases lasts for more than 6 weeks. Several recent studies have suggested a role for vitamin D in modulation of immune system and pathogenesis of chronic urticaria.	Parallel Assignment	Shiraz University of Medical Sciences	OTHER	All	\N	20	80	Anticipated	OTHER	Shiraz University of Medical Sciences	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2016-08-01	2016-12-01	2017-01-01	2016-08-19	\N	2016-08-19	\N	Shiraz University of Medical Sciences	Keramatallah Jahanshahi	Resident of internal medicine	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{Urticaria}	combination	cetirizine	https://pubmed.ncbi.nlm.nih.gov/32345077/ ???	f	Urticaria	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
187	2023-01-02 15:22:35.733	2023-03-20 19:37:33.057	NCT01916967	A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria.	An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)	Completed	This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with chronic urticaria. The primary hypothesis is that the efficacy of desloratadine 10 mg and 5 mg is superior to placebo as based on the change from Baseline in the sum score of pruritus/itch and rash as assessed by the Investigator at Week 2.	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	12	239	Actual	INDUSTRY	Organon and Co	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2013-08-27	2014-02-28	2014-03-13	2013-08-06	2014-10-30	2022-02-09	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{Urticaria}	main	desloratadine	\N	f	Urticaria	2022-09-15 19:16:20	{"Hide M, Maeda Y, Oshima N, Hisada S. A Phase III clinical trial of desloratadine in Japanese subjects with chronic urticaria: A randomized controlled trial. J Clin Therapeut Med. 2016;32(11):891-903.. [in Japanese] https://mol.medicalonline.jp/archive/search?jo=an9cltmd&ye=2016&vo=32&issue=11"}	PUBLISHED	https://mol.medicalonline.jp/archive/search?jo=an9cltmd&ye=2016&vo=32&issue=11	desloratadine
149	2023-01-02 15:22:35.73	2023-03-20 17:08:59.806	NCT02904304	National Clinical Trial,Phase III, Multicenter, Randomized, Prospective, Double-blind, Parallel, Placebo-controlled, to Evaluate the Efficacy, Safety and Superiority of Decongex Gripe in the Treatment of Symptoms Associated With Common Cold	Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu	Suspended	National clinical trial, phase III, multicenter, randomized, prospective, double-blind, parallel, placebo-controlled, which one hundred and fifty (150) subjects of both sexes aged equal or more than 18 years will be randomly allocated to one the drug group or placebo group.	Parallel Assignment	Ache Laboratorios Farmaceuticos S.A.	INDUSTRY	All	65	18	150	Anticipated	INDUSTRY	Ache Laboratorios Farmaceuticos S.A.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	The investigational product is a combination of desloratadine, phenylephrine hydrochloride and ibuprofen.\n\nThe desloratadine is a antihistamine and selectively block the activity of histamine receptor-1 (H1) resulting in a non sedative and prolong antiallergic effect.\n\nThe phenylephrine is a potent stimulator of the postsynaptic  receptor with minimal effect on  receptors in the heart.\n\nThe ibuprofen's mechanism is not fully known. It is a non selective inhibitor of cyclooxygenase, an enzyme that is involved in prostaglandin synthesis by the route from arachidonic acid. It is believed that the pharmacological effects are due to inhibition of cyclooxygenase-2 (COX-2), which reduces prostaglandin synthesis involved in the mediation of inflammation, pain, fever and swelling.	2020-12-01	2021-07-01	2021-09-01	2016-09-16	\N	2019-07-08	\N	\N	\N	\N	\N	\N	Sponsor	the viability of the study is being analyzed	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{Cold}	combination	desloratadine	\N	f	Cold	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
185	2023-01-02 15:22:35.732	2023-03-20 19:37:09.611	NCT00044811	A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120mg BID in Subjects With Mild to Moderate Persistent Asthma	Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma	Completed	The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma	Parallel Assignment	Sanofi	INDUSTRY	All	80	12	1000	Anticipated	INDUSTRY	Sanofi	Randomized	\N	Double	\N	\N	Treatment	\N	The incidence of respiratory allergy in the US has increased gradually over the past several years, and current estimates suggest that allergic rhinitis and bronchial asthma affect approximately 20% and 5% of the population, respectively. Rhinitis and asthma frequently coexist, and large-scale population surveys indicate that up to 38% of subjects with rhinitis have asthma, and up to 78% of subjects with asthma have chronic nasal symptoms. Safety concerns with the increased use of inhaled corticosteroids, the heterogeneity of the disease, and poor compliance with asthma medication regimens, point to the need for the development of safe and convenient oral therapies for asthma. Histamine is an important chemical mediator of inflammation in asthma. The benefits of antihistamine treatment in patients with mild to moderate asthma have been well documented, however their clinical use has been previously limited due to the high doses required for efficacy and their associated side effects including sedation and cognitive impairment.	2002-03-01	2003-10-01	2003-10-01	2002-09-17	\N	2008-08-21	\N	\N	\N	\N	ICD Study Director	sanofi-aventis	\N	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{Asthma}	main	fexofenadine	Repurpose? New	t	Asthma	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
104	2023-01-02 15:22:35.727	2023-03-20 16:33:39.544	NCT00152464	The Early Prevention of Asthma in Atopic Children (EPAAC) Study. A Multi-country, Double Blind, Placebo (PLC) Controlled, Randomized, Parallel Group Trial: Evaluation of the Efficacy and Safety of Levocetirizine (LCTZ) (5 mg/ml Oral Drops -0.125 mg/kg b.w. b.i.d.) Administered for 18 Months in Preventing the Onset of Asthma in 12 to 24 Months Old Children Who Suffer From Atopic Dermatitis and Are Sensitized to Grass Pollen and / or House Dust Mite Allergens.	Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)	Completed	The Early Prevention of Asthma in Atopic Children (EPAAC). 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.	Parallel Assignment	UCB Pharma SA	INDUSTRY	All	2	1	514	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2002-03-20	2006-03-15	2006-03-15	2005-09-09	2019-01-22	2019-01-22	Cares	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Dermatitis, Atopic"}	main	levocetirizine	Asthma or Dermatitis?	f	Asthma	2022-09-15 18:58:14	{}	CT_RESULTS	\N	levocetirizine
188	2023-01-02 15:22:35.732	2023-03-20 19:38:38.567	NCT00881127	A Single-Dose Comparative Bioavailability Study of Two Formulations of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release Tablets Under Fasting Conditions	To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions	Completed	To demonstrate the relative bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg ER tablets under fasting conditions.	Crossover Assignment	Sandoz	INDUSTRY	All	54	24	40	Actual	INDUSTRY	Sandoz	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2005-07-01	2005-07-01	2005-07-01	2009-04-15	\N	2017-03-28	\N	\N	\N	\N	Eric Mittleberg, Ph.D, VP of Product Development	Sandoz Inc.	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Allergies}	combination	cetirizine	\N	f	Bioavailability	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
150	2023-01-02 15:22:35.73	2023-03-20 17:09:26.623	NCT01444196	Multi-center, Double Blind, Dose Escalating Study to Compare the Effects of 5 mg, 10mg and 20mg of Desloratadine in Patients With Acquired Cold Urticaria (ACU)	Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria	Completed	The primary objective of the study is to assess the dosis of DL which is sufficient to inhibit cold urticaria symptoms.	Parallel Assignment	Marcus Maurer	OTHER	All	75	18	30	Actual	OTHER	Charite University, Berlin, Germany	Randomized	\N	Quadruple	\N	\N	Treatment	\N	A total of 30 patients (male and female) with ACU will be included in this study	2009-08-01	2010-04-01	2010-05-01	2011-09-30	\N	2011-10-03	\N	Charite University, Berlin, Germany	Marcus Maurer	Head of Research Dept. of Dermatology	\N	\N	Sponsor-Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Urticaria}	main	desloratadine	\N	f	Urticaria	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
125	2023-01-02 15:22:35.729	2023-03-20 16:52:19.967	NCT02646020	Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial	Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment	Completed	Study hypothesis is that aprepitant is more effective than desloratadine in relieving pruritus caused by EGFR TKIs. Primary endpoint is the effective rate of pruritus, effective treatment defined as visual analogue scale (VAS) decrease  50% after treatment compared to baseline score. 130 NSCLC patients undertaken EGFR-TKI and suffer from moderate or severe pruritus (VAS score  4) will be enrolled in this study, and stratified (gender, VAS 4-6 or 7-10, and 2nd generation TKI or non 2nd generation) randomized (1:1) into aprepitant or desloratadine treatment. VAS investigation will be taken once a week to treatment end (4 weeks).	Parallel Assignment	Sun Yat-sen University	OTHER	All	\N	18	138	Actual	OTHER	Sun Yat-sen University	Randomized	\N	Triple	\N	\N	Treatment	\N	This is a prospective, randomized control, double-blinded, phase II clinical trial. Study hypothesis is that aprepitant is more effective than desloratadine in relieving pruritus caused by EGFR TKIs. Primary endpoint is the effective rate of pruritus, effective treatment defined as visual analogue scale (VAS) decrease  50% after treatment (1 week) compared to baseline score. The VAS inquiry will be taken once a week for 4 weeks. Quality of life investigation will be performed at baseline, 1 week and 4 weeks after treatment using SKINDEX-16 questionnaire. 130 NSCLC patients undertaken EGFR-TKI and suffer from moderate or severe pruritus (VAS score  4) will be enrolled in this study, and stratified (gender,and VAS 4-6 or 7-10, and 2nd generation TKI or non 2nd generation) randomized (1:1) into aprepitant or desloratadine treatment. Aprepitant arm will be administrated aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28; desloratadine arm will be administrated placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28. Tolerance evaluation will be taken according to National Cancer Institute (NCI)-Common Terminology Criteria (CTC) For Adverse Events (AE) V4.03.	2015-12-01	2020-10-01	2020-12-01	2016-01-05	\N	2021-05-18	\N	Sun Yat-sen University	Li Zhang, MD	M.D. Professor	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Non-small Cell Lung Cancer"}	comparison	loratadine	\N	f	Pruritus	2022-08-17 18:44:47	{"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.","Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.","Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32. doi: 10.1056/NEJMoa050753.","Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.","Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; INFORM investigators. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012 May;13(5):466-75. doi: 10.1016/S1470-2045(12)70117-1. Epub 2012 Apr 17.","Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007 May;12(5):610-21. doi: 10.1634/theoncologist.12-5-610.","Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA; MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011 Aug;19(8):1079-95. doi: 10.1007/s00520-011-1197-6. Epub 2011 Jun 1.","Chan A, Tan EH. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer. 2011 Oct;19(10):1667-74. doi: 10.1007/s00520-010-0999-2. Epub 2010 Sep 5.","Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol. 2010 Apr;24(4):453-9. doi: 10.1111/j.1468-3083.2009.03446.x. Epub 2009 Sep 27.","Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007 Dec 1;25(34):5390-6. doi: 10.1200/JCO.2007.12.6987.","Porzio G, Aielli F, Verna L, Porto C, Tudini M, Cannita K, Ficorella C. Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage. 2006 Nov;32(5):397-8. doi: 10.1016/j.jpainsymman.2006.07.006. No abstract available.","Stander S, Siepmann D, Herrgott I, Sunderkotter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010 Jun 4;5(6):e10968. doi: 10.1371/journal.pone.0010968.","Stander S, Weisshaar E. Medical treatment of pruritus. Expert Opin Emerg Drugs. 2012 Sep;17(3):335-45. doi: 10.1517/14728214.2012.711316. Epub 2012 Aug 7.","Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007 Jun;156(6):1272-7. doi: 10.1111/j.1365-2133.2007.07935.x.","Quartara L, Altamura M. Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets. 2006 Aug;7(8):975-92. doi: 10.2174/138945006778019381.","Booken N, Heck M, Nicolay JP, Klemke CD, Goerdt S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011 Mar;164(3):665-7. doi: 10.1111/j.1365-2133.2010.10108.x. Epub 2011 Jan 28. No abstract available.","Vincenzi B, Fratto ME, Santini D, Tonini G. Aprepitant against pruritus in patients with solid tumours. Support Care Cancer. 2010 Sep;18(9):1229-30. doi: 10.1007/s00520-010-0895-9. Epub 2010 Jun 11. No abstract available.","Jimenez Gallo D, Albarran Planelles C, Linares Barrios M, Fernandez Anguita MJ, Marquez Enriquez J, Rodriguez Mateos ME. Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant. Dermatol Ther. 2014 May-Jun;27(3):178-82. doi: 10.1111/dth.12113. Epub 2013 Dec 2.","Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012 Oct;13(10):1020-4. doi: 10.1016/S1470-2045(12)70373-X. Epub 2012 Sep 18.","Marquez D, Ramonda C, Lauxmann JE, Romero CA, Vukelic VL, Martinatto C, Barron B, Novoa PA, Peixoto AJ, Orias M. Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin. J Bras Nefrol. 2012 Jun;34(2):148-52. doi: 10.1590/s0101-28002012000200007.","Bachert C, Maurer M. Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin Drug Investig. 2010;30(2):109-22. doi: 10.2165/11530930-000000000-00000.","Grob JJ, Auquier P, Dreyfus I, Ortonne JP. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. J Eur Acad Dermatol Venereol. 2008 Jan;22(1):87-93. doi: 10.1111/j.1468-3083.2007.02385.x.","Ortonne JP, Grob JJ, Auquier P, Dreyfus I. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol. 2007;8(1):37-42. doi: 10.2165/00128071-200708010-00005.","Zhou T, Zhang Y, Ma Y, Ma W, Wu X, Huang L, Feng W, Zhou H, Liu J, Zhao H, Zhang L, Yang Y, Huang Y. Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial. Cancer. 2022 Nov 15;128(22):3969-3976. doi: 10.1002/cncr.34474. Epub 2022 Oct 5."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/36197287/	desloratadine
67	2023-01-02 15:22:35.725	2023-03-20 15:02:57.444	NCT00805324	Evaluation of the Efficacy and Safety of Desloratadine Syrup in Children Suffering From Seasonal Allergic Rhinitis With or Without Intermittent Asthma	Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Hayfever With or Without Asthma (P03472)	Completed	The purpose of this study was to test the effectiveness and safety of desloratadine (Aerius) syrup in children with hayfever with or without asthma. Patients took desloratadine syrup once a day for 28 days. Once a week, the doctor measured the patient's hayfever symptoms. The doctor also rated how much relief the patient got from treatment and recorded any side effects.	Single Group Assignment	Organon and Co	INDUSTRY	All	12	6	54	Actual	INDUSTRY	Organon and Co	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2003-05-01	2003-08-01	2003-08-01	2008-12-09	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Rhinitis, Allergic, Seasonal",Asthma}	main	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{"Rossi GA, Tosca MA, Passalacqua G, Bianchi B, Le Grazie C, Canonica GW. Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. Allergy. 2005 Mar;60(3):416-7. doi: 10.1111/j.1398-9995.2005.00714.x. No abstract available."}	NO_PUBLICATION_FOUND	\N	desloratadine
416	2023-01-02 15:22:35.746	2023-03-21 13:30:36.533	NCT05042830	Contribution of Local Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Production Upon Nasal Allergen Contact - an Explorative Pilot Study	Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact	Recruiting	IgE-associated allergies are consistently on the rise forming an enormous wellbeing concern and affecting about 25% of the population around the world, with main prevalence in developed nations. Birch pollen is one important allergen driving allergic conjunctivitis and rhinitis. The characteristics and location IgE producing cells in the nose and their contribution to the subsequent increase in allergen-specific IgE levels in the serum have so far poorly been investigated. Understanding these mechanisms is critical for the development of new therapeutic approaches and is thus the aim of the proposed study. Thus, the investigators plan to conduct a two-armed study of a randomized placebo-controlled double-blind nasal allergen provocation where 30 patients will be provoked with birch pollen extract (n=20) or placebo (n=10) out of the birch pollen season (October) and follow them closely for up to 4 months. Therefore, the objective of this study is to investigate the localization and characteristics of IgE producing cells in the nasal mucosa contributing to the allergen-induced boosts of specific serum IgE upon natural and controlled nasal allergen exposure.	Parallel Assignment	Medical University of Vienna	OTHER	All	60	18	30	Anticipated	OTHER	Medical University of Vienna	Randomized	\N	Triple	\N	\N	Basic Science	\N	The nose represents an important and first site of allergen contact, both because it is the organ most frequently affected by allergic symptoms and also because it plays an important role for the regulation of IgE production and allergic inflammation. The nasal mucosa acts as a barrier against intruding allergens. This barrier function can be perturbed by various factors such as cigarette smoke, rhinovirus infection or interferon-. Exposure to these factors may lead to increased allergen penetration. Nasal allergen contact in sensitized subjects leads to allergic nasal inflammation and symptoms. The investigators of this study have previously demonstrated that allergen-specific IgE levels in sensitized individuals are strongly boosted upon nasal allergen contact during the relevant allergen season or in well controlled intranasal allergen challenge models. This allergen-induced rise in IgE levels consequently leads to increased sensitivity of allergic patients in terms of IgE-mediated mast cell and basophil activation as well as IgE-facilitated antigen presentation via the high (FcRI) or low (CD23) affinity receptor for IgE by antigen presenting cells, to T cells. In this context, the investigators have recently shown that not only allergen-specific IgE levels themselves but also the crosslinking ability of complexes formed between IgE and allergen dictate the extent of CD23-mediated T cell activation.\n\nThe observation that nasal allergen contact triggers boosting of systemic allergen-specific IgE levels indicates the presence of IgE+ producing cells locally in the nasal mucosa which can be stimulated upon allergen contact. This hypothesis is supported by the following observations: (A) there is an evidence that IgE-producing B cells and plasma cells are present in the nasal mucosa but nothing has been proven yet. (B) Upon ex vivo challenge of biopsies from nasal mucosa of allergic patients, local synthesis not only of  germline, but also of  circle transcripts as products of mature IgE synthesis were observed. However, to which extent this local nasal IgE production contributes to the observed systemic boost of IgE and the underlying kinetics of IgE production are so far unknown and are one important aim of this proposal.\n\nAlso, though local IgE production has been observed, the presence of the IgE producing cells themselves in the nasal mucosa has so far not been confirmed. One important reason for this is the difficulty of unambiguously identifying those cells by flow cytometry or fluorescence microscopy. In the past several step by step flow cytometry protocols have been developed with the aim of excluding non-relevant cells prior to gating for IgE+ B cells. However, it needs to be borne in mind that all currently used anti-IgE antibodies recognize not only surface IgE present in the form of the B cell receptor but also bound to CD23. As a consequence, most current studies overestimate the presence of IgE B cell receptor (BCR) bearing B cells. This has only recently been demonstrated in a study by Jimenez-Saiz et al. where the authors found that only around 0.0015% of B cells bear an IgE BCR. Here the authors employed a single cell nested polymerase chain reaction (PCR) approach to validate the nature of the BCR after flow cytometry-based cell sorting for IgE+ B cells using previously reported protocols. The overestimation is most likely due to detection of IgE+ B cells bearing CD23 bound IgE. One option to improve flow cytometric detection could be to exclude CD23 positive cells but this could also lead to exclusion of IgE producing cells expressing CD23. Thus, the only alternative to overcome this obstacle is to use an anti-IgE antibody that can distinguish between receptor bound and membrane anchored IgE. In this respect, an anti-IgE antibody fulfilling these requirements has recently been shown to successfully identify IgE producing cells. Thus, the investigators will employ this novel strategy to identify IgE producing cells both in the nasal mucosa as well as in the blood of allergic subjects.\n\nIn this project, the investigators aim to elucidate the sites and characteristics of allergen-specific IgE production in a two-armed study spanning birch pollen allergic subject undergoing controlled nasal birch pollen challenge outside the season (October). To that aim, IgE producing cells in blood will be determined using flow cytometry and IgE producing cells in the nasal mucosa will be revealed in nasal biopsies using confocal microscopy. Understanding the characteristics and locations of IgE producing cells is critical for the development of future new therapeutic approaches.	2021-11-11	2025-01-01	2026-09-01	2021-09-13	\N	2022-08-24	\N	Medical University of Vienna	Sven Schneider, MD	Principal Investigator	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Not Applicable"}	{Allergy}	rescue medication	desloratadine	\N	f	Allergy	2022-09-15 19:16:20	{"Gangl K, Reininger R, Bernhard D, Campana R, Pree I, Reisinger J, Kneidinger M, Kundi M, Dolznig H, Thurnher D, Valent P, Chen KW, Vrtala S, Spitzauer S, Valenta R, Niederberger V. Cigarette smoke facilitates allergen penetration across respiratory epithelium. Allergy. 2009 Mar;64(3):398-405. doi: 10.1111/j.1398-9995.2008.01861.x. Epub 2008 Dec 16.","Gangl K, Waltl EE, Vetr H, Cabauatan CR, Niespodziana K, Valenta R, Niederberger V. Infection with Rhinovirus Facilitates Allergen Penetration Across a Respiratory Epithelial Cell Layer. Int Arch Allergy Immunol. 2015;166(4):291-6. doi: 10.1159/000430441. Epub 2015 May 13.","Reisinger J, Triendl A, Kuchler E, Bohle B, Krauth MT, Rauter I, Valent P, Koenig F, Valenta R, Niederberger V. IFN-gamma-enhanced allergen penetration across respiratory epithelium augments allergic inflammation. J Allergy Clin Immunol. 2005 May;115(5):973-81. doi: 10.1016/j.jaci.2005.01.021.","Niederberger V, Ring J, Rakoski J, Jager S, Spitzauer S, Valent P, Horak F, Kundi M, Valenta R. Antigens drive memory IgE responses in human allergy via the nasal mucosa. Int Arch Allergy Immunol. 2007;142(2):133-44. doi: 10.1159/000096439. Epub 2006 Oct 19.","Egger C, Lupinek C, Ristl R, Lemell P, Horak F, Zieglmayer P, Spitzauer S, Valenta R, Niederberger V. Effects of nasal corticosteroids on boosts of systemic allergen-specific IgE production induced by nasal allergen exposure. PLoS One. 2015 Feb 23;10(2):e0114991. doi: 10.1371/journal.pone.0114991. eCollection 2015.","Eckl-Dorna J, Froschl R, Lupinek C, Kiss R, Gattinger P, Marth K, Campana R, Mittermann I, Blatt K, Valent P, Selb R, Mayer A, Gangl K, Steiner I, Gamper J, Perkmann T, Zieglmayer P, Gevaert P, Valenta R, Niederberger V. Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study. Allergy. 2018 May;73(5):1003-1012. doi: 10.1111/all.13343. Epub 2017 Dec 12.","Valenta R, Karaulov A, Niederberger V, Gattinger P, van Hage M, Flicker S, Linhart B, Campana R, Focke-Tejkl M, Curin M, Eckl-Dorna J, Lupinek C, Resch-Marat Y, Vrtala S, Mittermann I, Garib V, Khaitov M, Valent P, Pickl WF. Molecular Aspects of Allergens and Allergy. Adv Immunol. 2018;138:195-256. doi: 10.1016/bs.ai.2018.03.002. Epub 2018 Apr 26.","Eckl-Dorna J, Villazala-Merino S, Linhart B, Karaulov AV, Zhernov Y, Khaitov M, Niederberger-Leppin V, Valenta R. Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses. Front Immunol. 2019 Jan 17;9:3131. doi: 10.3389/fimmu.2018.03131. eCollection 2018.","Villazala-Merino S, Rodriguez-Dominguez A, Stanek V, Campion NJ, Gattinger P, Hofer G, Froeschl R, Fae I, Lupinek C, Vrtala S, Breiteneder H, Keller W, Perkmann T, Nakamura R, Pickl WF, Valenta R, Eckl-Dorna J, Niederberger V. Allergen-specific IgE levels and the ability of IgE-allergen complexes to cross-link determine the extent of CD23-mediated T-cell activation. J Allergy Clin Immunol. 2020 Mar;145(3):958-967.e5. doi: 10.1016/j.jaci.2019.11.019. Epub 2019 Nov 24.","KleinJan A, Vinke JG, Severijnen LW, Fokkens WJ. Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients. Eur Respir J. 2000 Mar;15(3):491-7. doi: 10.1034/j.1399-3003.2000.15.11.x.","Cameron L, Hamid Q, Wright E, Nakamura Y, Christodoulopoulos P, Muro S, Frenkiel S, Lavigne F, Durham S, Gould H. Local synthesis of epsilon germline gene transcripts, IL-4, and IL-13 in allergic nasal mucosa after ex vivo allergen exposure. J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):46-52. doi: 10.1067/mai.2000.107398.","Durham SR, Gould HJ, Thienes CP, Jacobson MR, Masuyama K, Rak S, Lowhagen O, Schotman E, Cameron L, Hamid QA. Expression of epsilon germ-line gene transcripts and mRNA for the epsilon heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. Eur J Immunol. 1997 Nov;27(11):2899-906. doi: 10.1002/eji.1830271123.","Takhar P, Smurthwaite L, Coker HA, Fear DJ, Banfield GK, Carr VA, Durham SR, Gould HJ. Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol. 2005 Apr 15;174(8):5024-32. doi: 10.4049/jimmunol.174.8.5024.","Cameron L, Gounni AS, Frenkiel S, Lavigne F, Vercelli D, Hamid Q. S epsilon S mu and S epsilon S gamma switch circles in human nasal mucosa following ex vivo allergen challenge: evidence for direct as well as sequential class switch recombination. J Immunol. 2003 Oct 1;171(7):3816-22. doi: 10.4049/jimmunol.171.7.3816.","Eckl-Dorna J, Niederberger V. What is the source of serum allergen-specific IgE? Curr Allergy Asthma Rep. 2013 Jun;13(3):281-7. doi: 10.1007/s11882-013-0348-x.","Heeringa JJ, Rijvers L, Arends NJ, Driessen GJ, Pasmans SG, van Dongen JJM, de Jongste JC, van Zelm MC. IgE-expressing memory B cells and plasmablasts are increased in blood of children with asthma, food allergy, and atopic dermatitis. Allergy. 2018 Jun;73(6):1331-1336. doi: 10.1111/all.13421. Epub 2018 Mar 30.","Oliveria JP, Salter BM, MacLean J, Kotwal S, Smith A, Harris JM, Scheerens H, Sehmi R, Gauvreau GM. Increased IgE+ B Cells in Sputum, but Not Blood, Bone Marrow, or Tonsils, after Inhaled Allergen Challenge in Subjects with Asthma. Am J Respir Crit Care Med. 2017 Jul 1;196(1):107-109. doi: 10.1164/rccm.201611-2274LE. No abstract available.","Jimenez-Saiz R, Ellenbogen Y, Bruton K, Spill P, Sommer DD, Lima H, Waserman S, Patil SU, Shreffler WG, Jordana M. Human BCR analysis of single-sorted, putative IgE+ memory B cells in food allergy. J Allergy Clin Immunol. 2019 Jul;144(1):336-339.e6. doi: 10.1016/j.jaci.2019.04.001. Epub 2019 Apr 5.","Selb R, Eckl-Dorna J, Twaroch TE, Lupinek C, Teufelberger A, Hofer G, Focke-Tejkl M, Gepp B, Linhart B, Breiteneder H, Ellinger A, Keller W, Roux KH, Valenta R, Niederberger V. Critical and direct involvement of the CD23 stalk region in IgE binding. J Allergy Clin Immunol. 2017 Jan;139(1):281-289.e5. doi: 10.1016/j.jaci.2016.04.015. Epub 2016 May 7.","Eckl-Dorna J, Villazala-Merino S, Campion NJ, Byazrova M, Filatov A, Kudlay D, Karsonova A, Riabova K, Khaitov M, Karaulov A, Niederberger-Leppin V, Valenta R. Tracing IgE-Producing Cells in Allergic Patients. Cells. 2019 Aug 28;8(9):994. doi: 10.3390/cells8090994.","Brightbill HD, Jeet S, Lin Z, Yan D, Zhou M, Tan M, Nguyen A, Yeh S, Delarosa D, Leong SR, Wong T, Chen Y, Ultsch M, Luis E, Ramani SR, Jackman J, Gonzalez L, Dennis MS, Chuntharapai A, DeForge L, Meng YG, Xu M, Eigenbrot C, Lee WP, Refino CJ, Balazs M, Wu LC. Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest. 2010 Jun;120(6):2218-29. doi: 10.1172/JCI40141. Epub 2010 May 10.","Harris JM, Maciuca R, Bradley MS, Cabanski CR, Scheerens H, Lim J, Cai F, Kishnani M, Liao XC, Samineni D, Zhu R, Cochran C, Soong W, Diaz JD, Perin P, Tsukayama M, Dimov D, Agache I, Kelsen SG. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir Res. 2016 Mar 18;17:29. doi: 10.1186/s12931-016-0347-2.","Boelke G, Berger U, Bergmann KC, Bindslev-Jensen C, Bousquet J, Gildemeister J, Jutel M, Pfaar O, Sehlinger T, Zuberbier T. Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: a GA2LEN study. Clin Transl Allergy. 2017 Sep 17;7:33. doi: 10.1186/s13601-017-0169-4. eCollection 2017.","Focke M, Marth K, Valenta R. Molecular composition and biological activity of commercial birch pollen allergen extracts. Eur J Clin Invest. 2009 May;39(5):429-36. doi: 10.1111/j.1365-2362.2009.02109.x."}	NO_PUBLICATION_FOUND	\N	desloratadine
155	2023-01-02 15:22:35.73	2023-03-20 17:15:00.592	NCT01916226	Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment With Fluticasone Propionate Nasal Spray Versus Cetirizine in Adult Subjects With Seasonal Allergic Rhinitis (SAR)	A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis	Completed	This phase IV investigational trial is being conducted to evaluate the efficacy of a 2-week treatment of fluticasone propionate nasal spray (FPNS) vs. cetirizine on allergic nasal and ocular symptoms and quality of life in adult subjects with SAR. It is hypothesized that FPNS provides greater nasal symptom relief than cetirizine. The primary measure used to test this hypothesis is the change from baseline over two weeks in reflective total nasal symptom score (rTNSS) compared between FPNS and cetirizine. Approximately 648 subjects will be randomized into a 1:1:1:1 ratio of treatment allocation across approximately twenty-five to thirty-five sites in the US during the 2013 fall allergy season. All subjects will be outpatients. The total duration of study will be approximately 21 days including 7 days of screening period, and 14 days of treatment period.	Parallel Assignment	GlaxoSmithKline	INDUSTRY	All	\N	18	682	Actual	INDUSTRY	GlaxoSmithKline	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2013-08-01	2013-10-01	2013-10-17	2013-08-05	2014-08-27	2018-06-20	GlaxoSmithKline	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Rhinitis, Allergic, Perennial and Seasonal"}	comparison	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Ford LB, Matz J, Hankinson T, Prillaman B, Georges G. A comparison of fluticasone propionate nasal spray and cetirizine in ragweed fall seasonal allergic rhinitis. Allergy Asthma Proc. 2015 Jul-Aug;36(4):313-9. doi: 10.2500/aap.2015.36.3860."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/26108088/	cetirizine
364	2023-01-02 15:22:35.743	2023-03-21 09:51:11.973	NCT00001910	Immunologic Mechanism of Allergen Immunotherapy	Mechanisms of Allergen Immunotherapy	Completed	This study will examine how allergen immunotherapy (allergy shots) works to reduce or prevent reactions to allergens such as pollen, dust or cat dander. Certain T cells (types of white blood cells) called Th2 cells produce substances that generate allergies. Other T cells called Th1 cells produce substances that have opposite effects. This study will determine if allergy shots change the immune response to allergens by reducing the number of Th2 cells or by changing them into Th1 cells. A better understanding of how this treatment works may help scientists develop more effective allergy therapies.\n\nPeople between 18 and 50 years of age who have had allergic asthma for at least 1 year may participate in this study. Candidates' medical, allergy and medication histories will be reviewed, and they will have a physical examination, including routine blood tests, urinalysis, electrocardiogram (EKG), and lung function test. Blood will also be drawn to test T cell response to allergens, and 12 skin tests (similar to a tuberculosis skin test) will be done to test for sensitivity to various allergens.\n\nParticipants will be admitted to the Clinical Center for 1 to 2 days for rush therapy (see below). They will have a brief history and physical examination. A heparin lock (thin plastic tube similar to an intravenous line) will be placed in an arm vein. They will then undergo the following procedures:\n\nRush/Cluster Immunotherapy - An allergen is given in increasing doses over 2 to 5 weeks. During rush therapy, the dose is increased rapidly over 1 to 2 days until a moderate level dose is reached. To reduce the chance of an allergic reaction, patients take prednisone, cetirizine (Zyrtec (Registered Trademark)), ranitidine (Zantac (Registered Trademark)) and montelukast (Singular (Registered Trademark)) starting 24 hours before treatment begins until rush therapy ends. After discharge on the third day, patients return to the clinic once a week for the next 2 to 5 weeks for cluster therapy, in which the dose is increased more gradually to a maintenance level.\nMaintenance Immunotherapy - Participants receive 12 weekly injections at the maintenance dose. Blood is drawn during one visit between weeks 2 and 7 of maintenance therapy.\nFollow-up Visits - Patients return to the clinic 2 and 3 weeks after the last maintenance dose for blood draws and evaluations. In addition, a "late-phase" allergen skin test is done at the 3-week follow-up to compare reaction results with those from the test done at the screening visit.\nEnd-of-Study Visit - 12 to 16 weeks after the last allergy shot, patients return for a final blood draw and brief evaluation.	\N	National Institute of Allergy and Infectious Diseases (NIAID)	NIH	All	\N	\N	50	\N	NIH	National Institutes of Health Clinical Center (CC)	\N	\N	\N	\N	\N	\N	\N	Asthma is a major public health problem due to its high prevalence and significant impact on activities of daily living. Allergen immunotherapy or vaccination consists of the therapeutic administration of allergen extract. The efficacy of allergen immunotherapy in asthma is modest, however immunotherapy remains the only known disease modifying therapy for allergic asthma. Because the exact mechanism through which immunotherapy works is unclear, a greater understanding of the mechanism of action of allergen immunotherapy is needed before modern immunopharmacologic methods can be applied to increase its therapeutic efficacy. This goal of the study is to determine the effects of allergen immunotherapy on allergen specific T cell responses. This is an open label study in which allergen specific CD4+T lymphocyte responses will be monitored before, during and after 12 weekly injections of maintenance immunotherapy, allowing the study of both the induction as well as decay of these changes. Immunotherapy will be employed in a rush/cluster schedule consisting of the serial administration of rapidly increasing doses of allergen delivered subcutaneously over a 2 day period (rush), followed by more gradually increasing weekly injections over 2-6 weeks (cluster), during which time the subject is brought to a maintenance allergen dose, which will then be repeatedly administered on a weekly basis. Immunological endpoints will consist of the frequency and cytokine profile of allergen specific T cell responses as measured by intracellular cytokine staining and the measurement of in vitro induced T cell cytokines by real time RT-PCR. Ten allergic asthmatic subjects will be enrolled in the therapeutic arm of the study.	1999-07-01	\N	2003-08-01	1999-11-04	\N	2008-03-04	\N	\N	\N	\N	\N	\N	\N	\N	Observational	{Child,Adult,"Older Adult"}	{}	{Asthma,Hypersensitivity}	minimal	cetirizine	To reduce the chance of an allergic reaction, patients take prednisone, cetirizine (Zyrtec (Registered Trademark)), ranitidine (Zantac (Registered Trademark)) and montelukast (Singular (Registered Trademark)) starting 24 hours before treatment begins until rush therapy ends	f	Allergy	2022-08-17 13:39:16	{"Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson NF Jr, Buncher CR, Busse WW, Bush RK, Gadde J, Li JT, et al. Ragweed immunotherapy in adult asthma. N Engl J Med. 1996 Feb 22;334(8):501-6. doi: 10.1056/NEJM199602223340804.","Bousquet J, Yssel H, Vignola AM, Chanez P. New developments in the immunology of asthma, with a focus on mechanisms and treatment. Curr Opin Pulm Med. 1997 Jan;3(1):42-50. doi: 10.1097/00063198-199701000-00007.","Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, Creticos PJ, Dayer JM, Durham SR, Demoly P, Goldstein RJ, Ishikawa T, Ito K, Kraft D, Lambert PH, Lowenstein H, Muller U, Norman PS, Reisman RE, Valenta R, Valovirta E, Yssel H. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998 Nov;81(5):401-5. doi: 10.1016/s1081-1206(10)63136-5. No abstract available."}	NO_PUBLICATION_FOUND	\N	cetirizine
72	2023-01-02 15:22:35.726	2023-03-20 15:10:47.852	NCT00963573	Efficacy and Safety of Loratadine-Betamethasone Oral Solution (1 mg/0.05 mg/1 mL) for Initial Treatment of Severe Perennial Allergic Rhinitis in School Age Children	Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)	Completed	This study attempts to document the therapeutic value of combining loratadine antihistamine action (no sedative) with anti-inflammatory effects of betamethasone at low doses, which may facilitate treatment adherence by patients whereas providing an effective and rapid perennial allergic rhinitis (PAR) symptoms relief.	Single Group Assignment	Merck Sharp & Dohme LLC	INDUSTRY	All	12	6	100	Actual	INDUSTRY	Merck Sharp & Dohme LLC	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2003-09-01	2006-11-01	2006-11-01	2009-08-21	\N	2015-04-21	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 4"}	{Rhinitis}	combination	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Mendoza de Morales T, Sanchez F. Clinical efficacy and safety of a combined loratadine-betamethasone oral solution in the treatment of severe pediatric perennial allergic rhinitis. World Allergy Organ J. 2009 Apr;2(4):49-53. doi: 10.1097/WOX.0b013e31819f2105."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/23282980/	loratadine
112	2023-01-02 15:22:35.728	2023-03-20 16:38:05.262	NCT00776217	An Open Label, Balanced, Randomized, Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover, Bioavailability Study on Loratadine Formulations Comparing Loratadine 10 mg Orally Disintegrating Tablets of Ohm Laboratories, Inc. (A Subsidiary of Ranbaxy Pharmaceuticals Inc) With Claritin Reditabs 10 mg Tablet (Containing Loratadine 10 mg) of Schering- Plough Healthcare Product Inc, in Healthy, Adult, Male, Human Subjects Under Fasting Condition	Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions	Completed	To compare the single-dose oral bioavailability of loratadine 10 mg orally disintegrating tablets of Ohm Laboratories (a subsidiary of Ranbaxy Pharmaceuticals Inc., USA) with Claritin Reditabs (containing loratadine 10 mg) of Schering-Plough Healthcare Product Inc., USA in healthy, adult, human male subjects under fasting condition.	Crossover Assignment	Ranbaxy Laboratories Limited	INDUSTRY	Male	45	18	80	Actual	INDUSTRY	Ranbaxy Inc.	Randomized	\N	None (Open Label)	\N	\N	\N	\N	The study was conducted as an open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose, crossover, bioavailability study on loratadine formulation comparing loratadine 10 mg orally disintegrating tablets of Ohm Laboratories, Inc. (a subsidiary of Ranbaxy pharmaceuticals Inc, USA) with Claritin Reditabs 10 mg tablet (containing loratadine 10 mg) of Schering- Plough Healthcare Product Inc, in healthy, adult, male, human subjects under fasting condition.\n\nA single oral dose of loratadine 10 mg orally disintegrating tablets was orally administered under low light condition during each period of the study under the supervision of a trained Medical Officer. Subjects were instructed to let the tablets completely dissolve on the tongue before swallowing the saliva and then, 240 mL of water was administered 30 seconds after drug administration.\n\nDuring the course of the study safety parameters assessed were vital signs, clinical examination, medical history and clinical laboratory safety tests (hematology, biochemical parameters and urine analysis) at baseline. Laboratory parameters of hematology and biochemistry were repeated at the end of the study.\n\nA total of 80 subjects were randomized to receive a single oral dose of the test or reference formulation for loratadine 10 mg. Seventy-four subjects completed both the periods of the study.	2006-06-01	2006-07-01	2006-09-01	2008-10-21	\N	2008-10-21	\N	\N	\N	\N	Dr Tausif Monif	Ranbaxy Research Laboratories	\N	\N	Interventional	{Adult}	{"Not Applicable"}	{Healthy}	main	loratadine	\N	f	Bioequivalence	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
95	2023-01-02 15:22:35.727	2023-03-20 16:28:23.012	NCT01000792	3-D Visualization of the Anti-Obstructive Effect of Levocetirizine - A Monocentric Clinical Trail With One Patient (Phase-IV-Study)	3-D Visualization of the Anti-Obstructive Effect of Levocetirizine	Completed	The prevalence of allergic rhinitis is high and appears to be rising worldwide. Therefore, it is important and necessary to understand and visualize therapy effects on this disease. In this study we will demonstrate the effect of levocetirizine on nasal cavity dimensions by assessing not only standard nasal flow diagnostics such as rhinomanometry and acoustic rhinometry, but supplement examination procedures with long-term rhinometry and magnetic resonance imaging (MRI). With the aid of a virtual model and computer fluid dynamics, we are able to simulate nasal air flow and provide three-dimensional visualization of the computed flow.\n\nIn previous trials ([Bachert], [deBlic], [Day] and [Deruaz]) it has been shown that allergic symptoms, especially nasal congestion, diminish significantly under treatment with levocetirizine. We will demonstrate this anti-obstructive effect by comparing the reaction to nasal allergen challenge before and after four-week treatment with levocetirizine.	Single Group Assignment	Clinical Research International Limited	INDUSTRY	All	65	18	1	Actual	INDUSTRY	Clinical Research International Limited	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2009-11-01	2010-01-01	2010-07-01	2009-10-23	\N	2011-06-22	\N	\N	\N	\N	Prof. Dr. med. Dipl.-Ing. Ralph Msges	CRI - Clinical Research International Ltd.	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Allergic Rhinitis"}	main	cetirizine	1 participant?!	f	Imaging	2022-08-17 13:39:16	{}	PUBLISHED	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512940/	levocetirizine
136	2023-01-02 15:22:35.729	2023-03-19 20:54:27.192	NCT03372473	Safety and Efficacy of Montelukast + Loratadine vs. Montelukast for the Control of Mild to Moderate Persistent Asthma in Children: Randomized Controlled Clinical Trial	Montelukast and Loratadine in Children With Asthma	Completed	Randomized controlled trial in 80 children with mild to persistent moderate asthma, who were randomized to receive montelukast 5mg + loratadine 5mg vs. montelukast 5mg + placebo for loratadine to evaluate the efficacy in terms of improvement of symptoms. Secondary outcome was the days off without the use of rescue medication; reduction of levels of cysteinyl leukotrienes (Cys-LTS), nitric oxide (FeNO), intracellular adhesion molecule type 1 (ICAM-1) and interleukin 8 (IL-8) in condensed exhaled air; the improvement of day and night symptoms; the reduction in the frequency of night awakenings; the improvement in the quality of life; the percentage of related adverse events; the need to use systemic steroids; the number of visits to the emergency department secondary to the presence of an asthma attack; the number of hospitalizations secondary to asthma attacks; and the improvement in the percentage of FEV1 in relation to the predicted.	Crossover Assignment	Innovacion y Desarrollo de Estrategias en Salud	OTHER	All	12	6	80	Actual	OTHER	Innovacion y Desarrollo de Estrategias en Salud	Randomized	Randomized clinical crossover trial, in 80 children who were allocated to receive montelukast + loratadine vs montelukast in two different periods of 4 weeks each, with a 2 weeks of wash-out between periods of treatment	Quadruple	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Children allocated on different arms will receive montelukast + loratadine vs. montelukast + placebo. Both product are identical in appearence and flavor	\N	Treatment	\N	Asthma is a disease with increasing prevalence worldwide that produces significant deterioration of the quality of life in children and development of important complications and economic, social impact. Considering the concept of a common airway (coexistence of asthma and rhinitis), joint management initiatives with anti-asthmatics and anti-histamines have been published. The primary objective of this clinical trial is to evaluate the efficacy and safety of the use of montelukast + loratadine in children with asthma on the improvement of symptoms and secondarily to evaluate the impact on a) the days off without the use of rescue medication; b) reduction of levels of cysteinyl leukotrienes (Cys-LTS), nitric oxide (FeNO), intracellular adhesion molecule type 1 (ICAM-1) and interleukin 8 (IL-8) in condensed exhaled air; c) the improvement of day and night symptoms; d) the reduction in the frequency of night awakenings; e) the improvement in the quality of life; f) the percentage of related adverse events; g) the need to use systemic steroids; h) the number of visits to the emergency department secondary to the presence of an asthma attack; i) the number of hospitalizations secondary to asthma attacks; and j) the improvement in the percentage of FEV1 in relation to the predicted. We included 80 children from 6 to 12 years old, any sex, with mild to moderate persistent asthma, after signing an informed consent letter by parents or guardians or signing the child's consent (> 8 years). Children with chronic diseases associated with the disease of interest were excluded (heart disease, nephropathy, liver disease of any kind); with any other lung disease other than asthma; with a history of hypersensitivity to montelukast or loratadine or with a history of concomitant use of medications that interact significantly with montelukast or loratadine	2016-01-10	2016-02-01	2017-06-30	2017-12-13	\N	2017-12-13	\N	Innovacion y Desarrollo de Estrategias en Salud	Pedro Gutierrez Castrellon	Head of Translational Research Center on Mother-Child Health	\N	\N	Principal Investigator	\N	Interventional	{Child}	{"Phase 3"}	{"Asthma in Children"}	combination	loratadine	\N	t	Asthma	2022-08-17 18:44:47	{"American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30. doi: 10.1164/rccm.200406-710ST. No abstract available.","Carpagnano GE, Spanevello A, Sabato R, Depalo A, Palladino GP, Bergantino L, Foschino Barbaro MP. Systemic and airway inflammation in sleep apnea and obesity: the role of ICAM-1 and IL-8. Transl Res. 2010 Jan;155(1):35-43. doi: 10.1016/j.trsl.2009.09.004.","Carraro S, Corradi M, Zanconato S, Alinovi R, Pasquale MF, Zacchello F, Baraldi E. Exhaled breath condensate cysteinyl leukotrienes are increased in children with exercise-induced bronchoconstriction. J Allergy Clin Immunol. 2005 Apr;115(4):764-70. doi: 10.1016/j.jaci.2004.10.043.","Zanconato S, Carraro S, Corradi M, Alinovi R, Pasquale MF, Piacentini G, Zacchello F, Baraldi E. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. J Allergy Clin Immunol. 2004 Feb;113(2):257-63. doi: 10.1016/j.jaci.2003.10.046. Erratum In: J Allergy Clin Immunol. 2004 Apr;113(4):676.","Massingham K, Fox S, Smaldone A. Asthma therapy in pediatric patients: a systematic review of treatment with montelukast versus inhaled corticosteroids. J Pediatr Health Care. 2014 Jan-Feb;28(1):51-62. doi: 10.1016/j.pedhc.2012.11.005. Epub 2013 Jan 9.","Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol. 2004 Mar;113(3):415-9. doi: 10.1016/j.jaci.2003.11.034."}	NO_PUBLICATION_FOUND	\N	loratadine
75	2023-01-02 15:22:35.725	2023-03-20 15:12:59.233	NCT00761527	Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Syrup Among Filipino Pediatric Patients	Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)	Completed	The purpose of this study is to observe the side effects of desloratadine syrup and how effective it is in relieving symptoms of allergic rhinitis or hives in Filipino children. The participants will take desloratadine syrup for 14 days. At the end of treatment, side effects will be recorded, as well as how the participants tolerate the medication. Effectiveness will also be rated at the end of treatment.	\N	Organon and Co	INDUSTRY	All	11	0.5	2980	Actual	INDUSTRY	Organon and Co	\N	\N	\N	\N	Ecologic or Community	\N	Prospective	Physicians who commonly prescribed desloratadine treatment as standard care of treatment were selected enroll participants.	2008-03-01	2010-05-01	2010-05-01	2008-09-29	2012-03-01	2022-02-09	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Child}	{}	{"Rhinitis, Allergic, Seasonal","Rhinitis, Allergic, Perennial",Urticaria}	main	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{}	CT_RESULTS	\N	desloratadine
153	2023-01-02 15:22:35.73	2023-03-20 17:13:12.521	NCT00435461	A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis	Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine	Completed	The primary objective of this study is to compare the nighttime symptom relief of fluticasone furoate nasal spray and oral fexofenadine	Parallel Assignment	GlaxoSmithKline	INDUSTRY	All	\N	12	1000	Actual	INDUSTRY	GlaxoSmithKline	Randomized	\N	\N	\N	\N	Treatment	\N	\N	2006-12-20	2007-02-01	2007-02-28	2007-02-15	2018-02-05	2018-03-07	GlaxoSmithKline	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{"Rhinitis, Allergic, Seasonal"}	comparison	fexofenadine	Is this really the right publication?	f	Allergic Rhinitis	2022-08-18 16:54:53	{"Andrews C, Martin B, Jacobs R, Toler T, Prillaman B, Philpot E. Efficacy of fluticasone furoate nasal spray versus oral fexofenadine on nighttime sleep disturbance caused by seasonal allergic rhinitis (SAR) nasal symptoms. Ann Allergy Asthma Immunol 2008; 100(1) (Supplement 1):A6 (abstract)","Andrews CP, Martin BG, Jacobs RL, Diaz J, Toler WT, Prillaman BA, Dalal AA, Philpot EE. Once-daily fluticasone furoate nasal spray showed greater improvement in nocturnal quality of life in subjects with seasonal allergic rhinitis compared with oral fexofenadine. J Allergy Clin Immunol 2008;121(2) (Supplement 1): S53 (abstract)","Andrews CP, Martin BG, Jacobs RL, Mohar DE, Diaz JD, Amar NJ, Kaiser HB, Vandewalker ML, Bernstein J, Toler WT, Prillaman BA, Dalal AA, Lee LA, Philpot EE. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc. 2009 Mar-Apr;30(2):128-38. doi: 10.2500/aap.2009.30.3204.","Martin BG, Andrews CP, Jacobs R, Mohar D, Toler WT, Prillaman BA, Philpot EE. Once-daily fluticasone furoate nasal spray showed greater improvements in relieving nighttime nasal symptoms and increasing peak nasal inspiratory flow versus oral fexofenadine in subjects with seasonal allergic rhinitis (SAR) J Allergy Clin Immunol 2008;121(2) (Supplement 1): S54-S55 (abstract)"}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19463203/	fexofenadine
189	2023-01-02 15:22:35.732	2023-03-20 19:39:07.838	NCT05118672	A Multicenter, Randomized, Parallel-group, Double-blind, Comparative Trial of the Superiority of Paracetamol 500mg/Fexofenadine 60mg/Phenylephrine 20mg Fixed-dose Combination Versus Placebo in the Symptomatic Treatment of Flu and Cold	Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment	Not yet recruiting	A Phase 3, multicenter, Randomized, Double-blind, comparative clinical trial to evaluate the association of paracetamol 500mg + Fexofenadine 60mg + Phenylephrine 20mg in the flu and common cold treatment.\n\nStudy will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).	Parallel Assignment	Eurofarma Laboratorios S.A.	INDUSTRY	All	\N	18	478	Anticipated	INDUSTRY	Eurofarma Laboratorios S.A.	Randomized	Adult participants (aged  18 years) of both sexes with common cold or flu will be randomized in a 1:1 ratio to receive the experimental drug (paracetamol 500 mg / fexofenadine 60 mg / phenylephrine 20 mg) or placebo, in the dosage of one (01) film-coated tablet every eight (08) hours, for 3 to 7 days.\n\nRandomized participants will be instructed to use the study treatment uninterruptedly, every eight (08) hours, for three (03) days, and may, after that, discontinue treatment at any time if they experience no more symptoms.	Double	Group 1: Eurofarma Laboratrios SA paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg FDC (experimental drug).\n\nGroup 2: Placebo.	\N	Treatment	\N	A multicenter, randomized, double-blind, parallel-group, superiority, placebo control clinical trial.\n\nAdult patients (aged  18 years) of both sexes with common cold or flu will be randomized in a 1:1 ratio to receive the experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg) or placebo, in the dosage of one (01) film-coated tablet every eight (08) hours, for 3 to 7 days.\n\nThe primary superiority assessment will be carry out compared the experimental drug to placebo in the relief of cold and flu symptoms through the absolute variation of the overall score obtained in the symptom assessment questionnaire after treatment start.\n\nStudy will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).	2023-08-17	2024-08-30	2025-03-30	2021-11-12	\N	2022-12-02	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{Cold,"Flu Symptom"}	combination	fexofenadine	\N	f	Cold	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
126	2023-01-02 15:22:35.729	2023-03-20 16:52:45.102	NCT01491503	Open Label, Randomized, 6-sequence Crossover Study to Evaluate the Drug-drug Interaction Between Montelukast Sodium and Levocetirizine Dihydrochloride in Health Male Volunteers	A Drug Interaction Study of Montelukast and Levocetirizine	Completed	The purpose of this study is to evaluate the drug-drug interaction between montelukast sodium and levocetirizine dihydrochloride in healthy male volunteers.	Crossover Assignment	Hanmi Pharmaceutical Company Limited	INDUSTRY	Male	55	20	30	Anticipated	INDUSTRY	Hanmi Pharmaceutical Company Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2011-11-01	2012-01-01	2012-01-01	2011-12-14	\N	2013-04-05	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	combination	cetirizine	\N	f	Pharmacokinetics	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
365	2023-01-02 15:22:35.743	2023-03-21 10:01:54.24	NCT02545361	A Phase 1/2a, Multi-center, Dose Escalation, 2 Stages Study to Evaluate the Safety, Tolerability, and Anti-cancer Activity of Subcutaneously Administered KAHR-102 for the Treatment of Lymphoma Patients Who Express Both B7 and FasR	Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients	Withdrawn	The purpose of this study is to evaluate the safety and to determine the Dose Limiting Toxicity (DLT) and the Maximal Tolerated Dose (MTD) of KAHR-102.	Single Group Assignment	Kahr Medical	INDUSTRY	All	\N	18	0	Actual	INDUSTRY	Kahr Medical	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	Subjects will have a screening visit for determination of eligibility. Up to 40 evaluable subjects will be included in the study; up to 30 in stage 1, and 10 in stage 2.\n\nThe study is divided into 2 stages:\n\nDose escalation - Stage 1A and 1B\nDose Confirmation Phase - Stage 2\n\nStage 1A:\n\nWill start with 3 subjects receiving premedication (20mg Dexamethasone Intravenous (IV), 10mg Loratadine Per Os (P.O), and 1gr Paracetamol (P.O), 1 hour before treatment) with 2 micrograms/kilograms (g/kg) KAHR-102 subcutaneous (SC) injection every 14 days for 3 injections. 3 injections will be defined as 1 cycle.\n\nEligible subjects will be hospitalized for 48 hours following each study drug administration. Blood will be collected before and 24 hours (h) following the study drug administration for biochemistry, hematology and cytokine levels.\n\nPharmacokinetic (PK) samples will be collected during hospitalization for the first and third KAHR-102 SC injections. Sampling for PK will be repeated on Day 4, 7, 32 and 35.\n\nSampling for Anti Drug Antibodies (ADAs) will be taken before all 3 KAHR-102 SC injections. CT scan and ADAs will be repeated at Day 49.\n\nStage 1B:\n\nBased on safety results from Stage 1A and Clinical Safety Committee (CSC) decision, 12 further eligible subjects will be assigned to 1 of 4 cohorts to receive a SC injection of KAHR-102 with pre-medication (20mg Dexamethasone (IV), 10mg Loratadine (P.O), and 1gr Paracetamol (P.O), all 1 hour before the KAHR-102 SC injection, once every 7 days for 3 injections starting with 2g/kg KAHR-102 SC injection. 3 injections will be defined as 1 Cycle.\n\nEligible subjects will be hospitalized for 48 hours following each KAHR-102 SC injection.\n\nBlood samples will be collected before and 24h following the administration of KAHR-102 SC injection for biochemistry, hematology and cytokines level.\n\nPK samples will be collected during hospitalization for first and third KAHR-102 SC injections. PK will also be assessed on Days 4, 7 (before administration of second KAHR-102 SC injection), 18 and 21.\n\nSampling for ADA testing will be taken before administration of first and third KAHR-102 SC injections. CT scan and ADA sampling will be performed on Day 35.\n\nStage 2:\n\nFollowing completion of Stage 1, safety assessment by CSC and determination of MTD will be performed. 10 subjects will be treated at MTD. KAHR-102 SC injection will be given every 7 days for 3 injections. 3 injections will be defined as 1 Cycle.\n\nSubjects will be hospitalized during treatment for 48 hours following each KAHR-102 SC injection.\n\nBlood will be collected before and 24h following the administration of KAHR-102 SC injection for biochemistry, hematology, cytokines level.\n\nPK sampling will be taken during hospitalization for first and third KAHR-102 SC injections and repeated on days 4, 7(before administration of second injection), 18, 21.\n\nSamples for ADA testing will be collected prior to the first and third KAHR-102 SC injections. At Day 35 ADA sampling and CT scan will be repeated.\n\nCycles will be repeated at a frequency of 28 days after third KAHR-102 SC injection of 1st cycle and 14 days after 2nd cycle and following cycles Treatment will be discontinued based on investigator decision if CT scan shows evidence of disease progression or for any safety issues. The process will be overseen by the CSC.	2018-04-01	2020-04-01	2020-04-01	2015-09-10	\N	2018-08-16	\N	\N	\N	\N	\N	\N	Sponsor	Program de-prioritized	Interventional	{Adult,"Older Adult"}	{"Phase 1","Phase 2"}	{Lymphoma}	pre-medication	loratadine	usecase was prev Lymphoma	f	Safety Evaluation	2022-08-17 18:44:47	{}	UNKNOWN	\N	loratadine
169	2023-01-02 15:22:35.731	2023-03-20 19:24:46.923	NCT00649857	Single-Dose Food In Vivo Bioequivalence Study of Cetirizine HCl Tablets (10 mg; Mylan) and Zyrtec (10 mg; Pfizer) in Healthy Volunteers	Food Study of Cetirizine HCl Tablets 10 mg and Zyrtec 10 mg	Completed	The objective of this study was to investigate the bioequivalence of Mylan's cetirizine HCl tablets to Pfizer's Zyrtec tablets following a single, oral 10 mg (1 x 10 mg) dose administered under fed conditions.	Crossover Assignment	Mylan Pharmaceuticals Inc	INDUSTRY	All	\N	18	18	Actual	UNKNOWN	MylanPharma	Randomized	\N	None (Open Label)	\N	\N	\N	\N	\N	2002-11-01	2002-12-01	2002-12-01	2008-04-01	\N	2008-04-01	\N	\N	\N	\N	Will Sullvan, Global Head of Product Risk and Safety Management	Mylan Inc.	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{Healthy}	main	cetirizine	\N	f	Taste, Form, Preference	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
193	2023-01-02 15:22:35.732	2023-03-20 19:40:38.954	NCT02320396	A Phase III, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Seasonal Allergic Rhinitis	Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)	Completed	This is an efficacy and safety study of desloratadine (MK-4117) in Japanese participants with seasonal allergic rhinitis (SAR). The primary hypothesis of this study is that the change from Baseline in Total Nasal Symptom Score (TNSS) is improved by desloratadine compared to placebo.	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	16	449	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	This study consists of a one-week Symptom Confirmation Period during which participants undergo a single-blinded placebo run-in, a two-week double-blind Treatment Period and a two-week Follow-up Period.	2015-01-09	2015-04-27	2015-04-27	2014-12-19	2016-05-30	2022-02-09	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	main	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{"Okubo K, Maeda Y, Oshima N, Hisada S. A Phase III clinical trial of desloratadine in Japanese subjects with seasonal allergic rhinitis: A randomized controlled trial. Arerugi. 2016;32(11):863-876.. [in Japanese] https://mol.medicalonline.jp/archive/search?jo=an9cltmd&ye=2016&vo=32&issue=11"}	PUBLISHED	https://mol.medicalonline.jp/archive/search?jo=an9cltmd&ye=2016&vo=32&issue=11	desloratadine
240	2023-01-02 15:22:35.735	2023-03-20 20:31:12.89	NCT00783354	A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius "Continuous Treatment" Versus Aerius "PRN Regimen" on Chronic Idiopathic Urticaria Patient Quality of Life	A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)	Completed	This double-blind pilot study was conducted to establish the best way of using desloratadine treatment to protect quality of life of chronic idiopathic urticaria (CIU) patients, after an initial 4-weeks of daily treatment: prolonging systematic daily treatment or as needed (PRN; in the case of symptoms).	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	18	129	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2003-04-01	2004-02-01	2004-04-01	2008-10-31	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Urticaria,"Chronic Idiopathic Urticaria"}	main	loratadine	\N	f	Urticaria	2022-08-17 18:44:47	{"Grob JJ, Auquier P, Dreyfus I, Ortonne JP. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy. 2009 Apr;64(4):605-12. doi: 10.1111/j.1398-9995.2008.01913.x. Epub 2008 Dec 30."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19133920/	desloratadine
140	2023-01-02 15:22:35.729	2023-03-20 17:02:20.862	NCT00621959	A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis	A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis	Completed	The study objective is to investigate the efficacy of levocetirizine in reducing symptoms associated with seasonal allergic rhinitis and in improving rhinitis-related Quality of Life	Parallel Assignment	UCB Pharma	INDUSTRY	All	65	18	596	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2008-03-01	2008-06-01	2008-06-01	2008-02-22	2009-08-06	2020-07-16	UCB Pharma	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	main	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{"Segall N, Gawchik S, Georges G, Haeusler JM. Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study. Ann Allergy Asthma Immunol. 2010 Mar;104(3):259-67. doi: 10.1016/j.anai.2009.12.003.","Mansfield LE, Hampel F, Haeusler JM, Georges G. Study of levocetirizine in seasonal allergic rhinitis. Curr Med Res Opin. 2010 Jun;26(6):1269-75. doi: 10.1185/03007991003745233."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/20377116/	levocetirizine
119	2023-01-02 15:22:35.728	2023-03-19 20:42:59.543	NCT03883386	Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use	Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use	Terminated	G-CSF causes a release of histamine that may be a cause of chronic bone pain. Loratadine targets histamine, and so may be effective in reducing bone pain.The researchers plan to prospectively assess the effectiveness of loratadine for chronic bone pain in patients with chronic G-CSF use.	Crossover Assignment	University of Michigan	OTHER	All	99	12	3	Actual	OTHER	University of Michigan	Randomized	\N	Triple	\N	\N	Supportive Care	\N	\N	2019-06-24	2019-10-18	2019-10-18	2019-03-20	2020-10-22	2020-10-22	University of Michigan Medical School	University of Michigan	Kelly Walkovich	Associate Professor of Pediatrics and Communicable Diseases	\N	\N	Principal Investigator	Poor enrollment	Interventional	{Child,Adult,"Older Adult"}	{"Phase 2"}	{"Bone Pain"}	main	loratadine	\N	t	Bone Pain	2022-08-17 18:44:47	{}	CT_RESULTS	\N	loratadine
100	2023-01-02 15:22:35.727	2023-03-20 16:32:44.018	NCT01445262	Drug Use Investigation for XYZAL	Drug Use Investigation for XYZAL	Completed	This post-marketing surveillance study (PMS) is conducted to collect safety and efficacy data among subjects with allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous who have never been treated with levocetirizine tablets before.	\N	GlaxoSmithKline	INDUSTRY	All	\N	\N	10728	Actual	INDUSTRY	GlaxoSmithKline	\N	\N	\N	\N	\N	\N	Prospective	\N	2011-02-01	2013-12-01	2013-12-01	2011-10-03	\N	2015-08-13	\N	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Child,Adult,"Older Adult"}	{}	{"Rhinitis, Allergic, Perennial and Seasonal"}	main	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
174	2023-01-02 15:22:35.73	2023-03-20 19:27:35.296	NCT03789422	Efficacy and Safety of Levocetirizine Alone or in Combination With Tranexamic Acid in the Treatment of Spontaneous Chronic Urticaria. Multicentric Controlled Randomized Study in Cross-over, Double-blind	Tranexamic Acid and Spontaneous Chronic Urticaria	Recruiting	Spontaneous chronic urticaria (UCS) is a disease that affects 1% of the general population with a potentially severe impact on quality of life. Most patients respond favorably to long-term antihistamine treatment, but sometimes it is necessary to give a high dose (4 times the formal dose, Berlin consensus 2016). These high doses are often accompanied by side effects requiring cessation of treatment. The therapeutic alternative is then omalizumab, an expensive biotherapy. UCS is secondary to non-specific mast cell activation. It has been shown to be associated with activation of fibrinolysis that correlates with the severity of symptoms. Patients with UCS resistant to levocetirizine were shown to have higher D-dimer levels than patients who responded to antihistamines. Tranexamic acid is a molecule with antifibrinolytic propertiesSeveral cases of severe chronic urticaria responding favorably to treatment with tranexamic acid have been reported. In our department, Investigators also noticed the improvement of some of their patients on tranexamic acid. The combination of these two treatments appears to be synergistic: action on histamine receptors and control of fibrinolysis.\n\nThe investigators propose to evaluate the association of tranexamic acid and levocetirizine for the treatment of chronic spontaneous urticaria.	Crossover Assignment	University Hospital, Grenoble	OTHER	All	\N	18	80	Anticipated	OTHER	University Hospital, Grenoble	Randomized	Multicentric controlled randomized crossover study, double-blind	Double	Double blind	\N	Treatment	\N	Multicentric controlled randomized crossover study, double-blind To evaluate the efficacy and safety of levocetirizine 10mg / day + tranexamic acid (AT) 2g / day versus levocetirizine 20mg / day alone in the chronic treatment of chronic urticaria evaluated at 4 weeks.\n\nA hierarchical analysis will be implemented in the following order:\n\nNon-inferiority of the combination levocetirizine 10 mg / day + tranexamic acid (TA) 2 g / day versus levocetirizine alone 20 mg / day in terms of effectiveness\nSuperiority of the combination levocetirizine 10 mg / day + tranexamic acid (AT) 2 g / day versus levocetirizine alone 20 mg / day in terms of tolerance\nSuperiority of levocetirizine 10mg / day + tranexamic acid (AT) 2g / day versus levocetirizine alone 20mg / day in terms of effectiveness Each objective will be tested sequentially if and only if the previous objective is validated.	2019-12-10	2022-09-01	2022-09-01	2018-12-28	\N	2021-04-28	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Chronic Spontaneous Urticaria"}	combination	cetirizine	\N	f	Urticaria	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
124	2023-01-02 15:22:35.729	2023-08-01 10:59:43.129	NCT00894231	Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis	Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis	Completed	The purpose of this study is to noninvasively measure the anti-inflammatory effect of levocetirizine after two weeks of treatment in allergic rhinitis subjects.	Crossover Assignment	AAADRS Clinical Research Center	OTHER	All	65	12	30	Anticipated	OTHER	AAADRS Clinical Research Center	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2009-01-01	2009-08-01	2009-08-01	2009-05-06	\N	2009-09-04	\N	\N	\N	\N	Miguel J Lanz MD FAAAAI	AAADRS	\N	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{"Perennial Allergic Rhinitis"}	main	levocetirizine	Anti-inflammatory effect	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/22185740/	levocetirizine
161	2023-01-02 15:22:35.731	2023-03-20 19:11:00.71	NCT00795522	An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria	An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)	Completed	This open-label study is being conducted to determine the effect of DL treatment for CIU on symptom and disease severity, quality of life, daytime functioning, and quality of sleep.	Single Group Assignment	Organon and Co	INDUSTRY	All	\N	18	51	Actual	INDUSTRY	Organon and Co	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2003-07-01	2005-02-01	2005-03-01	2008-11-21	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Urticaria}	main	desloratadine	\N	f	Urticaria	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
98	2023-01-02 15:22:35.727	2023-03-20 16:31:54.327	NCT04534153	The Effect of Sodium Lauryl Sulfate on the Oral Absorption of Fexofenadine in Humans	Excipient Effect on Drug Absorption in Humans	Not yet recruiting	The purpose of this study is to determine if sodium lauryl sulfate (SLS), a non-drug ingredient commonly added in drug products, affect absorption of drugs that are given together with the ingredient. Investigators want to find out if drug absorption is different in people taking the drug alone compared to people taking the drug with low and high amounts of sodium lauryl sulfate at the same time.	Crossover Assignment	University of California, San Francisco	OTHER	All	64	18	12	Anticipated	OTHER	University of California, San Francisco	Randomized	This is a single-center, randomized, double-blind, 3-period crossover trial. Subjects will be randomized to receive fexofenadine only under Treatment Arm 1 or fexofenadine and 3 mg SLS under Treatment Arm 2 or fexofenadine and 30 mg SLS under Treatment Arm 3.	Double	\N	\N	Basic Science	\N	This is a single-center, randomized, double-blind, 3-period crossover trial. Participants will be randomized to receive a Control capsule (fexofenadine single agent) under Treatment Arm 1 or a Test 1 capsule (fexofenadine and 3 mg SLS) under Treatment Arm 2 or Test 2 capsule (fexofenadine and 30 mg SLS) under Treatment Arm 3. Investigators will assess the effect of SLS on the absorption of fexofenadine by measuring SLS and fexofenadine concentrations in plasma and stool samples and determine the change in AUC (area under the curve), Cmax and other pharmacokinetic parameters, between Treatment Arms 2 or 3 and Treatment Arm 1.	2023-01-01	2023-08-01	2023-08-01	2020-09-01	\N	2022-12-01	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Early Phase 1"}	{"The Impact of Excipients on Drug Absorption"}	minimal	fexofenadine	Trial is not about fex but rather about SLS additive	f	Pharmacokinetics	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
195	2023-01-02 15:22:35.733	2023-03-20 19:42:10.895	NCT00319995	Efficacy and Safety of Combination Loratadine/Montelukast QD vs Pseudoephedrine and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis	Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)	Completed	This is a Phase 3, randomized, parallel-group, multicenter, double-dummy, double-blind study with a screening period. Subjects will receive one of the following three treatment groups for 15 days: loratadine 10 mg/montelukast 10 mg combination, pseudoephedrine 240 mg, or placebo. The primary objective of this study is to assess the efficacy of the combination of loratadine/montelukast, a once-daily tablet containing 10 mg loratadine and 10 mg montelukast, compared with placebo in subjects with seasonal allergic rhinitis (SAR) in relieving the symptom of nasal congestion. The safety profile of combined loratadine/montelukast relative to placebo and pseudoephedrine will also be evaluated.	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	15	1095	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2006-03-01	2006-06-01	2006-06-28	2006-04-27	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Rhinitis, Allergic, Seasonal"}	combination	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Prenner B, Anolik R, Danzig M, Yao R. Efficacy and safety of fixed-dose loratadine/montelukast in seasonal allergic rhinitis: effects on nasal congestion. Allergy Asthma Proc. 2009 May-Jun;30(3):263-9. doi: 10.2500/aap.2009.30.3228."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19549427/	loratadine
199	2023-01-02 15:22:35.733	2023-03-20 19:43:43.267	NCT00835640	A Relative Bioavailability Study of 180 mg Fexofenadine Hydrochloride Tablets Under Fed Conditions.	Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions	Completed	This study will compare the relative bioavailability (rate and extent of absorption) of 180 mg Fexofenadine Hydrochloride tablets manufactured for TEVA Pharmaceuticals Industries, Ltd. with that of 180 mg ALLEGRA Tablets by Aventis Pharmaceuticals, Inc. following a single oral dose (1 x 180 mg tablet) in healthy adult volunteers under fed conditions.	Crossover Assignment	Teva Pharmaceuticals USA	INDUSTRY	All	55	18	24	Actual	INDUSTRY	Teva Pharmaceuticals USA	Randomized	\N	None (Open Label)	\N	\N	\N	\N	Criteria for Evaluation: FDA Bioequivalence Criteria\n\nStatistical Methods: FDA bioequivalence statistical methods	2002-01-01	2002-01-01	2002-01-01	2009-02-03	2009-08-04	2009-08-20	Manager, Biopharmaceutics	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	main	fexofenadine	\N	f	Bioavailability	2022-08-18 16:54:53	{}	CT_RESULTS	\N	fexofenadine
147	2023-01-02 15:22:35.73	2023-03-20 17:06:56.051	NCT01673620	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety of Combination Montelukast/Loratadine (MK-0476A) in Mexican Patients With Allergic Rhinitis	A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)	Completed	The purpose of this study is to assess the safety and tolerability of montelukast 10 mg/loratadine 10 mg versus placebo in Mexican participants with allergic rhinitis.	Parallel Assignment	Organon and Co	INDUSTRY	All	65	15	69	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2012-07-04	2012-10-10	2012-10-10	2012-08-28	2014-11-14	2022-02-09	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Allergic Rhinitis"}	combination	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	CT_RESULTS	\N	loratadine
84	2023-01-02 15:22:35.726	2023-03-20 16:18:30.935	NCT01430260	A Multi-center, Open, Randomized, Three-arm, Parallel-group, Phase IV Study to Compare the Efficacy of Ciclesonide Nasal Spray and Levocetirizine, Alone and in Combination for the Patient With Allergic Rhinitis	Omnaris Versus Levocetirizine Phase 4 Study	Completed	This i a comparison of the efficacy ciclesonide nasal spray and levocetirizine, alone and in combination.	Parallel Assignment	Handok Inc.	INDUSTRY	All	\N	18	349	Actual	INDUSTRY	Handok Inc.	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	randomized, open-label, three arm, parallel group, multi-center study	2011-01-01	2012-07-01	2012-07-01	2011-09-08	\N	2012-09-06	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Allergic Rhinitis"}	comparison	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/25729623/	levocetirizine
173	2023-01-02 15:22:35.731	2023-03-19 20:57:23.899	NCT05095311	The Effects of Nedocromil Sodium and Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers	The Effects of Nedocromil Sodium and Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers	Recruiting	Exercise-induced arterial hypoxemia (EIAH), a reduced amount of oxygen in the arterial blood during exercise, has been observed in otherwise healthy, highly-trained endurance athletes during exercise at sea level. The extent of the arterial deoxygenation may be influenced by a histamine-mediated inflammatory response at the pulmonary capillary-alveolar membrane limiting oxygen diffusion. Moreover, while EIAH has been routinely explored in running and cycling, swimming is understudied despite potential mechanistic avenues which may put swimmers at further risk for EIAH. The purpose of this study is threefold: 1) to determine whether highly-trained swimmers experience EIAH during submaximal and maximal exercise, 2) to determine the extent to which histamine release influences oxyhemoglobin saturation during swimming exercise, and 3) to determine whether nedocromil sodium (NS), a mast cell stabilizer, and cetirizine HCl (CH), an H1-receptor competitive inhibitor, can improve oxyhemoglobin saturation during submaximal and maximal swimming exercise. Twenty-six (13 men, 13 women) highly-trained swimmers will complete an intense swimming protocol to assess the histamine response to intense exercise. A subset with the highest histamine responses will participate in three additional sessions (placebo, NS, and CH conditions) which will include a swimming aerobic capacity test and 5-minutes of swimming at both 70 and 85% of their maximal oxygen uptake.	Crossover Assignment	Indiana University	OTHER	All	35	18	26	Anticipated	OTHER	Indiana University	Non-Randomized	\N	Double	\N	\N	Basic Science	\N	For the first testing session, participants will report to the Indiana University Human Performance Laboratory to complete a medical screening and, if willing, consent to the procedures of the study. The medical screening will include measurements of height, weight, resting heart rate, resting blood pressure, and resting pulmonary function along with a health history questionnaire.\n\nThe second testing session consists of an assessment of risk factors for development of EIAH, specifically changes in blood biomarkers pre- and post-swimming exercise. Participants will report to the Counsilman-Billingsley Aquatics Center and complete an exercise protocol designed to elicit an inflammatory response. Venous blood draws will be performed to assess participants' pre-exercise complete blood count and pre- and post-intense exercise concentrations of plasma IL-1, IL-8, plasma histamine, whole blood histamine, and histamine release. Measurements of hemoglobin concentration and hematocrit will also be performed pre- and post-exercise in order to correct biomarker concentrations for fluid loss during exercise. Swimmers of each sex that exhibit the largest histamine release will be selected for further study until at least four swimmers of each sex complete all three experimental trials.\n\nParticipants that exhibit increases in inflammatory markers following swimming exercise will visit the Human Performance Laboratory on three occasions separated by at least 48 hours and no more than 60 days. Apart from receiving a placebo (PL) or different drug treatment (nedocromil sodium, NS; cetirizine HCl, CH) prior to exercise, participants will perform identical protocols on each visit to the laboratory. Participants will report to the lab and consume either a placebo or CH pill, followed by a health history update questionnaire and their resting pulmonary function will be measured. Participants will then complete a self-selected warm-up that will be standardized across all three testing sessions, followed by administration of either a placebo or NS through an inhaler and instrumentation. The exercise protocol beings with a progressive swimming test to maximum aerobic capacity (VO2max) in a swimming flume, followed by two constant load work bouts at approximately 70 and 85% of the previously recorded HRmax while peripheral capillary oxyhemoglobin saturation (SpO2) is continuously monitored. Participants will receive a 20-min break between each work bout. Drug treatments will be assigned in a double-blind, randomized crossover fashion such that each participant receives each treatment. Concentrations of plasma histamine, whole blood histamine, and histamine release will be assessed from pre- and post-exercise blood samples.	2021-05-19	2022-12-31	2022-12-31	2021-10-27	\N	2022-02-02	\N	Indiana University	Robert Chapman	Principal Investigator	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Phase 4"}	{"Exercise-induced Arterial Hypoxemia"}	combination	cetirizine	\N	t	Exercise-induced Arterial Hypoxemia	2022-08-17 13:39:16	{"Coyle MA, Goss CS, Manz WJ, Greenshields JT, Chapman RF, Stager JM. Nedocromil sodium and diphenhydramine HCl ameliorate exercise-induced arterial hypoxemia in highly trained athletes. Physiol Rep. 2022 Jan;10(1):e15149. doi: 10.14814/phy2.15149."}	NO_PUBLICATION_FOUND	\N	cetirizine
214	2023-01-02 15:22:35.734	2023-03-20 20:04:21.247	NCT01651481	Open-label, Randomized, Single Dose Crossover Study to Evaluate the Pharmacokinetics and Safety of Singulair (10 mg) and Xyzal (5 mg) in Free Combination and Fixed-dose Combination as HCP1102 in Healthy Male Volunteers	Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination	Completed	The purpose of this study is to evaluate the pharmacokinetics and safety of Singulair (10 mg) and Xyzal (5 mg) in free combination and fixed-dose combination as HCP1102	Crossover Assignment	Hanmi Pharmaceutical Company Limited	INDUSTRY	Male	55	20	28	Actual	INDUSTRY	Hanmi Pharmaceutical Company Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2012-07-01	2012-09-01	2012-12-01	2012-07-27	\N	2013-08-13	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Rhinitis}	combination	levocetirizine	\N	f	Pharmacokinetics	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
366	2023-01-02 15:22:35.743	2023-03-21 10:04:14.438	NCT02007434	A Single Center, Double-blind, Parallel-group, Two Factor Patient-Experience Management Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area	Patient Experience Study of Deoxycholic Acid Injection	Completed	The objectives of this study are to determine the safety of deoxycholic acid subcutaneous (SC) injections in the submental area and to evaluate the effects of four interventions, relative to placebo in the submental area, particularly with regard to assessment and management of pain, bruising, and swelling/edema.	Parallel Assignment	Kythera Biopharmaceuticals	INDUSTRY	All	65	18	84	Actual	INDUSTRY	Kythera Biopharmaceuticals	Randomized	\N	Double	\N	\N	Treatment	\N	This study evaluated the effects of four interventions, pre- and post-subcutaneous injections of deoxycholic acid injection relative to placebo in adults with submental fullness. Participants were randomized to either deoxycholic acid injection or placebo in a ratio of 4:1 and to one of four patient experience management paradigms.\n\nParticipants were required to visit the research facility on 10 separate occasions for protocol-defined treatments, procedures, tests, and observations.	2013-12-01	2014-06-01	2014-06-01	2013-12-10	2015-07-03	2015-07-28	Kythera	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Moderate or Severe Submental Fullness"}	minimal	loratadine	todo check usecase, compare to other trial about submental fat	f	Submental Fat	2022-08-17 18:44:47	{"Dover JS, Kenkel JM, Carruthers A, Lizzul PF, Gross TM, Subramanian M, Beddingfield FC 3rd. Management of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat. Dermatol Surg. 2016 Nov;42 Suppl 1:S288-S299. doi: 10.1097/DSS.0000000000000908. Erratum In: Dermatol Surg. 2017 Jul;43(7):1000."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/27787269/	loratadine
138	2023-01-02 15:22:35.73	2023-03-20 17:01:08.536	NCT00653224	A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis	A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis	Completed	The study objective is to investigate the efficacy of levocetirizine in reducing symptoms associated with seasonal allergic rhinitis and in improving rhinitis-related Quality of Life.	Parallel Assignment	UCB Pharma	INDUSTRY	All	65	18	580	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2008-04-01	2008-07-01	2008-07-01	2008-04-04	2009-11-17	2011-08-31	UCB Pharma	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	main	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	CT_RESULTS	\N	levocetirizine
85	2023-01-02 15:22:35.726	2023-03-20 16:19:20.758	NCT00152412	A 4 Week Open, Multi-center Study Evaluating the Safety of Levocetirizine 1.25 mg b.i.d. Given as 0.5 mg/mL Oral Solution in 2 to 6 Year-old Children Suffering From Allergic Rhinitis.	Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis	Completed	4 week open study to evaluate the safety of levocetirizine in young children (2 - 6 years) suffering from allergic rhinitis. As secondary objective, this study will assess the efficacy of the treatment by means of the T4SS (Total 4 symptoms scores of allergic rhinitis) and each of the 4 individual rhinitis symptom scores	Single Group Assignment	UCB Pharma	INDUSTRY	All	6	2	30	\N	INDUSTRY	UCB Pharma	Non-Randomized	\N	None (Open Label)	\N	\N	\N	\N	\N	2004-06-01	2004-12-01	2004-12-01	2005-09-09	\N	2014-08-26	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Child}	{"Phase 2"}	{"Allergic Rhinitis"}	main	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
164	2023-01-02 15:22:35.731	2023-03-20 19:12:57.763	NCT02653339	\N	Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.	Unknown status	This is a controlled clinical trials about traditional Chinese medicine named Qufeng Shengshi Fangwhich consisted of cicada sloughbombyx batryticatusradix angelicaeradix silerishoneysuckle flowerforsythialithospermum and radix glycyrrhizaeand Loratadine on treatment of Allergic Rhinitis.There are 180 Patients with allergic rhinitis recruited from Department of Allergy and Traditional Chinese.To carry on statistical analysis of the result of the self and between-group cross-reference by two questionnaires filled before and after treatment.	Parallel Assignment	Peking Union Medical College Hospital	OTHER	All	70	18	180	Anticipated	OTHER	Peking Union Medical College Hospital	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2016-06-01	2018-03-01	2018-08-01	2016-01-12	\N	2016-04-22	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{"Rhinitis, Allergic, Perennial"}	combination	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
207	2023-01-02 15:22:35.734	2023-03-20 19:59:42.027	NCT00598780	Long-term Evaluation of Safety and Treatment Satisfaction With Levocetirizine in Routine Clinical Practice in the Czech and Slovak Republics - Non-interventional Study	Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study	Completed	To evaluate over a period of 6 months the safety and the treatment satisfaction of newly prescribed levocetirizine in patients of age  2 years with persistent allergic rhinitis.	\N	UCB Pharma	INDUSTRY	All	\N	2	7870	Actual	INDUSTRY	UCB Pharma	\N	\N	\N	\N	Cohort	\N	Prospective	This is a non-interventional, prospective, post-authorization, multi-centre cohort study in patients treated with levocetirizine.\n\nThe baseline data will be collected at the visit to the physician when levocetirizine is prescribed for the first time for the patient for Persistent Allergic Rhinitis. The data will then be collected during 2 visits occurring within the first 6 months of treatment, as usually scheduled in normal clinical practice in the Czech and Slovak Republics. This is after approximately 4 weeks and 6 months of treatment or earlier, if the treatment is stopped	2007-09-01	2008-09-01	2008-09-01	2008-01-23	\N	2012-05-28	\N	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Child,Adult,"Older Adult"}	{}	{"Rhinitis Allergic, Persistent"}	main	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
367	2023-01-02 15:22:35.743	2023-03-21 10:13:06.052	NCT00080574	The Effects of Thyroid Hormone on Cytochrome P450 and P-Glycoprotein Activity in Thyroid Cancer Patients	The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients	Completed	This study will examine whether and how levothyroxine (Synthroid, a synthetic thyroid hormone) affects the way the body handles other drugs. If levothyroxine does affect the metabolism of other drugs, the dose of those medications may need to be increased to enhance their action or decreased to avoid adverse reactions.\n\nPatients 18 years of age and older with thyroid cancer who are participating in NIH protocol #77-DK-0096 and are receiving long-term suppression therapy with levothyroxine may be eligible for this study. This is not a study of thyroid cancer or of potential new drugs to treat it. Thyroid cancer patients are being studied because their treatment regimen provides an opportunity to study drug metabolism while patients are both on and off levothyroxine therapy.\n\nParticipants come to the NIH Clinical Center on two occasions: once while they are regularly taking their levothyroxine, and once while they are off the medication in preparation for their radioactive iodide diagnostic scan for the procedures outlined below. The time interval between the two clinic visits depends on whether the first visit is while the patient is on or off medication. Participants are asked to fast overnight before each visit and to abstain from certain foods and beverages for 48 to 72 hours before the visit. At each visit, patients undergo the following procedures:\n\nMedication history, limited physical examination, and blood draw for laboratory tests, including a test to look for genes important in eliminating medications from the body.\nInsertion of a catheter (thin plastic tube) into an arm vein for collecting blood samples.\nShave skin biopsy (optional) to explore how proteins in the skin that metabolize and transport drugs are affected by thyroid hormone. For this procedure, the skin is cleaned, numbed with medicine, and a small sample of the top layer is removed with a razor blade. The wound heals in 2 to 3 days.\nMedication dosing. Participants take all of the following substances by mouth at the same time: 1) 200 mg of caffeine, a compound commonly found in chocolate, soda/pop, coffee, tea and non-prescription products to prevent sleep; 2) 30 mg of dextromethorphan, a non-prescription cough suppressant; 3) 40 mg of omeprazole, a prescription drug for heartburn and stomach ulcers; 4) 8 mg of midazolam, a prescription drug used to cause relaxation and drowsiness; and 5) 120 mg of fexofenadine, a non-sedating prescription antihistamine used to treat allergies.\nBlood and urine sampling. Fifteen blood samples of about 5 mL (1 teaspoon) each are collected through the catheter and urine is collected over the next 24 hours to determine what happens to the test drugs in the body.\n\nParticipants may resume their normal diet 4 hours after taking the study medications.	\N	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NIH	All	\N	\N	20	\N	NIH	National Institutes of Health Clinical Center (CC)	\N	\N	\N	\N	\N	Treatment	\N	Interaction between thyroid hormones and commonly prescribed drugs has been well documented, resulting in augmentation or attenuation of the action of either compound. Phase I drug metabolism is mediated mostly by enzymes belonging to the cytochrome p450 superfamily. Studies in animals and cell cultures have shown that thyroid hormones play an important role in the constitutive expression of the p450 enzymes, thus potentially altering the metabolism and the effects of a variety of drugs. P-glycoprotein is expressed in the major organs associated with drug absorption, distribution, and elimination from the body (e.g. intestine, kidney, liver, skin, and the blood-brain barrier). Expression of intestinal P-glycoprotein in humans also appears to be influenced by thyroid hormones. We intend to study the effect of thyroid hormones on the activity of CYP1A2, CYP2C19, CYP2D6, CYP3A4 and P-glycoprotein by using a five-drug cocktail (caffeine, omeprazole, dextromethorphan, midazolam, and fexofenadine) administered in patients with thyroid cancer, both on thyroid hormone suppression therapy (in conditions of subclinical hyperthyroidism) and off this treatment (in conditions of hypothyroidism) at the time of their routine radioactive iodine scan. Additionally we will perform two skin biopsies in order to assess the pattern of expression of metabolic enzymes and drug transport proteins on and off thyroid hormone suppression therapy.	2004-04-01	\N	2005-11-01	2004-04-07	\N	2008-03-04	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 2"}	{"Thyroid Cancer"}	minimal	fexofenadine	usecase of fex is a probing substance	f	Pharmacokinetics	2022-08-18 16:54:53	{"Meisel C, Gerloff T, Kirchheiner J, Mrozikiewicz PM, Niewinski P, Brockmoller J, Roots I. Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med (Berl). 2003 Mar;81(3):154-67. doi: 10.1007/s00109-002-0417-4. Epub 2003 Mar 15.","Nolan SR, Self TH, Norwood JM. Interaction between rifampin and levothyroxine. South Med J. 1999 May;92(5):529-31. doi: 10.1097/00007611-199905000-00018.","Blackshear JL, Schultz AL, Napier JS, Stuart DD. Thyroxine replacement requirements in hypothyroid patients receiving phenytoin. Ann Intern Med. 1983 Sep;99(3):341-2. doi: 10.7326/0003-4819-99-3-341. No abstract available."}	NO_PUBLICATION_FOUND	\N	fexofenadine
130	2023-01-02 15:22:35.729	2023-03-20 16:56:14.602	NCT00502775	A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis	Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine	Completed	The primary objective of the study is to compare nighttime symptom relief of fluticasone furoate nasal spray versus oral fexofenadine	Parallel Assignment	GlaxoSmithKline	INDUSTRY	All	\N	12	680	Actual	INDUSTRY	GlaxoSmithKline	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2007-08-01	2007-11-01	2007-11-01	2007-07-18	2009-03-20	2016-12-09	GlaxoSmithKline	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{"Rhinitis, Allergic, Seasonal"}	comparison	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
181	2023-01-02 15:22:35.732	2023-03-20 19:31:06.257	NCT01332188	A Single Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Efficacy of Three Different Concentrations of Cetirizine (0.05%, 0.1%, and 0.24%) Ophthalmic Solution Versus Vehicle in the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model (CAC)	Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model	Completed	The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) Model.	Parallel Assignment	Aciex Therapeutics, Inc.	INDUSTRY	All	\N	10	101	Actual	INDUSTRY	Aciex Therapeutics, Inc.	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2011-04-01	2011-06-01	2011-10-01	2011-04-11	2017-08-30	2017-08-30	Nicox Ophthalmics Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 2","Phase 3"}	{"Allergic Conjunctivitis"}	main	cetirizine	\N	f	Allergic Conjunctivitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
111	2023-01-02 15:22:35.728	2023-03-20 16:37:51.288	NCT00741897	A Monitored Release Study On The Efficacy And Safety of Fexofenadine (Telfast) 30mg Pediatric Tablets On Filipino Children Aged 6 To 11 for The Relief of Perennial And Intermittent Allergic Rhinitis.	Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis	Completed	To determine the safety and efficacy of Fexofenadine (Telfast) 30mg pediatric tablets on Filipino children aged 6 to 11 for the relief of symptoms associated with perennial and intermittent allergic rhinitis.	Single Group Assignment	Sanofi	INDUSTRY	All	11	6	264	Actual	INDUSTRY	Sanofi	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2002-03-01	2003-12-01	\N	2008-08-26	\N	2009-09-15	\N	\N	\N	\N	Medical Affairs Study Director	sanofi-aventis	\N	\N	Interventional	{Child}	{"Phase 4"}	{"Rhinitis, Allergic, Perennial"}	main	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
209	2023-01-02 15:22:35.734	2023-03-20 20:01:37.567	NCT05461456	An Open Label, Single-Dose, Single-Treatment, Single-Period Safety and Bioavailability Study of Fexofenadine Hydrochloride Topical Lotion 1% in Healthy, Adult, Male Human Subjects	Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%	Completed	The investigational lotion is envisaged as an short- and long term "Ease & Prevent" monotherapy for adults and children with mild to moderate eczema. With itch representing the most burdensome symptom in eczema, the main objectives with the lotion is fast and efficient itch relief, high tolerability, and high short- and long term safety. This phase 1 study aims to monitor skin tolerability, and how much of the active compound that is absorbed to the bloodstream.	Single Group Assignment	OrchestratePharma GmbH	INDUSTRY	Male	45	18	12	Actual	INDUSTRY	OrchestratePharma GmbH	N/A	The study is an 'Open Label, Single-Dose, Single-Treatment, Single-Period Safety and Bioavailability Study in Healthy, Adult, Male Human Subjects, where the subjects will be housed in the clinical facility from not less than 11 hours pre-dose till at least 72 hours post-dose. Altogether, the subject will stay for consecutive 03 days and 04 nights in the facility.	None (Open Label)	\N	\N	Treatment	\N	Fexofenadine Hydrochloride Topical Lotion 1% (OP2101) is a novel patented formulation developed for the treatment of skin disorders characterized by pruritus. Research show that oral Fexofenadine Hydrochloride (FX) may lead to a small improvement of pruritus in patients with Atopic Dermatitis (AD). In clinical practice, oral antihistamines are widely used off-label for pruritus relief in AD, indicating a discrepancy in trial outcomes and real-life experience. The pre-study thesis postulates that the antipruritic effect of FX can be leveraged in a dose-response relationship facilitated by high topical concentration of FX in direct contact with the pathological process of the skin. The sponsor also suggest that the Cytosolic phospholipase A2 (cPLA2) blocking property of FX is an untapped resource that is likely to be dose-response dependent and manifested by means of high topical concentration in proximity to the inflammatory process. The repositioning of FX to a topical treatment has the potential for high safety, efficacy, fast relief, and ease of use. OP2101 is also aimed at inflammation control, suppression of bacterial imbalance, moisture retention, upregulation of antimicrobial peptides, and skin barrier restoration. As such, it targets six of the pathological pillars of AD. Assessment of topical tolerability and skin adsorption (systemic exposure) are the main objectives in this phase 1 study.	2022-04-01	2022-10-16	2022-10-16	2022-07-18	\N	2022-11-02	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{"Atopic Dermatitis","Atopic Dermatitis Eczema","Atopic Rash",Rash,Pruritus,Urticaria,"Urticaria Chronic",Psoriasis,"Psoriasis Vulgaris","Skin Rash","Skin Inflammation",Eczema}	main	fexofenadine	\N	f	Eczema	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
369	2023-01-02 15:22:35.743	2023-03-21 10:44:40.144	NCT04633967	Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.	Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.	Unknown status	To evaluate a Novel infusion protocol in MS patients treated with Alemtuzumab	\N	Maritime Neurology	NETWORK	All	65	18	30	Actual	NETWORK	Maritime Neurology	\N	\N	\N	\N	Cohort	\N	Retrospective	This observational study will evaluate and anaylse primary data investigating the effects of a novel peri-infusion regimen in MS patients in a Candian clinical setting infused with Alemtuzumab.\n\nThis observational study has been developed by a Canadian neurologist with the intent to treat MS patients receiving Alemtuzumab in order to mitigate infusion associated reactions (safety) by utilizing an alternative peri-infusion protocol which is a deviation from the recommendation in the Canadian Product Monograph.\n\nAll the patients' recruited for this observational study were informed and consented for this novel peri-infusion regimen and were clinically followed by the neurologist for the two Alemtuzumab infusion cycles and for any subsequent Alemtuzumab infusions for potential mitigation of infusion associated reactions associated with Alemtuzumab.	2016-05-15	2020-12-30	2021-02-28	2020-11-18	\N	2020-11-18	\N	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Adult,"Older Adult"}	{}	{"Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis"}	pre-medication	loratadine	\N	f	Infusion Reaction	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	desloratadine
113	2023-01-02 15:22:35.728	2023-03-20 16:39:14.6	NCT01451996	The Efficacy of Claritin in Healthy Subjects	The Efficacy of Claritin in Healthy Subjects	Completed	The primary goal of this study is to examine determinants of the efficacy of Claritin.	Parallel Assignment	University of Chicago	OTHER	All	65	18	340	Actual	OTHER	University of Chicago	Randomized	\N	Triple	\N	\N	Other	\N	Subjects will be given Claritin 10mg tablet. Subjects will be challenged with histamine via skin prick prior to Claritin administration and at 1 and 2 hours post administration. We will measure and record wheal and flare area 10 minutes following each challenge.	2011-10-01	2012-07-01	2012-12-01	2011-10-14	2018-03-13	2018-03-13	University of Chicago	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Healthy}	main	cetirizine	movies with commercials are being shown for Claritin and Zyrtec	f	Health	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	loratadine
171	2023-01-02 15:22:35.731	2023-03-20 19:25:52.356	NCT00816972	Pilot Efficacy and Safety Field Trial of Desloratadine Administered Concomitantly With Oxybutynin, in Subjects With Seasonal Allergic Rhinitis and Post-Nasal Drip	Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)	Completed	This was a 1-week study of desloratadine (DL) plus oxybutynin (OXY) at two dose levels in the treatment of post-nasal drip in participants with seasonal allergic rhinitis. Participants received either desloratadine twice a day, oxybutynin twice a day, desloratadine plus lower-dose oxybutynin twice a day, desloratadine plus higher-dose oxybutynin twice a day, or placebo for 7 days.	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	18	540	Actual	INDUSTRY	Organon and Co	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2005-04-01	2005-06-01	2005-06-01	2009-01-06	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Post-nasal Drip","Seasonal Allergic Rhinitis",Rhinorrhea}	combination	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	desloratadine
157	2023-01-02 15:22:35.73	2023-03-19 20:55:58.028	NCT04224428	Role of Fexofenadine in Reducing Albuminurea in Patients With Diabetic Kidney Disease	Role of Fexofenadine in Diabetic Kidney Disease	Completed	This study will that will be conducted on 60 outpatients previously diagnosed with type 2 diabetes mellitus.\nPatients will be recruited from Internal Medicine Department, Tanta University Hospital, Tanta, Egypt.\n\nThis study will be randomized, controlled, parallel, prospective clinical study. Accepted patients will be randomized into 2 groups as the following\n\nGroup 1 (Control group): 30 patients will receive maximum tolerated dose of ACEI for six months\nGroup 2 (Fexofenadine group): 30 patients will receive maximum tolerated dose of ACEI plus fexofenadine tablets 60 mg once daily for six months\n\nThe primary end point will be the change in Urinary albumin to creatinine ratio (UACR) after six months of treatment	Parallel Assignment	Tanta University	OTHER	All	70	18	60	Actual	OTHER	Tanta University	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2020-01-01	2022-02-01	2022-02-01	2020-01-13	\N	2022-05-05	\N	Tanta University	Basma Mahrous El-Fatatry	Principal investigator, Assistant lecturer of Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Diabetic Kidney Disease"}	main	fexofenadine	\N	t	Diabetes	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
146	2023-01-02 15:22:35.73	2023-03-20 17:06:37.068	NCT00520754	The Efficacy and Safety of Levocetirizine Dihydrochloride Oral Drops Given 0.125 mg/kg b.i.d. During 90 Days in the Treatment of Recurrent Cough Associated With Other Allergic Symptoms, e.g. Wheezing, in Children Aged 1-2 Years.	Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children	Completed	Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children	Single Group Assignment	UCB Pharma	INDUSTRY	All	2	0.1666666666666667	15	Actual	INDUSTRY	UCB Pharma	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2001-12-01	2003-03-01	2003-03-01	2007-08-27	\N	2013-12-12	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Child}	{"Phase 2"}	{Cough}	main	levocetirizine	Related: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896440/	f	Cough	2022-09-15 18:58:14	{"Cranswick N, Turzikova J, Fuchs M, Hulhoven R. Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. Int J Clin Pharmacol Ther. 2005 Apr;43(4):172-7. doi: 10.5414/cpp43172."}	NO_PUBLICATION_FOUND	\N	levocetirizine
121	2023-01-02 15:22:35.729	2023-03-20 16:46:58.644	NCT00704769	Observational Study Evaluating the Safety and Efficacy of Desloratadine Syrup for Perennial Allergic Rhinitis in Indonesian Pediatric Patients	Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)	Completed	Evaluate the safety and general clinical response of desloratadine syrup in the relief of symptoms associated with perennial allergic rhinitis in Indonesian pediatric patients.	\N	Organon and Co	INDUSTRY	All	11	2	591	Actual	INDUSTRY	Organon and Co	\N	\N	\N	\N	Cohort	\N	Prospective	Children, ages 2-11, with a history of perennial allergic rhinitis	2005-05-01	2007-12-01	2007-12-01	2008-06-25	2009-08-11	2022-02-09	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Child}	{}	{Rhinitis}	main	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{}	CT_RESULTS	\N	desloratadine
184	2023-01-02 15:22:35.732	2023-03-20 19:36:10.706	NCT00946608	Comparative, Randomized, Single-Dose, 3-way Crossover Bioavailability Study of Sandoz Inc. and Schering (Claritin) 10 mg Loratadine Tablets In Healthy Adult Male Volunteers Under Fed and Fasting Conditions	To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets	Completed	To demonstrate the relative bioavailability study of Loratadine 10 mg tablets.	Single Group Assignment	Sandoz	INDUSTRY	Male	45	18	30	Actual	INDUSTRY	Sandoz	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2005-06-01	2005-08-01	2005-08-01	2009-07-27	\N	2017-03-28	\N	\N	\N	\N	Eric Mittleberg, Ph.D, VP of Product Development	Sandoz Inc.	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Allergy}	main	loratadine	\N	f	Bioavailability	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
201	2023-01-02 15:22:35.733	2023-03-20 19:44:15.077	NCT02171546	A Two-part Study to Determine the Relative Bioavailability of Dabigatran Etexilate 150 mg Bid (Capsules) With and Without 600 mg Quinidine Sulfate Tablets (Part 1) and to Measure the Effect of Quinidine as a Probe Inhibitor of P-glycoprotein on the Absorption of Fexofenadine, a Probe Substrate of P-glycoprotein (Part 2) in Healthy Male and Female Volunteers (an Open-label, Randomised, Two Times Two-way Crossover Study)	Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers	Terminated	Part 1: To investigate the effect of quinidine, a P-glycoprotein (P-gp) probe inhibitor on the bioavailability of dabigatran etexilate,\n\nPart 2: To determine the effect of quinidine on the bioavailability of fexofenadine, a probe substrate for P-gp	Crossover Assignment	Boehringer Ingelheim	INDUSTRY	All	55	18	42	Actual	INDUSTRY	Boehringer Ingelheim	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2007-11-01	2008-01-01	\N	2014-06-24	\N	2014-06-24	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	combination	fexofenadine	\N	f	Bioavailability	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
376	2023-01-02 15:22:35.743	2023-03-21 10:55:56.042	NCT01384994	\N	Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients	Unknown status	Up to 50% of patients with colorectal cancer (CRC) develop liver metastasis during the course of their disease. In 30-40% of patients metastasis is confined to the liver. In these patients R0-resection of metastases may contribute to marked improvement of overall survival. Primary resection of liver metastasis is possible in about 15-20% of patients (Scheele 2005, Petrelli 2005). Recent studies indicate that perioperative chemotherapy may improve survival after resection of liver metastases (Portier 2007, Nordlinger 2007). Nevertheless, there is evidence that 70-80% of patients have recurrent disease after resection of liver metastasis. Stratification for the risk of recurrence may be performed using the FONG-score (Fong 1999).\n\nThis study is designed to investigate the efficacy of postoperative chemotherapy combined with an anti-EGFR treatment using panitumumab.\n\nThe majority of patients present to the surgeon after chemotherapeutic pretreatment with various not necessarily standardized regimens. Also postoperative therapy after resection of liver metastasis is not a clearly defined standard of care in Germany.\n\nBased on the study by Nordlinger et al. an oxaliplatin-based regimen is chosen for postoperative therapy (Nordlinger 2008). For reasons of practicability mFOLFOX6 was selected as the chemotherapy backbone for additive treatment (Allegra 2010).\n\nAlso, there is evidence that the combination of FOLFOX with panitumumab is associated with enhanced antitumor activity (Douillard et al. ESMO 2009). The experimental treatment arm will therefore evaluate the combination of FOLFOX plus panitumumab. Since in colorectal cancer monoclonal antibodies directed against the EGFR are not active in KRAS mutant patients, the experimental arm including panitumumab will only be performed in KRAS wild-type patients (Amado 2008).\n\nThe planned study aims to assess the efficacy of postoperative therapy with FOLFOX plus panitumumab followed by maintenance with panitumumab for 3 months in KRAS wild-type patients, compared to the historical data for standard FOLFOX chemotherapy alone, which are verified by a randomised control group without the antibody. (Figure 1: Study Design).\n\nThe study will allow preoperative treatment with regimens such as FOLFIRI, XELIRI, FOLFOX or XELOX +/-bevacizumab or +/- cetuximab. However, only those patients will be considered eligible who did not progress during preoperative therapy.\n\nAfter surgery, a treatment-free interval of at least 4 weeks, but no longer than 8 weeks will be granted.\n\nKRAS-wild-type patients (60% of all pts) will then be randomized in a 2:1 ratio to an experimental arm with FOLFOX + panitumumab or to a reference arm with FOLFOX alone. Combination treatment will be performed for a duration of 3 months, after which patients in the experimental arm will receive maintenance therapy with panitumumab for further 3 months. In the reference arm, treatment will, however, be ended after 3 months.	Parallel Assignment	PD Dr. med. Volker Heinemann	OTHER	All	\N	18	111	Anticipated	OTHER	Ludwig-Maximilians - University of Munich	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2011-08-01	2013-08-01	2014-08-01	2011-06-29	\N	2012-07-09	\N	Ludwig-Maximilians - University of Munich	PD Dr. med. Volker Heinemann	Sponsor Delegatated Person	\N	\N	Sponsor-Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Colorectal Cancer","KRAS Wildtype","After Resection of Liver Metastases"}	not included	fexofenadine	Allegra as name of some citation	f	Cancer	2022-08-18 16:54:53	{"Modest DP, Karthaus M, Kasper S, Moosmann N, Keitel V, Kiani A, Uhlig J, Jacobasch L, Fischer V Weikersthal L, Fuchs M, Kaiser F, Lerchenmuller C, Sent D, Junghanss C, Held S, Lorenzen S, Kaczirek K, Jung A, Stintzing S, Heinemann V. FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314). Eur J Cancer. 2022 Sep;173:297-306. doi: 10.1016/j.ejca.2022.07.012. Epub 2022 Aug 12."}	UNKNOWN	\N	fexofenadine
213	2023-01-02 15:22:35.734	2023-03-20 20:03:07.306	NCT01720485	A Double-blind,Double Dummy, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Adults With Moderate - Severe Persistent Allergic Rhinitis	Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis Treatment	Unknown status	The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the treatment of Moderate - Severe Persistent Allergic Rhinitis in Adults.	Parallel Assignment	EMS	INDUSTRY	All	\N	18	234	Anticipated	INDUSTRY	EMS	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2013-10-01	2013-12-01	2014-03-01	2012-11-02	\N	2013-09-25	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Allergic Rhinitis"}	combination	desloratadine	Results submitted	f	Allergic Rhinitis	2022-09-15 19:16:20	{}	CT_RESULTS	\N	desloratadine
117	2023-01-02 15:22:35.728	2023-03-20 16:44:35.861	NCT03376594	Efficacy and Safety of Benjakul Extract Capsules and Loratadine for Treatment Allergic Rhinitis Patients (Clinical Trial Phase II)	Benjakul Extract and Loratadine for Treatment Allergic Rhinitis Patients	Completed	To compare the effectiveness of Benjakul extract capsules at 300 mg per day with Loratadine drug in the treatment of allergic rhinitis patients in small group (Clinical Trial Phase II).\nTo study the safety and side effects of Benjakul extract capsules 300 mg per day and Loratadine drug for allergic rhinitis patients.	Parallel Assignment	Thammasat University	OTHER	All	70	20	60	Actual	OTHER	Thammasat University	Randomized	RCT	Double	Grouping uses Randomize controlled trial (RCT) and groups by using Random allocation by means of Simple Randomization as well as using the code with BJK followed by 3 digits (BJK001, BJK002, ...) and treating in double blinding form.	\N	Treatment	\N	Group 1consists of 30 patients, taking Benjakul dosage 100 mg or 1 capsule 3 times daily. beforeBreakfast, lunch and dinner.\nGroup 2 consists of 30 patients, taking Loratadine dosage 100 mg 1time daily.Taking drug is as follows\n\nVolunteers will be treated by drugs continuously for a period of six weeks. Taking three times a day 1 tablet before meals (breakfast, lunch, dinner), giving drug based on random.\n\nVolunteers groups receiving Benjakul take 1capsule 3 times daily. Volunteer groups receiving Loratadine take loratadine tablet first 1capsule 1 time daily and then taking placebo once 1 capsule during the day and 1 capsule in the evening.\n\nPatients have to report all the 42 days (6 weeks). The blood and urine samples will be collected and evaluated before the treatment and later following symptoms after 21 and 42 days (3 weeks and 6). Assessment methods to measure the nasal, other of nasal symptoms, assessment of quality of life and overall treatment (Global assessment),Acoustic Rhinometry and tools which are used to evaluate nasal congestion. measuring the narrowest cross-sectional area of the nasal cavity, this tool takes a short time to evaluate and can determine volume of nasal cavity by calculating of the CSA in the nasal cavity. In addition, the researchers areable to check the safety of using medications by taking blood and urine samples to check Hematology CBC, Lipid profile, FBS monitoring of renal function (Renal function test) and liver function tests (Liver Function Tests: LFTs). So, the volunteers must NPO before every blood drawing.	2017-07-30	2018-02-01	2018-03-31	2017-12-18	\N	2018-04-26	\N	Thammasat University	Katanchalee Houngiam	Faculty of Medicine	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Allergic Rhinitis"}	combination	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
194	2023-01-02 15:22:35.733	2023-03-20 19:40:59.315	NCT03108274	A Three-Part Phase 1 Study to Determine the Potential Drug Interaction Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil in Healthy Subjects	A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants	Completed	The purpose of this study was to determine the potential drug interaction between danicopan (ACH-0144471) and midazolam, fexofenadine, and mycophenolate mofetil. This was a 3-part study, with each part being an open-label, fixed-sequence, 2-treatment study in healthy adult participants.	Parallel Assignment	Alexion Pharmaceuticals	INDUSTRY	All	60	18	35	Actual	INDUSTRY	Alexion Pharmaceuticals	Non-Randomized	Part 1, Part 2, and Part 3 could be conducted concurrently or separately, and the order of the parts could be determined according to the needs of the program.	None (Open Label)	\N	\N	Basic Science	\N	\N	2017-04-18	2017-06-02	2017-06-16	2017-04-11	\N	2021-06-24	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	combination	fexofenadine	drug interaction	f	Pharmacokinetics	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
378	2023-01-02 15:22:35.743	2023-03-21 10:57:31.756	NCT01700192	A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)	Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)	Completed	The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults.\n\nThe primary hypothesis of this study is that administration of MK-8237, compared to placebo, results in significant reduction in the average total combined rhinitis score (TCRS).	Parallel Assignment	ALK-Abell A/S	INDUSTRY	All	\N	12	1482	Actual	INDUSTRY	ALK-Abell A/S	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2013-01-01	2015-04-01	2015-04-01	2012-10-04	2017-03-03	2017-09-15	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Rhinitis, Allergic, Perennial","Rhinitis, Allergic, Nonseasonal"}	rescue medication	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, Rehm D, Kaur A, Li Z, Lu S. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016 Dec;138(6):1631-1638. doi: 10.1016/j.jaci.2016.06.044. Epub 2016 Aug 10.","Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD011293. doi: 10.1002/14651858.CD011293.pub3.","Bernstein DI, Kleine-Tebbe J, Nelson HS, Bardelas JA Jr, Sussman GL, Lu S, Rehm D, Svanholm Fogh B, Nolte H. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration. Ann Allergy Asthma Immunol. 2018 Jul;121(1):105-110. doi: 10.1016/j.anai.2018.04.007. Epub 2018 Apr 12.","Nolte H, Bernstein DI, Sussman GL, Svanholm Fogh B, Lu S, Husoy B, Nelson HS. Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet. J Allergy Clin Immunol Pract. 2018 Nov-Dec;6(6):2081-2086.e1. doi: 10.1016/j.jaip.2018.01.037. Epub 2018 Feb 10."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/27521719/	loratadine
139	2023-01-02 15:22:35.73	2023-03-20 17:01:50.963	NCT03151720	A Single-Dose, Randomized, Open-Label, Two-Treatment, Four-Period, Crossover Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Subjects Compared to Clarityne Tablets	A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets	Completed	The purpose of this study is to establish the relative bioavailability of Xisimin (loratadine) compared to Clarityne in healthy participants receiving a single dose of 10 milligram (mg) under fasting condition as part of Cohort 1 and under fed condition as part of Cohort 2.	Crossover Assignment	Xian-Janssen Pharmaceutical Ltd.	INDUSTRY	All	55	20	28	Actual	INDUSTRY	Xian-Janssen Pharmaceutical Ltd.	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2017-06-01	2017-07-08	2017-07-08	2017-05-12	\N	2017-08-31	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	main	loratadine	\N	f	Bioavailability	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
191	2023-01-02 15:22:35.732	2023-03-20 19:39:49.582	NCT01918033	A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis	A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)	Completed	This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese participants with perennial allergic rhinitis. The primary hypothesis is that desloratadine is superior to placebo after 2 weeks of treatment with regard to change from baseline in Total Nasal Symptom Score among Japanese participants with perennial allergic rhinitis.	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	12	608	Actual	INDUSTRY	Organon and Co	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2013-08-20	2014-01-26	2014-01-26	2013-08-07	2014-08-15	2022-02-09	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Perennial Allergic Rhinitis"}	main	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{"Okamoto Y, Maeda Y, Oshima N, Hisada S. A Phase III clinical trial of desloratadine in Japanese subjects with perennial allergic rhinitis: A randomized controlled trial. J Clin Therapeut Med. 2016;32(12):967-978 [in Japanese] https://mol.medicalonline.jp/archive/search?jo=an9cltmd&ye=2016&vo=32&issue=12"}	PUBLISHED	https://mol.medicalonline.jp/archive/search?jo=an9cltmd&ye=2016&vo=32&issue=12	desloratadine
154	2023-01-02 15:22:35.73	2023-03-20 17:14:22.576	NCT03664882	Phase 3, Single-center, Sequential and Parallel-group, Double-blind, Randomized Study Evaluating the Efficacy and Safety of Fexofenadine Hydrochloride 180 mg (Allegra/Telfast) Versus Placebo in Subjects Suffering From Seasonal Allergic Rhinitis With Symptoms Aggravated in Presence of Pollutants	Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants	Completed	Primary Objectives:\n\nTo demonstrate that the aggravation of seasonal allergic rhinitis symptoms in the presence of pollutants is observed using an Environmental Exposure Unit.\nTo evaluate the efficacy of fexofenadine hydrochloride in subjects suffering from seasonal allergic rhinitis symptoms aggravated in the presence of diesel exhaust particulates.\n\nSecondary Objective:\n\nTo evaluate the safety of a single dose of fexofenadine hydrochloride 180 mg.	Parallel Assignment	Sanofi	INDUSTRY	All	65	18	240	Actual	INDUSTRY	Sanofi	Randomized	\N	Double	\N	\N	Treatment	\N	The total study duration per subject is expected to last up to 4.5 months, depending on the timing of the screening visit.	2018-09-17	2019-01-03	2019-01-03	2018-09-11	\N	2022-04-25	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Rhinitis Seasonal"}	main	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
204	2023-01-02 15:22:35.733	2023-03-20 19:45:01.983	NCT00490204	A Randomized, Double Blind, Placebo Controlled Study for Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup (CTZ DS) (2.5 mg or 5 mg Twice a Day) in Children (2 Years of Age or Older But Under 15 Years Old) Suffering From Perennial Allergic Rhinitis.	Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis	Completed	Study objective is to verify the superiority of CTZ DS to the placebo groups in the change of total nasal symptom score (TNSS) over the total treatment period from the score of the baseline assessment period.	Parallel Assignment	GlaxoSmithKline	INDUSTRY	All	14	2	239	Actual	INDUSTRY	GlaxoSmithKline	Randomized	\N	\N	\N	\N	Treatment	\N	\N	2007-07-27	2007-10-03	2007-10-03	2007-06-22	\N	2017-08-29	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Rhinitis, Allergic, Perennial"}	main	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
217	2023-01-02 15:22:35.734	2023-03-20 20:06:28.765	NCT01127620	A Phase III, Comparative Study for the Efficacy and Safety of Bilastine 20 mg Versus Cetirizine 10 mg and Placebo in the Treatment of Perennial Allergic Rhinitis During 4 Weeks, Followed by a Long-term Safety Extension With Bilastine 20 mg	Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension	Completed	Double-blind phase: The objective of the study was to evaluate the efficacy and safety of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of perennial allergic rhinitis.\n\nOpen-label Phase: The objective of this extension was to evaluate the long-term safety of Bilastine 20 mg during one year in the symptomatic treatment of perennial allergic rhinitis	Parallel Assignment	Faes Farma, S.A.	INDUSTRY	All	70	12	650	Actual	INDUSTRY	Faes Farma, S.A.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	Double-blind, randomized, placebo-controlled, parallel-group, international, multicenter study followed by an open label extension. Duration of the double-blind period was 28 days and the duration of the open label period was 12 additional months.\n\nThe primary efficacy variable of the double-blind period was the area under curve (AUC) of total symptoms scale (TSS) from baseline (defined as the mean of 6 last points of the patients' diary before randomization) to D28 visit according to the patient's assessment on reflective symptoms. 650 patients were included in the study and 614 completed the double-blind phase. Out of the 614 patients who completed the double blind period, a total of 513 patients started the open label period with Bilastine 20 mg (83.6%)	2004-05-01	2006-03-01	2006-11-01	2010-05-21	\N	2012-09-26	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Perennial Allergic Rhinitis"}	comparison	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Bousquet J, Ansotegui I, Canonica GW, Zuberbier T, Baena-Cagnani CE, Bachert C, Cruz AA, Gonzalez SN, Kuna P, Morais-Almeida M, Mullol J, Ryan DP, Sanchez-Borges M, Valiente R, Church MK. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin. 2012 Jan;28(1):131-9. doi: 10.1185/03007995.2011.648263. Epub 2011 Dec 22.","Sastre J, Mullol J, Valero A, Valiente R; Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin. 2012 Jan;28(1):121-30. doi: 10.1185/03007995.2011.640667. Epub 2011 Nov 30."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/22077106/	cetirizine
160	2023-01-02 15:22:35.731	2023-03-20 17:48:08.875	NCT03855228	Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in the Treatment of Seasonal Allergic Rhinitis (Study No. C94-145)	Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)	Completed	The purpose of this study is to evaluate the safety and efficacy of mometasone furoate nasal spray (MFNS) with the addition of loratadine vs MFNS alone, loratadine alone, or placebo, in the treatment of patients with seasonal allergic rhinitis.	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	12	704	Actual	INDUSTRY	Organon and Co	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	1995-03-01	1995-08-07	1995-08-07	2019-02-26	2019-07-26	2022-02-09	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Rhinitis, Allergic"}	combination	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	CT_RESULTS	\N	loratadine
116	2023-01-02 15:22:35.728	2023-03-20 16:40:26.388	NCT02372604	Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria Resistant to the Licensed Dosage	Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria	Completed	Chronic Spontaneous Urticaria (CSU), defined by the persistence of daily or almost daily urticaria over 6 weeks, affects 0.5% to 1% of the general population. In more than half of the cases, it lasts more than 2 years. It can dramatically alter the quality of life, in particular sleep, and generates numerous consultations and hospitalizations, with an average annual cost per patient close to 2000 euros in Europe. The treatment is based on the validated 2nd generation anti-H1 antihistamines dosage of one tablet per day whose effectiveness is satisfactory, however about half the time. In cases of severe CSU refractory to treatment with anti-H1 licensed dosage, few therapeutic alternatives exist, still off-label: the monketulast, an anti-leukotriene, ciclosporine or methotrexate, as immunosuppressants. Various studies have shown the important benefit of an expensive anti-IgE biological: the omaluzimab. Several open studies have also suggested superior efficacy and good tolerability of anti-H1 in higher dosage (double, triple or quadruple) including levocetirizine.\n\nThe off-label use of these high dosages of anti-H1 is growing very rapidly in France, tending to replace the use of anti-H1 first generation or substitution to another 2nd generation anti-H1 recommended by the French Society of Dermatology.\n\nThis study, under the aegis of the Urticaria Group of the French Society of Dermatology, intends to compare the efficacy of levocetirizine 4 tablets/day versus 1 tablet/day in the treatment of CSU resistant to anti-H1 licensed dosage.	Parallel Assignment	Hospices Civils de Lyon	OTHER	All	\N	18	15	Actual	OTHER	Hospices Civils de Lyon	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2015-07-01	2016-12-01	2016-12-01	2015-02-26	\N	2018-09-18	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Chronic Spontaneous Urticaria"}	main	cetirizine	\N	f	Urticaria	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
380	2023-01-02 15:22:35.744	2023-03-21 11:03:22.449	NCT04323566	A Randomized, Double-blinded, Placebo-controlled Study of Rituximab in Patients With Psychosis and/or Obsessive Compulsive Disorder, With an Indication of Immune System Involvement	Rituximab Treatment for Psychosis and/or Obsessive Compulsive Disorder With Probable Immune System Involvement	Enrolling by invitation	The primary objective for this study is to evaluate whether Rituximab as compared to placebo is a clinically effective treatment for a subgroup of patients suffering from psychosis and/or obsessive-compulsive disorder (OCD) or -behavior (OCB) where there is an indication of immune system involvement.\n\nThe secondary objectives of this study are\n\nTo assess whether Rituximab treatment (with the doses and timing described below) as compared to placebo is associated with amelioration in psychiatric symptomatology\nTo assess whether Rituximab treatment as compared to placebo is associated with improvement in executive functions\nTo assess whether Rituximab treatment as compared to placebo is associated with amelioration in neurological symptoms\nTo evaluate the longevity of psychiatric, neurological and executive improvements associated with Rituximab treatment for up to 16 months after the first infusion (i.e. 12 months after the last infusion)\nTo evaluate whether Rituximab treatment as described is safe for these patients.\n\nThe exploratory objectives of this study are\n\nTo assess changes in blood and cerebrospinal fluid (CSF) markers for immune activity associated with Rituximab treatment compared to placebo\nTo assess statistical associations between biological markers in blood or CSF and clinical response\nTo describe changes in somatic symptoms associated with treatment with Rituximab vs placebo for patients with initial symptoms in the questionnaires\nTo describe changes on MR and EEG associated with treatment with Rituximab vs placebo for patients with initial pathology in these examination\nTo study immune mechanisms coupled with psychiatric symptoms, possibly identifying novel biomarkers with potential for subtyping encephalopathies with immune engagement, using biobank cells, blood and CSF samples collected from the participants.	Crossover Assignment	Uppsala University Hospital	OTHER	All	55	18	40	Anticipated	OTHER	Uppsala University Hospital	Randomized	This is a placebo-controlled, interventional study of parallel groups with 40 participants, randomized to either treatment-first with 500 mg Rituximab i.v. at 0 (infusion 1) and at 4 months (infusion 2), or placebo-first, with NaCl-infusions at 0 and at 4 months. Main evaluation takes place at eight months. The study arms are then crossed over, i.e. those with treatment-first receive placebo at 8 (infusion 3) and 12 months (infusion 4), and those with placebo-first receive Rituximab at these time points. Final evaluation takes place at 16 months. Before each infusion, all patients are pre-treated with Solu-Medrol i.v., Paracetamol p.o. and Cetirizin p.o. Patients are monitored with psychiatric rating scales and blood samples at baseline (-1 month) and every four months. The evaluations at baseline, eight and 16 months also encompass collection of CSF (lumbar puncture), psychologic testing and extended blood samples.	Quadruple	The nurse(s) administering Rituximab or placebo (NaCl) infusions will be prevented from having insight into which of the infusions she/he is administering.	\N	Treatment	\N	METHODOLOGY:\n\nThis study is planned as a placebo-controlled, interventional study of parallel groups with 40 participants. Patients will be randomized to either treatment-first arm with 500 mg Rituximab i.v. (infusion 1) at 0 and again at 4 months (infusion 2), or placebo-first arm, receiving NaCl-infusion at 0 and at 4 months. Main evaluation will take place at eight months. The study arms are switched after eight months, i.e. patients starting in the treatment-first arm will receive placebo (NaCl) infusions at 8 months (infusion 3) and 12 months (infusion 4), and patients in the placebo-first arm receive 500 mg-Rituximab infusions at these time points. Final evaluation is scheduled at 16 months. Before each infusion, all patients in the Rituximab and control groups are pre-treated with injection Solu-Medrol 125 mg, i.v., tablet Paracetamol 1000 mg, p.o. and tablet Cetirizin 10 mg, orally.\n\nPatients will be monitored with psychiatric rating scales and blood samples at baseline and every four months. In addition, baseline (-1 months), main (8 months) and final evaluation (16 months) will encompass collection of CSF (lumbar puncture), psychologic testing and extended blood samples. Patient, nurse administering treatment and symptom evaluators are blinded to group randomization.\n\nINVESTIGATIONAL PRODUCT, DOSAGE AND MODE OF ADMINISTRATION:\n\nTreatment: Rituximab (Roche), 500 mg, dissolved in 250 ml NaCl 9 mg/ml, administered intravenously twice with 4 months interval.\nPlacebo: 250 ml NaCl 9 mg/ml, administered intravenously twice with 4 months interval.\n\nDuration of treatment:\n\nPatients are observed over the course of 16 months. Main evaluation is conducted after 8 months. Participants are randomized to either treatment-first (Rituximab infusion at 0 months and 4 months) or placebo-first (Rituximab infusion at 8 months and 12 months).\n\nSITE MONITORING AND SOURCE DATA VERIFICATION\n\nThe Investigator(s)/institution(s) will permit study-related monitoring, audits, review and regulatory inspection(s), providing access to source data/hospital records. Sponsor verifies that each patient has consented in writing to direct access to the original source data/hospital records by the use of written patient information and signed Informed Consent.\n\nIn accordance with the principles of Good Clinical Practice (GCP), monitoring of the study will be arranged by the Sponsor. During the study, the Monitor will have regular contacts with the study site(s), including visits to ensure that the study is conducted and documented properly in compliance with the protocol, GCP and applicable regulatory requirements.\n\nPrior to the start of the study, the monitor will review the protocol and CRFs with the investigator and his/her staff. The investigator will be visited by the monitor, who will check study procedures, including safety assessments, study medication handling, and data recording.\n\nTo assure the accuracy and completeness of the data recorded in the trial, the monitor will compare Case Report Forms (CRFs) with medical records and other relevant documentation during the on-site monitoring visits (source data verification, SDV). The monitor will have direct access to all source data according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) GCP. Incorrect or missing entries into the CRFs will be queried and must be corrected. Any discrepancies of data will be documented and explained in the monitoring reports. Study monitoring will not jeopardize patient confidentiality.\n\nThe study center may also be subject to inspection by the Swedish Medical Products Agency (MPA). The Investigator and other responsible personnel must be available during the monitoring visits and a possible inspection, and should devote sufficient time to these processes.\n\nDATA COLLECTION AND MANAGEMENT\n\nData management and handling of data will be conducted according to the study specific Data Management Plan with ICH guidelines and an assigned CRO's standard operating procedures (SOPs). An electronic CRF (eCRF) system will be used to capture data from the study. Data entry will be performed by the study site personnel. Validation and data queries will be handled by the CRO's Data Management Team. The data will be subjected to validation according to the CRO's SOPs in order to ensure accuracy in the collected CRF data.The CRF will have an audit trail with appropriate functionality for data capture, tracking and documentation of any queries or changes. Electronic signatures will be used to lock the data and identify the person entering or changing the data.\n\nBefore database closure a reconciliation will be performed between the Serious Adverse Events (SAEs) entered in the safety database and the study database. After database closure, the database will be exported as Statistical Analysis System (SAS) data sets. Any discrepancies and additions from the process defined in the Data Management Plan, will be described in a study specific Data Management Report.\n\nSTATISTICAL ANALYSIS:\n\nThe trial comprises a fully blinded randomized part, up to and including the 8 month visit, and a follow-up part, with preserved blinding but where it is known that the patient has received Rituximab treatment either in the fully blinded part of the trial or in the follow-up part. The main treatment comparisons will be based on the fully blinded 8 months of the trial, analyzed as a parallel group trial as described below. Data from the follow-up part will be presented descriptively and will be used for explorative modelling of treatment response and duration.\n\nANALYSIS POPULATION:\n\nThe full analysis set (FAS) will consist of all randomized patients that received at least one dose of investigational treatment, and will be used for all analyses unless specified. The number of patients with available data for each outcome analysis will be tabulated. In baseline-adjusted analyses, patients that lack baseline data will be excluded.\n\nDESCRIPTIVE STATISTICS:\n\nBrief Psychiatric Rating Scale (BPRS) score over time, for both parts of the trial, will be described using time series plots of individual data and randomized treatment arm mean values. BPRS and BPRS linear change from baseline at each time point will be described by randomized treatment using dot plots, scatter plots with baseline value on the x-axis, and tables of mean, standard deviation, median, min, max and quartiles.\n\nPRIMARY ANALYSIS:\n\nThe primary outcome, BPRS at 8 months, will primarily be analyzed using a linear model with randomized treatment and baseline BPRS as covariates, and presented as the mean difference between the treatment groups with 95% confidence interval (CI) and two-sided p-value. Primarily the analysis will be based on observed cases, which gives unbiased estimation under a mechanism with random missingness conditional on baseline BPRS and treatment arm.\n\nSENSITIVITY ANALYSES:\n\nTo address missing data,\n\nprimary analysis with missing 8-month values imputed by the 4-month value when available, and the baseline value otherwise. Under a scenario of no increase in BPRS over time and drop-out mainly due to lack of effect, this analysis would be biased against superiority of the Rituximab treatment.\nanalyses of a continuum of scenarios based on a model assuming a treatment group dependent missingness propensity estimated from the observed frequencies, and a treatment group dependent difference in baseline-adjusted mean BPRS between observed and missing outcomes. The results will be presented as contour plots of point estimates, lower and upper 95% CI limits, and 2-sided p-values, for each pair of treatment arm specific differences between observed and missing outcomes. The results will indicate what mean deviations from missing at random conditional on treatment and baseline BPRS would be necessary to affect the conclusions.\nTo address model misspecification, supplemental comparison of linear change in BPRS from baseline between treatment groups using the using Wilcoxon's rank-sum test and the Hodges-Lehmann estimate of location change with 95% confidence interval. In addition, model assumptions will be assessed by residual plots. Deviations from assumptions are not assumed to increase the Type I error, but may affect the interpretation of the estimated treatment contrast.\nTo address non-adherence and protocol deviations, supplemental analysis using the primary model, for patients with two doses of treatment and no major protocol deviations up to 8 months, as determined at data base lock before unblinding.\n\nBPRS at four months will be analyzed using the same method as for the primary time point, including sensitivity analyses. The main purpose of the four-month measurement is exploration of time to response.\n\nSECONDARY EFFICACY OUTCOMES:\n\nAll analyses will be performed without formal multiplicity adjustment, for observed cases.\n\nCGI-S over time will be presented by individual time series plots, and for each visit by number and percentage of patients in each category, and of patients satisfying the criteria for response (at least 2-point reduction from baseline), partial response (a 1 point reduction from baseline), and remission (CGI-S score 1-3). The categorical outcome response/partial response/no response will be analysed using logistic regression with randomized treatment as the only factor and presented as the common odds ratio with 95% CI and 2-sided p-value, at 8 months (primary time point) and at 4 months. Remission at the same time points will be analysed using logistic regression and presented as odds ratios with 95% CI and 2-sided p-value.\n\nWorld Health Organization Disability Assessment Schedule (WHODAS) results will be presented as domain scores based on item response theory based scoring, and total disability score. Domain and total scores over time will be described using individual time series plots and mean value plots by randomized treatment. Domain and total scores, and linear change from baseline scores, at each time point will be described by randomized treatment using dot plots, scatter plots with baseline value on the x-axis, and tables of mean, standard deviation, median, min, max and quartiles. Total disability score at 8 months (primary) and 4 months will be analysed using a linear model with randomized treatment and baseline score as covariates and presented as mean difference with 95% CI and 2-sided p-value.\n\nYale Brown Obsessive Compulsion Scale (Y-BOCS) results will be presented and analyzed in the same way as WHODAS disability score. In addition, the number and proportion of patients with score 15 or below will be presented and analyzed in the same way as remission defined by CGI-S.\n\nBush-Francis Catatonia Rating Scale (BFCRS) total score over time will be described using individual time series plots and mean value plots by randomized treatment. Domain and total scores, and linear change from baseline scores, at each time point will be described by randomized treatment using dot plots, scatter plots with baseline value on the x-axis, and tables of mean, standard deviation, median, min, max and quartiles.\n\nPittsburgh Sleep Quality Index (PSQI) global sum will be tabulated descriptively by randomized treatment for each time point, using mean, standard deviation, median, quartiles, min and max, and number and percentage of patients with global sum 5 or higher.\n\nEuroQol-5D (EQ-5D) domain scores will be presented for each time point using descriptive frequency tables and stacked bar charts by randomized treatment. EQ-5D Visual Analogue Scale (VAS) scale scores will be presented for each time point using descriptive tables of mean, standard deviation, median, min, max and quartiles.\n\nMismatch Negativity (MMN) amplitude and latency will be measured as the most negative data point within the 80-130 ms latency window, post-stimulus onset and compared between time points.\n\nBiomarkers over time will be presented descriptively using individual time series plots and plots of geometric mean values over time by randomized treatment, and for each visit scatter plots with baseline on the x-axis and tables of geometric mean, geometric coefficient of variation (CV), median, quartiles, min and max, based on values over the limit of quantification, and number of observations under the limit of quantification. For infusion safety markers, the number and proportion of patients with values outside normal will also be tabulated. Biomarker concentrations at 8 months (primary) and 4 months will be analysed using a linear model for the log-transformed biomarker with randomized treatment and log-transformed baseline biomarker as covariates, and presented as the geometric mean ratio with 95% CI and two-sided p-value.\n\nDETERMINATION OF SAMPLE SIZE Within- and between-patient standard deviation was estimated to 7.1 and 6.7 points respectively, from five case series with in total 35 measurements pre- and post-rituximab treatment, using a linear mixed-effect model with random intercept and rituximab treatment as a fixed factor.\n\nPower was estimated using simulation. Baseline and 8 months BPRS were simulated with a 7 point standard deviation (SD) normally distributed random variation both within and between patients (corresponding to a total SD=9.8 points for a single measurement), and a homogenous treatment effect, using R v. 3.3.1. 40 patients, 20 patients per group, would give 81% power to detect an 8 point adjusted mean difference in BPRS between the rituximab and placebo groups, and 89% power to detect a difference of 9 points. Reasonable power would be retained under 5% random drop-out, with 79% power to detect an 8 point difference and 87% power to detect a 9 point difference between the groups. The power to detect a 9 point difference would still be 85% with 10% random drop-out.	2022-05-01	2026-04-01	2026-05-01	2020-03-26	\N	2022-05-17	\N	Uppsala University Hospital	Janet Cunningham	MD Associate Professor Janet Cunningham	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Phase 2"}	{"Obsessive-Compulsive Disorder","Obsessive-Compulsive Behavior",Schizophrenia,"Delusional Disorder","Brief Psychotic Disorder","Schizo Affective Disorder","Other Psychoses","Unspecified Psychosis"}	pre-medication	cetirizine	Todo check usecase, prev: Obsessive-Compulsive Disorder	f	Infusion Reaction	2022-08-17 13:39:16	{"Debnath M, Venkatasubramanian G. Recent advances in psychoneuroimmunology relevant to schizophrenia therapeutics. Curr Opin Psychiatry. 2013 Sep;26(5):433-9. doi: 10.1097/YCO.0b013e328363b4da.","Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, Xu C, Richter MA, Kahn A, Kish SJ, Houle S, Ravindran L, Meyer JH. Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. JAMA Psychiatry. 2017 Aug 1;74(8):833-840. doi: 10.1001/jamapsychiatry.2017.1567.","Brimberg L, Benhar I, Mascaro-Blanco A, Alvarez K, Lotan D, Winter C, Klein J, Moses AE, Somnier FE, Leckman JF, Swedo SE, Cunningham MW, Joel D. Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology. 2012 Aug;37(9):2076-87. doi: 10.1038/npp.2012.56. Epub 2012 Apr 25.","Lee WJ, Lee ST, Byun JI, Sunwoo JS, Kim TJ, Lim JA, Moon J, Lee HS, Shin YW, Lee KJ, Kim S, Jung KH, Jung KY, Chu K, Lee SK. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology. 2016 May 3;86(18):1683-91. doi: 10.1212/WNL.0000000000002635. Epub 2016 Apr 1.","Dazzi F, Shafer A, Lauriola M. Meta-analysis of the Brief Psychiatric Rating Scale - Expanded (BPRS-E) structure and arguments for a new version. J Psychiatr Res. 2016 Oct;81:140-51. doi: 10.1016/j.jpsychires.2016.07.001. Epub 2016 Jul 4."}	NO_PUBLICATION_FOUND	\N	cetirizine
216	2023-01-02 15:22:35.734	2023-03-20 20:05:23.677	NCT00504933	Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Cetirizine 10 mg for the Treatment of Seasonal Allergic Rhinitis.	Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis	Completed	The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of seasonal allergic rhinitis.	Parallel Assignment	Faes Farma, S.A.	INDUSTRY	All	70	12	683	Actual	INDUSTRY	Faes Farma, S.A.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	In this pivotal, multicentre, international, randomized, double-blind, placebo and active-comparator controlled, parallel study, 683 patients with SAR will be enrolled. Patients will be required to be 12-70 years old, have SAR for 2 years, a positive skin test, total nasal and non-nasal score (TSS) 36 (out of 72) during run-in, and a composite instantaneous nasal symptom score 6 (out of 12) the morning before randomization. The primary efficacy endpoint will be the AUC of reflective TSS from baseline to Day 14.	2005-05-01	2005-11-01	2005-11-01	2007-07-20	\N	2012-04-05	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	comparison	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Bousquet J, Ansotegui I, Canonica GW, Zuberbier T, Baena-Cagnani CE, Bachert C, Cruz AA, Gonzalez SN, Kuna P, Morais-Almeida M, Mullol J, Ryan DP, Sanchez-Borges M, Valiente R, Church MK. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin. 2012 Jan;28(1):131-9. doi: 10.1185/03007995.2011.648263. Epub 2011 Dec 22.","Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf. 2011 Sep;10(5):779-93. doi: 10.1517/14740338.2011.604029. Epub 2011 Aug 11. Erratum In: Expert Opin Drug Saf. 2012 Jan;11(1):175.","Jauregui I, Garcia-Lirio E, Soriano AM, Gamboa PM, Antepara I. An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria. Expert Rev Clin Immunol. 2012 Jan;8(1):33-41. doi: 10.1586/eci.11.87.","Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, Roger A, Sologuren A, Valiente R; Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009 Sep;39(9):1338-47. doi: 10.1111/j.1365-2222.2009.03257.x. Epub 2009 May 4."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19438584/	cetirizine
170	2023-01-02 15:22:35.731	2023-03-20 19:25:14.571	NCT00650065	Single-Dose Fasting In Vivo Bioequivalence Study of Cetirizine HCl Tablets (10 mg; Mylan) and Zyrtec Tablets (10 mg; Pfizer) in Healthy Volunteers	Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec Tablets 10 mg	Completed	"The objective of this study was to investigate the bioequivalence of Mylan cetirizine HCl 10 mg tablets to Pfizer's Zyrtec 10 mg tablets following a single, oral 10 mg (1 x 10 mg) dose administration under fasting conditions.	Crossover Assignment	Mylan Pharmaceuticals Inc	INDUSTRY	All	\N	18	26	Actual	UNKNOWN	MylanPharma	Randomized	\N	None (Open Label)	\N	\N	\N	\N	\N	2002-11-01	2002-12-01	2002-12-01	2008-04-01	\N	2008-04-01	\N	\N	\N	\N	Will Sullvan, Global Head of Product Risk and Safety Management	Mylan Inc.	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{Healthy}	main	cetirizine	\N	f	Bioequivalence	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
388	2023-01-02 15:22:35.744	2023-03-21 12:02:17.475	NCT02424539	A Randomized, Doubled-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of Fluticasone Furoate Nasal Spray 55 mcg and 110 mcg for 4 Weeks in Chinese Pediatric Subjects Ages 2 to 12 Years With Allergic Rhinitis	A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)	Completed	This Phase IV interventional study is a multi-center, randomized, double-blind, placebo-controlled parallel study to evaluate the efficacy and safety of FFNS110 mcg and 55 mcg once daily versus vehicle placebo aqueous nasal spray in chinese pediatric subjects ages 2 to 12 years with AR.\n\nThis study comprises screening and run-in period (4 to14 days), double-blind treatment period (28 days) and follows up period (3 to7 days). Subjects entering the study will participate for maximum of 50 days, including five clinical visits and a follow-up contact.\n\nThe study is planned to enroll approximately 360 subjects.	Parallel Assignment	GlaxoSmithKline	INDUSTRY	All	12	2	358	Actual	INDUSTRY	GlaxoSmithKline	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2015-09-30	2017-10-25	2017-10-25	2015-04-23	2019-02-06	2021-01-11	GlaxoSmithKline	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 4"}	{"Rhinitis, Allergic, Perennial and Seasonal","Rhinitis, Allergic"}	rescue medication	loratadine	check publication url again	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Zhang Y, Wei P, Chen B, Li X, Luo X, Chen X, Xiang M, Li L, Zhao S, Xiao X, Yang X, Chen J, Fu Y, Xiao S, Liu H, Cheng L, Yao H. Intranasal fluticasone furoate in pediatric allergic rhinitis: randomized controlled study. Pediatr Res. 2021 May;89(7):1832-1839. doi: 10.1038/s41390-020-01180-0. Epub 2020 Oct 2."}	PUBLISHED	https://www.nature.com/articles/s41390-020-01180-0	loratadine
148	2023-01-02 15:22:35.73	2023-03-20 17:07:33.316	NCT02576808	Comparative Study of Efficacy and Adverse Effects of Ginger Extract and Loratadine for Treatment of Allergic Rhinitis Patients (Clinical Trial Phase II)	Study of Efficacy and Safety of Ginger Extract Compared With Loratadine for Treatment of Allergic Rhinitis	Completed	Efficacy and adverse effects of Ginger extract in treating allergic rhinitis patients compared with Loratadine.The double blind randomized controlled trial study was approved by the Human Research Ethics Committee of Thammasat University NO.1.	Parallel Assignment	Thai Traditional Medical Knowledge Fund	OTHER_GOV	All	70	18	80	Actual	OTHER_GOV	Thai Traditional Medical Knowledge Fund	Randomized	\N	Double	\N	\N	Treatment	\N	The double blind randomized controlled trial study. Patients who meet the inclusion criteria and do not fall into any exclusion criteria will be randomly placed into the experimental group, who will receive ginger extract capsules, or the control group, who will receive loratadine for 42 days.	2015-10-01	2017-10-01	2017-10-01	2015-10-15	\N	2017-10-10	\N	Thai Traditional Medical Knowledge Fund	Rodsarin Yamprasert	Faculty of Medicine Thammasat University	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Rhinitis,Allergic"}	comparison	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Yamprasert R, Chanvimalueng W, Mukkasombut N, Itharat A. Ginger extract versus Loratadine in the treatment of allergic rhinitis: a randomized controlled trial. BMC Complement Med Ther. 2020 Apr 20;20(1):119. doi: 10.1186/s12906-020-2875-z."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/32312261/	loratadine
218	2023-01-02 15:22:35.734	2023-03-20 20:07:57.313	NCT01306721	A Randomized, Double Blind, Parallel Group Study for Assessing the Efficacy and Safety of a Twice-daily Fexofenadine HCl 60 mg - Pseudoephedrine HCl 60 mg Combination or Fexofenadine HCl 60 mg - Pseudoephedrine HCl 120 mg Combination Versus Allegra 60 mg in Patients With Seasonal Allergic Rhinitis	Fexofenadine HCL - Pseudoephedrine HCL Combination Versus Allegra in Patients With Seasonal Allergic Rhinitis	Completed	Primary Objective:\n\n- To evaluate the efficacy on the nasal congestion of a twice-daily fexofenadine HCl 60 mg - pseudoephedrine HCl 60 mg combination (FEX60/PSE60) and fexofenadine HCl 60 mg - pseudoephedrine HCl 120 mg combination (FEX60/PSE120) versus fexofenadine HCl 60 mg (FEX60) in patients with seasonal allergic rhinitis (SAR).\n\nSecondary Objectives:\n\nTo evaluate the efficacy of a twice-daily FEX60/PSE60 and FEX60/PSE120 versus FEX60 on nasal symptoms (sneezing, rhinorrhea, and nasal congestion), eye symptom, and daily activity impairment.\nTo assess the safety of a twice-daily FEX60/PSE60 and FEX60/PSE120 versus FEX60.	Parallel Assignment	Sanofi	INDUSTRY	All	\N	12	520	Actual	INDUSTRY	Sanofi	Randomized	\N	Double	\N	\N	Treatment	\N	The study duration for each patient is 3 weeks and 3 days:\n\nLead-in period: 1 week\nTreatment period: 2 weeks\nFollow-up period: 3 days	2011-02-01	2011-04-01	2011-04-01	2011-03-02	\N	2013-10-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Rhinitis Seasonal"}	combination	fexofenadine	TODO: could also be classified als main or comparison	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
212	2023-01-02 15:22:35.734	2023-03-20 20:02:27.033	NCT02756624	A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution	A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution	Completed	This is study is evaluating the safety and tolerability of AC-170 Ophthalmic Solution	Parallel Assignment	Nicox Ophthalmics, Inc.	INDUSTRY	All	\N	2	516	Actual	INDUSTRY	Nicox Ophthalmics, Inc.	Randomized	\N	Triple	\N	\N	Treatment	\N	Central Cornea Endothelial Cell Counts will be done on a subset of approximately 150 subjects to complete 100 subjects as part of the safety measures.	2016-04-01	2016-08-01	2016-08-01	2016-04-29	2017-07-26	2017-09-11	Nicox Ophthalmics Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Healthy Subjects"}	main	cetirizine	\N	f	Safety Evaluation	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
162	2023-01-02 15:22:35.731	2023-03-20 19:11:37.816	NCT00600847	An Exploratory Phase IV, Randomised, Double-Blind, Placebo Controlled Crossover Study to Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Experimentally Induced Urticaria Lesions	A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions	Completed	The aim of this study is to compare cold urticaria lesions by thermography, volumetry and digital time lapse photography in ACU patients treated with placebo, 5 mg and 20 mg desloratadine. Hypothesis: The updosing of desloratadine (20 mg)is more effective in the treatment of ACU symptoms as compared to standard doses (5 mg desloratadine) and placebo.	Crossover Assignment	Charite University, Berlin, Germany	OTHER	All	75	18	33	Actual	OTHER	Charite University, Berlin, Germany	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2006-11-01	2007-11-01	\N	2008-01-25	\N	2008-01-25	\N	\N	\N	\N	Marcus Maurer, MD	Allergie-Centrum-Charit	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Acquired Cold Urticaria"}	main	loratadine	\N	f	Urticaria	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	desloratadine
180	2023-01-02 15:22:35.732	2023-03-20 19:30:47.176	NCT00311844	A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms	A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)	Completed	This study was a double-blind, placebo-controlled, cross-over, single-center study of desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of seasonal allergic rhinoconjunctivitis. This study was performed to examine the effects of desloratadine compared with placebo, on the signs and symptoms of allergic conjunctivitis induced by direct conjunctival challenges with a previously identified sensitizing antigen, in the eyes of a subject known to be sensitive to the antigen.	Crossover Assignment	Organon and Co	INDUSTRY	All	\N	18	41	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2005-03-01	2005-05-28	2005-05-28	2006-04-06	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Conjunctivitis, Allergic"}	main	desloratadine	\N	f	Allergic Conjunctivitis	2022-09-15 19:16:20	{"Torkildsen GL, Gomes P, Welch D, Gopalan G, Srinivasan S. Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms. Clin Exp Allergy. 2009 Jul;39(7):1052-9. doi: 10.1111/j.1365-2222.2009.03224.x. Epub 2009 Mar 10."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19302250/	desloratadine
196	2023-01-02 15:22:35.733	2023-03-20 19:42:30.531	NCT00835276	A Relative Bioavailability Study of 180 mg Fexofenadine Hydrochloride Tablets Under Fasting Conditions.	Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions	Completed	This study will compare the relative bioavailability (rate and extent of absorption) of 180 mg Fexofenadine Hydrochloride tablets manufactured for TEVA Pharmaceuticals Industries, Ltd. with that of 180 mg ALLEGRA Tablets by Aventis Pharmaceuticals, Inc. following a single oral dose (1 x 180 mg tablet) in healthy adult volunteers under fasting conditions.	Crossover Assignment	Teva Pharmaceuticals USA	INDUSTRY	All	55	18	60	Actual	INDUSTRY	Teva Pharmaceuticals USA	Randomized	\N	None (Open Label)	\N	\N	\N	\N	Criteria for Evaluation: FDA Bioequivalence Criteria\n\nStatistical Methods: FDA bioequivalence statistical methods	2002-03-01	2002-03-01	2002-03-01	2009-02-03	2009-08-04	2009-08-20	Manager, Biopharmaceutics	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	main	fexofenadine	\N	f	Bioavailability	2022-08-18 16:54:53	{}	CT_RESULTS	\N	fexofenadine
220	2023-01-02 15:22:35.734	2023-03-20 20:09:46.476	NCT01551056	A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of Cetirizine 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis	A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)	Completed	The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.	Parallel Assignment	Aciex Therapeutics, Inc.	INDUSTRY	All	\N	10	91	Actual	INDUSTRY	Aciex Therapeutics, Inc.	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2012-03-01	2012-06-01	2012-06-01	2012-03-12	2017-10-03	2017-11-07	Nicox Ophthalmics Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Allergic Conjunctivitis"}	main	cetirizine	\N	f	Allergic Conjunctivitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
389	2023-01-02 15:22:35.744	2023-03-21 12:05:05.548	NCT02394119	Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor-dependent Idiopathic Nephrotic Syndrome: an Open-label, Randomized, Controlled, Superiority Trial.	Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome	Completed	Open-label, two-parallel-arm, controlled randomized clinical trial testing the superiority of Ofatumumab over Rituximab in maintaining steroid- and calcineurin-inhibitor-free disease remission in SD-INS.\n\nEligible participants will enter a 1-month run-in period, during which instruction on urine collection and dipstick readings will be carefully reviewed, compliance assessed, and therapy with RAS inhibitors withdrawn and, in hypertensive children replaced by other anti-hypertensive drug.\n\nAfter run-in period, children will be randomized to either the intervention arm (Ofatumumab) or the comparator arm (Rituximab).\n\nAfter infusion of intervention or comparator, steroids will be maintained at initial dose for 30 days and then tapered off by 0.3 mg/kg per week until complete withdrawal.\n\nOne week after the steroid withdrawal calcineurin inhibitors will be decreased by 50% and withdrawn within 2 additional weeks.\n\nAll patients will be followed for up to 24 months. In case of relapses during the study (see outcome section for definition) patients will be treated with 60 mg/m2of prednisone p.o. in order to achieve remission. At remission, patients will be treated with another infusion of either Oftumumab or Rituximab, according to the initial randomization.\n\nAfter infusion of intervention or comparator, steroids will be maintained at initial dose for 30 days and then tapered off by 0.3 mg/kg per week until complete withdrawal.\n\nOne week after the steroid withdrawal calcineurin-inhibitors will be decreased by 50% and withdrawn within 2 additional weeks. This strategy will be repeated to treat full relapses during the study.	Parallel Assignment	Istituto Giannina Gaslini	OTHER	All	24	2	140	Actual	OTHER	Istituto Giannina Gaslini	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2015-06-01	2018-06-01	2019-05-01	2015-03-20	\N	2020-07-30	\N	Istituto Giannina Gaslini	Gian Marco Ghiggeri MD, PhD	MD, director of Nephrology, Dialysis and Transplantation Unit	\N	\N	Principal Investigator	\N	Interventional	{Child,Adult}	{"Phase 2"}	{"Nephrotic Syndrome"}	pre-medication	cetirizine	\N	f	Infusion Reaction	2022-08-17 13:39:16	{"McEnery PT, Strife CF. Nephrotic syndrome in childhood. Management and treatment in patients with minimal change disease, mesangial proliferation, or focal glomerulosclerosis. Pediatr Clin North Am. 1982 Aug;29(4):875-94. No abstract available.","Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001533. doi: 10.1002/14651858.CD001533.pub3.","Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl'Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. J Am Soc Nephrol. 2015 Sep;26(9):2259-66. doi: 10.1681/ASN.2014080799. Epub 2015 Jan 15.","Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y; Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014 Oct 4;384(9950):1273-81. doi: 10.1016/S0140-6736(14)60541-9. Epub 2014 Jun 22.","Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011 Jun;6(6):1308-15. doi: 10.2215/CJN.09421010. Epub 2011 May 12.","Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med. 2014 Mar 27;370(13):1268-70. doi: 10.1056/NEJMc1308488. No abstract available.","Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr Opin Mol Ther. 2008 Jun;10(3):294-309.","Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri GM. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol. 2012 Jun;23(6):1117-24. doi: 10.1681/ASN.2011080775. Epub 2012 May 10.","Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int. 2013 Nov;84(5):1025-33. doi: 10.1038/ki.2013.211. Epub 2013 Jun 5.","Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, Cravedi P, Lugani F, Antonini F, Prunotto M, Emma F, Angeletti A, Ghiggeri GM. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial. J Am Soc Nephrol. 2021 Oct;32(10):2652-2663. doi: 10.1681/ASN.2021040561. Epub 2021 Sep 20.","Ravani P, Bonanni A, Ghiggeri GM. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. BMJ Open. 2017 Mar 17;7(3):e013319. doi: 10.1136/bmjopen-2016-013319."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/28314744/	cetirizine
198	2023-01-02 15:22:35.733	2023-03-19 21:02:20.569	NCT05264025	Fexofenadine as Adjunct to Standard Rheumatoid Therapy in Patients With Active Rheumatoid	Fexofenadine in Patients With Active Rheumatoid Arthritis	Recruiting	Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting 1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying fexofenadine mediated inhibition of TNF- signalling	Parallel Assignment	October 6 University	OTHER	All	60	18	80	Anticipated	OTHER	October 6 University	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2022-06-01	2023-01-01	2023-04-01	2022-03-03	\N	2022-09-22	\N	October 6 University	engy wahsh	lecturer of clinical pharmacy	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Phase 1","Phase 2"}	{"Rheumatoid Arthritis"}	main	fexofenadine	\N	t	Rheumatoid Arthritis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
163	2023-01-02 15:22:35.731	2023-03-20 19:11:53.793	NCT00160680	A Pilot, Open, Monocenter, Randomized Two Parallel Groups, Clinical Efficacy Trial: Comparison Continuous Versus on Demand Regimen of Treatment With Levocetirizine 5 mg Oral Tablets, Once a Day, in Adults Suffering From Persistent Allergic Rhinitis (PER) Over 6 Months	ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)	Completed	Comparison of clinical efficacy and safety of levocetirizine in PER continuous versus on demand, measured by evolution of individual symptom scores during 6 months.	Parallel Assignment	UCB S.A. - Pharma Sector	INDUSTRY	\N	\N	18	62	Actual	INDUSTRY	UCB Pharma	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2005-03-01	2006-06-01	2006-06-01	2005-09-12	2019-01-22	2019-01-22	Cares	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Rhinitis, Allergic, Perennial"}	main	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	CT_RESULTS	\N	levocetirizine
241	2023-01-02 15:22:35.735	2023-03-20 20:32:37.361	NCT01062139	A Randomized, Parallel, Double-blind, Multi-center, Comparative Study to Exploratively Evaluate the Efficacy and Safety of Cosalin Monotherapy vs. Cosalin and Xarlin Combination Therapy in Patients With Allergic Rhinitis	Cosalin Monotherapy Versus Cosalin and Xarlin Combination Therapy	Unknown status	Title of Study:\n\nA randomized, parallel, double-blind, multi-center, comparative study to evaluate the efficacy and safety of Cosalin monotherapy versus Cosalin and Xarlin combination therapy in patients with allergic rhinitis\n\nObjective of study:\n\nTo exploratively evaluate superiority of combination therapy - twice-daily Cosalin Tab (Petasites hybridus CO2 extract) with once-daily Xarlin Tab (Levocetirizine HCl) - compared to monotherapy of Cosalin with allergic rhinitis subjects.	Parallel Assignment	HK inno.N Corporation	INDUSTRY	All	66	18	100	Actual	INDUSTRY	HK inno.N Corporation	Randomized	\N	Double	\N	\N	Treatment	\N	Number of Subjects:\n\nTotal 100 subjects / Each group 50 subjects (combination therapy group, monotherapy group / include 20% of subjects drop out rate)\n\nTest Products:\n\nCosarlin (Petasites hybridus CO2 extract) 30 mg tablet Xarlin (Levocetirizine HCl) 5 mg tablet\n\nStudy Design:\n\nDevelopment Phase: Phase IV Randomized, double blind, active-controlled, multi-center study\n\nThe subject, who is to satisfy inclusion criteria and not to satisfy any of exclusion criteria will be allocated 1:1 to combination therapy group or mono therapy group, randomized.\n\nWritten informed consent will be obtained from the subjects prior to study entry.\n\nDose, Mode of administration:\n\nMonotherapy group - Cosalin 30mg tablet two times daily. Combination therapy group - Cosalin 30mg tablet two times daily and Xarlin 5mg tablet once daily.\n\nDuration of Tx:\n\n2 Weeks\n\nSafety Endpoint:\n\nPhysical Exam, Adverse Events, Vital Signs at Visit 2 and 3.	2009-10-01	2010-04-01	\N	2010-02-04	\N	2010-02-04	\N	\N	\N	\N	Hyo Hyoung, Lee / CRA	CJ Cheiljedang Corporation	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Perennial Allergic Rhinitis"}	combination	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
232	2023-01-02 15:22:35.735	2023-03-20 20:22:27.889	NCT00423995	Study of the Decongestant Effect of the Combination of Loratadine and Montelukast Compared With Placebo in SAR Subjects Exposed to Pollen in an Environmental Exposure Unit	Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)	Completed	This is study of LMC, phenylephrine, and placebo in subjects with SAR. There are three visits: At Visit 1, subjects will be evaluated for participation and, if they qualify, will attend Visit 2 for priming. At Visit 2, ragweed pollen will be fed continuously and dispensed into the environmental exposure unit to induce an allergic reaction. Pollen counts will be monitored and recorded. During the priming visit(s), subjects will be evaluated to determine if they qualify. If qualified, they will return for Visit 3, where ragweed pollen will be fed continuously and dispensed into the environmental exposure unit to induce an allergic reaction. Pollen counts will be monitored and recorded as in the Priming Session. Subjects will complete symptom evaluations and if qualified, they will receive study medication and remain in the environmental exposure unit where symptoms will be evaluated for 8 hours after dosing. PNIF will be evaluated only during the treatment session. Four nasal symptoms (rhinorrhea, nasal congestion, sneezing, and nasal itching) and three non-nasal symptoms (itching/burning eyes, tearing/watery eyes, and itching of ears/palate) will be evaluated. Adverse events will be collected throughout the study to assess safety and tolerability, and vital signs will be collected at Visit 1 and at the end of Visit 3.	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	18	379	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2006-11-01	2007-03-01	2007-03-10	2007-01-18	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	combination	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Day JH, Briscoe MP, Ratz JD, Danzig M, Yao R. Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. Ann Allergy Asthma Immunol. 2009 Apr;102(4):328-38. doi: 10.1016/S1081-1206(10)60339-0."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19441605/	loratadine
178	2023-01-02 15:22:35.732	2023-03-20 19:29:48.719	NCT00638118	A Comparison of Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen	Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen	Completed	Examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (Allegra) and montelukast sodium 10 mg (Singulair) as compared to placebo on skin wheals and flares induced by seasonal allergen.	Crossover Assignment	Sanofi	INDUSTRY	All	55	15	48	Actual	INDUSTRY	Sanofi	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2003-02-01	\N	2003-05-01	2008-03-18	\N	2011-01-11	\N	\N	\N	\N	Study Director	sanofi-aventis	\N	\N	Interventional	{Child,Adult}	{"Phase 4"}	{"Allergic Rhinitis"}	combination	fexofenadine	it is not clear if it is combination or comparison 	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
233	2023-01-02 15:22:35.735	2023-03-20 20:23:24.335	NCT05265910	A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday Once Daily Relief Extra Strength to Claritin Tablets 24-Hour in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis	A Study Comparing the Efficacy of Pataday Once Daily Relief Extra Strength to Claritin Tablets 24-Hour in Subjects With Allergic Conjunctivitis	Completed	This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday Once Daily Relief Extra Strength and Claritin Tablets 24-Hour will be made using the Ora-CAC model, a validated clinical model accepted by regulatory agents for assessing the efficacy of products on the signs and symptoms of allergic conjunctivitis.	Parallel Assignment	Andover Research Eye Institute	INDUSTRY	All	\N	18	58	Actual	INDUSTRY	Andover Research Eye Institute	Randomized	\N	Double	double-masked	\N	Treatment	\N	\N	2021-12-14	2022-04-23	2022-04-23	2022-03-04	\N	2022-05-03	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Allergic Conjunctivitis"}	comparison	loratadine	\N	f	Allergic Conjunctivitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
238	2023-01-02 15:22:35.735	2023-03-20 20:28:31.281	NCT01103050	A Randomized, Double-blind, Double-dummy, Placebo Controlled Three-period Incomplete Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine on Total Nasal Symptom Score in Allergic Rhinitis Patients in an Environmental Exposure Chamber	A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine	Completed	This study will determine the capacity of more frequent dosing of QAV680 to suppress allergic inflammation. The study will investigate the paradigm of multiple receptor antagonism in allergic disease by combining QAV680 with a second generation H1 histamine receptor antagonist to assess possible additive or synergistic anti-allergic effects of the two compound classes.	Crossover Assignment	Novartis Pharmaceuticals	INDUSTRY	All	65	18	60	Actual	INDUSTRY	Novartis	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2010-03-22	2010-07-28	2010-07-28	2010-04-13	\N	2017-02-23	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Allergic Rhinitis"}	combination	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
394	2023-01-02 15:22:35.745	2023-03-21 12:10:12.367	NCT02604212	A Multicenter, Randomized, Double-blind, Placebo-controlled Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection	A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection	Terminated	Patients with HBeAG positive, chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.	Parallel Assignment	Arrowhead Pharmaceuticals	INDUSTRY	All	75	18	32	Actual	INDUSTRY	Arrowhead Pharmaceuticals	Randomized	\N	Quadruple	\N	\N	Treatment	\N	This is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study of ARC-520 in combination with entecavir or tenofovir administered to patients with HBeAg positive and immune active chronic HBV infection Eligible patients who have signed an Ethics Committee - approved informed consent, will be enrolled and will receive ARC-520 or placebo in combination with entecavir or tenofovir. The study will enroll up to a total of 90 eligible chronic HBV infected patients. Patients will undergo the following evaluations at regular intervals during the study: medical history, physical examinations, vital sign measurements (blood pressure, heart rate, respiratory rate and temperature), weight, adverse events assessment (AEs), 12 lead electrocardiograms (ECGs), liver fibrosis testing, concomitant medication assessment, blood sample collection for hematology, coagulation, chemistry, lactate, Pharmacokinetic (PK) measures (in a subset of patients), exploratory Pharmacodynamic (PD) measures, urinalysis, HBV serology, Follicle Stimulating Hormone (FSH) testing (post-menopausal females) and pregnancy testing for females of childbearing potential. Clinically significant changes including AEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the patient is lost to follow-up. For each patient the duration of the study is approximately 33 weeks from screening to the Day 169 follow-up visit. For patients enrolling into a planned extension study, the total duration of this study is approximately 25 weeks from screening to Day 113 end of study visit.	2015-11-01	2016-12-01	2016-12-01	2015-11-13	2019-04-16	2019-04-16	Arrowhead Pharmaceuticals, Inc.	\N	\N	\N	\N	\N	Sponsor	Company decision to discontinue trial	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Hepatitis B"}	pre-medication	cetirizine	\N	f	Hepatitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
224	2023-01-02 15:22:35.735	2023-03-20 20:13:08.333	NCT05478161	Investigation of the Safety and Performance of the NVT ALLEGRA THV System With a New Delivery System in Patients With Severe Calcified Aortic Stenosis or Failed Surgical Aortic Bioprosthesis	Investigation of the ALLEGRA THV System With a New Delivery System in Patients With Aortic Stenosis or Failed Surgical Bioprosthesis	Not yet recruiting	The EMPIRE study confirms the technical performance of the new IMPERIA Delivery System and evaluates the safety and efficacy of the entire ALLEGRA THV System.\n\nThe primary endpoint is device success rate at 7 days (discharge from index procedure or 7 days post implant, whichever comes first), as defined by VARC 2.\n\nBased on the outcomes of a study with a similar device and considering a drop-out rate of 5%, 107 patients need to be enrolled in the study.	Single Group Assignment	NVT GmbH	INDUSTRY	All	\N	18	107	Anticipated	INDUSTRY	NVT GmbH	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2022-12-01	2023-10-01	2024-10-01	2022-07-28	\N	2022-07-28	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{"Transcatheter Aortic Valve Implantation"}	not included	fexofenadine	ALLEGRA in this case does not refer to fex but rather is an acronym for some method	f	Transcatheter Aortic Valve Implantation	2022-08-18 16:54:53	{}	UNKNOWN	\N	fexofenadine
392	2023-01-02 15:22:35.743	2023-03-21 12:09:11.006	NCT05660083	Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)	Alpelisib/iNOS Inhibitor/Nab-paclitaxel_MpBC	Not yet recruiting	This is a research study to test the safety and effectiveness of using the drug alpelisib together with chemotherapy (nab-paclitaxel) and a drug called L-NMMA in patients with HER2 negative metastatic or locally advanced metaplastic breast cancer, who have not responded to previous treatments.\n\nParticipants in this study in addition to the standard care chemotherapy will also receive the drug alpelisib and L-NMMA. The therapies will be administered every 3 weeks (1 cycle) until disease progression, toxicity or until the participant withdraws from the study. The nab-paclitaxel chemotherapy will be administered intravenously on Day 1 of the 3 week cycles. Participants will take the drug alpelisib by mouth once daily at a dose determined by a safety study and the drug L-NMMA will be given intravenously on days 1 to 5 of the 3 week cycles.	Single Group Assignment	The Methodist Hospital Research Institute	OTHER	All	\N	18	36	Anticipated	OTHER	The Methodist Hospital Research Institute	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	This is a Phase II trial with a dose escalation/de-escalation lead-in that will investigate the efficacy and safety of an iNOS inhibitor and nab-paclitaxel in combination with alpelisib in patients with HER2 negative, metastatic or locally advanced MpBC. The prognosis for metastatic or locally advanced metaplastic breast cancer (MpBC), a rare and highly chemotherapy-resistant subtype of TNBC, is even worse than for non-metaplastic TNBC, with a median overall survival ranging from 3 to 8 months.1 Standard systemic chemotherapy remains the only available treatment option for patients with metastatic or locally advanced MpBC, even though this disease is largely refractory to cytotoxic drugs. Therefore, combination strategies to understand and overcome mechanisms of resistance to improve marginal chemotherapeutic efficacy are needed to improve the prognosis of these patients. We have found that inducible nitric oxide synthase (iNOS) is a critical target for overcoming chemotherapy resistance in TNBC.2,3 iNOS expression is increased and associated with poor prognosis in invasive TNBC and MpBC.2-5 It has been shown that nitric oxide (NO) through iNOS induces many of the major oncogenic pathways such as RAS/ERK, HIF1, NF- B, and others making this a unique oncogenic driver. One of the major oncogenic pathways activated by iNOS/NO is the phosphatidylinositol 3-kinase (PI3K)/Akt pathway.6-9 Alterations in the Pl3K/Akt pathway have also been linked with chemotherapy resistance, especially in MpBC.10-14 We hypothesize that addition of the PI3K inhibitor, alpelisib, to a pan-NOS inhibitor (L-NMMA) and nab-paclitaxel will increase objective response rate (ORR) in patients with HER2 negative metastatic or locally advanced MpBC. Both first- and second-line patients will be eligible for this trial. Patients may have received prior immunotherapy, per standard of care.	2023-01-01	2026-12-01	2028-12-02	2022-12-21	\N	2022-12-21	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"HER2-negative Breast Cancer","Metastatic Breast Cancer","Metaplastic Breast Carcinoma","TNBC - Triple-Negative Breast Cancer"}	minimal	\N	Todo usecase	f	Safety Evaluation	\N	{"Moreno AC, Lin YH, Bedrosian I, Shen Y, Babiera GV, Shaitelman SF. Outcomes after Treatment of Metaplastic Versus Other Breast Cancer Subtypes. J Cancer. 2020 Jan 1;11(6):1341-1350. doi: 10.7150/jca.40817. eCollection 2020.","Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS, Chang JC. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Breast Cancer Res. 2015 Feb 22;17(1):25. doi: 10.1186/s13058-015-0527-x.","Dave B, Gonzalez DD, Liu ZB, Li X, Wong H, Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD, Radovich M, KarinaEtrovic A, Gross SS, Elemento O, Mills GB, Gilcrease MZ, Chang JC. Role of RPL39 in Metaplastic Breast Cancer. J Natl Cancer Inst. 2016 Dec 31;109(6):djw292. doi: 10.1093/jnci/djw292. Print 2017 Jun.","Davila-Gonzalez D, Choi DS, Rosato RR, Granados-Principal SM, Kuhn JG, Li WF, Qian W, Chen W, Kozielski AJ, Wong H, Dave B, Chang JC. Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer. Clin Cancer Res. 2018 Mar 1;24(5):1152-1162. doi: 10.1158/1078-0432.CCR-17-1437. Epub 2018 Jan 4.","Garrido P, Shalaby A, Walsh EM, Keane N, Webber M, Keane MM, Sullivan FJ, Kerin MJ, Callagy G, Ryan AE, Glynn SA. Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways. Oncotarget. 2017 Jul 26;8(46):80568-80588. doi: 10.18632/oncotarget.19631. eCollection 2017 Oct 6.","Switzer CH, Glynn SA, Cheng RY, Ridnour LA, Green JE, Ambs S, Wink DA. S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Mol Cancer Res. 2012 Sep;10(9):1203-15. doi: 10.1158/1541-7786.MCR-12-0124. Epub 2012 Aug 9.","Ridnour LA, Barasch KM, Windhausen AN, Dorsey TH, Lizardo MM, Yfantis HG, Lee DH, Switzer CH, Cheng RY, Heinecke JL, Brueggemann E, Hines HB, Khanna C, Glynn SA, Ambs S, Wink DA. Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation. PLoS One. 2012;7(9):e44081. doi: 10.1371/journal.pone.0044081. Epub 2012 Sep 5.","Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, Hussain P, Vecoli C, Paolocci N, Ambs S, Colton CA, Harris CC, Roberts DD, Wink DA. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med. 2008 Jul 1;45(1):18-31. doi: 10.1016/j.freeradbiomed.2008.03.020. Epub 2008 Apr 4.","Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L, Pfiester CM, Yfantis HG, Cottrell JR, Lee DH, Remaley AT, Hofseth LJ, Wink DA, Ambs S. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer. 2007 Feb 15;120(4):796-805. doi: 10.1002/ijc.22336.","Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li JH, Xu XM, Liu S, Chen J, Liu F, Qi YL, Deng Q, Cao J, Liu SQ, Luo HS, Yu JP. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer. 2008 Jan 15;122(2):433-43. doi: 10.1002/ijc.23049.","Huang WC, Hung MC. Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc. 2009 Mar;108(3):180-94. doi: 10.1016/S0929-6646(09)60051-6.","Cai Y, Tan X, Liu J, Shen Y, Wu D, Ren M, Huang P, Yu D. Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. Chin J Cancer Res. 2014 Oct;26(5):564-72. doi: 10.3978/j.issn.1000-9604.2014.08.20.","Li B, Li J, Xu WW, Guan XY, Qin YR, Zhang LY, Law S, Tsao SW, Cheung AL. Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. Oncotarget. 2014 Nov 30;5(22):11576-87. doi: 10.18632/oncotarget.2596.","Wang Q, Shi YL, Zhou K, Wang LL, Yan ZX, Liu YL, Xu LL, Zhao SW, Chu HL, Shi TT, Ma QH, Bi J. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 2018 Jul 3;9(7):739. doi: 10.1038/s41419-018-0776-6.","Takala S, Heikkila P, Nevanlinna H, Blomqvist C, Mattson J. Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease. Breast J. 2019 May;25(3):418-424. doi: 10.1111/tbj.13234. Epub 2019 Mar 29.","Reddy TP, Rosato RR, Li X, Moulder S, Piwnica-Worms H, Chang JC. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Res. 2020 Nov 4;22(1):121. doi: 10.1186/s13058-020-01353-z.","Somasundaram V, Basudhar D, Bharadwaj G, No JH, Ridnour LA, Cheng RYS, Fujita M, Thomas DD, Anderson SK, McVicar DW, Wink DA. Molecular Mechanisms of Nitric Oxide in Cancer Progression, Signal Transduction, and Metabolism. Antioxid Redox Signal. 2019 Mar 10;30(8):1124-1143. doi: 10.1089/ars.2018.7527. Epub 2018 May 2.","Basudhar D, Bharadwaj G, Somasundaram V, Cheng RYS, Ridnour LA, Fujita M, Lockett SJ, Anderson SK, McVicar DW, Wink DA. Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective. Br J Pharmacol. 2019 Jan;176(2):155-176. doi: 10.1111/bph.14488. Epub 2018 Nov 6.","Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018 May;15(5):273-291. doi: 10.1038/nrclinonc.2018.28. Epub 2018 Mar 6.","Cossu-Rocca P, Orru S, Muroni MR, Sanges F, Sotgiu G, Ena S, Pira G, Murgia L, Manca A, Uras MG, Sarobba MG, Urru S, De Miglio MR. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer. PLoS One. 2015 Nov 5;10(11):e0141763. doi: 10.1371/journal.pone.0141763. eCollection 2015.","Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.","Kriegsmann M, Endris V, Wolf T, Pfarr N, Stenzinger A, Loibl S, Denkert C, Schneeweiss A, Budczies J, Sinn P, Weichert W. Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget. 2014 Oct 30;5(20):9952-65. doi: 10.18632/oncotarget.2481.","Zhai J, Giannini G, Ewalt MD, Zhang EY, Invernizzi M, Niland J, Lai LL. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing. Hum Pathol. 2019 Apr;86:85-92. doi: 10.1016/j.humpath.2018.11.023. Epub 2018 Dec 8.","Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009 May 15;69(10):4116-24. doi: 10.1158/0008-5472.CAN-08-3441. Epub 2009 May 12.","Afkhami M, Schmolze D, Yost SE, Frankel PH, Dagis A, Amanam IU, Telatar M, Nguyen K, Yu KW, Luu T, Pillai R, Aoun PA, Mortimer J, Yuan Y. Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. PLoS One. 2019 Nov 6;14(11):e0224726. doi: 10.1371/journal.pone.0224726. eCollection 2019.","Chan JJ, Tan TJY, Dent RA. Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond. Ther Adv Med Oncol. 2019 Oct 9;11:1758835919880429. doi: 10.1177/1758835919880429. eCollection 2019.","Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Papai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904.","Reddy T, et al. Combination PI3K and NOS targeted therapy for metaplastic breast cancer (abstract). In: European Journal of Cancer, Molecular Targeted Agents. 2020; 138:S49-S50.","Nelson RA, Guye ML, Luu T, Lai LL. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann Surg Oncol. 2015 Jan;22(1):24-31. doi: 10.1245/s10434-014-3890-4. Epub 2014 Jul 11.","Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999 Apr;10(4):413-9. doi: 10.1023/a:1008329910362.","Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol. 2015 Jul;26(7):1346-52. doi: 10.1093/annonc/mdv163. Epub 2015 Apr 15."}	NO_PUBLICATION_FOUND	\N	cetirizine
206	2023-01-02 15:22:35.733	2023-03-20 19:57:16.415	NCT02543346	Comparability and Standardization of Controlled Allergen Challenge Facilities	Comparability and Standardization of Controlled Allergen Challenge Facilities	Completed	Allergen challenge facilities have been utilized for many years in clinical drug trials studying onset of action, proof of concept, duration of action, and efficacy. Each facility has somewhat different design characteristics and pollen dispersal technologies. Facilities are located in disparate geographic areas and have populations of participants who are sensitized to allergens unique to that area. Therefore, facilities have operated as single sites with little effort to evaluate facility comparability or to attempt standardization across facilities. The purpose of this study is to compare the two sites and assess whether the sites are able to achieve similar symptom scores.	Crossover Assignment	Queen's University	OTHER	All	65	18	98	Actual	OTHER	Queen's University	Randomized	\N	Double	\N	\N	Other	\N	When CACF have been designed with a high degree of rigor, quality assurance and validation testing, the exposure to controlled levels of pollen in such facilities as the Environmental Exposure Unit (EEU) and the Biogenics Research Chamber (BRC) will demonstrate comparable/standardized symptomatic responses. This will be demonstrable not only following pollen exposure but will also have similar reductions in symptoms following treatment with a Food and Drug Administration (FDA) approved medication known to be effective for the treatment of seasonal allergic rhinoconjunctivitis ( SAR); cetirizine 10mg. Because of quality assurance and validation testing completed at these facilities a priori, this comparability will be demonstrated despite their disparate geographical physical locations and the utilization of these facilities of somewhat different mechanical and technical materials and methods to achieve similar outcomes.\n\nThis multi-center study of SAR will enroll 50 participants at each site. These participants will be age 18-65, male and female, with a mixture of ethnic groups. The study will involve 3 Phases: Screening, Treatment Exposure Visit, and a cross-over Treatment Exposure Visit. In all stages, a CACF visit will be pivotal to determine participant eligibility for enrollment and response to therapy. The qualifying participants will receive a double-blinded, placebo-controlled, crossover intervention with cetirizine HCl 10mg.\n\nAll participants will give written informed consent prior to any study related procedures being performed. Participants who meet all inclusion/exclusion criteria during the screening process will be asked to return to the EEU for their first pollen exposure visit (Treatment Visit #1). At the Screening Visit participants will provide a full medical history and undergo a physical examination. They will have their height/weight and vitals measured and skin testing will be performed to confirm allergic response to a panel of common aeroallergens. Women of child bearing potential will undergo a urine pregnancy test to rule out pregnancy. Eligible participants will be invited back to the research centre for 4 pollen exposure visits at 2 of these visits participants will receive either cetirizine or placebo. All participants will receive placebo at some point throughout the study.	2015-10-01	2016-02-01	2016-05-01	2015-09-07	2019-04-09	2019-04-09	Kingston General Hospital	Queen's University	Dr. Anne Ellis	Chair, Division of Allergy & Immunology	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Allergic Rhinitis"}	minimal	cetirizine	H1RAs are not the focus	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
227	2023-01-02 15:22:35.735	2023-03-20 20:17:13.908	NCT03012763	Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan After Oral Administration Using 240 ml Non-caloric Water, a Carbohydrate Enriched Drink and Grapefruit Juice in Correlation to the Intestinal Availability of Water as Quantified by MRI-based Volumetry in 9 Healthy Male and Female Subjects	Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums	Completed	The purpose of this study is to determine pharmacokinetics of the probe-drugs sulfasalazine, given in 240 ml non-caloric water and paracetamol, fexofenadine and valsartan after oral administration, given in 240 ml non-caloric water, in 240 ml caloric drink or in 240 ml grapefruit juice prior to ingestion and to visualize the localization and to measure the filling volume of stomach, small intestine as well as ascending, transverse and descending colon by T2-weighted magnetic resonance imaging after oral administration of 240 ml water (non-caloric water), after administration of 240 ml caloric drink and after administration of 240 ml grapefruit juice.	Crossover Assignment	University Medicine Greifswald	OTHER	All	45	18	9	Actual	OTHER	University Medicine Greifswald	Randomized	\N	None (Open Label)	\N	\N	Basic Science	\N	\N	2016-04-01	2017-01-01	\N	2017-01-06	\N	2017-01-06	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Pharmacokinetics,"Magnetic Resonance Imaging","Administration, Oral"}	combination	fexofenadine	one of many drugs tested; TODO check role again (Update: combination should be ok)	f	Pharmacokinetics	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
190	2023-01-02 15:22:35.733	2023-03-20 19:39:34.464	NCT00881634	A Single-Dose Comparative Bioavailability Study of Two Formulations of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release Tablets Under Fed Conditions	To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions	Completed	To demonstrate the relative bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg ER tablets under fed conditions.	Crossover Assignment	Sandoz	INDUSTRY	All	53	20	40	Actual	INDUSTRY	Sandoz	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2005-06-01	2005-07-01	2005-07-01	2009-04-15	\N	2017-03-28	\N	\N	\N	\N	Eric Mittleberg, Ph.D, VP of Product Development	Sandoz Inc.	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Allergies}	combination	cetirizine	\N	f	Bioavailability	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
243	2023-01-02 15:22:35.735	2023-03-19 21:06:01.338	NCT00240032	A Double-Blind, Randomized, Placebo Controlled Study of An Oral Antihistamine on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone Using Autoject 2 for Glass Syringe.	A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec) or Placebo Prior to Daily Injections of Copaxone.	Completed	This study is designed to compare injection skin (injection site) reactions when an antihistamine (Zyrtec) or placebo is taken prior to performing daily Copaxone injections. Patients will be assigned (like a flip of a coin) to take either a placebo or an antihistamine (Zyrtec) prior to performing their daily Copaxone injections. The patient and physician will be unaware whether they are taking a placebo or antihistamine during the study.	Parallel Assignment	Teva Branded Pharmaceutical Products R&D, Inc.	INDUSTRY	All	\N	18	80	Actual	INDUSTRY	Teva Branded Pharmaceutical Products R&D, Inc.	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2004-10-01	2006-06-01	2006-07-01	2005-10-17	\N	2011-04-11	\N	\N	\N	\N	Thomas Smith, MD, VP Medical Affairs	Teva Neuroscience	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Multiple Sclerosis"}	main	cetirizine	\N	t	Infusion Reaction	2022-08-17 13:39:16	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/20187348/	cetirizine
172	2023-01-02 15:22:35.731	2023-03-20 19:26:44.889	NCT00439712	Efficacy of Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Rhinitis	Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Allergic Rhinitis	Completed	The purpose of this study is to show that in patients suffering from perennial allergic rhinitis levocetirizine 5 mg OD relieves nasal obstruction. Furthermore the study is to investigate how relevant for these patients their nasal obstruction and the effect of levocetirizine on their nasal obstruction are.	Parallel Assignment	Institut fr Atemwegsforschung GmbH	INDUSTRY	All	65	18	60	Actual	INDUSTRY	Institut fr Atemwegsforschung GmbH	Randomized	\N	Triple	\N	\N	Treatment	\N	The study is performed according to a monocentre, double-blind, placebo controlled, two arm parallel group design. It is divided in 3 periods: A 7  2 day screening phase when patients are not to treat their perennial allergic rhinitis (PAR) is followed by a 29  4 day treatment period when patients administer either levocetirizine 5 mg OD or placebo and a 14  2 week post treatment observation period when again medication against PAR is not to be taken. However in all study periods patients are provided cromoglicine nasal spray and eye drops which in case of severe complaints they may use as rescue medication.\n\nThroughout the study patients keep a diary documenting the severity of their nasal and ocular symptoms of allergy. Every morning and every evening they use a 4-point scale (0 = no symptom, 1 = mild, 2 = moderate, 3 = severe) to rate nasal obstruction, rhinorrhea, nasal itching, sneezing and ocular complaints they experienced during the preceding 12 hours. Furthermore they report adverse events and intake of drugs inclusive of rescue and (during treatment period) study medication.\n\nPatients attend 5 visits to the study site. On visit 1 medical history and concomitant medication are assessed and patients undergo a physical examination, a pregnancy test in case of women of child bearing potential, and, if necessary, a skin prick test. Blood is taken to estimate creatinine clearance. Inclusion and exclusion criteria are checked and, if they do not contradict study continuation, patients enter the screening period which ends in the morning of the day visit 2. If on this visit morning diary reports show sufficiently high nasal obstruction scores and study participation still complies with the inclusion and exclusion criteria, patients are randomized and start the treatment period taking the first dose at the study site. On visit 2 as well as on the following visits adverse events and use of medication are surveyed and compliance is checked. Visit 3, 4 and 5 are scheduled after one week of treatment, between treatment and post treatment observation period and at the end of the study respectively. On visit 5 there is a final physical examination and again females of childbearing potential undergo a pregnancy test. To assess how relevant for patients nasal obstruction and the effect of the study medication on nasal obstruction are questionnaires are completed on each visit.	2007-02-01	2007-05-01	2007-05-01	2007-02-26	\N	2008-01-15	\N	\N	\N	\N	Claus Bachert MD PhD	Institut fr Atemwegsforschung GmbH	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Perennial Allergic Rhinitis"}	main	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
222	2023-01-02 15:22:35.734	2023-03-20 20:10:34.836	NCT00253058	Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup in Children -Suffering From Perennial Allergic Rhinitis-	Study Of Perennial Allergic Rhinitis In Pediatrics	Completed	To verify of cetirizine dry syrup to ketotifen dry syrup in the change of total nasal symptom score (TNSS) over the total treatment period from the score of the baseline assessment period	Parallel Assignment	GlaxoSmithKline	INDUSTRY	All	14	3	286	\N	INDUSTRY	GlaxoSmithKline	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2005-07-01	\N	\N	2005-11-15	\N	2013-05-06	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Rhinitis, Allergic, Perennial"}	comparison	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
228	2023-01-02 15:22:35.735	2023-03-20 20:17:59.573	NCT01748344	A Randomised, Placebo Controlled, Four Period Crossover Study to Evaluate the Efficacy, Safety of Oral Repeat Doses of ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis in the Vienna Challenge Chamber.	Phase II Study Evaluating ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis	Completed	The purpose of this study is to investigate if ONO-4053 relieves symptoms of allergic rhinitis in seasonal allergic rhinitis subjects exposed to pollen under controlled conditions.	Crossover Assignment	Ono Pharmaceutical Co. Ltd	INDUSTRY	All	65	18	58	Actual	INDUSTRY	Ono Pharmaceutical Co. Ltd	Randomized	\N	Triple	\N	\N	Treatment	\N	The purpose of this study is to investigate if ONO-4053 will impact allergic rhinitis symptoms in subjects with seasonal allergic rhinitis when they are exposed to pollen administered at a fixed rate in an inhalation exposure chamber compared to the standard treatment Cetirizine 10mg under the same conditions.	2012-11-01	2014-02-01	\N	2012-12-12	\N	2014-04-15	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Seasonal Allergic Rhinitis"}	comparison	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
242	2023-01-02 15:22:35.736	2023-03-20 20:33:05.898	NCT00547768	\N	Comparative Study Evaluating the Effects of Fexofenadine HCI 180 mg With Orange Juice Versus Placebo With Orange Juice in a Skin Wheal and Flare Challenge Model.	Completed	Compare the effect of a single dose of fexofenadine HCl 180 mg plus orange juice versus placebo plus orange juice on the change from baseline (pre-dose) in histamine skin flares.	Crossover Assignment	Sanofi	INDUSTRY	All	55	12	36	Actual	INDUSTRY	Sanofi	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2002-11-01	\N	2002-12-01	2007-10-23	\N	2011-01-11	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Child,Adult}	{"Phase 4"}	{Allergy}	main	fexofenadine	\N	f	Allergy	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
226	2023-01-02 15:22:35.734	2023-03-20 20:15:55.75	NCT00257569	Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup in Children -Suffering From Atopic Dermatitis-	Study Of Atopic Dermatitis In Pediatrics	Completed	To verify of cetirizine dry syrup to ketotifen dry syrup in the change in the severity of pruritus of the treatment period.	Parallel Assignment	GlaxoSmithKline	INDUSTRY	All	14	3	278	\N	INDUSTRY	GlaxoSmithKline	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2005-08-01	\N	\N	2005-11-23	\N	2013-05-06	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Dermatitis, Atopic"}	comparison	cetirizine	\N	f	Dermatitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
399	2023-01-02 15:22:35.745	2023-03-21 12:16:44.329	NCT02665754	The Efficacy and Adverse Effect of Intralymphatic Immunotherapy With Tyrosine S, Allergen Extract for Immunotherapy, in Patients With Allergic Rhinitis Induced by House Dust Mite, Dog, and Cat Allergen	Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S in Allergic Rhinitis	Completed	The investigators will perform double-blinded placebo-controlled randomized clinical trial which evaluates the efficacy and safety of allergen-specific intralymphatic immunotherapy (ILIT) for allergens including Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus (Dp), cat, and dog that are sensitized and provoke rhinitis-related symptoms in patients with allergic rhinitis (AR), using allergen extracts for allergen-specific immunotherapy (Tyrosine S, Allergy Therapeutic, West Sussex, UK).	Parallel Assignment	Gachon University Gil Medical Center	OTHER	All	\N	19	32	Actual	OTHER	Gachon University Gil Medical Center	Randomized	\N	Quadruple	\N	\N	Treatment	\N	After informed consent, subjects will be randomly assigned to ILIT group or placebo group in double-blind manner. In both group, causal allergen or placebo will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval. In ILIT group, initial dose of allergen will be 1,000-fold diluted solution from maximal concentration of allergen extract for subcutaneous immunotherapy (Tyrosine S, Allergy Therapeutic, West Sussex, UK) in volume of 0.1ml. If skin is highly reactive in skin prick test, the initial dose will be 10-fold dilution from maximal concentration where diameter of wheal is less than that of histamine. After the first dose, allergen concentration will be escalated 3-fold at second dose, and 10-fold at third dose if there are no (or mild) local or systemic hypersensitivity reaction. The allergen concentration will not change at second or third dose if there is moderate local or systemic reaction. The allergen concentration will decrease by 10 or 100-fold from previous concentration or further injection will be held if there is severe local or systemic reaction after sufficient explanation and discussion with subjects.\n\nThe investigators will evaluate allergic rhinitis symptom score before and 4, 12 months after the initial treatment. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and Sino-Nasal Outcome Test (SNOT-20) will be used. Visual analogue scale (VAS) of symptoms including rhinorrhea, sneezing, nasal obstruction, postnasal drip, eye/nose/ear/palate itching, dyspnea, wheezing, chest discomfort as well as urticaria, angioedema, and itching on exposed skin during exposure to causal allergen in daily life will be also evaluated. Skin prick test (SPT), intradermal test (IDT), blood sampling for serum total immunoglobulin E (IgE), allergen-specific IgE, and allergen-specific immunoglobulin G4 (IgG4), nasal lavage for Th1, Th2, and Treg cytokines, and nasal provocation test (NPT) with Df and/or Dp allergen (in subjects whose AR symptoms are provoked by Df and/or Dp) will be also performed before and 4, 12 months after the initial treatment. In addition, the investigators evaluated the change of subjects' recognition of causal allergens, their avoidance, and AIT during this study. Using VAS, subjects were requested to score the rate of agreement with "Allergen provokes allergic symptoms in daily life", "Allergen avoidance can reduce allergic symptoms", "Allergen-specific Immunotherapy (AIT) can reduce allergic symptoms", "I can pay 50,000 Korean Won (KRW)/month for allergen avoidance", "I can pay 100,000 KRW/month for allergen avoidance", "I can pay 200,000 KRW/month for allergen avoidance", "I can pay 150,000 KRW for each injection of ILIT", "I can pay 300,000 KRW for each injection of ILIT", "I can pay 600,000 KRW for each injection of ILIT" before and after SPT/IDT, after NPT, 4 months and 1 year after ILIT.\n\nAdverse events will be recorded and graded according to Muller classification and Ring and Meissner classification.	2016-07-01	2019-12-01	2020-01-01	2016-01-28	\N	2020-02-11	\N	Gachon University Gil Medical Center	Sangmin Lee, MD	Assistant Professor	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Allergic Rhinitis"}	rescue medication	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):537-43. doi: 10.1097/ACI.0b013e3283310ff7.","Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol. 2011;352:71-84. doi: 10.1007/82_2011_133.","Kundig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol. 2014 Mar;133(3):930-1. doi: 10.1016/j.jaci.2013.11.036. Epub 2014 Jan 15. No abstract available.","Johansen P, Kundig TM. Intralymphatic immunotherapy and vaccination in mice. J Vis Exp. 2014 Feb 2;(84):e51031. doi: 10.3791/51031.","Graf N, Dinkel B, Rose H, Hothorn LA, Gerhard D, Johansen P, Kundig TM, Klimek L, Senti G. A critical appraisal of analyzing nasal provocation test results in allergen immunotherapy trials. Rhinology. 2014 Jun;52(2):137-41. doi: 10.4193/Rhino13.145.","Zaleska A, Eiwegger T, Soyer O, van de Veen W, Rhyner C, Soyka MB, Bekpen C, Demiroz D, Treis A, Sollner S, Palomares O, Kwok WW, Rose H, Senti G, Kundig TM, Ozoren N, Jutel M, Akdis CA, Crameri R, Akdis M. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine. Allergy. 2014 Sep;69(9):1162-70. doi: 10.1111/all.12461. Epub 2014 Jul 12. Erratum In: Allergy. 2016 Jan;71(1):129.","Senti G, Kundig TM. Intralymphatic immunotherapy. World Allergy Organ J. 2015 Mar 7;8(1):9. doi: 10.1186/s40413-014-0047-7. eCollection 2015.","Hjalmsdottir A, Wackerle-Men Y, Duda A, Kundig TM, Johansen P. Dosing intervals in intralymphatic immunotherapy. Clin Exp Allergy. 2016 Mar;46(3):504-7. doi: 10.1111/cea.12657. No abstract available.","Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, Simard JJ, Wuthrich B, Crameri R, Graf N, Johansen P, Kundig TM. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17908-12. doi: 10.1073/pnas.0803725105. Epub 2008 Nov 10.","Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, Steiner M, Hothorn LA, Gronlund H, Tivig C, Zaleska A, Soyer O, van Hage M, Akdis CA, Akdis M, Rose H, Kundig TM. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012 May;129(5):1290-6. doi: 10.1016/j.jaci.2012.02.026. Epub 2012 Mar 30.","Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013 Feb;131(2):412-20. doi: 10.1016/j.jaci.2012.10.056.","Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013 Nov;132(5):1248-1252.e5. doi: 10.1016/j.jaci.2013.07.033. Epub 2013 Sep 13. No abstract available.","Patterson AM, Bonny AE, Shiels WE 2nd, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2016 Feb;116(2):168-70. doi: 10.1016/j.anai.2015.11.010. Epub 2015 Dec 17. No abstract available.","Park HJ, Kim SH, Shin YS, Park CH, Cho ES, Choi SJ, Park SH, Jung JH, Kang IG, Lee MS, Kim DW, Lee SM, Yang MS, Lee SP. Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial. Respir Res. 2021 Jun 4;22(1):170. doi: 10.1186/s12931-021-01766-0."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/34088322/	cetirizine
177	2023-01-02 15:22:35.732	2023-03-20 19:28:13.163	NCT00805584	A Multi-center, Open-label, Non-comparative Study of the Relief of Nasal Symptoms and Tolerability in Subjects With Seasonal Allergic Rhinitis (SAR) Treated With Aerius.	Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)	Completed	The purpose of this study was to test the effectiveness and side effects of desloratadine (Aerius) in patients with hayfever. Patients took desloratadine once a day for 15 days. At the end of therapy, they scored how severe their hayfever symptoms were and how they responded to therapy. Side effects were recorded.	Single Group Assignment	Organon and Co	INDUSTRY	All	\N	18	311	Actual	INDUSTRY	Organon and Co	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2003-05-01	2003-06-01	2003-06-01	2008-12-09	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Rhinitis, Allergic, Seasonal"}	main	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
197	2023-01-02 15:22:35.732	2023-03-20 19:43:28.735	NCT00295022	Double-blind, Three Parallel Randomized Groups, Therapeutic Confirmatory Clinical Trial to Compare the Efficacy of Oral Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Ragweed Sensitive Subjects Exposed to Ragweed Pollen in an Environmental Exposure Unit (EEU)	Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects	Completed	To compare the clinical efficacy of levocetirizine 5 mg and montelukast 10 mg on symptoms of seasonal allergic rhinitis occurring in subjects exposed to ragweed pollen in an environmental exposure unit.	Parallel Assignment	UCB S.A. - Pharma Sector	INDUSTRY	All	\N	18	418	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2006-07-29	2006-10-01	2006-10-01	2006-02-22	2018-07-23	2018-09-11	Cares	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Rhinitis, Allergic, Seasonal"}	combination	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/18387222/	levocetirizine
230	2023-01-02 15:22:35.735	2023-03-20 20:18:43.534	NCT01685242	A Single-Center, Double-Masked, Randomization, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis	A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle	Completed	The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.	Parallel Assignment	Aciex Therapeutics, Inc.	INDUSTRY	All	\N	10	100	Actual	INDUSTRY	Aciex Therapeutics, Inc.	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2012-09-01	2012-11-01	2012-11-01	2012-09-14	2017-10-10	2017-10-10	Nicox Ophthalmics Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Allergic Conjunctivitis"}	main	cetirizine	\N	f	Allergic Conjunctivitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
249	2023-01-02 15:22:35.736	2023-03-20 20:36:49.277	NCT01244217	An Open-label, Uncontrolled 4-week Study to Assess the Safety, Efficacy and Pharmacokinetics of Allegra (Dry Syrup Formulation) 15 mg or 30 mg Twice Daily in Pediatric Patients With Perennial Allergic Rhinitis	Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)	Completed	Primary Objective:\n\n- To evaluate safety (4 weeks)\n\nSecondary Objectives:\n\nTo evaluate the long-term safety (12 weeks)\nTo evaluate the efficacy\nTo characterize the pharmacokinetic profile	Parallel Assignment	Sanofi	INDUSTRY	All	11	0.5	100	Actual	INDUSTRY	Sanofi	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	The study consists of four phases: up to 9-day screening phase, main 4-week treatment phase, up-to 8-week extension phase, and up-to 5-day post-treatment phase.	2010-10-01	2011-07-01	2011-08-01	2010-11-19	\N	2013-10-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 2","Phase 3"}	{"Rhinitis Perennial"}	main	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
202	2023-01-02 15:22:35.733	2023-03-20 19:44:37.033	NCT00257582	Long-term Study of Cetirizine Dry Syrup in Children Suffering From Various Type of Cutaneous Disease Accompanied With Pruritus.	Study Of Cutaneous Disease Accompanied With Pruritus In Pediatrics	Completed	To assess the safety of long-term use of cetirizine dry syrup in children with various type of cutaneous disease accompanied on pruritus.	Single Group Assignment	GlaxoSmithKline	INDUSTRY	All	14	2	60	\N	INDUSTRY	GlaxoSmithKline	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2005-08-01	\N	\N	2005-11-23	\N	2013-05-06	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{Pruritus}	main	cetirizine	\N	f	Pruritus	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
400	2023-01-02 15:22:35.745	2023-03-21 12:18:43.954	NCT04935515	C Reactive Protein Based Early Intervention for Home Quarantined COVID -19 Patients to Avoid Complications and Hospitalization.	C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.	Completed	During the peak of the second COVID -19 wave, the hospitals were over-crowded. Many COVID -19 positive patients had to stay at home and reach out to their family physicians for guidance. Medical follow-up for these patients was a daunting challenge. As in - patient hospital facilities were not readily accessible due to over crowding, early objective tests to identify home quarantined patients prone to deterioration and timely medical intervention to avoid hospitalization were required.\n\nBased on early assessment of inflammatory markers like CRP and clinical signs like persistent high-grade fever, need-based early medical intervention was initiated in home quarantined COVID -19 patients prior to the onset of hypoxia, in order to avoid complications and hospitalization	Parallel Assignment	Manimarane Arjunan, MD,DM (Cardiology)	OTHER	All	80	18	25	Actual	OTHER	UR Anoop Research Group	Non-Randomized	\N	None (Open Label)	\N	\N	Supportive Care	\N	25 home quarantined COVID -19 patients who contacted online for medical guidance underwent clinical and biochemical evaluation. Radiological evaluation was done only if indicated.\n\nBased on early objective biochemical tests like elevated CRP and clinical signs like persistent high-grade fever on the third or fourth day after onset of symptoms, early medical treatment was initiated prior to onset of hypoxia.\n\nAll the 25 patients recovered without any complications and did not require hospitalization.	2021-04-15	2021-05-09	2021-06-06	2021-06-23	\N	2021-06-23	\N	UR Anoop Research Group	Manimarane Arjunan, MD,DM (Cardiology)	Principal Investigator	\N	\N	Sponsor-Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{"COVID -19"}	combination	cetirizine	\N	f	COVID	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
182	2023-01-02 15:22:35.731	2023-03-20 19:31:34.485	NCT00261079	The Evaluation of Efficacy and Safety of Fexofenadine 180mg Tablets for 7 Days in the Treatment of Pruritic Skin Disease	Fexofenadine in Pruritic Skin Disease	Completed	Primary objective:\n\nTo compare the efficacy and safety profile of Fexofenadine 180mg tablets plus prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin disease\n\nSecondary objective:\n\nTo evaluate patient's satisfaction of Allegra treatment	Parallel Assignment	Handok Inc.	INDUSTRY	All	70	12	435	Actual	INDUSTRY	Handok Inc.	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2005-04-01	\N	2006-10-01	2005-12-02	\N	2007-11-07	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{Pruritus}	main	fexofenadine	\N	f	Pruritus	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
235	2023-01-02 15:22:35.735	2023-03-20 20:24:45.538	NCT02175485	Evaluation of Efficacy of Dellegra Combination Tablet (Fexofenadine Hydrochloride 30mg /Pseudoephedrine Hydrochloride 60mg) in Allergic Rhinitis After Japanese Cedar Antigen Exposure in Japanese Population. Open Label Study	Evaluation of Efficacy of Dellegra in Exposure Unit	Completed	Primary Objective:\n\nTo collect and analyze clinical data of Allergic Rhinitis patients' Total Nasal Symptom Score (TNSS) change after Dellegra internal use under high density pure Japanese cedar pollen exposure.\n\nSecondary Objective:\n\nTo collect and analyze clinical data of Allergic Rhinitis patients' change in Total Symptom Score (TSS) and amount of nasal discharge, safety, and overall patients' impression about efficacy of Dellegra after Dellegra internal use under high density pure Japanese cedar pollen exposure.	Single Group Assignment	Sanofi	INDUSTRY	All	65	20	24	Actual	INDUSTRY	Sanofi	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	It will be 8 days at minimum and up to 17 days depending on screening visit and post-treatment observation allowances.	2014-06-01	2014-06-01	2014-06-01	2014-06-26	\N	2015-12-18	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Rhinitis Allergic"}	combination	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
236	2023-01-02 15:22:35.735	2023-03-20 20:26:10.216	NCT02339714	Effect Comparison of Acupuncture Combined With Moxibustion and Loratadine for Perennial Allergic Rhinitis: a Randomized Controlled Trial	Effectivness and Safety of Acupuncture Combined With Moxibustion for Allergic Rhinitis	Completed	A multi-centre clinical trial done by usISRCEN90807007showed that active acupuncture had significantly greater effect on symptoms of allergic rhinitis than either sham acupuncture or no active treatment. The object of that study was to evaluate the effectiveness and safety of acupuncture for allergic rhinitis. As an explanatory research, acupuncture was defined as the only intervention for treatment group and sham acupuncture, no active treatment as its control groups. Besides, acupuncture combined moxibustion showed better and longer effect than acupuncture on allergic rhinitis patients in our previous pilot study. According to this result, we are taking a pragmatic randomized controlled trial to further evaluate whether acupuncture combined moxibustion is more effective than conventional treatment.	Parallel Assignment	Zhao Hong	OTHER	All	60	18	98	Actual	OTHER	China Academy of Chinese Medical Sciences	Randomized	\N	Single	\N	\N	Treatment	\N	\N	2015-03-01	2016-05-01	2018-06-01	2015-01-15	\N	2018-07-18	\N	China Academy of Chinese Medical Sciences	Zhao Hong	Vice president of acupuncture and moxibustion hospital	\N	\N	Sponsor-Investigator	\N	Interventional	{Adult}	{"Phase 2"}	{"Rhinitis, Allergic, Perennial"}	control	loratadine	Check if ltd was only used as control\n	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Sun Y, Zhao H, Ye Y, Nie W, Bai W, Liu J, Li S, Wang F, Han M, He L. Efficacy and safety of using a warming needle for persistent allergic rhinitis: study protocol for a randomized controlled trial. Trials. 2016 Jun 30;17(1):305. doi: 10.1186/s13063-016-1432-z."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/27363578/	loratadine
246	2023-01-02 15:22:35.736	2023-03-20 20:33:36.142	NCT00257595	Long-term Study of Cetirizine Dry Syrup in Children. Suffering From Perennial Allergic Rhinitis.	Perennial Allergic Rhinitis In Pediatric Subjects	Completed	To assess the safety of long-term use of cetirizine dry syrup in children with perennial allergic rhinitis.	Single Group Assignment	GlaxoSmithKline	INDUSTRY	All	14	2	30	\N	INDUSTRY	GlaxoSmithKline	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2005-08-01	\N	\N	2005-11-23	\N	2013-05-06	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Rhinitis, Allergic, Perennial"}	main	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
254	2023-01-02 15:22:35.736	2023-03-20 21:14:49.559	NCT02173249	\N	A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%	Completed	The purpose of this study is to evaluate the Plasma Pharmacokinetics and Safety of AC 170 0.24% in Healthy, Adult Subjects when used twice daily for one week.	Single Group Assignment	Aciex Therapeutics, Inc.	INDUSTRY	All	55	18	11	Actual	INDUSTRY	Aciex Therapeutics, Inc.	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2014-06-01	2014-08-01	2014-08-01	2014-06-24	\N	2017-09-14	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	main	cetirizine	\N	f	Pharmacokinetics	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
402	2023-01-02 15:22:35.745	2023-03-21 12:20:08.388	NCT03635957	A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA (Pegloticase) (MIRROR Open-Label [OL])	Study of Pegloticase (KRYSTEXXA) Plus Methotrexate in Patients With Uncontrolled Gout	Completed	The overall objective of the study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of the concomitant use of pegloticase with methotrexate (MTX) to enhance the response rate seen with pegloticase alone in adults with uncontrolled gout.	Single Group Assignment	Horizon Therapeutics Ireland DAC	INDUSTRY	All	65	18	14	Actual	INDUSTRY	Horizon Pharma Ireland, Ltd., Dublin Ireland	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	The study design will include: 1) up to a 2-week Screening Period (screening should be complete within 2 weeks prior to Week -4), 2) a 4-week MTX Run in Period (Week - 4 through Day 1); 3) a 52-week Pegloticase + IMM (immunomodulator), (Pegloticase + MTX) Period 4) a Safety Follow-up (Phone/Email/Site Visit) and 5) a 3 and 6 month Post Treatment Follow-up.	2018-09-26	2019-10-23	2020-10-26	2018-08-17	2020-11-18	2021-05-19	Horizon Therapeutics Ireland DAC	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Gout}	pre-medication	fexofenadine	\N	f	Infusion Reaction	2022-08-18 16:54:53	{"Botson JK, Tesser JRP, Bennett R, Kenney HM, Peloso PM, Obermeyer K, Song Y, LaMoreaux B, Zhao L, Xin Y, Chamberlain J, Ramanathan S, Weinblatt ME, Peterson J. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study. Arthritis Res Ther. 2022 Aug 25;24(1):208. doi: 10.1186/s13075-022-02865-z.","Dalbeth N, Becce F, Botson JK, Zhao L, Kumar A. Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy. Rheumatology (Oxford). 2022 Nov 28;61(12):4898-4904. doi: 10.1093/rheumatology/keac173.","Botson JK, Tesser JRP, Bennett R, Kenney HM, Peloso PM, Obermeyer K, LaMoreaux B, Weinblatt ME, Peterson J. Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). J Rheumatol. 2021 May;48(5):767-774. doi: 10.3899/jrheum.200460. Epub 2020 Sep 15."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/32934137/	fexofenadine
248	2023-01-02 15:22:35.736	2023-03-20 20:35:40.074	NCT00963599	A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients With Seasonal Allergic Rhinitis-Fall Study	Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)	Completed	This study will evaluate the ability of oral montelukast/loratadine to improve the signs and symptoms of seasonal allergic rhinitis compared with loratadine alone, montelukast alone and placebo.	Parallel Assignment	Organon and Co	INDUSTRY	All	85	15	907	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	\N	1999-09-01	1999-11-01	1999-11-01	2009-08-21	2010-06-16	2022-02-09	Merck Sharp & Dohme Corp	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	comparison	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Nayak AS, Philip G, Lu S, Malice MP, Reiss TF; Montelukast Fall Rhinitis Investigator Group. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol. 2002 Jun;88(6):592-600. doi: 10.1016/S1081-1206(10)61891-1."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/12086367/	loratadine
223	2023-01-02 15:22:35.734	2023-03-20 20:12:50.124	NCT00334698	A Randomized, Double Blind, Placebo-controlled, Four Way Cross-over Study to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Cetirizine Alone on Symptoms Scores and Rhinomanometry in Patients With Allergic Rhinitis Following Pollen Exposure in the Fraunhofer Environmental Challenge Chamber (ECC)	Study to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Cetirizine Alone on Symptoms in Patients With Allergic Rhinitis	Completed	The aim of this study is to assess the efficacy on nasal congestion and other allergic symptoms and the onset of action of an oral combination of cetirizine and pseudoephedrine in comparison to the single substances under controlled pollen exposure in an Environmental Challenge Chamber (ECC).	Crossover Assignment	Fraunhofer-Institute of Toxicology and Experimental Medicine	OTHER	All	55	18	51	Anticipated	OTHER	Fraunhofer-Institute of Toxicology and Experimental Medicine	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2006-07-01	\N	2006-09-01	2006-06-08	\N	2010-02-03	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult}	{"Not Applicable"}	{"Seasonal Allergic Rhinitis"}	combination	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19203562	cetirizine
239	2023-01-02 15:22:35.735	2023-03-20 20:29:32.255	NCT03443843	A Double-Blind Placebo-Controlled Crossover Study to Evaluate Objective Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure in an Environmental Exposure Unit	A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure	Completed	The purpose of the study is to evaluate changes in nasal airflow caused by loratadine 5 mg/pseudoephedrine sulfate 120 mg (Claritin D) tablet and fluticasone propionate 50 mcg per spray nasal spray (Flonase) in subjects suffering from nasal congestion and other allergy symptoms.	Crossover Assignment	Bayer	INDUSTRY	All	65	18	82	Actual	INDUSTRY	Bayer	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2018-02-21	2018-05-11	2018-05-11	2018-02-23	\N	2019-12-20	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Rhinitis, Allergic"}	combination	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Ng CC, Romaikin D, Steacy LM, Stevens DA, Walker TJ, Adams DE, Ellis AK. Comparative nasal airflow with loratadine-pseudoephedrine and fluticasone nasal spray for allergic rhinitis. Ann Allergy Asthma Immunol. 2021 Sep;127(3):342-348.e2. doi: 10.1016/j.anai.2021.05.001. Epub 2021 May 14."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/34000435/	loratadine
251	2023-01-02 15:22:35.736	2023-03-20 20:40:12.642	NCT01244230	An Open-label, Uncontrolled 4-week Study to Assess the Safety, Efficacy and Pharmacokinetics of Allegra (Dry Syrup Formulation) 15 mg or 30 mg Twice Daily in Pediatric Patients With Atopic Dermatitis	Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)	Completed	Primary Objective:\n\nTo evaluate safety (4 weeks)\n\nSecondary Objectives:\n\nTo evaluate the long-term safety (12 weeks)\nTo evaluate the efficacy\nTo characterize the pharmacokinetic profile	Parallel Assignment	Sanofi	INDUSTRY	All	11	0.5	100	Actual	INDUSTRY	Sanofi	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	The study consists of four phases: up to 9-day screening phase, main 4-week treatment phase, up-to 8-week extension phase, and up-to 5-day post-treatment phase.	2010-11-01	2011-07-01	2011-08-01	2010-11-19	\N	2013-10-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 2","Phase 3"}	{"Atopic Dermatitis"}	main	fexofenadine	\N	f	Dermatitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
396	2023-01-02 15:22:35.745	2023-03-21 12:12:16.214	NCT00670293	Imaging of Dopamine Systems in Anorexia Nervosa	Changes in Dopamine Levels Before and After Weight Restoration in People With Anorexia Nervosa	Completed	This study will use positron emission tomography imaging to investigate changes in dopamine systems in people with anorexia nervosa before and after weight restoration.	\N	New York State Psychiatric Institute	OTHER	All	45	18	50	Actual	OTHER	New York State Psychiatric Institute	\N	\N	\N	\N	Case-Control	\N	Cross-Sectional	Anorexia nervosa (AN) is a disordered eating disease characterized by a persistent pursuit of thinness, intense fear of weight gain, distorted body image, and obsessive eating habits. People with AN are at high risk for certain health problems, such as depression, osteoporosis, substance abuse, and cardiovascular and neurological complications. Current treatments for AN include different forms of psychotherapy and medications, but the success of these treatments is highly variable among people with AN. A better pathophysiologic understanding of AN is needed in order to develop novel therapeutic strategies for preventing and treating the disorder. Current research is targeting dopamine (DA), a neurotransmitter that is released in response to pleasurable stimuli, such as food and drugs. Animal studies have found that chronic food restriction may alter functioning of the DA system by reducing DA response to food and drug stimuli. A better understanding of the effects of disordered eating on the DA systems of people with AN may provide insight into the development of new and improved treatments for people with AN. This study will use positron emission tomography (PET) imaging to investigate changes in DA systems in people with AN before and after both weight restoration and administration of methylphenidate, a psychostimulant medication. The study will also use PET imaging to compare DA systems of people with AN with DA systems of people who are healthy.\n\nThis study will involve both healthy participants and participants with AN. Study participation for healthy participants will include two PET scans and one magnetic resonance imaging (MRI) scan, which, if the participants prefer, can all be completed in one study visit. Study participation for participants with AN will include three PET and two MRI scans. The first PET and MRI scans will be performed upon entry into the hospital as an inpatient. The remaining scans will be conducted 2 to 4 weeks after participants have accomplished weight restoration.\n\nIncluding preparation, each MRI study will last about 45 minutes and each PET study will last about 3 hours. For each MRI study, participants will be asked to lie on their backs for 15 minutes in the MRI scanner. For each PET study, participants will first be injected with a dose of [11C]raclopride, a radioactive drug used in brain imaging, and will then lie on their backs for 30 minutes in the PET scanner.\n\nOne hour before the second PET scan for healthy participants and the third PET scan for participants with AN, participants will receive an oral dose of methylphenidate. During these scans, participants will also undergo blood pressure monitoring and an electrocardiogram (EKG). Once participants no longer feel the effects of the methylphenidate and their vital signs have returned to normal, they will be discharged from the medical center and study participation will be complete.	2008-07-01	2015-07-01	2015-12-01	2008-05-01	\N	2016-04-07	\N	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Adult}	{}	{"Eating Disorders"}	not included	fexofenadine	name of investigator\n	f	Eating Disorders	2022-08-18 16:54:53	{}	UNKNOWN	\N	fexofenadine
208	2023-01-02 15:22:35.734	2023-03-20 20:00:44.172	NCT01529242	A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Acute Cutaneous Rash	Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment	Terminated	The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the treatment of acute cutaneous rash in children between 2 and 12 years old.	Parallel Assignment	EMS	INDUSTRY	All	11	2	17	Actual	INDUSTRY	EMS	Randomized	\N	Quadruple	\N	\N	Treatment	\N	double-blind, non-inferiority, prospective, parallel group trial.\nExperiment duration: 05 days.\n03 visits (day 0, 48 hours and day 5).\nEfficacy will be evaluated for acute cutaneous rash based on symptoms score\nAdverse events evaluation.	2014-02-01	2016-08-01	2016-10-20	2012-02-08	\N	2017-02-16	\N	\N	\N	\N	\N	\N	Sponsor	By sponsor decision due to difficulty of recruitment	Interventional	{Child}	{"Phase 3"}	{"Cutaneous Hypersensitivity"}	combination	desloratadine	Alt Usecase dermatitis?	f	Cutaneous Hypersensitivity	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
229	2023-01-02 15:22:35.735	2023-03-20 20:18:14.355	NCT01881113	A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis	A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle	Completed	The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.	Parallel Assignment	Aciex Therapeutics, Inc.	INDUSTRY	All	\N	10	101	Actual	INDUSTRY	Aciex Therapeutics, Inc.	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2013-06-01	2013-10-01	2013-10-01	2013-06-19	2017-11-09	2017-11-09	Nicox Ophthalmics Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Allergic Conjunctivitis"}	main	cetirizine	\N	f	Allergic Conjunctivitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
234	2023-01-02 15:22:35.735	2023-03-20 20:23:48.747	NCT01651871	A Phase 2, Multicenter, Parallel-Group, Randomized, Double-Blind, Placebo- And Active Comparator-Controlled, Combination Study Of S-555739 And Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis	Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis	Completed	The primary objective of the study was to examine the efficacy and safety of S-555739/cetirizine HCl compared with the individual components and placebo.	Parallel Assignment	Shionogi	INDUSTRY	All	64	18	779	Actual	INDUSTRY	Shionogi Inc.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2012-07-01	2012-11-01	2013-05-01	2012-07-27	\N	2018-04-27	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 2"}	{"Seasonal Allergic Rhinitis"}	combination	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
405	2023-01-02 15:22:35.745	2023-03-21 12:24:33.353	NCT04088721	A Ib/IIa Randomized, Placebo Controlled, Intranasal Administration Study on Safety, Tolerability and Potential Efficacy of LTh() in Subjects With House Dust Mite (HDM) Allergic Rhinitis	Tolerability and Potential Efficacy of LTh() in Subjects With Allergic Rhinitis	Completed	A single center, double-blind, randomized, dose-escalation study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo.	Parallel Assignment	Advagene Biopharma Co. Ltd.	INDUSTRY	All	49	20	48	Actual	INDUSTRY	Advagene Biopharma Co. Ltd.	Randomized	\N	Quadruple	\N	\N	Prevention	\N	A single center, double-blind, randomized, dose-escalation study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo. The following treatment cohorts are featured in a dose-escalating manner:\n\nA. Cohort 1 will comprise 16 subjects who will receive, in a double-blind manner, either 20 g AD17002 (n=12) or placebo (n=4) on Study Day 1, 8, and 15.\n\nB. Cohort 2 will comprise 16 subjects who will receive, in a double-blind manner, either 40 g AD17002 (n=12) or placebo (n=4) on Study Day 1, 8, and 15.\n\nC. Cohort 3 will comprise 16 subjects who will receive, in a double-blind manner, either 60 g AD17002 (n=12) or placebo (n=4) on Study Day 1, 8, and 15.\n\nA total of 16 subjects in cohort 1 will receive the assigned study preparation before the remainder of the Cohort. Study drug administration to the next subject for the first 8 subjects in the cohort 1 will be separated for at least one day elapse (at least 24 hrs). The progression to the next cohort will take place after the SRT review the whole follow-up period safety data of previous cohort.	2019-03-26	2020-07-30	2020-12-11	2019-09-13	\N	2021-09-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1","Phase 2"}	{"Allergic Rhinitis"}	minimal	desloratadine	only as outcome measure	f	Allergic Rhinitis	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
225	2023-01-02 15:22:35.735	2023-03-20 20:14:43.389	NCT05637710	Multicenter,Randomized,Parallel,Double-blind,Double-dummy,Comparative Superiority Study of Levocetirizine 5mg / Pseudoephedrine 240mg From Eurofarma vs Zina5mg in the Symptomatic of Allergic Rhinitis	Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil	Not yet recruiting	AR is the most common respiratory disease worldwide and is clinically defined by the presence of nasal symptoms induced by exposure to allergens, particularly nasal obstruction and pruritus, runny nose and sneezing. The treatment purpose is to prevent or alleviate symptoms as safely and effectively as possible. Above all, it is recommended that patients avoid contact with allergens to which they are sensitive. However, this is often not enough, and pharmacological interventions are often required.\n\nH1 antihistamines (anti-H1) are considered first-line drugs in the treatment of AR1. These drugs effectively relieve symptoms of the immediate phase of AR, such as nasal pruritus, sneezing, runny nose and associated eye symptoms, and partially the nasal blockage characteristic of the late phase of the disease. Due to their excellent safety profile and therapeutic advantages in the treatment of AR, second-generation anti-H1 drugs, such as levocetirizine, should always be prioritized over older compounds in all age groups1.\n\nThe combined administration of an antihistamine and an oral decongestant was shown to b more effective than the administration of an antihistamine alone for the relief of AR-associated nasal obstruction1.\n\nLevocetirizine is an active pharmaceutical ingredient (API) registered in the country as a monodrug for oral administration at a dose of 5mg. Pseudoephedrine is not marketed as a monodrug for oral use in our area, but it is registered in FDC with antihistamines, which is why there is no comparator arm treating with pseudoephedrine only. These products are widely used and their efficacy and safety are well known in daily clinical practice in the proposed indication.\n\nOnce the absence of a pharmacokinetic interaction between levocetirizine and pseudoephedrine has been confirmed in relative bioavailability studies (RBA), this phase 3 study will be conducted in order to demonstrate the superiority of FDC levocetirizine 5mg / pseudoephedrine 240mg over levocetirizine 5mg administered alone in the symptomatic treatment of AR, particularly with regard to nasal obstruction. The registration seeks to provide a new effective and safe therapeutic option to address these cases.	Parallel Assignment	Eurofarma Laboratorios S.A.	INDUSTRY	All	65	12	754	Anticipated	INDUSTRY	Eurofarma Laboratorios S.A.	Randomized	Participants who meet all eligibility criteria will be randomized to one of the following treatment groups:\n\nInvestigational group: FDC levocetirizine 5mg / pseudoephedrine 240mg from Eurofarma Laboratrios S.A. (investigational drug) Participants randomized to this group will receive one (01) film-coated tablet of the investigational drug + one (01) levocetirizine placebo tablet, once a day, for seven (07) days.\n\nComparator group: Levocetirizine 5mg (Zina - comparator drug) Participants randomized to this group will receive one (01) levocetirizine 5mg tablet (Zina 5mg) + one (01) FDC placebo tablet, once daily, for seven (07) days.	Triple	\N	\N	Treatment	\N	The investigational drug consists of a fixed-dose combination (FDC) that contains levocetirizine, a second-generation anti-H1 antihistamine agent, and pseudoephedrine, an oral decongestant, in doses of 5mg and 240mg, respectively, in the dosage form of film-coated tablets. This product is an unprecedented FDC in the country that is indicated for the symptomatic treatment of allergic rhinitis (AR) in patients aged  12 years.\n\nA multicenter, randomized, parallel-group, double-blind, double-dummy, superiority, active-controlled clinical trial.\n\nAdolescents and adults (aged  12 years) of both sexes with intermittent or persistent AR will be randomized in a 1:1 ratio to receive the investigational drug (FDC levocetirizine 5mg / pseudoephedrine 240mg from Eurofarma Laboratrios S.A.) or levocetirizine 5mg (Zina), once daily (morning), for seven (07) days.\n\nThe severity of nasal allergy symptoms in the last 24 hours (nasal obstruction, runny nose, sneezing and nasal pruritus) will be evaluated through the application of the assessment questionnaire for nasal symptoms in the last 24 hours before, during and at the end of treatment. The severity of the nasal obstruction at that timepoint will also be evaluated immediately before and one (01) hour after the administration of the first dose of the study treatment, carried out at the research site (also in the morning). Participants will be monitored for an additional seven (07) days for safety assessment.	2024-03-01	2025-03-30	2025-11-30	2022-12-05	\N	2022-12-14	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Allergic Rhinitis"}	combination	\N	\N	f	Allergic Rhinitis	\N	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
237	2023-01-02 15:22:35.735	2023-03-20 20:28:07.145	NCT01322282	A Randomized, Open-Label, Single-Dose, Three-Period Crossover Bioequivalence Study to Compare an Orodispersible Tablet (ODT) Formulation of Cetirizine HCl 10 mg Taken With and Without Water Compared With a Standard Marketed 10 mg Tablet Taken With Water	To Test Bioequivalence Between Two Tablet Formulations in the Treatment of Allergy	Completed	This study is designed to assess bioequivalence between two products used for treatment of allergy.	Crossover Assignment	McNeil AB	INDUSTRY	All	55	18	36	Actual	INDUSTRY	Johnson & Johnson Consumer and Personal Products Worldwide	Randomized	\N	Single	\N	\N	Basic Science	\N	This study is designed to evaluate if a test formulation of cetirizine 10 mg orodispersible tablet (ODT) taken with and without water is bioequivalent to a marketed reference formulation of cetirizine 10 mg tablet (Benadryl One A Day, McNeil Products Ltd, UK) taken with water. This study will also evaluate the tolerability of test and reference formulations.	2011-02-01	2011-03-01	2011-03-01	2011-03-24	\N	2012-07-10	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Allergy}	main	cetirizine	\N	f	Bioequivalence	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
255	2023-01-02 15:22:35.736	2023-03-20 21:15:34.696	NCT04399525	Influence of H1-antihistamines on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin	Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.	Completed	In order to validate the accuracy and reliability of the histamine skin prick model for histaminergic itch and vasodilation, the dermal blood flow response induced by a histamine skin prick will be evaluated after the administration of certain H1-antihistamines. Besides, the influence of these H1-antihistamines on the dermal blood flow response induced by the topical application of cinnamaldehyde and capsaicin will be evaluated. Changes in dermal blood flow will be measured with laser speckle contrast imaging.	Crossover Assignment	Universitaire Ziekenhuizen KU Leuven	OTHER	Male	45	18	12	Actual	OTHER	Universitaire Ziekenhuizen KU Leuven	Randomized	Randomized, double-blind, cross-over study	Double	\N	\N	Basic Science	\N	\N	2019-10-28	2020-03-12	2020-03-12	2020-05-22	\N	2020-05-27	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Not Applicable"}	{Pruritus}	pre-medication	cetirizine	\N	f	Pruritus	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	desloratadine|levocetirizine
408	2023-01-02 15:22:35.745	2023-03-21 13:13:54.44	NCT04052945	Efficacy, Safety and Underlying Mechanisms of Sphenopalatine Ganglion Acupuncture for Seasonal Allergic Rhinitis: a Randomized, Double-blind, Placebo Controlled Study	Efficacy, Safety and Underlying Mechanisms of Sphenopalatine Ganglion Acupuncture for Seasonal Allergic Rhinitis	Recruiting	In recent years, a number of randomized controlled trials have confirmed the efficacy and safety of acupuncture in the treatment of allergic rhinitis (AR). Indeed, the latest American clinical guidelines recommended acupuncture treatment for AR patients who are interested in non-pharmacological treatment.\n\nIn conventional acupuncture treatment for AR, needles are inserted at specific acupoints in the body; with several studies demonstrating acupuncture of sphenopalatine ganglion (SPG) to improve nasal symptoms and quality of life in nasal inflammatory diseases.\n\nThe investigators hypothesize that, compared with sham acupuncture and rescue medication (RM), active SPG acupuncture combined with RM would lead to greater improvements in symptoms score and reduction in overall need for antihistamines. To test this hypothesis the investigators design a randomized, double blind, controlled trial to evaluate the efficacy of SPG acupuncture in pollen-induced seasonal AR patients and to explore the potential underlying mechanisms.	Parallel Assignment	Beijing Tongren Hospital	OTHER	All	60	18	70	Anticipated	OTHER	Beijing Tongren Hospital	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2020-03-25	2020-10-31	2022-12-31	2019-08-12	\N	2022-08-22	\N	Beijing Tongren Hospital	Luo Zhang	Vice president	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Not Applicable"}	{"Seasonal Allergic Rhinitis"}	rescue medication	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Choi SM, Park JE, Li SS, Jung H, Zi M, Kim TH, Jung S, Kim A, Shin M, Sul JU, Hong Z, Jiping Z, Lee S, Liyun H, Kang K, Baoyan L. A multicenter, randomized, controlled trial testing the effects of acupuncture on allergic rhinitis. Allergy. 2013 Mar;68(3):365-74. doi: 10.1111/all.12053. Epub 2012 Dec 18.","Xue CC, Zhang AL, Zhang CS, DaCosta C, Story DF, Thien FC. Acupuncture for seasonal allergic rhinitis: a randomized controlled trial. Ann Allergy Asthma Immunol. 2015 Oct;115(4):317-324.e1. doi: 10.1016/j.anai.2015.05.017. Epub 2015 Jun 11.","Wang K, Chen L, Wang Y, Wang C, Zhang L. Sphenopalatine Ganglion Acupuncture Improves Nasal Ventilation and Modulates Autonomic Nervous Activity in Healthy Volunteers: A Randomized Controlled Study. Sci Rep. 2016 Jul 18;6:29947. doi: 10.1038/srep29947.","Brinkhaus B, Ortiz M, Witt CM, Roll S, Linde K, Pfab F, Niggemann B, Hummelsberger J, Treszl A, Ring J, Zuberbier T, Wegscheider K, Willich SN. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med. 2013 Feb 19;158(4):225-34. doi: 10.7326/0003-4819-158-4-201302190-00002."}	NO_PUBLICATION_FOUND	\N	loratadine
231	2023-01-02 15:22:35.735	2023-03-20 20:20:31.713	NCT01856348	Effects of Vitamin D3 (1,25 Dihydroxyvitamin D3) on Pharmacokinetics and Absorption of Folic Acid and Fexofenadine in Healthy Volunteers	Vitamin D3, Folic Acid and Fexofenadine in Healthy Volunteers	Completed	The study is conducted to assess the effect of a vitamin D3 supplementation on the activities of two intestinal transporters and on the pharmacokinetics of the transporter substrates folic acid and fexofenadine.\n\nTrial with medicinal product	Single Group Assignment	University of Zurich	OTHER	All	65	18	10	Actual	OTHER	University of Zurich	N/A	\N	None (Open Label)	\N	\N	Prevention	\N	\N	2013-05-01	2013-07-01	2013-07-01	2013-05-17	\N	2013-08-13	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Physiological Effects of Vitamin D"}	combination	fexofenadine		f	Healthy	2022-08-18 16:54:53	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/27023466/	fexofenadine
250	2023-01-02 15:22:35.736	2023-03-20 20:38:26.047	NCT01940393	Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria	Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria	Completed	The antihistamines with inhaled steroids are the cornerstone on the symptomatic therapy in the management of patients with rhinitis and the first line of treatment in patients with urticaria. Currently, the use of antihistamines has become popular due to its excellent safety profile and clinical efficacy, however to the investigators knowledge, there are no studies about the pharmacokinetic and pharmacodynamic effects of these drugs in patients of tropical Latin America. The investigators main interest is to evaluate if skin test inhibition correlates with the clinical effect of five anti-histamines.	Parallel Assignment	Grupo de Alergologa Clnica y Experimental	OTHER	All	50	12	150	Actual	OTHER	Grupo de Alergologa Clnica y Experimental	Randomized	\N	Triple	\N	\N	Treatment	\N	This was a randomized, double-blind, study that was conducted in six health care centers from Medelln and Bogot (Colombia). This study was conducted in compliance with the ethical principles of the Declaration of Helsinki and with Good Clinical Practice guidelines. Written informed consent was obtained from all subjects or they parents in patients under 18 years. Ethical committee of University of Antioquia (Medelln, Colombia) approved the protocol. Considering the large number of articles that demonstrate the efficacy of antihistamines as first-line treatment in patients with urticaria, the ethics committee request that all participants would receive an antihistamine during the two months of the study because a placebo group would provide little information for the principal objective and the high risk of airway angioedema. Thirty heath subjects were used as a control group to evaluated the characteristics of the wheal in the prick test with histamine.	2013-08-01	2013-12-01	2014-01-01	2013-09-12	\N	2014-02-19	\N	Grupo de Alergologa Clnica y Experimental	Jorge Sanchez	M.D, M.Sc, Allergist	\N	\N	Principal Investigator	\N	Interventional	{Child,Adult}	{"Phase 4"}	{Urticaria}	comparison	cetirizine	\N	f	Urticaria	2022-08-17 13:39:16	{"Sanchez J, Zakzuk J, Cardona R. Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria. J Allergy Clin Immunol Pract. 2018 Jan-Feb;6(1):177-182.e1. doi: 10.1016/j.jaip.2017.06.002. Epub 2017 Jul 12.","Sanchez J, Zakzuk J, Cardona R. Prediction of the Efficacy of Antihistamines in Chronic Spontaneous Urticaria Based on Initial Suppression of the Histamine- Induced Wheal. J Investig Allergol Clin Immunol. 2016;26(3):177-84. doi: 10.18176/jiaci.0039."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/28709817/	cetirizine|desloratadine|fexofenadine
123	2023-01-02 15:22:35.729	2023-03-20 16:47:29.822	NCT03196531	A Single-Dose, Randomized, Open-Label, Two-Treatment, Four-Period, Crossover Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Subjects Compared With Clarityne Tablets	A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets	Completed	The purpose of this study is to assess the bioequivalence of Xisimin (loratadine) compared with Clarityne in healthy participants receiving a single dose of 10 milligram (mg) under fasting condition as part of Cohort 1 and under fed condition as part of Cohort 2.	Crossover Assignment	Xian-Janssen Pharmaceutical Ltd.	INDUSTRY	All	55	18	108	Actual	INDUSTRY	Xian-Janssen Pharmaceutical Ltd.	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2017-11-07	2018-03-31	2018-03-31	2017-06-22	\N	2020-05-13	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	main	loratadine	\N	f	Bioequivalence	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
99	2023-01-02 15:22:35.727	2023-03-20 16:32:21.908	NCT02157558	A Phase 1, Open-label, Single-center, 2-period, Single Sequence Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose Telotristat Etiprate on the Pharmacokinetics of Single-dose Fexofenadine, a Sensitive P Glycoprotein Substrate, in Healthy Male and Female Subjects	An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects	Completed	The purpose of this study is to evaluate the effects of steady-state telotristat ethyl on the pharmacokinetics (PK) of single-dose fexofenadine in healthy subjects.	Single Group Assignment	Lexicon Pharmaceuticals	INDUSTRY	All	55	18	24	Actual	INDUSTRY	Lexicon Pharmaceuticals	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2014-07-01	2014-08-01	\N	2014-06-06	\N	2014-09-08	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{"Drug Interactions"}	combination	fexofenadine	\N	f	Pharmacokinetics	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
141	2023-01-02 15:22:35.73	2023-03-20 17:02:41.682	NCT00521040	Evaluation of the Efficacy and Safety of Levocetirizine During 8 Weeks Preceding and Following the Anticipated Onset of the Grass Pollen Season in Subjects Suffering From Seasonal Allergic Rhinitis Associated With Pollen-induced Asthma	Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR	Completed	Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR	Parallel Assignment	UCB Pharma	INDUSTRY	All	\N	12	459	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2004-02-01	2004-07-01	2004-07-01	2007-08-27	\N	2013-12-12	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Child,Adult,"Older Adult"}	{"Not Applicable"}	{"Rhinitis, Allergic, Seasonal"}	main	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
166	2023-01-02 15:22:35.731	2023-03-20 19:14:26.592	NCT00649376	Single-Dose Fasting In Vivo Bioequivalence Study of Fexofenadine Tablets (180 mg; Mylan) and Allegra Tablets (180 mg; Aventis) in Healthy Adult Volunteers	Fasting Study of Fexofenadine Tablets 180 mg and Allegra Tablets 180 mg	Completed	The objective of this study was to investigate the bioequivalence of Mylan's fexofenadine 180 mg tablets to Aventis' Allegra 180 mg tablets following a single, oral 180 mg (1 x 180 mg) dose administered under fasting conditions.	Crossover Assignment	Mylan Pharmaceuticals Inc	INDUSTRY	All	\N	18	68	Actual	UNKNOWN	MylanPharma	Randomized	\N	None (Open Label)	\N	\N	\N	\N	\N	2003-10-01	2003-11-01	2003-11-01	2008-04-01	\N	2008-04-01	\N	\N	\N	\N	Will Sullvan, Global Head of Product Risk and Safety Management	Mylan Inc.	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{Healthy}	main	fexofenadine	\N	f	Bioequivalence	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
192	2023-01-02 15:22:35.732	2023-03-20 19:40:04.346	NCT00355771	Placebo Controlled Pilot Study on the Efficacy of Levocetirizine 5 mg in Reducing Symptoms, Airway Resistance, and Sleep Impairment in Patients With Persistent Allergic Rhinitis	Levocetirizine 5 mg: Reduction of Symptoms, Airway Resistance and Sleep Impairment in Persistent Allergic Rhinitis	Completed	The purpose of this study is to investigate, whether levocetirizine 5 mg relieves nasal and ocular symptoms of persistent allergic rhinitis and reduces increased airway resistance and sleep impairment due to this condition.	Parallel Assignment	Institut fr Atemwegsforschung GmbH	INDUSTRY	All	50	18	100	Actual	INDUSTRY	Institut fr Atemwegsforschung GmbH	Randomized	\N	Triple	\N	\N	Treatment	\N	Levocetirizine 5 mg is well established as the treatment of seasonal and perennial rhinoconjunctivitis. This study has been designed, to investigate its efficacy in patients suffering from persistent allergic rhinitis as defined by the ARIA (Allergic Rhinitis and its Impact on Asthma) working group of the WHO.\n\nThe study is divided in an 8  2 day screening and a 56  3 day treatment phase. During both periods patients keep a diary reporting on the severity of their nasal and ocular complaints, the use of rescue medication (cromoglycate eye drops and nasal spray), other concomitant medication and adverse events. They apply a 0 to 3 point score (0 = no, 1= mild, 2 = moderate, 3 = severe symptoms) to rate nasal obstruction, rhinorrhea, nasal itching, sneezing and ocular symptoms in regard to their experience during the preceding 24 hours. During the treatment period they additionally report the time of intake of study medication and their assessments of their nasal peak inspiratory flow (NPIF). NPIF is measured every evening before symptom scoring and additionally before each intake of rescue nasal spray. A device similar to the peak flow meters employed for monitoring bronchial asthma is used. Before the treatment period in its middle and at its end patients undergo a polysomnography. Furthermore 2 weeks after the start of treatment and at its end patients and investigators employ a 5-step scale (1 = very good, 2 = good, 3 = moderate, 4 = poor, 5= not at all effective) to assess the efficacy of the study medication.\n\nEfficacy is to be established by comparison of a levocetirizine and a placebo treated group.	2006-06-01	2007-11-01	2007-11-01	2006-07-25	\N	2008-01-15	\N	\N	\N	\N	Claus Bachert, MD PhD	Institut fr Atemwegsforschung GmbH	\N	\N	Interventional	{Adult}	{"Phase 4"}	{"Allergic Rhinitis"}	main	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
219	2023-01-02 15:22:35.734	2023-03-20 20:09:36.229	NCT01529229	A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Moderate - Severe Persistent Allergic Rhinitis	Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment	Completed	The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the treatment of Moderate - Severe Persistent Allergic Rhinitis.	Parallel Assignment	EMS	INDUSTRY	All	11	2	210	Actual	INDUSTRY	EMS	Randomized	\N	Quadruple	\N	\N	Treatment	\N	double-blind, non-inferiority, prospective, parallel group trial.\nExperiment duration: 07 days.\n02 visits (days 0 and 7).\nEfficacy will be evaluated for persistent allergic rhinitis based on nasal symptoms score\nAdverse events evaluation.	2013-11-01	2014-10-01	2014-10-01	2012-02-08	\N	2015-01-15	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Allergic Rhinitis"}	combination	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/27670203/	desloratadine
387	2023-01-02 15:22:35.744	2023-03-21 11:12:23.593	NCT04706559	Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis	Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis	Completed	Various clinical studies have evaluated the role of probiotics in children with atopic dermatitis, with some studies showing improvement in clinical outcome after supplementation of probiotics and others showing no additional benefit. This study is to provide clinical evidence of effect of a mixture of probiotics in Atopic Dermatitis (AD) patients based on improvement in SCORAD (SCORing Atopic Dermatitis) index.	Parallel Assignment	B.P. Koirala Institute of Health Sciences	OTHER	All	17	4	98	Actual	OTHER	B.P. Koirala Institute of Health Sciences	Randomized	Assessor blinded, randomized controlled trial.	Single	In this study, there will be three investigators i.e, one principal investigator, and two co-investigators. Among them, one of the co-investigators will be blinded who will act as an assessor.	\N	Treatment	\N	Atopic dermatitis (AD) is the common chronic inflammatory skin disease with relapsing courses that often start in infancy and childhood. It is characterized by erythema, itchy papules, occasionally vesicles (in infants), which may become excoriated and lichenified and have a typical flexural distribution. Atopy is defined as a "personal or familial tendency to produce immunoglobulin antibodies in response to even low doses of allergen, and associated with development of AD, asthma and rhinoconjunctivitis.The worldwide prevalence of AD is estimated to be 20% in children and 2-10% in adults. The incidence of AD has increased by 2 to 3 folds in past 3 decades in the industrialized countries and represents a major public health burden. According to the International Study of Asthma and Allergies in Childhood (ISAAC) phase 3, the prevalence of AD among the age group of 13 to 14 in Africa and Latin America was at 12-14% and 6-10% respectively. The Asian Pacific countries, the Eastern Mediterranean region and the Indian subcontinent, it was 3-6% among the same age groups (13-14 years). Whereas among 6 to 7 years children, for Asian Pacific countries, Africa and Latin America the prevalence of AD was around 10% and in Indian subcontinent and Eastern Mediterranean region, value was lower at 3-5%\n\nIn Nepal the frequency of AD in all age group was 2% as per a year hospital based study done by Singh S and Agrawal S et.al in 2012. (Unpublished data, on personal communication)\n\nThe pathogenesis of AD appears to result from interaction between various genetic and environmental factors. It is associated with skin barrier dysfunction and immune dysregulation. The barrier dysfunction is early feature of AD which may be a primary but may also be a secondary to skin inflammation. Lack of exposure to microbial stimuli in early life programs the immune system towards Th2-type allergic response as described by 'hygiene hypothesis'.In allergic disorders there is shift of the Th1/Th2 cytokine balance towards a Th2 response, and causes the release of Interleukin-4, interleukin-5 and interleukin-13 as well as Immunoglobulin E production.\n\nThe diagnosis of AD is mainly clinical as there is no specific test for AD. Diagnosis of AD is based on specific a criterion which includes patient's history, clinical presentations as well as family history. In 1980 Hanifin and Rajka proposed major and minor diagnostic criteria based on clinical symptoms of AD. Williams coordinated a UK working party to attempt to simplify and refine the criteria given by Hanifin and Rajka in 1994. Severity of disease is evaluated by using widely accepted SCORing Atopic Dermatitis (SCORAD), based on extent of area involved, severity of symptoms and intensity of the subjective symptoms of pruritus and sleep disturbances.The chronic and recurrent nature of AD negatively impacts the quality of life (QOL) of patients as well as their family members. The symptoms of AD limit patient's physical, psychosocial development and quality of sleep.\n\nThe main goals of treatment are to improve the skin barrier function and hydration, to suppress inflammation and to control microbial colonization. It can be achieved through emollients, topical corticosteroids and topical calcineurin inhibitor like tacrolimus. Oral drugs like corticosteroids, methotrexate and cyclosporine are reserved for severe cases.\n\nProbiotics are defined by World Health Orgnization as "live microorganisms, which when consumed in adequate amounts, confer a health effect on the host."Under the hypothesis that probiotics have global allergy protective effect, they have been extensively used for several conditions like inflammatory bowel disease, bronchial asthma and other allergic diseases. If children who are genetically predisposed to AD are supplemented with probiotics early in their life, series of events like antigenic competition, immune regulation and stimulation of innate immunity will occur, all of which might minimize their susceptibility to allergic disorders. Hence, investigators planned this study to see its role in AD.\n\nStatement of problem and rationale:\n\nThe rationale for this therapeutic option is based on well-established effects of bacteria on cellular immune responses. The probiotics has an immunomodulatory property that plays an essential role in the development of normal immune tolerance. Early life exposure to these microbial agents plays an important role in maturation of Type 1 helper cell (Th1) immune responses and could inhibit development of allergic Type 2 helper cell (Th2) responses and IgE antibody production. Therefore the onset of AD could be prevented by probiotics and this treatment strategy could also be effective even when AD is already established.\n\nIn a meta-analysis conducted in 2017, involving 13 randomized controlled trials (RCT) with 1,070 children, significant difference in SCORAD values favoring probiotics over the control group was observed. Though, a high degree of heterogeneity was observed across these 13 trials.\n\nCochrane review, 2018 which included 39 RCTs found that probiotic treatment may slightly reduce SCORAD value. However the researcher concluded that the differences were not clinically significant. Recent review in 2019 on "prebiotics and probiotics in atopic dermatitis" based on various RCT and meta-analysis support the supplementation of probiotics for at least 8 weeks in improving severity score of AD.\n\nInvestigators have observed conflicting results of different studies with some showing significant advantages while some studies revealing no benefit. Almost all of the studies have suggested further research in different populations. Therefore, we are conducting this study to find out the effect of probiotics in AD in our institute.\n\nOBJECTIVES\n\nPrimary objective: To investigate the efficacy of oral probiotics in the clinical outcome of Atopic dermatitis based on the SCORAD index\nSecondary objectives: To find out the total duration of topical corticosteroid use in the interventional and conventional group.\n\nTo assess the impact of AD in children's family members based on FDLQI (Family Dermatology Life Quality Index)\n\nMATERIALS AND METHODS Type of study design: Assessor blinded, randomized controlled trial. Setting: Hospital (Dermatology Outpatient Department, BPKIHS, Dharan). The probable duration of the study will be one year after approval from the Institutional Review Committee and Nepal Health Research Council (NHRC). Ethical Clearance: taken from the Institutional Review Committee (IRC), BPKIHS, and Nepal Health Research Council (NHRC).\n\nCalculation of the sample size: According to a study done by Ekaputri et.al, it is reported that mean SD of SCORAD index after intervention in probiotic group and control group was (18.09  8.59) and (23.21 8.71) respectively. Considering the least difference, 5.12 and pooled SD- 8.65, the sample size has been calculated at 95% CI and 80% power, using two means formula.\n\nn = 44.56, adding 10% in calculated value for lost to follow-up, final sample size is 45 in each group. Thus a total of 98 patients will be enrolled.\n\nn = 22 (Z /2 + Z ) 2 (1- 2) 2\n\nn= sample size of each group.  = standard deviation 8.65 Z = reliability coefficient. 1.96  = significance level. 0.05 Z= at 20% power 0.84 1 = mean (Probiotic) 18.09 2 = mean (Control) 23.21 d = mean difference 5.12\n\nRandomization and allocation concealment:\n\nA block randomization list will be generated with the block sizes 4, 6 and 8. Two parallel groups (1:1 ratio) of patients following computerized randomization will be produced. Prior to the enrollment of the patients a sequentially generated number with the treatment group will be written in sealed envelope, which will be prepared by independent dermatologist.\n\nInterventional and conventional groups:\n\nInterventional group: Children with AD meeting eligibility criteria receiving probiotics and conventional treatment (topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients) Conventional group: Children with AD meeting eligibility criteria, under conventional treatment only.\n\nFollow up:\n\nEach patient will be asked for their follow up at 2, 4, 6, 8, 10 and 12 weeks of commencing treatment. In each follow up, every patient will be evaluated for the side effects and compliance to treatment. SCORAD index will be measured at baseline and at 4, 8, 10 and 12 weeks. FDLQI will be measured at baseline and at 8 weeks. Parents will be provided a card to record for flare of symptoms; total days of steroid use for the same and total flare episode will be recorded during 12 weeks follow up. Flare is defined as worsening of clinical features leading to use of corticosteroids for at least 3 consecutive days.\n\nFamily dermatology life quality index:\n\nParents or guardian of each children will be asked to fill the questionnaire intended to measure quality of life of family members whose relative have dermatological conditions. The standardized nepali version of FDLQI (MKA Basra, AY Finlay. Cardiff University 2005) will be used. Questions concern the influence of disease on parents QOL in the last month. Each question can be answered by selecting 1 out of 4 answers scored 0-3. The maximum score is 30 points and minimum 0 point. The higher the score lower the parents QOL.\n\nSeverity Index (SCORAD) It uses the rule of nine to assess extent of disease and evaluates five clinical characteristics to determine disease severity: i) erythema, ii) edema/ papulation, iii) oozing/crusts, iv) excoriation and v) lichenification. It also assesses subjective symptoms of pruritus and sleep loss with Visual Analogue Scales (VAS).\n\nBased on SCORAD score, AD is categorized as\n\nMild AD (SCORAD <25)\nModerate (SCORAD 25-50)\nSevere (SCORAD >50)\n\nStatistical Analysis:\n\nStatistical analysis will be conducted both per protocol and intention to treat population (defined as all enrolled children to whom study drug will be given; with the last observation carried forward) basis using two sided tests.\n\nStatistical methods proposed:\n\nDescriptive statistics will be summarized as mean, median, percentage, standard deviation (SD) and interquartile range along with appropriate graphical and tabular presentation.\nIntragroup SCORAD index and FDLQI score will be compared by paired t-test and between the groups by independent t- test.\nIn case of nonparametric data Mann- Whitney U test for independent groups and Wilcoxon signed- rank test for paired group will be used.\nChi-square test will be used to compare the categorical data. All statistical tests will be carried out at a significance level P<0.05.	2021-01-03	2021-09-30	2021-12-15	2021-01-13	\N	2021-12-16	\N	B.P. Koirala Institute of Health Sciences	Kamala Acharya	Junior Resident, Department of Dermatology and Venereology	\N	\N	Principal Investigator	\N	Interventional	{Child}	{"Not Applicable"}	{"Atopic Dermatitis"}	control	cetirizine	is that the right publication?	f	Dermatitis	2022-08-17 13:39:16	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/35155534/	cetirizine
409	2023-01-02 15:22:35.745	2023-03-21 13:19:17.779	NCT04234451	Efficacy, Safety and Underlying Mechanisms of Sphenopalatine Ganglion Acupuncture for Perennial Allergic Rhinitis: a Randomized, Double-blind, Placebo Controlled Study	Efficacy, Safety and Underlying Mechanisms of Sphenopalatine Ganglion Acupuncture for Perennial Allergic Rhinitis	Not yet recruiting	In recent years, a number of randomized controlled trials have confirmed the efficacy and safety of acupuncture in the treatment of allergic rhinitis (AR). Indeed, the latest American clinical guidelines recommended acupuncture treatment for AR patients who are interested in non-pharmacological treatment.\n\nIn conventional acupuncture treatment for AR, needles are inserted at specific acupoints in the body; with several studies demonstrating acupuncture of sphenopalatine ganglion (SPG) to improve nasal symptoms and quality of life in nasal inflammatory diseases.\n\nThe investigators hypothesize that, compared with sham acupuncture and rescue medication (RM), active SPG acupuncture combined with RM would lead to greater improvements in symptoms score and reduction in overall need for antihistamines. To test this hypothesis the investigators design a randomized, double blind, controlled trial to evaluate the efficacy of SPG acupuncture in perennial AR patients (allergic to indoor allergens, including house dust mite, fungi, animal dander and so one) and to explore the potential underlying mechanisms.	Parallel Assignment	Beijing Tongren Hospital	OTHER	All	60	18	40	Anticipated	OTHER	Beijing Tongren Hospital	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2021-12-01	2022-02-01	2022-09-30	2020-01-21	\N	2021-07-26	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Not Applicable"}	{"Perennial Allergic Rhinitis"}	rescue medication	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Choi SM, Park JE, Li SS, Jung H, Zi M, Kim TH, Jung S, Kim A, Shin M, Sul JU, Hong Z, Jiping Z, Lee S, Liyun H, Kang K, Baoyan L. A multicenter, randomized, controlled trial testing the effects of acupuncture on allergic rhinitis. Allergy. 2013 Mar;68(3):365-74. doi: 10.1111/all.12053. Epub 2012 Dec 18.","Xue CC, Zhang AL, Zhang CS, DaCosta C, Story DF, Thien FC. Acupuncture for seasonal allergic rhinitis: a randomized controlled trial. Ann Allergy Asthma Immunol. 2015 Oct;115(4):317-324.e1. doi: 10.1016/j.anai.2015.05.017. Epub 2015 Jun 11.","Wang K, Chen L, Wang Y, Wang C, Zhang L. Sphenopalatine Ganglion Acupuncture Improves Nasal Ventilation and Modulates Autonomic Nervous Activity in Healthy Volunteers: A Randomized Controlled Study. Sci Rep. 2016 Jul 18;6:29947. doi: 10.1038/srep29947.","Brinkhaus B, Ortiz M, Witt CM, Roll S, Linde K, Pfab F, Niggemann B, Hummelsberger J, Treszl A, Ring J, Zuberbier T, Wegscheider K, Willich SN. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med. 2013 Feb 19;158(4):225-34. doi: 10.7326/0003-4819-158-4-201302190-00002."}	NO_PUBLICATION_FOUND	\N	loratadine
410	2023-01-02 15:22:35.745	2023-03-21 13:20:09.624	NCT05234580	A Phase 2 Clinical Study to Evaluate the Safety and Efficacy of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis	Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis	Recruiting	PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Nasal Spray in patients with seasonal allergic rhinitis.	Parallel Assignment	Anhui Palo Alto Pharmaceuticals, Inc.	INDUSTRY	All	\N	12	200	Anticipated	INDUSTRY	Anhui Palo Alto Pharmaceuticals, Inc.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	This is a multicenter, randomized, double-blind, parallel, placebo-controlled clinical trial. Subjects of 200 with seasonal allergic rhinitis are planned to be included in this study. With a ratio of 1: 1: 1: 1 to be randomized allocated to receive PA9159 Nasal Spray of 10 g, 20 g, and 40 g, or placebo, with 50 subjects in each group. The duration of this study is approximately 12 months, including screening, baseline, treatment observation, and follow-up.	2022-04-15	2022-10-01	2022-12-01	2022-02-10	\N	2022-06-30	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 2"}	{"Allergic Rhinitis"}	not included	loratadine	only as outcome measure	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
314	2023-01-02 15:22:35.739	2023-03-20 22:02:21.36	NCT00562120	A Randomized, Double Blind, Double Dummy, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of An H3 Receptor Antagonist (PF-03654746) On Congestion Following A Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis.	A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge	Completed	An H3 receptor antagonist should reduce the congestion associated with allergic rhinitis. A nasal allergen challenge will be given to patients to induce rhinitis symptoms and acoustic rhinometry will be used to measure the congestion.	Crossover Assignment	Pfizer	INDUSTRY	All	55	19	21	Actual	INDUSTRY	Pfizer	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2007-12-01	2008-08-01	2008-08-01	2007-11-21	2014-04-16	2014-04-16	Pfizer, Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 2"}	{"Allergic Rhinitis"}	comparison	fexofenadine	H3 antagonist is main focus?	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	CT_RESULTS	\N	fexofenadine
252	2023-01-02 15:22:35.736	2023-03-20 21:13:59.227	NCT04645979	The Perception of Celestamine Treatment in Mexico: a Retrospective Assessment of Consumer Perception of Prior Celestamine Use	A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico	Completed	Acute allergic rhinitis is a common allergic reaction to things like pollen or dust. It causes inflammation inside the nose, resulting in symptoms similar to the common cold. Allergic rhinitis is also known as hay fever.\n\nIn this study, the researchers want to learn what participants think of betamethasone plus loratadine as a treatment for their acute allergic rhinitis. These participants will have used betamethasone plus loratadine as a treatment for their acute allergic rhinitis within the past two months. During the study, participants will complete an online questionnaire about their experience with betamethasone plus loratadine.	\N	Bayer	INDUSTRY	All	50	20	153	Actual	INDUSTRY	Bayer	\N	\N	\N	\N	Other	\N	Retrospective	\N	2020-11-11	2020-11-27	2020-11-27	2020-11-27	\N	2021-11-29	\N	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Adult}	{}	{"Rhinitis, Allergic"}	combination	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
414	2023-01-02 15:22:35.745	2023-03-21 13:28:50.685	NCT05038202	Study on the Efficacy and Safety of Bencycloquidium Bromide Nasal Spray Alone or in Combination With Mometasone Furoate Aqueous Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis	Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis	Recruiting	450 subjects with moderate-severe persistent allergic rhinitis will be enrolled in the trial and divided into three groups for different treatments. Group ASubjects with Bencycloquidium Bromide Nasal Spray, Group BSubjects with Mometasone Furoate Aqueous Nasal Spray, Group CSubjects with Bencycloquidium Bromide Nasal Spray in combination with Mometasone Furoate Aqueous Nasal Spray.The main purpose of the trial is to evaluate the efficacy of Bencycloquidium Bromide Nasal Spray alone or in combination with Mometasone Furoate Aqueous Nasal Spray in the treatment of moderate-severe persistent allergic rhinitis and rhinorrhea.	Parallel Assignment	Yingu Pharmaceutical Co., Ltd	INDUSTRY	All	65	18	450	Anticipated	INDUSTRY	Yingu Pharmaceutical Co., Ltd	Randomized	450 subjects with moderate-severe persistent allergic rhinitis will be enrolled in the trial and divided into three groups for different treatment.	None (Open Label)	\N	\N	Treatment	\N	The Secondary purpose is to evaluate the effectiveness of Bencycloquidium Bromide Nasal Spray alone or in combination with Mometasone Furoate Aqueous Nasal Spray in the treatment of moderate-severe persistent allergic rhinitis with nasal itching, nasal congestion, and sneezing. And evaluate the safety of Bencycloquidium Bromide Nasal Spray alone or in combination with Mometasone Furoate Aqueous Nasal Spray.	2021-06-16	2021-12-31	2022-02-28	2021-09-08	\N	2021-09-08	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Allergic Rhinitis"}	not included	loratadine	as outcome measure only	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
348	2023-01-02 15:22:35.742	2023-03-21 09:38:41.543	NCT03673384	Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation	Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation	Completed	Allergic rhinitis is one of the chronic illnesses. At present, the major treatments for allergic rhinitis are avoiding allergens, medical treatment and surgery. However, inadequate effects, and possible side effects of these treatments are still problems to these patients. Therefore, to find an effective non-medical and non-surgical treatment will be of great help in treating patients with allergic rhinitis.\n\nInfrared-C (far-infrared) ray irradiation is able to promote normal operation of autonomic nervous system, to improve blood circulation and thereby assumed to relieve discomfort symptoms of patients with vascular, specific or non-specific allergic rhinitis. Consequently, infrared-C ray irradiation is expected to be effective for the treatment of allergic rhinitis.\n\nThe investigators aimed to probe the adjunct effects of infrared-C ray irradiation in terms of infrared-C hot compress in improving allergy symptoms like sneezing, rhinorrhea, nasal obstruction, nose and conjunctiva itching during a medical treatment for patients with allergic rhinitis. Moreover, the impact of infrared-C irradiation on health and life quality enhancement will also be studied.	Parallel Assignment	Nanhua University	OTHER	All	50	20	50	Actual	OTHER	Nanhua University	Randomized	The sampling method is purposive sampling. The inclusion criteria are adults between 20 and 50 year-old with a definite clinical diagnosis of allergic rhinitis. Subjects were randomly divided into experimental and control groups. Thirty persons in the experimental group received both medical and infrared-C irradiation as intervention. On the other hand, twenty persons in the control group received only medical treatment. Patients in experimental group received anti-histamine, steroid nasal spray and infrared-C irradiation by hot compress for 40 minutes per time, and more than three times per week. The regions of hot compress included head, neck and shoulder, back and lower back, which covered many acupuncture points frequently used by traditional Chinese medicine for the treatment of allergic rhinitis. In addition, patients also received hot compress over face, eyes and nose during acute stage of allergic rhinitis.	Single	\N	\N	Treatment	\N	This is a quasi-experimental design. The study subjects are recruited from patients visited to a Ear-Nose-Throat Out Patient Department in a regional teaching hospital in south Taiwan. The sampling method is purposive sampling. The inclusion criteria are adults between 20 and 50 year-old with a definite clinical diagnosis of allergic rhinitis. Subjects were randomly divided into experimental and control groups. Thirty persons in the experimental group received both medical and infrared-C ray irradiation by hot compress as intervention. On the other hand, twenty persons in the control group took only medical treatment. Patients in experimental group received anti-histamine, steroid nasal spray and infrared-C ray irradiation for 40 minutes each time, and more than three times per week. The regions for hot compress included head, neck and shoulder, back and lower back, which covered many acupuncture points frequently used by traditional Chinese medicine for the treatment of allergic rhinitis, including point Dazhui (GV14), Dingchuan (EX-B1) , Dazhu (BL11), Fengmen (BL12), Feishu (BL13), Pishu (BL20), and Shenshu (BL23). In addition, patients also received infrared-C hot compress over face, eyes and nose during acute stage of allergic rhinitis. The investigators used a questionnaire as a pre-test to collect basic information of the subjects, and Taiwan's Sino-Nasal Outcome Test-20 (SNOT-20) nose and sinusitis evaluation form as pre-middle and post-test to evaluate the effect of the interventions. World Health Organization Quality of Life Instruments (WHOQOL-BREF) and Taiwan's concise edition of WHOQOL II questionnaire were also used as basic data collection tools for allergic rhinitis. Furthermore, blood tests for patient's serum Immunoglobulin E (IgE) and eosinophil cationic protein levels were determined before and after experiment. Pre-test for the experimental and control group was carried out before the intervention, the first post-test was performed 4 weeks later, and the second post-test was carried out 12 weeks later. Data was analyzed by SPSS 22.0 software.	2015-03-02	2017-07-30	2017-07-30	2018-09-17	\N	2018-09-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Not Applicable"}	{"Allergic Rhinitis"}	combination	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{"Marciniak D, Tomaszewicz-Fryca J, Plusa T, Chcialowski A. [Eosinophil cationic protein in children with allergic diseases of the respiratory tract in exacerbation and remission of symptoms]. Pol Merkur Lekarski. 1998 Feb;4(20):75-7. Polish.","Alvarez Gutierrez FJ, Valenzuela Mateos F, Rodriguez Portal JA, Sanchez Gil R, Tabernero Huguet E, Castillo Gomez J. [Blood levels of eosinophil cationic protein in patients with allergic rhinitis. Evolution after treatment with corticoids]. Arch Bronconeumol. 1997 Jan;33(1):6-11. Spanish.","Ahmadiafshar A, Taghiloo D, Esmailzadeh A, Falakaflaki B. Nasal eosinophilia as a marker for allergic rhinitis: a controlled study of 50 patients. Ear Nose Throat J. 2012 Mar;91(3):122-4. doi: 10.1177/014556131209100309.","Beever R. Far-infrared saunas for treatment of cardiovascular risk factors: summary of published evidence. Can Fam Physician. 2009 Jul;55(7):691-6.","Bentley AM, Jacobson MR, Cumberworth V, Barkans JR, Moqbel R, Schwartz LB, Irani AM, Kay AB, Durham SR. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol. 1992 Apr;89(4):877-83. doi: 10.1016/0091-6749(92)90444-7.","Braido F, Arcadipane F, Marugo F, Hayashi M, Pawankar R. Allergic rhinitis: current options and future perspectives. Curr Opin Allergy Clin Immunol. 2014 Apr;14(2):168-76. doi: 10.1097/ACI.0000000000000043.","Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schunemann HJ; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010 Sep;126(3):466-76. doi: 10.1016/j.jaci.2010.06.047.","Chang Y, Liu YP, Liu CF. The effect on serotonin and MDA levels in depressed patients with insomnia when far-infrared rays are applied to acupoints. Am J Chin Med. 2009;37(5):837-42. doi: 10.1142/S0192415X09007272.","Cheng KJ, Xu YY, Liu HY, Wang SQ. Serum eosinophil cationic protein level in Chinese subjects with nonallergic and local allergic rhinitis and its relation to the severity of disease. Am J Rhinol Allergy. 2013 Jan;27(1):8-12. doi: 10.2500/ajra.2013.27.3845.","Davis WE, Nishioka GJ. Endoscopic partial inferior turbinectomy using a power microcutting instrument. Ear Nose Throat J. 1996 Jan;75(1):49-50.","Everhart RS, Kopel SJ, Esteban CA, McQuaid EL, Klein R, McCue CE, Koinis-Mitchell D. Allergic rhinitis quality of life in urban children with asthma. Ann Allergy Asthma Immunol. 2014 Apr;112(4):365-70.e1. doi: 10.1016/j.anai.2014.02.002. Epub 2014 Feb 28.","Gale GD, Rothbart PJ, Li Y. Infrared therapy for chronic low back pain: a randomized, controlled trial. Pain Res Manag. 2006 Autumn;11(3):193-6. doi: 10.1155/2006/876920.","Groger M, Bernt A, Wolf M, Mack B, Pfrogner E, Becker S, Kramer MF. Eosinophils and mast cells: a comparison of nasal mucosa histology and cytology to markers in nasal discharge in patients with chronic sino-nasal diseases. Eur Arch Otorhinolaryngol. 2013 Sep;270(10):2667-76. doi: 10.1007/s00405-013-2395-2. Epub 2013 Feb 22.","Huang CY, Yang RS, Kuo TS, Hsu KH. Phantom limb pain treated by far infrared ray. Annu Int Conf IEEE Eng Med Biol Soc. 2009;2009:1589-91. doi: 10.1109/IEMBS.2009.5334124.","Honda K, Inoue S. Sleep-enhancing effects of far-infrared radiation in rats. Int J Biometeorol. 1988 Jun;32(2):92-4. doi: 10.1007/BF01044900. No abstract available.","Hu KH, Li WT. Clinical effects of far-infrared therapy in patients with allergic rhinitis. Annu Int Conf IEEE Eng Med Biol Soc. 2007;2007:1479-82. doi: 10.1109/IEMBS.2007.4352580.","Ishibashi J, Yamashita K, Ishikawa T, Hosokawa H, Sumida K, Nagayama M, Kitamura S. The effects inhibiting the proliferation of cancer cells by far-infrared radiation (FIR) are controlled by the basal expression level of heat shock protein (HSP) 70A. Med Oncol. 2008;25(2):229-37. doi: 10.1007/s12032-007-9020-4. Epub 2007 Oct 30.","Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. 1994 Feb;93(2):413-23. doi: 10.1016/0091-6749(94)90349-2.","Kim KS, Won HR, Park CY, Hong JH, Lee JH, Lee KE, Cho HS, Kim HJ. Analyzing serum eosinophil cationic protein in the clinical assessment of chronic rhinosinusitis. Am J Rhinol Allergy. 2013 May-Jun;27(3):e75-80. doi: 10.2500/ajra.2013.27.3901.","Lin CC, Chiang YS, Lung CC. Effect of infrared-C radiation on skin temperature, electrodermal conductance and pain in hemiparetic stroke patients. Int J Radiat Biol. 2015 Jan;91(1):42-53. doi: 10.3109/09553002.2014.937512. Epub 2014 Aug 11.","Luo H, Zhang J, Yu Y, Liu J, Jiang Y, Yan N, Wang P, Kong W. [Relationship between eosinophils in nasal discharge and responses to treatment of inhaled glucocorticosteroid in patients with persistent allergic rhinitis]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012 Jun;26(11):494-8. Chinese.","Masuda A, Kihara T, Fukudome T, Shinsato T, Minagoe S, Tei C. The effects of repeated thermal therapy for two patients with chronic fatigue syndrome. J Psychosom Res. 2005 Apr;58(4):383-7. doi: 10.1016/j.jpsychores.2004.11.005.","Masuda A, Koga Y, Hattanmaru M, Minagoe S, Tei C. The effects of repeated thermal therapy for patients with chronic pain. Psychother Psychosom. 2005;74(5):288-94. doi: 10.1159/000086319.","Masuda A, Munemoto T, Tei C. [A new treatment: thermal therapy for chronic fatigue syndrome]. Nihon Rinsho. 2007 Jun;65(6):1093-8. Japanese.","Sin A, Terzioglu E, Kokuludag A, Sebik F, Kabakci T. Serum eosinophil cationic protein (ECP) levels in patients with seasonal allergic rhinitis and allergic asthma. Allergy Asthma Proc. 1998 Mar-Apr;19(2):69-73. doi: 10.2500/108854188778607228.","Toyokawa H, Matsui Y, Uhara J, Tsuchiya H, Teshima S, Nakanishi H, Kwon AH, Azuma Y, Nagaoka T, Ogawa T, Kamiyama Y. Promotive effects of far-infrared ray on full-thickness skin wound healing in rats. Exp Biol Med (Maywood). 2003 Jun;228(6):724-9. doi: 10.1177/153537020322800612.","Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.","Winther L, Moseholm L, Reimert CM, Stahl Skov P, Kaergaard Poulsen L. Basophil histamine release, IgE, eosinophil counts, ECP, and EPX are related to the severity of symptoms in seasonal allergic rhinitis. Allergy. 1999 May;54(5):436-45. doi: 10.1034/j.1398-9995.1999.00910.x.","Yu SY, Chiu JH, Yang SD, Hsu YC, Lui WY, Wu CW. Biological effect of far-infrared therapy on increasing skin microcirculation in rats. Photodermatol Photoimmunol Photomed. 2006 Apr;22(2):78-86. doi: 10.1111/j.1600-0781.2006.00208.x."}	NO_PUBLICATION_FOUND	\N	levocetirizine
327	2023-01-02 15:22:35.74	2023-03-19 21:28:16.172	NCT04612803	Observational Study of the Prevalence of Antihistamine Responsive Gastrointestinal Symptoms in Patients Diagnosed With Irritable Bowel Syndrome With Diarrhea	Prevalence of Antihistamine Responsive Irritable Bowel Syndrome With Diarrhea	Unknown status	Irritable bowel syndrome is a functional disorder of the gastrointestinal tract diagnosed with the Rome criteria. The Rome IV criteria are based on abdominal pain symptoms and stool habits including stool frequency and stool forms [1]. They define 3 main subtypes based on symptoms: 1) IBS with diarrhea; 2) IBS with constipation: and 3) mixed symptoms of constipation and diarrhea. The IBS with diarrhea (IBS-D) subtype has the highest prevalence. Currently, treatment of IBS-D includes antidiarrheals, bile acid sequestrants, antispasmodics, tricyclic antidepressants, and FODMAP diet. However, many patients are intolerant or unresponsive to the above treatments. Outside of IBS, chronic diarrhea affects about 5% of adults. We have described a syndrome in a subset of IBS patients presenting with post prandial diarrhea, flushing and dermatographia whose symptoms are prevented by pre-treatment with combined H1 and H2 antihistamines [2]. However, the prevalence of this syndrome among the IBS + D patients is not known nor have the clinical characteristics or predictors of antihistamine responsive IBS + D been defined.	\N	University of Cincinnati	OTHER	All	\N	18	100	Anticipated	OTHER	University of Cincinnati	\N	\N	\N	\N	Case-Only	\N	Prospective	We have published a series of 5 patients with chronic post prandial diarrhea (PPD) that begins within 3 hours after eating, associated with dermatographia, responsive to antihistamines [2]. In these cases, no underlying causes were identified to explain PPD; diagnoses of food allergy, lactose intolerance, celiac disease, dumping syndromes, inflammatory bowel disease, systemic mastocytosis were excluded. Patients with the syndrome have prior histories of chronic urticaria and experience associated transient symptoms of flushing, headache, tachycardia, and abdominal bloating during PPD episodes.\n\nThis syndrome, except for our published report, have not been previously described in the medical literature. Patients with systemic mastocytosis and mast cell activation syndrome experience PPD but along with anaphylactic manifestations (e.g. wheezing, hypotension) and measurable mast cell biomarkers are identifiable in affected patients (i.e. serum mast cell tryptase or 24 hour urine methylhistamine, PGF2a). Therefore, it is important to characterize PPD responsive to antihistamines in a general GI patient population and to publish our findings. The impact on human health will be substantial; we found that these patients are undiagnosed and untreated for many years.\n\nOur aim is to recruit 50-100 patients from the UC Health affiliated gastroenterology clinics with access UC health which has 300-500 potential subjects. We would need to recruit 10-20% percentage of these potential subjects. Kris Ramprasad MD, a faculty member in the Division of Gastroenterology, David Bernstein MD, a faculty member in the Division of Allergy and Rheumatology, allergy fellows and GI fellows will direct and implement subject screening and consenting.	2020-11-15	2021-08-01	2021-08-01	2020-11-03	\N	2020-11-03	\N	University of Cincinnati	David Bernstein	Emeritus Professor of Medicine	\N	\N	Principal Investigator	\N	Observational	{Adult,"Older Adult"}	{}	{"Irritable Bowel Syndrome",Dermatographism,"Post-prandial Diarrhea"}	combination	cetirizine	\N	t	Bowel Syndrome	2022-08-17 13:39:16	{"Functional Gastrointestinal Disorders and the Rome IV process. In: Drossman DA, Chang L, Chey WD, Kellow J, Tack J, Whitehead WE, editors. Rome IV functional gastrointestinal disorders: disorders of gut-brain interaction.","Hassoun Y, Stevenson MR, Bernstein DI. Idiopathic postprandial diarrhea responsive to antihistamines. Ann Allergy Asthma Immunol. 2019 Oct;123(4):407-409. doi: 10.1016/j.anai.2019.06.022. Epub 2019 Jul 3. No abstract available.","Mlynek A, Vieira dos Santos R, Ardelean E, Weller K, Magerl M, Church MK, Maurer M. A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clin Exp Dermatol. 2013 Jun;38(4):360-6; quiz 366. doi: 10.1111/ced.12107.","Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998 Feb;43(2):400-11. doi: 10.1023/a:1018831127942.","McHugh KR, Swamy GK, Hernandez AF. Engaging patients throughout the health system: A landscape analysis of cold-call policies and recommendations for future policy change. J Clin Transl Sci. 2018 Dec;2(6):384-392. doi: 10.1017/cts.2019.1.","Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997 Apr;11(2):395-402. doi: 10.1046/j.1365-2036.1997.142318000.x.","Passos MC, Lembo AJ, Conboy LA, Kaptchuk TJ, Kelly JM, Quilty MT, Kerr CE, Jacobson EE, Hu R, Friedlander E, Drossman DA. Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol. 2009 Apr;104(4):912-9. doi: 10.1038/ajg.2009.13. Epub 2009 Mar 17.","Gordon S, Ameen V, Bagby B, Shahan B, Jhingran P, Carter E. Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy. Dig Dis Sci. 2003 Jul;48(7):1317-23. doi: 10.1023/a:1024159226274.","B O'Neil, Some useful moment results in sampling problems. American Statistician Volume 69, Issue 4, 2014"}	NO_PUBLICATION_FOUND	\N	cetirizine
343	2023-01-02 15:22:35.741	2023-03-21 09:31:46.545	NCT00562159	A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Adult Subjects With a History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma	Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)	Completed	This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet.	Parallel Assignment	ALK-Abell A/S	INDUSTRY	All	65	18	439	Actual	INDUSTRY	ALK-Abell A/S	Randomized	\N	Triple	\N	\N	Treatment	\N	This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study in participants 18 to 65 years of age, of either sex, and of any race with a history of grass pollen induced rhinoconjunctivitis with or without asthma. While receiving treatment, participants will receive either grass sublingual tablet or placebo. Open-label rescue medications for the hinoconjunctivitis and asthma symptoms will be provided. Participants will visit the study site for at least 12 visits. A total of 10 allergic symptoms, 6 rhinoconjunctivitis and 4 lung symptoms, will be recorded daily on an electronic diary by the participant.\n\nThe start and end of the grass pollen season (GPS) was determined based on the regional grass pollen count, and lasted up to 162 days. For each region, the GPS is defined as the first day of 3 consecutive recorded days with a grass pollen count of  10 grains/m^3, to the last day of the last occurrence of 3 consecutive recorded days with a grass pollen count  10 grains/m^3, inclusively.	2007-11-01	2009-09-01	2009-09-01	2007-11-21	2012-09-07	2017-03-03	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{Rhinoconjunctivitis,Rhinitis,Conjunctivitis,Allergy}	rescue medication	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011 Jan;127(1):72-80, 80.e1-2. doi: 10.1016/j.jaci.2010.11.035.","Hebert J, Blaiss M, Waserman S, Kim H, Creticos P, Maloney J, Kaur A, Li Z, Nelson H, Nolte H. The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children. Allergy Asthma Clin Immunol. 2014 Oct 30;10(1):53. doi: 10.1186/1710-1492-10-53. eCollection 2014."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/21211643/	loratadine
415	2023-01-02 15:22:35.746	2023-03-21 13:30:16.953	NCT03724240	A Multicentre, International, Randomised, Double-blind, Placebo-controlled Study to Demonstrate the Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis	Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis	Unknown status	This is a randomised, double-blind, placebo-controlled, international, multicentre, confirmatory Phase III study in patients with grass pollen-related allergic rhinoconjunctivitis. After having given written informed consent, the patients will be examined to establish eligibility according to inclusion/exclusion criteria. The eligible patients will be randomised to Placebo or gpASIT+ treatment according to a 1:1 ratio. Study treatment will be administered before the start of the pollen season in 2019	Parallel Assignment	ASIT Biotech S.A.	INDUSTRY	All	64	18	624	Anticipated	INDUSTRY	ASIT Biotech S.A.	Randomized	\N	Quadruple	Double blind	\N	Treatment	\N	\N	2019-01-02	2019-09-01	2019-12-01	2018-10-30	\N	2018-10-30	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 3"}	{"Hay Fever"}	rescue medication	desloratadine	\N	f	Allergic Conjunctivitis	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
330	2023-01-02 15:22:35.74	2023-03-21 09:15:51.412	NCT02478398	A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia Artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma	Efficacy and Safety Study of RAGWITEK (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)	Completed	The purpose of this study is to assess the efficacy and safety of short ragweed pollen allergen extract (MK-3641, SCH 039641, RAGWITEK) sublingual immunotherapy tablets in children aged 5 to 17 years with ragweed-induced allergic rhinitis/rhinoconjunctivitis with or without asthma. The primary hypothesis of this study is that administration of short ragweed pollen allergen extract sublingual immunotherapy tablets to children 5 to 17 years of age, compared with placebo, will result in a significant reduction in the combination of rhinoconjunctivitis symptoms and medication use over the peak ragweed season (RS).	Parallel Assignment	Merck Sharp & Dohme LLC	INDUSTRY	All	17	4	1025	Actual	INDUSTRY	Merck Sharp & Dohme LLC	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2015-07-20	2018-11-09	2018-11-19	2015-06-23	2019-07-09	2019-09-06	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Rhinitis, Allergic, Seasonal"}	minimal	loratadine	ltd as needed for symptoms (really minor role)	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Ellis AK, Gagnon R, Bernstein DI, Nolte H. Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis. Allergy Asthma Clin Immunol. 2021 Dec 9;17(1):127. doi: 10.1186/s13223-021-00626-2.","Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD011293. doi: 10.1002/14651858.CD011293.pub3.","Field K, Blaiss MS. Sublingual Versus Subcutaneous Immunotherapy for Allergic Rhinitis: What Are the Important Therapeutic and Real-World Considerations? Curr Allergy Asthma Rep. 2020 Jun 16;20(9):45. doi: 10.1007/s11882-020-00934-4.","Nolte H, Bernstein DI, Nelson HS, Ellis AK, Kleine-Tebbe J, Lu S. Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial. J Allergy Clin Immunol Pract. 2020 Jul-Aug;8(7):2322-2331.e5. doi: 10.1016/j.jaip.2020.03.041. Epub 2020 Apr 15."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/32304832/	loratadine
375	2023-01-02 15:22:35.742	2023-03-21 10:55:19.987	NCT03886506	Expanded Access to Provide Intramuscular Injections of PLX-PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization	Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization	Available	A Phase III study of PLX-PAD for CLI patients with minor tissue loss who are unsuitable for revascularization has been initiated (PLX-CLI-03, PACE study). In parallel, this expanded access program (EAP) will be conducted to allow the treatment of patients who are ineligible to be enrolled in the PACE study.\n\nThe EAP treatment is administered in addition to standard of care of the subjects.PLX-PAD 300106 cells in a mixture containing 10% DMSO, 5% human serum albumin and Plasma-Lyte, will be administered via 30 IM injections (0.5 mL each) delivered into the leg twice,at 8 weeks interval. The locations of injections of the PLX-PAD are detailed in Appendix 1.\n\nAntihistamine treatment should be given at least 1 hour and no more than 1.5 hours prior to PLXPAD administration to ensure coverage for 24 hours, and as long as necessary post PLX-PAD treatment. Consider treatment with second generation H1 inhibitors such as Cetirizine 10 mg once per day.Subjects will be followed-up until 12 months after the 2nd treatment according to the schedule of routine medical visits at the medical institutions. In addition to this routine follow-up, a phone call will be made 12 months after 2nd treatment to inquire on the occurrence of subsequent intervention, amputation, or death.	\N	Pluristem Ltd.	INDUSTRY	All	99	45	\N	\N	INDUSTRY	Pluristem Ltd.	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	2019-03-22	\N	2020-07-28	\N	\N	\N	\N	\N	\N	Sponsor	\N	Expanded Access	{Adult,"Older Adult"}	{}	{"Critical Limb Ischemia (CLI)"}	minimal	cetirizine	"Consider treatment with second generation H1 inhibitors such as Cetirizine 10 mg once per day"	f	Critical Limb Ischemia	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
421	2023-01-02 15:22:35.746	2023-03-21 13:34:45.149	NCT02130440	Evaluation of the Beneficial Effects of a Nasal Spray of Resveratrol in Children With Seasonal Allergic Rhinitis	Evaluation of the Beneficial Effects of a Nasal Spray of Resveratrol in Children With Seasonal Allergic Rhinitis	Completed	The aim of this study is to evaluate whether treatment with a nasal spray based on resveratrol has some benefit in patients with seasonal allergic rhinitis, mild, moderate, or severe.	Parallel Assignment	University of Campania "Luigi Vanvitelli"	OTHER	All	17	4	100	Actual	OTHER	University of Campania "Luigi Vanvitelli"	Randomized	\N	Double	\N	\N	Prevention	\N	The aim of this study is to evaluate whether treatment with a nasal spray based on resveratrol has some benefit in patients with seasonal allergic rhinitis, mild, moderate, or severe. The primary objective is to assess whether the treatment with nasal spray based resveratrol is able to improve the allergic rhinitis symptoms during the two months of treatment. The secondary aim is to evaluate if the resveratrol nasal spray is able to reduce respiratory infections and wheezing episodes.	2012-11-01	2013-12-01	2014-04-01	2014-05-05	\N	2014-05-05	\N	University of Campania "Luigi Vanvitelli"	Prof. Michele Miraglia del Giudice	Prof. Michele Miraglia del Giudice	\N	\N	Principal Investigator	\N	Interventional	{Child}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	not included	cetirizine	only as outcome measure, not really used in trial	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Miraglia Del Giudice M, Maiello N, Capristo C, Alterio E, Capasso M, Perrone L, Ciprandi G. Resveratrol plus carboxymethyl-beta-glucan reduces nasal symptoms in children with pollen-induced allergic rhinitis. Curr Med Res Opin. 2014 Oct;30(10):1931-5. doi: 10.1185/03007995.2014.938731. Epub 2014 Jul 7."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/24983742/	cetirizine
425	2023-01-02 15:22:35.746	2023-03-21 13:39:54.164	NCT02878850	Randomized Trial of Early Hemodynamic Management of Patients Following Acute Spinal Cord Injury	Randomized Trial of Early Hemodynamic Management of Patients Following Acute Spinal Cord Injury	Recruiting	The purpose of this study is to learn more about how participants heal from acute spinal cord injury.	Parallel Assignment	Oregon Health and Science University	OTHER	All	\N	18	152	Anticipated	OTHER	Oregon Health and Science University	Randomized	\N	Single	\N	\N	Treatment	\N	In this study, the investigators will learn about the effect of targeted blood pressure management (TPM) on participants healing from acute spinal cord injury.\n\nThe investigators want to learn:\n\nThe effect of two types of TPM on long term motor and sensory outcomes. The effect of two types of TPM on long-term pain and functional independence outcomes.\n\nHow safe TPM is for participants.	2017-04-10	2023-03-01	2023-12-01	2016-08-25	\N	2022-05-24	\N	Oregon Health and Science University	Miriam Treggiari	Professor	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{"Spinal Cord Injury"}	not included	\N	drug not found	f	\N	\N	{"Weinberg JA, Farber SH, Kalamchi LD, Brigeman ST, Bohl MA, Varda BM, Sioda NA, Radosevich JJ, Chapple KM, Snyder LA. Mean arterial pressure maintenance following spinal cord injury: Does meeting the target matter? J Trauma Acute Care Surg. 2021 Jan 1;90(1):97-106. doi: 10.1097/TA.0000000000002953."}	UNKNOWN	\N	\N
275	2023-01-02 15:22:35.737	2023-03-20 21:28:34.292	NCT00972738	A Multi-Center, Double-blind, Randomized, Parallel-Group Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Spring 2001 Study	Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)	Completed	This study will assess the treatment effect of montelukast versus placebo over a 2 week period in patients with seasonal allergic rhinitis. Loratadine is included in the study as an active comparator.	Parallel Assignment	Organon and Co	INDUSTRY	All	85	15	1214	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2001-04-01	2001-07-01	2001-07-01	2009-09-07	2010-06-16	2022-02-03	Merck Sharp & Dohme Corp	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	control	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"van Adelsberg J, Philip G, LaForce CF, Weinstein SF, Menten J, Malice MP, Reiss TF; Montelukast Spring Rhinitis Investigator Group. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003 Feb;90(2):214-22. doi: 10.1016/S1081-1206(10)62144-8."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/12602669/	loratadine
328	2023-01-02 15:22:35.741	2023-03-21 09:13:19.246	NCT05275933	Assessing the Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang as Adjuvant Treatment in Mild COVID-19 Patients on Home Recovery Program in Singapore: a Randomised, Double-blind, Placebo-controlled Study	Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang in Mild COVID-19 Patients	Recruiting	This research aims to investigate the adjuvant effect of LH in reducing the symptomatic duration of fully vaccinated, mild COVID-19 patients on home recovery program in Singapore. It is aimed to assist policymakers in incorporating clinically proven TCM treatment for mild COVID-19 patients on home recovery program, and establishing a guideline on TCM pandemic treatment protocol which is suitable to be integrated into the healthcare system.	Parallel Assignment	Singapore Chung Hwa Medical Institution	OTHER	All	79	21	300	Anticipated	OTHER	Singapore Chung Hwa Medical Institution	Randomized	A randomised, double-blind, placebo-controlled study	Triple	Double-blinded	\N	Treatment	\N	Importance With the emergence of Covid-19 variants and despite having 93% population vaccination rate, the daily number of community cases in Singapore is still surging. Lian Hua Qing Wen Capsules (LH) was reported to have effective inhibitory action on Delta SARS-CoV-2 in-vitro. Due to limited availability and prioritisation of approved anti-viral drugs (Paxlovid) to moderate and severe inpatients, validating Traditional Chinese Medicine (TCM) intervention LH as a good adjuvant treatment for local population on home recovery program is important.\n\nObjectives This research aims to investigate the adjuvant effect of LH in reducing the symptomatic duration of fully vaccinated, mild COVID-19 patients on home recovery program in Singapore. It is aimed to assist policymakers in incorporating clinically proven TCM treatment for mild COVID-19 patients on home recovery program, and establishing a guideline on TCM pandemic treatment protocol which is suitable to be integrated into the healthcare system.\n\nHypothesis The investigators hypothesize TCM intervention could shorten (1) the time of 8 major clinical symptoms of COVID-19 to no symptoms and (2) lesser days to COVID-19 Antigen Rapid Test (ART) negativity by 1.5 times in mild COVID-19 patients on home recovery program.\n\nMethods 300 eligible participants will be enrolled. Equal number of participants will be randomised and double blinded in the two arms of placebo control and LH, both with standard care. Communication and consultation will be conducted through telecommunication. Primary outcome measures time to no symptoms. Secondary outcomes measure days to ART negativity, symptom severity scores and risk ratio. Exploratory outcomes include days of TCM Excess syndromes (symptoms caused by pathogenic factors) will be collated.\n\nSignificance Adjuvant treatment of mild COVID-19 patients can shorten symptomatic duration, slow disease progression, mitigate post-isolation COVID-19 symptoms, and allow isolated individuals to return to the community earlier.	2022-04-05	2023-09-01	2023-12-01	2022-03-11	\N	2022-10-26	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2","Phase 3"}	{COVID-19}	combination	cetirizine	ctz is used in combination with other medications as standard care	f	COVID	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
253	2023-01-02 15:22:35.736	2023-03-20 21:14:32.24	NCT01108783	Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Desloratadine 5 mg for the Treatment of Seasonal Allergic Rhinitis	A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine	Completed	The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.	Parallel Assignment	Faes Farma, S.A.	INDUSTRY	All	70	12	720	Actual	INDUSTRY	Faes Farma, S.A.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	Pivotal, double-blind, randomized, placebo-controlled, comparative with desloratadine, parallel group, international, multicenter study.The Primary endpoint was the Change in total reflective score on the scale of symptoms associated with seasonal allergic rhinitis indicated by patients at the baseline assessment and over the 2 weeks of the study. A total of 720 patients with seasonal allergic rhinitis were enrolled. Duration of treatment was 14 days, preceded by one week (7 days) of placebo.	2003-04-01	2003-08-01	2004-02-01	2010-04-22	\N	2012-04-05	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	comparison	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{"Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, van de Heyning P, Loureiro A; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009 Jan;64(1):158-65. doi: 10.1111/j.1398-9995.2008.01813.x."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19132976/	desloratadine
390	2023-01-02 15:22:35.744	2023-03-21 12:05:37.364	NCT05232825	A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis	A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis	Recruiting	This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).	Parallel Assignment	Hoffmann-La Roche	INDUSTRY	All	65	18	232	Anticipated	INDUSTRY	Hoffmann-La Roche	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2022-05-02	2023-09-10	2025-02-22	2022-02-10	\N	2022-12-15	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Relapsing Multiple Sclerosis","Primary Progressive Multiple Sclerosis"}	pre-medication	desloratadine	\N	f	Infusion Reaction	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
277	2023-01-02 15:22:35.738	2023-03-20 21:30:25.016	NCT01068223	A Single-Center, Single-Dose, Double-Blind, Modified-Double-Dummy, Placebo and Active-Controlled, Randomized, Three-Way, Six-Sequence Cross-Over Study to Investigate the Effect of JNJ-39758979 on Histamine Induced Pruritus in Healthy Male Subjects	A Study To Investigate The Effect of JNJ-39758979 on Histamine Induced Itch in Healthy Male Volunteers	Completed	The purpose of this study is to investigate the effect of JNJ-39758979 compared to placebo on histamine induced itch in healthy male volunteers.	Crossover Assignment	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	INDUSTRY	Male	55	18	24	Actual	INDUSTRY	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	The goal of this study is to evaluate the effect and safety of a single oral dose of JNJ-39758979 on histamine-induced itch and hive in 24 healthy male volunteers. This is a three-treatment, double-blind (neither the volunteer nor the study physician will know the identity of the treatment), cross-over (each volunteer receives all three treatments) study. The study is also randomized, meaning that the order in which treatments are given is determined randomly (by chance, like flipping a coin). The total participation time is approximately 8 to 9 weeks, which includes a screening visit, three treatment periods, two wash-out periods (breaks), and a follow-up visit after the third treatment period. All three treatment periods require a 2-day stay in the clinic. Volunteers will have a histamine test at the screening visit and three times during each treatment period (total of 10 tests). The histamine test consists of an injection of a small amount of histamine solution into the upper layer of the skin, which may cause itchiness, a flare response (redness on the skin) and wheal response (elevated bump in the skin) lasting for 30 to 60 minutes. Volunteers will be blindfolded during the procedure and asked to rate the severity of the itch. The areas of the wheal and flare will be measured by a laser scanner, which will not cause harm to the volunteer. During the treatment periods, volunteers will receive the histamine test on the day before study drug and/or placebo is given and at 2 and 6 hours after study drug and/or placebo is given. During the study, safety evaluations, which will include ECGs (a cardiac function test) and vital signs, will be performed, and side effects will be monitored. Blood and urine samples will be collected at the screening visit, during the first day of each treatment period in the clinic and at the follow-up visit for evaluation. Volunteers will receive single doses of 600mg JNJ-39758979, placebo, and 10mg cetirizine in random order over three treatment periods. The first two treatment periods will be followed by an approximately 14 day wash-out period.	2010-02-01	\N	2010-05-01	2010-02-12	\N	2013-09-04	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{"Histamine Induced Itch"}	control	cetirizine	\N	f	Itch	2022-08-17 13:39:16	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/24817035/	cetirizine
286	2023-01-02 15:22:35.737	2023-03-20 21:35:16.981	NCT05356143	A Single-Dose, Partial-Replicate, Pharmacokinetic, and Comparative Bioavailability Study of Rupatadine 10 mg Tablets and Clarinex 5 mg Tablets Under Fasting Conditions	A Comparative Study of Rupatadine 10 mg Tablets and Clarinex 5 mg Tablets Under Fasting Conditions	Active, not recruiting	This is an open-label, single-dose, randomized, three-period, two-treatment, threesequence, crossover, PK, partial replicate, and comparative bioavailability study. This study may be conducted in groups. The same protocol requirements and procedures will be followed for each group.	Crossover Assignment	J. Uriach and Company	INDUSTRY	All	\N	18	45	Actual	INDUSTRY	J. Uriach and Company	Randomized	This is an open-label, single-dose, randomized, three-period, two-treatment, threesequence, crossover, PK, partial replicate, and comparative bioavailability study.	None (Open Label)	\N	\N	Other	\N	This study will allow for the determination of the PK and intra-subject variability of rupatadine and metabolites. In addition, this study will compare the bioavailability of the rupatadine formulation (Drug Product 1) to a FDA-approved reference product (Clarinex) (Drug Product 2) as far as the rupatadine metabolite desloratadine, and the derived compounds, is concerned.\n\nComparative bioavailability between Drug Product 1 and Drug Product 2 will be determined by a statistical comparison of the AUCt, AUCinf, and Cmax parameters for desloratadine (UR-12790), 3-OH desloratadine (UR-12788), 5-OH desloratadine (UR-12767), 6-OH desloratadine (UR-12766), and 3-OH-glucuronide-desloratadine (UR-12335).	2021-12-02	2022-01-13	2022-05-01	2022-05-02	\N	2022-05-02	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{Healthy}	comparison	desloratadine	\N	f	Bioavailability	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
304	2023-01-02 15:22:35.739	2023-03-20 21:52:11.395	NCT05263206	Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)	Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)	Recruiting	The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO.\n\nThis is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO. Study B design may be adapted based on the results of Study A.\n\nFor both Study A and B, after an up-to-4-week screening period, participants with severe pruritus (worst-itch numerical rating scale [WI-NRS 7) will enter a 4-week run-in period during with a non-sedative antihistamine and an emollient (moisturizer). Participants with severe pruritus (WI-NRS 7) at baseline will be randomized (1:1) to be treated for 24 weeks (Study A) or 12 weeks (Study B) with either dupilumab or matching placebo in addition to their antihistamine and emollient regimen. The treatment period for both study A and B will be followed by a 12-week follow-up period.	Parallel Assignment	Sanofi	INDUSTRY	All	90	18	208	Anticipated	INDUSTRY	Sanofi	Randomized	\N	Quadruple	\N	\N	Treatment	\N	Study duration per participant will be up to 44 weeks (Study A) and 32 weeks (Study B).	2022-02-15	2025-03-21	2025-10-03	2022-03-02	\N	2022-11-22	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{Pruritus}	combination	loratadine	ldt only as replacment for fex if it is not available	f	Pruritus	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
211	2023-01-02 15:22:35.734	2023-08-01 12:52:59.991	NCT01496911	Study to Investigate the Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving at 2 Bar and 4 Bar in Professional Navy Divers	Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving	Completed	Antihistamines are commonly used and currently levocetirizine is most frequently prescribed in the Netherlands. They are commonly used by divers, to solve ear, nose and throat problems, especially to open tubal passage. However, the effects of these drugs on cognitive performance have not been investigated during diving.The objective of this study is to investigate the effects of levocetirizine, hydroxyzine and placebo on cognitive and psychomotor functioning during controlled simulated diving in a hyperbaric chamber in professional navy divers at 10 mt (2 bar) and 30 mt (4 bar).It is hypothesized that hydroxyzine will produce significant impairment, and that the magnitude of impairment is related to hyperbaric pressure.	Crossover Assignment	Utrecht Institute for Pharmaceutical Sciences	OTHER	Male	55	18	24	Actual	OTHER	Utrecht Institute for Pharmaceutical Sciences	Randomized	\N	Double	\N	\N	Basic Science	\N	This double-blind, randomized, placebo-controlled cross-over study will comprise of 1 training day and 3 test days. Twenty-four healthy male divers from the Royal Netherlands Navy will participate in this study.The objective of this study is to investigate the single dose effects of levocetirizine (5 mg), hydroxyzine (50 mg) and placebo.\n\nVisit 1 is a training day, and Visit 2-4 are test days. At the test day, subjects receive one of the three medications. One hour after administration of the drugs, subjects will start with the dive in the recompression chamber. After one hour, medication has reached their peak plasma concentration, and effects can be expected. There will be a wash-out period of at least 7 days between the test days.\n\nSubjects will perform one simulated dive at each test day. They first descend in 2 min to a pressure of 4 bar (30 mt), stay for 20 min, the dive continues when they ascend to a pressure of 2 bar (10 mt) with another stay for 20 min. At both depths the 20 min periods are the measuring period to perform the test. At the end they will go to the surface according the decompression profile and stop for 3 min at 9 mt, 8 min at 6 mt and 23 min at 3 mt. These decompression stops are regular for the profile and necessary to prevent decompression sickness.Before and after diving, and at 2 and 4 bar, tests measuring attention, memory, psychomotor, concentration and comprehension ability of the participants are conducted.	2012-04-01	2012-10-01	2012-10-01	2011-12-21	\N	2013-11-06	\N	Utrecht Institute for Pharmaceutical Sciences	Dr Joris C Verster	Assistant professor	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Phase 4"}	{"Healthy Volunteers"}	main	levocetirizine	Is that really repurpose or safety evaluation?	f	Safety Evaluation	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
26	2023-01-02 15:22:35.724	2023-07-31 18:44:57.325	NCT02908750	An Open-label, Non-randomised, Phase I Study to Assess the Effect of Single and Multiple Oral Doses of Osimertinib (TAGRISSO) on the Pharmacokinetics of a P-glycoprotein Probe Drug (Fexofenadine) in Patients With Advanced EGFRm NSCLC That Have Progressed on a Prior EGFR-TKI Regimen	Study to Assess the Effect of Osimertinib (TAGRISSO ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC	Completed	This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior therapy with an approved EGFR tyrosine kinase inhibitor (TKI) agent.\n\nPart A will assess the effect of osimertinib on the pharmacokinetic (PK) parameters of fexofenadine, following single and multiple oral dosing of osimertinib in a fasted state.\n\nContinuous Access will allow patients further access to osimertinib after the PK phase (Part A). All patients from Part A who completed treatment may continue to receive osimertinib 80 mg once daily until: they are no longer deriving clinical benefit; or any other reason	Single Group Assignment	AstraZeneca	INDUSTRY	All	130	18	24	Actual	INDUSTRY	AstraZeneca	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	This is a Phase I, open-label, non-randomised, two-part study in patients with EGFRm+ NSCLC who have progressed on an EGFR-TKI.\n\nThe PK phase will assess the effect of osimertinib on the PK parameters of fexofenadine following both single and multiple oral dosing of osimertinib. Continued access will provide patients with further access to osimertinib after the PK phase.\n\nThe study will be conducted at approximately 10 sites across Asia and Western Europe, with approximately 24 patients enrolled in order to achieve at least 18 evaluable patients. Additional patients may be dosed to ensure the minimum number of evaluable patients.\n\nPK phase The PK phase is a non-randomised, open-label, 2-period design. Treatment Period 1 and Treatment Period 2 are separated by a 3 to 7 day washout period between doses. A study flow chart for the PK phase is presented in Figure 1. Patients will receive osimertinib 80 mg as a single dose on Day 1 of Treatment Period 2, then 80 mg once daily for 38 days (from Day 4 to Day 41 in Treatment Period 2). Patients will also receive a single oral dose of fexofenadine on Day 1 in Treatment Period 1, and on Days 1 and 39 in Treatment Period 2.\n\nContinued access On completion of the PK phase (ie, following collection of the 72-hour fexofenadine sample on Day 42), patients may continue to take osimertinib tablets (80 mg once daily) as a single agent in continued access if they and the Investigator agree that this is appropriate. This will continue until the Investigator believes they are no longer deriving clinical benefit, or they stop taking osimertinib for any other reason. No clinical data will be collected during this phase other than sudden death of unknown reason, serious adverse events (SAEs) that may be related to osimertinib, outcomes of pregnancy and drug dispensing/accountability.\n\nIf a patient discontinues treatment during the PK phase, they will return to the clinic for follow-up assessments 30 days (7 days) after their last dose of treatment in the PK phase. If the patient's last dose of osimertinib is in continued access, the patient should be contacted 30 days after their last dose of osimertinib to follow-up any existing SAEs, monitor for new SAEs that may be related to the IP, and record any sudden deaths of unknown cause.	2017-03-02	2017-07-31	2022-10-11	2016-09-21	\N	2022-11-14	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Non Small Cell Lung Cancer"}	combination	fexofenadine	TODO, more pharmakokinetics?\n	f	Cancer	2022-08-18 16:54:53	{"Calvo E, Lee JS, Kim SW, Moreno V, deCastro Carpeno J, Weilert D, Laus G, Mann H, Vishwanathan K. Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer. J Clin Pharmacol. 2019 Aug;59(8):1099-1109. doi: 10.1002/jcph.1403. Epub 2019 Mar 15."}	PUBLISHED	\N	fexofenadine
278	2023-01-02 15:22:35.738	2023-03-20 21:31:15.896	NCT00979901	A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Seasonal Allergic Rhinitis--Spring Study	Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)	Completed	This study will evaluate the ability of montelukast to improve the signs and symptoms of seasonal allergic rhinitis compared with loratadine and placebo.	Parallel Assignment	Organon and Co	INDUSTRY	All	85	15	1577	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2000-03-01	2000-05-01	2000-05-01	2009-09-18	2010-06-08	2022-02-09	Merck Sharp & Dohme Corp	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	control	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, Malice MP, Reiss TF; Montelukast Spring Rhinitis Study Group. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002 Jul;32(7):1020-8. doi: 10.1046/j.1365-2222.2002.01422.x. Erratum In: Clin Exp Allergy. 2009 Oct;39(10):1622."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/12100048/	loratadine
338	2023-01-02 15:22:35.74	2023-03-21 09:24:19.501	NCT01134328	A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Cetirizine 0.1%/Fluticasone 0.005% Ophthalmic Solution Compared to Its Components and Vehicle in a Modified Conjunctival Allergen Challenge (CAC) Model During Pollen Season	Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC Model	Completed	The purpose of this study is to evaluate the efficacy of AC-150 compared to vehicle and its components in the prevention of the signs and symptoms of allergic conjunctivitis in Enviro-CAC Model.	Parallel Assignment	Aciex Therapeutics, Inc.	INDUSTRY	All	\N	10	83	Actual	INDUSTRY	Aciex Therapeutics, Inc.	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2010-05-01	2010-07-01	2010-07-01	2010-06-02	2017-09-14	2017-09-14	Nicox Ophthalmics Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 2"}	{"Allergic Conjunctivitis"}	combination	cetirizine	official title: "[...] Efficacy of Cetirizine 0.1%/Fluticasone 0.005% Ophthalmic Solution [...]"	f	Allergic Conjunctivitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
297	2023-01-02 15:22:35.738	2023-03-20 21:44:14.883	NCT00561717	A Four-Way Double-Blind, Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of Azelastine Nasal Spray and Antihistaminic Agents in Adult Subjects With Allergen Induced Seasonal Allergic Rhinitis	A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis	Completed	Finding out how fast azelastine nasal spray works in subjects with hay fever.	Crossover Assignment	Bayer	INDUSTRY	All	65	18	70	Actual	INDUSTRY	Bayer	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2007-10-01	2007-12-01	2008-02-01	2007-11-21	\N	2013-05-07	\N	\N	\N	\N	Medical Affairs Therapeutic Area Head	Bayer Consumer Care Inc.	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	control	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Tenn MW, Steacy LM, Ng CC, Ellis AK. Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score. Allergy Asthma Clin Immunol. 2018 Jan 16;14:5. doi: 10.1186/s13223-017-0227-4. eCollection 2018."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/23635091/	loratadine|cetirizine
319	2023-01-02 15:22:35.74	2023-03-21 08:52:58.654	NCT02592317	Drug-drug Interaction Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Subjects With Castration-Resistant Prostate Cancer	A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer	Active, not recruiting	The purpose of this study is to evaluate the effects of repeat dosing of JNJ-56021927 on the pharmacokinetics for single-dose multiple cytochrome P450 (CYP450) enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2C8) and transporter (P-gp and BRCP) substrates in participants with castration-resistant prostate cancer (CRPC).	Single Group Assignment	Aragon Pharmaceuticals, Inc.	INDUSTRY	Male	\N	18	23	Actual	INDUSTRY	Aragon Pharmaceuticals, Inc.	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	This is a Phase 1, multicenter, open-label study in participants with CRPC. The study will consist of a Screening Phase to determine eligibility, a Pretreatment Phase, a Treatment Phase, and a Follow-up Phase. The study is designed to estimate the magnitude of the effects of JNJ-56021927 on the pharmacokinetics of probe substrates. In vitro studies have indicated that JNJ-56021927 and its active metabolite JNJ-56142060 (M3) have the potential to affect multiple cytochrome P450 (CYP) enzymes (CYP3A4, CYP2C9, CYP2C19, and CYP2C8) and drug transporters proteins (P-glycoprotein [P-gp] and breast cancer resistance protein [BRCP]) via inhibition or induction. In human hepatocytes, JNJ 56021927 and JNJ-56142060 (M3) were found to be inducers of CYP3A4. The induction of CYP3A4 suggests that JNJ-56021927 and M3 will induce other CYP isozymes and drug transporters (eg, CYP2C and P-gp via activation of pregnane X receptor). The study is designed to confirm the in vivo significance of these non-clinical findings.	2016-02-12	2016-11-07	2023-10-15	2015-10-30	\N	2022-12-21	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Prostatic Neoplasms, Castration-Resistant"}	combination	fexofenadine	\N	f	Pharmacokinetics	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
391	2023-01-02 15:22:35.744	2023-03-21 12:06:54.847	NCT00633919	A Randomised, Double-blind, Placebo-controlled Trial Assessing the Efficacy of SLITone in House Dust Mite Allergic Patients	Efficacy of SLITone in House Dust Mite Allergic Patients	Completed	This trial has been designed to evaluate the efficacy of specific immunotherapy with SLITone Dermatophagoides mix compared with placebo in subjects with house dust mite allergic asthma, based on asthma medication use during a period of 2 months with a high environmental exposure to mites (autumn 2008).	Parallel Assignment	ALK-Abell A/S	INDUSTRY	All	65	18	124	Actual	INDUSTRY	ALK-Abell A/S	Randomized	\N	Triple	\N	\N	Treatment	\N	This trial was conducted as a multi-centre, randomised, double-blind, parallel-group, placebo-controlled phase III trial, assessing the efficacy of SLITone Dermatophagoides mix in adults (18-65 years). 5 centres in Spain participated.\n\nSubjects with house dust mite allergic asthma were randomised to receive either SLITone Dermatophagoides mix (active) or placebo treatment (1:1) for approximately 1 year. The trial duration was extended to 2 years. Administration was done sublingually (under the tongue) once daily preferably in the morning. A monodose container comprised the daily dose of 200 STU.\n\nSubjects were kept in asthma control during the entire trial (2 years). Except for during 2 evaluation periods of 2 months in autumn 2007 and autumn 2008, subjects used the medications prescribed by their physician. During the 2 evaluation periods of 2 months in autumn 2007 and autumn 2008, subjects used provided and standardised rhinoconjunctivitis and asthma medications. The asthma medication use was to reflect the subject's asthma status. This was done by treatment with a low maintenance dose of control medication supplemented with rescue medication as needed.\n\nRhinoconjunctivitis medication during the 2 evaluation periods in autumn 2007 and autumn 2008; to standardise the medication used to relieve rhinoconjunctivitis symptoms, subjects were provided with the following free medications as needed:\n\nDesloratadine tablet (5 mg per tablet; anti-histamine; Aerus)\nBudesonide nasal spray (64 g per puff; inhaled corticosteroid)\nPrednisone tablet (5 mg per tablet; oral corticosteroid)\n\nSubjects were instructed to use this medication instead of their usual medication during the 2 evaluation periods in autumn 2007 and autumn 2008, and to record the used medication and symptoms in the daily diary.\n\nAsthma medication during the evaluation period in autumn 2007; prior to the 2 months evaluation period in autumn 2007, the asthma control medication use was interrupted to obtain a medication-free period. Subjects were provided with the following free medications to standardise the treatment used to relieve asthma symptoms:\n\nSalbutamol inhaler (200 g per puff; a short acting 2-agonist; Ventilastin).\nBudesonide/formoterol inhaler (80/4.5 g per inhalation; a combination of inhaled corticosteroids and long acting 2-agonist; Symbicort).\nPrednisone tablet (5 mg per tablet; oral corticosteroid).\n\nSubjects were instructed to use this medication instead of their usual medication during the evaluation period in autumn 2007 as follows:\n\nThey were to use salbutamol inhaler as asthma rescue medication until they either:\n\nneeded more than 4 inhalations of salbutamol per day for 2 consecutive days\nsuffered from nocturnal asthma forcing them to wake up\nsuffered from exercise-induced dyspnoea doing ordinary tasks In these cases, subjects were to contact the investigator to determine the amount of budesonide/formoterol to use as daily asthma control medication. The budesonide/formoterol inhaler was thereafter to be used as rescue medication as needed instead of salbutamol. Prednisone could be used as a last option.\n\nAsthma medication during the evaluation period in autumn 2008: At the 2 months evaluation period in autumn 2008, subjects were maintained at a low dose of budesonide/formoterol (daily asthma control medication) and they used the budesonide/formoterol inhaler as rescue medication as needed. Prednisone could be used as a last option.\n\nAsthma medication used during the evaluation periods in autumn 2007 and autumn 2008 were recorded in a daily diary.\n\nOne primary efficacy endpoint and 16 secondary efficacy endpoints were assessed; the result of the primary efficacy endpoint, 3 secondary endpoints and adverse event reportings are posted here. None of the other secondary endpoints demonstrated a difference between treatment groups.	2006-07-01	2008-12-01	2009-02-01	2008-03-12	2011-02-21	2011-06-08	ALK-Abell S.A.	\N	\N	\N	Santiago Martn -Trial Manager; ALK-Abell S.A.	ALK-Abell S.A.	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2","Phase 3"}	{Allergy}	comparison	desloratadine	\N	f	Allergy	2022-09-15 19:16:20	{}	CT_RESULTS	\N	desloratadine
71	2023-01-02 15:22:35.725	2023-07-31 19:25:34.451	NCT00867191	A Multi-Centre, Double-Blind, Randomised Comparison Of The Effects Of Desloratadine (Aerius) And Placebo In The Relief Of Nasal Symptom Scores In Subjects With Seasonal Allergic Rhinitis (Sar) To Cypress Pollen	Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836)	Completed	The purpose of this study was to demonstrate the efficacy (% of change from baseline) of desloratadine to improve the nasal total symptom score of SAR to cypress pollen.	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	18	233	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2002-02-01	2003-04-01	2003-04-01	2009-03-23	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	main	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{"Demoly P, Dreyfus I, Dhivert-Donnadieu H, Mesbah K. Desloratadine for the treatment of cypress pollen-induced allergic rhinitis. Ann Allergy Asthma Immunol. 2009 Sep;103(3):260-6. doi: 10.1016/S1081-1206(10)60191-3."}	PUBLISHED	\N	desloratadine
77	2023-01-02 15:22:35.726	2023-07-31 19:27:52.604	NCT00776139	An Open Label, Randomized, Single-Center, Single-Dose, Two-Treatment, Two-Period, Crossover Bioavailability Study Comparing Cetirizine Hydrochloride 10 mg Tablet of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy, Inc) With Zyrtec Cetirizine Hydrochloride, 10 mg Tablet of Pfizer Labs (Division of Pfizer Inc.) in Healthy, Adult, Human Subjects Under Fasting Condition	Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions	Completed	An open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability study comparing Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) with Zyrtec Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs (Division of Pfizer Inc.) in healthy, adult, human subjects under fasting condition	Crossover Assignment	Ranbaxy Laboratories Limited	INDUSTRY	\N	50	18	32	Actual	INDUSTRY	Ranbaxy Inc.	Randomized	\N	None (Open Label)	\N	\N	\N	\N	The study was conducted as an open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability of the test formulation of cetirizine hydrochloride tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) containing containing 10 mg cetirizine hydrochloride study comparing to the marketed product, Zyrtec, containing 10 mg of cetirizine hydrochloride of Pfizer Labs (Division of Pfizer Inc.), in healthy, adult, human, subjects under fasting condition.\n\nSafety measures were performed throughout the study and included a physical examination, laboratory evaluation, and measurement of vital signs.\n\nA total of 32 subjects were randomized to receive single oral dose of cetirizine hydrochloride 10 mg tablet and 31 subjects completed both the periods of the study.	2004-10-01	2004-10-01	2004-12-01	2008-10-20	\N	2008-10-20	\N	\N	\N	\N	Dr. Tausif Monif	Ranbaxy Laboratories Limited	\N	\N	Interventional	{Adult}	{"Not Applicable"}	{Healthy}	main	cetirizine	\N	f	Bioequivalence	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
357	2023-01-02 15:22:35.742	2023-08-01 18:33:50.354	NCT04688788	Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Comparing the Efficacy of Ocrelizumab and Rituximab in Active Multiple Sclerosis	Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis	Recruiting	The DanNORMS study is phase 3 non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.	Parallel Assignment	Rigshospitalet, Denmark	OTHER	All	65	18	594	Anticipated	OTHER	Rigshospitalet, Denmark	Randomized	A prospective, 2:1 randomized, open-label, multi-centre, phase 3 non-inferiority clinical trial with blinded primary endpoint.	Single	MRI scan data will be transfered to the MRI Reader Centre with pseudonymized identity and without any information regarding the treatment allocation of the patient.	\N	Treatment	\N	The DanNORMS study will include patients with active multiple sclerosis aged 18-65 years. Patients will be randomized in a 2:1 ratio to either rituximab or ocrelizumab. The study duration is 24 months, and patients can continue in an extension phase for additional 36 month. The primary endpoint is the percentage of patients without new or enlarging T2 white matter lesions on brain MRI scans from month 6 to month 24, which will be assessed by radiologists blinded to the treatments status. The study will evaluate a number of efficacy and safety endpoints using clinical, MRI, routine blood samples and research biomarkers.	2021-04-28	2025-04-28	2028-04-28	2020-12-30	\N	2022-05-04	\N	Rigshospitalet, Denmark	Jeppe Romme Christensen	National coordinating principal investigator	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Relapsing Remitting Multiple Sclerosis","Secondary Progressive Multiple Sclerosis","Primary Progressive Multiple Sclerosis"}	pre-medication	fexofenadine	TODO	f	Infusion Reaction	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
186	2023-01-02 15:22:35.733	2023-08-01 12:19:34.342	NCT01055756	\N	Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis	Withdrawn	The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D  (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D  (loratadine + pseudoephedrine sulfate - Schering Plough) in patients with allergic rhinitis by quantification of the scores of clinical parameters (signs and symptoms) and laboratory (nasal flow) down through time.	Crossover Assignment	Azidus Brasil	INDUSTRY	All	60	18	0	Actual	INDUSTRY	Azidus Brasil	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	Secondly, it will be observed safety (tolerability) clinic after the administration of the drug in patients by comparing the clinical parameters and the incidence of adverse events.	2010-01-01	2010-04-01	2010-06-01	2010-01-26	\N	2022-10-31	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 3"}	{"Allergic Rhinitis"}	comparison	loratadine	comparison is between two forms of the same drug, \nTODO: check if Claritin D includes Pseudoephedrine	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
347	2023-01-02 15:22:35.741	2023-03-21 09:37:02.995	NCT01981499	A Phase 1, Placebo-Controlled, Crossover, Subject- And Investigator-Blind, Sponsor-Open Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of A Modified-Release Formulation Of PF-05180999 In Healthy Adult Subjects	A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults	Terminated	PF-05180999 is a phosphodiesterase-2 inhibitor that is hypothesized to be able to reduce vascular permeability. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and effects on histamine-induced wheal of single doses of PF-05180999 in healthy adult subjects. Histamine-induced wheals are biomarkers of vascular permeability.	Crossover Assignment	Pfizer	INDUSTRY	Male	55	18	31	Actual	INDUSTRY	Pfizer	Randomized	\N	Double	\N	\N	Basic Science	\N	\N	2014-01-01	2014-04-01	2014-04-01	2013-11-11	\N	2014-05-08	\N	\N	\N	\N	\N	\N	Sponsor	The trial was prematurely terminated on 01April2014 due to safety concerns.	Interventional	{Adult}	{"Phase 1"}	{Migraine}	control	cetirizine	Todo check usecase	f	Safety Evaluation	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
290	2023-01-02 15:22:35.738	2023-03-20 21:37:35.306	NCT00723736	Non-Interventional Study of the Safe Use of Aerius in Pediatric Patients With Allergic Rhinitis or Chronic Idiopathic Urticaria.	Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic Rhinitis or Chronic Idiopathic Urticaria (Study P04446AM1)(COMPLETED)	Completed	The objective of this non-interventional study is to evaluate the safety of Aerius syrup in pediatric patients aged 1-5 years old with allergic rhinitis or chronic idiopathic uticaria. The patients will receive 2.5 ml (1.25 mg) once daily.	\N	Organon and Co	INDUSTRY	All	5	1	100	Actual	INDUSTRY	Organon and Co	\N	\N	\N	\N	Cohort	\N	Prospective	Pediatric patients aged 1-5 years	2007-12-01	2008-06-01	2008-06-01	2008-07-29	2009-08-06	2022-02-09	Merck, Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Child}	{}	{Rhinitis,Urticaria}	main	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{}	CT_RESULTS	\N	desloratadine
379	2023-01-02 15:22:35.743	2023-03-21 11:01:09.038	NCT02438072	Cocktail Phenotypic Approach to Explore Antidepressant Pharmacokinetic Variability: a Pilot Study	Drug Metabolism and Antidepressant	Unknown status	We propose here to explore systematically the association between drug-metabolizing enzymes activity assessed by a phenotypical approach and antidepressant plasma concentration, efficacy and tolerance in the clinical setting. During one year, patients receiving antidepressant will be included in tis prospective clinical, naturalistic and descriptive pilot study.	Single Group Assignment	University Hospital, Geneva	OTHER	All	70	18	100	Anticipated	OTHER	University Hospital, Geneva	N/A	\N	None (Open Label)	\N	\N	\N	\N	Objectives To describe drug metabolism variability in depressive patients using a phenotypic approach\nStudy design Prospective, clinical, naturalistic, descriptive study During a consultation with their clinician, depressive patients will receive information.\n\nDuring the visit V0 with an investigator: patients will be included:\n\nVerification of inclusion and non inclusion criteria\nReminder participation conditions\nInclusion, signature of consent\nCollection of clinical and demographic features Between V0 and V1, for patients with change in antidepressant therapy, will take place telephone interviews every two weeks, conducted by the clinician to evaluate treatment depression response (tolerance and efficacy)\n\nDuring the visit V1, will take place:\n\nPhenotypic study\nGenetic study\nDosage of current antidepressant drug\n\nClinical evaluation: efficacy and tolerance\n\nNumber of patients During one year, the protocol will be proposed to all patients with depression and decision of change in antidepressant therapy, and all patients with stability od prescription since almost 6 weeks. The inclusion of approximately 100 patients is expected.\nName of the finished product Zyban, Froben, Antra, Bexine, Dormicum Telfast\nName of the active substance Omeprazole (10 mg, A02BC01) Caffeine (50 mg, N06BC01) Flurbiprofen (10 mg, M01AE09) Dextromethorphan (10 mg, R05DA09) Midazolam (1 mg, N05CD08) Fexofenadine (25mg, R06AX26 ) Bupropion (20 mg, N06AX12)\nDuration of treatment One time during the study, one day (Visit 1)\nTime plan of research -Duration for the patient: The study will stop when the patient has performed the V1 study Minimal delay between V0 and V1: 6 weeks (5-7 weeks) : for patient with decision to change the treatment, 5 days for patients with stability of treatment since almost 6 weeks.\n\nMaximal delay of participation for the patient: 4 months even when V1 was not performed\n\n-Overall duration of inclusion: one year Maximal overall duration of the study: 12 months+4 months= 16 months Maximal duration for the analytical study since the beginning of the study= 16 months+6 months: 22 months.\n\nMaximal delay for communication of the results: 2 years after the beginning of the study	2014-12-01	2015-12-01	2015-12-01	2015-05-08	\N	2015-05-08	\N	University Hospital, Geneva	Celia Lloret-Linares	Doctor	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{Depression}	minimal	fexofenadine	usecase  prev despression	f	Pharmacokinetics	2022-08-18 16:54:53	{"Bosilkovska M, Samer CF, Deglon J, Rebsamen M, Staub C, Dayer P, Walder B, Desmeules JA, Daali Y. Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther. 2014 Sep;96(3):349-59. doi: 10.1038/clpt.2014.83. Epub 2014 Apr 10.","Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, Drews MS, Eisterhold LL, Geske J, Mrazek DA. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013 Oct;23(10):535-48. doi: 10.1097/FPC.0b013e3283649b9a.","Lloret-Linares C, Bosilkovska M, Daali Y, Gex-Fabry M, Heron K, Bancila V, Michalopoulos G, Perroud N, Richard-Lepouriel H, Aubry JM, Desmeules J, Besson M. Phenotypic Assessment of Drug Metabolic Pathways and P-Glycoprotein in Patients Treated With Antidepressants in an Ambulatory Setting. J Clin Psychiatry. 2018 Mar/Apr;79(2):16m11387. doi: 10.4088/JCP.16m11387."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/24018772/	fexofenadine
349	2023-01-02 15:22:35.742	2023-03-21 09:40:29.459	NCT02646904	Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis	Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis	Completed	The purpose of this study is to examine in children with persistent AR the effect of the topically applied beclomethasone in comparison with cetirizine on nasal patency evaluated by acoustic rhinometry and subjective nasal symptoms.	Parallel Assignment	Stefania La Grutta, MD	OTHER	All	16	6	68	Actual	OTHER	Istituto per la Ricerca e l'Innovazione Biomedica	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2016-05-01	2017-06-01	2017-07-01	2016-01-06	\N	2017-11-20	\N	Istituto per la Ricerca e l'Innovazione Biomedica	Stefania La Grutta, MD	MD, Senior Researcher, Coordinator of Pediatric Allergy and Asthma Research Group. Institute of Biomedicine and Molecular Immunology, IBIM, National Research Council of Palermo, Italy.	\N	\N	Sponsor-Investigator	\N	Interventional	{Child}	{"Phase 4"}	{"Allergic Rhinitis"}	comparison	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
309	2023-01-02 15:22:35.739	2023-03-20 21:57:37.137	NCT03287856	Investigation of the Safety and Performance of the NVT ALLEGRA TAVI System TF in Patients With Failed Surgical Aortic Bioprosthesis and Elevated Surgical Risk	NVT ALLEGRA TAVI System TF in Failing Surgical Aortic Bioprosthesis	Completed	The study investigates the technical feasibility of the replacement of failed surgical bioprosthetic aortic valves by the ALLEGRA Transcatheter Heart Valve (THV) and describes the safety and performance profile	Single Group Assignment	NVT GmbH	INDUSTRY	All	\N	18	30	Actual	INDUSTRY	NVT GmbH	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2017-08-11	2018-09-27	2019-10-27	2017-09-19	\N	2020-01-10	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{"Transcatheter Aortic Valve Implantation"}	not included	fexofenadine	ALLERGRA does not refer to fex	f	Transcatheter Aortic Valve Implantation	2022-08-18 16:54:53	{"Schafer U, Butter C, Landt M, Frerker C, Treede H, Schirmer J, Koban C, Allali A, Schmidt T, Charitos E, Conradi L. Thirty-day outcomes of a novel transcatheter heart valve to treat degenerated surgical valves: the VIVALL multicentre, single-arm, pilot study. EuroIntervention. 2019 Oct 4;15(9):e757-e763. doi: 10.4244/EIJ-D-19-00331."}	UNKNOWN	\N	fexofenadine
258	2023-01-02 15:22:35.736	2023-03-20 21:16:55.976	NCT00972504	A Randomised, Double-blind, Placebo-controlled 4-period Cross-over Study to Assess the Efficacy and Safety of Repeat Dose Intranasal GSK1004723 (1000g), Oral GSK835726 (10mg) and Cetirizine (10mg) in the Environmental Challenge Chamber in Subjects With Seasonal Allergic Rhinitis	723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover	Completed	This is a randomised, double-blind, placebo-controlled 4-period cross-over study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000g), oral GSK835726 (10mg) and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal allergic rhinitis.	Crossover Assignment	GlaxoSmithKline	INDUSTRY	All	65	18	54	Actual	INDUSTRY	GlaxoSmithKline	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2009-06-01	2009-08-01	2009-08-14	2009-09-07	2017-08-02	2017-08-02	GlaxoSmithKline	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Rhinitis, Allergic, Seasonal"}	comparison	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Daley-Yates P, Ambery C, Sweeney L, Watson J, Oliver A, McQuade B. The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol. 2012;158(1):84-98. doi: 10.1159/000329738. Epub 2011 Dec 29."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/22212854/	cetirizine
205	2023-01-02 15:22:35.734	2023-08-01 12:26:01.656	NCT05638880	Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease	Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease	Recruiting	The prevalence of diabetes mellitus is increasing worldwide, and its complications are one of the leading causes of mortality from non-communicable diseases. Due to the high prevalence of diabetes and because 30-40% of diabetic patients [both type 1 (T1DM) and type 2 (T2DM) diabetes mellitus] develop kidney dysfunction, diabetic nephropathy (DN) is the main cause of end-stage renal disease worldwide. The renin-angiotensin-aldosterone system (RAAS), endothelin, and urotensin II are vasoactive hormones that have been extensively studied as other mediators although their relation to diabetic nephropathy is still speculative.	Parallel Assignment	Mostafa Bahaa	OTHER	All	65	40	60	Anticipated	OTHER	Tanta University	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2022-12-20	2025-12-20	2026-10-20	2022-12-06	\N	2022-12-06	\N	Tanta University	Mostafa Bahaa	Teaching Assistant	\N	\N	Sponsor-Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Diabetic Nephropathies"}	main	\N	TODO, repurpose?	f	Safety Evaluation	\N	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
397	2023-01-02 15:22:35.745	2023-03-21 12:14:05.331	NCT00895531	Comparison of Peripheral Nerve Blocks vs. Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement: A Prospective, Randomized Study	Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement	Terminated	The investigators hypothesize that patients who receive a femoral catheter with low dose epidural Depodur will experience comparable or superior pain relief than those who receive both femoral and sciatic catheters. In addition, the investigators hypothesize that the one catheter will be less time consuming to place and facilitate early ambulation of the patient.	Parallel Assignment	University of Louisville	OTHER	All	70	18	75	Actual	OTHER	University of Louisville	Randomized	\N	Single	\N	\N	Treatment	\N	After obtaining written informed consent, all patients will be sedated with 1-5 mg midazolam and up to 100 mcg fentanyl before any procedure is performed. They will be attached to standard ASA monitors and their vital signs recorded before sedation and every 5 minutes throughout the procedure. They will receive supplemental oxygen 2-4 LPM with a nasal canula. They will be given 1 g acetaminophen orally with a sip of water before sedation.\n\nThe randomization envelope will be opened and the patient will be randomized to one of the two groups.\n\nAll patients will receive a femoral nerve block after identification of the landmarks or with ultrasound guidance and a femoral catheter will be inserted perineurally. The patients will be placed supine position for the procedure. The femoral artery will be identified either by ultrasound or a hand held Doppler. A point 1 cm lateral to the femoral artery and 1 cm below the inguinal crease is marked. A 5 cm Tuohy needle (Pajunk Medical) will be inserted at a 45 angle at 1.5 mA and 1 Hz. Once a brisk quadriceps twitch is identified, the needle will be positioned accurately so as to establish quadriceps stimulation at  0.5 mA.\n\nThe peripheral nerve catheter will be inserted through the needle. Once the catheter is positioned satisfactorily in the perineural area, it will be tunneled subcutaneously and a sterile dressing will be applied to cover the catheter completely. Ropivacaine (30 mL of 0.5%) will be injected through the catheter after frequent aspirations. The block will be assessed by sensory and motor assessments at 5, 10, 15, and 30 minutes. Sensory testing will be performed on the anterior aspect of the knee (femoral nerve), medial aspect of the knee (obturator nerve) and the lateral aspect of the thigh (lateral femoral cutaneous nerve). The block will be considered complete when no cold discrimination was observed (Score 2), partial when cold discrimination was decreased (score 1), and absent when normal cold discrimination was observed (Score 0). Femoral motor block will also be assessed during the same period by testing knee extension, and will be considered complete when no extension is observed, partial when quadriceps motor force is decreased and absent when normal quadriceps function is observed. Patients with complete sensory block of the femoral and obturator nerves after 15 minutes will be included in the study.\n\nGroup I: Peripheral Nerve group: This group will have a sciatic catheter placed either before or after surgery. They will receive a sciatic catheter by subgluteal approach with the use of ultrasound. The ischial tuberosity will be identified with the ultrasound probe and its midpoint marked. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45 angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.\n\nGroup II: Depodur Group: Preoperatively this group of patients will have an L2-L3 epidural placed while they are in the sitting position before or after femoral catheter placement. They will receive 7.5 mg Depodur via the epidural catheter. All of these patients will receive Singular 10 mg and Claritin 10 mg before the epidural Depodur is placed, as per our protocol of patients receiving EREM.\n\nAll patients will receive general anesthesia with fentanyl 2 mcg/kg, ketamine 0.2 mg/kg, and propofol, as needed, for induction of anesthesia. The patients will be paralyzed with succinylcholine, rocuronium, or any other non-depolarizing muscle relaxant of choice of anesthesiologist. Analgesia will be maintained at the discretion of the anesthesiologist overseeing the case. Anesthesia will be maintained with a volatile anesthetic and oxygen or TIVA to maintain BIS between 40 and 50. Vital signs will be recorded every 15 minutes. They will also receive dexamethasone 4 mg, metoclopramide 20 mg IV at induction and ondansetron 4 mg after induction, if they have more than 40% risk of PONV as per their Apfel score.\n\nPatients will be extubated at the end of the case and transferred to PACU. If patients complain of pain, they will receive fentanyl 25-50-mcg increments as per the discretion of PACU nurse to achieve a VRS < 4. Patients may be prescribed a morphine PCA (1 mg morphine with a 6-minute lockout) for postoperative pain relief in the PACU once their pain is stable at VRS<4.\n\nAll patients will be prescribed acetaminophen 1000 mg every 6 hours for 3 days after surgery. They will be prescribed metoclopramide 20 mg IV PRN every 6 hours as rescue medication for nausea and/or vomiting for 2 days postoperatively. Patients still nauseous will get Promethazine (Phenergan) 6.25-12.5 mg as second line rescue.\n\nOnce the patients are transported to the floor, they will be monitored with continuous pulse-oximetry for the first 48 hours. Other vital signs (Pulse, NIBP and Respiratory Rate) will be monitored every hour for the first 12 hours, every 2 hrs from 12-24 hours, and every 4 hours from 24 to 48 hours (ASA 2009 Guidelines for neuraxial opioids).\n\nPostoperative knee joint rehabilitation will involve continuous passive motion (CPM) of the knee joint twice a day. The physical therapist will be asked to record the VRS on movement and the range of motion after placement of the CPM machine.	2009-12-01	2012-12-01	2012-12-01	2009-05-08	2017-07-27	2017-07-27	University Louisville	\N	\N	\N	\N	\N	Sponsor	Investigator left institution	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Arthroplasty, Replacement, Knee"}	not included	loratadine	did not find drug anywhere?	f	Knee Joint Replacement	2022-08-17 18:44:47	{}	UNKNOWN	\N	loratadine
300	2023-01-02 15:22:35.739	2023-03-20 21:46:53.735	NCT05565729	A Phase 1, Randomized, Placebo-controlled, Participant- and Investigator-blind, Single-dose Study of the Pharmacokinetics of LY3471851 Following Subcutaneous Dosing of LY3471851 in Healthy Participants	A Phase I Study of LY3471851 in Healthy Participants	Recruiting	The purpose of this study is to compare two different formulations (test & reference) of LY3471851 in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will also be collected. Participants will remain in the study for about 12 weeks, after receiving the study drug that is LY3471851.	Parallel Assignment	Eli Lilly and Company	INDUSTRY	All	64	18	42	Anticipated	INDUSTRY	Eli Lilly and Company	Randomized	\N	Double	\N	\N	Basic Science	\N	\N	2022-10-05	2023-02-07	2023-02-07	2022-10-04	\N	2022-10-20	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	combination	\N	\N	f	Bioavailability	\N	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
329	2023-01-02 15:22:35.74	2023-03-21 09:14:25.941	NCT00481676	A Randomized, 24 Weeks, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Adult Patients With Chronic Urticaria Who Exhibit IgE Against Thyroperoxidase	Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria	Completed	This study evaluated the safety and efficacy of omalizumab in adult patients with moderate to severe chronic urticaria who exhibit IgE against thyroperoxidase.	Parallel Assignment	Novartis	INDUSTRY	All	70	18	49	Actual	INDUSTRY	Novartis	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2007-05-01	2009-04-01	2009-04-01	2007-06-04	2011-10-21	2011-10-21	Novartis Pharmaceuticals	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Chronic Urticaria"}	combination	loratadine	ltd as standard medication in combination with Omalizumab	f	Urticaria	2022-08-17 18:44:47	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/21636116/	loratadine
350	2023-01-02 15:22:35.742	2023-03-21 09:41:30.162	NCT02613910	OPV117059: A Long-Term Extension Study of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris	Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris	Terminated	This study is designed as a multi-country, multicenter, open label extension to Phase III trial OPV116910. The primary objective is to provide continued treatment with ofatumumab subcutaneous (SC) for eligible subjects who complete the OPV116910 trial in order to obtain further long term safety and tolerability information in subjects with pemphigus vulgaris receiving ofatumumab SC every 4 weeks (wk).	Single Group Assignment	GlaxoSmithKline	INDUSTRY	All	\N	\N	1	Actual	INDUSTRY	GlaxoSmithKline	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2015-12-23	2016-03-23	2016-03-23	2015-11-25	2017-06-14	2017-06-14	GlaxoSmithKline	\N	\N	\N	\N	\N	Sponsor	Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{Pemphigus}	minimal	cetirizine	ctz is not really playing a big role in this trial	f	Pemphigus	2022-08-17 13:39:16	{}	UNKNOWN	\N	cetirizine
247	2023-01-02 15:22:35.736	2023-08-01 13:07:17.967	NCT03183297	A Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Pharmacokinetics and Pharmacodynamics at Two Dose Levels of JMI-001 in Comparison With Fexofenadine and Naproxen Administered in Conjunction With Alcohol.	Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001	Unknown status	This will be a double-blind, placebo-controlled study with a 4-way crossover design with subjects administered study drug (JMI-001), placebo, fexofenadine alone and naproxen alone on different study days, in conjunction with a quantity of alcohol estimated to be sufficient to produce a hangover the next day. The primary objective of the study is the evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of two different doses of JMI-001 administered in conjunction with alcohol to healthy adult subjects.	Crossover Assignment	Sen-Jam Pharmaceutical	OTHER	All	65	21	48	Anticipated	OTHER	Sen-Jam Pharmaceutical	Randomized	A Double-Blind, Placebo-Controlled, 4-Way Crossover Study	Triple	\N	\N	Prevention	\N	This will be a double-blind, placebo-controlled study with a 4-way crossover design with subjects administered study drug (JMI-001), placebo, fexofenadine alone and naproxen alone on different study days, in conjunction with a quantity of alcohol estimated to be sufficient to produce a hangover the next day. The primary objective of the study is the evaluate the pharmacokinetics and pharmacodynamics of two different doses of JMI-001 administered in conjunction with alcohol to healthy adult subjects. The secondary objective of this study is to compare the PK characteristics of fexofenadine administered as JMI-001 with administration of fexofenadine alone, and the PK characteristics of naproxen administered as JMI-001 with administration of naproxen alone. To compare overall hangover severity after administering JMI-001 with overall hangover severity after administration of fexofenadine alone or naproxen alone. To analyze possible quantitative differences in symptom profiles by treatment.	2017-08-01	2017-10-01	2017-12-01	2017-06-12	\N	2017-06-12	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{Veisalgia}	comparison	fexofenadine	not really included as main medication	f	Pharmacokinetics	2022-08-18 16:54:53	{}	UNKNOWN	\N	fexofenadine
266	2023-01-02 15:22:35.737	2023-08-01 13:15:23.883	NCT05348148	Camillian Saint Mary's Hospital Luodong	Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis	Recruiting	Background: Shiners are caused when blood and other fluids accumulate in the infraorbital groove. It develops resulting from lots of problems. In patient with rhinitis, either allergic rhinitis or non-allergic rhinitis, shiners are believed to be caused by venous stasis resulting from nasal congestion. This study is aiming that comparison of the effectiveness of treatment of rhinitis (either allergic rhinitis or non-allergic rhinitis) to lighten not only the rhinitis but also the shiners. Randomized control studies.\n\nDesign: The investigators will recruit children (6-12 y/0), adolescent (13-18 y/o), or adults (19-65 y/o) with either allergic rhinitis or non-allergic rhinitis, and patients will be randomly assigned to groups (oral antihistamine, combined nasal corticosteroids with oral antihistamine, combined nasal corticosteroids with oral antihistamine plus nasal decongestant, combined nasal corticosteroids with oral antihistamine plus nasal irrigation, combined oral antihistamine with nasal irrigation, or nasal antihistamine only). Digital image will be recorded and analyzed to compare the change of shiners between before and after treatment for rhinitis. The clinical data were collected including patient's data, history, laboratory data, Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), Adolescent Rhinoconjunctivitis Quality of Life Questionnaire (AdolRQLQ), or mini Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ), and medications. The primary outcome is to answer whether the levels of shiners can be alleviated by using therapies in patient with rhinitis. And the secondary outcome is to figure out which therapies work most effectively.\n\nKeywords: allergic rhinitis, vasomotor rhinitis, shiners, nasal corticosteroids	Parallel Assignment	Camillians Saint Mary's Hospital Luodong	OTHER	All	65	6	450	Anticipated	OTHER	Camillians Saint Mary's Hospital Luodong	Randomized	\N	Single	The independent researchers will carry out the digital image analyze.	\N	Treatment	\N	Background:\n\nShiners results from the accumulation of body fluid in the infraorbital groove. The physiology and pathology in children include nasal congestion, inammation of nose and eyes, trauma to the nose or the forehead, facial surgery, or facial cancer. In patient with either allergic rhinitis or non-allergic rhinitis, nasal congestion arouses venous stasis, leading to the blue-gray to purple discoloration under the bilateral lower eyelids, called shiners. In patients with allergic rhinitis, allergic shiners, termed by Marks since 1954, have been regarded as a significant sign of allergic rhinitis generally.\n\nIn 2009, Chiang and members established a digital-analyzed tool to quantify allergic shiners, and the results demonstrated the darkness and the area values of allergic shiners correlate with the severity of allergic rhinitis.\n\nA stepwise approach for the treatment of allergic rhinitis and non-allergic rhinitis is documented, including oral antihistamine, intranasal antihistamine, intranasal corticosteroids, intranasal decongestant, oral or intranasal leukotriene antagonist, as well as nasal irrigation, but the response of shiners after treatment, and the efficiency of the therapies to alleviate the shiners were unknown. In this study, the primary outcome is to answer whether the levels of shiners can be alleviated by using nasal therapies in patients with allergic rhinitis or non-allergic rhinitis. And the secondary outcome is to figure out which nasal therapies work most effectively.\n\nDesign:\n\nThe investigators will recruit children (6-12 years old), adolescent (13-18 years old), and adults (19-65 years old) with moderate to severe rhinitis, either allergic rhinitis or non-allergic rhinitis. Those with chronic rhinosinusitis, trauma to the forehead or nose, face surgery, malignancy, pregnancy, and respiratory tract infections or usage of medications for rhinitis within a week before beginning the study will be excluded. Study population will be classified into children, adolescent and adults according to the age.\n\nThis study will be divided into three stages. In the first stage, three kinds of therapies for rhinitis were compared. Patients will be randomly assigned into three groups. Patients in group 1 will use oral antihistamine only, another in group 2 will use combined intranasal corticosteroids with oral antihistamine, and the other in group 3 will use combined intranasal corticosteroids with oral antihistamine plus one-week intranasal decongestant. In the second stage, three kinds of therapies will be compared, including combined intranasal corticosteroids and oral antihistamine, combined intranasal corticosteroids and oral antihistamine plus nasal irrigation, and oral antihistamine plus nasal irrigation. The third stage will compare oral antihistamine only, combined intranasal corticosteroids with oral antihistamine, and intranasal antihistamine. The estimated sample size was 50 cases in each groups, and total 150 cases in each population and total 450 cases in each stage. Patients will be randomized by a randomization table. Minimization will be performed when over 100 cases in each population and in each stage.\n\nA standardized digital photograph of every participant will be recorded and further analyzed to compare the change of shiners between before and after treatment for rhinitis. The clinical data will be collected including patient's data, history, laboratory data, Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) of every children, Adolescent Rhinoconjunctivitis Quality of Life Questionnaire (AdolRQLQ) of every adolescent, or mini Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ) of every adult, and medications.\n\nDigital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.\n\nThe detail method to take a standardized digital photography, and analyze digital image were described in the previous study. Briefly, in order to standardize both the size and color of the photographs, a color checker used as a reference was set in front of the every participant's chin. Pixel, the elemental unit of digital image, was calculated in each photographs. After completing preprocess in every digital sample, the investigators converted the intensity value of each pixel into the gray level, then measured the gray-level mean values in the infraorbital groove (Sm) and cheek (Cm), respectively. Darkness (D) was equal to Cm-Sm. The blacker a shiner appeared, the bigger the darkness value was. Shiner's area value was figured out by sampling the curve of each lower eyes. The investigators translated the value from pixels to square centimeters, and finally normalized by body surface area to gain the parameter A (in square centimeters per square meter) represented as the area value of shiner.\n\nThe independent researchers will carry out the digital image analyze.\n\nThe primary outcome is to answer whether the levels of shiners can be alleviated by using therapies in patient with rhinitis. And the secondary outcome is to figure out which therapies work most effectively.\n\nStatistical analysis The investigators compared the categorical variables between the two groups using the Pearson's Chi square test. The investigators compared the continuous variables between the two groups using Mann-Whitney U test. The correlation between two parameters was analyzed by Pearson correlation test. The investigators used paired samples t-test and/or multiple regression analysis to what kind of treatment was more effective to alleviate the shiners with/without improvement of rhinitis. To account for correlation among repeated measures from the same patient, the study was analyzed with the usage of linear generalized estimating equations. A p value < 0.05 was considered statistically significant. All statistical analyses were performed with International Business Machines Corporation Statistical Product and Service Solutions statistical software (version 20.0.0, IBM Corp., Armonk, NY).	2020-06-16	2032-03-31	2032-03-31	2022-04-27	\N	2022-04-27	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Not Applicable"}	{"Allergic Rhinitis","Vasomotor Rhinitis"}	combination	cetirizine	check again for repurpose	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Marks MB. Allergic shiners. Dark circles under the eyes in children. Clin Pediatr (Phila). 1966 Nov;5(11):655-8. doi: 10.1177/000992286600501106. No abstract available.","Goren SB. Eye disorders: common ocular injuries: assessing the severity. Postgrad Med. 1975 Dec;58(7):99-102. doi: 10.1080/00325481.1975.11714225.","Chuan MT, Tsai TF, Wu MC, Wong TH. Atrophic pigmented dermatofibrosarcoma presenting as infraorbital hyperpigmentation. Dermatology. 1997;194(1):65-7. doi: 10.1159/000246061.","Lai L, Casale TB, Stokes J. Pediatric allergic rhinitis: treatment. Immunol Allergy Clin North Am. 2005 May;25(2):283-99, vi. doi: 10.1016/j.iac.2005.02.003.","Marks MB. Photo of eye depression. In: Vaughan WT, Black JR, editors. Practice of allergy. Philadelphia: C.V. Mosby Co; 1954. p. 1023","MARKS MB. Nasal allergy in childhood. Observations in the South Florida area. Ann Allergy. 1960 Oct;18:1110-6. No abstract available.","Marks MB. Significance of discoloration in the lower orbitopalpebral grooves in allergic children (allergic shiners). Ann Allergy 1963;21:26-32.","Berger WE. Allergic rhinitis in children : diagnosis and management strategies. Paediatr Drugs. 2004;6(4):233-50. doi: 10.2165/00148581-200406040-00003.","Quillen DM, Feller DB. Diagnosing rhinitis: allergic vs. nonallergic. Am Fam Physician. 2006 May 1;73(9):1583-90.","Prenner BM, Schenkel E. Allergic rhinitis: treatment based on patient profiles. Am J Med. 2006 Mar;119(3):230-7. doi: 10.1016/j.amjmed.2005.06.015.","Chen CH, Lin YT, Wen CY, Wang LC, Lin KH, Chiu SH, Yang YH, Lee JH, Chiang BL. Quantitative assessment of allergic shiners in children with allergic rhinitis. J Allergy Clin Immunol. 2009 Mar;123(3):665-71, 671.e1-6. doi: 10.1016/j.jaci.2008.12.1108.","Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001 Nov;108(5 Suppl):S147-334. doi: 10.1067/mai.2001.118891. No abstract available.","Sur DKC, Plesa ML. Chronic Nonallergic Rhinitis. Am Fam Physician. 2018 Aug 1;98(3):171-176.","Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T, Durham SR, Farooque S, Jones N, Leech S, Nasser SM, Powell R, Roberts G, Rotiroti G, Simpson A, Smith H, Clark AT. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 2017 Jul;47(7):856-889. doi: 10.1111/cea.12953.","Agnihotri NT, McGrath KG. Allergic and nonallergic rhinitis. Allergy Asthma Proc. 2019 Nov 1;40(6):376-379. doi: 10.2500/aap.2019.40.4251.","Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, Azar A, Baroody FM, Bachert C, Canonica GW, Chacko T, Cingi C, Ciprandi G, Corey J, Cox LS, Creticos PS, Custovic A, Damask C, DeConde A, DelGaudio JM, Ebert CS, Eloy JA, Flanagan CE, Fokkens WJ, Franzese C, Gosepath J, Halderman A, Hamilton RG, Hoffman HJ, Hohlfeld JM, Houser SM, Hwang PH, Incorvaia C, Jarvis D, Khalid AN, Kilpelainen M, Kingdom TT, Krouse H, Larenas-Linnemann D, Laury AM, Lee SE, Levy JM, Luong AU, Marple BF, McCoul ED, McMains KC, Melen E, Mims JW, Moscato G, Mullol J, Nelson HS, Patadia M, Pawankar R, Pfaar O, Platt MP, Reisacher W, Rondon C, Rudmik L, Ryan M, Sastre J, Schlosser RJ, Settipane RA, Sharma HP, Sheikh A, Smith TL, Tantilipikorn P, Tversky JR, Veling MC, Wang Y, Westman M, Wickman M, Zacharek M. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018 Feb;8(2):108-352. doi: 10.1002/alr.22073.","Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, Brignardello-Petersen R, Canonica GW, Casale T, Chavannes NH, Correia de Sousa J, Cruz AA, Cuello-Garcia CA, Demoly P, Dykewicz M, Etxeandia-Ikobaltzeta I, Florez ID, Fokkens W, Fonseca J, Hellings PW, Klimek L, Kowalski S, Kuna P, Laisaar KT, Larenas-Linnemann DE, Lodrup Carlsen KC, Manning PJ, Meltzer E, Mullol J, Muraro A, O'Hehir R, Ohta K, Panzner P, Papadopoulos N, Park HS, Passalacqua G, Pawankar R, Price D, Riva JJ, Roldan Y, Ryan D, Sadeghirad B, Samolinski B, Schmid-Grendelmeier P, Sheikh A, Togias A, Valero A, Valiulis A, Valovirta E, Ventresca M, Wallace D, Waserman S, Wickman M, Wiercioch W, Yepes-Nunez JJ, Zhang L, Zhang Y, Zidarn M, Zuberbier T, Schunemann HJ. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017 Oct;140(4):950-958. doi: 10.1016/j.jaci.2017.03.050. Epub 2017 Jun 8.","Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. N Engl J Med. 2015 Jan 29;372(5):456-63. doi: 10.1056/NEJMcp1412282.","Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, Dawson DE, Dykewicz MS, Hackell JM, Han JK, Ishman SL, Krouse HJ, Malekzadeh S, Mims JW, Omole FS, Reddy WD, Wallace DV, Walsh SA, Warren BE, Wilson MN, Nnacheta LC; Guideline Otolaryngology Development Group. AAO-HNSF. Clinical practice guideline: Allergic rhinitis. Otolaryngol Head Neck Surg. 2015 Feb;152(1 Suppl):S1-43. doi: 10.1177/0194599814561600.","Sur DK, Plesa ML. Treatment of Allergic Rhinitis. Am Fam Physician. 2015 Dec 1;92(11):985-92.","Piromchai P, Puvatanond C, Kirtsreesakul V, Chaiyasate S, Thanaviratananich S. Effectiveness of nasal irrigation devices: a Thai multicentre survey. PeerJ. 2019 May 27;7:e7000. doi: 10.7717/peerj.7000. eCollection 2019.","Chong LY, Head K, Hopkins C, Philpott C, Glew S, Scadding G, Burton MJ, Schilder AG. Saline irrigation for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016 Apr 26;4(4):CD011995. doi: 10.1002/14651858.CD011995.pub2.","Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol. 1998 Feb;101(2 Pt 1):163-70. doi: 10.1016/s0091-6749(98)70380-x.","Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. 1994 Feb;93(2):413-23. doi: 10.1016/0091-6749(94)90349-2.","Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy. 2000 Jan;30(1):132-40. doi: 10.1046/j.1365-2222.2000.00668.x."}	NO_PUBLICATION_FOUND	\N	levocetirizine
289	2023-01-02 15:22:35.738	2023-03-20 21:36:53.021	NCT03371849	A Randomized, Open Label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of HCP1102 in Comparison to HGP0813 and HGP1408 Administered in Healthy Male Volunteers	PK and Safety Study of HCP1102, HGP0813 and HGP1408	Completed	This study is a randomized, open label, single dose, two-way crossover clinical trial to investigate the pharmacokinetics and safety/tolerability of HCP1102 in comparison to HGP0813 and HGP1408 administered in healthy male volunteers.	Crossover Assignment	Hanmi Pharmaceutical Company Limited	INDUSTRY	Male	45	19	24	Actual	INDUSTRY	Hanmi Pharmaceutical Company Limited	Randomized	\N	None (Open Label)	\N	\N	Basic Science	\N	\N	2017-07-19	2017-08-03	2017-08-03	2017-12-13	\N	2017-12-13	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	combination	levocetirizine	\N	f	Pharmacokinetics	2022-09-15 18:58:14	{"Moon SJ, Yu KS, Jung J, Kim YI, Kim MG. Comparative pharmacokinetics of a montelukast/levocetirizine fixed-dose combination chewable tablet versus individual administration of montelukast and levocetirizine after a single oral administration in healthy Korean male subjects . Int J Clin Pharmacol Ther. 2020 Jun;58(6):354-362. doi: 10.5414/CP203709."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/32271144/	levocetirizine
41	2023-01-02 15:22:35.724	2023-03-20 09:27:53.942	NCT01563081	A Multi-Center, Open-labelled Study to Evaluate the Safety of Levocetirizine Hydrochloride Oral Solution in Children Aged 6 Months to 2 Years With Allergic Rhinitis or Pruritus Associated With the Skin Diseases.	Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics	Completed	To evaluate the safety of treatment with levocetirizine oral solution in pediatric patients aged form 6 months to 2 years old with allergic rhinitis or pruritus associated with the skin diseases.	Single Group Assignment	GlaxoSmithKline	INDUSTRY	All	1.916666666666667	0.5	60	Actual	INDUSTRY	GlaxoSmithKline	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	This is a multi-center, open-labelled study to confirm the safety as main objective, and consisting of minimum 1-week screening period and 2-week treatment period. The subjects who meet the inclusion criteria are to be placed on one of the following two regimens according to their ages at the start of treatment period: once daily administration of levocetirizine at a dose of 1.25 mg (in the morning) to infants aged between 6 months and 1 year old (younger age group), and twice daily administration of levocetirizine at a dose of 1.25 mg (in the morning, in the evening before sleep) to infants aged between 1 year and 2 years old (older age group).	2012-04-01	2012-08-01	2012-08-01	2012-03-26	2013-06-03	2017-02-28	GlaxoSmithKline	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{Rhinitis}	main	cetirizine	\N	f	Safety Evaluation	2022-08-17 13:39:16	{}	CT_RESULTS	\N	levocetirizine
346	2023-01-02 15:22:35.741	2023-03-21 09:35:46.369	NCT02771249	Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers	Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers	Completed	People with human immunodeficiency virus (HIV) often take several medicines to control HIV. Dolutegravir and darunavir boosted with cobicistat are HIV medicines that people may take. They may also need to take medicines for an infection called latent tuberculosis (TB). Researchers think a once-weekly treatment for latent TB would be easier for people with HIV to take. This once weekly treatment consists of two drugs: rifapentine and isoniazid. However, they need to see how TB drugs and HIV drugs interact.\n\nObjective:\n\nTo learn how anti-HIV and anti-TB drugs affect each other so that people taking these drugs together can be treated safely.\n\nEligibility:\n\nHealthy adults ages 18 65.\n\nDesign:\n\nParticipants will be screened with a medical history and physical exam. They will have vital signs taken and give a blood sample. Women will have a pregnancy test.\n\nParticipants cannot take any other medicines during the study, including vitamins. Only occasional, infrequent use of acetaminophen (Tylenol , max 2000 mg/day), ibuprofen (Motrin or Advil ), naproxen (Aleve ), loperamide (Imodium ), and/or antihistamines (such as Benadryl , Zyrtec , Claritin , etc.) will be allowed.\n\nParticipants will be assigned to one of three groups. Each group will take a different study drug, once or twice a day, for 19 23 days. At the baseline study visit, they will get a supply of the study drug tablets and instructions for taking them. Participants will keep a medicine diary to serve as a memory aid for taking medicine and reporting any side effects that they may experience.\n\nParticipants will have 8 or 9 study visits over about 40 days. The number of visits depends on which group the person is assigned to. All visits will take place at the NIH Clinical Center. Participants will fast before study visits.\n\nThe baseline visit will last about 2 3 hours. There will be 3-4 long visits that will last for about 12 hours. The other 4-5 visits will last about 1 hour.\n\nDuring all study visits, screening procedures will be repeated. During long visits, an intravenous (IV) line will be inserted into an arm vein with a needle. It will be used to take blood.	Single Group Assignment	National Institutes of Health Clinical Center (CC)	NIH	All	65	18	37	Actual	NIH	National Institutes of Health Clinical Center (CC)	N/A	\N	None (Open Label)	\N	\N	Basic Science	\N	Rifapentine (RPT) is a long-acting rifamycin that can be used weekly with isoniazid (INH) as a first-line regimen in the treatment of latent tuberculosis infection (LTBI). Although this regimen offers several potential benefits, the use of weekly RPT plus INH is not currently recommended in adults infected with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) due to limited evidence on drug interactions with antiretrovirals (ARVs).1Darunavir boosted with cobicistat (DRV/c) comprises part of alternative treatment regimens recommended for the treatment of HIV.2However, drug interactions between these ARV agents and RPT are of concern. Thus, the purpose of this study is to determine the effects of concomitant RPT and INH administration on the steady state PK of DRV/c.\n\nThis is an open-label, fixed sequence, intrasubject drug-drug interaction study designed to evaluate the steady state PK of DRV/c with coadministration of once weekly RPT and INH given at doses used to treat LTBI. Arm B will be comprised of two phases: (1) DRV/c once daily alone (days 1-4) and (2) DRV/c once daily + (RPT and INH) once weekly (days 5-19). Participants in Arm B will undergo periodic serial ARV PK blood draws on days 4, 14, and 19.\n\nDRV/c PK parameters will be determined using non-compartmental methods. Cobicistat levels will only be assessed if DRV concentrations are significantly decreased. The following PK parameters will be compared between phases: area under the curve over the dosing interval, maximum plasma concentration, time to maximum plasma concentration, terminal half-life, apparent oral clearance, and minimum plasma concentration. Adverse events will be graded and recorded.	2016-06-03	2021-08-17	2021-08-17	2016-05-13	\N	2022-04-18	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"HIV Infected Population With Latent Tuberculosis"}	not included	cetirizine	Only in description because it may be taken during trial	f	HIV	2022-08-17 13:39:16	{"Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011 Jul 7;365(1):11-20. doi: 10.1056/NEJMoa1005136.","Brooks KM, George JM, Pau AK, Rupert A, Mehaffy C, De P, Dobos KM, Kellogg A, McLaughlin M, McManus M, Alfaro RM, Hadigan C, Kovacs JA, Kumar P. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine. Clin Infect Dis. 2018 Jul 2;67(2):193-201. doi: 10.1093/cid/ciy082."}	UNKNOWN	\N	cetirizine
362	2023-01-02 15:22:35.743	2023-08-01 18:37:15.326	NCT02495077	Randomized Controlled Trial of Infliximab (Remicade) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)	Effects of Inhibiting Early Inflammation in Kidney Transplant Patients	Completed	During transplant surgery, there is a period of time when a donated kidney is removed from a donor's body and stored until the time of the transplant surgery. The storage procedure results in buildup of various proteins within the kidney that can injure the donated kidney after it is transplanted. One of these proteins is tumor necrosis factor-alpha (TNF-alpha).\n\nThe purpose of this study is to evaluate whether taking infliximab, which blocks tumor necrosis factor alpha (TNF-alpha), just prior to transplant surgery, along with usual transplant medicines will protect the donated kidney from damage caused by TNF-alpha and help keep the transplanted kidney healthy for a longer period of time.	Parallel Assignment	National Institute of Allergy and Infectious Diseases (NIAID)	NIH	All	\N	18	290	Actual	NIH	National Institute of Allergy and Infectious Diseases (NIAID)	Randomized	\N	Triple	\N	\N	Treatment	\N	This is a Phase 2, multicenter, randomized, double blind (masked), placebo-controlled, 2-arm clinical trial of 300 deceased donor kidney transplant recipients. Participants will be randomized (1:1) to the experimental or control arm (150 subjects per arm).	2015-11-02	2021-07-23	2021-07-23	2015-07-13	2022-08-16	2022-08-16	DAIT/NIAID	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Kidney Transplant"}	pre-medication	loratadine	ToDo	f	Infusion Reaction	2022-08-17 18:44:47	{}	CT_RESULTS	\N	loratadine
318	2023-01-02 15:22:35.74	2023-03-21 08:51:43.52	NCT00623701	A Multicentre, Multinational, Placebo-controlled, Double-blind, Randomized Study to Evaluate Efficacy and Safety of a Perennial, Sublingual, Specific Immunotherapy in Patients With Rhinoconjunctivitis With/Without Controlled Asthma Caused by Grass Pollen	Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation	Completed	Efficacy and Safety from a high-dosed sublingual grass pollen preparation	Parallel Assignment	Allergopharma GmbH & Co. KG	INDUSTRY	All	65	18	126	Actual	INDUSTRY	Allergopharma GmbH & Co. KG	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2008-03-01	2011-10-01	2012-10-01	2008-02-26	\N	2013-11-08	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{Allergy,Rhinitis,Conjunctivitis}	not included	\N	ALLEGRA6 is study identifier, fexofenadine is not included	f	\N	\N	{}	UNKNOWN	\N	fexofenadine
283	2023-01-02 15:22:35.738	2023-03-20 21:33:53.808	NCT03590912	Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion (OME) Compared to That of Combination of Antibiotic, Antihistaminic, and Nasal Decongestant	Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion	Completed	We intend to study the cost of treatment, efficacy and adverse effects for Otitis media with effusion.	Parallel Assignment	Lumbini Medical College	OTHER	All	12	1	160	Actual	OTHER	Lumbini Medical College	Randomized	\N	Double	\N	\N	Treatment	\N	Treatment groups would be:\n\nCefpodoxime + oxymetaxoline drops + levocetirizine\nFluticasone intranasal spray\nShort term oral steroids\nWait and watch	2018-09-05	2020-02-16	2020-03-18	2018-07-18	\N	2020-06-19	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 4"}	{"Otitis Media With Effusion"}	combination	cetirizine	\N	f	Otitis Media	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
374	2023-01-02 15:22:35.742	2023-08-01 18:41:40.343	NCT04179461	Personalized Treatment Algorithms for Difficult-to-treat Asthma: Bench to Community	Personalized Treatment Algorithms for Difficult-to-treat Asthma	Completed	Asthma is a common, complex and costly chronic condition. Moreover, asthma is heterogeneous in terms of treatment response. This heterogeneity contributes to the difficulty in both studying and treating asthma. This is a pilot study to improve health outcomes in youths with difficult to treat asthma with ongoing symptoms and healthcare utilization despite medium to high doses of inhaled corticosteroids. Asthma heterogeneity in both disease pathophysiology and treatment response contributes to the difficulty in both studying and managing asthma. In order to begin to develop personalized algorithms for patients, investigators need to model novel biomarkers and other factors that contribute to individual differences in asthma outcome and test other factors that contribute to individual differences in asthma outcome and test personalized treatment strategies.	Single Group Assignment	Children's Hospital Medical Center, Cincinnati	OTHER	All	17	6	21	Actual	OTHER	Children's Hospital Medical Center, Cincinnati	N/A	The study has 3 study phases: baseline, intervention, and observation. Each participant will independently transition through these study phases.\n\nBaseline period: Each participant will be given a treatment recommendation according to their asthma severity/control using the National Asthma Education and Prevention Program (NAEPP asthma guidelines).\n\nIntervention period: Each participant will be given a personalized treatment plan based on their asthma severity/control during the baseline period, biologic, and environmental factors.\n\nObservation period: All participants will be observed for at least 6 months. Investigators will track the participant's personal outcomes (comparing to baseline) for reutilization, symptom-free days, and quality of life.	None (Open Label)	\N	\N	Treatment	\N	With this study investigators will conduct study visits to determine and quantify known molecular, genetic, genomic, epigenetics, immunologic, and exposure biomarkers that will help elucidate molecular disease endotype within the difficult-to-treat phenotype. This information will be used along with clinical, psychosocial, and adherence data to develop a personalized treatment plan. Following the personalized treatment plan, study clinicians will prescribe the medications through a home delivery or routine pharmacy depending on the family's preference and covered by the participant's health insurance. Investigators will track disease outcome metrics including exacerbations, symptom-free days, and asthma symptom scores to determine the effectiveness of this personalized approach.	2018-03-16	2019-10-03	2019-10-03	2019-11-27	2021-08-20	2021-08-20	Cincinnati Children's Hospital Medical Center	Children's Hospital Medical Center, Cincinnati	Theresa Guilbert, MD	Principal Investigator	\N	\N	Principal Investigator	\N	Interventional	{Child}	{"Phase 2"}	{"Asthma in Children"}	combination	cetirizine	TODO	f	Asthma	2022-08-17 13:39:16	{"Guilbert TW, Biagini JM, Ramsey RR, Keidel K, Curtsinger K, Kroner JW, Durrani SR, Stevens M, Pilipenko V, Martin LJ, Kercsmar CM, Hommel K, Hershey GKK. Treatment by biomarker-informed endotype vs guideline care in children with difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2022 May;128(5):535-543.e6. doi: 10.1016/j.anai.2022.01.030. Epub 2022 Feb 3."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/35123074/	cetirizine|loratadine
57	2023-01-02 15:22:35.722	2023-03-20 14:50:56.742	NCT00637455	Single Center, Randomized,Double-Blind,Crossover Study Comparing the Effects of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel	Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel	Completed	To compare the effects of fexofenadine HCl 180 mg, cetirizine 10 mg, and placebo on computerized scores derived from the Aeromedical Vigilance Task (AVT), a computerized objective measure of attention, accuracy and reaction time in healthy naval flight personnel. Specifically, the primary objective is to compare the AVT overall (average of the 18 blocks) mean change from baseline in total number of errors (commission errors + omission errors) between fexofenadine HCl and cetirizine 10 mg. Safety of these single-dose treatments also will be assessed.	Crossover Assignment	Sanofi	INDUSTRY	All	\N	18	72	Actual	INDUSTRY	Sanofi	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2003-09-01	\N	2005-01-01	2008-03-18	\N	2011-01-11	\N	\N	\N	\N	Study Director	sanofi-aventis	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	comparison	cetirizine	\N	f	Safety Evaluation	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	fexofenadine|cetirizine
355	2023-01-02 15:22:35.742	2023-03-21 09:46:43.204	NCT02401191	A Non-controlled, Open Study for Assessing the Safety and Effectiveness of a Twice-daily FEX 60 mg - PE 10 mg (FEX60/PE10) Fixed Combination Tablet in Patients With Allergic Rhinitis	A Study Assessing the Safety and Effectiveness of FEX60/PE10 Fixed Combination Tablet in Patients With Allergic Rhinitis	Completed	Primary Objective:\n\nTo assess the safety of twice-daily fexofenadine 60 mg/phenylephrine 10 mg (FEX60/PE10) combination tablet in patients with allergic rhinitis.\n\nSecondary Objective:\n\nTo evaluate the effectiveness of a twice-daily FEX60/PE10 combination tablet on nasal symptoms (sneezing, rhinorrhea, and nasal congestion), and daily activity impairment.	Single Group Assignment	Sanofi	INDUSTRY	All	\N	15	105	Actual	INDUSTRY	Sanofi	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	It will be 22 days at minimum and up to 32 days depending on screening, treatment, and post-treatment observation allowances.	2015-03-01	2015-07-01	2015-07-01	2015-03-27	\N	2015-11-30	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Rhinitis Allergic"}	combination	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
417	2023-01-02 15:22:35.746	2023-03-21 13:31:38.078	NCT04709575	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis	Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis	Completed	The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.	Parallel Assignment	Regeneron Pharmaceuticals	INDUSTRY	All	\N	18	353	Actual	INDUSTRY	Regeneron Pharmaceuticals	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2021-01-14	2021-08-24	2021-08-24	2021-01-14	2022-10-27	2022-10-27	Regeneron Pharmaceuticals, Inc	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Allergic Rhinitis",Conjunctivitis}	not included	desloratadine	desltd only as outcome measure	f	Allergic Rhinitis	2022-09-15 19:16:20	{}	CT_RESULTS	\N	desloratadine
332	2023-01-02 15:22:35.74	2023-03-21 09:18:19.006	NCT00866788	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)	A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)	Completed	The study is a Phase II, dose-ranging, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of a single subcutaneously administered omalizumab dose as add-on therapy for the treatment of adolescent and adult patients 12-75 years old who have been diagnosed with CIU and remain symptomatic despite treatment with therapeutic doses of an H1 antihistamine. The study will enroll approximately 76 patients at approximately 45 study centers in the United States and Germany.	Parallel Assignment	Genentech, Inc.	INDUSTRY	All	75	12	90	Actual	INDUSTRY	Genentech, Inc.	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2009-03-01	2010-01-01	2010-01-01	2009-03-23	2011-09-09	2017-07-11	Hoffmann-LaRoche	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 2"}	{"Chronic Idiopathic Urticaria"}	combination	cetirizine	other H1RAs were also allowed	f	Urticaria	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
354	2023-01-02 15:22:35.742	2023-03-21 09:46:10.632	NCT05476679	An Open Label Phase 2 Study to Evaluate the Effects of a Local Anesthetic, Anti-inflammatory Medications and Compression Garments on RZL-012-Induced Adverse Events	Evaluation the Effects of a Local Anesthetic, Anti-inflammatory Medications and Compression Garments on RZL-012-Induced Adverse Events	Not yet recruiting	This is a Phase 2, open-label, 2-stage, adaptive-design study in which subjects will be randomized into one of 5 treatment groups comprised of RZL-012 with or without additional study treatments:	Single Group Assignment	Raziel Therapeutics Ltd.	INDUSTRY	All	65	18	75	Anticipated	INDUSTRY	Raziel Therapeutics Ltd.	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	In the first stage of the study, 5 subjects will be randomized into each of the treatment groups. Study outcomes will be assessed up to one week thereafter to determine the need to modify additional study treatments. Subsequently up to 10 additional subjects will be randomized into each of the treatment groups for the second stage of the study.\n\nFor each subject, the study will consist of a screening period, baseline period in which subjects will receive a single treatment session of RZL-012 and a follow-up period. RZL-012 will be administered during a single treatment session via multiple injections into the submental area under the chin. Subjects will thereafter be monitored for safety and efficacy for at least 84 days.\n\nEach subject will be treated with the same dose of RZL-012 :\n\n RZL-012 (concentration of injected solution 50 mg/mL RZL-012) of 7.5 mg/0.15 mL/injection point that results in a total dose/volume of 24030mg mg/4.80.6 mL RZL-012, Each subject will receive additional study treatments in accordance with the treatment group to which the subject is randomized.	2022-09-25	2023-03-30	2023-06-15	2022-07-27	\N	2022-07-27	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1","Phase 2"}	{"Submental Fat"}	minimal	cetirizine	Todo usecase	f	Safety Evaluation	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
403	2023-01-02 15:22:35.745	2023-03-21 12:21:38.587	NCT02577029	A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination With Other Therapeutics in Patients With Chronic Hepatitis B Virus (HBV) Infection (MONARCH)	Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)	Terminated	Patients with chronic HBV infection will receive either ARC-520 alone or ARC-520 in combination with other treatments such as entecavir (ENT) or tenofovir (TDF) and/or pegylated interferon (PEG IFN) alpha 2a therapy, and be evaluated for safety and efficacy.	Parallel Assignment	Arrowhead Pharmaceuticals	INDUSTRY	All	75	18	79	Actual	INDUSTRY	Arrowhead Pharmaceuticals	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	This is a multicenter, open-label study of ARC-520 based treatment regimens administered to patients with HBeAg positive or HBeAg negative immune active chronic Hepatitis B Virus (HBV) infection of various genotypes, or patients with Hepatitis D Virus (HDV). Eligible patients naive to previous treatment, and who have signed an Ethics Committee - approved informed consent, will be enrolled and will receive ARC-520 alone or ARC-520 plus additional treatments such as entecavir (ETV) or tenofovir (TDF) and/or pegylated interferon alpha 2a (PEG IFN) therapy. The study may initially involve up to a total of 96 eligible chronic HBV and HDV infected patients. Patients in all cohorts will receive a total of 13 doses of ARC-520 at 2mg/kg or 4 mg/kg. Patients will undergo the following evaluations at regular intervals during the study: medical history, physical examinations, vital sign measurements (blood pressure, heart rate, respiratory rate, and temperature), weight, adverse events assessment (AEs), 12-lead ECGs, liver fibrosis testing, concomitant medication assessment, blood sample collection for hematology, coagulation, chemistry, exploratory Pharmacodynamic (PD) measures, urinalysis, HBV serology, cytokines, Follicle Stimulating Hormone (FSH) testing (post-menopausal females) and pregnancy testing for females of childbearing potential. Clinically significant changes including AEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the patient is lost to follow-up. For each patient, the duration of the study is approximately 96 weeks, from enrolment to last visit. Prior to enrolment there is a 60 day screening period. Addition of new cohorts and additional treatment regimens are anticipated for this study.	2015-12-01	2016-12-01	2016-12-01	2015-10-15	2019-04-12	2019-04-12	Arrowhead Pharmaceuticals, Inc.	\N	\N	\N	\N	\N	Sponsor	Company decision to discontinue trial	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Hepatitis B","Hepatitis D"}	pre-medication	cetirizine	could also be use case Infusion Reaction	f	Hepatitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
340	2023-01-02 15:22:35.741	2023-03-21 09:26:40.111	NCT02966665	Vascular Function in Health & Disease: Rehabilitation for Hypertension; Exercise and Skeletal Muscle Afferent Feedback	: Vascular Function in Health and Disease	Recruiting	Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perfusion to the muscle tissue is the host of chemical factors originating from the vascular endothelium and the muscle tissue, which collectively sets the level of vascular tone. With advancing age and in many disease states, deleterious adaptations in the production and sensitivity of these vasodilator and vasoconstrictor substances may be observed, leading to a reduction in skeletal muscle blood flow and compromised perfusion to the muscle tissue. Adequate perfusion is particularly important during exercise to meet the increased metabolic demand of the exercising tissue, and thus any condition that reduces tissue perfusion may limit the capacity for physical activity. As it is now well established that regular physical activity is a key component in maintaining cardiovascular health with advancing age, there is a clear need for further studies in populations where vascular dysfunction is compromised, with the goal of identifying the mechanisms responsible for the dysfunction and exploring whether these maladaptations may be remediable. Thus, to better understand the etiology of these vascular adaptations in health and disease, the current proposal is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease. While there are clearly a host of vasoactive substances which collectively act to govern vasoconstriction both at rest and during exercise, four specific pathways that may be implicated have been identified in these populations: Angiotensin-II (ANG-II), Endothelin-1 (ET-1), Nitric Oxide (NO), and oxidative stress.	Parallel Assignment	Russell Richardson	OTHER	All	\N	18	420	Anticipated	OTHER	University of Utah	Non-Randomized	\N	None (Open Label)	\N	\N	Basic Science	\N	Angiotensin-II (ANG-II) is the end-product of the renin-angiotensin cascade, and acts as a potent endogenous vasoconstrictor through binding to the angiotensin receptor (AT1) on arteriolar vascular smooth muscle. With advancing age, there is a notable decline in plasma renin activity accompanied by decrements in circulating ANG-II and an increase in AT1 receptor density. However, the functional consequence of this age-related adaptation of the renin-angiotensin system (RAS) on the peripheral circulation is not well understood. Likewise, in recent years it has become apparent that cardiovascular disease is a major cause of morbidity in COPD, which may be related to vascular dysfunction and associated adoption of a sedentary lifestyle. In these patients, changes in RAS activity have been linked to peripheral vascular dysfunction, with compelling evidence for improvements in peripheral oxygen use following angiotensin-converting enzyme (ACE) inhibition. Like the aging population, systematic studies evaluating AT1 receptor sensitivity and the efficacy of AT1 receptor blockade on peripheral hemodynamics have not been undertaken.\n\nThe ubiquitous substance nitric oxide (NO) is now recognized as a key pathway for endothelium-dependent vasodilation, with the bioavailability of NO serving as an indicator for overall vascular health. Cardiac risk factors have been shown to cause impairment in endothelial vasodilator function in both the peripheral and coronary arteries. Coronary vascular dysfunction is an important phase in atherogenesis and is associated with myocardial ischemia. Furthermore, peripheral vascular function has been linked to coronary vascular dysfunction which could have important clinical implications in terms of health screening. Impaired endothelium-dependent vasodilation has been associated with the elderly, patients with COPD, and most cardiovascular diseases including pulmonary hypertension, and heart failure (HF), though the functional consequence of this adaptation on peripheral blood flow regulation remains unclear. Thus, we propose the use of a compound which inhibits the enzyme responsible for NO production in endothelial cells, N-monomethyl-L-arginine (L-NMMA), to temporarily block production of NO and thus determine the importance of this pathway at rest and during physical activity. Additionally, we propose the use of acetylcholine (Ach) to determine endothelial-dependent vasodilation and sodium nitroprusside (SNP) and nitroglycerin (NTG) to determine the endothelial-independent vasodilation in the coronary arteries and the periphery. Oxidative stress associated with aging has been shown to reduce vascular function and antioxidant supplementation restores vascular function to levels that are indistinguishable from healthy young adults. The manner by which this improvement in vascular function occurs is not known by may be acting through a NO dependent mechanism.\n\nHistamine has been reported to mediate sustained post-exercise vasodilation through histamine-1 (H1) and histamine-2 (H2) receptor activity, which results in a ~50% elevation in femoral artery blood flow (above resting levels) that lasts for more than 100 minutes after a single bout of moderate-intensity dynamic exercise. Vasodilation can be markedly reduced by giving either fexofenadine (Allegra, a selective H1-receptor antagonist) or ranitidine (Zantac, a selective H2-receptor antagonist). The combination of H1/H2 blockade abolishes ~80% of the post-exercise vasodilation seen after whole-body exercise such as cycling and this observation has been observed in multiple studies in young sedentary, recreationally active, and endurance trained men and women. The impact of histamine on the post-exercise vasodilatory response is substantial; however, the role of H1/H2 receptors in regulating skeletal muscle blood flow during exercise is unknown. Thus, we intend to investigate the role of H1/H2 receptors in the regulation of skeletal muscle blood during exercise as this may be an important pathway in age and disease related reductions in blood flow during exercise.\n\nExercise training and rehabilitation can be used as an alternative approach to combat the deleterious effects oxidative stress on aging and disease. An effective exercise training intervention can decrease sympathetic nervous system activity, improve arterial compliance and vascular endothelial function, and alter the pro- and antioxidant balance resulting in improved endogenous antioxidant defense mechanisms. Moreover, exercise training concomitantly improves musculoskeletal strength and function, glucose regulation and insulin sensitivity, cardiovascular function, body composition, blood chemistry (decreased triglyceride and cholesterol levels), and overall well-being. The physiologic effect of an exercise rehabilitation program in diseases such as COPD, and pulmonary arterial hypertension (PAH) is incompletely understood. However, recent studies suggest that exercise training in this patient population is well tolerated and associated with clinically significant physiologic improvements as well as improvements in various quality of life scores.\n\nA unique feature of the proposed studies identified herein is the inclusion of a novel methodological approach to comprehensively evaluate the functional outcome of the proposed pharmacologic interventions. The recent development of a unique combination of nuclear magnetic resonance (NMR) techniques by members of our group enables near-simultaneous measurements of both muscle perfusion and metabolism in vivo. The arterial spin labeling (ASL) technique allows the measurement of both spatially and temporally resolved quantification of perfusion, while the kinetics of phosphocreatine (PCr) depletion and recovery provide high resolution measurements of muscle energetics. The interweaving of these imaging and spectroscopic modules provides the opportunity for determination of skeletal muscle perfusion and metabolism kinetics during and following the stress of physical exercise. Thus, this NMR-based approach, combined with direct measures of muscle fatigue, offers the potential to further define the individual and collective contribution of these variables to the attenuated limb blood flow in the elderly and in patients with COPD and PAH.\n\nWe propose that each of these pathways outlined above represent an avenue by which vascular function is compromised in the elderly and in patients with COPD, PAH and cardiovascular disease. However, because these pathways are not mutually exclusive, the proposed studies are designed to systematically evaluate hemodynamic responses to intra-arterial or intravenous administration of pharmacologic agents specific for the AT1 receptor (ANG-II and Diovan, AT1 agonist and antagonist, respectively), the Endothelin receptor Type-A (ETA receptor) (BQ-123, ETA antagonist), and the NO pathway (L-NMMA, Ach, and SNP) both before and after exercise training.	2008-09-01	2025-08-01	2025-08-01	2016-11-17	\N	2022-10-05	\N	University of Utah	Russell Richardson	Ph.D.	\N	\N	Sponsor-Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Chronic Obstructive Pulmonary Disease","Pulmonary Artery Hypertension","Heart Failure",Hypertension}	pre-medication	fexofenadine	Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).	f	Vascular Function	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
310	2023-01-02 15:22:35.739	2023-03-20 21:58:26.5	NCT02583594	A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis	A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis	Completed	Primary Objective:\n\nTo characterize the pharmacodynamic profile of 2 treatment courses of alemtuzumab administered by subcutaneous injection and 2 treatment courses of alemtuzumab administered by intravenous infusion in patients with progressive multiple sclerosis.\n\nSecondary Objectives:\n\nTo characterize the pharmacokinetic profiles of alemtuzumab administered by subcutaneous injection or intravenous infusion to patients with progressive multiple sclerosis.\nTo characterize the safety and tolerability of alemtuzumab administered by subcutaneous injection or intravenous infusion to patients with progressive multiple sclerosis.	Parallel Assignment	Genzyme, a Sanofi Company	INDUSTRY	All	\N	18	24	Actual	INDUSTRY	Sanofi	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	The duration of study per patient will be approximately 61 months.	2015-12-06	2016-03-01	2021-03-01	2015-10-22	\N	2021-03-10	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Progressive Multiple Sclerosis"}	pre-medication	cetirizine	\N	f	Infusion Reaction	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	loratadine|cetirizine
344	2023-01-02 15:22:35.741	2023-03-21 09:34:27.81	NCT02435563	Dose Adaptation to Offset the Pharmacokinetic Interaction Between Ticagrelor and Ritonavir in Healthy Volunteers by Population-based PK Modeling (Simcyp)	Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling	Completed	Ticagrelor is a new generation antiplatelet agent with higher efficacy as compared to clopidogrel and prasugrel in treatment of patients with moderate and high ischemic risks. Ticagrelor is active as such and its hepatic metabolism by CYP3A generates also an active metabolite. Because of the remarkable progress in HIV therapies the number of older age patients is on the rise, requiring adequate cardiovascular treatment. Since frontline HIV therapies include ritonavir, a strong inhibitor of CYP3A enzyme, ticagrelor is contraindicated in these patients because of the expected interaction and bleeding risk. A lower efficacy of clopidogrel and prasugrel, which are both pro-drugs, in the presence of ritonavir has been already demonstrated. Therefore, administration of a lower dose of ticagrelor may be a good alternative in HIV patients in order to lessen the impact of this pharmacokinetic interaction. The aim of this study is to adjust the dose of ticagrelor in case of co-treatment with ritonavir to achieve the same pharmacokinetic profile as administered alone using a physiologically-based pharmacokinetic (PBPK) model.\n\nAs the first step, a pharmacokinetic (PK) model for ticagrelor and its active metabolite will be created based on available in vitro and in vivo parameters in healthy volunteers.\n\nAn open-label, 2 sessions cross over study will be conducted with 20 healthy male volunteers at Clinical Research Center (CRC) of Geneva University Hospitals (HUG). During the first session of the clinical trial, a single dose 180 mg ticagrelor will be administered to the volunteers and obtained pharmacokinetic data will be fitted into the model for optimization. Thereafter a simulated trial by the Simcyp simulator in presence of a single dose 100 mg ritonavir will allow evaluating the impact of CYP3A inhibition on the concentration-time profile of ticagrelor and its active metabolite. The necessary dose of ticagrelor to minimize the magnitude of this interaction will be calculated. This new dose will be co-administered with ritonavir in the same volunteers during the second session of the clinical trial. The purpose is to obtain the same PK profile with single dose of 180 mg ticagrelor administered alone and with an adapted dose of ticagrelor co-administered with a single dose 100 mg ritonavir. Moreover, the pharmacodynamic effect of ticagrelor will be measured in both sessions of the clinical trial using two specific platelet function tests: the VAsodilator-Stimulated Phosphoprotein assay (VASP) and VerifyNow P2Y12. With the same PK profile, the same pharmacodynamic activity is expected. The modulation of activity of CYP3A and P-gp by ritonavir will be also monitored using micro dose midazolam and fexofenadine as probe substrates.\n\nThe purpose of this study is to use the Simcyp Simulator mechanistic PBPK modeling to broaden the application field of ticagrelor, especially in HIV patients. Since PK models are often created after clinical observations, the prospective aspect of this study is of particular value as the model will be first created and then applied to an unknown clinical scenario.	Crossover Assignment	University Hospital, Geneva	OTHER	Male	60	18	22	Actual	OTHER	University Hospital, Geneva	Non-Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2014-08-01	2015-04-01	2015-04-01	2015-05-06	\N	2017-02-07	\N	University Hospital, Geneva	Jules Desmeules	Dr	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Phase 2"}	{Healthy}	minimal	fexofenadine	TODO but fex only as probe substance\nCheck if publication is correct	f	Pharmacokinetics	2022-08-18 16:54:53	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/27264793/	fexofenadine
288	2023-01-02 15:22:35.738	2023-03-20 21:36:05.653	NCT00610584	Acupuncture for Seasonal Allergic Rhinitis (ACUSAR) - A Randomised Controlled Trial	Acupuncture for Seasonal Allergic Rhinitis	Completed	Acupuncture is widely use by patients with seasonal allergic rhinitis (SAR), although there is only limited evidence of its effectiveness. The aim of this three armed randomised controlled multicentre trial is to investigate the efficacy of acupuncture plus rescue medication vs. minimal (sham) acupuncture plus rescue medication vs. (b) rescue medication alone in the treatment of seasonal allergic rhinitis.	Parallel Assignment	Charite University, Berlin, Germany	OTHER	All	45	16	422	Actual	OTHER	Charite University, Berlin, Germany	Randomized	\N	Single	\N	\N	Treatment	\N	Acupuncture is widely use by patients with seasonal allergic rhinitis (SAR), although there is only limited evidence of its effectiveness. The aims of this 3-armed, randomised controlled trial are to investigate whether acupuncture plus rescue medication is non-inferior (closed testing procedure: in case of success in non-inferiority: test of superiority) to minimal acupuncture plus rescue medication in the treatment of SAR (closed testing procedure: closed testing procedure: in case of success in non-inferiority: test of superiority), and whether acupuncture plus rescue medication is non-inferior to rescue medication alone consisting only of oral antihistamines for this indication. The trial interventions will be performed in approximately 40 outpatient centres in Germany. In total, 400 patients with SAR will be randomised to one of three groups: acupuncture plus rescue medication, minimal acupuncture (i.e. superficial needling at non-acupuncture points) plus rescue medication, or rescue medication only. Rescue medication will consist of oral antihistamines. Acupuncture and minimal acupuncture will be administered by physicians specialised in acupuncture and will consist of 12 sessions per patient in the first 8 weeks. Patients in the rescue medication group will receive 12 sessions of acupuncture after 8 weeks. The primary outcome measures will be the mean of Rhinitis Quality of Life Questionnaire score (RQLQ scores between weeks 6 and 8 of the first year (adjusted for baseline values) and the Rescue Medication Score (RMS) between weeks 6 and 8 of the first year (adjusted for baseline values).	2008-04-01	2011-04-01	2011-04-01	2008-02-08	\N	2012-10-23	\N	Charite University, Berlin, Germany	Benno Brinkhaus	Prof. MD	\N	\N	Principal Investigator	\N	Interventional	{Child,Adult}	{"Not Applicable"}	{"Seasonal Allergic Rhinitis"}	rescue medication	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Adam D, Grabenhenrich L, Ortiz M, Binting S, Reinhold T, Brinkhaus B. Impact of acupuncture on antihistamine use in patients suffering seasonal allergic rhinitis: secondary analysis of results from a randomised controlled trial. Acupunct Med. 2018 Jun;36(3):139-145. doi: 10.1136/acupmed-2017-011382. Epub 2018 Feb 10.","Ortiz M, Witt CM, Binting S, Helmreich C, Hummelsberger J, Pfab F, Wullinger M, Irnich D, Linde K, Niggemann B, Willich SN, Brinkhaus B. A randomised multicentre trial of acupuncture in patients with seasonal allergic rhinitis--trial intervention including physician and treatment characteristics. BMC Complement Altern Med. 2014 Apr 6;14:128. doi: 10.1186/1472-6882-14-128.","Reinhold T, Roll S, Willich SN, Ortiz M, Witt CM, Brinkhaus B. Cost-effectiveness for acupuncture in seasonal allergic rhinitis: economic results of the ACUSAR trial. Ann Allergy Asthma Immunol. 2013 Jul;111(1):56-63. doi: 10.1016/j.anai.2013.04.008. Epub 2013 May 3.","Brinkhaus B, Ortiz M, Witt CM, Roll S, Linde K, Pfab F, Niggemann B, Hummelsberger J, Treszl A, Ring J, Zuberbier T, Wegscheider K, Willich SN. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med. 2013 Feb 19;158(4):225-34. doi: 10.7326/0003-4819-158-4-201302190-00002."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/23420231/	cetirizine
307	2023-01-02 15:22:35.739	2023-03-20 21:56:21.018	NCT01484119	Multi-center, Double-blind, Double-dummy, Randomized, Placebo-controlled, Active-reference, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-129968 in Adolescent, Adult & Elderly Patients With Seasonal Allergic Rhinitis	Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis	Completed	This study will assess the efficacy and safety of ACT-129968 in adolescent, adult and elderly patients with seasonal allergic rhinitis, due to mountain cedar pollen.	Parallel Assignment	Idorsia Pharmaceuticals Ltd.	INDUSTRY	All	76	12	630	Actual	INDUSTRY	Idorsia Pharmaceuticals Ltd.	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2011-12-01	2012-02-01	2012-03-01	2011-12-02	\N	2018-09-28	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	control	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Ratner P, Andrews CP, Hampel FC, Martin B, Mohar DE, Bourrelly D, Danaietash P, Mangialaio S, Dingemanse J, Hmissi A, van Bavel J. Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies. Allergy Asthma Clin Immunol. 2017 Apr 4;13:18. doi: 10.1186/s13223-017-0183-z. eCollection 2017."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/28392807/	cetirizine
326	2023-01-02 15:22:35.74	2023-03-21 09:11:25.095	NCT02590185	Xploring Venlafaxine Pharmacokinetic Variability by a Phenotyping Approach	MetAbolism vaRiability of VEnLafaxine	Unknown status	Regarding the direct costs and the social value of depression, the decision of an antidepressant treatment prescription must be optimized as much as possible. The development of a personalized medicine in psychiatry may reduce treatment failure, intolerance or resistance, and hence burden and costs of affective disorders.\n\nThere is hope that biomarkers will be found to guide treatment selection. It might be of decisive interest to be able to assess an individual's metabolism activity. We propose here to explore the relationship between the activity of drug-metabolizing enzymes (DME) and transporters- assessed by a phenotypic approach and the efficacy of antidepressants. We will focus on venlafaxine (V) that provides a reasonable second-step choice for patients with depression and is used extensively in psychiatric practice, and the metabolism of which involves several cytochromes (CYP) P450 enzymes and the transporter P-gp.\n\nThus, the primary objective of this study is to study the correlation between the concentration of V and its metabolite ODesmethylV (V+ODV) and drug metabolism variability assessed by a phenotypic approach, in patients with major depressive disorder and MADRS  20 despite 4 weeks of V at 150mg or less	Single Group Assignment	Assistance Publique - Hpitaux de Paris	OTHER	All	80	18	205	Anticipated	OTHER	Assistance Publique - Hpitaux de Paris	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2015-12-01	2019-12-01	2020-04-01	2015-10-28	\N	2019-02-19	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{"Major Depressive Disorders"}	combination	fexofenadine	Prev. usecase was despression	f	Pharmacokinetics	2022-08-18 16:54:53	{"Lloret-Linares C, Daali Y, Chevret S, Nieto I, Moliere F, Courtet P, Galtier F, Richieri RM, Morange S, Llorca PM, El-Hage W, Desmidt T, Haesebaert F, Vignaud P, Holtzmann J, Cracowski JL, Leboyer M, Yrondi A, Calvas F, Yon L, Le Corvoisier P, Doumy O, Heron K, Montange D, Davani S, Deglon J, Besson M, Desmeules J, Haffen E, Bellivier F. Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study). BMC Pharmacol Toxicol. 2017 Nov 7;18(1):70. doi: 10.1186/s40360-017-0173-2."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/29115994/	\N
358	2023-01-02 15:22:35.742	2023-03-21 09:47:59.414	NCT00727727	Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices.	SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)	Completed	The objective of the Post Marketing Surveillance Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Neurologists in private practices in Germany should document the safety and course of the disease/change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonist treatment under routine conditions. Piribedil should be prescribed according to its marketing authorisation.	\N	Desitin Arzneimittel GmbH	INDUSTRY	All	\N	18	750	Anticipated	INDUSTRY	Desitin Arzneimittel GmbH	\N	\N	\N	\N	\N	\N	Prospective	\N	2008-03-01	2008-12-01	2008-12-01	2008-08-04	\N	2009-02-25	\N	\N	\N	\N	Dr. Martina Wangemann	Desitin Arzneimittel GmbH	\N	\N	Observational	{Adult,"Older Adult"}	{}	{"Parkinson's Disease"}	not included	loratadine	Clarium  ldt	f	Parkinson	2022-08-17 18:44:47	{"Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P; Parkinson-Control Study Group. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord. 2006 Apr;21(4):500-9. doi: 10.1002/mds.20750.","Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A; Parkinson REGAIN Study Group. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Mov Disord. 2006 Dec;21(12):2110-5. doi: 10.1002/mds.21122.","Rascol O, Pathak A, Bagheri H, Montastruc JL. Dopaminagonists and fibrotic valvular heart disease: further considerations. Mov Disord. 2004 Dec;19(12):1524-5. doi: 10.1002/mds.20328. No abstract available."}	UNKNOWN	\N	loratadine
259	2023-01-02 15:22:35.736	2023-03-20 21:17:37.859	NCT01033396	A Randomized, Double Blind, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of PF-03654764 +/- Allegra (Fexofenadine) On Symptoms Of Allergic Rhinitis In Subjects Exposed To Ragweed Pollen In An Environmental Exposure Unit.	The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis	Completed	PF-03654764 should reduce the symptoms of allergic rhinitis. In this study patients will be exposed to pollen and their symptoms observed.	Crossover Assignment	Pfizer	INDUSTRY	All	60	18	64	Actual	INDUSTRY	Pfizer	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2010-01-01	2010-05-01	2010-05-01	2009-12-16	\N	2010-08-17	\N	\N	\N	\N	Director, Clinical Trial Disclosure Group	Pfizer, Inc.	\N	\N	Interventional	{Adult}	{"Phase 2"}	{"Allergic Rhinitis"}	combination	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{"North ML, Walker TJ, Steacy LM, Hobsbawn BG, Allan RJ, Hackman F, Sun X, Day AG, Ellis AK. Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit. Allergy Asthma Clin Immunol. 2014 Jul 3;10(1):33. doi: 10.1186/1710-1492-10-33. eCollection 2014."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/25024716/	fexofenadine
315	2023-01-02 15:22:35.74	2023-03-20 22:05:33.746	NCT00517946	An Investigation to Evaluate the Technique of MRI as an Assessment of the Effect of Anti-allergy Drug Treatment on Internal Nasal and Sinus Mucosal Anatomy Following Intranasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis.	A Study To Investigate If MRI Scanning Is Effective At Seeing What Hayfever Drugs Do In Nasal Passage.	Completed	The purpose of this study is to establish whether MRI scanning is a sensitive measure of the effects of existing drug treatments on nasal dimensions following challenge with intranasal allergen in subjects with hayfever. If successful this technique could be applied to increase confidence for internal decision making and ultimately may be used to assess how effective a new drug treatment is.	\N	GlaxoSmithKline	INDUSTRY	All	60	18	21	Actual	INDUSTRY	GlaxoSmithKline	\N	\N	\N	\N	\N	\N	\N	\N	2007-03-01	2007-04-01	2007-04-01	2007-08-17	\N	2013-09-02	\N	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Adult}	{}	{"Seasonal Allergic Rhinitis",Sinusitis}	minimal	cetirizine	Could be this: https://pubmed.ncbi.nlm.nih.gov/26733348/#affiliation-1\nTODO: Check publication again	f	Imaging	2022-08-17 13:39:16	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/26733348/	cetirizine
342	2023-01-02 15:22:35.741	2023-03-21 09:31:02.574	NCT02517957	\N	Xia Shi Surgical Treatment for Eczema Multi-center Clinical Research	Unknown status	On the basis of Xiashi skin surgery clinical experience, this project adopts the multicenter, randomized, double-blind, controlled trial of design type. Objective, normative evaluation of traditional Chinese medicine cool blood latent town effectiveness of therapeutic regimen in the treatment of eczema, security, and control of the relapse of situation, provide high-level evidence-based basis for traditional Chinese medicine treatment of eczema, aims to form suitable for popularization and application of traditional Chinese medicine in the treatment of eczema.	Parallel Assignment	Shanghai Yueyang Integrated Medicine Hospital	OTHER	All	65	18	342	Anticipated	OTHER	Shanghai Yueyang Integrated Medicine Hospital	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2015-08-01	2017-08-01	\N	2015-08-07	\N	2015-08-07	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{Eczema}	combination	loratadine	\N	f	Eczema	2022-08-17 18:44:47	{}	PUBLISHED	https://www.researchgate.net/publication/355869449_Efficacy_of_a_Chinese_Herbal_Medicine_Qinzhuliangxue_Granules_for_The_Treatment_of_Eczema_A_Randomized_Double-Blind_Multi-Center_Clinical_Trial	loratadine
372	2023-01-02 15:22:35.743	2023-03-21 10:49:41.705	NCT04489121	The Efficacy of Preseasonal Omalizumab Treatment in Seasonal Allergic Rhinitis Patients	The Efficacy of Preseasonal Omalizumab Treatment	Completed	Allergic rhinitis (AR) is induced by an immunoglobulin E (IgE)-mediated reaction in the allergen-sensitized subjects, affecting 10% to 40% of the world population. AR could be divided into two kinds, perennial AR and seasonal AR (SAR).\n\nIn recent years, biologics have become promising drugs for allergic diseases. The efficacy and safety of Omalizumab in treating SAR have been well proven by previous studies. However, the efficacy in preseasonal treatment for SAR has not yet been studied before.	Parallel Assignment	Beijing Tongren Hospital	OTHER	All	60	18	31	Actual	OTHER	Beijing Tongren Hospital	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2020-07-28	2020-09-26	2020-10-01	2020-07-28	\N	2021-01-28	\N	Beijing Tongren Hospital	Luo Zhang	President, Beijing TongRen Hospital	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Not Applicable"}	{"Seasonal Allergic Rhinitis"}	rescue medication	loratadine	not really included, only as outcome measure	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/35024137/	loratadine
276	2023-01-02 15:22:35.737	2023-03-20 21:28:54.378	NCT00974571	A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis	Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)	Completed	This study will assess the ability of montelukast to improve the signs and symptoms of perennial allergic rhinitis compared to placebo. Cetirizine is included in the study as an active control.	Parallel Assignment	Organon and Co	INDUSTRY	All	85	15	1365	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2001-11-01	2002-05-01	2002-05-01	2009-09-10	2010-06-07	2022-02-03	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Perennial Allergic Rhinitis"}	control	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Philip G, Williams-Herman D, Patel P, Weinstein SF, Alon A, Gilles L, Tozzi CA, Dass SB, Reiss TF. Efficacy of montelukast for treating perennial allergic rhinitis. Allergy Asthma Proc. 2007 May-Jun;28(3):296-304. doi: 10.2500/aap.2007.28.3000."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/17619558/	cetirizine
351	2023-01-02 15:22:35.742	2023-03-21 09:41:47.401	NCT05115136	The Use of Doxepin for Urticaria in the Emergency Department	Using Doxepin for Urticaria	Recruiting	Isolated urticaria in the emergency department is widely treated by physicians with histamine blocking agents such as diphenhydramine, cetirizine, and cimetidine. Doxepin is a tricyclic antidepressant that has been shown to have much higher concentrations of histamine blocking activity and therefore may be useful in treating urticaria. The purpose of this study is to compare the effectiveness of using doxepin verses a traditional medication, diphenhydramine (Benadryl), in the treatment of isolated urticaria in the emergency department.	Parallel Assignment	State University of New York - Upstate Medical University	OTHER	All	65	18	160	Anticipated	OTHER	State University of New York - Upstate Medical University	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2022-05-23	2023-01-31	2023-07-01	2021-11-10	\N	2022-05-18	\N	State University of New York - Upstate Medical University	David Andonian	Principal Investigator	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{Urticaria}	not included	cetirizine	Certizine not included, only mentioned in description	f	Urticaria	2022-08-17 13:39:16	{}	UNKNOWN	\N	cetirizine
404	2023-01-02 15:22:35.745	2023-03-21 12:22:58.656	NCT02604199	A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Negative, Chronic Hepatitis B Virus (HBV) Infection	A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection	Terminated	Patients with chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.	Parallel Assignment	Arrowhead Pharmaceuticals	INDUSTRY	All	75	18	58	Actual	INDUSTRY	Arrowhead Pharmaceuticals	Randomized	\N	Quadruple	\N	\N	Treatment	\N	This is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study of ARC-520 in combination with entecavir or tenofovir administered to patients with Hepatitis B 'e' Antigen (HBeAg) negative and immune active chronic HBV infection. Eligible patients who have signed an Ethics Committee - approved informed consent, will be enrolled and will receive ARC-520 or placebo in combination with entecavir or tenofovir. The study will enroll up to a total of 60 eligible chronic HBV infected patients. Patients will undergo the following evaluations at regular intervals during the study: medical history, physical examinations, vital sign measurements (blood pressure, heart rate, respiratory rate and temperature), weight, adverse events assessment (AEs), 12-lead electrocardiograms (ECGs), liver fibrosis testing, concomitant medication assessment, blood sample collection for hematology, coagulation,chemistry, lactate, Pharmacokinetic (PK) measures (in a subset of patients), exploratory Pharmacodynamic (PD) measures, urinalysis, HBV serology, Follicle Stimulating Hormone (FSH) testing (post-menopausal females) and pregnancy testing for females of childbearing potential. Clinically significant changes including AEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the patient is lost to follow-up. For each patient, the duration of the study is approximately 33 weeks from screening to the Day 169 follow-up visit. For patients enrolling into a planned extension study, the total duration of this study is approximately 25 weeks from screening to Day 113 end of study visit.	2015-09-01	2017-01-01	2017-01-01	2015-11-13	2019-04-16	2019-04-16	Arrowhead Pharmaceuticals, Inc.	\N	\N	\N	\N	\N	Sponsor	Company decision to discontinue trial	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Hepatitis B"}	pre-medication	cetirizine	\N	f	Hepatitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
316	2023-01-02 15:22:35.739	2023-03-20 22:06:48.941	NCT02024152	\N	Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg	Completed	This study is to investigate the pharmacokinetics (PK) together with the safety and tolerability of JDP-205 at 5 mg and 10 mg intravenous doses and 10 mg intramuscular dose, in comparison to the marketed cetirizine oral product Zyrtec 10 mg tablets (an OTC product) in healthy male and female volunteers after a single dose administration.	Crossover Assignment	JDP Therapeutics, Inc.	INDUSTRY	All	\N	18	24	Actual	INDUSTRY	JDP Therapeutics, Inc.	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2011-03-01	2011-07-01	2011-07-01	2013-12-31	\N	2014-01-03	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Acute Urticaria"}	comparison	cetirizine	\N	f	Urticaria	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
339	2023-01-02 15:22:35.741	2023-08-01 18:23:43.676	NCT03994731	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (Pegloticase) (MIRROR Randomized Controlled Trial [RCT])	Study of KRYSTEXXA (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout	Completed	The purpose of this study is to assess the potential for pegloticase with methotrexate (MTX) to increase the response rate seen with pegloticase alone, and to characterize the safety, tolerability and pharmacokinetics (PK) of the concomitant use of pegloticase with MTX, by comparing pegloticase co-administered with MTX to pegloticase co-administered with placebo for MTX in adults with uncontrolled gout.	Parallel Assignment	Horizon Therapeutics Ireland DAC	INDUSTRY	All	\N	18	152	Actual	INDUSTRY	Horizon Pharma Ireland, Ltd., Dublin Ireland	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2019-06-13	2021-03-17	2022-04-11	2019-06-21	2022-05-16	2022-05-16	Horizon Therapeutics USA, Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Gout}	minimal	fexofenadine	Fex only for prevention of infusion reaction\nTODO	f	Infusion Reaction	2022-08-18 16:54:53	{}	CT_RESULTS	\N	fexofenadine
359	2023-01-02 15:22:35.742	2023-03-21 09:48:05.478	NCT00725478	Stabilization on, or Change-over to the Non-ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Parkinson Clinic Ambulances and Larger Private Practices.	SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease	Completed	The aim of the non-interventional Post Marketing Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Tolerability and course of the disease or change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonists will be documented under routine conditions. Piribedil should be prescribed according to its marketing authorisation by the responsible neurologist.	\N	Desitin Arzneimittel GmbH	INDUSTRY	All	\N	18	250	Actual	INDUSTRY	Desitin Arzneimittel GmbH	\N	\N	\N	\N	\N	\N	Prospective	\N	2008-01-01	2008-06-01	2008-06-01	2008-07-30	\N	2010-03-31	\N	\N	\N	\N	Dr. Martina Wangemann	Desitin Arzneimittel GmbH	\N	\N	Observational	{Adult,"Older Adult"}	{}	{"Parkinson's Disease"}	not included	loratadine	Clarium  ldt	f	Parkinson	2022-08-17 18:44:47	{"Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P; Parkinson-Control Study Group. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord. 2006 Apr;21(4):500-9. doi: 10.1002/mds.20750.","Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A; Parkinson REGAIN Study Group. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Mov Disord. 2006 Dec;21(12):2110-5. doi: 10.1002/mds.21122.","Rascol O, Pathak A, Bagheri H, Montastruc JL. Dopaminagonists and fibrotic valvular heart disease: further considerations. Mov Disord. 2004 Dec;19(12):1524-5. doi: 10.1002/mds.20328. No abstract available."}	UNKNOWN	\N	loratadine
303	2023-01-02 15:22:35.739	2023-03-19 21:24:16.751	NCT04248712	A Phase II, Randomized, Placebo-controlled Study Evaluating the Efficacy of Antihistamines in the Treatment of Eosinophilic Esophagitis (the ATEE Study)	Antihistamines in Eosinophilic Esophagitis	Terminated	Researchers are assessing the safety and effectiveness of antihistamines in the treatment of eosinophilic esophagitis.	Parallel Assignment	Mayo Clinic	OTHER	All	\N	18	1	Actual	OTHER	Mayo Clinic	Randomized	\N	Single	\N	\N	Treatment	\N	The purpose of this research is to determine if antihistamines are safe and effective for the treatment of eosinophilic esophagitis. Antihistamines are frequently used for the treatment of gastroesophageal reflux disease and allergic disorders, and we hypothesize they will be effective in the treatment of eosinophilic esophagitis as well. The two antihistamines used in this study are loratadine and famotidine.	2020-07-10	2021-12-31	2021-12-31	2020-01-30	2022-12-20	2022-12-20	Mayo Clinic	Mayo Clinic	Dawn Francis	Principal Investigator	\N	\N	Principal Investigator	low enrollment	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Eosinophilic Esophagitis"}	combination	loratadine	\N	t	Eosinophilic Esophagitis	2022-08-17 18:44:47	{}	CT_RESULTS	\N	loratadine
312	2023-01-02 15:22:35.737	2023-03-20 22:00:17.391	NCT00862225	Randomized, Double-blind Prospective Clinical Study to Examine the Mechanism of Action of IG-RD-001 (Ze-339) Compared to Desloratadine and Placebo in Patients With Seasonal Allergic Rhinitis Who Are Sensitized to Grasses	MOA Study of Ze 339 in Seasonal Allergic Rhinitis	Completed	Randomised, double-blind and prospective clinical study to examine the mechanism of action of the Petasites hybridus leaf extract IG-RD-001 (Ze-339, petasol butenoate complex) compared to desloratadine and placebo in patients with seasonal allergic rhinitis of all degrees of severity (provoked by grasses). The treatment arm with desloratadine is an established standard treatment and is intended to ensure the comparative methodology of the study.	Crossover Assignment	Max Zeller Soehne AG	INDUSTRY	All	\N	18	18	Actual	INDUSTRY	Max Zeller Soehne AG	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2008-01-01	2008-04-01	2008-12-01	2009-03-16	\N	2012-01-26	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Seasonal Allergic Rhinitis"}	comparison	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
336	2023-01-02 15:22:35.741	2023-03-21 09:21:54.495	NCT01241214	A Multi-center, Double-blind, Randomized, Placebo-controlled, Active Reference, Parallel-group, Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis	Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis	Completed	This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.	Parallel Assignment	Idorsia Pharmaceuticals Ltd.	INDUSTRY	All	70	18	579	Actual	INDUSTRY	Idorsia Pharmaceuticals Ltd.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2010-11-01	2011-02-01	2011-02-01	2010-11-16	\N	2019-05-15	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Seasonal Allergic Rhinitis"}	control	cetirizine	ctz as reference	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Ratner P, Andrews CP, Hampel FC, Martin B, Mohar DE, Bourrelly D, Danaietash P, Mangialaio S, Dingemanse J, Hmissi A, van Bavel J. Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies. Allergy Asthma Clin Immunol. 2017 Apr 4;13:18. doi: 10.1186/s13223-017-0183-z. eCollection 2017."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/28392807/	cetirizine
370	2023-01-02 15:22:35.743	2023-03-21 10:45:14.43	NCT03523221	Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis	Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis	Recruiting	Anaphylaxis is an acute serious allergic reaction, with multi-organ system manifestations caused by the release of chemical mediators and it is potentially fatal .\n\nBetween 5% and 14% of patients may experience a recurrence of anaphylaxis 8-12 hours after the initial presentation, called biphasic (late-phase) .\n\nThe mainstay of treatment for children experiencing anaphylaxis remains adrenaline and H1-antihistamines. Corticosteroids are not life-saving and do not have an immediate effect on the symptoms of anaphylaxis but may help reduce or prevent a biphasic "late phase" reaction .\n\nThe aim of this study is to compare the efficacy of oral glucocorticoids in prevention of the second phase or biphasic reaction of anaphylaxis, as compared to placebo in children, presenting to the pediatric emergency department (PEC Al-Sadd) with mild to moderate anaphylaxis (Prospective Study).\n\nPatients will be randomized to either one of the two treatment:\n\nTreatment 1: Dexamethasone 0.6mg/kg oral. Treatment 2 : Placebo All patients will be urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of the study medications orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.\n\nThe treating physician will discharge patient when he/she looks well, breathing comfortably, has oxygen saturation >94%, stable blood pressure and no gastrointestinal or neurological manifestation.\n\nDischarge patients will be sent home on anti-histamine (cetirizine) for 5days. All patients will be followed up for one week post discharge by a phone call asking about the general condition, relapse of symptoms, or need for readmission.	Parallel Assignment	Hamad Medical Corporation	INDUSTRY	All	14	0.25	210	Anticipated	INDUSTRY	Hamad Medical Corporation	Randomized	\N	Single	\N	\N	Treatment	\N	Anaphylaxis is an acute serious allergic reaction, with multi-organ system manifestations caused by the release of chemical mediators . It requires immediate recognition and intervention.\n\nThe estimated rate of anaphylaxis in children was 10.5 per 100,000 persons-years . Although the Rochester Epidemiology Project showed a rate of 75.1 per 100,000 person-years in children aged 9 years and 65.2 per 100,000 person-years in children aged 10-19-years old.\n\nIn the state of Qatar with approximately 280,000 visits annually to Pediatric Emergency Center (PEC), there were 171 cases of anaphylaxis seen at the facility from September 2015 to September 2016.\n\nAnaphylaxis is a clinical diagnosis based on typical systemic manifestations, due to exposure to a causative agent. There are many possible triggers, including food, medication, insect venoms, rubber latex and vaccines . In some individuals, anaphylaxis is idiopathic. Both IgE and non-IgE activation of mast cells and basophils that results in the release and production of several inflammatory and vasoactive substances, these substances most commonly involve the skin, respiratory, cardiovascular, and gastrointestinal systems. As a result, urticarial, angioedema, bronchospasm, laryngospasm, increased vascular permeability and decreased vascular tone.\n\nAnaphylaxis involves a range of signs and symptoms from hives, wheezing and angioedema to cardiovascular collapse and death [9,10]. More than 80% of the patients will present with flushing, itching, hives, angioedema, or other skin or mucosal symptoms. Generally up to 70%, at least 2 organ systems (skin, respiratory, cardiovascular, gastrointestinal systems) are involved; however, only 10-45% have cardiovascular symptoms, including chest pain, hypotension, or shock . Between 5% and 14% of patients may experience a recurrence of anaphlactoid reaction 8-12 hours after the initial presentation, called Biphasic (late-phase) . Most of these reactions are mild or moderate . Risk factors for biphasic reactions include a severe initial reaction; presence of laryngeal edema or hypotension; delay in the administration of adrenaline (epinephrine); too small a dose of adrenaline; and a history of a previous biphasic reaction . Delayed symptoms can develop despite treatment .\n\nThe mainstay of treatment for children experiencing anaphylaxis remains adrenaline 1:1000 intramuscularly (IM) . H1-antihistamines are also commonly administered in anaphylaxis. The combination of H1 and H2 antihistamines appears to be more effective, especially for cutaneous symptoms . The onset of activity of these agents is slower than epinephrine and is considered next-in-line treatment.\n\nInternational guidelines consider antihistamines and glucocorticoids as second-line . Corticosteroids are not life-saving and do not have an immediate effect on the symptoms of anaphylaxis, since it takes 4-6 hours to work.\n\nGlucocorticoids are administered to 50% of individuals with anaphylaxis, despite a lack of compelling evidence supporting their use.\n\nRecent retrospective study in emergency department, evaluated the association between glucocorticoids administration and prolonged length of stay. In 4years retrospective chart review study on anaphylaxis patient, 70% of study patients received glucocorticoids as part of their treatment. Glucocorticoids were not found to reduce follow up revisit in the three days post discharge. And it didn't decrease the likelihood of extra epinephrine need for flare of symptoms, and only found to decrease length of stay in severe anaphylaxis.\n\nThe existing evidence for the use of glucocorticoids appears to consist mainly of retrospective studies, case reports, and other descriptive literature. The need exists, however, for a prospective study on the use of glucocorticoids in the treatment of anaphylaxis and its effectiveness in prevention of biphasic reaction. The objective of the current study, therefore, is to complement the current research on anaphylaxis and to investigate if glucocorticoids are effective in the treatment of anaphylaxis and if it can prevent or limit biphasic reaction.\n\nThis will be the first randomized controlled trial to look at steroid use in anaphylaxis and its impact on anaphylaxis treatment on a prospective fashion which will be used to help standardize care in the use of steroid for this common condition.	2018-04-15	2022-04-01	2022-09-01	2018-05-14	\N	2021-08-31	\N	Hamad Medical Corporation	DR. KHALID AL-ANSARI	Director of Pediatrics Emergency Centeres	\N	\N	Principal Investigator	\N	Interventional	{Child}	{"Phase 1"}	{Anaphylaxis}	minimal	cetirizine	Discharge patients will be sent home on anti-histamine (cetirizine) for 5days. All patients will be followed up for one week post discharge by a phone call asking about the general condition, relapse of symptoms, or need for readmission.	f	Anaphylaxis	2022-08-17 13:39:16	{"Burroughs-Ray DC, Wells DR, Dennis MM, Jackson CD. Clinical Guideline Highlights for the Hospitalist: Anaphylaxis Management in Adults and Children. J Hosp Med. 2021 Feb;16(2):98-99. doi: 10.12788/jhm.3553."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/33496659/	cetirizine
371	2023-01-02 15:22:35.743	2023-03-21 10:48:02.432	NCT01125644	Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study	Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis	Unknown status	Recruitment of at least 10 adult patients (men and women) among individuals affected and admitted to the hospitals identified for the clinical study. All patients shall be between 18 and 75 years of age, with confirmed diagnosis of cryptococcosis or aspergillosis . During therapy (14 days) and examination (28 days), the patients will be subject to 7 doctor's visits (day 1,3,7,10,14,21, and 28).	Single Group Assignment	Proaparts srl	INDUSTRY	All	75	18	10	Anticipated	INDUSTRY	Proaparts srl	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	Objective: primary objective Evaluation of the overall global clinical response based on secondary end points from 1 to 6 at the end of the therapy (Study day 14) and at the final visit at the end of the study - follow-up- (Study day 28) in comparison to the initial clinical state.\n\nThe evaluation will be based on: improvement/normalization in relation to the semi-quantitative scales at 3, 4 and 5 items or at opinion expressed as positive for at least 3 of the first 6 secondary end points.\n\nsecondary objectives\n\nImprovement on the basis of clinical symptoms;\nAntifungal efficacy from the cultures;\nImprovement on the basis of mycological blood testing;\nImprovement on the basis of laboratory diagnosis (hemogasanalysis, ESR, CPR);\nImprovement on the basis of radiological imaging (Rx, CAT HR,);\nImprovement on the basis of endoscopic examination;\nEvaluate the plasma levels of SPK-843 after single dose and after multiple doses;\nEvaluate the safety in the administration of SPK-843.\n\nMethodology: Open label multi center study	2010-05-01	2011-10-01	2011-12-01	2010-05-18	\N	2011-06-08	\N	\N	\N	\N	Tiberio Bruzzese	Proaparts srl	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Cryptococcosis or Aspergillosis Infections"}	not included	fexofenadine	Study director's name is allegra	f	Cryptococcosis	2022-08-18 16:54:53	{}	UNKNOWN	\N	fexofenadine
385	2023-01-02 15:22:35.744	2023-03-21 11:08:45.068	NCT00310466	A Multicentre, Randomised, Double-blind, Placebo-controlled Parallel Group Clinical Trial to Investigate the Efficacy and Safety of Specific Sublingual Immunotherapy With SLITone Birch in Patients With Seasonal Birch Pollen Induced Rhinoconjunctivitis	Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever	Completed	The trial is performed to assess the efficacy and safety of SLIT One birch for treatment of birch pollen induced allergy	Parallel Assignment	ALK-Abell A/S	INDUSTRY	All	65	18	226	Actual	INDUSTRY	ALK-Abell A/S	Randomized	\N	Double	\N	\N	Treatment	\N	Daily rhinoconjunctivits symptom and medication scores from patient diaries, adverse events	2005-06-01	2006-08-01	2007-01-01	2006-04-04	2009-08-06	2013-05-14	ALK-Abell A/S	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{Allergy}	rescue medication	desloratadine	\N	f	Allergy	2022-09-15 19:16:20	{}	CT_RESULTS	\N	desloratadine
401	2023-01-02 15:22:35.745	2023-03-21 12:19:33.184	NCT02205489	Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA	Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA	Completed	Primary Objective:\n\nTo assess the distribution of IARs by severity grade when LEMTRADA is administered to RRMS patients who will be medicated according to specified algorithm designed to manage infusion associated reactions.	Single Group Assignment	Genzyme, a Sanofi Company	INDUSTRY	All	\N	18	58	Actual	INDUSTRY	Sanofi	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	The total duration of participation in the study per patient is approximately 13.5 months.\n\nAfter the end of the second course of LEMTRADA treatment, patients will be followed by their physician in a regular healthcare setting until 48 months safety monitoring period is completed.	2014-10-01	2016-04-01	2016-04-01	2014-07-31	\N	2016-06-09	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Relapsing-remitting Multiple Sclerosis"}	combination	cetirizine	\N	f	Infusion Reaction	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
382	2023-01-02 15:22:35.744	2023-03-21 11:06:58.471	NCT04527562	Colchicine in Moderate Symptomatic COVID-19 Patients: Double Blind, Randomized, Placebo Controlled Trial to Observe the Efficacy	Colchicine in Moderate Symptomatic COVID-19 Patients	Completed	This is a prospective, double blind, randomized, placebo controlled clinical trial. The participants will be randomized into two groups (group A and group B). Patients of group-A are the treatment group. They will be treated with optimal treatment based on the algorithm proposed in National Guidelines on Clinical Management of Coronavirus Disease 2019 (Covid-19) Version 7.0, 28 May 2020, along with Colchicine for 14 days. The patients in group-B will be controlled group. They will be treated with optimal treatment based on the algorithm proposed in National Guideline along with a placebo.	Parallel Assignment	Dhaka Medical College	OTHER	All	\N	18	299	Actual	OTHER	Dhaka Medical College	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2020-07-14	2020-11-15	2020-12-10	2020-08-26	\N	2021-01-11	\N	Dhaka Medical College	Dr. Md. Motlabur Rahman	Associate Professor, Department of Medicine	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{Covid19}	minimal	fexofenadine	Fex only as symptomatic treatment for COVID as per standard guidelines	f	COVID	2022-08-18 16:54:53	{"Rahman M, Datta PK, Islam K, Haque M, Mahmud R, Mallik U, Hasan P, Haque M, Faruq I, Sharif M, Ratul RH, Azad KAK, Miah T, Rahman MM. Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial. PLoS One. 2022 Nov 16;17(11):e0277790. doi: 10.1371/journal.pone.0277790. eCollection 2022."}	PUBLISHED	https://europepmc.org/article/med/36383611	fexofenadine
377	2023-01-02 15:22:35.743	2023-03-21 10:56:20.564	NCT04324918	Efficacy and Safety of HCP1102 in Patients With Perennial Allergic Rhinitis : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial	Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis	Completed	Efficacy and safety of HCP1102 in patients with perennial allergic rhinitis :\n\nA randomized, double-blind, active-controlled, multicenter phase 3 clinical trial	Parallel Assignment	Hanmi Pharmaceutical Company Limited	INDUSTRY	All	\N	15	174	Actual	INDUSTRY	Hanmi Pharmaceutical Company Limited	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2018-10-23	2019-06-24	2019-06-24	2020-03-27	\N	2020-03-27	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Perennial Allergic Rhinitis"}	combination	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
393	2023-01-02 15:22:35.744	2023-03-21 12:09:44.037	NCT00557284	A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens	Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens	Completed	AD is a disease found in children; the focus of the study is the mechanisms associated in children with AD induced by food allergies.\n\nThis study will be a randomized, double-blind, placebo-controlled, parallel group trial conducted in participants diagnosed with atopic dermatitis and food allergies. The study duration for participants will be approximately 9 weeks. A total of 20 participants will be recruited for the entire study. Each arm will consist of 10 participants.The study will enroll 20 children, male or female, 1 - 8 years of age with atopic dermatitis (AD) associated with food allergens, previously documented by skin or RAST test, before enrollment. Atopic dermatitis and gastrointestinal (GI) symptoms will be scored and followed throughout the study.	Parallel Assignment	1st Allergy & Clinical Research Center	OTHER	All	8	1	20	Actual	INDUSTRY	IMMUNOe Research Centers	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2008-03-01	2009-05-01	2009-05-01	2007-11-12	2014-12-09	2015-04-21	IMMUNOe International Research Centers	1st Allergy & Clinical Research Center	Isaac Melamed	Principle Investigator	\N	\N	Principal Investigator	\N	Interventional	{Child}	{"Phase 4"}	{"Atopic Dermatitis"}	rescue medication	cetirizine	\N	f	Dermatitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
384	2023-01-02 15:22:35.744	2023-03-21 11:08:10.162	NCT04093531	Pilot Trial of Ustekinumab for Primary Sjgren's Syndrome	Pilot Trial of Ustekinumab for Primary Sjgren's Syndrome	Completed	This pilot study will make a preliminary determination of the safety of ustekinumab in patients with Primary Sjogren's Syndrome (PSS) and assess the response of systemic measures of inflammation (biomarkers).	Single Group Assignment	University of Rochester	OTHER	All	75	18	8	Actual	OTHER	University of Rochester	N/A	Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.	None (Open Label)	\N	\N	Treatment	\N	This is a single-center, open label, pilot trial of ustekinumab in patients with Primary Sjgren's Syndrome (PSS). Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.	2020-01-15	2022-05-11	2022-05-11	2019-09-18	\N	2022-07-08	\N	University of Rochester	Ummara Shah	Assistant Professor of Medicine	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Primary Sjgren Syndrome"}	pre-medication	fexofenadine	\N	f	Infusion Reaction	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
373	2023-01-02 15:22:35.743	2023-03-21 10:51:38.408	NCT03296358	A Randomized, Double-blinded, Controlled Trial of Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines	Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.	Completed	A randomized, double-blinded, controlled trial of adding a short burst of corticosteroid to the conventional treatment of H1 antihistamines	Parallel Assignment	Chulalongkorn University	OTHER	All	50	18	75	Actual	OTHER	Chulalongkorn University	Randomized	\N	Triple	\N	\N	Treatment	\N	Research Methodology\n\nTarget Population Patients visit emergency room at King chulalongkorn memorial hospital (KCMH) age between 18-50 years who meet the following criteria of acute urticarial such as\n\neruption of wheals, central swelling of various sizes, with or without surrounding erythema; with or without angioedema\npruritus or occasional burning sensation\nskin returning to normal appearance, usually within 1-24 hours\n\nExclusion criteria\n\npatients who have urticarial for more than 48 hours\nhave severe underlying disease such as heart disease, kidney disease, liver disease\npregnancy\nhistory of Chlorpheniramine, steroid, antihistamines allergy\nhistory of antihistamine or steroid uses within 48 hours before emergency department visit\ndiabetes mellitus\nsuspected of more severe disease or severe allergic reaction\npatients who don't have pruritus\npatients who have history of chronic urticaria\n\nInformed consent process The doctor who is the principal investigator or his assigned colleagues describe the research's details and methods to an enrolled patients. The documents which contain the details of the research project are also given. Inform consents then were signed before the beginning of the experiment.\n\nThe volunteer would be in a research process during their first 1-2 hours in emergency department, with the follow up time at 1 week and 1 month\n\nAfter the investigator complete the inclusion and exclusion criteria, the participants would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination :\n\nControl group : Chlorpheniramine 10 mg/amp ; 1 ampule and cetirizine 10 mg 7 tabs\nExperiment group : Chlorpheniramine 10 mg/amp ; 1 ampule, Dexamethasone 5 mg/amp; 1 ampule and cetirizine 10 mg 7 tabs\nExperiment group : Chlorpheniramine 10 mg/amp ; 1 ampule, Dexamethasone 5 mg/amp; 1 ampule, cetirizine 10 mg 7 tabs, and prednisolone 5 mg 20 tabs After the envelopes are sealed, it will be code in an order of number. All of the enrolled patients will get Chlorpheniramine 10 mg intravenous. The patients who are assigned in experiment group will get an additional Dexamethasone 5 mg intravenous. The preparation of both drugs will be result to be a 10 ml of clear fluid. The control group will get a 10 ml of sterile fluid in 10 ml syringe as a placebo. The drugs will be prepared and delivered be the nurse who knows about the research process but does not get involved in other process of the research.\n\nAfter the experiment period in emergency department, all of the enrolled patients will get cetirizine 10 mg 7 tabs as a home medication. One experiment group will get prednisolone 5 mg 20 tabs. They will be appointed to an outpatient department in 1 week and 1 month for the follow up of an acute urticarial rash.\n\nSample size calculation Investigators do the hypothesis that the experiment groups who get both Chlorpheniramine 10 mg and Dexamethasone 5 mg intravenous would have the itch score decrease at least 2 points so this experiment wants minimal clinical difference at "2". This number got from our expert in immunology and skin disease. The standard deviation for this experiment is 2.1 from the previous research. Calculated by G*Power version 3.1 (Dusseldorf, Germany) for an independent t-test , two-tailed analysis, alpha error probability = 0.05 and power of analysis (1-beta error probability) = 0.90 The sample size for each group is 23 persons so the patients enroll in this research would be 69 persons.\n\nData Collection\n\nSex and age\nTime since the first rash erupt before coming to emergency department (hrs)\n%body surface area of rash involved\nUrticarial activity score (UAS) before and after treatment\nItch score (Visual analog scale (VAS) score) by letting the patients mark a cross on a straight line. The end of the left side of a line represents "0 = no pain at all", and the end of the right side of a line represents "10 = the worst pain ever possible". The patients aren't allowed to compare the previous VAS score before doing the cross.\nSide effect of drugs\nOther medicine used as indicated\nPatients' satisfaction score\nThe recurrence of rash 1 week after the rash onset\nThe recurrence of rash 1 month after the rash onset which will be evaluate by an expert in immunology and skin disease.\n\nData Analysis and Statistics\n\nDescriptive statistics : Chi-square Student t-test and paired t-test for data analysis of continuous variables (such as itch score (VAS) and pair wise comparison for cumulative increase in the proportion of the "responder" over the time\n\nStatistical significant when p-value < 0.05	2017-10-01	2019-10-31	2019-10-31	2017-09-28	\N	2020-02-11	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Not Applicable"}	{Urticaria,Allergy}	combination	cetirizine	drug role could also be classified as minimal	f	Allergy	2022-08-17 13:39:16	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/32139204/	cetirizine
368	2023-01-02 15:22:35.742	2023-03-21 10:15:04.303	NCT00103012	The Influence of Concurrent Administration of Echinacea Purpurea, Ginkgo Biloba, or Panax Ginseng on the Steady State Pharmacokinetic Profile of Lopinavir/Ritonavir in Healthy Volunteers	Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers	Completed	This study will examine the interaction of the HIV combination medication lopinavir/ritonavir with the herbal products echinacea, ginseng, and ginkgo biloba. Patients with HIV infection often take herbal products and dietary supplements in addition to their doctor-prescribed medicines to treat the disease, lessen the side effects of anti-viral drugs, and improve their overall well being. Alternative medicines such as these may, however, interfere with the elimination of lopinavir/ritonavir from the body, causing either higher or lower blood levels of these drugs than would be expected. This study will assess in healthy subjects any potential harms of taking echinacea, ginseng, or ginkgo biloba together with lopinavir/ritonavir.\n\nHealthy normal volunteers between 18 and 50 years of age may be eligible for this study. Candidates are screened with a history, physical examination, and blood tests, including an HIV test and a pregnancy test for women. Pregnant women are excluded from the study. Participants come to the NIH Clinical Center after fasting overnight for the following procedures:\n\nVisits 1 and 2: A catheter (plastic tube) is placed in an arm vein to collect blood samples. After the first sample is drawn, the subject takes 8 mg of midazolam syrup and two fexofenadine tablets. Midazolam is a sedative, and fexofenadine (Allegra) is a medicine used to treat allergies. Subjects are given breakfast an hour after taking the drugs. Blood samples are collected at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8 and 24 hours after taking the drugs to measure blood levels of fexofenadine. An extra sample is collected at the 4-hour mark to measure the midazolam level. The catheter is removed after the 8-hour blood draw and subjects are dismissed home. They return the following morning (visit 2) for the 24-hour blood draw.\n\nVisit 3: From 7 to 28 days after visit 1, subjects begin taking lopinavir/ritonavir capsules twice a day by mouth for a total of 29.5 days. On day 15 they return to the clinic for lopinavir/ritonavir blood levels as were done for fexofenadine, except that samples are collected once before breakfast and then at 0.5, 1, 2, 3, 4, 6, 8 and 12 hours after the lopinavir/ritonavir dose. An extra sample is collected for routine tests. The catheter is removed after the 12-hour draw and the subject is dismissed home.\n\nThe next morning, subjects begin taking one of the following: echinacea 500 mg 3 times a day; ginkgo biloba 120 mg twice a day; or ginseng 500 mg 3 times a day for 28 days.\n\nVisit 4: On the last day of taking lopinavir/ritonavir, subjects return to the clinic again for blood level measurements of these drugs as on visit 3, except that the catheter is removed and the subject dismissed home after the 8-hour blood draw.\n\nVisits 5 and 6: On the last day of taking the herbal supplement, subjects return to the clinic for repeat measurement of fexofenadine and midazolam levels, as described in visits 1 and 2. At the final visit (visit 6) an additional blood sample is collected for repeat laboratory testing.\n\n...	Crossover Assignment	National Institutes of Health Clinical Center (CC)	NIH	All	50	18	47	Actual	NIH	National Institutes of Health Clinical Center (CC)	Randomized	\N	None (Open Label)	\N	\N	\N	\N	Patients with HIV commonly use herbal products and dietary supplements in addition to medications prescribed by their physicians. Up to 73% of patients with HIV have reported using some form of complementary or alternative medicine. As such, the potential for clinically significant drug interactions between herbs and antiretrovirals is becoming increasingly appreciated. Despite this awareness, little is known about the effect of commonly used herbal products, such as echinacea, ginkgo biloba, and ginseng, on antiretroviral pharmacokinetics. Interacting herbal supplements have the potential to alter protease inhibitor (PI) plasma concentrations, as has been shown with St. John's Wort and garlic. Drug interactions may potentially increase antiretroviral concentrations, putting patients at risk for toxicities, or lower drug concentrations below the threshold of viral susceptibility, putting patients in jeopardy of antiretroviral failure. The protease inhibitors lopinavir and ritonavir both rely principally on cytochrome P450 (CYP) 3A4 metabolism for their elimination. In addition, both drugs are substrates for the transport protein p-glycoprotein (P-gp), which may also contribute to their distribution and elimination.\n\nThe primary purpose of this investigation is to determine whether the herbal supplements Echinacea purpurea, ginkgo biloba, and Panax ginseng alter the pharmacokinetic properties of the HIV protease inhibitor (PI) lopinavir, administered as the PI combination lopinavir/ritonavir (LPV/r). This is an open label pharmacokinetic study that will be performed on an outpatient basis. A total of 42 study participants who have met inclusion criteria will be sequentially divided into one of 3 groups, such that 14 subjects each will receive LPV/r alone and in combination with either E. purpurea, G. biloba, or P. ginseng.\n\nSubjects will begin taking LPV/r (400mg/100mg twice daily x 29.5 days), returning to the NIH on Day 15 of dosing for post-dose plasma collection and determination of lopinavir and ritonavir concentrations. On Day 16 participants will begin taking either E. purpurea (500mg, three times daily), G. biloba extract (120 mg, twice daily), or P. ginseng (500 mg, twice daily) for 28 days. On the 30th day of LPV/r (Day 15 of the herb), subjects will return to the NIH where they will take their final LPV/r dose and then have their plasma collected for determination of lopinavir concentrations. Data from this investigation will determine whether echinacea, ginseng, or ginkgo biloba supplements alter the pharmacokinetics of lopinavir.	2005-01-01	2011-01-01	2011-06-01	2005-02-07	2012-04-16	2012-04-16	National Institutes of Health, Clinical Center, Department of Pharmacy	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 4"}	{Healthy}	minimal	fexofenadine	fex only as comparison and probe for blood level\nTodo usecase	f	Pharmacokinetics	2022-08-18 16:54:53	{"Fairfield KM, Eisenberg DM, Davis RB, Libman H, Phillips RS. Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med. 1998 Nov 9;158(20):2257-64. doi: 10.1001/archinte.158.20.2257.","Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998 Nov 11;280(18):1569-75. doi: 10.1001/jama.280.18.1569.","Risa KJ, Nepon L, Justis JC, Panwalker A, Berman SM, Cinti S, Wagener MM, Singh N. Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy. Int J STD AIDS. 2002 Oct;13(10):706-13. doi: 10.1258/095646202760326471."}	CT_RESULTS	\N	fexofenadine
381	2023-01-02 15:22:35.744	2023-03-21 11:04:24.26	NCT02196324	A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis	A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)	Completed	The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.	Parallel Assignment	Vyne Therapeutics Inc.	INDUSTRY	All	80	18	128	Actual	INDUSTRY	Vyne Therapeutics Inc.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	The sensation of itch is transmitted to the brain through the nervous system. Several chemicals are involved in transmitting this signal.This trial of VPD 737 is intended to treat this condition by blocking one of the chemicals involved in the transmission of the itch signal. This is an oral drug administered once daily It has been used in other trials and has shown to be safe at the doses used in this trial. The trial will involve once daily pills for 8 weeks. Subject will be asked to fill out questionnaires both electronically and on paper during the study period. Patients will also be monitored for safety and will have blood taken for testing and several points during the trial. Overall participation will last about 14 weeks	2014-07-09	2016-05-27	2016-06-10	2014-07-22	2021-02-02	2021-05-20	Menlo Therapeutics Inc. (formerly Tigercat Pharma, Inc.)	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Prurigo Nodularis"}	rescue medication	cetirizine	\N	f	Pruigo Nodularis	2022-08-17 13:39:16	{"Kimel M, Zeidler C, Kwon P, Revicki D, Stander S. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2020 Dec 1;156(12):1354-1358. doi: 10.1001/jamadermatol.2020.3071."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/32936233/	cetirizine|desloratadine
386	2023-01-02 15:22:35.744	2023-03-21 11:10:04.943	NCT02394106	Ofatumumab in Children With Steroid- and Calcineurin-inhibitor-resistant Nephrotic Syndrome: a Double-blind Randomized, Controlled, Superiority Trial	Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome	Terminated	Double-blind, two-parallel-arm, placebo-controlled randomized clinical trial testing the superiority of Ofatumumab versus placebo in the treatment of children with DR-INS. Participants will be stratified according to eGFR at enrollment.\n\nEligible participants will enter a 3-months run-in period, during which instructions on urine collection and dipstick readings will be carefully reviewed, compliance assessed and any immunosuppressive therapies withdrawn according to the following schemes:\n\nprednisone will be tapered off by 0.3 mg/kg per week until complete withdrawal;\ncalcineurin inhibitors and mofetile mycophenolate will be decreased by 50% and withdrawn after 2 additional weeks In order to minimize the risk of complications of uncontrolled INS a treatment with ACE-inhibitor at 6 mg/m2 will be maintained or started in all patients.\n\nAfter run-in period, children will be randomized to the intervention arm (Ofatumumab) or comparator arm (placebo). Randomization will be stratified by eGFR at randomization: 90 and <90 ml/min/1.73 m2.\n\nAll patients will be followed up to 12 months and they will leave the study at time of relapse.\n\nRelapse will be defined as uPCR 2000 mg/g (200 mg/mmol) or  3+ protein on urine dipstick for 3 consecutive days.	Parallel Assignment	Istituto Giannina Gaslini	OTHER	All	18	2	13	Actual	OTHER	Istituto Giannina Gaslini	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2015-07-01	2019-06-01	2019-06-01	2015-03-20	\N	2020-07-29	\N	Istituto Giannina Gaslini	Gian Marco Ghiggeri MD, PhD	MD, director of Nephrology, Dialysis and Transplantation Unit	\N	\N	Principal Investigator	\N	Interventional	{Child,Adult}	{"Phase 2"}	{"Nephrotic Syndrome"}	pre-medication	cetirizine	\N	f	Infusion Reaction	2022-08-17 13:39:16	{"Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med. 2014 Mar 27;370(13):1268-70. doi: 10.1056/NEJMc1308488. No abstract available.","Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr Opin Mol Ther. 2008 Jun;10(3):294-309.","Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri GM. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol. 2012 Jun;23(6):1117-24. doi: 10.1681/ASN.2011080775. Epub 2012 May 10.","Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011 Jun;6(6):1308-15. doi: 10.2215/CJN.09421010. Epub 2011 May 12.","Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl'Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. J Am Soc Nephrol. 2015 Sep;26(9):2259-66. doi: 10.1681/ASN.2014080799. Epub 2015 Jan 15.","McEnery PT, Strife CF. Nephrotic syndrome in childhood. Management and treatment in patients with minimal change disease, mesangial proliferation, or focal glomerulosclerosis. Pediatr Clin North Am. 1982 Aug;29(4):875-94. No abstract available.","Ghiggeri GM, Catarsi P, Scolari F, Caridi G, Bertelli R, Carrea A, Sanna-Cherchi S, Emma F, Allegri L, Cancarini G, Rizzoni GF, Perfumo F. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther. 2004 Sep;26(9):1411-8. doi: 10.1016/j.clinthera.2004.09.012.","Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient. Kidney Int. 2012 Oct;82(8):840-56. doi: 10.1038/ki.2012.280. Epub 2012 Aug 15.","Caridi G, Bertelli R, Di Duca M, Dagnino M, Emma F, Onetti Muda A, Scolari F, Miglietti N, Mazzucco G, Murer L, Carrea A, Massella L, Rizzoni G, Perfumo F, Ghiggeri GM. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol. 2003 May;14(5):1278-86. doi: 10.1097/01.asn.0000060578.79050.e0.","Ravani P, Pisani I, Bodria M, Caridi G, Degl'Innocenti ML, Ghiggeri GM. Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial. Pediatr Nephrol. 2020 Jun;35(6):997-1003. doi: 10.1007/s00467-020-04481-y. Epub 2020 Jan 28."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/31993781/	cetirizine
335	2023-01-02 15:22:35.741	2023-03-21 09:21:30.492	NCT01902836	Efficacy of Human Dialyzed Leukocytes Extracts in Paediatrics Patients With Moderate Atopic Dermatitis.	Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis	Completed	Patients with atopic dermatitis treated with conventional treatment plus Dialyzed Leukocyte Extracts (DLE-oral Transferon) as adjuvant, have better clinical outcome than patients treated only with conventional treatment.	Parallel Assignment	National Polytechnic Institute, Mexico	OTHER	All	17	2	58	Actual	OTHER	National Polytechnic Institute, Mexico	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2011-08-01	2012-12-01	2013-01-01	2013-07-18	\N	2013-07-29	\N	Instituto de Oftalmologa Fundacin Conde de Valenciana	Maria C Jimenez Martinez	PhD	\N	\N	Principal Investigator	\N	Interventional	{Child}	{"Phase 2"}	{"Childhood Atopic Dermatitis"}	minimal	cetirizine	ctz play only a minimal role because it is part of the conventional treatment but is not the focus in this study	f	Dermatitis	2022-08-17 13:39:16	{}	PUBLISHED	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082099/	cetirizine
353	2023-01-02 15:22:35.742	2023-03-21 09:43:48.145	NCT04814498	A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of BLD-0409 on the Single Dose Pharmacokinetics of a Cocktail of Probe Substrates for CYP450 Enzymes in Healthy Volunteers	Drug-Drug Interaction (DDI) Study in Healthy Volunteers	Completed	A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of BLD-0409 on the Single Dose Pharmacokinetics of a Cocktail of Probe Substrates for CYP450 Enzymes in Healthy Volunteers	Sequential Assignment	Blade Therapeutics	INDUSTRY	All	55	18	16	Actual	INDUSTRY	Blade Therapeutics	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	This is a single center, open label study designed to determine the effect of BLD-0409 on the PK of probe substrates and to evaluate the safety and tolerability of BLD-0409 administered alone and co-administered with a cocktail of probe substrates (i.e., Geneva cocktail less fexofenadine) in healthy adult volunteers.\n\nGeneva Cocktail (Less Fexofenadine):\n\nCYP1A2 Caffeine 50 mg\nCYP2C Flurbiprofen 10 mg\nCYP2C19 Omeprazole 10 mg\nCYP2D6 Dextromethorphan 10 mg\nCYP3A4 Midazolam 1 mg\nCYP2B6 Bupropion 20 mg	2021-05-03	2021-09-17	2022-01-11	2021-03-24	\N	2022-05-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{"Drug Drug Interaction"}	minimal	fexofenadine	fex only in test drug cocktail and there "less"	f	Pharmacokinetics	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
261	2023-01-02 15:22:35.736	2023-03-20 21:19:00.637	NCT00474890	A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Assess the Efficacy's Reproducibility of a Combination of Pseudoephedrine and Cetirizine on Symptom Scores and Rhinomanometry in Patients With Allergic Rhinitis Following Pollen Exposure in the Fraunhofer Environmental Challenge Chamber (ECC) in- and Outside the Grass Pollen Season	Study to Compare the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Placebo on Symptoms in Patients With Allergic Rhinitis Within/Out of Season	Completed	A previous study has shown very clearly that the treatment with the combination of cetirizine and pseudoephedrine is superior to the treatment with the single agents regarding the reduction of symptoms in patients with allergic rhinitis. These data, obtained after controlled pollen exposure out of the pollen season, showed highly reproducible individual responses prior to dosing. It is not clear, however, whether the same results can be obtained during the pollen season, when additional natural pollen exposure may influence the variability of the individual reactions.	Crossover Assignment	Fraunhofer-Institute of Toxicology and Experimental Medicine	OTHER	All	55	18	70	Anticipated	OTHER	Fraunhofer-Institute of Toxicology and Experimental Medicine	Randomized	\N	Double	\N	\N	Treatment	\N	The aim of this study is to evaluate prospectively, if reproducible results can be shown when testing a combination of cetirizine and pseudoephedrine in an Environmental Exposure Unit setting once inside and once outside the grass pollen season. An equivalent outcome would validate the ECC for testing anti-allergic substances during the pollen season in the future. Up to now these studies have been restricted to the pollen-free season.	2007-06-01	2007-12-01	2008-02-01	2007-05-17	\N	2008-02-13	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult}	{"Not Applicable"}	{Atopy,Rhinitis}	combination	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Badorrek P, Dick M, Hecker H, Schaumann F, Sousa AR, Murdoch R, Hohlfeld JM, Krug N. Anti-allergic drug testing in an environmental challenge chamber is suitable both in and out of the relevant pollen season. Ann Allergy Asthma Immunol. 2011 Apr;106(4):336-41. doi: 10.1016/j.anai.2010.12.018. Epub 2011 Feb 5."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/21457883/	cetirizine
420	2023-01-02 15:22:35.745	2023-03-21 13:33:40.172	NCT03181685	Subcutaneous Versus Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles: Which is the Preference Expressed by the Patients?	Patients' Preference for Subcutaneous or Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles	Terminated	This randomized, controlled, prospective, crossover, open-label, two-treatments, two-period trial aimed to evaluate the preference expressed by the patient concerning the subcutaneous administration of progesterone versus the vaginal one.\n\nThe couples, scheduled for performing 2 In Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) cycles will be randomized to receive, as luteal phase supplementation, Pleyris 25 milligram (mg) (a single subcutaneous administration per day) or Prometrium 200 mg (3 vaginal administrations per day).	Crossover Assignment	Andros Day Surgery Clinic	OTHER	Female	44	18	60	Actual	OTHER	Andros Day Surgery Clinic	Randomized	This is randomized, controlled, prospective, crossover, open-label, two-treatments, two-period trial	Single	\N	\N	Supportive Care	\N	Each participant will receive both treatments. During the first IVF/ICSI cycle, the luteal phase will be supplemented with subcutaneous progesterone (S) or vaginal progesterone (V). At the end of the cycle (on the day of beta-hCG), a survey for determining the level of satisfaction will be administered and filled in by the patient during the waiting time and always before the knowledge of the result. This practical organization allows the elimination of emotional biases correlated with the outcome. In case of a negative beta-hCG, the patient will be scheduled for a second IVF/ICSI cycle after a washout (W) period (between 2 and 6 months). In the second cycle, the patient will undergo, during the luteal phase, the opposite treatment (V or S). Also in this case, the survey for evaluating the level of satisfaction will be administered on the day of beta-hCG, with the same modalities of the first cycle. The domains of the surveys are focused on facility of the administration, comfort, level of complaint, side effects, overall level of satisfaction.\n\nThe sequence S-V or V-S will be randomly assigned (random assignment) with the concealment of the allocation.\n\nIn case of a negative beta-hCG also in the second cycle, a post-hoc comparison between the two treatments will be carried out through a Semantic Differential Scale, in the "follow-up" phase.	2016-12-20	2019-12-01	2019-12-01	2017-06-09	\N	2020-01-10	\N	\N	\N	\N	\N	\N	Sponsor	27 couples were recruited. This unexpected poor recruitment was due to more clinical pregnancies (for a better patients' selection) and more freeze-all cycles.	Interventional	{Adult}	{"Phase 4"}	{Infertility,"In Vitro Fertilization"}	not included	fexofenadine	name of investigator	f	Infertility	2022-08-18 16:54:53	{"Beltsos AN, Sanchez MD, Doody KJ, Bush MR, Domar AD, Collins MG. Patients' administration preferences: progesterone vaginal insert (Endometrin(R)) compared to intramuscular progesterone for Luteal phase support. Reprod Health. 2014 Nov 11;11:78. doi: 10.1186/1742-4755-11-78.","van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015 Jul 7;2015(7):CD009154. doi: 10.1002/14651858.CD009154.pub3.","Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein M. Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study. Fertil Steril. 2010 Dec;94(7):2596-9. doi: 10.1016/j.fertnstert.2010.02.033. Epub 2010 Mar 27."}	UNKNOWN	\N	fexofenadine
395	2023-01-02 15:22:35.745	2023-03-21 12:10:26.91	NCT01183221	The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders	The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders	Completed	This study examines the effects of a single dose of intranasal oxytocin (vs. placebo) on complex social cognition in adults with autism spectrum disorders.	Crossover Assignment	Alexander Kolevzon	OTHER	All	45	18	30	Actual	OTHER	Icahn School of Medicine at Mount Sinai	Randomized	Participants are randomized to receive 24IU intranasal oxytocin or placebo on days separated by a minimum of 3 weeks. Randomization order to drug condition is counter-balanced.	Double	Both the participant and investigator are blind to drug condition.	\N	Basic Science	\N	Participants receive a one-time administration of 24-IU intranasal oxytocin (or placebo) and perform an empathic accuracy task, a novel and ecologically valid measure of complex social cognition, in conjunction with functional magnetic resonance imaging (fMRI). The investigators will investigate the effects of oxytocin (versus placebo) on the behavioral and neural correlates of empathic accuracy.	2010-06-18	2014-04-25	2014-04-25	2010-08-17	2021-04-15	2021-04-15	Icahn School of Medicine at Mount Sinai	Icahn School of Medicine at Mount Sinai	Alexander Kolevzon	Professor	\N	\N	Sponsor-Investigator	\N	Interventional	{Adult}	{"Phase 2"}	{Autism,ASD}	not included	fexofenadine	Images will be acquired using a 3.0 Tesla Siemens Allegra MRI... name	f	Autism	2022-08-18 16:54:53	{}	UNKNOWN	\N	fexofenadine
262	2023-01-02 15:22:35.737	2023-08-01 13:13:35.198	NCT04162795	An Open Label, Multi-center Study to Evaluate Sensory Attributes of an Antihistamine Product	A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies	Completed	In this study, researchers were primarily interested in evaluating the level of agreement of cooling sensation provided by this chewable, flavored, allergy medicine. Participants joining this study received one test drug tablet and were asked to chew completely before swallowing the drug. A questionnaire was used to collect the feedback from participants. The study involved only one (1) visit and participant stayed in this study for about 60-75 minutes to evaluate the cooling sensation as well as other sensory attributes perceived in the mouth, nose and throat.	Single Group Assignment	Bayer	INDUSTRY	All	65	18	468	Actual	INDUSTRY	Bayer	N/A	\N	None (Open Label)	Participants were blinded to product brand	\N	Other	\N	\N	2019-11-12	2019-11-13	2019-11-13	2019-11-14	2021-02-04	2021-02-04	Bayer	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Allergic Rhinitis"}	main	loratadine	not really allergic rhinitis but rather taste, form and preference of a product, specifically its cooling ability	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	CT_RESULTS	\N	loratadine
263	2023-01-02 15:22:35.737	2023-03-20 21:20:14.525	NCT00967967	Validation of a Rhinitis Control Tool : the Rhinitis Control Scoring System (RCSS)	Validation of the Rhinitis Control Scoring System (RCSS)	Suspended	Many patients suffering from allergic rhinitis do not recognize or perceive their symptoms. Instruments have been developed to assess quality of life in rhinitis, asthma or both, but there is a need to develop validated tools or methods to assess rhinitis control among rhinitis and/or asthmatic patients. The aim of this study is to assess the discriminative and evaluative properties of the RCSS in asthmatic patients with allergic rhinitis.	Single Group Assignment	Laval University	OTHER	All	65	18	50	Anticipated	OTHER	Laval University	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	Allergic asthmatic subjects showing seasonal rhinitis symptoms will be recruited. The discriminative (internal consistency, cross sectional construct validity and reliability) and evaluative (responsiveness and longitudinal construct validity) properties of the RCSS will be evaluated as well as the relationship between rhinitis control and asthma control. RCSS will be completed at various time points during the seasonal allergic period.	2009-03-01	2014-06-01	2014-09-01	2009-08-28	\N	2013-05-27	\N	Laval University	Louis-Philippe Boulet	Professeur	\N	\N	Principal Investigator	Awaiting results from sub analysis to decide if study continues	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{Asthma,Rhinitis}	minimal	desloratadine	the main focus is not the drug but rather a scoring system	f	Allergic Rhinitis	2022-09-15 19:16:20	{"Boulay ME, Boulet LP. The Rhinitis Control Scoring System: Development and validation. Am J Rhinol Allergy. 2016 Jan-Feb;30(1):54-9. doi: 10.2500/ajra.2016.30.4260."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/26867531/	desloratadine
398	2023-01-02 15:22:35.745	2023-03-21 12:14:55.24	NCT00096278	A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon	Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer	Completed	This randomized phase III trial is studying giving oxaliplatin, leucovorin, and fluorouracil together with bevacizumab to see how well it works compared to oxaliplatin, leucovorin, and fluorouracil alone in treating patients who have undergone surgery for stage II or stage III colon cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Bevacizumab may also stop the growth of tumor cells by stopping blood flow to the tumor. Giving chemotherapy together with bevacizumab may kill more tumor cells. It is not yet known whether treatment with oxaliplatin, leucovorin, and fluorouracil is more effective with or without bevacizumab in treating patients who have undergone surgery for colon cancer.	Parallel Assignment	National Cancer Institute (NCI)	NIH	All	\N	18	2710	Actual	NIH	National Cancer Institute (NCI)	Randomized	\N	Double	\N	\N	Treatment	\N	PRIMARY OBJECTIVES:\n\nI. To compare the relative efficacy of mFOLFOX6 + bevacizumab with that of mFOLFOX6 alone in prolonging disease-free survival (DFS).\n\nSECONDARY OBJECTIVES:\n\nI. To compare the relative efficacy of mFOLFOX6 + bevacizumab with that of mFOLFOX6 alone in prolonging survival (S).\n\nTERTIARY OBJECTIVES:\n\nI. To assess the persistence of proteinuria following the discontinuation of bevacizumab.\n\nII. To correlate the development of proteinuria with clinical sequelae. III. To evaluate the risk factors for development of proteinuria. IV. To determine the effect of discontinuation of bevacizumab on hypertension. V. To estimate the incidence of delayed vascular events such as myocardia infarction, CNS ischemia, and thrombosis in patients receiving chemotherapy + bevacizumab.\n\nVI. To assess the effect of bevacizumab on ovarian function in premenopausal women.\n\nVII. To assess the incidence rate of immunogenicity and examine post-treatment serum levels of bevacizumab in patients receiving bevacizumab.\n\nOUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.\n\nARM I: Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.\n\nARM II: Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.\n\nPatients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.	2004-09-15	2009-03-12	2012-12-31	2004-11-09	2012-12-03	2019-07-30	NSABP Foundation, Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Colon Adenocarcinoma","Stage IIA Colon Cancer AJCC v7","Stage IIB Colon Cancer AJCC v7","Stage IIC Colon Cancer AJCC v7","Stage IIIA Colon Cancer AJCC v7","Stage IIIB Colon Cancer AJCC v7","Stage IIIC Colon Cancer AJCC v7"}	not included	fexofenadine	Name of investigator	f	Cancer	2022-08-18 16:54:53	{"Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, Alberts S, Allegra C, de Gramont A, Seitz JF, O'Connell M, Haller D, Wolmark N, Erlichman C, Zaniboni A, Lonardi S, Kerr R, Grothey A, Sinicrope FA, Andre T, Shi Q. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol. 2021 Feb 20;39(6):642-651. doi: 10.1200/JCO.20.01600. Epub 2020 Dec 23.","Penney KL, Banbury BL, Bien S, Harrison TA, Hua X, Phipps AI, Sun W, Song M, Joshi AD, Alberts SR, Allegra CJ, Atkins J, Colangelo LH, George TJ, Goldberg RM, Lucas PC, Nair SG, Shi Q, Sinicrope FA, Wolmark N, Yothers G, Peters U, Newcomb PA, Chan AT. Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. Clin Gastroenterol Hepatol. 2020 Nov;18(12):2717-2723.e3. doi: 10.1016/j.cgh.2019.11.046. Epub 2019 Dec 4.","Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, Andre T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol. 2019 Sep 1;30(9):1466-1471. doi: 10.1093/annonc/mdz208.","Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol. 2017 Apr 1;3(4):472-480. doi: 10.1001/jamaoncol.2016.5469.","Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, Wolmark N. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013 Jan 20;31(3):359-64. doi: 10.1200/JCO.2012.44.4711. Epub 2012 Dec 10.","Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW; ACCENT Collaborative Group. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011 Oct 19;103(20):1498-506. doi: 10.1093/jnci/djr310. Epub 2011 Oct 12."}	UNKNOWN	\N	fexofenadine
264	2023-01-02 15:22:35.736	2023-03-20 21:21:00.729	NCT00851344	A Randomised, Double-blind, Placebo-controlled, 4-period Incomplete Block Crossover Study of Single Oral Dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and Placebo to Evaluate the Efficacy and Safety Using an Environmental Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis	Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo	Completed	A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and safety using an Environmental challenge chamber in male subjects with seasonal allergic rhinitis	Crossover Assignment	GlaxoSmithKline	INDUSTRY	Male	60	18	54	Actual	INDUSTRY	GlaxoSmithKline	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2008-09-01	2008-11-01	2008-11-01	2009-02-25	\N	2016-11-06	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 2"}	{"Rhinitis, Allergic, Seasonal"}	minimal	cetirizine	only minimal role of ctz because main focus is the challange chamber\nResults submitted	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Daley-Yates P, Ambery C, Sweeney L, Watson J, Oliver A, McQuade B. The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol. 2012;158(1):84-98. doi: 10.1159/000329738. Epub 2011 Dec 29."}	CT_RESULTS	\N	cetirizine
267	2023-01-02 15:22:35.737	2023-03-20 21:23:11.269	NCT01400828	Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg After 14-day Oral Administration in Patients With Seasonal Allergic Rhinitis	Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis	Completed	The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.	Parallel Assignment	Yuhan Corporation	INDUSTRY	All	70	12	239	Actual	INDUSTRY	Yuhan Corporation	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2011-06-01	2013-06-01	2014-05-01	2011-07-22	\N	2014-07-10	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	control	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
418	2023-01-02 15:22:35.745	2023-03-21 13:33:17.251	NCT02738008	A Multicenter, Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis B Virus (HBV) Infection	Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection	Terminated	Chronic HBV patients will receive 9 doses of open-label ARC-520 once every 4 weeks and be evaluated for safety and efficacy.	Single Group Assignment	Arrowhead Pharmaceuticals	INDUSTRY	All	75	18	12	Actual	INDUSTRY	Arrowhead Pharmaceuticals	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	Open-label, multi-center extension study of intravenous ARC-520 in combination with entecavir or tenofovir in patients with chronic HBV infection. Patients who successfully completed the Heparc-2002 (NCT02604199) and Heparc-2003 (NCT02604212) studies and responded to therapy are eligible to participate. Responders are defined as patients who showed a  log or greater reduction in their serum Hepatitis B Surface Antigen (HBsAg) levels from baseline to day 71  3 days of the primary Heparc-2002 and Heparc-2003 studies. Patients who have signed a Human Research Ethics Committee approved informed consent and have met all of the protocol eligibility criteria will continue receiving daily oral entecavir or tenofovir and intravenous (IV) injections of ARC-520. Study visits will occur once every 4 weeks for a total of 9 visits for monitoring and ARC-520 administration.\n\nPatients will undergo the following evaluations at regular intervals during the study: medical history, physical examinations, vital sign measurements (blood pressure, heart rate, respiratory rate and temperature), weight, adverse events (AEs), 12-lead electrocardiograms (ECGs), concomitant medications, blood sample collection for hematology, coagulation, chemistry, creatine kinase, troponin, hemoglobin A1c, exploratory pharmacodynamic (PD) measures, urinalysis, HBV serology, immunogenicity, and pregnancy testing for females of childbearing potential. Patients will be monitored for HBV virology, AEs, and exploratory PD measures for a total of 24 weeks after the last dose of ARC-520.	2016-03-01	2016-12-01	2016-12-01	2016-04-14	2019-04-16	2019-04-16	Arrowhead Pharmaceuticals, Inc.	\N	\N	\N	\N	\N	Sponsor	Company decision to discontinue trial	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Hepatitis B"}	pre-medication	cetirizine	\N	f	Hepatitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
265	2023-01-02 15:22:35.737	2023-03-20 21:21:24.414	NCT01495338	\N	A Comparison of the Safety and Comfort of AC-170	Completed	The purpose of this study is to evaluate the safety and comfort of AC-170 compared to a placebo.	Parallel Assignment	Aciex Therapeutics, Inc.	INDUSTRY	All	\N	18	60	Actual	INDUSTRY	Aciex Therapeutics, Inc.	Randomized	\N	Single	\N	\N	Treatment	\N	\N	2011-12-01	2011-12-01	2011-12-01	2011-12-20	\N	2017-09-14	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Normal Ocular Health"}	main	cetirizine	\N	f	Safety Evaluation	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
269	2023-01-02 15:22:35.737	2023-03-20 21:24:11.598	NCT01985789	The Effect of Antihistamines on Methacholine Challenge Testing in Asthma Patients	Anti-histamines and Methacholine Challenges.	Completed	The asthmatic airway is identified and studied using inhaled agents such as histamine and methacholine. The use of antihistamines prior to the test will inhibit the test result if histamine is used to cause airway constriction. If using methacholine, this may also be true depending on whether old (e.g. benadryl) or new (e.g. desloratadine) antihistamines are used. This study will look at the effect of old and new antihistamines on inhaled methacholine challenge response in individuals with mild asthma.	Crossover Assignment	Don Cockcroft	OTHER	All	\N	18	12	Actual	OTHER	University of Saskatchewan	Randomized	\N	Triple	\N	\N	Diagnostic	\N	\N	2013-11-01	2014-05-01	2014-05-01	2013-11-15	\N	2015-04-08	\N	University of Saskatchewan	Don Cockcroft	Professor	\N	\N	Sponsor-Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Asthma}	combination	cetirizine	No abstract available	f	Asthma	2022-08-17 13:39:16	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/25441635/	cetirizine|desloratadine
270	2023-01-02 15:22:35.737	2023-03-20 21:25:19.691	NCT01852318	A Multicenter, Double-blind, Randomized, Placebo and Active-controlled Study of Pregabalin for the Treatment of Uremic Pruritus	Pregabalin for the Treatment of Uremic Pruritus	Unknown status	Pruritus s a very distressing problem affecting patients with uremia and the prevalence of uremic pruritus (UP) ranges between 22% to 66%. Although some studies suggested pruritus is being decreased recently by use of better dialysis techniques, accumulating studies have shown the still high prevalence of UP. Because of its long duration, frequency and high intensity, UP has been reported to have a negative impact upon the patients' quality of life (QoL). However, the therapies in use, including antihistamines, ultraviolets, opioid antagonists and topical agents, are generally of insufficient efficacy, failing to provide adequate and long-lasting relief. Based on the neuropathic hypothesis and frequent co-occurrence of chronic pruritus and peripheral neuropathy in the patients undergoing hemodialysis, gabapentin, a medication widely used for a spectrum of neuropathic pain syndromes, has recently been suggested to be effective in the treatment of UP.Pregabalin, another gabaergic drug structurally related to gabapentin, have an advantage over gabapentin in terms of its more rapid response to stressful symptoms. Only two very recently small-scaled studies evaluate the effect of pregabalin for UP. However, both these studies were not randomized, placebo-controlled trails.As UP is still one of the most vexing and disabling symptoms in patients with ESRD, we decided to do this multicenter, randomized double-blind placebo-controlled trial (RCT) with a larger sample size and a longer duration.	Parallel Assignment	National Taiwan University Hospital	OTHER	All	\N	20	210	Anticipated	OTHER	National Taiwan University Hospital	Randomized	\N	Quadruple	\N	\N	Treatment	\N	Pruritus s a very distressing problem affecting patients with uremia and the prevalence of uremic pruritus (UP) ranges between 22% to 66%. Although some studies suggested pruritus is being decreased recently by use of better dialysis techniques, accumulating studies have shown the still high prevalence of UP. Because of its long duration, frequency and high intensity, UP has been reported to have a negative impact upon the patients' quality of life (QoL). However, the therapies in use, including antihistamines, ultraviolets, opioid antagonists and topical agents, are generally of insufficient efficacy, failing to provide adequate and long-lasting relief. Based on the neuropathic hypothesis and frequent co-occurrence of chronic pruritus and peripheral neuropathy in the patients undergoing hemodialysis, gabapentin, a medication widely used for a spectrum of neuropathic pain syndromes, has recently been suggested to be effective in the treatment of UP.\n\nPregabalin, another gabaergic drug structurally related to gabapentin, have an advantage over gabapentin in terms of its more rapid response to stressful symptoms. Only two very recently small-scaled studies evaluate the effect of pregabalin for UP. However, both these studies were not randomized, placebo-controlled trails.\n\nStudies focusing on the treatment of UP were limited and no studies comparing the efficacy between pregabalin and antihistamine, most widely used for the therapy of UP currently, were conducted. Additionally. there were few studies investigating the effect of the drugs used for UP on the QoL outcomes, though UP has a great impact on the patients' QoL. As UP is still one of the most vexing and disabling symptoms in patients with ESRD, we decided to do this multicenter, randomized double-blind placebo-controlled trial (RCT) with a larger sample size and a longer duration.\n\nObjectives:\n\nTo investigate the efficacy and the safety of pregabalin, as compared with fexofenadine and placebo, in the treatment of uremic pruritus.\n\nMethods:\n\nThis is a multicenter RCT. Haemodialysis patients with established UP were enrolled from multiple medical centers in Taiwan. All patients will be randomly allocated to receive one of three treatments -pregabalin 75mg daily, fexofenadine 60 mg daily, or placebo-for 12 weeks. The primary endpoint of the study is the change in the visual analogue score and pruritus score. The changes in QoL measures, including Skindex-10, Brief Itching Inventory and Itch Medical Outcomes Study, are also assessed before, during and after therapy. Safety is assessed at all visits throughout the study. A follow-up visit will be performed 2 weeks after administration of the final dose of study	2014-04-01	2015-05-01	2015-05-01	2013-05-13	\N	2014-04-15	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Uremic Pruritus"}	control	fexofenadine	Assoicated trial: https://pubmed.ncbi.nlm.nih.gov/33283264/ (but it is a meta anaylsis)	f	Pruritus	2022-08-18 16:54:53	{"Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev. 2020 Dec 7;12(12):CD011393. doi: 10.1002/14651858.CD011393.pub2."}	UNKNOWN	\N	fexofenadine
424	2023-01-02 15:22:35.746	2023-03-21 13:38:58.926	NCT04404660	An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia	A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)	Recruiting	This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).	Single Group Assignment	Autolus Limited	INDUSTRY	All	\N	18	215	Anticipated	INDUSTRY	Autolus Limited	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	This Phase Ib/II, open-label, multi-center, single arm study is designed to evaluate the safety and efficacy of AUTO1 in adult patients with B-cell ALL by determining the overall response rate (ORR).\n\nAdult patients with relapsed or refractory ALL will be enrolled in both phases of the study. Consented patients will go through the following five sequential stages: screening, leukapheresis, pre-conditioning, treatment, and follow-up. All patients will receive a total target dose of 410E+6 of CAR T cells as a split dose on Day 1 and on Day 10 (2 days).	2020-03-04	2023-06-01	2025-04-01	2020-05-27	\N	2022-08-31	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1","Phase 2"}	{"Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia"}	not included	\N	drug not found	f	\N	\N	{}	UNKNOWN	\N	\N
271	2023-01-02 15:22:35.737	2023-03-20 21:26:25.865	NCT00960141	A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Fall Study	A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)	Completed	A study of the ability of montelukast to improve signs and symptoms of seasonal allergic rhinitis compared with placebo. Loratadine is included in the study as an active control.	Parallel Assignment	Organon and Co	INDUSTRY	All	85	15	829	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2000-08-01	2000-10-01	2000-11-01	2009-08-17	2010-06-09	2022-02-03	Merck Sharp & Dohme Corp	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	control	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Chervinsky P, Philip G, Malice MP, Bardelas J, Nayak A, Marchal JL, van Adelsberg J, Bousquet J, Tozzi CA, Reiss TF. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol. 2004 Mar;92(3):367-73. doi: 10.1016/S1081-1206(10)61576-1."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/15049402/	loratadine
272	2023-01-02 15:22:35.737	2023-03-20 21:27:08.123	NCT01330017	A Randomized, Dose-ranging, Placebo-controlled Trial to Evaluate the Effects of Phenylephrine HCl Immediate Release Tablets on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis	Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)	Completed	The trial will evaluate the nasal congestion symptom relief of the approved 10 mg phenylephrine (PE) dose and the higher 20 mg, 30 mg, and 40 mg PE doses compared with placebo in participants with histories of seasonal allergic rhinitis, using loratadine as background medication.	Parallel Assignment	Bayer	INDUSTRY	All	\N	18	539	Actual	INDUSTRY	Bayer	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2011-03-01	2011-05-01	2011-06-01	2011-04-06	2012-11-07	2015-03-11	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{Rhinitis,"Seasonal Rhinitis"}	combination	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Meltzer EO, Ratner PH, McGraw T. Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study. J Allergy Clin Immunol Pract. 2015 Sep-Oct;3(5):702-8. doi: 10.1016/j.jaip.2015.05.007. Epub 2015 Jul 2."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/26143019/	loratadine
422	2023-01-02 15:22:35.746	2023-03-21 13:37:21.593	NCT03812653	Sleep for Stroke Management and Recovery Trial	Sleep for Stroke Management and Recovery Trial	Recruiting	The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.	Parallel Assignment	University of Michigan	OTHER	All	\N	18	3062	Anticipated	OTHER	University of Michigan	Randomized	Intervention group receives automatically adjusting continuous positive airway pressure (CPAP) plus usual care.The control group receives usual care.	Single	Eligible participants will be allocated in a 1:1 fashion to CPAP or no CPAP using a randomization method to protect subject treatment allocation and prevent potential selection biases.	\N	Prevention	\N	Sleep SMART has a prospective, randomized, open-label, blinded-endpoint (PROBE) design. It is a multi-site, parallel-group superiority trial that compares 6 months of OSA treatment to usual care. The study includes two trials: a prevention study with an embedded recovery trial. 3062 subjects will be randomized over 5 years at 110 sites within the NINDS-funded StrokeNet clinical trials network.	2019-05-09	2023-11-01	2023-11-01	2019-01-23	\N	2022-12-08	\N	University of Michigan	Devin L. Brown, MD	Professor of Neurology	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{"Ischemic Stroke","Sleep Apnea","Sleep Apnea, Obstructive",TIA,Stroke,CPAP,Telemedicine,"Home Sleep Apnea Test","Randomized Clinical Trial","Multicenter Trial"}	not included	\N	No info about drug found	f	\N	\N	{}	UNKNOWN	\N	\N
273	2023-01-02 15:22:35.737	2023-03-20 21:27:39.344	NCT03613246	Clinical Outcomes of the NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population With Elevated Surgical Risk	NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population	Recruiting	The study collects real-world data of patients who were treated with the ALLEGRA TAVI System TF and evaluates early and midterm clinical and quality of life outcome.	\N	NVT GmbH	INDUSTRY	All	\N	18	200	Anticipated	INDUSTRY	NVT GmbH	\N	\N	\N	\N	Other	\N	Prospective	\N	2019-02-20	2022-12-01	2025-02-01	2018-08-03	\N	2022-04-06	\N	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Adult,"Older Adult"}	{}	{"Transcatheter Aortic Valve Implantation"}	not included	fexofenadine	ALLEGRA does not refer to fex 	f	Transcatheter Aortic Valve Implantation	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
274	2023-01-02 15:22:35.737	2023-03-20 21:28:04.866	NCT00963469	A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period-Fall 2001	Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)	Completed	This is a study to evaluate the treatment effect of montelukast 10 mg taken in the morning, versus placebo, in patients with seasonal allergic rhinitis. Loratadine is included in the study as an active control.	Parallel Assignment	Organon and Co	INDUSTRY	All	85	15	1079	Actual	INDUSTRY	Organon and Co	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2001-08-01	2001-11-01	2001-11-01	2009-08-21	2010-06-09	2022-02-03	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	control	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"van Adelsberg J, Philip G, Pedinoff AJ, Meltzer EO, Ratner PH, Menten J, Reiss TF; Montelukast Fall Rhinitis Study Group. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy. 2003 Dec;58(12):1268-76. doi: 10.1046/j.1398-9995.2003.00261.x. Erratum In: Allergy. 2004 Mar;59(3):357. Allergy. 2009 Nov;64(11):1697."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/14616102/	loratadine
279	2023-01-02 15:22:35.738	2023-03-20 21:32:02.885	NCT03004131	Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (MP-AzeFlu) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo and Free Combination of Fluticasone Propionate Nasal Spray and Oral Loratadine	MP-AzeFlu Allergen Chamber - Onset of Action Study	Completed	This study is to assess the onset of action of fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (MP-AzeFlu) in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Chamber (EEC).	Crossover Assignment	MEDA Pharma GmbH & Co. KG	INDUSTRY	All	55	18	82	Actual	INDUSTRY	Viatris Inc.	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2017-01-07	2017-03-29	2017-03-29	2016-12-28	\N	2022-02-22	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	control	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/29425904/	loratadine
406	2023-01-02 15:22:35.745	2023-03-21 13:12:26.221	NCT03923140	Efficacy and Safety of Tranilast in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS): A Single-Arm Prospective Cohort Study	A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)	Recruiting	This is a prospective cohort study to observe the efficacy and safety of tranilast in CAPS patients. The investigators would analyze the changes in Auto-Inflammatory Diseases Activity Index (AIDAI) before and after treatment as well as changes in inflammatory markers, patients' and physician's global assessment of disease activity to determine the efficacy and safety of tranilast.	Single Group Assignment	Peking Union Medical College Hospital	OTHER	All	\N	\N	71	Anticipated	OTHER	Peking Union Medical College Hospital	N/A	a single-arm prospective cohort study	None (Open Label)	\N	\N	Treatment	\N	Seventy-one patients with CAPS will be recruited. After signing the informed consent, they will be administrated with tranilast (For juvenile patients, 5mg/kg.d with a maximum dose of 0.3g per day; For adult patients, the dose is 0.1g each time, three times a day). These patients will be followed up for 6 months. AIDAI is recorded by patients' or their parents one month before the start of treatment, and at the 1st, 3rd and 6th month after the treatment. Inflammatory markers, and patients' and physician's global assessment of disease activity will be assessed during the 1st, 3rd and 6th month follow-up. Side effects will be monitored and recorded as well. Experimental data before and after the administration of tranilast will be analyzed and be statistically processed, to figure out whether tranilast is effective and safe for CAPS patients.	2019-05-23	2024-04-01	2024-10-01	2019-04-22	\N	2019-06-04	\N	Peking Union Medical College Hospital	Hongmei Song	Professor	\N	\N	Principal Investigator	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 2"}	{"Cryopyrin-Associated Periodic Syndromes"}	not included	cetirizine	Cetrizine not found?	f	CAPS	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
280	2023-01-02 15:22:35.738	2023-03-20 21:33:02.907	NCT02935699	A Phase III, Multi-center, Double Blind, Randomized, Active Controlled Clinical Trial to Evaluate the Non-Inferiority Comparing Cetirizine Injection 10 mg to Diphenhydramine Injection, 50 mg, for the Treatment of Acute Urticaria	Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria	Completed	This is a multicenter, parallel group, randomized, double-blind, active controlled, Phase III clinical study of cetirizine injection, 10 mg/mL, compared to diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent) with acute urticaria requiring treatment.	Parallel Assignment	JDP Therapeutics, Inc.	INDUSTRY	All	\N	18	262	Actual	INDUSTRY	JDP Therapeutics, Inc.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	This was a multi-center, parallel group, randomized, double-blind, active controlled, Phase III clinical trial of cetirizine injection 10 mg/mL versus diphenhydramine injection 50 mg/mL (Benadryl or generic equivalent) in approximately 256 subjects who either presented to Emergency Departments, hospitals, allergy clinics or Urgent Care Centers with acute urticaria, or developed acute urticaria following allergen challenge at an Allergy Clinic.\n\nPatients signed an informed consent and were evaluated for eligibility for inclusion to treat. Eligible subjects were assessed for baseline characteristics, medical and surgical histories, concomitant medications and given a brief physical exam.\n\nSubjects were then randomized, in a 1:1 ratio, to blindly receive either cetirizine 10 mg/mL injection or diphenhydramine 50 mg/mL injection.\n\nEfficacy assessments included patient-rated severity of pruritus, physician assessments of extent of urticaria/erythema, and sedation score. Subjects remained in the treatment center for at least after the 1 hr assessment, after which they may have been discharged at the physician's discretion.\n\nSafety was monitored through the reporting of adverse events for up to 28 days following treatments and by monitoring vital signs at planned intervals from admission into the treating facility until readiness for discharge. After 24 and 48 hrs after discharge, subjects were contacted by phone for follow-up questions regarding recurrence of symptoms, new symptoms, additional medication taken, side effects from medication taken after discharge, relapse requiring a return to treatment center, and return to normal activities.	2017-03-01	2018-04-30	2018-04-30	2016-10-17	2019-11-27	2019-11-27	TerSera Therapeutics	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Acute Urticaria"}	comparison	cetirizine	\N	f	Urticaria	2022-08-17 13:39:16	{"Abella BS, Berger WE, Blaiss MS, Stiell IG, Herres JP, Moellman JJ, Suner S, Kessler A, Klausner HA, Caterino JM, Du J. Intravenous Cetirizine Versus Intravenous Diphenhydramine for the Treatment of Acute Urticaria: A Phase III Randomized Controlled Noninferiority Trial. Ann Emerg Med. 2020 Oct;76(4):489-500. doi: 10.1016/j.annemergmed.2020.05.025. Epub 2020 Jul 9."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/32653333/	cetirizine
284	2023-01-02 15:22:35.738	2023-03-20 21:34:25.004	NCT01413958	A Randomized, Placebo-Controlled Trial to Evaluate the Effects of Phenylephrine HCl 30 mg Extended-Release Tablets on Nasal Congestion in Subjects With Allergic Rhinitis	Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)	Completed	This study will compare the nasal congestion symptom relief of phenylephrine extended release tablets and placebo in participants with allergic rhinitis.	Parallel Assignment	Bayer	INDUSTRY	All	\N	18	575	Actual	INDUSTRY	Bayer	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2011-08-01	2011-10-01	2011-10-01	2011-08-10	2013-01-29	2015-03-11	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	rescue medication	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Meltzer EO, Ratner PH, McGraw T. Phenylephrine hydrochloride modified-release tablets for nasal congestion: a randomized, placebo-controlled trial in allergic rhinitis patients. Ann Allergy Asthma Immunol. 2016 Jan;116(1):66-71. doi: 10.1016/j.anai.2015.10.022. Epub 2015 Nov 7."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/26560899/	loratadine
291	2023-01-02 15:22:35.738	2023-03-20 21:38:37.26	NCT03545464	COrticosteroids in acUte uRticAria in emerGency dEpartment	COrticosteroids in acUte uRticAria in emerGency dEpartment	Recruiting	To demonstrate the non-inferiority of the efficacy of a single antihistamine in comparison with an association of antihistamine and corticosteroid in the treatment of acute urticaria in emergency departments	Parallel Assignment	Assistance Publique - Hpitaux de Paris	OTHER	All	\N	18	240	Anticipated	OTHER	Assistance Publique - Hpitaux de Paris	Randomized	\N	Double	\N	\N	Treatment	\N	Acute urticaria (hives) is a common skin disease. The prevalence of acute urticaria in life is about 15 to 20% in the general population. It is responsible for a frequent use of emergency departments (ED). The usual treatment is based on early administration of an association of antihistamines and corticosteroid. The therapeutic efficacy of corticosteroids has never been established by high evidence studies. However, corticosteroids are frequently used. When stopped, corticosteroids could promote the occurence of urticaria recurrences, and a transition to chronic urticaria. In addition, corticosteroids may be rarely responsible for gastrointestinal bleeding, hypertension and diabetes.	2019-09-21	2022-03-28	2023-09-21	2018-06-04	\N	2022-12-09	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{Urticaria,Angidema}	comparison	levocetirizine	comparison or main?	f	Urticaria	2022-09-15 18:58:14	{"Javaud N, Soria A, Maignan M, Martin L, Descamps V, Fain O, Bouillet L, Berard F, Tazarourte K, Roy PM, Fontaine JP, Bagot M, Khellaf M, Goulet H, Lapostolle F, Casalino E, Doutre MS, Gil-Jardine C, Caux F, Chosidow O, Pateron D, Vicaut E, Adnet F. Glucocorticoids for acute urticaria: study protocol for a double-blind non-inferiority randomised controlled trial. BMJ Open. 2019 Aug 21;9(8):e027431. doi: 10.1136/bmjopen-2018-027431."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/31439599/	levocetirizine
407	2023-01-02 15:22:35.744	2023-03-21 13:12:55.87	NCT03796377	Effects of Hypericum Perforatum (St. John's Wort) on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Humans	Rivaroxaban Hypericum Trial	Completed	Single-center, open-label, sequential treatment study to investigate the influence of the combined P-glycoprotein and CYP3A4 inducer hypericum perforatum on the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy volunteers.	Sequential Assignment	University Hospital Inselspital, Berne	OTHER	All	45	18	12	Actual	OTHER	University Hospital Inselspital, Berne	Non-Randomized	\N	None (Open Label)	\N	\N	Other	\N	Each session (one with and one without preceding CYP induction) will start with phenotyping using 25 mg fexofenadine orally for P-gp phenotyping and 2 mg midazolam orally for cytochrome P450 (CYP) 3A4 phenotyping. After a washout period of 5 days, subjects will receive a single oral dose of 20 mg rivaroxaban, a dose currently approved for human use in clinical routine. The same procedure will be repeated after pretreatment with St. John's wort extract (Jarsin) twice daily 450 mg po (dose usually used in clinical routine) for 2 weeks.	2019-02-13	2019-04-09	2019-04-09	2019-01-08	\N	2020-11-03	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{"Drug Interaction Study"}	minimal	fexofenadine	Phenotyping	f	Pharmacokinetics	2022-08-18 16:54:53	{"Scholz I, Liakoni E, Hammann F, Grafinger KE, Duthaler U, Nagler M, Krahenbuhl S, Haschke M. Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. Br J Clin Pharmacol. 2021 Mar;87(3):1466-1474. doi: 10.1111/bcp.14553. Epub 2020 Oct 25."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/32959922/	fexofenadine
292	2023-01-02 15:22:35.736	2023-03-20 21:39:55.506	NCT00421109	Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria	Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria	Completed	The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg Q.D., compared to Levocetirizine 5 mg Q.D. and placebo for the treatment of Chronic Idiopathic Urticaria.	Parallel Assignment	Faes Farma, S.A.	INDUSTRY	All	70	18	522	Actual	INDUSTRY	Faes Farma, S.A.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	A total of 540 patients with CIU will be enrolled in this pivotal, randomised, multicentre, international, double-blind, placebo and active-comparator controlled, parallel study . Patients will be selected from both public and private clinical practices. The study population includes males and females between 18 and 70 years of age, suffering from CIU for at least 6 weeks prior to entry in the study with no identifiable cause.	2006-07-01	2007-07-01	2007-07-01	2007-01-11	\N	2012-04-05	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{Urticaria}	comparison	levocetirizine	\N	f	Urticaria	2022-09-15 18:58:14	{"Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf. 2011 Sep;10(5):779-93. doi: 10.1517/14740338.2011.604029. Epub 2011 Aug 11. Erratum In: Expert Opin Drug Saf. 2012 Jan;11(1):175.","Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Antepara I, Jauregui I, Valiente R; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010 Apr;65(4):516-28. doi: 10.1111/j.1398-9995.2009.02217.x. Epub 2009 Oct 23."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19860762/	levocetirizine
293	2023-01-02 15:22:35.738	2023-03-20 21:40:51.67	NCT02391688	\N	Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail	Completed	Phenotyping is an approach largely used for the evaluation of the activity of cytochromes and transporters in vivo. It consists of the administration of probe substances metabolised by a specific cytochrome or transported by P-glycoprotein (P-gp) for example, followed by the determination of a metabolic ratio or the evaluation of the plasmatic or urinary concentrations of the probe substances. The administration of a cocktail containing several probe substances allows the simultaneous evaluation of the activity of several cytochromes and P-gp in a single test.\n\nWhen a cocktail approach is used it is important to make sure that no drug-drug interactions occur between the probes within the cocktail. The validation of the lack of interactions, which is the aim of the study, consists of demonstrating that there is no difference in the pharmacokinetic parameters and/or metabolic ratios when a probe is administered alone or as part of the cocktail. The Geneva cocktail consists of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam and fexofenadine for the simultaneous phenotyping of CYP1A2, CYP2B6, CYP2C9, CAP2C19, CYP2D6, CYP3A4 and P-gp, respectively.\n\nProbe and metabolite concentrations will be measured in capillary blood using a dried blood spot (DBS) analysis. To further facilitate sampling, a new simple device will be used to ensure the precision of capillary blood collection.	Crossover Assignment	Jules Desmeules	OTHER	All	60	18	30	Actual	OTHER	University Hospital, Geneva	Randomized	\N	None (Open Label)	\N	\N	Diagnostic	\N	\N	2014-11-01	2015-04-01	2015-04-01	2015-03-18	\N	2017-02-07	\N	University Hospital, Geneva	Jules Desmeules	Professor	\N	\N	Sponsor-Investigator	\N	Interventional	{Adult}	{"Phase 1"}	{"Drug Interaction"}	combination	fexofenadine	\N	f	Pharmacokinetics	2022-08-18 16:54:53	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/31581637/	fexofenadine
298	2023-01-02 15:22:35.739	2023-03-20 21:45:18.639	NCT01519856	Efficacy and Safety of Long-term Therapy With Piribedil (CLARIUM) in Patients With M. Parkinson Under Consideration of Quality of Life Parameters and Cognitive Function	PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy	Completed	Non-Ergot Dopamine agonists are meanwhile the drugs of first-choice in the treatment of Parkinson's disease. The receptor profile of the non-ergot dopamine-agonist piribedil is unique. In addition to agonistic effects on dopaminergic D2- and D3-receptors piribedil has adrenergic alpha-2A- and alpha-2C-receptors antagonisic properties. There is evidence from the literature that the antagonistic properties of piribedil are correlated with an improvement of cognitive function and vigilance parameters in parkinson's disease. The aim of the present non-interventional study is to investigate the safety and efficacy of piribedil during long-term therapy of patients with M. Parkinson under consideration of cognitive functions and quality of life.	\N	Desitin Arzneimittel GmbH	INDUSTRY	All	\N	18	908	Actual	INDUSTRY	Desitin Arzneimittel GmbH	\N	\N	\N	\N	\N	\N	Prospective	\N	2009-06-01	2014-12-01	2015-02-01	2012-01-27	\N	2016-01-29	\N	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Adult,"Older Adult"}	{}	{"Parkinson's Disease"}	not included	loratadine	Clarium	f	Parkinson	2022-08-17 18:44:47	{"Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P; Parkinson-Control Study Group. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord. 2006 Apr;21(4):500-9. doi: 10.1002/mds.20750.","Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A; Parkinson REGAIN Study Group. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Mov Disord. 2006 Dec;21(12):2110-5. doi: 10.1002/mds.21122.","Peretti CS, Gierski F, Harrois S. Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil. Psychopharmacology (Berl). 2004 Nov;176(2):175-81. doi: 10.1007/s00213-004-1869-8. Epub 2004 May 12.","Schuck S, Bentue-Ferrer D, Kleinermans D, Reymann JM, Polard E, Gandon JM, Allain H. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol. 2002 Feb;16(1):57-65. doi: 10.1046/j.1472-8206.2002.00070.x."}	UNKNOWN	\N	loratadine
299	2023-01-02 15:22:35.739	2023-03-20 21:45:58.964	NCT02360644	Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease	Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease	Completed	This study investigates the effect of vitamin D deficiency on drug metabolism and transport in patients with chronic kidney disease (CKD) and in healthy controls.\n\nThe central hypothesis is that vitamin D concentrations independently affect metabolism and transport function in CKD patients. An over-arching goal of this proposal is to make drug therapies safer and more effective to reduce the significant morbidity and mortality in patients with CKD.	Single Group Assignment	University of Colorado, Denver	OTHER	All	70	18	23	Actual	OTHER	University of Colorado, Denver	Non-Randomized	\N	None (Open Label)	\N	\N	Other	\N	Specific Aim 1: Determine the effect of vitamin D deficiency and repletion on xenobiotic clearance in vivo. The study will mechanistically evaluate the function of major pathways of metabolism and transport by prospectively studying clearance phenotypes utilizing "probe" drugs commonly used for this purpose in CKD patients and healthy volunteers under vitamin D deficient and replete states. Bupropion, midazolam, olmesartan, fexofenadine, in addition to an endogenous probe (N-methylnicotinamide), will be used to phenotype major phase I drug metabolizing enzymes [cytochrome P450 2B6 (CYP2B6), cytochrome P450 3A4/5 (CYP3A4/5)], and transporters [multidrug resistance associated protein 2 (MRP2), P-glycoprotein (P-gp), and multidrug and toxin extrusion protein 1/2K (MATE1/2K)], respectively. Hypothesis: The in vivo function of individual pathways of xenobiotic metabolism and transport are affected by vitamin D status (and CKD).\n\nSpecific Aim 2: Determine the effect of CKD on the in vivo function of individual CYPs responsible for vitamin D metabolism and the pharmacokinetics of cholecalciferol (vitamin D3). The research will prospectively measure the activity of CYP450s responsible for cholecalciferol metabolism, and simultaneously evaluate the pharmacokinetics (PK) of cholecalciferol after single- and multiple-dose administration to CKD patients (stages 1-5) and healthy volunteers. Hypothesis: CKD alters the activity of individual CYPs responsible for vitamin D metabolism, leading to modified clearance of cholecalciferol.	2014-10-01	2019-02-01	2019-02-01	2015-02-10	\N	2021-06-30	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{"Chronic Kidney Diseases","Deficiency, Vitamin D"}	minimal	fexofenadine	fex only as test drug	f	Kidney Disease	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
301	2023-01-02 15:22:35.739	2023-03-20 21:47:11.782	NCT04369482	Posterior Capsule Opafication of Different Hydrophobic Acrylic Intraocular Lenses: Vivinex iSert P261 vs.Clareon IOL	Posterior Capsule Opafication of Different Hydrophobic Acrylic Intraocular Lenses: Vivinex iSert P261 vs.Clareon IOL	Active, not recruiting	On the day of surgery, the first eye to be operated is randomised to receive a Vivinex , HOYA Surgical Optics GmbH or an Clareon, Alcon, Fort Worth, Texas. The second eye to be operated receives the other IOL type.\n\nA complete biomicroscopic examination, visual acuity testing using autorefractometer, contrast sensitivity testing, and standardised retroillumination photography for PCO evaluation, will be performed 6 month (30-60 days), 1.5 years ( 3 months) and 3 ( 3 months) years postoperatively.	Parallel Assignment	Medical University of Vienna	OTHER	All	90	40	100	Actual	OTHER	Medical University of Vienna	Randomized	The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Cataract surgery with precedent bilateral randomized IOL implantation will be performed in subjects who have signed an informed consent form. Postoperative examinations will be implemented in accordance with the approved Investigational Plan on subjects and includes: visual acuity, slitlamp examination, fibrosis, posterior capsule opacification (PCO) score and YAG capsulotomy rate.	Double	\N	\N	Diagnostic	\N	\N	2019-01-01	2022-12-01	2023-02-01	2020-04-30	\N	2022-05-17	\N	Medical University of Vienna	Rupert Menapace	Clinical Professor	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{"Age Related Cataracts"}	not included	desloratadine	Other Study id is clarinex	f	Cataracts	2022-09-15 19:16:20	{}	UNKNOWN	\N	desloratadine
302	2023-01-02 15:22:35.739	2023-03-20 21:51:06.089	NCT03991845	A Randomised Controlled Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria	A Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria	Unknown status	This study will be an assessor-blind, randomized controlled trial in patients with CSU. The investigators will compared Vit D level in patients with Chronic spontaneous urticaria (CSU) and controls. Enrolled CSU patients with Vit D level <30ng/ml will be then randomized into three intervention arms in the ratio of 1:1:1. Patients belonging to intervention group A will be treated with low dose Vit D (2000 IU/day) for 12 weeks according to the Indian council of medical research (ICMR) guidelines. Intervention group B patients will be treated with high dose Vit D (60,000 IU/week) for 12 weeks and group C will not be given any Vit D supplements. All patients will be evaluated after 12 weeks. The urticaria activity score over 4 days (UAS4) will be used to assess the disease severity using the number of wheals and pruritus intensity based on the EAACI/GA2LEN/EDF guidelines. The patient's disease severity levels will be graded as mild (0-8), moderate (9-16), and severe (17-24).	Parallel Assignment	Postgraduate Institute of Medical Education and Research	OTHER_GOV	All	\N	18	262	Actual	OTHER_GOV	Postgraduate Institute of Medical Education and Research	Randomized	\N	Double	\N	\N	Treatment	\N	This is a prospective, randomized, single-centre clinical study. Serum Vit D level will be assessed in all patients at baseline. Patients with Vit D level 30 will be excluded from the trial but included in the study and those with Vit D level <30 will be randomized into 3 groups A, B and C. Patients with Vit D level 30 will be categorized into Group D. Patients belonging to Group A will be treated with low dose Vit D (2000 IU/day) according to Indian council of medical research (ICMR) guidelines. Those in Group B will be treated with high dose Vit D (60,000 IU/week) and group C will not be given any Vit D supplements. Patients belonging to Group A and B will be treated for 12 weeks in order to safely restore Vit D and achieve a steady state. In addition levocetirizine, 10 mg will be given to all patients in groups to control urticaria symptoms. All patients will be treated according to EAACI/GA2LEN/EDF guidelines after 12 weeks. All participants will also be provided with rescue prednisone use for intolerable or uncontrolled symptoms. At 6 weeks and 12 weeks, a physician assessment (physician blinded to treatment arm) will be conducted to check if patients had intolerable symptoms or took rescue prednisolone 40 mg therapy. Safety monitoring will be completed throughout the entirety of the study. Specific stopping rules and discontinuation of the study included pregnancy, a serum Vit D level higher than 100 ng/mL, or a serum calcium level higher than 11 mg/dL. Patients will be followed for 6 weeks after the study completion and thereafter data analysis will be done in 3 steps:\n\nStep 1: Comparison of serum Vit D level in CSU patients vs. controls Step 2 : Assessment of factors associated with Vit D deficiency in urticaria patients Step 3: Effect of Vit D supplementation (group A (low dose), group B (high dose), group C(no supplementation) on urticaria severity using UAS4	2019-06-21	2019-11-27	2019-12-28	2019-06-19	\N	2019-06-24	\N	Postgraduate Institute of Medical Education and Research	Davinder Parsad	Professor	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Urticaria,"Vitamin D Deficiency"}	combination	levocetirizine	main focus of study is Vitamin D\n\nQuestionable if that is the right publication but could be	f	Urticaria	2022-09-15 18:58:14	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/31926152/	levocetirizine
306	2023-01-02 15:22:35.739	2023-03-20 21:55:52.559	NCT02056743	Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers; Open-label, Parallel Group	Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers	Completed	The purpose of this study is to evaluate the possibility of drug interactions before and after taking red ginseng or fermented-red ginseng by estimating metabolic rate of indicator drugs for cytochrome P450 and P-glycoprotein.	Parallel Assignment	Chonbuk National University Hospital	OTHER	Male	55	20	30	Actual	OTHER	Chonbuk National University Hospital	Randomized	\N	None (Open Label)	\N	\N	\N	\N	\N	2013-09-01	2013-10-01	\N	2014-02-06	\N	2014-02-06	\N	Chonbuk National University Hospital	Dal-Sik Kim	Professor, MD	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	minimal	fexofenadine	only as test drug	f	Healthy	2022-08-18 16:54:53	{"Kim DS, Kim Y, Jeon JY, Kim MG. Effect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteers. J Ginseng Res. 2016 Oct;40(4):375-381. doi: 10.1016/j.jgr.2015.11.005. Epub 2015 Dec 17.","Kim MG, Kim Y, Jeon JY, Kim DS. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach. Br J Clin Pharmacol. 2016 Dec;82(6):1580-1590. doi: 10.1111/bcp.13080. Epub 2016 Oct 9."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/27495955/	fexofenadine
305	2023-01-02 15:22:35.739	2023-03-20 21:54:12.474	NCT01318681	Effects of Treated and Untreated Allergic Rhinitis on Mood, Cognitive Functions and Actual Driving Performance	Rhinitis, Cognition and Driving Performance	Completed	This study investigates the effects of Allergic Rhinitis (AR) on driving ability and memory functions. Our group has previously shown that patients suffering from AR symptoms perform less well on tasks requiring sustained attention compared to non symptomatic controls. Car driving is a typical behavior that is susceptible for changes in sustained attention and might therefore become worse under conditions when patients suffer from AR symptoms. We will compare the driving performance of untreated, symptomatic AR patients with the performance of symptomatic patients that have been treated with either a systemic AR medication (a pill) or a topical medication (nasal spray)	Crossover Assignment	Maastricht University Medical Center	OTHER	All	45	21	22	Actual	OTHER	Maastricht University Medical Center	Randomized	\N	Double	\N	\N	\N	\N	\N	2011-01-01	2012-03-01	2012-10-01	2011-03-18	\N	2013-11-08	\N	Maastricht University Medical Center	Vuurman	DR Eric Vuurman	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Not Applicable"}	{"Seasonal Allergic Rhinitis","Driving Ability",Cognition}	main	cetirizine	slightly different numbers in publication but should be a match	f	Safety Evaluation	2022-08-17 13:39:16	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/24815889/	cetirizine
308	2023-01-02 15:22:35.739	2023-03-20 21:57:05.719	NCT00449072	A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the 12 Month Effect of Treatment With Once Daily Triamcinolone Acetonide (NASACORT AQ Nasal Spray 110 g) on the Growth Velocity of Children, 3 to 9 Years of Age, With Perennial Allergic Rhinitis (PAR)	Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)	Completed	The primary objective of the study was to characterize the difference in prepubescent growth velocity in children 3 to 9 years of age with perennial allergic rhinitis (PAR) treated with triamcinolone acetonide (TAA) nasal spray (NASACORT AQ 110 g treatment group) or placebo (NASACORT AQ placebo group) for 12-months.\n\nThe secondary objectives were to compare the following in prepubertal participants treated with TAA nasal spray versus placebo:\n\nthe 24-hour urinary free cortisol levels and the cortisol/creatinine ratio (to measure the Hypothalamic-Pituitary Adrenal [HPA] axis function)\nthe rate of treatment-emergent-adverse-events (TEAE)\nglobal efficacy rated by the investigator and the participant separately\nthe rate of use of rescue medication during the study	Parallel Assignment	Sanofi	INDUSTRY	All	9	3	299	Actual	INDUSTRY	Sanofi	Randomized	\N	Double	\N	\N	Treatment	\N	The study consisted of:\n\na 4- to 6-month screening/baseline period\na 12-month (up to Day 360+/-5 days) double-blind treatment period starting on Day 1\na 2-month follow-up period (up to Day 420+/-5 days)	2007-03-01	2011-10-01	2011-10-01	2007-03-19	2012-08-07	2012-08-10	sanofi-aventis	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 4"}	{"Rhinitis, Allergic, Perennial"}	rescue medication	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/25624374/	loratadine
411	2023-01-02 15:22:35.745	2023-03-21 13:21:14.117	NCT00078195	Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered With Omalizumab, an Anti-IgE Monoclonal Antibody (ITN019AD)	Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies	Completed	A series of allergy shots may reduce symptoms of seasonal ragweed allergies. This study will determine whether taking a drug called omalizumab (also known as Xolair) before getting the allergy shots is more effective than allergy shots alone or other treatments, such as prescription antihistamines.	Parallel Assignment	National Institute of Allergy and Infectious Diseases (NIAID)	NIH	All	50	18	168	\N	NIH	National Institute of Allergy and Infectious Diseases (NIAID)	Randomized	\N	Double	\N	\N	Treatment	\N	Allergic rhinitis affects 20 to 40 million Americans annually. Allergy symptoms, which can range from mild to seriously debilitating, may affect quality of life. Left untreated, allergic rhinitis can exacerbate or trigger more serious conditions, such as asthma and sinus inflammation.\n\nIndividuals with allergies react to harmless particles such as dust or pollen. Proteins in the blood called IgE antibodies treat the harmless particles as invaders and trigger an immune system response. The immune response results in harmful inflammation of healthy tissues. In ragweed allergy, inflammation occurs in the airways and causes familiar allergy symptoms like sneezing, coughing, and general discomfort.\n\nOmalizumab is an investigational drug that has been shown to block the effects of IgE antibodies. The blocking effect of omalizumab is temporary, but giving the drug to people before their regular allergy shots may make the shots more effective.\n\nParticipants in this study will be randomly assigned to receive injections of omalizumab or a placebo before an accelerated course of allergy shots (given over 12 weeks). The participants will return for follow-up for up to one year, and they may have as many as 27 study visits.	2003-04-01	2005-05-01	2005-05-01	2004-02-20	\N	2016-10-18	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 2"}	{"Hay Fever",Hypersensitivity,Allergy,Rhinitis}	rescue medication	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{"Nayak A, Casale T, Miller SD, Condemi J, McAlary M, Fowler-Taylor A, Della Cioppa G, Gupta N. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2003 Sep-Oct;24(5):323-9.","Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y; Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006 Jan;117(1):134-40. doi: 10.1016/j.jaci.2005.09.036. Epub 2005 Dec 2.","Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN; Immune Tolerance Network Group. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol. 2007 Sep;120(3):688-95. doi: 10.1016/j.jaci.2007.05.034. Epub 2007 Jul 12."}	NO_PUBLICATION_FOUND	\N	fexofenadine
311	2023-01-02 15:22:35.74	2023-03-20 21:59:29.589	NCT00533637	A Double-Blind, Randomized, Placebo-Controlled, Cross-Over, Allergen Challenge Study to Evaluate Taste and Local Tolerance of NLA Nasal Spray in Patients With Allergic Rhinitis	Taste and Local Tolerance Study of NLA Nasal Spray in Patients With Allergic Rhinitis	Completed	Evaluation of NLA Nasal Spray with regard to taste perversion and local tolerance	Crossover Assignment	Biolipox AB	INDUSTRY	All	50	18	28	Actual	INDUSTRY	Biolipox AB	Randomized	\N	Quadruple	\N	\N	Treatment	\N	Oral or intranasal antihistamines is the first line treatment for allergic rhinitis. Cetirizine is a second-generation selective antihistamine widely used in an oral formulation for the treatment of allergic rhinitis. Local administration of cetirizine has been shown to reduce symptoms after allergen challenge, and has the potential to shorten the time to onset and decrease systemic side effects. However, local irritation and nasal burning/pain has been reported after nasal administration. For the compliance of the patients taking a nasal spray, the taste and tolerance of the product is of particular importance. NLA Nasal Spray contains cetirizine in a liposomal formulation aiming to improve the tolerability. The present study aims to compare the NLA Nasal Spray with cetirizine in an aqueous formulation and placebo with regard to taste perversion and local tolerance. This will be investigated off-season in patients with seasonal allergic rhinitis after provocation with allergen.	2007-09-01	\N	2007-12-01	2007-09-21	\N	2008-03-05	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult}	{"Phase 2"}	{"Allergic Rhinitis"}	main	cetirizine	Could also be Taste, Preference...	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
313	2023-01-02 15:22:35.739	2023-03-20 22:01:52.392	NCT00796211	A Single-Center, Randomized, Blinded, Vehicle- Controlled Exploratory Study to Assess the Activity of CRx-197 in Subjects With Plaque Psoriasis	A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis	Completed	This will be a phase 2a single-center, randomized, blinded, vehicle-controlled exploratory study to assess the activity and safety of CRx-197 in subjects with plaque psoriasis. Approximately 20 male or female subjects with chronic plaque type psoriasis, 18 to 70 years of age, will be included in this study.\n\nAll subjects with stable psoriatic plaques will receive all of the following treatments each in a separate test field, once each day for four weeks under occlusion:\n\nCRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)\nCRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)\n0.1% nortriptyline HCl topical cream\n0.005% calcipotriol topical cream\nVehicle of CRx-197 topical cream (placebo)	Parallel Assignment	Zalicus	INDUSTRY	All	70	18	20	Anticipated	INDUSTRY	Zalicus	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2008-11-01	2008-12-01	2009-01-01	2008-11-24	\N	2009-01-15	\N	\N	\N	\N	Alka Batycky, Executive Director, Clinical Programs	CombinatoRx	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Plaque Psoriasis"}	combination	loratadine	Repurpose?	f	Psoriasis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
412	2023-01-02 15:22:35.746	2023-03-21 13:25:44.297	NCT03369704	A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled Severe Japanese Cedar Pollinosis Despite the Current Recommended Therapies	Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients	Completed	The purpose of this study was to demonstrate the efficacy and safety of omalizumab compared with placebo, on top of SoC (anti-histamine and nasal corticosteroid) in adult and adolescent patients with severe Japanese cedar pollinosis, whose symptoms were inadequately controlled despite the current recommended therapies (nasal corticosteroids plus one or more medications out of anti-histamine, leukotriene receptor antagonist, or prostaglandin D2/thromboxane A2 receptor antagonist) in the previous 2 Japanese cedar pollen seasons.	Parallel Assignment	Novartis Pharmaceuticals	INDUSTRY	All	75	12	337	Actual	INDUSTRY	Novartis	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2017-12-15	2018-05-11	2018-10-20	2017-12-12	2019-11-04	2021-01-05	Novartis Pharmaceuticals	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Seasonal Allergic Rhinitis"}	minimal	fexofenadine	TODO role	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/32422373/	fexofenadine
317	2023-01-02 15:22:35.739	2023-03-21 08:50:28.938	NCT01683552	Aprepitant in the Management of Biological Therapies-related Severe Pruritus: a Pilot Study in 45 Cancer Patients	Aprepitant in the Management of Biological Therapies-related Severe Pruritus	Completed	Itch is a common side effect of anti-epidermal growth factor receptor antibodies and tyrosine kinase inhibitors. Investigators designed a pilot single-center phase II study evaluating the effects of Aprepitant, a neurokinin receptor inhibitor, in managing biological therapy-induced pruritus.	Parallel Assignment	Campus Bio-Medico University	OTHER	All	85	18	45	Actual	OTHER	Campus Bio-Medico University	Non-Randomized	\N	None (Open Label)	\N	\N	Supportive Care	\N	Investigators enroll patients affected by solid tumors which present itch refractory to standard treatment ("refractory group") and patients who did not receive any treatment for pruritus ("nave group"). The intensity of itch will be evaluated with Visual Analogue Scale (VAS) score. In the refractory group Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) will be administered after at least 1 week of standard systemic treatment. In the nave group, Aprepitant will be administered after the first onset of severe pruritus. The primary end point is to evaluate the effect of aprepitant in managing pruritus both in naive and refractory group.	2010-09-01	2011-11-01	2011-11-01	2012-09-12	\N	2012-09-12	\N	Campus Bio-Medico University	Daniele Santini	MD, PhD	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{ITCH}	control	fexofenadine	fex as standard therapy	f	Pruritus	2022-08-18 16:54:53	{"Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012 Oct;13(10):1020-4. doi: 10.1016/S1470-2045(12)70373-X. Epub 2012 Sep 18."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/22995650/	fexofenadine
413	2023-01-02 15:22:35.746	2023-03-21 13:27:01.194	NCT00451321	TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD)	TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)	Terminated	The purpose of this study is to optimize several multi-dose regimens of otelixizumab, determine the highest biologically active dose, evaluate biomarkers and surrogates of efficacy, and to evaluate the effects of each multi-dose regimen of otelixizumab against standard safety and efficacy parameters.	Single Group Assignment	GlaxoSmithKline	INDUSTRY	All	45	12	88	Actual	INDUSTRY	GlaxoSmithKline	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2006-07-31	2011-12-01	2011-12-01	2007-03-23	2017-11-13	2017-11-13	GlaxoSmithKline	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult}	{"Phase 2"}	{"Diabetes Mellitus, Type 1"}	pre-medication	cetirizine	\N	f	Infusion Reaction	2022-08-17 13:39:16	{"Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005 Jun 23;352(25):2598-608. doi: 10.1056/NEJMoa043980."}	CT_RESULTS	\N	cetirizine
320	2023-01-02 15:22:35.74	2023-03-21 09:04:44.482	NCT01154153	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 g and 220 g Once Daily on Basal Hypothalamic-Pituitary-Adrenal (HPA) Axis Function in Children [>=2 to < 12 Years of Age] With Allergic Rhinitis (AR).	Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis	Completed	The primary objective was to evaluate the effect of a 6-week treatment with TAA-AQ (110 g) and TAA-AQ (220 g) once daily (QD) versus placebo on hypothalamic-pituitary-adrenal (HPA) axis function as measured by serum cortisol AUC(0-24 hr) in children (>=2 to <12 years old) with allergic rhinitis (AR).	Parallel Assignment	Sanofi	INDUSTRY	All	12	2	140	Actual	INDUSTRY	Sanofi	Randomized	\N	Triple	\N	\N	Treatment	\N	The study consisted of a run-in single-blind screening phase (prerandomization) followed by an approximately 6-week double-blind treatment phase (postrandomization).\n\nTotal study duration per participant lasted from 7.5 to 13 weeks and consisted of:\n\nScreening and single-blind phases (these 2 phases ran concurrently, prerandomization) for 8 to 24 days. During the screening phase participants were given a single-blind placebo nasal spray to enable them to practice their intranasal application technique once daily in the morning (1 actuation/nostril).\nRandomization to the double-blind treatment phase. Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).\nDouble-blind treatment phase which lasted at least 42 days and ran up to 47 days. Participants were administered either TAA-AQ nasal spray or placebo nasal spray.\nAn evaluation at the end of treatment 1-3 days after completion of the double-blind phase.	2010-06-01	2010-10-01	2010-10-01	2010-06-30	2011-10-28	2012-06-26	sanofi-aventis	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 4"}	{"Rhinitis, Allergic, Perennial and/or Seasonal"}	rescue medication	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Georges G, Kim KT, Ratner P, Segall N, Qiu C. Effect of intranasal triamcinolone acetonide on basal hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Allergy Asthma Proc. 2014 Mar-Apr;35(2):163-70. doi: 10.2500/aap.2014.35.3728."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/24717794/	loratadine
321	2023-01-02 15:22:35.74	2023-03-21 09:05:16.008	NCT03720366	A Phase 1, 2-Part, Multicenter, Open-Label, 3-Arm Study to Determine the Effect of Enasidenib (CC-90007) on the Pharmacokinetics of Single Oral Doses of Caffeine, Dextromethorphan, Fexofenadine, Flurbiprofen, Midazolam, Omeprazole, Pioglitazone, and Rosuvastatin in Patients With Acute Myeloid Leukemia	A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients	Active, not recruiting	This is a 2-part, open-label, interventional study conducted in approximately 42 subjects with AML harboring an IDH2 mutation.\n\nThe overall study is a 3-arm investigation of the PK effects of enasidenib at steady state on the probe compounds. (Part 1), followed by treatment continuation up to 28 months (Part 2).\n\nEach arm utilizes different probe compounds; enrolls a separate cohort of approximately 14 subjects; and consists of 2 parts - investigation of the PK effects of enasidenib on the respective probe compound(s) (Part 1), followed by an enasidenib treatment extension (Part 2).	Parallel Assignment	Celgene	INDUSTRY	All	\N	18	40	Anticipated	INDUSTRY	Celgene	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	Subjects can only be enrolled in one treatment arm. The probes (which are given twice) used in the study are approved for use in the countries where the study will be conducted. The probes in Arm 1 consist of single doses of caffeine (100mg), dextromethorphan (30 mg), flurbiprofen (50 mg), midazolam (0.03 mg/kg), and omeprazole (40 mg). Arm 2 probes consist of digoxin (0.25 mg), and rosuvastatin (10 mg). Arm 3 probe is pioglitazone (15 mg). Enasidenib is administered orally. All probes, except for midazolam, are administered orally. Midazolam will be administered intravenously.\n\nIn Part 1 (equivalent to Cycle 1), eligible subjects will receive the probes on Day -1, followed by the first dose of enasidenib on Day 1. Enasidenib will continue to be taken once daily for 28 days. Blood samples for pharmacokinetic analysis will be collected according to a set schedule. Subjects will receive the probes a second time on Day 28. Part 2 of the study begins the next day when the subject begins a second round of daily enasidenib doses (equivalent to Cycle 2). Safety assessment s and procedures consistent with AML standard of care will continue.	2018-12-11	2023-09-22	2023-09-22	2018-10-25	\N	2022-06-08	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Leukemia, Myeloid, Acute"}	not included	fexofenadine	TODO: fex not in study description but in official title?	f	Pharmacokinetics	2022-08-18 16:54:53	{}	UNKNOWN	\N	fexofenadine
322	2023-01-02 15:22:35.739	2023-03-21 09:07:35.618	NCT04568902	A Phase 1 Study of H3B-6545 in Japanese Women With Estrogen Receptor-positive, HER2 Negative Breast Cancer	Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer	Active, not recruiting	The purpose of study is to determine tolerability and safety profile of H3B-6545 in Japanese women with ER-positive, HER2-negative breast cancer, and also to confirm the dose applicability to Japanese.	Sequential Assignment	Eisai Co., Ltd.	INDUSTRY	Female	\N	20	33	Actual	INDUSTRY	Eisai Inc.	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2020-09-30	2023-11-30	2023-11-30	2020-09-29	\N	2022-12-20	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Breast Neoplasms"}	minimal	cetirizine	Prev. usecase was Breast Neoplasms	f	Safety Evaluation	2022-08-17 13:39:16	{"Furman C, Puyang X, Zhang Z, Wu ZJ, Banka D, Aithal KB, Albacker LA, Hao MH, Irwin S, Kim A, Montesion M, Moriarty AD, Murugesan K, Nguyen TV, Rimkunas V, Sahmoud T, Wick MJ, Yao S, Zhang X, Zeng H, Vaillancourt FH, Bolduc DM, Larsen N, Zheng GZ, Prajapati S, Zhu P, Korpal M. Covalent ERalpha Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer. Mol Cancer Ther. 2022 Jun 1;21(6):890-902. doi: 10.1158/1535-7163.MCT-21-0378."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/35642432/	fexofenadine|loratadine|cetirizine
323	2023-01-02 15:22:35.74	2023-03-21 09:08:10.668	NCT01096615	Evaluation of the Effect of Probiotic Lactobacillus Paracasei Lp-33 for the Management of Rhinitis in People Sensitized to Allergens. A Double Blind Randomized Parallel Placebo Controlled Study. (GA2LEN STUDY) BIONATLANTA Project	Effect Of Probiotic Lactobacillus Paracasei Lp-33 For The Management Of Rhinitis In People Sensitized To Allergens	Completed	The aim of the study is to show an improvement of quality of life on the 5th week of product consumption (probiotic Lactobacillus paracasei LP-33)(as assessed by RQLQ global score) in subjects with persistent allergic rhinitis currently treated with Loratadine or oral anti-histaminic treatment.	Parallel Assignment	Merck Medication Familiale	INDUSTRY	All	60	18	500	Actual	INDUSTRY	Merck Medication Familiale	Randomized	\N	Quadruple	\N	\N	Supportive Care	\N	Oral H1-antihistamines are first treatment recommended for allergic rhinitis (Bousquet et al, 2008) however they do not completely alleviate symptoms. This new study will therefore assess the effect of Lactobacillus paracasei LP-33 in the management of nasal and ocular symptoms, in addition to H1-antihistamines treatment. The main objective is to evaluate the effect of Lactobacillus paracasei LP-33 on quality of life. Additionally allergic rhinitis symptoms (nasal and eye symptoms) and immunological parameters will be evaluated, before and during the supplementation. Lactobacillus paracasei LP-33 is targeting the general population and improving quality of life of people sensitized to allergens. The study will be conducted in Europe on adult subjects with persistent allergic rhinitis.	2010-04-01	2011-09-01	2011-09-01	2010-03-31	\N	2012-07-26	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 3"}	{Rhinitis}	not included	loratadine	Not really included: The aim of the study is to show an improvement of quality of life on the 5th week of product consumption (as assessed by RQLQ global score) in subjects with persistent allergic rhinitis currently treated with Loratadine or oral anti-histaminic treatment.	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	UNKNOWN	\N	loratadine
324	2023-01-02 15:22:35.74	2023-03-21 09:09:39.006	NCT01601522	Peanut Allergy Oral Immunotherapy Desensitization	Peanut Allergy Oral Immunotherapy Desensitization	Completed	The purpose of the study is to determine how a type of treatment for peanut allergy known as oral desensitization works in the immune system.\n\nObjectives\n\nTo determine whether premedication with desloratidine and ranitidine results in fewer side effects during desensitization procedure.\nTo assess quality of life in peanut allergic subjects before and after desensitization.\nTo compare serum metabolites in peanut allergic and non peanut allergic subjects.	Parallel Assignment	Hamilton Health Sciences Corporation	OTHER	All	10	5	43	Actual	OTHER	McMaster University	Randomized	\N	Quadruple	\N	\N	Treatment	\N	Allergic reactions to peanuts and tree nuts account for the majority of fatal and near fatal food allergic reactions, and the only treatment is complete avoidance of peanut. Despite avoidance, the majority of peanut allergic people will accidently ingest peanut. OIT has been shown to desensitize peanut allergic subjects (Hofmann et al. 2009). This would protect patients who have no other treatment, and may even form the basis for true tolerance to peanut in the future.\n\nObjectives:\n\nTo determine whether premedication with desloratidine and ranitidine results in fewer side effects during desensitization procedure.\nTo assess quality of life in peanut allergic subjects before and after desensitization.\nTo compare serum metabolites in peanut allergic and non peanut allergic subjects.	2012-02-01	2021-09-01	2021-09-01	2012-05-18	\N	2022-02-02	\N	McMaster University	Dr. Susan Waserman	Professor	\N	\N	Principal Investigator	\N	Interventional	{Child}	{"Phase 2"}	{"Peanut Allergy"}	combination	desloratadine	\N	f	Allergy	2022-09-15 19:16:20	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/35643280/	desloratadine
331	2023-01-02 15:22:35.74	2023-03-21 09:16:55.469	NCT01731067	\N	Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot	Completed	Phenotyping is an approach largely used for the evaluation of the activity of cytochromes and transporters in vivo. It consists of the administration of probe substances metabolised by a specific cytochrome or transported by P-glycoprotein (P-gp) for example, followed by the determination of a metabolic ratio or the evaluation of the plasmatic or urinary concentrations of the probe substances. The administration of a cocktail containing several probe substances allows the simultaneous evaluation of the activity of several cytochromes and P-gp in a single test.\n\nThe aim of this project is the validation of a phenotyping cocktail of low dose probe drugs for the assessment of cytochrome P450 and P-gp activities by simple capillary blood sampling and dried blood spot (DBS) analysis. The cocktail consists of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam and fexofenadine for the simultaneous phenotyping of CYP1A2, CYP2B6, CYP2C9, CAP2C19, CYP2D6, CYP3A4 and P-gp, respectively.\n\nThe modulation of the activity of cytochromes or P-gp will be evaluated by the administration of inhibitors (fluvoxamine, voriconazole, quinidine) or inducer (rifampicin) of the metabolic pathways or the P-gp mediated transport.	Crossover Assignment	Jules Desmeules	OTHER	Male	65	18	10	Anticipated	OTHER	University Hospital, Geneva	Non-Randomized	\N	None (Open Label)	\N	\N	Diagnostic	\N	\N	2012-11-01	2013-05-01	2014-01-01	2012-11-21	\N	2014-09-16	\N	University Hospital, Geneva	Jules Desmeules	Pr	\N	\N	Sponsor-Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{"Healthy Volunteers"}	combination	fexofenadine	\N	f	Pharmacokinetics	2022-08-18 16:54:53	{"Bosilkovska M, Samer CF, Deglon J, Rebsamen M, Staub C, Dayer P, Walder B, Desmeules JA, Daali Y. Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther. 2014 Sep;96(3):349-59. doi: 10.1038/clpt.2014.83. Epub 2014 Apr 10."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/24722393/	fexofenadine
333	2023-01-02 15:22:35.741	2023-03-21 09:19:21.262	NCT00550550	A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age With a History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma	Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)	Completed	The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.	Parallel Assignment	ALK-Abell A/S	INDUSTRY	All	17	5	345	Actual	INDUSTRY	ALK-Abell A/S	Randomized	\N	Quadruple	\N	\N	Treatment	\N	This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in participants aged 5 to <18 years of either sex, and of any race with a history of grass pollen induced rhinoconjunctivitis with or without asthma. While receiving treatment, participants will receive either grass sublingual tablet or placebo. Open-label rescue medications for the rhinoconjunctivitis and asthma symptoms will be provided. Participants will visit the study site for at least 12 visits. A total of 10 allergic symptoms, 6 rhinoconjunctivitis and 4 lung symptoms, will be recorded daily on an electronic diary by the participant/parent/guardian.\n\nThe start and end of the grass pollen season (GPS) was determined based on the regional grass pollen count, and lasted up to 162 days. For each region, the GPS is defined as the first day of 3 consecutive recorded days with a grass pollen count of  10 grains/m^3, to the last day of the last occurrence of 3 consecutive recorded days with a grass pollen count  10 grains/m^3, inclusively.	2007-11-01	2009-09-01	2009-09-01	2007-10-30	2012-09-07	2017-03-03	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{Rhinoconjunctivitis,Rhinitis,Conjunctivitis,Allergy}	rescue medication	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{"Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol. 2011 Jan;127(1):64-71, 71.e1-4. doi: 10.1016/j.jaci.2010.11.034. Erratum In: J Allergy Clin Immunol. 2011 Aug;128(2):436.","Hebert J, Blaiss M, Waserman S, Kim H, Creticos P, Maloney J, Kaur A, Li Z, Nelson H, Nolte H. The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children. Allergy Asthma Clin Immunol. 2014 Oct 30;10(1):53. doi: 10.1186/1710-1492-10-53. eCollection 2014."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/21211642/	loratadine
419	2023-01-02 15:22:35.746	2023-03-21 13:33:28.426	NCT01375790	Neuromuscular Training With Whole Body Vibration in Older People: A Randomized Multicentre Clinical Trial With Blinded to Evaluator	Whole-body Vibration Training in Older People	Completed	This is a randomized, multicentre, and parallel clinical trial with blinded to evaluator.\n\nThe principal hypothesis is that whole-body vibration training plus exercise improves the body balance and prevents falls more than only exercise training in institutionalized older people. The number needed of patients is 160 (80 per group).	Parallel Assignment	Asociacion Colaboracion Cochrane Iberoamericana	OTHER	All	\N	65	160	Actual	OTHER	Asociacion Colaboracion Cochrane Iberoamericana	Randomized	\N	Single	\N	\N	Treatment	\N	\N	2010-11-01	2011-09-01	2012-03-01	2011-06-17	\N	2012-08-29	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{"Older Adult"}	{"Phase 3"}	{Aging}	not included	fexofenadine	name of location	f	Aging	2022-08-18 16:54:53	{"Sitja-Rabert M, Martinez-Zapata MJ, Fort Vanmeerhaeghe A, Rey Abella F, Romero-Rodriguez D, Bonfill X. Effects of a whole body vibration (WBV) exercise intervention for institutionalized older people: a randomized, multicentre, parallel, clinical trial. J Am Med Dir Assoc. 2015 Feb;16(2):125-31. doi: 10.1016/j.jamda.2014.07.018. Epub 2014 Oct 3.","Sitja-Rabert M, Martinez-Zapata MJ, Fort-Vanmeerhaeghe A, Rey-Abella F, Romero-Rodriguez D, Bonfill X. Whole body vibration for older persons: an open randomized, multicentre, parallel, clinical trial. BMC Geriatr. 2011 Dec 22;11:89. doi: 10.1186/1471-2318-11-89."}	UNKNOWN	\N	fexofenadine
423	2023-01-02 15:22:35.746	2023-03-21 13:38:00.715	NCT03722485	Hydromechanical Cleansing With V.A.C. VERAFLO CLEANSE CHOICE Dressing and NPWTi-d vs. Collagenase Ointment in the Management of Full-thickness Wounds	Negative Pressure Wound Therapy With Instillation of Saline Solution Versus Collagenase Ointment in Full-thickness Wounds	Recruiting	Evaluation of wound bed surface area containing clean, healthy viable tissue in full-thickness wounds.	Parallel Assignment	3M	INDUSTRY	All	\N	18	60	Anticipated	INDUSTRY	3M	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	This study evaluates changes in wound bed surface area of clean, healthy viable tissue in subjects with full-thickness wounds using negative pressure wound therapy with instillation of saline solution versus a collagenase ointment.	2018-12-12	2021-12-01	2021-12-01	2018-10-29	\N	2021-04-12	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{"Wounds and Injuries","Wound Healing","Granulation Tissue"}	not included	\N	name is allegra	f	\N	\N	{}	UNKNOWN	\N	fexofenadine
334	2023-01-02 15:22:35.741	2023-03-21 09:20:23.738	NCT01507792	Effect of Iron Repletion in Women With Chronic Cough and Iron Deficiency	Iron Repletion in Chronic Cough and Iron Deficiency	Completed	Chronic cough is more frequent and severe in women than in men. Women often have decreased iron stores, due to menses and pregnancies. Aim of the study: to investigate if iron deficiency has a role in chronic cough by favouring airway hypersensitivity to inhaled irritants.	Single Group Assignment	University of Turin, Italy	OTHER	Female	70	15	22	Actual	OTHER	University of Turin, Italy	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	Women with chronic cough and iron deficiency, cough unresponsive to empiric treatment (suggested by cough guidelines) with antiH1-histaminic drug plus proton pump inhibitor.\n\nCough VAS (score from 1,best, to 5, worst). Histamine inhalation challenge, performed to assess bronchial, laryngeal, and cough thresholds, performed by delivering doubling concentrations, from 0.5 mg/ml up to 32 mg/ml, by a nebulizer. After each dose FEV1, as bronchial index, maximum mid-inspiratory flow (MIF50) as laryngeal index, and coughs number are assessed. Bronchial threshold is the concentration causing 20% decrease in FEV1, laryngeal threshold that causing 25% decrease in MIF50, cough threshold that causing 5 coughs. Histamine hyperresponsiveness of the bronchi (BHR), larynx (LHR) and cough (coughHR) are defined for thresholds equal or below 8 mg/ml.\n\nHistamine thresholds and cough VAS obtained in baseline, after cough empiric treatment with antiH1-histaminic and proton pump inhibitor, and after iron supplementation.	2002-01-01	2011-01-01	2011-01-01	2012-01-11	\N	2012-01-11	\N	University of Turin, Italy	Caterina Bucca	Associate Professor of Internal Medicine	\N	\N	Principal Investigator	\N	Interventional	{Child,Adult,"Older Adult"}	{"Not Applicable"}	{Cough,"Laryngeal Disease","Bronchial Disease","Iron Deficiency"}	minimal	loratadine	Antihistamines: This is not an intervention of interest, but it is a selection criterion to define unexplained cough, as suggested by cough guidelines.	f	Cough	2022-08-17 18:44:47	{"Bucca CB, Bugiani M, Culla B, Guida G, Heffler E, Mietta S, Moretto A, Rolla G, Brussino L. Chronic cough and irritable larynx. J Allergy Clin Immunol. 2011 Feb;127(2):412-9. doi: 10.1016/j.jaci.2010.10.038. Epub 2010 Dec 16.","Bucca CB, Culla B, Guida G, Sciascia S, Bellone G, Moretto A, Heffler E, Bugiani M, Rolla G, Brussino L. Unexplained chronic cough and vitamin B-12 deficiency. Am J Clin Nutr. 2011 Mar;93(3):542-8. doi: 10.3945/ajcn.110.000802. Epub 2011 Jan 19.","Bucca C, Culla B, Brussino L, Ricciardolo FL, Cicolin A, Heffler E, Bugiani M, Rolla G. Effect of iron supplementation in women with chronic cough and iron deficiency. Int J Clin Pract. 2012 Nov;66(11):1095-100. doi: 10.1111/ijcp.12001."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/23067033/	loratadine
24	2023-01-02 15:22:35.723	2023-01-02 15:22:35.723	NCT02865018	An Open Label, add-on Trial of Cetirizine for Patients With Neuromyelitis Optica	Neuromyelitis Optica (NMO) & Cetirizine	Completed	Neuromyelitis optica (NMO) is an autoimmune disease that affects the central nervous system. Patients have relapses (also known as attacks) which are often quite severe and leave them with significant disability. Without treatment, within 5 years 50% of NMO patients are blind in one or both eyes or require walking assistance (cane, walker or wheelchair).\n\nNMO has only been relatively recently described and is fairly rare. Most NMO patients' immune systems produce abnormal antibodies against aquaporin-4 (AQP4), which is found in certain cells in the central nervous system. When these AQP4 antibodies bind to AQP4, they trigger a cascade of events involving the immune system which eventually leads to damage to the nervous system. This ultimately leads to disability, some of which is permanent.\n\nUntil now, treatments for NMO have been mostly focused on decreasing production of this AQP4 antibody. However, recent experiments in animal models of NMO have shown the importance of what happens inside the central nervous system after the antibody binds to the nervous system cell. Specifically, researchers have noted the importance of a specific cell type, eosinophils, in causing damage in NMO lesions. In a recent study, researchers showed they could prevent damage from NMO by blocking eosinophils using cetirizine, which is a popular over-the-counter allergy medicine.\n\nCetirizine is already known to be safe and well-tolerated in the general population. In this study, the researchers plan to add cetirizine on to patients' current NMO treatment. The researchers aim to show that it is safe, well-tolerated, and that with cetirizine, NMO patients have less relapses and therefore less disability over the course of the year following initiation of treatment. The researchers also plan to study how cetirizine changes the immunological profile in NMO patients by examining blood and cerebrospinal fluid.	Single Group Assignment	Icahn School of Medicine at Mount Sinai	OTHER	All	85	18	16	Actual	OTHER	Icahn School of Medicine at Mount Sinai	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	The researchers hypothesize that cetirizine, an allergy medication that acts as an eosinophil-stabilizer, will decrease the relapse rate when added to current standard therapy in patients with neuromyelitis optica.\n\nMedication compliance will be assessed by the research coordinator at each visit through discussion with the patient and pill counting.	2014-04-01	2016-02-01	2016-02-01	2016-08-12	\N	2016-08-12	\N	Icahn School of Medicine at Mount Sinai	Ilana Katz Sand	Assistant Professor of Neurology	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1","Phase 2"}	{"Neuromyelitis Optica"}	main	cetirizine	\N	t	Neuromyelitis Optica	2022-08-17 13:39:16	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/30426035/	cetirizine
1	2023-01-02 15:22:35.721	2023-03-19 21:56:39.007	NCT00794794	A Single-Center, Pediatric, Comparative Taste Test of Desloratadine and Cetirizine Antihistamine Syrup Medications	Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)	Completed	This study was conducted to compare the taste acceptability of Zyrtec syrup with desloratadine syrup in children. Children between 6 and 11 years of age received 5 mL of each syrup, separated by 15 to 20 minutes on a single day.	Crossover Assignment	Organon and Co	INDUSTRY	All	11	6	204	Actual	INDUSTRY	Organon and Co	Randomized	\N	Quadruple	\N	\N	Other	\N	This study is a cross-over study design.	2004-11-01	2004-11-01	2004-11-01	2008-11-20	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Allergic Rhinitis"}	comparison	cetirizine		f	Taste, Form, Preference	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	desloratadine|cetirizine
179	2023-01-02 15:22:35.732	2023-02-14 16:43:39.739	NCT00044824	A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120mg BID in Subjects With Mild to Moderate Persistent Asthma	Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma	Completed	The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma	Parallel Assignment	Sanofi	INDUSTRY	All	80	12	1000	Anticipated	INDUSTRY	Sanofi	Randomized	\N	Double	\N	\N	Treatment	\N	The incidence of respiratory allergy in the US has increased gradually over the past several years, and current estimates suggest that allergic rhinitis and bronchial asthma affect approximately 20% and 5% of the population, respectively. Rhinitis and asthma frequently coexist, and large-scale population surveys indicate that up to 38% of subjects with rhinitis have asthma, and up to 78% of subjects with asthma have chronic nasal symptoms. Safety concerns with the increased use of inhaled corticosteroids, the heterogeneity of the disease, and poor compliance with asthma medication regimens, point to the need for the development of safe and convenient oral therapies for asthma. Histamine is an important chemical mediator of inflammation in asthma. The benefits of antihistamine treatment in patients with mild to moderate asthma have been well documented, however their clinical use has been previously limited due to the high doses required for efficacy and their associated side effects including sedation and cognitive impairment.\n\nRecent evidence indicates that in addition to H1-receptor antagonism, some of the newer nonsedating, non-impairing antihistamines appear to possess various anti-inflammatory properties at concentrations achieved at therapeutic dosages suggesting an additional benefit of these drugs in the management of allergic diseases and asthma. The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma.	2002-02-01	2003-10-01	2003-10-01	2002-09-17	\N	2008-08-21	\N	\N	\N	\N	ICD Study Director	sanofi-aventis	\N	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{Asthma}	main	fexofenadine	\N	t	Asthma	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	\N
31	2023-01-02 15:22:35.724	2023-01-02 15:22:35.724	NCT01008592	The Effect of Levocetirizine (Xyzal) on the Skin Levels of Inflammatory Mediators Histamine, Serine Proteases, Prostaglandin E2, Leukotriene B4 and Cathepsins in Patients With Symptomatic Dermatographism and Chronic Idiopathic Urticaria	The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism	Terminated	Levocetirizine (Xyzal), the active levorotatory enantiomer of cetirizine (Zyrtec), is a FDA-approved drug used in the treatment of symptoms associated with seasonal and perennial allergic rhinitis and chronic idiopathic urticaria. The parent compound, cetirizine was shown to be effective against experimental dermatographism, however no study has been conducted so far on the effect of levocetirizine on the inhibition of dermatographism. It is known that cetirizine is a mast-cell stabilizer and decreases histamine levels and the number of tryptase positive mast cells. Cetirizine inhibits the production of interleukin 8 (IL8) and leukotriene B4 (LTB4) by immune cells - two potent chemoattractants - and induces the release from monocytes of prostaglandin E2 (PGE2), a suppressor of antigen presentation and MHC class II expression. However, the effects of the most active enantiomer levocetirizine on these inflammatory mediators have not been evaluated so far. Therefore, we aim to conduct a study in humans with dermatographism and chronic idiopathic urticaria to evaluate the effect of levocetirizine on the above-mentioned mediators. The study will involve the use of skin microdialysis, a minimally invasive technique to measure inflammatory mediators in the extracellular space in dermis.	\N	Wake Forest University	OTHER	All	60	18	11	Actual	OTHER	Wake Forest University Health Sciences	\N	\N	\N	\N	Case-Crossover	\N	Cross-Sectional	\N	2009-04-01	2010-08-01	2010-09-01	2009-11-06	\N	2017-02-28	\N	\N	\N	\N	\N	\N	Sponsor	Mediators of interest were not consistently detectable with the analytical methods employed.	Observational	{Adult}	{}	{Rhinitis,Urticaria}	main	cetirizine	\N	t	Dermatographism	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND		levocetirizine
74	2023-01-02 15:22:35.724	2023-02-14 20:05:36.593	NCT05190627	Phase II Clinical Trial Evaluating the Effect of Loratadine Associated to Rapamicyn in Patients With Lymphangioleiomyomatosis	Effect of Loratadine in Lymphangioleiomyomatosis	Recruiting	INTRODUCTION: LAM is a rare and lethal disease characterized by progressive cystic lung destruction. Inhibition of mTOR with rapamycin is the current standard of care (SOC), which can slow-down disease. Plasma major histamine metabolite (Methylimidazoleacetic acid [MIAA]) is increased in LAM. Loratadine is a histamine receptor antagonist (HR1), which inhibits LAM cell proliferation. Therefore, a novel phase-II clinical trial for assessing safety and potential benefits of loratadine in LAM has been initiated.\n\nMETHODS: LORALAM clinical trial, phase-II, double-blind, randomized, placebo controlled, parallel-group, multicentre study initiates recruitment in July 2020. Enrollment plan includes 62 subjects with LAM on treatment with rapamycin 3 months, randomized 1:1 to add oral loratadine 10mg/day or placebo, once daily, for 52 weeks. Recruitment will end in June 2021. The primary endpoints are 1) to assess the safety profile of loratadine associated with rapamycin, 2) lung function decline after 52 weeks of treatment. The secondary endpoints are a) quality of life and progression free-survival time, b) changes in the established LAM serum biomarker VEGFD, c) the utility of MIAA for monitoring disease progression and biological treatment effect.\n\nETHICS AND DISSEMINATION: The study will be carried out in accordance with Good Clinical Practice guidelines, Declaration of Helsinki principles, and each ethical committee. This clinical trial contemplates the possibility of increasing the number of centers and including patients from patient support groups (LAM foundation, AELAM)	Parallel Assignment	Institut d'Investigaci Biomdica de Bellvitge	OTHER	All	\N	18	62	Anticipated	OTHER	Institut d'Investigaci Biomdica de Bellvitge	Randomized	\N	Triple	\N	\N	Treatment	\N	Lymphangioleiomyomatosis (LAM) is a rare and lethal lung disease affecting almost exclusively women of childbearing age and characterized by progressive cystic lung destruction. LAM results from germline and somatic loss-of-function mutations in the tuberous sclerosis complex 1 and 2 genes (TSC1/2), and therefore diseased cells show abnormal activation of the mechanistic target of rapamycin (mTOR). Inhibition of mTOR with rapamycin (also known as sirolimus) is the current standard of care. However, this therapy does not fully kill LAM cells, shows variable tolerability and treatment answer. Therefore, sirolimus has slowed-down disease progression but young patients still need lung transplantation despite treatment. In addition, LAM diagnosis and clinical monitoring is also challenging due to the heterogeneity of symptoms and insufficiency of non-invasive tests. Here, guided by comprehensive preclinical data obtained in the context of a Spanish research network for LAM, and with the support of the national Association of LAM patients (AELAM), the investigators propose a phase-II clinical trial for assessing if the tricyclic antihistamine loratadine is effective in slowing the progression of lung disease in LAM. Loratadine is an histamine receptor 1 (HR1) antagonist, widely used for allergic process, that also acts through different intracellular signaling, including Akt/MITF and PKCBII-tyrosine kinase. Recent studies have demonstrated that co-treatment with loratadine sensitize KBV20C resistant cells to vincristine, which improve the onco-therapeutical effect. The primary study objective is to assess the safety profile of loratadine 10 mg/day associated with the current standard treatment (sirolimus) and its potential benefit abrogating the lung function decline after 52 weeks of treatment. The secondary objectives include; a) an assessment of quality of life and progression free-survival time, and, b) to determine the clinical usefulness of the major histamine-derived metabolite methylimidazoleacetic acid (MIAA) for monitoring of disease progression and biological treatment effect.	2021-11-01	2022-12-30	2023-12-30	2022-01-13	\N	2022-01-27	\N	Institut d'Investigaci Biomdica de Bellvitge	Maria Molina	Chief of Interstitial Lung Diseases Unit, Respiratory Department. Associated Professor (University of Barcelona)	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{Lymphangioleiomyomatosis}	main	loratadine	\N	t	Lymphangioleiomyomatosis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
203	2023-01-02 15:22:35.733	2023-03-19 21:03:26.491	NCT00045955	A Multicenter, Open-Label, Randomized, Parallel Groups Study to Assess the Long-Term Safety Performance of Fexofenadine Compared to Montelukast in Subjects With Asthma	Long-Term Safety Performance of Fexofenadine in Asthma	Completed	The purpose of this study is to assess the long-term safety performance of fexofenadine compared to montelukast in subjects with asthma	Parallel Assignment	Sanofi	INDUSTRY	All	80	12	1200	Anticipated	INDUSTRY	Sanofi	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	The incidence of respiratory allergy in the US has increased gradually over the past several years, and current estimates suggest that allergic rhinitis and bronchial asthma affect approximately 20% and 5% of the population, respectively. Rhinitis and asthma frequently coexist, and large-scale population surveys indicate that up to 38% of subjects with rhinitis have asthma, and up to 78% of subjects with asthma have chronic nasal symptoms. Safety concerns with the increased use of inhaled corticosteroids, the heterogeneity of the disease, and poor compliance with asthma medication regimens, point to the need for the development of safe and convenient oral therapies for asthma. Oral leukotriene receptor antagonists (eg montelukast) are the latest class of inflammation-modulating asthma drugs and appear to cause fewer long-term side effects than systemic corticosteroids and reduce the need for shorter-acting bronchodilator reliever medicines. However variability in response between patients has been observed and clinical experience with these agents is still limited.\n\nHistamine is an important chemical mediator of inflammation in asthma. The benefits of antihistamine treatment in patients with mild to moderate asthma have been well documented, however their clinical use has been previously limited due to the high doses required for efficacy and their associated side effects including sedation and cognitive impairment. Recent evidence indicates that in addition to H1-receptor antagonism, some of the newer nonsedating, non-impairing antihistamines appear to possess various anti-inflammatory properties at concentrations achieved at therapeutic dosages suggesting an additional benefit of these drugs in the management of allergic diseases and asthma. The purpose of this study is to assess the long-term safety performance of fexofenadine compared to montelukast in subjects with asthma.	2002-02-01	2003-11-01	2003-11-01	2002-09-19	\N	2008-08-21	\N	\N	\N	\N	ICD Study Director	sanofi-aventis	\N	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{Asthma}	comparison	fexofenadine	comparison to montelukast	t	Asthma	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
175	2023-01-02 15:22:35.732	2023-03-19 20:58:05.534	NCT01172522	A Pilot Randomized Double Blind Study to Assess the Safety and Efficacy of 1% Ibuprofen/ 1%Fexofenadine Topical Cream for the Treatment of Dark Circles Under the Eyes	Topical Treatment of Under Eye Dark Circles and Swelling	Completed	This study examines topical treatment of under eye circles and swelling.	Parallel Assignment	The Connecticut Sinus Center, PC	OTHER	All	\N	18	30	Actual	OTHER	The Connecticut Sinus Center, PC	Randomized	\N	Double	\N	\N	Treatment	\N	This study examines topical treatment of under eyes dark circles and under eye swelling.	2010-09-01	2010-12-01	2011-01-01	2010-07-29	2015-02-19	2015-02-19	ConnecticutSC	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{Edema}	main	fexofenadine	\N	t	Eye circles	2022-08-18 16:54:53	{}	CT_RESULTS	\N	fexofenadine
245	2023-01-02 15:22:35.734	2023-03-19 21:10:06.98	NCT00424580	Airway Responses to Montelukast and Desloratadine.	Airway Responses to Montelukast and Desloratadine.	Completed	Montelukast (for asthma) and desloratadine (for allergies) are effective therapy for their current uses. Part of what happens when your allergies trigger your asthma should be prevented by either of these drugs. This project is being conducted to determine if these drugs are effective, either alone or in combination, on controlling asthma that is triggered by allergies.	Crossover Assignment	University of Saskatchewan	OTHER	All	\N	18	12	\N	OTHER	University of Saskatchewan	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2007-01-01	2007-08-01	2007-08-01	2007-01-19	\N	2008-01-23	\N	\N	\N	\N	Dr. Donald W. Cockcroft	Department of Medicine, University of Saskatchewan	\N	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{Asthma}	combination	desloratadine	\N	t	Asthma	2022-09-15 19:16:20	{"Davis BE, Illamperuma C, Gauvreau GM, Watson RM, O'Byrne PM, Deschesnes F, Boulet LP, Cockcroft DW. Single-dose desloratadine and montelukast and allergen-induced late airway responses. Eur Respir J. 2009 Jun;33(6):1302-8. doi: 10.1183/09031936.00169008. Epub 2009 Jan 22."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19164343/	desloratadine
256	2023-01-02 15:22:35.736	2023-03-19 21:10:22.989	NCT01392859	Characterization of the Role of Histamine in Children With Asthma	Characterization of the Role of Histamine in Children With Asthma	Completed	Asthma, a chronic disease which produces significant morbidity and mortality in children, is a significant health problem to a large segment of society. Despite considerable advances in the diagnosis and treatment of asthma over the past several years, a sizeable portion of patients do not respond to the "core" treatments. The investigators are now learning that the underlying pathophysiology of disease is different among patients with asthma therefore; treatments which are beneficial in some patient groups may be not achieve affect in other groups.\n\nAntihistamines have been studied in the past for the treatment of asthma. These studies have shown that there may be a beneficial effect of antihistamines in patients with allergic asthma where histamine likely plays a large role in disease and treatment response. However, there is not enough evidence to include these drugs in the standard treatment of asthma.\n\nThe investigators hypothesize that histamine plays a definable, significant role in disease pathogenesis and treatment response in children with allergic asthma. The investigators plan to test this overall hypothesis through two specific aims. The first aim will characterize the relative contribution of histamine in allergic vs. non-allergic asthma. This aim will be accomplished by comparison of the microvasculature response to histamine in children with allergic asthma and children with non-allergic asthma, measured by histamine iontophoresis with laser Doppler (HILD) monitoring, to determine potential phenotype-associated differences in the pharmacodynamic response to histamine.	Crossover Assignment	Children's Mercy Hospital Kansas City	OTHER	All	17	7	211	Actual	OTHER	Children's Mercy Hospital Kansas City	Randomized	\N	Double	\N	\N	Diagnostic	\N	\N	2011-06-01	2015-03-29	2015-03-29	2011-07-13	2021-08-30	2021-08-30	Children's Mercy Hospital	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 2","Phase 3"}	{Asthma,"Allergic Asthma","Non-allergic Asthma"}	main	levocetirizine	focus of study is not primarily lzt but rather histamine	t	Asthma	2022-09-15 18:58:14	{}	CT_RESULTS	\N	levocetirizine
200	2023-01-02 15:22:35.733	2023-03-19 21:03:15.705	NCT01712009	Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim	NOLAN: Naproxen or Loratadine and Neulasta	Completed	The primary objective of the study is to estimate the difference in bone pain between breast cancer patients receiving chemotherapy and pegfilgrastim and either no prophylactic intervention, prophylactic naproxen, or prophylactic loratadine.	Parallel Assignment	Amgen	INDUSTRY	Female	100	18	600	Actual	INDUSTRY	Amgen	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	In this study, the investigational products are naproxen, a non-steroidal antiinflammatory drug (NSAID), and loratadine, an anti-histamine. Both agents are being investigated as prophylactic medications to reduce the incidence and/or severity of bone pain in breast cancer patients receiving adjuvant or neoadjuvant myelosuppressive chemotherapy and pegfilgrastim prophylaxis.\n\nPegfilgrastim treatment is used to stimulate bone marrow to produce more neutrophils to help fight infections in patients undergoing chemotherapy.	2012-11-01	2015-03-18	2015-03-18	2012-10-23	2016-03-09	2018-01-30	Amgen Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Bone Pain in Stage I - III Breast Cancer"}	comparison	loratadine	\N	t	Bone Pain	2022-08-17 18:44:47	{"Kirshner JJ, McDonald MC 3rd, Kruter F, Guinigundo AS, Vanni L, Maxwell CL, Reiner M, Upchurch TE, Garcia J, Morrow PK. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Support Care Cancer. 2018 Apr;26(4):1323-1334. doi: 10.1007/s00520-017-3959-2. Epub 2017 Nov 16."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/29147854/	loratadine
135	2023-01-02 15:22:35.729	2023-03-19 20:53:58.04	NCT01722162	Phase II Study of Levocetirizine in Combination With Capecitabine + Bevacizumab to Overcome Resistance to Anti-angiogenic Therapy in Patients With Refractory Colorectal Cancer	Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer	Completed	This randomized phase II trial studies how giving a drug called levocetirizine to patients with colorectal cancer affects their tumor response to capecitabine and bevacizumab. Capecitabine is a chemotherapy drug that blocks tumor growth by disrupting DNA and RNA synthesis and repair (cell division and survival). Bevacizumab is a monoclonal antibody that blocks the ability of tumors to grow and spread by inhibiting the growth of blood vessels that feed them. Patients with colorectal cancer can develop a resistance to the effects of bevacizumab. Levocetirizine may decrease tumor resistance to bevacizumab. Giving bevacizumab, capecitabine, and levocetirizine dihydrochloride together may be an effective treatment for refractory colorectal cancer.	Parallel Assignment	Washington University School of Medicine	OTHER	All	\N	18	47	Actual	OTHER	Washington University School of Medicine	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2013-04-01	2015-10-01	2015-10-01	2012-11-06	2017-02-13	2017-04-20	Washington University School of Medicine	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Colorectal Neoplasms"}	combination	levocetirizine	\N	t	Colorectal Cancer	2022-09-15 18:58:14	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/31183190/	levocetirizine
244	2023-01-02 15:22:35.736	2023-03-22 13:15:16.834	NCT03192488	Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia	Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia	Completed	This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec use can improve exercise performance of active individuals when acutely exposed to altitude. For this project, healthy subjects will perform steady state and progressive work rate exercise, endurance performance time trials, and repeated sprint performance time trials in the laboratory at a simulated altitude of 3000m (9900ft) after dosing with 10 mg of Cetirizine or a placebo in a repeated measures design.	Crossover Assignment	Indiana University	OTHER	All	35	18	13	Actual	OTHER	Indiana University	Randomized	\N	Double	\N	\N	Basic Science	\N	This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec use can improve exercise performance of active individuals when acutely exposed to altitude. For this project, healthy subjects will perform steady state and progressive work rate exercise, endurance performance time trials, and repeated sprint performance time trials in the laboratory at a simulated altitude of 3000m (9900ft) after dosing with 10 mg of Cetirizine or a placebo in a repeated measures design. Non-invasive techniques (pulse oximetry, near-infrared spectroscopy [NIRS]) will be utilized to measure changes in arterial oxyhemoglobin saturation and skeletal muscle oxygenation at the level of the microvasculature during exercise. It is expected that after Cetirizine, blood and muscle microvascular oxygenation during heavy exercise will improve compared to placebo, ultimately improving exercise performance at altitude. Subjects will be asked to report to the laboratory on a three occasions, separated by a minimum of 48 hours and a maximum of 14 days. For each subject, all testing sessions will be performed at the same time of day. Prior to each testing session, subjects will be asked to abstain from caffeine consumption for 12 hours. Subjects will also be asked to avoid alcohol consumption for 24 hours before testing, be at least 3-hour post prandial and avoid high-intensity exercise during the 24 hours leading to the exercise testing. Finally, subjects will be asked to consume a similar diet the night before, and the morning of, Sessions 2 and 3.	2017-08-31	2018-06-06	2018-06-06	2017-06-20	2020-06-16	2020-06-16	Indiana University	Indiana University	Robert Chapman	Associate Professor	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Phase 4"}	{"Hypoxia, Altitude"}	main	cetirizine	\N	t	Exercise	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
70	2023-01-02 15:22:35.725	2023-03-21 19:58:39.849	NCT01781507	Assessment of Bronchodilatory Effects of Cetirizine in Adults With Concomitant Allergic Rhinitis and Mild Asthma as Measured by Impulse Oscillometry.	Study of Bronchodilation Effects of Cetirizine	Completed	Primary Objective :\n\nTo compare the acute bronchodilatory effects of cetirizine 10 mg tablet and nebulized levalbuterol using impulse oscillometry technique in asthmatic subjects aged 18 to 65 years old who have allergic rhinitis and show clinical evidence of bronchial hyper-reactivity.\n\nSecondary Objective:\n\nTo assess the bronchodilatory effects of cetirizine 10 mg tablet versus placebo after two weeks of therapy using impulse oscillometry technique in subjects 18 to 65 years old who have allergic rhinitis and show clinical evidence of bronchial hyper-reactivity.	Single Group Assignment	California Allergy and Asthma Medical Group, Inc.	OTHER	All	65	18	21	Actual	OTHER	California Allergy and Asthma Medical Group, Inc.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	OBJECTIVES:\n\nPrimary Objective :\n\nTo compare the acute bronchodilatory effects of cetirizine 10 mg tablet and nebulized levalbuterol using impulse oscillometry technique in asthmatic subjects aged 18 to 65 years old who have allergic rhinitis and show clinical evidence of bronchial hyper-reactivity.\n\nSecondary Objective:\n\nTo assess the bronchodilatory effects of cetirizine 10 mg tablet versus placebo after two weeks of therapy using impulse oscillometry technique in subjects 18 to 65 years old who have allergic rhinitis and show clinical evidence of bronchial hyper-reactivity.\n\nSUBJECT SELECTION:\n\nInclusion Criteria\n\nAge between 18 to 65 years of age\nPhysician diagnosis of mild asthma based on the NIH guidelines\nPhysician diagnosis of allergic rhinitis and confirmed by at least 3+ skin test response to at least one allergen\nEvidence of abnormal, reversible airway function on impulse oscillometry\nAbility to cooperate in measurement of impulse oscillometry Exclusion Criteria\nTreatment with inhaled or oral corticosteroids within one month of screening visit\nChange in dosage of intranasal corticosteroids, or oral anti- leukotrienes within one month of screening visit. Subjects on constant dose of intranasal corticosteroids or anti-leukotrienes for one month or more will be allowed in the study.\nKnown history of reflux, lung disease, or congenital heart disease\nKnown history of adverse reaction to cetirizine\n\nMETHODS:\n\nGeneral Design:\n\nThis study, is a double-blinded, randomized , placebo- controlled study to assess 1) the acute bronchodilatory effects of cetirizine 10 mg tablet compared to levalbuterol and 2) the bronchodilatory effect of cetirizine 10 mg compared to placebo after two weeks of treatment . There will be minimum of five total study visits. The study drug will be encapsulated with methylcellulose and the placebo capsules will have methylcellulose alone.\n\nVisit Schedule:\n\nInitial Screening Visit On a regularly scheduled clinic day, following completion of a signed informed consent the study, the first patient evaluation will compose of: '\n\nHistory and Physical Exam The subject's demographic, medical, family, and history will be recorded by standardized questionnaire. All previous medications used to treat allergic rhinitis will be recorded.\n\nSkin prick testing using the Multi-test method will be used to test for common environmental allergens. This is a standard procedure done in evaluating patients with a clinical history suggestive of allergic rhinitis and takes 15 minutes from initial prick to interpretation of results.\n\nAs part of the standard assessment for skin testing, patients will be asked to not take any oral or intranasal anti-histamines for one week before the visit. Antihistamines can mask the histamine effects, and subsequently positive skin test results. If they are interested in participating in the study, they will be asked to remain off antihistamines until their enrollment into the study has been determined. Allergens on the environmental panel to be tested include cat, dust mite, weed mix, tree mix, grass mix, mold mix, saline, and histamine.\n\nSecond Screening Visit\n\nAfter withholding beta-agonist treatment for at least 6 hours, testing for baseline pulmonary function will be performed with impulse oscillometry and spirometry. They will undergo impulse oscillometry technique under the guidance of a trained technician. If the subject is.able to, he/she will also perform spirometry after oscillometry is completed. If airway obstruction is detected by oscillometry, subjects will be given levalbuterol by hand-held nebulizer and both impulse oscillometry and spirometry will be repeated 15 minutes after the nebulizer treatment is completed. If there is evidence of reversibility (i.e. lung function improvement), then the subject will have fulfilled the inclusion criteria and be asked to continue with the study.\n\nFirst Study Visit The first study visit will be a continuation of the second screening visit after the subject has fulfilled the inclusion criteria as evidenced by reversible airway obstruction following levalbuterol treatment. The subject will be asked to continue with the study period and he/she will have repeat lung function testing at 15, 30, 60,90, 120, 180, and 240 minutes after treatment. Lung function testing will be by impulse oscillometry. If the subject is able to, he/she will perform spirometry at 60 and 240 minutes post-levalbuterol.\n\nSubjects will be instructed to complete a daily diary for allergic rhinitis and asthma symptom scores.\n\nSecond Study Visit (1 to 7 days after First Study Visit) All beta-agonist treatment needs to be withheld at least 6 hours prior to the visit. Baseline lung function testing by impulse oscillometry and spirometry will be done. The subject will be given Cetirizine 10 mg tablet or placebo. The subject and the coordinator will be blinded to the study treatment. Lung function testing will be assessed by impulse oscillometry. at 15, 30, 60, 90, 120, 180, and 240 minutes after the cetirizine. Spirometry will also be performed at 60 and 240 minutes post.-cetirizine .\n\nDaily diary entries will be reviewed with the subject. The subject will be sent home on the study medication. He/she take 1 tablet of the study medication daily starting the day after the study visit.\n\nThird Study Visit (7 to 10 days after Second Study Visit) The subject will take his/her usual study medication dose in the office. He/she will perform impulse oscillometry, and if able to, spirometry to assess lung function. Daily diary entries will be reviewed with subject. The subject will be instructed to continue taking the study medication at the same dosing regimen.\n\nFourth Study Visit ,(7 to 10 days after Third Study Visit)\n\nThe subject will take his/her usual study medication dose in the office. He/she will perform impulse oscillometry and spirometry to assess lung function. Daily diary entries will be reviewed with the subject. The subject will be instructed to stop taking the study medication and continue putting in diary entries.\n\nFifth Study Visit (7 to 10 days after Fourth Study Visit) The subject will perform impulse oscillometry and spirometry to assess lung function. Daily diary entries will be reviewed with the parent or caregiver.\n\nLaboratory Studies:\n\nThere will be no laboratory studies in this project.	2011-06-01	2011-12-01	2011-12-01	2013-02-01	\N	2013-09-04	\N	California Allergy and Asthma Medical Group, Inc.	Sheldon Spector, MD	Principal Investigator	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Allergic Rhinitis",Asthma}	main	cetirizine	Results submitted but cannot be viewed\nUsecase prev was Bronchodilation	t	Asthma	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
158	2023-01-02 15:22:35.731	2023-03-19 20:56:26.842	NCT02392039	Randomized, Placebo Controlled Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma	Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma	Terminated	The goal of this clinical research study is to learn if loratadine can control bone pain caused by pegfilgrastim (a drug given after chemotherapy to help raise white blood cell counts).	Crossover Assignment	M.D. Anderson Cancer Center	OTHER	All	\N	18	1	Actual	OTHER	M.D. Anderson Cancer Center	Randomized	\N	Double	\N	\N	Treatment	\N	Study Groups:\n\nIf you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 groups. You will have an equal chance of being in either group.\n\nIf you are in Group 1, during Cycles 1 and 3 you will receive loratadine. During Cycles 2 and 4, you will receive a placebo.\nIf you are in Group 2, during Cycles 1 and 3 you will receive a placebo. During Cycles 2 and 4, you will receive a loratadine.\n\nA placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.\n\nBoth groups will receive pegfilgrastim after standard of care chemotherapy.\n\nNeither you nor the study staff will know when you are receiving the study drug or the placebo. However, if needed for your safety, the study staff will be able to find out what you are receiving.\n\nStudy Drug Administration:\n\nEach study cycle is 21 days.\n\nOn Day 1 of Cycles 1-6, you will receive pegfilgrastim through a needle under the skin.\n\nOn Days 1-7 of Cycles 1-4, you will take loratadine/placebo by mouth 1 time every day.\n\nIf you have any bone pain during Cycles 1-4, you will take loratadine on Days 1-7 of Cycles 5 and 6. If you do not have bone pain, you will be off study after Cycle 4.\n\nThe study doctor will decide if you need any extra pain medication.\n\nYou will be given a diary to write down when you take loratadine/placebo, and to write down the amount and time of any pain medications they need, and to describe the location, severity, and description of the pain you experience.\n\nStudy Visits:\n\nDuring Cycles 1-4 (and if you have pain, during Cycles 6-7), before you receive pegfilgrastim and on Day 7, you will complete 3 questionnaires about your bone pain and how you are feeling. The should take about 20 minutes to complete. If you are not coming into the clinic, you will be asked to mail in the questionnaires and your diary.\n\nBefore each cycle starts, blood (about 2-4 teaspoons) will be drawn for routine tests and to test your liver, bone, and kidneys.\n\nOn Day 1 of Cycles 2-6, you will have a physical exam, and blood (about 3-4 teaspoons) will be drawn for routine tests.\n\nOn Days 7 and 14 of each cycle (+/- 3 days), blood (about 2-4 teaspoons) will be drawn for routine tests.\n\nLength of Study:\n\nYou may continue taking the study drugs for up to 18 weeks (6 cycles). You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.\n\nYour participation in this study will be over after the end-of-study visit.\n\nEnd-of-Study Visit:\n\nWithin 8 weeks after your last dose of study drugs:\n\nYou will have a physical exam.\nYou will complete the 3 questionnaires about your bone pain and how you are feeling.\nBlood (about 2-4 teaspoons) will be drawn for routine tests and to test your liver, bone, and kidneys.\n\nThis is an investigational study. Loratadine is FDA approved and commercially available for the treatment of seasonal allergies. Pegfilgrastim is FDA approved and commercially available for improvement of chemotherapy-related neutropenia. The use of loratadine to control bone pain is investigational.\n\nUp to 56 participants will be enrolled in this study. All will take part at MD Anderson.	2015-12-14	2018-04-04	2018-04-04	2015-03-18	\N	2019-04-23	\N	\N	\N	\N	\N	\N	Sponsor	Slow Accrual	Interventional	{Adult,"Older Adult"}	{"Early Phase 1"}	{Lymphoma}	main	loratadine	\N	t	Bone Pain	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
296	2023-01-02 15:22:35.738	2023-03-20 21:42:49.2	NCT03933007	Comparison of Maximum Blood Concentrations of Colchicine Between Responders and Non-responders to Colchicine Treatment During Gout Flare	Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare	Recruiting	Gout, secondary to sodium urate crystal deposition, is responsible of recurrent inflammatory painful flares. Efficacy of colchicine which is the first line drug for the treatment and prophylaxis of gout flare varies and only half of treated patients experience good response. This study aims to optimize colchicine prescription for the treatment and prophylaxis of gout flare.\n\nCurrent data suggest that efficiency of colchicine relies on its maximum blood concentration (Cmax).\n\nIn this study, the investigators hypothesize that responders to colchicine treatment have higher colchicine Cmax than non-responder patients following the recommended dose regimen (1 mg then 0.5 mg 1 hour later).\n\nThe individual pharmacokinetics (PK) of colchicine remains poorly investigated while the assessment of individual drug metabolisms can be performed.\n\nThe hypothesis of this study stands that several factors contribute to the variability of colchicine Cmax. The analysis of individual PK profile and a well-characterized metabolism of colchicine will permit a personalized treatment regimen for the treatment and prophylaxis of gout flares.	Single Group Assignment	Assistance Publique - Hpitaux de Paris	OTHER	All	\N	18	88	Anticipated	OTHER	Assistance Publique - Hpitaux de Paris	N/A	all participants will perform the pharmacokinetic study and take colchicine 1 mg + 0.5 mg 1 hour later, midazolam 1 mg and fexofenadine 120 mg.\n\nA pharmacokinetic study is an interventional study with only one arm.	None (Open Label)	all participants will perform the pharmacokinetic study and take colchicine 1 mg + 0.5 mg 1 hour later, midazolam 1 mg and fexofenadine 120 mg.	\N	Treatment	\N	Gout flare is driven by interleukin (IL)-1 production and can be treated by colchicine, NSAID, corticoid or IL-1 blockers (PMID 27457514).\n\nColchicine is an alkaloid compound that disrupts cytoskeletal functions through inhibition of microtubule polymerization and consequently interferes with the intracellular assembly of the inflammasome NLRP3 complex that mediates activation of IL-1 (PMID 16407889).\n\nEfficacy of colchicine treatment in gout flare varies between 37.5 and 64% (PMID 3314832; 20131255). Previous study suggests that colchicine efficiency relies on its blood maximum concentration (Cmax) (PMID 20131255). However this hypothesis needs to be confirmed.\n\nThe hypothesis of this study stands that colchicine Cmax varies with individual colchicine pharmacokinetics and that this individual variation may explain the variation response of colchicine treatment.\n\nAbsorption of orally administrated colchicine varies between 24 et 88% with an average of 45%. Thus, following oral administration of 1.8 mg colchicine over 1 hour to healthy young adults, under fasting condition, the colchicine Cmax (mean 6.2 ng/ml) is reached within a median of 1.8 hours (range 1.0-2.5) (PMID 20131255).\n\nColchicine is demethylated to two metabolites, 2-O-demethylcolchicine and 3-O-demethylcolchicine (2- and 3-DMC, respectively). In vitro studies have shown that hepatic cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of colchicine to 2- and 3-DMC. Colchicine is also a substrate of liver and intestinal P-glycoprotein (P-gp) transporter.\n\nColchicine is eliminated in urine and stools. 40-65% of orally administrated colchicine is recovered unchanged in urine. Enterohepatic recirculation and biliary excretion account for around 50% of colchicine elimination. The mean half-live elimination is 20 to 40 hours.\n\nThus, blood concentration of colchicine depends on kidney and hepatic functions, intestinal absorption and secretion, the presence of drug-drug interactions and individual characteristics of CYP3A4 and P-gp activities (PMID 21480191).\n\nThe individual CYP3A4 and P-gp activities can be assessed with specific probe and/or substrate of these proteins in the so-called phenotyping assay. Thus, using micro dose of midazolam and fexofenadine the activity of CYP3A4 and P-gp, respectively, can be determined and subsequently the individual pharmacokinetic profile of colchicine characterized (PMID 24722393).\n\nCYP3A4 activity is given by the ratio of hydroxy-midazolam/midazolam assessed 2 hours after an oral administration of 1 mg midazolam (PMID 24722393).\n\nP-gp activity is given by the area under the curve (AUC) of a short kinetic that measures fexofenadine concentrations at 2, 3 and 6 hours after its oral administration of 120 mg (PMID 24722393).\n\nThese CYP3A4 and P-gp activities will be correlated with blood colchicine concentrations determined at different time points after an oral administration of 1.5 mg over 1 hour under fasting condition.\n\nThe CYP3A4 and P-gp phenotyping will be proposed to all gouty patients who experienced gout flare and who fulfilled the inclusion and exclusion criteria.\n\nParticipants will have 3 visits :\n\nV0: inclusion visit of patients who had untreated gout flare. Signed consent to the study will be collected and blood analysis performed. A blood collection and biobank of serum will be done using the blood harvested for gout care. Colchicine will be initiated at 1.5 mg over 1 hour (1 mg + 0.5 mg)\nV1: treatment efficiency will be assessed 48 h after V0 using Visual Analogue Scale (VAS) (0-100) pain measurement. Patients who will have an improvement of VAS more than 50% of baseline VAS will be considered as responders to colchicine. In contrast an improvement less than 50% of baseline VAS will be considered as non-responders. Gout flare treatment will be adapted according to patient response. Colchicine treatment will be stopped after gout flare resolution\nV2: this visit will be appointed 1 month after V1 (far enough after resolution of gout flare). During this visit, the CYP3A4 and P-gp phenotyping will be performed. Patients will receive colchicine (1.5 mg over 1 hour) and midazolam (1 mg) and fexofenadine (120 mg) orally. A kinetic of blood samples will be harvested with a total of 8 time points from T0 prior to drug administration to T6 6 hour post-drug administration. At the end of the phenotyping kinetic, urate-lowering therapy will be introduced according to usual care and dosage. This visit is the last visit of the protocol and patients will be followed-up as usual care.\n\nPlasma concentrations of colchicine, midazolam, hydroxymidazolam and fexofenadine will be quantified by liquid chromatography-tandem mass spectrometry (PMID 24295116).\n\nPlasma concentrations of colchicine will then correlate to CYP3A4 and P-gp activities estimated by midazolam and fexofenadine metabolism, respectively.\n\nThe phenotyping will be performed in 34 colchicine responder and 34 colchicine non-responder patients.	2019-09-10	2019-10-10	2022-04-01	2019-05-01	\N	2021-11-22	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Gout Flare"}	combination	fexofenadine	In this study fexofenadine is only used to characterize the pharmacokinetic profile of colchicine: The individual CYP3A4 and P-gp activities can be assessed with specific probe and/or substrate of these proteins in the so-called phenotyping assay. Thus, using micro dose of midazolam and fexofenadine the activity of CYP3A4 and P-gp, respectively, can be determined and subsequently the individual pharmacokinetic profile of colchicine characterized (PMID 24722393).	f	Gout Flare	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
80	2023-01-02 15:22:35.726	2023-02-14 17:25:48.611	NCT03425097	A Randomized, Double Blind, Crossover Trial Comparing Fexofenadine to Placebo for the Treatment of Proton Pump Inhibitor Refractory Gastroesophageal Reflux Symptoms	Fexofenadine Use in Gastroesophageal Reflux Symptoms	Terminated	The investigators wish to study the effectiveness of Fexofenadine (an over the counter allergy pill) for the treatment of gastroesophageal reflux symptoms in patients who still have symptoms despite being on a proton pump inhibitor. The investigators will do this by giving participants both Fexofenadine (an H1 blocker) for 2 weeks and placebo (sugar pill) for 2 weeks. The participants will not know which drug they are getting at a particular time. This will help the investigators better assess the true effectiveness of Fexofenadine.	Crossover Assignment	Stanford University	OTHER	All	90	18	11	Actual	OTHER	Stanford University	Randomized	\N	Double	\N	\N	Treatment	\N	Around 18-28% of North American adults have gastroesophageal reflux symptoms once per week. Of those patients up to 60% may have an inadequate response to proton pump inhibitors and have persistent symptoms. One possible explanation is that this group of patients has nerve related pain. It is thought that H1 receptor activation may sensitize the gastrointestinal tract and esophagus to pain. H1 blockers such as anti-histamines may play a role in treatment of gastroesophageal reflux symptoms that are refractory to proton pump inhibitors by reducing pain perception. The investigators wish to conduct a randomized control trial to test this hypothesis. The investigators will do this by giving participants both Fexofenadine (an H1 blocker) for 2 weeks and placebo (sugar pill) for 2 weeks. The participants will not know which drug they are getting at a particular time. This will help the investigators better assess the true effectiveness of Fexofenadine.	2018-02-07	2019-01-08	2019-01-08	2018-02-07	2021-02-17	2021-02-17	Stanford University	Stanford University	Thomas Zikos	Fellow in Gastroenterology	\N	\N	Principal Investigator	The study was terminated due to insufficient evidence for Fexofenadine efficacy to treat GERD symptoms after the interim analysis.	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Gastroesophageal Reflux"}	main	fexofenadine	\N	t	Gastroesophageal Reflux	2022-08-18 16:54:53	{}	CT_RESULTS	\N	fexofenadine
101	2023-01-02 15:22:35.727	2023-02-14 17:29:19.399	NCT04175834	Comparing the Risk and Severity of Infusion-Related Reactions in Patients Premedicated With Cetirizine Versus Diphenhydramine Prior to Ocrelizumab Infusions	Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab	Active, not recruiting	This 6-month randomized controlled pilot study will determine whether there is some evidence that cetirizine is better tolerated than diphenhydramine without an increase in Infusion-Related Reactions (IRRs) in subjects receiving ocrelizumab(OCR) for multiple sclerosis (MS).	Parallel Assignment	Providence Health & Services	OTHER	All	70	18	52	Anticipated	OTHER	Providence Health & Services	Randomized	Randomized, controlled, pilot study to determine there is evidence that cetirizine is non-inferior to diphenhydramine in limiting the proportion and severity of infusion related reactions to ocrelizumab infusions.	None (Open Label)	\N	\N	Treatment	\N	Ocrelizumab was approved by the US Food and Drug administration in March 2017 for the indication of Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS). The landmark studies used to gain approval found ocrelizumab (OCR) to be well tolerated, but that at least one Infusion-Related Reaction (IRR) occurred in about one-third of patients. Because of this, neurologists typically prescribe prophylactic premedication with 100mg of methylprednisolone, 1 gram of acetaminophen, and 50 mg of IV diphenhydramine. However, many patients experience extreme sedation that interferes with their lifestyle considerably.\n\nThis 6-month randomized controlled pilot study will determine whether there is some evidence that cetirizine is better tolerated than diphenhydramine without an increase in IRRs. Fifty-two patients, 26 patients per arm, will be randomized in a 1:1 ratio to receive cetirizine or diphenhydramine as premedication prior to OCR infusions on day 0 (1st half dose of 300mg), day 14 (2nd half dose of 300mg) and week 24 (1st full dose of 600mg).	2020-02-05	2023-01-01	2024-06-01	2019-11-25	\N	2022-01-12	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Multiple Sclerosis","Infusion Reaction"}	comparison	cetirizine	\N	t	Infusion Reaction	2022-08-17 13:39:16	{"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed 02/13/19, 2019.","Genentech Inc. Ocrevus: Highlights of Prescribing Information. 2018; https://www.gene.com/download/pdf/ocrevus_prescribing.pdf. Accessed 02/13/2019.","Mylan Pharmaceuticals. cetirizine hydrochloride 10 mg tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd0dc7f6-5fb9-4381-bd81-b150b75a2c68. Accessed 9/3/2019, 2019.","Major Pharmaceuticals. diphenhydramine hydrochloride 25mg capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04e70311-6412-4a20-84e3-f6e26d5f19ab. Accessed 9/3/2019, 2019.","US Food and Drug Administration. Non-Inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry. 2016.","Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.","Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21."}	NO_PUBLICATION_FOUND	\N	cetirizine
114	2023-01-02 15:22:35.728	2023-03-22 13:04:56.816	NCT03340740	The Effect of Cetirizine on Bronchoconstriction in Patients With Allergic Rhinitis and Wheezing in the Pediatric Emergency Department	The Effect of Cetirizine on Bronchoconstriction	Completed	The purpose of this study is to determine the effect of cetirizine, an oral antihistamine, on wheezing in patients with allergic rhinitis. Patients presenting to the pediatric emergency department who have a history of allergic rhinitis and who are wheezing will be asked to participate. Half of patients will receive a dose of cetirizine and the other half will receive placebo and their response will be monitored over the course of their emergency department visit with vital signs, physical examinations, and measurement of bronchoconstriction with spirometry.	Parallel Assignment	New York City Health and Hospitals Corporation	OTHER	All	20	6	40	Actual	OTHER	New York City Health and Hospitals Corporation	Randomized	\N	Quadruple	The medication and placebo doses will be prepared in the pharmacy at the study site and provided to the investigators in deidentified bottles.	\N	Treatment	\N	This is a prospective randomized, placebo-controlled trial to look at the effect of cetirizine on bronchoconstriction in patients with allergic rhinitis who present to the Pediatric Emergency Department with wheezing. Oral second generation antihistamines such as cetirizine are already the standard of care for allergic rhinitis. Wheezing pediatric patients with allergic rhinitis who are not already on this therapy will be randomized to receive either age-appropriate-dosed cetirizine or placebo in addition to standard asthma therapy at the discretion of the treating clinician, and will be monitored every 30 minutes with asthma scores and FEV1 measurements. At the conclusion of 3 hours, each patient who received placebo will receive a dose of cetirizine, and each patient who received cetirizine will receive a placebo medication dose, such that initiating therapy for allergic rhinitis is delayed by no more than 3 hours.	2018-05-11	2021-08-30	2021-08-30	2017-11-13	\N	2022-10-18	\N	New York City Health and Hospitals Corporation	Stephen M. Blumberg	Primary Investigator	\N	\N	Principal Investigator	\N	Interventional	{Child,Adult}	{"Phase 4"}	{"Allergic Rhinitis",Asthma}	main	cetirizine	Prev. usecase was bronchoconstriction	t	Asthma	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
210	2023-01-02 15:22:35.733	2023-03-19 21:04:12.251	NCT04237090	Feasibility of a Randomized Controlled Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel	Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel	Completed	Explore the randomized, controlled, double-blind design targeted for the final clinical trial to assess the acceptability of interventions and clinical outcome measures and to provide data making it possible to estimate the parameters necessary for the preparation, modification or even abandonment of the final study.	Parallel Assignment	Ciusss de L'Est de l'le de Montral	OTHER	All	\N	18	27	Actual	OTHER	Ciusss de L'Est de l'le de Montral	Randomized	\N	Triple	\N	\N	Prevention	\N	Paclitaxel is known to cause 30 to 40% of infusion-related reactions when no premedication is administered. It is agreed that all patients should receive premedication with dexamethasone, an H1 antagonist, such as diphenhydramine, and an H2 antagonist before the administration of paclitaxel. There are several cases where undesirable effects (eg. drowsiness, dry mouth, motor impatience) have been reported following the administration of this conventional premedication. Diphenhydramine is often accused because of its pharmacological properties.\n\nA definitive, randomized, double-blind, non-inferiority study can assess whether cetirizine, a non-sedating H1 antagonist, can be used as an effective and safe alternative to diphenhydramine in the prevention of paclitaxel infusion-related reactions.\n\nIn the current proposed feasibility study, patients will be followed for the first two doses of paclitaxel. The goal is to explore the randomized, controlled, double-blind design targeted for the final clinical trial to assess the acceptability of interventions and clinical outcome measures and to provide data making it possible to estimate the parameters necessary for the preparation, modification or even abandonment of the final study.	2020-02-14	2020-08-28	2020-09-04	2020-01-22	\N	2020-10-12	\N	Ciusss de L'Est de l'le de Montral	Matthieu Picard	Assitant clinical professor	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Breast Cancer","Lung Cancer","Ovarian Cancer","Oesophageal Cancer","Head Cancer Neck","Cervical Cancer","Endometrial Cancer"}	main	cetirizine	\N	t	Infusion Reaction	2022-08-17 13:39:16	{"Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B. Hypersensitivity reactions from taxol. J Clin Oncol. 1990 Jul;8(7):1263-8. doi: 10.1200/JCO.1990.8.7.1263.","Picard M, Castells MC. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review. Clin Rev Allergy Immunol. 2015 Oct;49(2):177-91. doi: 10.1007/s12016-014-8416-0.","Picard M. Management of Hypersensitivity Reactions to Taxanes. Immunol Allergy Clin North Am. 2017 Nov;37(4):679-693. doi: 10.1016/j.iac.2017.07.004. Epub 2017 Aug 18.","Durham CG, Thotakura D, Sager L, Foster J, Herrington JD. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions. J Oncol Pharm Pract. 2019 Sep;25(6):1396-1401. doi: 10.1177/1078155218811505. Epub 2018 Nov 12.","Siderov J, Wendel N, Davis ID. Non-Sedating Antihistamines for Premedication in Ambulatory Oncology Patients. Journal of Pharmacy Practice and Research 2002; 32(2): 108-9.","del Cuvillo A, Mullol J, Bartra J, Davila I, Jauregui I, Montoro J, Sastre J, Valero AL. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16 Suppl 1:3-12. No abstract available.","Banerji A, Long AA, Camargo CA Jr. Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: a literature review. Allergy Asthma Proc. 2007 Jul-Aug;28(4):418-26. doi: 10.2500/aap.2007.28.3015.","Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg MB. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer. 2015 Jul;23(7):2019-24. doi: 10.1007/s00520-014-2556-x. Epub 2014 Dec 18.","Beaucage-Charron J, Gaudet L, Lamothe S, Pelletier C, Pepin AS, Roy V, Charpentier F, Lordkipanidze M, Projean D, Bouchard P, Picard M. A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMED-F1 study. Support Care Cancer. 2022 Apr;30(4):3389-3399. doi: 10.1007/s00520-021-06734-4. Epub 2022 Jan 8."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/34997314/	cetirizine
127	2023-01-02 15:22:35.729	2023-03-19 20:44:08.727	NCT04189588	A Phase 2 Exploratory Study of Intravenous QUZYTTIR (Cetirizine Hydrochloride Injection) Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions	Phase 2 Study IV QUZYTTIR (Cetirizine Hydrochloride Injection) vs V Diphenhydramine	Completed	This study is designed to compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan (rituximab) or Taxol (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan (rituximab) or Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan (rituximab) or Paclitaxel after 6 months or in patients with persistent infusion reactions while on maintenance or retreatment.	Single Group Assignment	TerSera Therapeutics LLC	INDUSTRY	All	\N	18	34	Actual	INDUSTRY	TerSera Therapeutics LLC	Randomized	Randomized Double Blind Study	Triple	Double Blind	\N	Treatment	\N	This will be a randomized, double-blind exploratory study of IV cetirizine HCl 10 mg/mL versus IV diphenhydramine 50 mg/mL in approximately 34 patients who require premedication for hypersensitivity infusion reactions associated with an anti-CD20 such as Rituxan (rituximab) or Paclitaxel. The objectives and purpose of the study will be described to patients presenting at the participating infusion centers. The patients will be randomized to receive either IV cetirizine HCl or IV diphenhydramine.	2020-03-25	2020-11-23	2020-12-23	2019-12-06	2022-05-17	2022-05-17	TerSera Therapeutics Inc.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Oncology Patients Receiving Chemotherapy"}	comparison	cetirizine	\N	t	Infusion Reaction	2022-08-17 13:39:16	{"Holmes JP, Peguero JA, Garland RC, North J, Young S, Brent LD, Joseph-Ridge N. Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study. J Infus Nurs. 2021 Nov-Dec 01;44(6):315-322. doi: 10.1097/NAN.0000000000000444."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/34555839/	cetirizine
102	2023-01-02 15:22:35.727	2023-02-14 19:52:47.707	NCT04293822	Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia	Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia	Unknown status	Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss. It is a polygenetic condition with variable degree of severity, age of onset, and location of hair loss.\n\nMale AGA (MAGA) is clearly an androgen-dependent condition and, although the mode of inheritance is uncertain, a genetic predisposition is observed.\n\nRegarding treatment of AGA; in most cases it's challenging and unsatisfactory. Finasteride and Minoxidil 2-5 % solution are the only US Food and Drug Administration (FDA) approved treatment options for MAGA.\n\nOn the basis of hypertrichosis observed in patients treated with analogues of prostaglandin PGF2a (i.e. latanoprost used for glaucoma), it was supposed that prostaglandins would have an important role in the hair growth (Nieves et al., 2014).\n\nMultiple studies had claimed that prostaglandins are deregulated in both alopecia areata (AA) and AGA.\n\nCetirizine, is a safe and selective second-generation histamine H1 receptor antagonist widely used. It has anti-inflammatory properties. Studies have shown cetirizine causes a significant reduction in both the inflammatory cell infiltrate and PGD2 production.\n\nThe oral administration of cetirizine is commonly leads to different systemic side effects. Thus the topical formulation is expected to be an effective tool for avoiding the oral side effects as well as better targeting, but unfortunately, no topical formulation of cetirizine is available in the market till date.	Parallel Assignment	Assiut University	OTHER	Male	50	18	60	Anticipated	OTHER	Assiut University	Randomized	\N	Triple	The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.	\N	Treatment	\N	Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss. It is a polygenetic condition with variable degree of severity, age of onset, and location of hair loss.\n\nHair loss typically begins with bi-temporal recession of the frontal hairline, followed by diffuse hair thinning at the vertex, and eventual complete loss of hair at the center of the vertex. The bald patch at the vertex subsequently joins the frontal receding hairline, leaving an island of hair on the frontal scalp, which finally disappears leaving hair only in the parietal and occipital zones producing the characteristic "horseshoe" pattern.\n\nAndrogenetic alopecia is classified according to the Hamilton-Norwood scale into grades (from I to VII).\n\nAGA features a progressive miniaturization of the hair follicle leading to vellus transformation of terminal hair which results from an alteration in hair cycle dynamics: anagen phase duration gradually decreases and that of the telogen phase increases. As the anagen phase duration determines hair length, the new anagen hair becomes shorter, eventually leading to bald appearance.\n\nThe etiology of AGA is multifactorial and polygenetic. Male AGA (MAGA) is clearly an androgen-dependent condition and, although the mode of inheritance is uncertain, a genetic predisposition is observed, while in female AGA (FAGA) the role of androgens is still uncertain.\n\nRegarding treatment of AGA; in most cases it's challenging and unsatisfactory. Finasteride and Minoxidil 2-5 % solution are the only US Food and Drug Administration (FDA) approved treatment options for MAGA.\n\nFinasteride is a type 2 5-reductase inhibitor that decreases the conversion of testosterone to dihydrotestosterone (DHT), which is responsible for the miniaturization of the hair follicle seen in MAGA.\n\nMinoxidil is a direct arteriolar vasodilator acts by opening potassium channels. Unwanted hair growth was observed as an adverse effect in 24-100 % of patients treated by Minoxidil for hypertension. Minoxidil 2 % solution was approved in 1988, while the 5 % solution was approved in 1991, and the 5 % foam in 2016 for MAGA.\n\nOn the basis of hypertrichosis observed in patients treated with analogues of prostaglandin PGF2a (i.e. latanoprost used for glaucoma), it was supposed that prostaglandins would have an important role in the hair growth.\n\nTheir action is variable depending on the class they belong to: PGE and PGF2a play a generally positive role on the hair growth, while PGD2 an inhibitory role on the hair growth.\n\nMultiple studies had claimed that prostaglandins are deregulated in both alopecia areata (AA) and AGA.\n\nGarza in 2012 found elevated levels of prostaglandin D2 synthase (PTGDS) at the mRNA and protein levels in bald scalp versus haired scalp of men with AGA. Also found that the enzymatic product of PTGDS and prostaglandin D2 (PGD2) are raised in bald human scalp tissue. These results implicate that PGD2 might has a role in pathogenesis of AGA, thus suggest new receptor targets for its treatment.\n\nCetirizine, the active carboxylic acid metabolite of hydroxyzine, is a safe and selective second-generation histamine H1 receptor antagonist widely used in daily practice. It has anti-inflammatory properties and high specific affinity for histamine H1 receptors. Studies have shown cetirizine causes a significant reduction in both the inflammatory cell infiltrate and PGD2 production, and these effects are not related to its anti-H1 activity.\n\nThe oral administration of cetirizine is commonly leads to different systemic side effects as sedation, ocular dryness, tiredness and dry mouth. Thus, the topical formulation for cetirizine is expected to be a rational and effective tool for avoiding the oral side effects as well as better targeting, but unfortunately, no topical formulation of cetirizine is available in the market till date.\n\nAs the stratum corneum is the main barrier for the effective topical drug application, numerous attempts have been made to enhance topical drug delivery such as lipid nanocarriers (nano-transferosomes (NTF), follicular penetration, microbubbles and microneedles.\n\nRossi in 2018 evaluated for the first time in literature the tolerability and efficacy of topical cetirizine 1% lotion inpatients with AGA and claimed that topical cetirizine causes a significant improvement of the initial framework of AGA in both males and females and recommended further studies to allow better investigation for the role of cetirizine in AGA.\n\nTo the best of the investigators knowledge the use of topical cetirizine 1% gel has not yet been tried in the therapeutic management of Egyptian males with AGA.	2020-06-01	2020-11-01	2021-11-01	2020-03-03	\N	2020-03-04	\N	Assiut University	Reham Abdalla Ibrahim	Doctor	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Phase 4"}	{"Androgenetic Alopecia"}	comparison	cetirizine	The publication published at the url is for the exact same topic but seems to be from another university	t	Alopecia	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	https://pubmed.ncbi.nlm.nih.gov/33909554/	cetirizine
325	2023-01-02 15:22:35.74	2023-03-19 21:28:04.658	NCT04450134	Role of Histamine H1/H2 Receptors in the Health- and Performance-promoting Adaptations to High-intensity Interval Training	Histamine H1/H2 Receptors and Training Adaptations	Completed	Exercise training is beneficial for both health and performance. Histamine has been shown to be involved in the acute exercise response. The current study addresses the role of histamine H1/H2 receptor signaling in the chronic training-induced adaptations. Results from this study will yield more insights into the molecular mechanisms of adaptations to exercise training.	Parallel Assignment	Wim Derave	OTHER	Male	50	18	20	Actual	OTHER	University Ghent	Randomized	Placebo + exercise vs histamine blockade + exercise	Quadruple	Double-blind for researchers and participants	\N	Basic Science	\N	\N	2019-10-02	2019-12-18	2021-04-14	2020-06-29	\N	2021-07-30	\N	University Ghent	Wim Derave	Professor	\N	\N	Sponsor-Investigator	\N	Interventional	{Adult}	{"Not Applicable"}	{"Exercise Training","Physical Activity"}	combination	fexofenadine	Some differences in paper to trial. interventions were identical, author matches	t	Exercise	2022-08-18 16:54:53	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/33853781/	fexofenadine
78	2023-01-02 15:22:35.726	2023-02-14 20:01:13.534	NCT04836806	Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Cetirizine and Famotidine in Reducing the Duration of Symptoms in Patients With COVID-19: A Pilot Study	Cetirizine and Famotidine for COVID-19	Withdrawn	This study is a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of cetirizine and famotidine in reducing the duration of symptoms in patients with COVID-19. Secondary aims are to determine if cetirizine and famotidine decrease severity and duration of symptoms, incidence of hospitalizations, ICU admissions, and death.	Parallel Assignment	Emory University	OTHER	All	\N	18	0	Actual	OTHER	Emory University	Randomized	\N	Double	\N	\N	Treatment	\N	COVID-19 is a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with COVID-19 may present with a myriad of symptoms ranging from fever and cough to more severe symptoms such as shortness of breath. Cetirizine and famotidine are commonly administered medications that can be found over-the-counter. They are well tolerated and have low potential for drug-drug interaction. With it's anti-inflammatory properties via modulation of proinflammatory cytokines, cetirizine may be an effective symptomatic therapeutic for COVID-19. With possible antiviral properties, famotidine may have a role in therapy as well.\n\nAfter a positive COVID test has been confirmed, participants with be randomized to take cetirizine and famotidine or a placebo for 10 days and the study medication will be shipped to them. Participants will record their symptoms for 30 days and any serious adverse events will be followed for up to 60 days.	2021-08-01	2022-07-01	2022-07-01	2021-04-08	\N	2021-08-20	\N	Emory University	Humphrey Lam	Assistant Professor	\N	\N	Principal Investigator	Study stopped due to issues with enrollment and lack of funding.	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Covid19}	combination	cetirizine	There are no results for the study, but there is a paper for ctz/famotidine: https://pubmed.ncbi.nlm.nih.gov/32871242/	t	COVID	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
221	2023-01-02 15:22:35.734	2023-03-19 21:05:41.933	NCT04699604	A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma	A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)	Recruiting	This is a randomized, double-blind, placebo-controlled, crossover study comparing asthma control post treatment in African American/Black and Caucasian/White children in both hyper and hypo responsive HILD (Histamine Lontophoresis with Laser Doppler monitoring) phenotypes with uncontrolled persistent allergic asthma using Levocetirizine (LTZ) vs placebo.	Crossover Assignment	Children's Mercy Hospital Kansas City	OTHER	All	17	6	300	Anticipated	OTHER	Children's Mercy Hospital Kansas City	Randomized	Randomized, double-blind, placebo-controlled, crossover study	Triple	Identity of the study article will be known only by the investigational pharmacist charged with dispensing the product and the research coordinator responsible for administering the study articles and obtaining timed blood specimens associated with pharmacokinetic and pharmacodynamic study objectives. Blinding of the principal investigator and co-investigators will be safeguarded by blinding the identity of the study articles (LTZ 0.5 mg/ml oral solution or placebo solution similar in color, flavoring and consistency) and preventing access to specific source documents that will be used for recording of collected blood samples until the time of data analysis.	\N	Treatment	\N	The investigator hypothesizes that children with a hyper-responsive HILD (Histamine Lontophoresis with Laser Doppler monitoring) response type are more likely to have improved asthma control after the addition of the antihistamine LTZ (Levocetirizine) to standard asthma regimen in comparison to children with hypo-responsive HILD type. This study will provide a model for a functional biomarker to inform decision making for therapeutics in children. This work is novel in testing and validating a biomarker accurately and predicting response to asthma treatment in children. This work is significant because it has the potential to alter the current treatment paradigms for children with asthma where response to treatment is predicted a priority. The proposed research will be immediately relevant by expanding knowledge in the field of asthma therapeutics by linking biologically and mechanistically based approaches to an effective and inexpensive treatment for asthma. The primary objective is to determine HILD prediction of therapeutic response in males and females 6-17 years old who identify as African American/Black and Caucasian/White to an antihistamine among children with allergic asthma, and the secondary objective is to develop a robust predictive model of therapeutic response to an antihistamine among children with allergic asthma. There will be 300 participants for approximately 17 weeks.\n\nThe primary outcome measure of therapeutic response to antihistamine will be determined by change in asthma control as guidelines recognize asthma control as a major goal of therapy. Asthma control will be determined based on the Asthma Control Test (ACT) (children  12 years of age) or the Child-Asthma Control Test (C-ACT) (children <12 years of age), validated measures to assess asthma control in children. Children with an ACT or C-ACT score <19 will be classified as having uncontrolled asthma. Assessments will occur at screening, visit 2, 3 and 4 (4 weeks and 6 weeks after the participant is started on drug/placebo.) The secondary measures will include assessment of asthma impairment, risk, and quality of life. These assessments will occur at baseline/pre-dose, 4 weeks after starting drug/placebo, and 6 weeks after drug/placebo for both the LTZ and placebo arms.\n\nThe study team is utilizing HILD a surrogate marker of histamine response and will determine if HILD can predict which participants have improvement in asthma control after treatment with Levocetirizine.	2021-04-28	2025-10-01	2025-10-01	2021-01-07	\N	2022-04-28	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Allergic Asthma"}	main	levocetirizine	\N	t	Asthma	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
108	2023-01-02 15:22:35.728	2023-02-14 20:05:49.219	NCT05243706	Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy	Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy	Not yet recruiting	All vinca alkaloids causes neuropathy. The incidence of peripheral neuropathy is 30 %-40 % in patients treated with vincristine. The incidence of long term neurological adverse events from vinblastine ranged from 50% to 97%. In this study, the investigators will study the effect of using either loratadine or diosmin 450mg/ hesperidin 50 mg combination on neuropathy caused by Vinca alkaloids therapy. This study is a prospective, controlled, randomized, interventional and open-label clinical trial.	Parallel Assignment	Ain Shams University	OTHER	All	80	18	90	Anticipated	OTHER	Ain Shams University	Randomized	\N	None (Open Label)	\N	\N	Prevention	\N	Ninety patients will be randomly assigned to three groups as follows:\n\nGroup 1 (Control group): 30 patients will receive Vincristine 1.5 mg/m2 (maximum: 2 mg) or Vinblastine 6 mg/m2 according to treatment protocol.\n\nGroup 2 (Loratadine group): 30 patients will receive One tablet 10 mg orally once daily starting with vincristine or vinblastine administration for three cycles.\n\nGroup 3 (hesperidin 50 mg/diosmin 450mg group): 30 patients will receive 50 mg Hesperidin and Micronized purified flavonoid fraction (MPFF) 450 diosmin combination one film coated tablet orally twice daily starting with vincristine or vinblastine administration for three cycles .\n\nVincristine or Vinblastine dose will be adjusted as follows: Serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN or alkaline phosphatase increased: Administer 50% of dose.\n\nTreatment allocation will follow a predefined randomization list and it will be computer generated.	2022-03-01	2023-09-30	2023-12-30	2022-02-17	\N	2022-02-17	\N	Ain Shams University	Noha Kamal Morsy Ibraheem	Assistant lecturer at faculty of Pharmacy, University of Sadat City	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Vinca Alkaloid Adverse Reaction"}	comparison	loratadine	\N	t	Neuropathy	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
383	2023-01-02 15:22:35.744	2023-03-19 21:28:38.119	NCT05131555	Influence of Endurance Training and Histamine Receptor Antagonists on the Transcriptome Response in Human Muscle	Influence of Endurance Exercise and Histamine Receptors on the Gene Expression in Skeletal Muscle	Active, not recruiting	Blocking histamine H1/H2 receptors blunts chronic endurance training adaptations. The current study addresses a twofold research question: "What is the influence of endurance training (1) and histamine H1 and H2 signaling (2) on the gene expression in human skeletal muscle." Results from this study will yield more insights into the molecular mechanisms of adaptations to exercise training.	Crossover Assignment	University Ghent	OTHER	All	45	18	14	Actual	OTHER	University Ghent	Randomized	Randomized double-blinded placebo-controlled cross-over interventional study	Triple	\N	\N	Basic Science	\N	\N	2021-08-16	2023-12-31	2023-12-31	2021-11-23	\N	2022-11-09	\N	University Ghent	Wim Derave	Full Professor	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Not Applicable"}	{Exercise,Histamine}	combination	fexofenadine	See other study by Wim Derave	t	Exercise	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
295	2023-01-02 15:22:35.739	2023-03-20 21:42:11.814	NCT04399148	Influence of Antipruritics on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin	Influence of Antipruritics on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.	Completed	In order to validate the accuracy and reliability of the histamine skin prick model for histaminergic itch and vasodilation, the dermal blood flow response induced by a histamine skin prick will be evaluated after the administration of certain antipruritics. Besides, the influence of these antipruritics on the dermal blood flow response induced by the topical application of cinnamaldehyde and capsaicin will be evaluated. Changes in dermal blood flow will be measured with laser speckle contrast imaging.	Crossover Assignment	Universitaire Ziekenhuizen KU Leuven	OTHER	Male	45	18	13	Actual	OTHER	Universitaire Ziekenhuizen KU Leuven	Randomized	Randomized, double-blind, cross-over study	Double	\N	\N	Basic Science	\N	\N	2019-06-11	2019-09-23	2019-09-23	2020-05-22	\N	2020-05-27	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Not Applicable"}	{Pruritus}	comparison	desloratadine		f	Pruritus	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
52	2023-01-02 15:22:35.722	2023-01-02 15:22:35.722	NCT01311336	Randomized Phase II Pilot Study of Loratadine for the Prevention of Pain Caused by the Granulocyte Colony Stimulating Factor Pegfilgrastim	Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain	Unknown status	The purpose of this study is to determine the incidence of pegfilgrastim-induced back and leg pain and to determine whether the antihistamine loratadine can prevent pegfilgrastim-induced back and leg pain.	Parallel Assignment	University of Vermont	OTHER	All	\N	18	55	Anticipated	OTHER	University of Vermont	Randomized	\N	Quadruple	\N	\N	Supportive Care	\N	Pegfilgrastim is a myeloid growth factor that stimulates neutrophil precursors and can be used to decrease infection risk associated with neutropenia. However pegfilgrastim may induce back and leg pain in 20-50% of patients. No intervention has been consistently successful in treating or preventing this pain.\n\nThe exact mechanism of pegfilgrastim-induced pain is unknown but may be related to histamine-mediated inflammation. Several case reports and anecdotal reports have suggested efficacy of antihistamines for this indication.\n\nThis study will have two parts. In the first part (Observational Phase), patients receiving pegfilgrastim will be surveyed to document the incidence of significant pegfilgrastim-induced back and leg pain. In the second part (Treatment Phase), patients who previously experienced such pain will be randomized to receive a 7-day course of either the antihistamine loratadine or placebo to determine whether pegfilgrastim-induced back and leg pain can be prevented with this intervention.	2011-05-01	2013-06-01	2013-06-01	2011-03-09	\N	2013-01-24	\N	University of Vermont	Steven Grunberg	Professor of Medicine	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Pegfilgrastim-induced Back and Leg Pain"}	main	loratadine	\N	t	Bone Pain	2022-08-17 18:44:47	{"Moukharskaya J, Abrams DM, Ashikaga T, Khan F, Schwartz J, Wilson K, Verschraegen C, Openshaw T, Valentine J, Eneman J, Unger P, Ades S. Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim. Support Care Cancer. 2016 Jul;24(7):3085-93. doi: 10.1007/s00520-016-3119-0. Epub 2016 Feb 19."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/26894485/	loratadine
81	2023-01-02 15:22:35.725	2023-02-14 17:19:17.617	NCT02305979	Evaluation of Loratadine for Granulocyte-Colony Stimulating Factor Induced Bone Pain in Patients With Hematologic Malignancies	Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies	Completed	The purpose of this project is to assess the efficacy of loratadine in decreasing the incidence and severity of bone pain following G-CSF administration in patients with hematologic malignancies, patients undergoing mobilization of hematopoietic progenitor cells, and patients who have undergone an autologous hematopoietic cell transplant. This is a different patient population than those being assessed in current clinical trials.	\N	Wake Forest University Health Sciences	OTHER	All	\N	18	61	Actual	OTHER	Wake Forest University Health Sciences	\N	\N	\N	\N	Cohort	\N	Prospective	Objectives\n\nThe primary objective is to determine the incidence of bone pain following G-CSF administration in patients with hematologic malignancies, patients undergoing mobilization of hematopoietic progenitor cells, and patients who have undergone an autologous hematopoietic cell transplant. Incidence will be determined via patient-reported incidence following G-CSF administration.\n\nSecondary objectives include determining the efficacy of loratadine for bone pain prevention as indicated by a decrease in incidence and a decrease in severity (questions 4 and 5 of the survey).	2014-12-01	2017-09-01	2017-09-01	2014-12-03	\N	2018-07-03	\N	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Adult,"Older Adult"}	{}	{Leukemia,Lymphoma}	main	loratadine	\N	t	Bone Pain	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
159	2023-01-02 15:22:35.731	2023-03-20 17:47:30.974	NCT01916980	A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus.	Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)	Completed	This is an efficacy and safety study of up to 12 weeks of desloratadine in Japanese participants with eczema/dermatitis and dermal pruritus. The primary hypothesis of this study is that the sum of the daytime and nighttime pruritus/itch scores for both the eczema/dermatitis group and the dermal pruritus group will be significantly improved at Week 2 compared to Baseline.	Single Group Assignment	Organon and Co	INDUSTRY	All	\N	12	94	Actual	INDUSTRY	Organon and Co	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2013-08-27	2014-03-08	2014-03-22	2013-08-06	2014-11-19	2022-02-09	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{Eczema,Dermatitis,"Dermal Pruritus"}	main	desloratadine	Repurpose??\nPublication not in english?	f	Dermatitis	2022-09-15 19:16:20	{"Furue M, Maeda Y, Oshima N, Hisada S. A Phase III clinical trial of desloratadine in Japanese subjects with eczema/dermatitis and cutaneous pruritus: An open label long-term trial. J Clin Therapeut Med. 2016;32(11):877-889.. [in Japanese] https://mol.medicalonline.jp/archive/search?jo=an9cltmd&ye=2016&vo=32&issue=11"}	PUBLISHED	https://mol.medicalonline.jp/archive/search?jo=an9cltmd&ye=2016&vo=32&issue=11	desloratadine
91	2023-01-02 15:22:35.727	2023-02-14 19:57:33.665	NCT04481412	The Role of Cetirizine in Androgenetic Alopecia in Females	Topical Cetirizine in Androgenetic Alopecia in Females	Active, not recruiting	Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist, widely used in daily practice. A study showed that cetirizine causes a significant reduction in both the inflammatory cell infiltrate and PGD2 production. A pilot study on topical cetirizine showed that cetirizine increased total hair density, terminal hair density and diameter. Also, its lower potential side effects if compared with other drugs commonly used for AGA, as minoxidil, can promote a wider use and better compliance of cetirizine in the future for the treatment of AGA. Combinations of therapies are likely to be more efficacious than single treatments.\n\nTreatments to clinically improve scalp hair density and reduce mid-pattern thinning leading to improved scalp coverage are highly important for the affected women. On the basis of the above evidence and lacking studies that confirm the effectiveness of cetirizine in AGA treatment, the aim of this study is to evaluate the efficacy and tolerability of topical cetirizine in female patients with AGA.	Parallel Assignment	Cairo University	OTHER	Female	50	20	66	Actual	OTHER	Cairo University	Randomized	\N	Triple	\N	\N	Treatment	\N	Androgenetic alopecia (AGA) is the most common form of alopecia in men and women. It is a hereditary, androgen-dependent, progressive thinning of scalp hair that follows a defined pattern. The disease mechanism is still relatively poorly understood, but involves a strong genetic contribution as well as some environmental input. AGA manifests as a noticeable reduction of scalp hair coverage, shorter miniaturized telogen vellus hair follicles, and significantly slower rates of hair growth. Approximately 6% to 38% of healthy women experience some degree of frontal and frontoparietal hair loss. AGA may have significant impact on quality of life in female patients. When female AGA is associated with high levels of androgens, systemic antiandrogenic therapy may be needed. However, treating it with oral antiandrogens is usually ineffective suggesting that most female AGA cases are not systemic androgen dependent and topical treatment may be more appropriate.\n\nCurrently, the only clinically validated and licensed medication approved for increasing hair density in women with AGA is 2 % minoxidil topical solution, and up to 5% minoxidil in several countries. The collective effects of minoxidil lead to increased cutaneous blood flow, prolongation of the anagen growth phase, and increase in the size of smaller hair follicles. However, it produces moderate results, and must continue to be used to have a continued benefit, and may produce adverse side effects. The use of higher concentrations of minoxidil in women is supported by results from an early study suggesting that concentrations higher than 2% could improve efficacy without increasing the rates of adverse events when applying not more than 60 mg of minoxidil per day.\n\nBased on the hypertrichosis observed in patients treated with analogues of prostaglandin F2a (PGF2a) (i.e. latanoprost used for glaucoma), it was supposed that prostaglandins would have an important role in hair growth. Their action is variable depending on the class they belong to: prostaglandin E(PGE) and PGF2a play a generally positive role on the hair growth, while PGD2 has an inhibitory role on the hair growth. Elevated levels of prostaglandin D2 synthase (PGDS) were found at the messenger ribonucleic acid (mRNA) and protein levels in bald scalp versus haired scalp of men with AGA; as well as the enzymatic product of PGDS, (PGD2), is generally elevated in bald human scalp tissue.\n\nCetirizine is a safe and selective, second-generation histamine H1 receptor antagonist, widely used in daily practice. A study showed that cetirizine causes a significant reduction in both the inflammatory cell infiltrate and PGD2 production. However, these effects apparently are not related to its anti-H1 activity. A pilot study on topical cetirizine showed that cetirizine increased total hair density, terminal hair density and diameter. Also, its lower potential side effects if compared with other drugs commonly used for AGA, as minoxidil (which often cause of hypertrichosis, contact allergic dermatitis, headache and hypotension), can promote a wider use and better compliance of cetirizine in the future for the treatment of AGA. Combinations of therapies are likely to be more efficacious than single treatments.\n\nTreatments to clinically improve scalp hair density and reduce mid-pattern thinning leading to improved scalp coverage are highly important for the affected women. On the basis of the above evidence and lacking studies that confirm the effectiveness of cetirizine in AGA treatment, the aim of this study is to evaluate the efficacy and tolerability of topical cetirizine in female patients with AGA.	2020-07-25	2021-11-30	2022-03-31	2020-07-22	\N	2022-03-08	\N	Cairo University	Samar Farghali Farid	Head and professor of clinical pharmacy department	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Phase 2","Phase 3"}	{"Androgenetic Alopecia"}	main	cetirizine	\N	t	Alopecia	2022-08-17 13:39:16	{"Jaworsky C, Kligman AM, Murphy GF. Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. Br J Dermatol. 1992 Sep;127(3):239-46. doi: 10.1111/j.1365-2133.1992.tb00121.x.","Guo H, Gao WV, Endo H, McElwee KJ. Experimental and early investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs. 2017 Aug;26(8):917-932. doi: 10.1080/13543784.2017.1353598. Epub 2017 Jul 12.","Rossi A, Campo D, Fortuna MC, Garelli V, Pranteda G, De Vita G, Sorriso-Valvo L, Di Nunno D, Carlesimo M. A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. J Dermatolog Treat. 2018 Mar;29(2):149-151. doi: 10.1080/09546634.2017.1341610. Epub 2017 Jun 29."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/36571611/	cetirizine
122	2023-01-02 15:22:35.729	2023-03-19 20:43:24.984	NCT04211259	The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization	Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization	Recruiting	This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.	Parallel Assignment	Rutgers, The State University of New Jersey	OTHER	All	\N	18	70	Anticipated	OTHER	Rutgers, The State University of New Jersey	Randomized	\N	Quadruple	\N	\N	Treatment	\N	PRIMARY OBJECTIVE:\n\nI. To evaluate the efficacy of the second-generation antihistamine, loratadine, as prophylaxis for filgrastim (i.e., Neupogen, Zarxio) induced bone pain during stem cell mobilization in multiple myeloma patients.\n\nSECONDARY OBJECTIVES:\n\nI. To examine the frequency and quantity of supportive analgesic medications needed in addition to loratadine or placebo for filgrastim induced bone pain.\n\nII. To identify risk factors associated with developing filgrastim induced bone pain.\n\nOUTLINE: Patients are randomized to 1 of 2 cohorts.\n\nCOHORT I: Beginning 5 days before the first dose of standard of care filgrastim, patients receive loratadine orally (PO) once daily (QD). Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.\n\nCOHORT II: Beginning 5 days before the first dose of standard of care filgrastim, patients receive placebo PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.	2022-04-18	2023-06-30	2025-06-30	2019-12-26	\N	2022-10-19	\N	Rutgers Cancer Institute of New Jersey	Mansi Shah, MD	Assistant Professor of Medicine	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Early Phase 1"}	{"Plasma Cell Myeloma"}	main	loratadine	\N	t	Bone Pain	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
129	2023-01-02 15:22:35.729	2023-03-19 20:53:47.754	NCT00160563	The Prolongation of the EPAAC Trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). A Multi-country, Double Blind, Placebo (PLC) Controlled, Follow-up Trial With 3 Parallel Groups (LCTZ-LCTZ, LCTZ-PLC and PLC-PLC) : Evaluation of the Long Term Efficacy and Safety of Levocetirizine (LCTZ) (5 mg/ml Oral Drops -0.125 mg/kg b.w. b.i.d.) Administered for an Additional 18 Months Period in Preventing the Onset of Asthma in Children Coming From the EPAAC Trial.	Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)	Terminated	Prolongation of the EPAAC trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children).\n\n36 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in young atopic children.	Parallel Assignment	UCB Pharma	INDUSTRY	All	3.5	2.5	207	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2004-06-01	2006-03-01	2006-03-01	2005-09-12	2009-08-04	2015-03-03	UCB Pharma	\N	\N	\N	\N	\N	Sponsor	The predecessor study A00309 (NCT00152464) did not show statistical significance in time to onset of asthma between the levocetirizine and placebo groups.	Interventional	{Child}	{"Phase 3"}	{Asthma}	main	levocetirizine	\N	t	Asthma	2022-09-15 18:58:14	{}	CT_RESULTS	\N	levocetirizine
137	2023-01-02 15:22:35.729	2023-03-19 20:55:08.303	NCT05446480	Potential Off-label Use of Desloratadine to Mitigate Inflammation Caused by PPE-induced Heat Stress	Role of Desloratadine in Reducing Inflammation From Occupational Heat Strain	Recruiting	The aim of this initial investigational study is to compare the effect of desloratadine on the inflammatory responses to heat stress in firefighters exercising in their personal protective equipment.	Crossover Assignment	University of Victoria	OTHER	Male	50	19	12	Anticipated	OTHER	University of Victoria	Randomized	Own-control study - all participants perform each trial arm/intervention separated by a washout period. Order of trials is randomized for each participant.	Double	\N	\N	Prevention	\N	Significant heat strain where temperatures approach and exceed 39.0 degrees celsius is known to increase intestinal permeability and induce a graded systemic inflammatory response which includes increases in interleukin-6, tumor necrosis factor alpha, and c-reactive protein. Recent data examining firefighters found fire service instructors possessed greater resting levels of inflammatory markers and that 18-29% of the variation in these markers could be explained by frequency of heat strain. Firefighters themselves are susceptible to core temperatures ranging between 38.5 and 39.0C in as little as 2-3 work cycles. Considering resource limitation in the fire service, such workloads is a realistic possibility when at structural fires, particularly for first alarm apparatus.\n\nThough there is a well-defined role of the inflammatory response in adaptive changes, elevated resting levels begs the question of whether such frequency of exposure and acute inflammatory flux in fire service workers may contribute to chronic elevations of inflammatory markers and altered disease risk. Elevations in c-reactive protein are associated with cardiovascular risk with studies indicating a causative role of monomeric c-reactive protein in platelet activation and thrombus growth.\n\nCooling methods save for cryotherapy have demonstrated limited to mild effectiveness for mitigating the inflammatory responses to heat strain resulting in no solution to attenuate acute inflammatory responses. The mast-cell stabilizing properties of desloratadine and its safety profile make it an interesting candidate for investigating its use in this context.\n\nThis study seeks to determine whether 10mg desloratadine taken before and 24h after exertional heat strain to a core temperature to a core temperature of 39.5 degrees celsius reduces the associated inflammatory response measured over a 72-hour period.	2022-07-01	2023-08-01	2023-08-01	2022-07-06	\N	2022-07-06	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Not Applicable"}	{"Heat Stress, Exertional","Inflammatory Response","Firefighter Personal Protective Equipment"}	main	desloratadine	\N	t	Heat Stress	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
215	2023-01-02 15:22:35.734	2023-03-19 21:05:27.729	NCT04726345	Effect of Antihistamines on Ureteral Stent-Related Symptoms: Randomized Controlled Trial	Effect of Antihistamines on Ureteral Stent-Related Symptoms	Recruiting	This is a prospective, double-blind, randomized, open-label, single-center trial of up to 78 participants who are adult patients (aged 18-80 years) and are undergoing unilateral retrograde ureteroscopy with planned ureteral stent placement for treatment of urinary tract stones. Eligible patients will be randomly and divided into two groups in a 1:1 ratio. Group A will receive fexofenadine 180 mg once daily in addition to standard of care treatment. Group B will receive placebo in addition to standard of care treatment. The routine standard of care treatment will consist of oral non-steroidal anti-inflammatory drugs (NSAIDs).\n\nThe primary outcomes of the study are the Ureteral Stent Symptom Questionnaire (USSQ) urinary symptom score and pain score. Secondary outcomes include (i) number of office phone calls due to urinary symptoms; (ii) duration of analgesic use; (iii) duration and quantity of narcotic use; (iv) number of emergency department visits; (v) drug-related adverse effects; (vi) other domains of the USSQ.	Parallel Assignment	Columbia University	OTHER	All	80	18	78	Anticipated	OTHER	Columbia University	Randomized	Subjects will be randomized in a 1:1 ratio to receive fexofenadine or placebo in addition to the standard of care. A total of 39 subjects will be randomized to each group.	Double	Subjects and the study urologist will be blinded to treatment allocation. Treatment allocation will be known by the investigator performing data analysis, who will not be directly participating in patient care.	\N	Supportive Care	\N	Ureteral stents treat ureteral obstruction, allow for passive dilation of the ureter, maintain urine flow to the bladder, and aid in the recovery of the ureter after endoscopic surgery or ureteral injury. These stents are routinely utilized after urologic procedures for the treatment of urolithiasis and are generally kept in place for 1-2 weeks following the procedure. Despite their advantages, indwelling ureteral stents cause discomfort and reduce patient quality of life. These symptoms are partially attributed to local irritation to the ureter and bladder. Bothersome stent-related symptoms include urinary urgency, frequency, flank pain, hematuria, dysuria, sexual side effects, and emotional distress. The majority of patients with ureteral stents experience symptoms post-operatively.\n\nSeveral studies have indicated that agents such as antimuscarinics or alpha-1 adrenergic receptor antagonists may improve stent-related symptoms. The indications for anticholinergic medications are based on blocking involuntary bladder muscle contraction; however, the efficacy of these drugs is still controversial. Furthermore, these medications have potential adverse side effects.\n\nAntihistamines also show potential in alleviating stent-related symptoms. Multiple in vitro studies have shown H1 receptor activity involved both in ureteral peristalsis and in bladder contraction. Both first- and second-generation H1 antagonists have shown activity in the urinary tract. In clinical practice, antihistamines are commonly utilized in the management of bladder pain caused by interstitial cystitis. Additionally, a randomized controlled trial found efficacy of antihistamines for pain management in the setting of renal colic from obstructing ureteral stones. There is novel evidence that in patients with indwelling stents, there are inflammatory changes in the bladder with an associated eosinophilic reaction. Eosinophilic cystitis is commonly associated with bladder irritation or allergy, and these findings point to a novel paradigm of treating patients with antihistamines. To our knowledge, no studies have evaluated the efficacy of antihistamines for managing stent-related symptoms.	2021-06-29	2022-03-01	2022-03-01	2021-01-27	\N	2021-07-20	\N	Columbia University	Ojas Shah	George F. Cahill Professor of Urology	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{Nephrolithiasis}	main	fexofenadine	\N	t	Nephrolithiasis	2022-08-18 16:54:53	{"Aboutaleb H, Gawish M. Correlation of Bladder Histopathologic Changes Due to Double-J Stenting to the Period of Stenting: A Preliminary Study. J Endourol. 2017 Jul;31(7):705-710. doi: 10.1089/end.2017.0113. Epub 2017 May 31.","Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003 Mar;169(3):1060-4. doi: 10.1097/01.ju.0000049198.53424.1d.","Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol. 2003 Mar;169(3):1065-9; discussion 1069. doi: 10.1097/01.ju.0000048980.33855.90.","Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ. Meta-analysis showing the beneficial effect of alpha-blockers on ureteric stent discomfort. BJU Int. 2011 Dec;108(11):1894-902. doi: 10.1111/j.1464-410X.2011.10170.x. Epub 2011 Mar 31.","Lingeman JE, Preminger GM, Goldfischer ER, Krambeck AE; Comfort Study Team. Assessing the impact of ureteral stent design on patient comfort. J Urol. 2009 Jun;181(6):2581-7. doi: 10.1016/j.juro.2009.02.019. Epub 2009 Apr 16.","Sivalingam S, Streeper NM, Sehgal PD, Sninsky BC, Best SL, Nakada SY. Does Combination Therapy with Tamsulosin and Tolterodine Improve Ureteral Stent Discomfort Compared with Tamsulosin Alone? A Double-Blind, Randomized, Controlled Trial. J Urol. 2016 Feb;195(2):385-90. doi: 10.1016/j.juro.2015.08.104. Epub 2015 Sep 21.","Yilmaz E, Batislam E, Deniz T, Yuvanc E. Histamine 1 receptor antagonist in symptomatic treatment of renal colic accompanied by nausea: two birds with one stone? Urology. 2009 Jan;73(1):32-6. doi: 10.1016/j.urology.2008.08.494. Epub 2008 Oct 11."}	NO_PUBLICATION_FOUND	\N	fexofenadine
257	2023-01-02 15:22:35.736	2023-03-19 21:10:55.858	NCT01825655	Effect of Long Acting Antihistamine on Opioid- Induced Pruritus: A Double-blind Placebo Controlled Study	Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching	Terminated	The purpose of this study is determine if long acting antihistamine like cetirizine can help with itching induced by opioid pain medications.	Parallel Assignment	Virginia Commonwealth University	OTHER	All	18	6	3	Actual	OTHER	Virginia Commonwealth University	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2014-09-01	2017-11-01	2017-11-01	2013-04-05	2018-09-11	2018-10-10	Virginia Commonwealth University	\N	\N	\N	\N	\N	Sponsor	Unable to recruit patients	Interventional	{Child,Adult}	{"Phase 4"}	{Pruritus}	main	cetirizine	\N	t	Pruritus	2022-08-17 13:39:16	{}	CT_RESULTS	\N	cetirizine
268	2023-01-02 15:22:35.737	2023-03-19 21:11:15.285	NCT03167216	Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction	Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction	Completed	The objective of this study is to evaluate inhibition of mast cells and the histamine 1 receptor (H1R) for treatment of chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS).	Single Group Assignment	Northwestern University	OTHER	Male	80	21	20	Actual	OTHER	Northwestern University	N/A	Comparison of mast cell tryptase levels and changes in symptom scores after treatment with cromolyn sodium and cetirizine hydrochloride	None (Open Label)	\N	\N	Basic Science	\N	Chronic pelvic pain is a hallmark of patients with CPPS, a non-bacterial category of prostatitis that is a significant source of morbidity in men. The cause of CPPS is unknown and there is a lack of biomarkers for diagnosis of this syndrome. Research in animal models of CP/CPPS have pointed to a role for mast cells and their degranulation constituents including mast cell tryptase in the development of pelvic pain and lower urinary tract symptoms. This study aims to evaluate the ability of FDA approved and marketed drugs to inhibit the release of mast cell tryptase and to ameliorate symptoms in patients with CP/CPPS.\n\nThis is an open label study to evaluate the efficacy of Cromolyn Sodium Oral Solution and Cetirizine hydrochloride (tablet) in men with CP/CPPS to reduce mast cell tryptase levels in expressed prostatic fluids and to show improvement in symptoms of CP/CPPS. There is no control group for the study. The difference between pre- and post-treatment levels across individuals will be assessed.\n\nThe study will consist of 3 periods: the Screening Period (Days -7 to -1), the Treatment Period (Days 1 to 21), and the Follow-up Period (7 days) after the last dose at Day 21.\n\nDuring screening, subjects will be admitted to the clinic, undergo specimen (Expressed prostatic secretions (EPS), urine and blood) collection and recording of their baseline questionnaire responses Subjects will provide a basic health history, including current general health, adverse events, medications or treatments within the past 5 years. A physical examination including vital heart rate, breathing rate, blood pressure, temperature, height, weight and body mass will be taken. Subsequently, EPS from eligible subjects will be collected by the clinical team and assayed for the levels of mast cell tryptase within 24 hours of sample collection at the screening visit. 20 subjects with elevated mast cell tryptase will be identified and will be eligible for receiving the study medication from the Investigational pharmacy at Northwestern University.\n\nEligible subjects will be required to take medication for days 1-21 (Week 1-3), record their symptom scores weekly using the NIH-CPSI, and record all safety related symptoms.\n\nSubjects will return to the clinic after the completion of three weeks of treatment. Expressed prostatic secretions (EPS), blood as well as a voided bladder 1, 2 and 3 (VB1-3) urine specimens will be collected as at baseline and after the last dose at day 21 for evaluating mast cell tryptase levels. A review subject's general health, adverse events, and any medications that have changed since the last visit will be collected. Vital signs (heart rate, breathing rate, blood pressure, temperature, weight and BMI will be collected.\n\nTreated subjects will be contacted by phone 7 days after treatment by the study coordinator to follow up on any study related adverse effects or changes in symptoms.	2017-08-01	2022-04-01	2022-06-30	2017-05-25	\N	2022-11-03	\N	Northwestern University	Praveen Thumbikat	Professor	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Early Phase 1"}	{"Chronic Prostatitis With Chronic Pelvic Pain Syndrome"}	combination	cetirizine	\N	t	Prostatitis	2022-08-17 13:39:16	{"Done JD, Rudick CN, Quick ML, Schaeffer AJ, Thumbikat P. Role of mast cells in male chronic pelvic pain. J Urol. 2012 Apr;187(4):1473-82. doi: 10.1016/j.juro.2011.11.116. Epub 2012 Feb 17.","Murphy SF, Schaeffer AJ, Thumbikat P. Immune mediators of chronic pelvic pain syndrome. Nat Rev Urol. 2014 May;11(5):259-69. doi: 10.1038/nrurol.2014.63. Epub 2014 Apr 1.","Roman K, Done JD, Schaeffer AJ, Murphy SF, Thumbikat P. Tryptase-PAR2 axis in experimental autoimmune prostatitis, a model for chronic pelvic pain syndrome. Pain. 2014 Jul;155(7):1328-1338. doi: 10.1016/j.pain.2014.04.009. Epub 2014 Apr 13."}	NO_PUBLICATION_FOUND	\N	cetirizine
281	2023-01-02 15:22:35.738	2023-03-19 21:12:46.89	NCT05043350	Potential Therapeutic Outcome of Combined Antihistaminics Therapy in COVID 19 Patients	Combined Antihistaminics Therapy in COVID 19 Patients	Not yet recruiting	The use of antihistaminic medications could result in a significant immune modulation which may help in the treatment of cytokine storm of COVID-19.Thus, the aim of this study is to evaluate efficacy and safety of famotidine and loratadine combination in covid 19 treatment protocol.	Parallel Assignment	Ain Shams University	OTHER	All	\N	\N	214	Anticipated	OTHER	Ain Shams University	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	On admission to hospital, the patient will be diagnosed for suspected COVID-19 based primarily upon pulmonary symptoms, and will be confirmed positive for COVID-19 by RT-PCR diagnostic test and then will be located within a COVID-19 ward. According to Ministry of Health guidelines, moderate cases of COVID 19 will be identified if the Patient has pneumonia manifestations on radiology associated with symptoms (fever, cough, general weakness /fatigue, headache, sore throat, anorexia, diarrhea and vomiting) and / or leucopenia or lymphopenia.\n\nTreatment will be initiated in ER with standard of care per admitting provider. Standard of care includes radiologic assessments, supplemental oxygen when necessary, and intravenous (IV) hydration when necessary. In addition to concomitant treatments like the antimalarial drug hydroxychloroquine, the anti-inflammatory drug dexamethasone (IV).plus, Famotidine 40 mg po twice daily and loratadine 10 mg po once daily (Interventional group) and Control group will receive standard drug therapy according to the treatment protocols of the National Committee of COVID-19 + Famotidine 40 mg twice daily po. The COVID-19 standard of care as provided by the ministry of health is attached in appendix1.Blood samples will be withdrawn from the patients at baseline and every 7 days to assess the following parameters using routine laboratory methods Complete blood picture: Lymphopenia, eosinopenia, neutrophil/lymphocyte ratio and platelet count, C-reactive protein and ferritin, lactate dehydrogenase (LDH), d-dimer Cardiac markers, IL-6, Procalcitonin, Prothrombin time, Activated partial thromboplastin time, Creatine kinase (CK), Glutamic-pyruvic transaminase (SGPT) and Urea, and serum creatinine to determine the incidence of organ failure Sample handling: Syringes used in sample withdrawal will be discarded in appropriate safety box and serum samples will be discarded in biohazards box. These biohazard waste will be sent to incinerators through the hospital laboratory as per hospital protocol.\n\nPrecaution against infections:\n\nThe principal investigator and all healthcare professional must wear full protective personal equipment (PPE) as per hospital protocol including full gown, full facial mask and safety gloves when in direct contact with patients for follow ups. These PPE are removed before the exit of COVID-19 ward and discarded as hazard waste. Disinfectant will be used by all personal before leaving the ward	2021-09-13	2021-12-13	2022-01-13	2021-09-14	\N	2021-09-14	\N	Ain Shams University	Samar Saad elDeen Azab	Professor of Pharmacology & Toxicology	\N	\N	Principal Investigator	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 2","Phase 3"}	{Covid19}	combination	loratadine	\N	t	COVID	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
282	2023-01-02 15:22:35.738	2023-03-19 21:13:08.274	NCT02451579	A Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy	A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy	Completed	A double-blind, placebo controlled study conducted at a single study site. Evaluating the role of systemic antihistamine therapy in the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy.	Parallel Assignment	Goldman, Butterwick, Fitzpatrick and Groff	OTHER	All	\N	19	20	Anticipated	OTHER	Goldman, Butterwick, Fitzpatrick and Groff	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2015-02-01	2016-12-01	2017-01-01	2015-05-22	\N	2017-03-01	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Not Applicable"}	{"Actinic Keratoses"}	main	cetirizine	\N	t	Actinic Keratoses	2022-08-17 13:39:16	{"Vanaman Wilson MJ, Jones IT, Wu DC, Goldman MP. A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy. Lasers Surg Med. 2017 Oct;49(8):738-742. doi: 10.1002/lsm.22682. Epub 2017 May 10."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/28489298/	cetirizine
285	2023-01-02 15:22:35.738	2023-03-19 21:13:16.751	NCT05150899	Comparative Study Between Use of Alpha Blocker Versus Alpha Blocker and Antihistaminic in Management of Acute Renal Colic Prevent Pain Recurrence and Increase Expulsion Rate of Ureteric Stone  1cm	Role of Antihistaminic in Acute Renal Colic Prevent Pain Recurrence and Expulsion of Ureteric Stone  1cm	Not yet recruiting	Urolithiasis is one of the most common urological diseases. The risk of stone disease ranges between 5% and 12% worldwide. Ureteric stones account for 20% of all urinary tract stones and >70% of the ureteric stones are located in the lower third of the ureter, i.e., distal ureteric stones (DUS). The colicky-type pain in the ureter, an increase in proximal peristalsis through activation of intrinsic ureteral pacemakers may contribute to the perception of pain. Muscle spasm increased proximal peristalsis, local inflammation, irritation, and oedema at the site of obstruction may contribute to the development of pain through chemoreceptor activation and stretching of submucosal free nerve endings. -adrenergic blockers, anti-inflammatory drugs, antihistaminic and calcium channel blockers, which have a relaxant effect on the ureteric smooth musculature. The presence of histamine receptors in the ureter have been presented in various studies. The histamine-1 (H1) receptors have been shown to have a wide distribution Histamine, which is secreted from the mast cells, causes strong peristaltic contractions in the ureter. alpha adrenoreceptor antagonists (i.e., tamsulosin) have been employed in the treatment of ureteric colic due to smooth muscle relaxation so their potential ability to increase stone passage, reduce pain medication use and reduce urologic interventions. According to the currently accepted view, renal colic management starts with NSAI drugs also NSAI has role in decrease inflammation and oedema and increase expulsion rate . in this study we will compare the use of alpha blocker versus alpha blocker and antihistaminic in management of acute renal colic prevent pain recurrence and increase expulsion rate of ureteric stone  1cm, with analgesic use in case of acute stage.	\N	Assiut University	OTHER	All	85	18	100	Anticipated	OTHER	Assiut University	\N	\N	\N	\N	Other	\N	Prospective	All the patients will be included within inclusion criteria After providing written informed consent, these patients were randomly divided into 2 groups by use of a computer-generated random number table.\n\nhistory taken about patient pain onset, duration and type with scoring the pain by World Health Organization numerical pain score of 0-10.\nUltrasonography done to determine if kidney obstructed and grade of obstruction at the day 1 day 15 and day 30.\ngroup A receive Tamsulosin 0.4mg in combination of NSAI drug if patient present with colic, if not in renal colic at bed time Tamsulosin 0.4mg with analgesic on demand, group B receive pheniramine maleate 50mg injection every 12hr for 24 hr in combination of Tamsulosin 0.4mg and NSAI drug then fexofenadine 180 mg in combination of Tamsulosin 0.4mg and NSAI drug on demand if patient present with colic. if not in renal colic at bed time fexofenadine 180 mg in combination of Tamsulosin with NSAI on demand.\nIn case of patient presented by acute renal colic the time of administration of treatment recorded and the time of relief pain recorded.\nCT scan done to ensure urolithiases if no CT done at the first day and after 30 days.\nFull labs done especially serum creatinine and serum uric acid.	2021-11-30	2022-11-25	2022-11-25	2021-12-09	\N	2021-12-09	\N	Assiut University	Mostafa Kamel Abdel Rahman	Director	\N	\N	Principal Investigator	\N	Observational	{Adult,"Older Adult"}	{}	{"Renal Colic","Ureter Stone"}	combination	fexofenadine	\N	t	Nephrolithiasis	2022-08-18 16:54:53	{"Bader MJ, Eisner B, Porpiglia F, Preminger GM, Tiselius HG. Contemporary management of ureteral stones. Eur Urol. 2012 Apr;61(4):764-72. doi: 10.1016/j.eururo.2012.01.009. Epub 2012 Jan 14.","Coll DM, Varanelli MJ, Smith RC. Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT. AJR Am J Roentgenol. 2002 Jan;178(1):101-3. doi: 10.2214/ajr.178.1.1780101.","Hollingsworth JM, Rogers MA, Kaufman SR, Bradford TJ, Saint S, Wei JT, Hollenbeck BK. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet. 2006 Sep 30;368(9542):1171-9. doi: 10.1016/S0140-6736(06)69474-9.","Giuliano F, Uckert S, Maggi M, Birder L, Kissel J, Viktrup L. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013 Mar;63(3):506-16. doi: 10.1016/j.eururo.2012.09.006. Epub 2012 Sep 11.","Gratzke C, Uckert S, Kedia G, Reich O, Schlenker B, Seitz M, Becker AJ, Stief CG. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res. 2007 Feb;35(1):49-54. doi: 10.1007/s00240-006-0073-1. Epub 2006 Nov 11.","Kumar S, Jayant K, Agrawal MM, Singh SK, Agrawal S, Parmar KM. Role of tamsulosin, tadalafil, and silodosin as the medical expulsive therapy in lower ureteric stone: a randomized trial (a pilot study). Urology. 2015 Jan;85(1):59-63. doi: 10.1016/j.urology.2014.09.022.","Ugaily-Thulesius L, Thulesius O. The effects of urine on mast cells and smooth muscle of the human ureter. Urol Res. 1988;16(6):441-7. doi: 10.1007/BF00280026.","Hollingsworth JM, Canales BK, Rogers MA, Sukumar S, Yan P, Kuntz GM, Dahm P. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ. 2016 Dec 1;355:i6112. doi: 10.1136/bmj.i6112.","Shokeir AA. Renal colic: new concepts related to pathophysiology, diagnosis and treatment. Curr Opin Urol. 2002 Jul;12(4):263-9. doi: 10.1097/00042307-200207000-00001."}	NO_PUBLICATION_FOUND	\N	fexofenadine
287	2023-01-02 15:22:35.738	2023-03-19 21:22:22.574	NCT03047278	Gabapentin Kinetic Disposition and Renal Excretion: Role of Transporters for Organic Cations and the Effect of Glycemic Control in Patients With Neuropathic Pain.	Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain.	Completed	This study aimed to investigate the influence of the glycemic control of type 2 diabetes (DM2) and of cetirizine (OCTs inhibitor) on gabapentin kinetics disposition and pharmacodynamics (PK-PD) in patients with neuropathic pain. Thus, non-diabetic patients (Control Group, n=10), patients with controlled diabetes (n=9) and patients with uncontrolled diabetes (n=10), all with neuropathic pain of intensity  4 in pain visual analog scale (0-10) were investigated.	Parallel Assignment	Natalia Valadares de Moraes	OTHER	All	59	18	29	Actual	OTHER	Universidade Estadual Paulista Jlio de Mesquita Filho	Non-Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	Gabapentin (GBP), anticonvulsant used to neuropathic pain treatment, is mainly eliminated unchanged in urine. Renal active tubular secretion has been suggested to contribute on GBP excretion by renal excretion. Studies performed on rats with experimental diabetes suggest that hyperglycemia reduces the activity of organic cation transporters (Oct). Thus, the aim of the study was to investigate the role of OCTs on kinetic disposition and pharmacodynamics of GBP in patients with neuropathic pain and to verify the regulation of these transporters' activity by glycemic control in diabetes. A cross-over clinical study was performed in patients with neuropathic pain (n=10, Control) to evaluate the influence of CTZ on GBP kinetic disposition. To evaluate the effect of glycemic control, patients with controlled DM2 (DC, n=9) and uncontrolled DM2 (DNC, n=10) were investigated. All participants investigated had neuropathic pain of intensity  4 evaluated by analogue visual scale (EVA) and were treated with oral single-dose of 300 mg of GBP (Phase 1) or cetirizine (20 mg/day) for 5 days and single-dose of GBP on the last day (Phase 2). Only participants of Control group participated of Phase 2. Serial blood and urine samples were collected up to 36 hours after GBP administration. The intensity of pain was evaluated at the same time of blood sampling, using the visual analog scale. GBP concentration in plasma and urine was validated by JPLC-UV. All participants were genotyped for polymorphisms SLC22A2 808G>T and SLC22A4 1507C>T. The pharmacokinetic parameters were estimated by non-compartmental analysis.	2015-11-01	2018-05-01	2019-07-01	2017-02-08	\N	2019-07-05	\N	Universidade Estadual Paulista Jlio de Mesquita Filho	Natalia Valadares de Moraes	Assistant Professor	\N	\N	Sponsor-Investigator	\N	Interventional	{Adult}	{"Phase 4"}	{"Neuropathic Pain","Type 2 Diabetes Mellitus","Diabetic Neuropathy, Painful"}	main	cetirizine	\N	t	Neuropathic Pain	2022-08-17 13:39:16	{}	PUBLISHED	https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/jcph.1603	cetirizine
294	2023-01-02 15:22:35.738	2023-03-19 21:23:47.642	NCT01007864	Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine Agonists	Influence of Piribedil (Clarium) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists	Completed	The purpose of this clinical trial is to investigate the effects of the non-ergot dopamine agonist piribedil on vigilance and cognitive performances in patients with Parkinson's disease in comparison with other oral non-ergot dopamine agonists.\n\nIt should be tested whether piribedil is superior to continued pramipexole or ropinirole treatment regarding improvement of reduced vigilance and cognitive performance in patients with Parkinson's disease.	Parallel Assignment	Desitin Arzneimittel GmbH	INDUSTRY	All	80	35	80	Actual	INDUSTRY	Desitin Arzneimittel GmbH	Randomized	\N	Single	\N	\N	Treatment	\N	Treatment of motor symptoms associated with PD by non-ergot dopamine agonists has been proven to be effective, both as monotherapy and in combination with levodopa. Non-motor symptoms like cognitive or sleep-related disorders and disturbed vigilance, however, are common in PD and can significantly worsen health and quality of life of the patient and family members. Some of these non-motor symptoms may also be caused by the antiparkinsonian medication per se. The Committee for Proprietary Medicinal Products (CPMP) initiated a review of dopamine agonists in relation to episodes of sudden onset of sleep already in 2000 which resulted in special warnings of somnolence and sudden sleep attacks in the non-ergot dopamine agonists' summary of product characteristics.\n\nBeneficial effects of piribedil on parameters of vigilance and cognition have been described in several studies. But, as it seems, no study has been performed so far to identify such effects in the setting of a comparative study with different oral non-ergot dopamine agonists in patients with PD, and utilizing vigilance and cognitive parameters as primary and main secondary objective. The neuropsychological tests being applied in this study are validated and routinely used tests in studies investigating different aspects of attention or vigilance and cognition.	2010-01-01	2011-12-01	2011-12-01	2009-11-04	\N	2012-05-24	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{"Idiopathic Parkinson's Disease"}	not included	loratadine	Only in exclusion criteria	t	Parkinson	2022-08-17 18:44:47	{}	UNKNOWN	\N	loratadine
2	2023-01-02 15:22:35.722	2023-03-19 21:57:21.707	NCT00751166	A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU)	A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)	Terminated	This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (cetirizine) and a placebo control to evaluate desloratadine 5 mg once daily during a 28-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.	Parallel Assignment	Organon and Co	INDUSTRY	All	70	12	149	Actual	INDUSTRY	Organon and Co	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2004-03-01	2005-05-01	2005-05-01	2008-09-11	\N	2022-02-16	\N	\N	\N	\N	\N	\N	Sponsor	Study could not be re-supplied with study medication in a timely manner.	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{Urticaria}	comparison	cetirizine	\N	f	Urticaria	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	desloratadine|cetirizine
5	2023-01-02 15:22:35.722	2023-03-19 22:00:11.639	NCT00826943	Is Levocetirizine Less Sedating Than Cetirizine? A Randomized, Double-blind, Placebo Controlled Trial.	Is Levocetirizine Less Sedating Than Cetirizine?	Completed	The purpose of this study is to determine whether cetirizine (zyrtec), levocetirizine (xyzal), and placebo differ in the degree of sedation they produce and their relief of allergy symptoms.	Crossover Assignment	Vanderbilt University	OTHER	All	77	18	30	Actual	OTHER	Vanderbilt University	Randomized	\N	Double	\N	\N	Treatment	\N	Levocetirizine, the R-enantiomer of cetirizine, has been found to be less sedating relative to placebo than was cetirizine in separate trials. We plan to examine whether patients who did not tolerate cetirizine due to sedation are able to tolerate levocetirizine. This study will utilize a randomized, double-blind, placebo controlled trial comparing levocetirizine, cetirizine, and placebo in regards to sedation and allergy symptom scores. Each patient will receive levocetirizine, cetirizine, and placebo in randomized order and thus serve as their own control.	2009-01-01	2009-05-01	2009-05-01	2009-01-22	2014-02-20	2014-02-20	Vanderbilt University	Vanderbilt University	Douglas Tzanetos	Fellow	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Allergic Rhinitis"}	main	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Devalia JL, De Vos C, Hanotte F, Baltes E. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy. 2001 Jan;56(1):50-7. doi: 10.1034/j.1398-9995.2001.00726.x.","de Blic J, Wahn U, Billard E, Alt R, Pujazon MC. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol. 2005 May;16(3):267-75. doi: 10.1111/j.1399-3038.2005.00216.x.","Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J, Van Cauwenberge PB, Van Hammee G; XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004 Oct;114(4):838-44. doi: 10.1016/j.jaci.2004.05.070."}	CT_RESULTS	\N	levocetirizine
4	2023-01-02 15:22:35.721	2023-03-19 22:00:25.603	NCT00780403	A Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec  5.0 mg Chewable Tablet Medications	Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec  5.0 mg Chewable Tablet Medications (Study P04573) (Completed)	Completed	The primary objective of this study was to determine whether children ages 6-11 years prefer desloratadine RediTabs (2.5 mg) or a marketed competitor (Zyrtec 5 mg Chewable Tablets). The secondary objectives of this study were to compare acceptance of the two attributes, taste and feeling in the mouth, of desloratadine 2.5 mg RediTabs and Zyrtec 5 mg Chewable Tablets	Crossover Assignment	Organon and Co	INDUSTRY	All	11	6	220	Actual	INDUSTRY	Organon and Co	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2005-08-01	2005-10-01	2005-10-01	2008-10-27	2010-07-30	2022-02-09	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 4"}	{Allergies}	comparison	cetirizine	\N	f	Healthy	2022-08-17 13:39:16	{}	CT_RESULTS	\N	desloratadine|cetirizine
7	2023-01-02 15:22:35.721	2023-03-19 22:02:43.297	NCT00794248	Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis	Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179)	Completed	This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex or Allegra. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.	Crossover Assignment	Organon and Co	INDUSTRY	All	\N	18	122	Actual	INDUSTRY	Organon and Co	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2002-11-01	2003-05-01	2003-05-01	2008-11-20	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Seasonal Allergic Rhinitis"}	comparison	fexofenadine	\N	f	Allergic Rhinitis	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	desloratadine|fexofenadine
9	2023-01-02 15:22:35.721	2023-03-19 22:03:29.125	NCT01622283	Pharmacokinetic Study of Levocetirizine Oral Solution-An Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, the Safety and Tolerability of Levocetirizine Oral Solution (5 mg) and Cetirizine Dry Syrup (10 mg), Following a Single Dose in Japanese Healthy Male Subjects-	Pharmacokinetic Study of Levocetirizine Oral Solution	Completed	This study will be a single center, open-label, randomized, single dose, in the fasted condition and 2-way crossover study to evaluate the pharmacokinetics, the safety and tolerability of levocetirizine oral solution 5 mg and cetirizine dry syrup 10 mg in Japanese healthy male subjects.\n\nApproximately 20 subjects will receive both treatments of levocetirizine oral solution 5 mg and cetirizine dry syrup 10 mg in the design. Serial pharmacokinetic samples will be collected and safety assessments will be performed following each dose.\n\nThe primary objective of the study is to demonstrate the bioequivalence of levocetirizine in plasma, when given as levocetirizine oral solution 5 mg relative to cetirizine DS 10 mg in Japanese healthy male subjects.	Crossover Assignment	GlaxoSmithKline	INDUSTRY	Male	55	20	20	Actual	INDUSTRY	GlaxoSmithKline	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2012-05-02	2012-06-10	2012-06-10	2012-06-19	\N	2017-06-12	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{"Rhinitis, Allergic, Perennial and Seasonal"}	main	cetirizine	\N	f	Pharmacokinetics	2022-08-17 13:39:16	{"Ino H, Hara K, Honma G, Doi Y, Fukase H. Comparison of levocetirizine pharmacokinetics after single doses of levocetirizine oral solution and cetirizine dry syrup in healthy Japanese male subjects. J Drug Assess. 2014 Jun 3;3(1):38-42. doi: 10.3109/21556660.2014.928302. eCollection 2014."}	UNKNOWN	\N	levocetirizine
11	2023-01-02 15:22:35.723	2023-03-19 22:06:12.853	NCT00264303	A Comparative Study on Clinical Efficacy and Safety of Levocetirizine 5 mg Oral Capsules Once Daily in the Morning vs. Desloratadine 5 mg Oral Capsules Once Daily in the Morning in Patients Suffering From Chronic Idiopathic Urticaria (CIU)	CUTE (Chronic Urticaria Treatment Evaluation)	Completed	A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus severity score over the first week of treatment	Parallel Assignment	UCB Pharma	INDUSTRY	All	\N	18	886	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2005-12-01	2007-01-01	2007-01-01	2005-12-12	2009-07-09	2011-08-31	UCB Pharma	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Chronic Idiopathic Urticaria"}	comparison	levocetirizine	\N	f	Urticaria	2022-09-15 18:58:14	{}	CT_RESULTS	\N	levocetirizine|desloratadine
53	2023-01-02 15:22:35.725	2023-03-20 09:41:09.373	NCT01506076	An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg With XYZAL Tablets 5 mg in Healthy Subjects Under Fasting Conditions	Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fasting Conditions	Completed	The purpose of this study is to assess the Bioequivalence of Levocetirizine DiHCl Tablets 5mg with XYZAL tablets 5 mg and to monitor clinical status, adverse events and laboratory investigations and assess relative safety and tolerance, under fasting conditions.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	All	45	18	29	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	A pivotal study to compare the Bioequivalence of Levocetirizine DiHCl Tablets 5 mg of Dr.Reddy's Laboratories Limited with XYZAL Tablets 5 mg of UCB Farchim S.A. in healthy, human subjects under fasting conditions.	2007-12-01	2008-01-01	2008-01-01	2012-01-09	\N	2012-01-09	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Fasting}	main	levocetirizine	\N	f	Bioequivalence	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
16	2023-01-02 15:22:35.722	2023-03-19 22:13:31.654	NCT00150761	A Randomized, Double-blind, Double Dummy, Placebo Controlled, Cross-over Exploratory Trial in Healthy Male Adult Subjects: Comparison by Means of Infrared Thermography of the Anti-H1 Potency of Levocetirizine 5 mg and Cetirizine 10 mg Tablet Single Oral Dose After Nasal Histamine Provocation.	Facial Thermography Study of Levocetirizine Versus Cetirizine	Completed	Phase IV, human pharmacology, exploratory, randomized, 3-way (3 treatment periods) cross-over, double blind, double dummy, placebo controlled study to compare levocetirizine and cetirizine by means of IR thermography.	Crossover Assignment	UCB Pharma	INDUSTRY	Male	55	18	60	\N	INDUSTRY	UCB Pharma	Randomized	\N	Double	\N	\N	\N	\N	\N	2004-07-01	2004-10-01	2004-10-01	2005-09-08	\N	2014-08-26	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult}	{"Phase 4"}	{"Anti-allergic Agents"}	main	cetirizine	Publication with levoctz and fex: https://pubmed.ncbi.nlm.nih.gov/16842390/	f	Imaging	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	levocetirizine|cetirizine
19	2023-01-02 15:22:35.723	2023-03-19 22:17:34.444	NCT00521170	Randomized, Monocenter, Double Blind, Placebo-controlled, Single Oral Dose, Three-way Cross Over Study, to Compare Levocetirizine and Desloratadine on Allergen-induced Wheal and Flare Reaction During 24 Hours in 18 Adult Allergic Volunteers.	Wheal and Flare Reaction During 24 Hours in Allergic Volunteers.	Completed	Compare the activity of 5 mg levocetirizine and 5 mg desloratadine on allergen-induced wheal and flare reaction.	Crossover Assignment	UCB Pharma	INDUSTRY	All	50	18	\N	\N	INDUSTRY	UCB Pharma	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2004-11-01	2005-01-01	2005-01-01	2007-08-27	\N	2013-12-16	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Allergy}	main	levocetirizine	\N	f	Allergy	2022-09-15 18:58:14	{}	NO_PUBLICATION_FOUND	\N	levocetirizine
22	2023-01-02 15:22:35.723	2023-03-19 22:20:52.423	NCT01064115	A Two Way, Open Label, Single Dose, Cross Over, Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Cetirizine Hydrochloride Tablets 10 mg in Healthy Adult Human Male Subjects Under Fed Conditions.	Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition	Completed	A Two Way, Open Label, Single Dose, Cross Over, Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys laboratories with Zyrtec 10 mg of Pfizer labs in Healthy Adult Human Male Subjects Under Fed Conditions.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	Male	45	18	30	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Cross Over, and Comparative Oral Bioavailability study in healthy, adult, human, male subjects under Fed Conditions.	2006-01-01	2006-01-01	2006-02-01	2010-02-08	\N	2010-02-08	\N	\N	\N	\N	Senior Manager - Research & Development	Dr. Reddy's Laboratories Limited	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	main	cetirizine	\N	f	Bioequivalence	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
23	2023-01-02 15:22:35.723	2023-03-19 22:21:13.886	NCT01066767	Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg Tablets and Allegra 180 mg Tablets Administered as 1 x 180 mg Tablet in Healthy Subjects Under Fed Conditions	Bioequivalence Study of Dr. Reddy's Laboratories Limited Fexofenadine Hydrochloride 180 mg Tablets Under Fed Conditions	Completed	Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg Tablets of Dr.Reddy's Laboratories Limited, and Allegra 180 mg Tablets aventis Administered as\n\n1 x 180 mg Tablet in Healthy Subjects under Fed Conditions	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	All	\N	18	30	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	The objective of this study is to compare the rate and extent of absorption of fexofenadine hydrochloride 180 mg tablets (test) versus Allegra (reference) administered as 1 x 180 mg tablet under fasting conditions. Single oral dose (1 x 180 mg) in each period with a washout of at least 7 days between doses.	2002-04-01	2002-05-01	2002-05-01	2010-02-10	\N	2010-02-10	\N	\N	\N	\N	Assistant Manager	Dr. Reddy's Laboratories Limited	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{Healthy}	main	fexofenadine	\N	f	Bioequivalence	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
15	2023-01-02 15:22:35.723	2023-03-19 22:11:40.565	NCT01586091	Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response	Safety Study of Levocetirizine and Fexofenadine	Completed	This Study is to comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once daily with Fexofenadine 60 mg twice daily in the histamine induced wheal, flare and itch Response.	Crossover Assignment	Charite University, Berlin, Germany	OTHER	Male	65	18	18	Actual	OTHER	Charite University, Berlin, Germany	Randomized	\N	Double	\N	\N	Treatment	\N	This will be a randomized, double-blind, placebo-controlled study with intra-individual comparison of the histamine induced wheal and flare reaction. In September 2009, Fexofenadine was approved as an antihistamine against allergies in Japan and it is currently used widely. It has been approved in 120 countries, including the US, UK, France and Germany [11]. In Europe and the United States, fexofenadine is marketed at 120 mg once daily for allergic rhinitis and 180mg once daily for urticaria. In Japan, fexofenadine is marketed at 60 mg twice daily for both conditions. But is this dosage regimen as effective as levocetirizine, 5 mg once daily? The above described study from Takahashi et al, comparing 60 mg twice daily versus cetirizine 10 mg once daily suggests that it is not [4]. The aim of the study is to compare the efficacy and consistency of action of levocetirizine 5 mg once daily with fexofenadine 60 mg twice daily over a 24 hour period in the histamine induced wheal, flare and itch response. Furthermore, we would like to investigate whether a different between Japanese and Caucasian exists or not. Each volunteer will receive the study medication at time point 0 and 12 hour later. Skin Prick Test (SPT) will be performed in each volunteer using histamine (10 mg/ml), 15 minutes before drug admission (baseline) and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours afterwards. Volumetric optical scanning system and infrared camera will be used for objective evaluation of the wheal- and flare reduction. Additionally, measurement of the erythema diameter with a transparent ruler will be performed. The subjective intensity of itching will be assessed using a Visual Analogue Scale (VAS). To relate the pharmacokinetics of the drugs to their pharmacodynamics, blood samples for assay of drug concentrations will be taken at baseline and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours later. Subjects will undergo the same procedure on three separate occasions to receive each treatment option. The options are: placebo at time 0 hours + placebo at 12 hours, Levocetirizine 5mg at time 0 hours + placebo at 12 hours or fexofenadine 60mg at time 0 hours + fexofenadine 60mg at 12 hours. There will be a washout period of at least 6 days between the treatments.	2011-02-01	2011-11-01	2012-02-01	2012-04-26	2019-10-04	2019-10-04	University of Charit Berlin; Dpt. of Dermatology and Allergy	Charite University, Berlin, Germany	Martin Metz	Prof. Dr. med.	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Pruritus,"Chronic Urticaria","Allergic Rhinitis"}	comparison	fexofenadine	check usecase again	f	Safety Evaluation	2022-08-18 16:54:53	{"Schoepke N, Church MK, Maurer M. The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers. Acta Derm Venereol. 2013 May;93(3):286-93. doi: 10.2340/00015555-1490."}	CT_RESULTS	\N	levocetirizine|fexofenadine
83	2023-01-02 15:22:35.726	2023-03-20 16:16:39.357	NCT00619801	A Multi-Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d Dosing in Children Aged 1 to < 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin	Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin	Completed	The purpose of this study is to determine the safety of the oral formulation of levocetirizine in children ages 1 to less than 6 years old who suffer from allergic rhinitis or chronic urticaria of unknown origin.	Parallel Assignment	UCB Pharma	INDUSTRY	All	6	2	173	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2008-03-01	2008-07-01	2008-07-01	2008-02-21	2009-09-04	2015-03-06	UCB	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Allergic Rhinitis","Chronic Urticaria"}	main	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{"Hampel F, Ratner P, Haeusler JM. Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Allergy Asthma Proc. 2010 Jul-Aug;31(4):290-5. doi: 10.2500/aap.2010.31.3349."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/20819318/	levocetirizine
32	2023-01-02 15:22:35.724	2023-03-20 09:21:33.841	NCT01250652	Efficacy and Safety of 20 mg Levocetirizine and 15 mg Levocetirizine + 50 mg Bed-Time Hydroxyzine in Severe Chronic Urticaria in Adults: a Pilot, Randomized, Double-blind, Cross-over and Parallel, Active-controlled, Single-centre Study	Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses	Completed	Allen Kaplan is a prominent American allergist with the reputation of leader in the field of chronic urticaria. He advocates treatment with first generation hydroxyzine, which he considers at least as effective as modern second generation H1-blockers in suppressing the symptoms of difficult-to-treat / systemic-steroid-dependant cases of chronic urticaria. He further speculates that hydroxyzine may have the advantage to better suppress itch and improve nighttime sleep. This has prompted many practitioners around the world to believe that adding hydroxyzine to the treatment regimen at bed time at night may be beneficial to patients. At the same time European guidelines indicate modern second generation H1-blockers in higher than conventional doses as drugs of choice for such cases. However, there is no evidence from clinical trials addressing this controversy. The investigators' previous studies suggest that levocetirizine at quadruple doses may be beneficial in difficult to treat urticaria by reducing lesions and itch, improving quality of life and night time sleep, while not causing day time somnolence. First generation H1-receptor antagonists and hydroxyzine among them are known to penetrate the blood / brain barrier and to cause sedation. The question stays whether this sedation is beneficial to the subjects with chronic urticaria at night, whether it has any hang-over unwanted effects the following day and whether this has any influence on the overall urticaria-specific quality of life.	Crossover Assignment	Association Asthma, Bulgaria	OTHER	All	80	18	24	Actual	OTHER	Association Asthma, Bulgaria	Randomized	\N	Double	\N	\N	Treatment	\N	Study design:\n\nThe study will involve two distinct parts (flow chart):\n\nIn-hospital assessment of effectiveness and tolerability of 10 & 20 mg levocetirizine vs. 100 & 200 mg hydroxyzine in subjects to be weaned off corticosteroid treatment.\nSubsequent ambulatory treatment of the same patients with 20 mg levocetirizine alone and 15 mg levocetirizine + 50 hydroxyzine at night\n\nProtocol description Patients with chronic urticaria treated with systemic steroids are traditionally admitted to the Clinic of Allergy and Asthma in Sofia to try to wean them off this class of drugs. Hospitalized patients will be invited to take part in the study and will sign an informed consent. They will be assessed by standard questionnaire and by objective assessment of the urticarial lesions, QoLQ will be filled in, discomfort due to urticaria, day time somnolence and night time sleep quality will be assessed on a visual analogue scale. Systemic steroids will be withheld and patients would be given 10 mg levocetirizine on Days 1 & 2; after a new assessment of quality of night time sleep and day time somnolence, 100 mg hydroxyzine will be given on Days 3 & 4. The cycle will be repeated on Days 5 & 6 and Days 7 & 8 with 20 mg levocetirizine and 200 hydroxyzine respectively. At this point patients will be discharged and randomized to two treatment arms: levocetirizine 20 mg per day and levocetirizine 15 mg + hydroxyzine 50 mg as evening dose for 5 days. Diaries will be given to patients for assessment of daily SS, day time somnolence score, quality of night time sleep, facial tissue swelling, rescue medication with oral prednisolone, adverse events, intake of any other medications. After 5 days the patients from arm 1 and 2 will be crossed over to the alternative treatment. QoLQ questionnaire will be filled out at onset, at cross over (day 5) and at the end of the 10 day treatment period. On completion of the study subjects will be asked to state there preference for one treatment or the other.	2011-03-01	2013-02-01	2013-03-01	2010-12-01	\N	2013-07-17	\N	Association Asthma, Bulgaria	Prof. Todor Popov	Prof. Todor Popov	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Chronic Urticaria"}	comparison	cetirizine	\N	f	Urticaria	2022-08-17 13:39:16	{"Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004 Sep;114(3):465-74; quiz 475. doi: 10.1016/j.jaci.2004.02.049.","Kaplan AP. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol. 2009 Mar;123(3):713-7. doi: 10.1016/j.jaci.2008.10.050. Epub 2008 Dec 10. No abstract available.","Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, Church DS, Dimitrov V, Church MK. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010 Mar;125(3):676-82. doi: 10.1016/j.jaci.2009.11.047."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/24472058/	levocetirizine
36	2023-01-02 15:22:35.724	2023-03-20 09:22:35.438	NCT00346606	A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of Desloratadine 5mg (Denosin) With Levocetirizine 5mg (Xyzal) in the Treatment of Chronic Idiopathic Urticaria Patients	The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria	Unknown status	Objective: To compare the efficacy of desloratadine 5mg (Denosin) and levocetirizine 5mg (Xyzal) once daily in the treatment of patients with CIU over 6 weeks.\n\nTrial design: Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.\n\nPrimary end point: To evaluate the change in average AM/PM reflective pruritus score from baseline recorded in the subjects' diaries during the first two weeks of the treatment.\n\nSecondary Objectives: To assess the efficacy and safety of desloratadine 5mg (Denosin) and levocetirizine 5mg (Xyzal) once daily in the treatment of subjects with CIU over 6 weeks.	Parallel Assignment	Lotus Pharmaceutical	INDUSTRY	All	\N	12	60	\N	INDUSTRY	Lotus Pharmaceutical	Randomized	\N	Double	\N	\N	Treatment	\N	Objective: To compare the efficacy of desloratadine 5mg (Denosin) and levocetirizine 5mg (Xyzal) once daily in the treatment of patients with CIU over 6 weeks.\n\nTrial design: Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.\n\nPrimary endpoint: To evaluate the change in average AM/PM reflective pruritus score from baseline recorded in the subjects' diaries during the first two weeks of the treatment.\n\nSecondary Objectives: To assess the efficacy and safety of desloratadine 5mg (Denosin) and levocetirizine 5mg (Xyzal) once daily in the treatment of subjects with CIU over 6 weeks.\n\nPrimary endpoint:\n\nTo evaluate the change in average AM/PM reflective pruritus score from baseline recorded in the patient diaries during the first two weeks of treatment\n\nSecondary Endpoints- To evaluate the change in average AM/PM reflective pruritus score from baseline recorded in the subjects' diaries over the 6 weeks.\n\nTo evaluate the reflective average AM/PM scores for number of hives, size of largest hive, and total symptom score (sum of pruritus, number of hives, and size of largest hive scores).\n\nAverage individual AM/PM instantaneous scores for pruritus, number of hives, and size of largest hive are also evaluated.\n\nAM instantaneous scores for pruritus, number of hives, and size of largest hive are also evaluated.\n\nPM instantaneous scores for pruritus, number of hives, and size of largest hive are also evaluated.\n\nPM reflective scores for pruritus, number of hives, and size of largest hive are also evaluated.\n\nThe interference with sleep (AM reflective), and interference with daily activities (PM reflective) are other secondary efficacy outcomes.\n\nTherapeutic response will be evaluated at visit 3~5.\n\nSafety will be evaluated including vital signs are recorded at all visits, whereas sleep latency using Epworth Sleepiness Scale (ESS) questionnaire and Visual analogue Scale (VAS) are scored at visit 2~5. Stanford Sleepiness Scale (SSS) are scored according to the instructions of diary cards at all visits. All adverse events are recorded and graded for severity at visit 2~5.	2006-01-01	\N	\N	2006-06-30	\N	2006-06-30	\N	\N	\N	\N	\N	\N	\N	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 4"}	{"Chronic Idiopathic Urticaria",Urticaria}	combination	levocetirizine	\N	f	Urticaria	2022-09-15 18:58:14	{}	UNKNOWN	\N	desloratadine|levocetirizine
86	2023-01-02 15:22:35.726	2023-03-20 16:20:47.236	NCT01506791	Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Desloratadine and Pseudoephedrine 5 mg/240 mg Extended-Release Tablet and Clarinex-D 24-Hour (Reference) Following a 5 mg/240 mg Dose in Healthy Subjects Under Fed Conditions	Bioequivalence Study of Desloratadine and Pseudoephedrine Extended-release Tablets Under Fed Conditions	Completed	This is an open label, randomised, 2-way crossover, comparative bioequivalence study.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	All	45	18	44	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Laboratories Ltd., India, desloratadine-pseudoephedrine and Schering Corporation, U.S.A.(Clarinex-D 24-HOUR), desloratadine-pseudoephedrine, administered as a 1 x 5 mg/240 mg extended-release tablet under fed conditions. The treatment phases were separated by a washout period of 14 days. 44 subjects were dosed and were enrolled in the study; 43 of these enrolled subjects completed the study.	2006-04-01	\N	2006-04-01	2012-01-10	\N	2012-01-10	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	combination	desloratadine	\N	f	Bioequivalence	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
39	2023-01-02 15:22:35.724	2023-03-20 09:27:19.232	NCT00291642	Double Blind, Double-dummy, Five Parallel Groups, Randomized, Exploratory Clinical Trial to Compare the Efficacy of Single Dose of Levocetirizine 2.5 mg Oral Drops (5 mg/mL), Levocetirizine 5 mg Oral Tablets, Cetirizine 5 mg Oral Drops (10 mg/mL) and Cetirizine 10 mg Oral Tablets to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Ragweed Sensitive Subjects Exposed to Ragweed Pollen in an Environmental Exposure Unit (EEU)	A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen	Completed	The purpose of the study is to assess the efficacy comparability of cetirizine and levocetirizine, by comparing the effects of single intake of the two drugs to placebo in reducing symptoms of seasonal allergic rhinitis (SAR) in ragweed sensitive adult subjects exposed to ragweed pollen in an Environmental Exposure Unit.	Parallel Assignment	UCB Pharma	INDUSTRY	All	\N	16	551	Actual	INDUSTRY	UCB Pharma	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2006-01-01	2006-04-01	2006-04-01	2006-02-14	2018-07-20	2018-09-11	UCB S.A.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 2"}	{Rhinitis,Allergic,Seasonal}	main	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	CT_RESULTS	\N	levocetirizine
40	2023-01-02 15:22:35.724	2023-03-20 09:27:36.757	NCT01314352	A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Healthy Subjects Under Fed Conditions	Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions	Completed	The purpose of this study is to compare the rate and extent of absorption of Dr. Reddy's Desloratadine 5 mg tablet to that of Clarinex 5 mg tablet in healthy subjects under fed conditions.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	All	45	18	28	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in fed Normal,Healthy subjects.	2005-12-01	2005-12-01	2006-03-01	2011-03-14	\N	2011-06-08	\N	\N	\N	\N	Dr. M.S. Mohan/Vice President - R&D	Dr. Reddy's Laboratories Limited	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Fed}	main	desloratadine	\N	f	Bioavailability	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
38	2023-01-02 15:22:35.724	2023-03-20 09:24:21.852	NCT00359138	A Double-blind, Double-dummy, Parallel-group, Placebo-controlled, Randomized Study to Assess the Duration of the Suppressive Effects of Desloratadine on the Cutaneous Allergen-induced Wheal and Flare (1) Response After Discontinuation	The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)	Completed	This is a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single center study in subjects with positive histamine skin prick test and a positive RadioAllergoSorbent Test (RAST) (class > 2) to one of the tested standardized allergenic extracts: tree pollen, cat dander, house dust mite, or a mixture of five grass pollens. Subjects will be randomized to desloratadine 5 mg once daily, levocetirizine 5mg once daily, or placebo once daily for 8 days of treatment followed by 11 days of skin testing after discontinuation of the antihistamine treatment phase. The duration of the suppressive effects of desloratadine on cutaneous allergen-induced wheal and flare responses after discontinuation of a one-week treatment will be established.	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	18	36	Actual	INDUSTRY	Organon and Co	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2006-02-01	2006-05-01	2006-05-01	2006-08-01	2010-11-01	2022-02-09	Merck, Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{Hypersensitivity}	comparison	cetirizine	\N	f	Allergy	2022-08-17 13:39:16	{}	CT_RESULTS	\N	desloratadine|levocetirizine
42	2023-01-02 15:22:35.725	2023-03-20 09:28:18.549	NCT01133483	An Open Label, Balanced, Randomized, Two-way, Single Dose, Crossover Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tabs of Dr. Reddy's and Allegra-D 24 hr ER Tabs of Aventis, in Healthy Subjects Under Fed Conditions	Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr.Reddy's Under Fed Conditions	Completed	The purpose of this study is to\n\nCompare and evaluate the single dose, crossover, bioequivalence study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets and Allegra-D 24 hr tablets.\nMonitor the adverse events and ensure the safety of subjects.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	All	45	18	38	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover bioequivalence study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals Inc., USA in healthy, adult, human subjects under fed conditions.	2007-04-01	2007-04-01	2007-05-01	2010-05-28	\N	2010-06-14	\N	\N	\N	\N	Mr. Indu Bhushan / Senior Director	Dr. Reddy's Laboratories Limited	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	combination	fexofenadine	\N	f	Bioequivalence	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
51	2023-01-02 15:22:35.721	2023-03-20 09:40:47.127	NCT00779116	A Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications	Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)	Completed	This was a randomized, open-label, 2-way cross-over study, comparing desloratadine RediTab 2.5 mg to a marketed chewable antihistamine oral medication (Zyrtec 5 mg\n\nChewable Tablet). Subject preference for one product or the other was determined. Acceptability of product attributes (Taste and Feeling in the Mouth) was rated using a "smile" face scale.	Crossover Assignment	Organon and Co	INDUSTRY	All	11	6	217	Actual	INDUSTRY	Organon and Co	Randomized	\N	None (Open Label)	\N	\N	Other	\N	\N	2005-09-01	2005-10-01	2005-10-01	2008-10-24	2010-07-05	2022-02-09	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 4"}	{Allergies}	comparison	cetirizine	\N	f	Taste, Form, Preference	2022-08-17 13:39:16	{"Tassinari P, Suarez NR, Centeno J, Velasquez JV, Aguirre-Mariscal H, Gonzalezdiaz SN, Jerves AF; LA Desloratadine Study Group. Desloratadine therapy improves allergic rhinitis symptoms in latin american children aged 6 to 12 years. World Allergy Organ J. 2009 Apr;2(4):42-8. doi: 10.1097/WOX.0b013e31819cdfdb."}	CT_RESULTS	\N	desloratadine|cetirizine
55	2023-01-02 15:22:35.725	2023-03-20 14:47:56.936	NCT00420082	A Randomized, Double-Blind, 4 Way Cross-over, Placebo Controlled Trial to Evaluate the Onset of Action of Bilastine 20 mg vs. Placebo, Cetirizine 10 mg, and Fexofenadine 120 mg in the Vienna Challenge Chamber	A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber	Completed	This is a randomized, double blind, active and placebo controlled, 4 way crossover study in patients with seasonal allergic rhinitis. Patients will receive a single dose of bilastine 20 mg, Cetirizine 10 mg, Fexofenadine 120 mg, and placebo in the Vienna Challenge Chamber.	Crossover Assignment	Faes Farma, S.A.	INDUSTRY	All	55	18	75	Actual	INDUSTRY	Faes Farma, S.A.	Randomized	\N	Quadruple	\N	\N	Treatment	\N	The objective of the study is to determine the effect of a single dose of bilastine 20 mg on nasal symptoms of allergic rhinitis provoked by spending 4 hours in the Vienna Challenge Chamber . This effect will be compared to that action of Cetirizine 10 mg, Fexofenadine 120 mg, and placebo. To explore the onset of action, patients will receive study drug two hours after the start of the provocation on Day 1.Patients will remain in theVCC for an additional four hours. On Day 2, patients will return to the VCC post-dose hours 22-26.	2006-10-01	\N	2006-12-01	2007-01-09	\N	2012-04-05	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 2"}	{"Seasonal Allergic Rhinitis"}	comparison	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{"Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010 May;59(5):391-8. doi: 10.1007/s00011-009-0117-4. Epub 2009 Nov 27."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19943178/	fexofenadine|cetirizine
56	2023-01-02 15:22:35.721	2023-03-20 14:49:40.451	NCT02932774	Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Zyrtec (Cetirizine HCl) Syrup vs. Claritin (Loratadine) Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)	Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)	Completed	The objective of this clinical trial was to assess the efficacy and safety of cetirizine HCl syrup vs. loratadine syrup vs. placebo syrup in the treatment of SAR in children 6 to 11 years old.	Parallel Assignment	Johnson & Johnson Consumer and Personal Products Worldwide	INDUSTRY	All	11	6	683	Actual	INDUSTRY	Johnson & Johnson Consumer and Personal Products Worldwide	Randomized	\N	Triple	\N	\N	Treatment	\N	This was a multi-center, randomized, double-blind, parallel-group, placebo-controlled, double dummy study of children with SAR conducted during the Spring tree and grass allergy season. Subjects qualified for randomization if the diary cards included (1) symptom scores of 2 for at least 2 of the following 4 rhinoconjunctivitis symptoms on 4 or more days: sneezing, runny nose, itchy eyes, and watery eyes; and (2) a total rhinoconjunctivitis (or Total Symptom Severity Complex [TSSC]) score of 5 on any 4 days. The TSSC score was expressed as the sum of the 4 individual symptoms scores recorded in the daily diary cards for the following symptoms: sneezing, runny nose, itchy eyes, and watery eyes.\n\nSubjects were randomized to receive 1 of 3 treatments in a double-blind fashion using a 1:1:1 allocation ratio: cetirizine HCl syrup and placebo loratadine syrup; loratadine syrup and placebo cetirizine HCl syrup; or cetirizine placebo syrup and loratadine placebo syrup.\n\nNumber of Subjects (Planned and Analyzed): 1100 planned; 1536 screened; 683 randomized: 231 (33.8%) randomized to the cetirizine HCl treatment group, 221 (32.4%) to the loratadine treatment group, and 231 (33.8%) to the placebo treatment group.\n\nTest Product and Reference Therapy: Subjects randomized to receive cetirizine HCl syrup also received placebo syrup; subjects randomized to receive loratadine syrup also received placebo syrup; and both placebo syrups were received by subjects randomized to receive placebo.\n\nDuration of Double-Blind Treatment: 2 weeks.\n\nSafety measures included the incidence and severity of treatment-emergent adverse events (AEs), vital signs, concomitant medications, and physical examination findings. Clinical laboratory evaluation was not required for this study.\n\nStatistical Methods: All statistical tests related to treatment effect were 2-sided, and statistical significance was declared at the 0.05 probability level. Least squares means (LSMeans) were used to estimate treatment effect. Populations analyzed included the Full Analysis (intent-to-treat [ITT]) Set (FAS), Per-Protocol Set (PPS), Safety-Analyzable Set, and All-Screened Analysis Set. Demographic and baseline data for all subjects in the Safety-Analyzable Set were summarized and listed. The effects of treatment at the Overall and all other analysis Time Points were assessed using ANCOVA models. The main effects model contained terms for treatment and Investigator site, with baseline TSSC value as a covariate. The LSMeans and standard errors were based on the main effects model. Methods of analysis of secondary efficacy data included analysis of covariance (ANCOVA) models and Cochran-Mantel-Haenszel (CMH) row mean scores tests. Analysis of drug safety included the incidence of treatment-emergent AEs (TEAE), concomitant medications, vital signs, and physical examination findings for the Safety-Analyzable Set.	2001-03-01	2001-07-01	2001-07-01	2016-10-13	\N	2017-04-20	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 4"}	{"Allergic Rhinitis","Hay Fever",SAR,"Rhinitis, Allergic, Seasonal"}	comparison	cetirizine	\N	f	Allergic Rhinitis	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine|loratadine
87	2023-01-02 15:22:35.727	2023-03-20 16:22:03.614	NCT00884325	Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study	Management of Pruritus With Xyzal in Atopic Dermatitis	Completed	It is historically well known that the management of pruritus in atopic dermatitis is very difficult. Most of the patients are not controlled with traditional antihistamines such as Clarinex, Claritin, and Allegra. It will be a welcome addition to our treatment armamentarium if a drug such as Xyzal can control pruritus associated with atopic dermatitis.	Parallel Assignment	Derm Research, PLLC	OTHER	All	\N	18	40	Actual	OTHER	Derm Research, PLLC	Randomized	\N	Double	\N	\N	Treatment	\N	\N	2009-02-01	2010-01-01	2010-01-01	2009-04-20	2013-08-16	2013-08-16	DermResearch, PLLC	Derm Research, PLLC	Leon Kircik, M.D.	Principal Investigator	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Atopic Dermatitis",Pruritus}	main	loratadine		f	Dermatitis	2022-08-17 18:44:47	{"Hannuksela M, Kalimo K, Lammintausta K, Mattila T, Turjanmaa K, Varjonen E, Coulie PJ. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy. 1993 Feb;70(2):127-33."}	CT_RESULTS	\N	levocetirizine
88	2023-01-02 15:22:35.726	2023-03-20 16:23:20.462	NCT01373138	Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Desloratadine and Pseudoephedrine 5 mg/240 mg Extended-Release Tablet and Clarinex-D 24-Hour (Reference) Following a 5 mg/240 mg Dose in Healthy Subjects Under Fasting Conditions	Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions	Completed	This is an open label randomised, 2-way crossover, comparative bioequivalence study.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	All	45	18	34	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Laboratories Ltd., India, desloratadine-pseudoephedrine and Schering Corporation, U.S.A.(Clarinex-D 24-HOUR), desloratadine-pseudoephedrine, administered as a 1 x 5 mg/240 mg extended-release tablet under fasting conditions. The treatment phases were separated by a washout period of 14 days. 34 subjects(19 males and 15 females) were dosed and were enrolled in the study; 31 of these enrolled subjects completed the study.	2006-04-01	\N	2006-05-01	2011-06-14	\N	2011-06-14	\N	\N	\N	\N	Vice President - Research & Development	Dr. Reddy's Laboratories Limited	\N	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	combination	desloratadine	\N	f	Bioequivalence	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
62	2023-01-02 15:22:35.725	2023-03-20 14:59:25.245	NCT01888718	Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of Allegra  (Containing Fexofenadine Hydrochloride) Orally Disintegrating Tablets 30 mg of Sanofi - Aventis U.S. LLC, Bridgewater, NJ 08807 in Healthy, Adult, Human Subjects Under Fasting Conditions.	Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition	Completed	To assess the bioequivalence of Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr. Reddy's Laboratories Limited, India comparing with that of Allegra (containing fexofenadine hydrochloride) Orally Disintegrating Tablets 30 mg of Sanofi - aventis U.S. LLC, Bridgewater, NJ 08807 in healthy, adult, human subjects under fasting conditions. To monitor adverse events and ensure the safety of subjects.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	Male	45	18	80	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	An open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of Allegra  (Containing Fexofenadine Hydrochloride) Orally Disintegrating Tablets 30 mg of Sanofi - Aventis U.S. LLC, Bridgewater, NJ 08807 in Healthy, Adult, Human Subjects Under Fasting Conditions.	2011-02-01	2011-02-01	2011-03-01	2013-06-28	\N	2013-06-28	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	main	fexofenadine	\N	f	Bioequivalence	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
65	2023-01-02 15:22:35.725	2023-03-20 15:01:45.892	NCT00757562	Multiple-Dose Safety and Tolerance Study of Desloratadine in Atopic Pediatric Subjects and Pediatric Subjects With Chronic Idiopathic Urticaria, Ages >=2 to <12 Years, Who Are Poor Metabolizers of Desloratadine	Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)	Completed	This study was conducted to evaluate the safety and tolerance of desloratadine after 5 weeks of repetitive dosing in children ages 2 to 12 years old with allergic hypersensitivity or chronic hives. All of the subjects enrolled in this trial were previously identified in an earlier trial to be poor metabolizers of desloratadine.	Parallel Assignment	Organon and Co	INDUSTRY	All	12	2	97	Actual	INDUSTRY	Organon and Co	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2002-11-01	2003-10-01	2003-10-01	2008-09-23	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child}	{"Phase 3"}	{"Chronic Idiopathic Urticaria",Atopy}	main	loratadine	\N	f	Urticaria	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	desloratadine
66	2023-01-02 15:22:35.725	2023-03-20 15:02:02.572	NCT01506050	Randomized, Single Dose, 2-Way Crossover, Relative Bioavailability Study of Desloratadine Orally Disintegrating Tablet Fasting Conditions	Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fasting Condition	Completed	This is an open label, randomised, single dose, 2-way crossover, comparative bioequivalence study.	Crossover Assignment	Dr. Reddy's Laboratories Limited	INDUSTRY	All	45	18	35	Actual	INDUSTRY	Dr. Reddy's Laboratories Limited	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Laboratories Ltd., India, desloratadine ODT 5 mg and Schering Corporation, U.S.A.(Clarinex 5 mg), desloratadine ODT 5 mg under fasting conditions. The treatment phases were separated by a washout period of 14 days. 38 subjects were dosed and were enrolled in the study; 35 of these enrolled subjects completed the study.	2006-01-01	\N	2006-02-01	2012-01-09	\N	2012-01-09	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Healthy}	main	desloratadine	\N	f	Bioequivalence	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
73	2023-01-02 15:22:35.726	2023-03-20 15:11:47.634	NCT02507635	In Vivo Anti-inflammatory Effect of H1 Antihistamines in Allergic Rhinitis	Anti-inflammatory H1 Antihistamines Allergic Rhinitis	Completed	The main purpose of the treatment of persistent allergic rhinitis is to improve symptoms and patients' quality of life and prevent the development of asthma. Therapeutic strategies also target a reduction of pro-inflammatory mediators released from activated cells, including mast cells and epithelial cells. The presence of allergic inflammation in nasal mucosa may increase the risk of asthma occurrence, especially in patients with persistent allergic rhinitis. H1 antihistamines are widely recommended in all types of allergic rhinitis, regardless of symptom severity or persistence. They control all of the symptoms, but to a lesser extent nasal congestion. New generation agents, such as levocetirizine and desloratadine, possess anti-inflammatory properties, reducing allergic inflammation.	Parallel Assignment	Iuliu Hatieganu University of Medicine and Pharmacy	OTHER	All	\N	18	115	Actual	OTHER	Iuliu Hatieganu University of Medicine and Pharmacy	Randomized	\N	None (Open Label)	\N	\N	Treatment	\N	Allergic rhinitis is characterized by a chronic inflammation of nasal mucosa and represents a risk factor for asthma occurrence. H1 antihistamines reduce the rhinitis' symptoms, but some compounds may have anti-inflammatory properties.\n\nWe evaluated the plasmatic level of some cytokines in patients with persistent allergic rhinitis (PAR) and their evolution after 4-week treatment with H1 antihistamines and the risk of asthma after 1.5 year.\n\nEighty-five patients with PAR and 30 healthy volunteers were included in the study. The patients with PAR were randomly divided into 2 groups: 41 patients treated with desloratadine 5 mg/day and 44 patients under levocetirizine 5 mg/day for 4 weeks.\n\nThe clinical evaluation include the presence and severity of allergic rhinitis' symptoms: rhinorrhea, nasal congestion, sneezing, nasal and ocular itching and duration of the disease.\n\nEach symptom was evaluated on scale from 0 to 3 (0=absent, 1=mild, 2=moderate, 3=severe) and after that we calculated the total symptoms score (TSS).\n\nA TSS<6 means a mild rhinitis, while a TSS> 6 represented a moderate severe one.\n\nThe patients were clinically evaluated after 1.5 year to determine the possible onset of bronchial asthma.\n\nThe biological evaluation means determination of total IgE and plasmatic level of IL-1 beta, IL-6, IL-8 and TNF alpha.\n\nClinical and biological evaluation were performed before and after treatment	2009-02-01	2011-11-01	2013-05-01	2015-07-24	\N	2015-07-24	\N	Iuliu Hatieganu University of Medicine and Pharmacy	Stefan Cristian Vesa	Assistant professor	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Allergic Rhinitis"}	comparison	levocetirizine	\N	f	Allergic Rhinitis	2022-09-15 18:58:14	{"Bocsan CI, Bujor AI, Miron N, Vesa SC, Deleanu D, Buzoianu AD. In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial. Balkan Med J. 2015 Oct;32(4):352-8. doi: 10.5152/balkanmedj.2015.15884. Epub 2015 Oct 1."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/26740893/	levocetirizine|fexofenadine
89	2023-01-02 15:22:35.726	2023-03-20 16:23:46.394	NCT03772158	A Randomized, Single-Dose, Four-Treatment Crossover Bioequivalence and Food Effect Study of Test Formulation of Cetirizine 10mg Chewable Tablets Versus Two Marketed Cetirizine 10mg Immediate Release Tablets.	Cetirizine Chewable Bioequivalence and Food Effect Study	Completed	The purpose of this study is to determine and compare the amount of study drug that gets into your blood after the administration of each of the three formulations of cetirizine under different conditions. Another objective of this study is to evaluate the effect of food on the amount of study drug that gets into your blood after the administration of the investigational formulation. Other objectives of this study are to determine the sensory experience and ease of swallowing the investigational formulation, as well as to determine the safety of test and reference formulations of cetirizine.	Crossover Assignment	Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division	INDUSTRY	All	55	18	40	Actual	INDUSTRY	Johnson & Johnson Consumer and Personal Products Worldwide	Randomized	This is a randomized, single-dose, four-treatment crossover bioequivalence and food effect study of Cetirizine Chewable Tablets versus ZYRTEC Immediate Release (IR) Tablets (US reference) and REACTINE IR Tablets (EU and Australian marketed reference product).\n\nThe study will be conducted in two parts. Part 1 of the study will have a randomized, four way crossover study design in which 40 healthy subjects, ages 18 to 55 years, will be randomized to four sequences of Treatments A, B, D and E over consecutive periods. No less than approximately 40% of either gender will be represented in the study population. Part 2 of the study will assess a potential food effect in which all subjects will be administered Treatment C in the fifth period.	Single	Blinding of the test and reference products to study subjects is not feasible, because the products are different dosage forms (chewable tablets and IR tablets) and administered in different ways (with or without water and fasted or fed). Personnel conducting the bioanalyses of samples will not know the treatment sequence. The randomization code will not be available to them until the analytical tables have been finalized and audited by the Algorithme Pharma (An Altasciences Company) Quality Assurance (QA) department.	\N	Other	\N	The purpose of this study is to establish bioequivalence of a cetirizine 10 mg chewable tablet manufactured at Johnson & Johnson Consumer Inc. (McNeil LLC) with two commercially marketed cetirizine 10 mg immediate release (IR) tablets (ZYRTEC, US reference) and (Australian/EU reference), establish bioequivalence between the two commercial products (ZYRTEC, US reference and REACTINE, Australian/EU reference), and to evaluate the effect of food on bioavailability of the cetirizine 10 mg chewable tablet compared to the bioavailability of cetirizine 10 mg chewable tablet administrated with water only. In addition, subject's sensory experience and ease of swallowing of the test product will be assessed.	2018-12-11	2019-02-03	2019-02-03	2018-12-11	\N	2021-12-01	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Allergy}	main	cetirizine	\N	f	Bioequivalence	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
76	2023-01-02 15:22:35.725	2023-03-20 15:14:01.171	NCT03555890	A Single Centre, Single Dose, Open-label, Randomized, 2-part, 2-way Crossover Study to Determine the Bioequivalence of Levocetirizine Oral Disintegrating Tablet Given With Water and Without Water Compared to Levocetirizine Immediate Release Tablet in Healthy Japanese Male Subjects	Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)	Completed	This study will be an open-label, randomized 2-way cross-over study to evaluate bioequivalence study between levocetirizine ODT and levocetirizine IRT in healthy Japanese male subjects. Approximately 48 subjects will participate in this study to receive a single dose treatments of levocetirizine ODT 5 milligram (mg) or levocetirizine IRT 5 mg. In Part 1, subjects will randomized in 1:1 ratio (12 in each Period) in Period 1 and 2 to receive single dose of levocetirizine ODT 5 mg with water or single dose levocetirizine IRT 5 mg with water in fasted state. In this part, comparison of bioavailability of levocetirizine ODT and levocetirizine IRT when taken with water in the fasted state will be assessed. In Part 2, subjects will be randomized in 1:1 ratio (12 in each Period) in Period 1 and 2 to receive single dose levocetirizine ODT 5 mg without water or single dose levocetirizine IRT 5 mg with water in fasted state. In this part, comparison of bioavailability of levocetirizine ODT without water and levocetirizine IRT with water in the fasted state will be assessed. There will be at least a 5-day wash out period between the intervention periods. The duration of each subject's participation in each part will be approximately 7 weeks from screening to follow-up.	Crossover Assignment	GlaxoSmithKline	INDUSTRY	Male	55	20	72	Actual	INDUSTRY	GlaxoSmithKline	Randomized	This study is 2-way crossover 2 part study. In Part 1, comparison of bioavailability of levocetirizine ODT and levocetirizine IRT taken with water in the fasted state will be done and In Part 2, comparison of bioavailability of levocetirizine ODT without water and levocetirizine IRT with water in the fasted state will be done.	None (Open Label)	\N	\N	Treatment	\N	\N	2018-05-18	2018-09-17	2018-09-17	2018-06-14	2019-09-12	2020-06-02	GlaxoSmithKline	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult}	{"Phase 1"}	{Rhinitis}	main	cetirizine	\N	f	Bioequivalence	2022-08-17 13:39:16	{}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/32196954/	levocetirizine
82	2023-01-02 15:22:35.726	2023-03-20 16:15:49.974	NCT00864279	Single Dose Two-Way Crossover Fasted Bioequivalence Study of Cetirizine Hydrochloride 10 mg Tablets in Healthy Volunteers	A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions	Completed	To determine the pharmacokinetics and bioequivalence of cetirizine hydrochloride formulations after administration of single doses to normal healthy subjects under fasted conditions. These data were to be evaluated statistically to determine if the products meet bioequivalence criteria.	Crossover Assignment	Actavis Inc.	INDUSTRY	All	\N	18	26	Actual	INDUSTRY	Actavis Inc.	Randomized	\N	None (Open Label)	\N	\N	\N	\N	Study Type: Interventional Study Design: Single-dose two-way, crossover bioequivalence study with an adequate washout period (7 days) between the two periods of the study and with an equal number of subjects randomly assigned to receive the study test (Treatment A) and study reference (Treatment B).\n\nOfficial Title: Single Dose Two-Way Crossover Fasted Bioequivalence Study of Cetirizine Hydrochloride 10 mg Tablets in Healthy Volunteers\n\nFurther study details as provided by Actavis Elizabeth LLC:\n\nPrimary Outcome Measures:\n\nRate and Extend of Absorption	2006-08-01	2006-09-01	2006-09-01	2009-03-18	\N	2010-08-16	\N	\N	\N	\N	Meena Venugopal, Director, Clinical R&D	Actavis Inc	\N	\N	Interventional	{Adult,"Older Adult"}	{"Phase 1"}	{Healthy}	main	cetirizine	\N	f	Bioavailability	2022-08-17 13:39:16	{}	NO_PUBLICATION_FOUND	\N	cetirizine
92	2023-01-02 15:22:35.727	2023-03-20 16:25:39.706	NCT00837915	Comparative, Randomized, Single-Dose, Fully Replicated, 4-Way Crossover Bioavailability Study of Ranbaxy and Schering (Claritin_D 24 Hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets, in Healthy Adult Volunteers Under Fasting Conditions	Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions	Completed	The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets, in a fully replicated design, under fasting conditions.	Crossover Assignment	Ranbaxy Laboratories Limited	INDUSTRY	All	45	18	40	Actual	INDUSTRY	Ranbaxy Inc.	Randomized	\N	None (Open Label)	\N	\N	\N	\N	The study was conducted as an open-label, randomized, Single-Dose, Fully replicated, 4-way Crossover Study to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin_D 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets, in Healthy adult Volunteers Under Fasting Conditions A total of 40 subjects (30 males and 10 females) were included in this study, of which 36 (27 males and 9 females) finished the study according to the protocol.	2002-06-01	2002-08-01	2002-11-01	2009-02-06	\N	2009-02-06	\N	\N	\N	\N	Dr. Tausif Monif	Ranbaxy Research Labs	\N	\N	Interventional	{Adult}	{"Not Applicable"}	{Healthy}	comparison	loratadine	\N	f	Bioequivalence	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
93	2023-01-02 15:22:35.727	2023-03-20 16:26:16.754	NCT03640273	The Study of Efficacy and Adverse Effects of Prapchompoothaweep Remedy Crude Drug and Loratadine for Treatment in Allergic Rhinitis Patients (Clinical Trials Phase II)	Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients	Completed	To compare the effectiveness of Prapchompoothaweep crude drug at 3,000 mg per day and Loratadine 10 mg per day for treatment in Allergic Rhinitis patients. (Clinical Trial Phase II)\nTo evaluate the safety and adverse effect of Prapchompoothaweep crude drug at 3,000 mg and Loratadine 10 mg for Allergic Rhinitis patients.	Parallel Assignment	Thammasat University	OTHER	All	70	18	72	Actual	OTHER	Thammasat University	Randomized	this study is a double blind randomized controlled trial study. the volunteers will be divided into 2 groups. One is received Prapchompoothaweep crude drug capsule at 1,000 mg 3 times a day before meals and the other is received Loratadine 10 mg per day before meals. it takes 6 weeks to complete the project for each volunteers.\n\nBefore enrolling, volunteers will stop using any anti-histamine drug for 1 week (wash-out period). All volunteers will be followed up in the 3rd and 6th week to evaluate the efficacy and adverse effect after received drugs.\n\nThe researcher will record characteristic data such as gender, age, BMI, vital signs and symptoms . The adverse effect will be monitored by hematology test e.g. liver function test, renal function test, lipid profile and blood sugar test.	Double	\N	\N	Treatment	\N	this study is a double blind randomized controlled trial study.\n\nthe volunteers will be divided into 2 groups. One is received Prapchompoothaweep crude drug capsule at 1,000 mg 3 times a day before meals and the other is received Loratadine 10 mg per day before meals. it takes 6 weeks to complete the project for each volunteers.\n\nBefore enrolling, volunteers will stop using any anti-histamine drug for 1 week (wash-out period). All volunteers will be followed up in the 3rd and 6th week to evaluate the efficacy and adverse effect after received drugs.\n\nThe researcher will record characteristic data such as gender, age, BMI, vital signs and symptoms . The adverse effect will be monitored by hematology test e.g. liver function test, renal function test, lipid profile and blood sugar test.	2017-11-23	2018-01-04	2018-06-24	2018-08-21	\N	2018-08-22	\N	Thammasat University	Supasuta Leangpanich	Principal Investigator	\N	\N	Principal Investigator	\N	Interventional	{Adult,"Older Adult"}	{"Phase 2"}	{"Allergic Rhinitis","Adverse Drug Event","Quality of Life"}	comparison	loratadine	\N	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
96	2023-01-02 15:22:35.727	2023-03-20 16:30:26.707	NCT00795158	An Open-Label Study of the Effects of Desloratadine Treatment on the Quality of Life of Patients With Chronic Urticaria	How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)	Completed	The purpose of this study was to determine the effect of desloratadine treatment on quality of life, daytime functioning, quality of sleep, symptoms, and disease severity in patients who had hives for 6 weeks or longer. Patients took desloratadine for 1 month. Once a week, patients filled out a questionnaire to tell how their hives affected their lives. This questionnaire is called the Dermatology Life Quality Index or DLQI. They also filled out a diary every day to tell how much itching they had, how many hives they had, and how their hives had affected their sleep or daily activities. The patients and doctors rated the patients' overall condition and how much relief patients got from treatment.	Single Group Assignment	Organon and Co	INDUSTRY	All	\N	18	282	Actual	INDUSTRY	Organon and Co	N/A	\N	None (Open Label)	\N	\N	Treatment	\N	\N	2002-11-01	2004-01-01	2004-01-01	2008-11-21	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 3"}	{Urticaria}	main	desloratadine	\N	f	Urticaria	2022-09-15 19:16:20	{"Seidenari S, Cirillo A, Amoroso S, Flori ML, Amerio P, Ricciuti E, Vena GA, Berardesca E, Le Grazie C and the Italian Study Group on Desloratadine (DL) in Chronic Urticaria. Desloratadine 5 milligrams once daily improves quality of life in chronic idiopathic urticaria. G Ital Dermatol Venereol. 2006;141(3):207-214"}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/16503889/	desloratadine
97	2023-01-02 15:22:35.727	2023-03-20 16:31:07.722	NCT00845546	Comparative, Randomized, Single-Dose, Fully Replicated, 4-Way Crossover Bioavailability Study of Ranbaxy and Schering (Claritin_D 24 Hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets, in Healthy Adult Volunteers Under Fed Conditions	Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions	Completed	The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets, in a fully replicated design, under fed conditions.	Crossover Assignment	Ranbaxy Laboratories Limited	INDUSTRY	All	45	18	40	Actual	INDUSTRY	Ranbaxy Inc.	Randomized	\N	None (Open Label)	\N	\N	\N	\N	The study was conducted as an open-label, randomized, Single-Dose, Fully replicated, 4-way Crossover Study to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin_D 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets, in Healthy adult Volunteers Under Fed Conditions In each period, subjects were housed from the evenings before the dosing until after the 36 hour blood draw and were to return for subsequent blood draws at 48, 72, 96 and 120 hours post dose. Single oral 10 mg Loratadine/ 240 mg Pseudoephedrine Sulfate doses were separated by a washout period of 21 days.\n\nA total of 40 subjects and 1 alternate (34 males and 7 females) were included in this study, of which 37 (32 males and 5 females) finished the study according to the protocol.	2002-06-01	2002-08-01	2002-11-01	2009-02-18	\N	2009-02-18	\N	\N	\N	\N	Dr. Tausif Monif	Ranbaxy Research labs	\N	\N	Interventional	{Adult}	{"Not Applicable"}	{Healthy}	comparison	loratadine	\N	f	Bioequivalence	2022-08-17 18:44:47	{}	NO_PUBLICATION_FOUND	\N	loratadine
105	2023-01-02 15:22:35.727	2023-03-20 16:34:32.046	NCT00762983	Claritin Tablet 10 mg, Claritin RediTabs 10 mg, Claritin Dry Syrup 1% Drug Use Investigation (Pediatrics)	Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)	Completed	The purpose of this study is to collect information on unexpected adverse reactions (ADRs), how often ADRs occur, and factors that can affect the safety and effectiveness of Claritin (loratadine) when used in children. Patients will be observed while they are taking Claritin, and ADRs and symptom scores will be recorded. At the end of treatment, improvement in symptoms will be recorded.\n\nPost-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.	\N	Merck Sharp & Dohme LLC	INDUSTRY	All	15	3	1003	Actual	INDUSTRY	Merck Sharp & Dohme LLC	\N	\N	\N	\N	Ecologic or Community	\N	Prospective	\N	2008-03-01	2009-02-01	2009-02-01	2008-09-30	\N	2015-02-13	\N	\N	\N	\N	\N	\N	Sponsor	\N	Observational	{Child}	{}	{"Rhinitis, Allergic, Seasonal","Rhinitis, Allergic, Perennial",Urticaria,Pruritus}	main	loratadine	could also be Safety	f	Allergic Rhinitis	2022-08-17 18:44:47	{}	UNKNOWN	\N	loratadine
106	2023-01-02 15:22:35.727	2023-03-20 16:34:52.645	NCT01767272	Dose Proportionality of Fexofenadine	Dose Proportionality of Fexofenadine in Healthy Human Egyptian Volunteers	Completed	The present study was adopted to evaluate the pharmacokinetics and dose linearity of fexofenadine after oral administration.	Crossover Assignment	Damanhour University	OTHER	Male	45	18	25	Actual	OTHER	Damanhour University	Randomized	\N	None (Open Label)	\N	\N	\N	\N	The present study was adopted to evaluate the pharmacokinetics and dose linearity of fexofenadine after administration of single oral doses of 60 to 360 mg in an open-label, five-way crossover study.	2012-12-01	2013-01-01	2013-01-01	2013-01-14	\N	2013-01-14	\N	Damanhour University	Sally Helmy, PhD, CPHQ	Lecturer of Pharmaceutics, Faculty of Pharmacy	\N	\N	Principal Investigator	\N	Interventional	{Adult}	{"Not Applicable"}	{Healthy}	main	fexofenadine	\N	f	Pharmacokinetics	2022-08-18 16:54:53	{}	NO_PUBLICATION_FOUND	\N	fexofenadine
109	2023-01-02 15:22:35.728	2023-03-20 16:37:12.041	NCT00406783	Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Intermittent Allergic Rhinitis (IAR)	Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)	Completed	This study will investigate the effectiveness of desloratadine in treating subjects with allergic rhinitis (AR) who meet the criteria for intermittent allergic rhinitis.	Parallel Assignment	Organon and Co	INDUSTRY	All	\N	12	547	Actual	INDUSTRY	Organon and Co	Randomized	\N	Quadruple	\N	\N	Treatment	\N	\N	2006-08-01	2007-11-01	2007-11-01	2006-12-04	2009-03-06	2022-02-15	Merck Sharp & Dohme Corp.	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Child,Adult,"Older Adult"}	{"Phase 3"}	{"Rhinitis, Allergic, Seasonal","Rhinitis, Allergic, Perennial"}	main	desloratadine	\N	f	Allergic Rhinitis	2022-09-15 19:16:20	{"Bousquet J, Bachert C, Canonica GW, Mullol J, Van Cauwenberge P, Bindslev Jensen C, Fokkens WJ, Ring J, Keith P, Lorber R, Zuberbier T; ACCEPT-1 study group. Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy. 2009 Oct;64(10):1516-1523. doi: 10.1111/j.1398-9995.2009.02115.x. Epub 2009 Jul 14."}	PUBLISHED	https://pubmed.ncbi.nlm.nih.gov/19624554/	desloratadine
110	2023-01-02 15:22:35.727	2023-03-20 16:37:31.941	NCT00779636	Efficacy and Safety of Desloratadine 10 mg Daily vs. Placebo in Subjects With Allergic Airway Disease During the Pollen Season	Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)	Completed	This was a placebo controlled study designed to evaluate the effectiveness of desloratadine in relieving symptoms of allergic airway disease during the pollen season. Patients received desloratadine 10 mg or placebo once daily for 28 days, and had their allergy symptoms and side effects to medication measured on Day 1, Day 15, and Day 29 (one day after stopping study drug).	Parallel Assignment	Organon and Co	INDUSTRY	All	65	18	506	Actual	INDUSTRY	Organon and Co	Randomized	\N	Triple	\N	\N	Treatment	\N	\N	2003-07-01	2004-11-01	2004-11-01	2008-10-24	\N	2022-02-17	\N	\N	\N	\N	\N	\N	Sponsor	\N	Interventional	{Adult,"Older Adult"}	{"Phase 4"}	{"Allergic Airway Disease"}	main	desloratadine	\N	f	Allergy	2022-09-15 19:16:20	{}	NO_PUBLICATION_FOUND	\N	desloratadine
\.


--
-- Data for Name: InterventionMeshTermOnEntries; Type: TABLE DATA; Schema: public; Owner: tim
--

COPY public."InterventionMeshTermOnEntries" (id, "createdAt", "updatedAt", "meshId", "entryId", description) FROM stdin;
1	2023-01-02 15:22:35.751	2023-01-02 15:22:35.751	5	1	Each subject received 5 mL of desloratadine syrup one time
2	2023-01-02 15:22:35.751	2023-01-02 15:22:35.751	4	1	Each subject received 5 mL of cetirizine syrup
3	2023-01-02 15:22:35.753	2023-01-02 15:22:35.753	5	2	Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days
4	2023-01-02 15:22:35.757	2023-01-02 15:22:35.757	5	3	Each subject received 5 mL of desloratadine syrup one time
5	2023-01-02 15:22:35.753	2023-01-02 15:22:35.753	4	2	Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days
6	2023-01-02 15:22:35.757	2023-01-02 15:22:35.757	4	3	Each subject received 5 mL of cetirizine syrup
7	2023-01-02 15:22:35.757	2023-01-02 15:22:35.757	4	4	Zyrtec (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
8	2023-01-02 15:22:35.757	2023-01-02 15:22:35.757	5	4	desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day
9	2023-01-02 15:22:35.761	2023-01-02 15:22:35.761	5	5	Cetirizine 10 mg tab daily x 7 days
10	2023-01-02 15:22:35.761	2023-01-02 15:22:35.761	3	5	5 mg tab daily x 7 days
11	2023-01-02 15:22:35.766	2023-01-02 15:22:35.766	5	6	desloratadine, 5mg oral tablets, once daily for 28 days
12	2023-01-02 15:22:35.768	2023-01-02 15:22:35.768	5	8	levocetirizine
13	2023-01-02 15:22:35.766	2023-01-02 15:22:35.766	4	6	placebo, once daily for 28 days
14	2023-01-02 15:22:35.768	2023-01-02 15:22:35.768	3	8	cetiridine
15	2023-01-02 15:22:35.769	2023-01-02 15:22:35.769	9	7	Clarinex 5 mg daily x 7 days
16	2023-01-02 15:22:35.769	2023-01-02 15:22:35.769	4	7	Allegra 180 mg daily x 7 days
17	2023-01-02 15:22:35.77	2023-01-02 15:22:35.77	9	10	group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
18	2023-01-02 15:22:35.77	2023-01-02 15:22:35.77	16	10	group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
19	2023-01-02 15:22:35.77	2023-01-02 15:22:35.77	3	10	\N
20	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	4	11	5mg oral capsules, once daily, 4 week duration
21	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	3	11	5mg oral capsules, once daily, 4 week duration
22	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	9	15	\N
23	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	3	15	\N
24	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	3	13	\N
25	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	3	17	\N
26	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	3	18	\N
27	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	3	19	\N
28	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	9	23	Fexofenadine Hydrochloride 180 mg Tablets
29	2023-01-02 15:22:35.777	2023-01-02 15:22:35.777	5	20	Cetirizine Hydrochloride Tablets 10 mg
30	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	5	22	Cetirizine Hydrochloride Tablets 10 mg
31	2023-01-02 15:22:35.777	2023-01-02 15:22:35.777	9	21	Fexofenadine Hydrochloride 180 mg Tablets
32	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	5	24	\N
33	2023-01-02 15:22:35.781	2023-01-02 15:22:35.781	9	25	\N
34	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	9	26	Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2
35	2023-01-02 15:22:35.782	2023-01-02 15:22:35.782	3	27	\N
37	2023-01-02 15:22:35.782	2023-01-02 15:22:35.782	3	28	Levocetirizine DiHCl Tablets 5 mg
36	2023-01-02 15:22:35.782	2023-01-02 15:22:35.782	8	29	Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.
38	2023-01-02 15:22:35.783	2023-01-02 15:22:35.783	5	32	20 mg levocetirizine for 5 days
39	2023-01-02 15:22:35.783	2023-01-02 15:22:35.783	21	32	24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
40	2023-01-02 15:22:35.783	2023-01-02 15:22:35.783	3	32	\N
41	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	8	33	Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks
42	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	3	31	oral administration, single tablet, 5 mg.
43	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	8	35	The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
44	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	9	35	The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
45	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	24	35	\N
46	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	25	35	\N
47	2023-01-02 15:22:35.785	2023-01-02 15:22:35.785	4	37	10-mg desloratadine tablets, once daily for four weeks.
48	2023-01-02 15:22:35.785	2023-01-02 15:22:35.785	8	37	5-mg desloratadine tablets, once daily for four weeks.
49	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	3	39	Pharmaceutical form: Tablets for oral administration\nRoute of administration: Oral use
50	2023-01-02 15:22:35.785	2023-01-02 15:22:35.785	5	39	Pharmaceutical form: Drops for oral administration\nRoute of administration: Oral use
51	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	8	38	5 mg capsule once daily
52	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	5	38	5 mg tablet once daily
53	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	5	41	Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered once daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning to infants aged between 6 months and 1 year old
54	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	3	41	Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered twice daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning and evening before sleep to infants aged between 1 year and 2 years old
55	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	3	38	once daily
56	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	4	38	once daily
57	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	4	40	Desloratadine Tablets, 5 mg
58	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	9	42	Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
59	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	24	42	\N
60	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	25	42	\N
61	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	4	68	desloratadine syrup; 5.0 mL once daily for 28 days
62	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	9	44	Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited
64	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	4	43	Desloratadine Tablets, 5 mg
63	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	24	44	\N
65	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	3	53	Levocetirizine DiHCl Tablets 5 mg
66	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	25	44	\N
67	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	9	55	Encapsulated Fexofenadine 120 mg tablets Q.D.
68	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	5	55	Encapsulated Bilastine 20 mg tablets Q.D.
69	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	5	58	A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
70	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	4	65	desloratadine syrup: 1.25 mg (2.5 mL) for subjects >=2 to <6 years, 2.5 mg (5 mL) for subjects >=6 to <12 years, orally once daily in the morning for 36 days.
71	2023-01-02 15:22:35.789	2023-01-02 15:22:35.789	9	62	Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg
72	2023-01-02 15:22:35.789	2023-01-02 15:22:35.789	4	64	Desloratadine ODT 5 mg
77	2023-01-02 15:22:35.79	2023-01-02 15:22:35.79	8	69	FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratrios SA
76	2023-01-02 15:22:35.79	2023-01-02 15:22:35.79	8	81	\N
102	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	5	84	5mg once daily
110	2023-01-02 15:22:35.804	2023-01-02 15:22:35.804	24	92	\N
113	2023-01-02 15:22:35.805	2023-01-02 15:22:35.805	40	91	96% ethanol that will be applied once daily.
118	2023-01-02 15:22:35.806	2023-01-02 15:22:35.806	3	95	Levocetirizine
133	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	45	101	\N
136	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	8	103	Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors.
144	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	9	111	Fexofenadine: One 30 mg Tablet once daily for two weeks
169	2023-01-02 15:22:35.821	2023-01-02 15:22:35.821	5	128	Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
175	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	9	132	PF-03654764 2.5mg plus fexofenadine 60mg twice daily for 7 days
181	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	4	134	single dose, oral, 5 mg
182	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	13	130	\N
218	2023-01-02 15:22:35.838	2023-01-02 15:22:35.838	9	154	Pharmaceutical form: tablet Route of administration: oral
251	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	3	192	Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
265	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	9	189	Subjects randomized to this group will receive one (01) experimental drug film-coated tablet every eight (08) hours for three (03) days (nine [09] dosage administration). Subjects will be instructed to, thereafter, maintain treatment at the same dosage (one [01] film-coated tablet every eight [08] hours) in case of persistence of symptoms, discontinuing treatment when they present with no symptoms.
275	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	24	190	\N
292	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	9	198	tablet
293	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	90	201	\N
300	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	5	204	\N
305	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	3	205	Levocetirizine, Histamine-1 receptor antagonists provide a highly successful approach for controlling allergic and inflammatory conditions
314	2023-01-02 15:22:35.878	2023-01-02 15:22:35.878	4	219	\N
325	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	5	216	20 mg (encapsulated) tablets QD/14days
330	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	13	218	Pharmaceutical form:tablet\n\nRoute of administration: oral
331	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	24	218	Pharmaceutical form:tablet\n\nRoute of administration: oral
339	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	9	227	Oral administration of 50 mg sulfasalazine
340	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	102	227	Oral administration of 120 mg fexofenadine
351	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	106	233	Claritin Tablets 24-Hour (tablet)
363	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	24	239	Placebo Nasal Spray, 2 sprays per nostril
385	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	8	248	montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
387	2023-01-02 15:22:35.898	2023-01-02 15:22:35.898	4	253	20 mg (encapsulated) tablets QD/14 days
389	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	4	255	Levocetirizine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively.
393	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	5	257	\N
397	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	13	259	Fexofenadine single dose 60 mg
411	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	5	268	Mast cell stabilizer
424	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	16	274	loratadine 10 mg tablet orally once daily in the morning for 4 weeks
430	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	8	278	10 mg montelukast tablet given once daily at bedtime for 2 weeks
438	2023-01-02 15:22:35.91	2023-01-02 15:22:35.91	119	279	\N
454	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	133	283	\N
479	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	8	297	One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.
498	2023-01-02 15:22:35.923	2023-01-02 15:22:35.923	5	305	a placebo nasal spray and placebo capsule are available for double dummy treatment
507	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	8	308	Placebo to TAA-AQ was administered once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration
516	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	165	310	Pharmaceutical form:solution for infusion Route of administration: intravenous
522	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	5	311	2x110L in each nostril twice daily for 7 days
543	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	45	332	Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
549	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	142	331	\N
557	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	188	329	All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
562	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	106	330	Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing 30 kg (66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.
583	2023-01-02 15:22:35.943	2023-01-02 15:22:35.943	199	341	\N
602	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	217	339	Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone  10 mg/day) for  1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines [Khanna D et al. 2012] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA < 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA < 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.
609	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	227	345	consists of the same components as the formulation buffer for UX053
610	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	5	345	participants will receive oral premedication prior to infusion
623	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	195	348	used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.
634	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	235	357	Premedication with oral. paracetamol 1000 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
643	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	72	374	Nasal spray
665	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	165	360	Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
673	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	84	362	Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated
74	2023-01-02 15:22:35.789	2023-01-02 15:22:35.789	3	63	\N
82	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	4	67	desloratadine syrup; 5.0 mL once daily for 28 days
97	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	3	73	administration of Levocetirizine 5 mg/day for 4 weeks
108	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	5	89	Chewable tablet
127	2023-01-02 15:22:35.81	2023-01-02 15:22:35.81	41	102	The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.\n\nThis group will use Minoxidil 5% gel
171	2023-01-02 15:22:35.821	2023-01-02 15:22:35.821	3	128	Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
198	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	3	143	\N
212	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	4	149	\N
220	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	9	153	\N
272	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	24	188	\N
286	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	16	203	\N
319	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	99	213	\N
354	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	5	234	\N
361	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	57	239	Placebo tablet orally
416	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	9	270	oral pregabalin 75mg daily for 12 weeks
440	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	44	282	Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy
448	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	132	283	\N
465	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	3	291	Cortancyl oral Tablet 20 mg
478	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	5	297	One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
485	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	4	295	Ketotifen (H1-antihistamine and mast cell stabilizer): capsule (1 x 1 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
505	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	145	306	\N
539	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	49	332	Participants received a single subcutaneous placebo injection on Day 0 of the study.
555	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	85	331	\N
561	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	8	330	One placebo sublingual tablet, QD for up to 35 weeks.
591	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	210	340	\N
620	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	140	343	Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day\n\n(maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of  4 despite treatment with loratadine and mometasone furoate nasal spray.
631	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	29	350	Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
651	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	242	374	\N
669	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	159	361	\N
672	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	49	362	500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion
691	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	261	366	Loratadine 10 mg orally from Day -7 until Day 7
695	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	106	378	Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
734	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	290	407	20 mg rivaroxaban after supplementation with St. John's wort extract (Jarsin) twice daily 450 mg po for 2 weeks.
749	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	300	396	The second PET scan for healthy participants and third PET scan for participants with AN will be performed after administration of 60 mg of methylphenidate, a psychostimulant that allows for accumulation of dopamine (DA) extraneuronally.
764	2023-01-02 15:22:35.973	2023-01-02 15:22:35.973	312	420	A single subcutaneous administration per day from the day of oocyte retrieval
783	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	328	410	PA9159 of 10 g is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
78	2023-01-02 15:22:35.79	2023-01-02 15:22:35.79	29	69	Desloratadine 0.5 mg/mL (Leg - Eurofarma Laboratrios SA)
83	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	4	71	Placebo, 1 tablet daily, per os., 15 days
92	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	24	88	Desloratadine and pseudoephedrine 5/240 mg
122	2023-01-02 15:22:35.808	2023-01-02 15:22:35.808	25	97	\N
134	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	44	101	\N
155	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	8	122	Given PO
183	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	8	134	singel dose, oral, 20 mg
189	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	4	137	Oral ingestion 10mg pill 2 hours prior to heat strain trial. Second 10mg dose 24-hours later.
199	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	25	145	\N
225	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	56	153	Fluticasone furoate and fexofenadine
232	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	3	163	Pharmaceutical form: Tablet\nConcentration: 5 mg\nRoute of administration: Oral use
285	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	87	200	The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
303	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	3	211	a single oral dose of 50 mg
315	2023-01-02 15:22:35.878	2023-01-02 15:22:35.878	31	219	Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
346	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	8	232	\N
364	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	8	239	Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril
382	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	9	251	Pharmaceutical form:dry syrup formulation to be suspended in water\n\nRoute of administration: oral
402	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	4	263	\N
426	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	69	272	10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
450	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	5	283	Children in this group will be treated with antiboitics (syp cefpodoxime) at 10 mg/kg/day in two divided dose for a week, plus antihistamine and nasal decongestants. Oral levocetirizine (Syrup levocet 2.5 mg/5ml) 1.25 mg once daily for age up to six years, 2.5 mg once daily for elder children for a month, plus oxymetazoline (Nasivion) 0.025%, 4 drops twice daily for two weeks
494	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	8	304	Injection solution subcutaneous
500	2023-01-02 15:22:35.925	2023-01-02 15:22:35.925	5	316	\N
512	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	162	313	CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
535	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	182	324	500 mg
611	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	34	345	participants will receive oral premedication prior to infusion
625	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	56	348	Infrared-C irradiation by hot compress with a powered heating compress
654	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	45	374	\N
662	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	52	360	Rituxan 1000 mg administered by IV on Day 1 and Day 15
680	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	256	362	30 to 60 minutes prior to the start of the infusion\n\nClaritin (Loratadine) 10mg by mouth or\nBenadryl (Diphenhydramine) 25 or 50 mg by mouth
690	2023-01-02 15:22:35.959	2023-01-02 15:22:35.959	166	369	This observational study is collecting clinical data focusing on infusion associated reactions and changes in vital signs in MS patients Novel Infusion protocol: The protocol consisted of the following Pre-infusion Protocol\n\nPremedication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days prior to the infusion.\n\nPremedication with 50 mg of prednisone orally for 5 days before the infusion.\n\nDuring Infusion Protocol During infusions methylprednisolone is administered in a dosage of 500 mg on every day of the infusion.\n\nPost Infusion Medication\n\nPost-medication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days after the infusion.\n\nPost-medication with 50 mg of prednisone orally for 5 days after the infusion.\n\nMedications to be used PRN throughout the peri-infusion protocol Benadryl, acetaminophen or other analgesics were allowed
700	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	250	373	The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in emergency department (ED).
736	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	164	401	Pharmaceutical form:tablet Route of administration: oral
751	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	216	398	Given IV
766	2023-01-02 15:22:35.973	2023-01-02 15:22:35.973	316	395	One dose of 24 IU (3 sprays/nostril)
792	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	45	403	\N
827	2023-01-02 15:22:36.007	2023-01-02 15:22:36.007	4	14	Zyrtec 10 mg daily x 7 days
75	2023-01-02 15:22:35.79	2023-01-02 15:22:35.79	4	66	Desloratadine ODT 5 mg
103	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	9	80	Fexofenadine 180 mg in the morning
128	2023-01-02 15:22:35.81	2023-01-02 15:22:35.81	13	98	with sodium lauryl sulfate
140	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	4	107	5-mg Desloratadine tablet, once daily for 12 weeks
164	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	51	127	\N
172	2023-01-02 15:22:35.821	2023-01-02 15:22:35.821	16	128	Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
200	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	8	145	Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
248	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	4	177	Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
262	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	69	189	\N
269	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	5	188	\N
317	2023-01-02 15:22:35.878	2023-01-02 15:22:35.878	5	212	\N
355	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	5	241	Combination therapy compared to mono therapy
390	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	3	255	Desloratadine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively
398	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	24	261	\N
410	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	106	265	1 drop in one eye at one timepoint
418	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	5	269	\N
429	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	5	276	montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
452	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	44	283	\N
471	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	143	293	\N
493	2023-01-02 15:22:35.92	2023-01-02 15:22:35.92	3	302	Vit D supplementation was done
497	2023-01-02 15:22:35.923	2023-01-02 15:22:35.923	57	305	nasal spray 25ug per dose
560	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	189	330	Inhalation of albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed as asthma rescue medication for those participants with asthma
571	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	72	333	Grass sublingual tablet, once daily
579	2023-01-02 15:22:35.942	2023-01-02 15:22:35.942	161	337	Topical
586	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	208	340	Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
605	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	223	346	\N
646	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	237	374	\N
659	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	246	356	comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg
668	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	105	361	Vitamin D will be taken orally, 10,000 IU (0.25 mg) three times per week.
675	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	165	362	30 to 60 minutes prior to the start of the infusion\n\nClaritin (Loratadine) 10mg by mouth or\nBenadryl (Diphenhydramine) 25 or 50 mg by mouth
689	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	189	366	Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
698	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	108	378	Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.
712	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	142	379	\N
720	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	52	389	1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline
722	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	289	384	Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.
727	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	165	390	Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
747	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	295	401	\N
770	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	45	394	\N
781	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	44	418	All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
788	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	332	403	300 mg once daily; oral
803	2023-01-02 15:22:35.982	2023-01-02 15:22:35.982	72	414	The content of this product is a colorless and clear liquid, press the sprayer, the liquid will be sprayed out in mist.\n\nThis product is suitable for improving the symptoms of runny nose, nasal congestion, nasal itching and sneezing caused by allergic rhinitis.
823	2023-01-02 15:22:36.004	2023-01-02 15:22:36.004	4	49	fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
835	2023-01-02 15:22:36.01	2023-01-02 15:22:36.01	9	59	fexofenadine, one 180 mg tablet, orally
79	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	5	70	Cetirizine is an antihistamine currently indicated for allergic rhinitis
101	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	3	84	Omnaris (ciclesonide) 200  once daily\nLevocetirizine 5mg once daily
137	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	4	96	desloratadine 5 mg tablets; one tablet orally once a day for 28 days
180	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	56	130	\N
197	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	3	146	\N
210	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	3	174	\N
223	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	8	160	Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
230	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	8	162	single dose for 7 days, oral, 20mg
242	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	5	170	10mg, single dose fasting
253	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	16	197	Pharmaceutical form: Over-encapsulated tablet\nRoute of administration: Oral use
271	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	24	186	\N
326	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	9	215	Fexofenadine 180mg tablet to be taken orally once a day until stent removal.
334	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	25	218	Pharmaceutical form:tablet\n\nRoute of administration: oral
341	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	96	227	Oral administration of 40 mg valsartan
347	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	16	232	\N
381	2023-01-02 15:22:35.895	2023-01-02 15:22:35.895	4	250	Drug administration
403	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	69	266	\N
425	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	8	272	10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days
443	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	127	285	antihistaminic
458	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	69	284	Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
488	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	34	303	10 mg tab once daily by mouth for 12 week duration
509	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	9	314	A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
520	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	44	322	H3B-6545 oral tablets.
551	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	144	331	\N
558	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	187	329	All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
576	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	56	333	Placebo sublingual tablet, once daily
590	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	209	340	Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
618	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	8	343	Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
632	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	44	350	\N
637	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	165	357	Ocrelizumab is a recombinant humanised monoclonal IgG1 antibody which depletes CD20-positive cells. Ocrelizumab is approved for multiple sclerosis.
693	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	8	378	Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
705	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	271	376	85 mg/m2 d1, q2w
723	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	49	390	IV Injection
744	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	165	401	Pharmaceutical form:tablet Route of administration: oral
756	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	271	398	\N
772	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	324	400	Low dose oral methyl prednisolone was added.
819	2023-01-02 15:22:36.002	2023-01-02 15:22:36.002	9	54	Clarinex 5 mg daily x 7 days
834	2023-01-02 15:22:36.009	2023-01-02 15:22:36.009	9	50	\N
80	2023-01-02 15:22:35.79	2023-01-02 15:22:35.79	4	69	\N
86	2023-01-02 15:22:35.792	2023-01-02 15:22:35.792	25	86	\N
115	2023-01-02 15:22:35.805	2023-01-02 15:22:35.805	5	91	Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.
124	2023-01-02 15:22:35.809	2023-01-02 15:22:35.809	5	167	cetirizine HCl 10mg in a gummy formulation
132	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	5	101	prophylaxis
141	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	4	109	5-mg Desloratadine tablet, once daily for 15 days
147	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	5	116	Week 1 to week 5, every day : - the morning : 5 mg of levocetirizine (capsule)\n\nthe evening : placebo capsule\n\nWeek 6 to week 10, every day : - the morning : 10 mg of levocetirizine (capsule)\n\nthe evening : 10 mg of levocetirizine (capsule))
233	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	9	165	180mg, single dose fed
250	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	5	176	montelukast sodium
372	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	3	260	\N
435	2023-01-02 15:22:35.91	2023-01-02 15:22:35.91	56	279	\N
444	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	8	281	107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to oral famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
457	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	8	284	Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
470	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	142	293	\N
536	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	49	352	\N
550	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	141	331	\N
597	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	205	340	Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
640	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	56	374	Oral administration
653	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	243	374	\N
674	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	8	362	Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure
735	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	5	401	Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
762	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	310	398	\N
771	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	323	397	7.5 mg Depodur via the epidural catheter
780	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	321	418	IV injection
796	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	322	404	Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
806	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	341	421	\N
808	2023-01-02 15:22:35.999	2023-01-02 15:22:35.999	3	9	Cetirizine
81	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	4	75	Desloratadine (Aerius) Syrup;\n\nDose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:\n\nChildren 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg [milligrams] of desloratadine)\nChildren 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)\nChildren 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)
87	2023-01-02 15:22:35.792	2023-01-02 15:22:35.792	4	86	\N
107	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	3	90	Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
120	2023-01-02 15:22:35.808	2023-01-02 15:22:35.808	4	110	Desloratadine 10 mg daily x 28 days
126	2023-01-02 15:22:35.809	2023-01-02 15:22:35.809	8	105	Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.\n\nClaritin Dry Syrup 1%: For pediatric patients aged 3 to < 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.\n\nThe observation period will not be specified.
145	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	8	115	\N
165	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	5	127	Compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan (Rituximab) or Taxol (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.
178	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	9	130	\N
193	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	5	142	Ketotifen dry syrup 0.1%; 1 mg b.i.d.; for 2 weeks
211	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	68	149	01 tablet, orally, every 12 hours.
245	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	9	182	\N
263	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	83	189	Subjects randomized to this group will receive one (01) experimental drug film-coated tablet every eight (08) hours for three (03) days (nine [09] dosage administration). Subjects will be instructed to, thereafter, maintain treatment at the same dosage (one [01] film-coated tablet every eight [08] hours) in case of persistence of symptoms, discontinuing treatment when they present with no symptoms.
274	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	5	190	\N
291	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	91	201	\N
304	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	95	205	Valsartan is an angiotensin receptor blocker.
345	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	8	236	Points: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14).\n\nPierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether.
353	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	108	233	Placebo tablet (tablet)
369	2023-01-02 15:22:35.887	2023-01-02 15:22:35.887	5	243	Copaxone injection 20 mg, Oral Zyrtec 10 mg tablet
419	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	8	271	montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
433	2023-01-02 15:22:35.905	2023-01-02 15:22:35.905	50	280	Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of ~2 minutes
442	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	9	285	alpha blocker
449	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	29	283	\N
528	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	168	320	Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).\n\nFor children who were >=2 to <6 years old, 1 spray/nostril (110 g TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.\nFor children who were >=6 yrs to <12 years old, either 1 spray/nostril (110 g TAA-AQ) or 2 sprays/nostril (220 g TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.
533	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	5	352	\N
544	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	50	332	Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
563	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	190	330	5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rhinoconjunctivitis symptoms
572	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	106	333	Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to <18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score 4.
577	2023-01-02 15:22:35.942	2023-01-02 15:22:35.942	8	337	Topical
587	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	96	340	Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
619	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	57	343	SCH 697243 (2800 Bioequivalent Allergen Units [BAU] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
630	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	5	350	Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
647	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	231	374	\N
660	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	152	359	\N
667	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	250	370	use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis
671	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	83	362	A single dose, of 3mg/kg infusion
708	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	141	379	\N
732	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	4	391	5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
742	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	254	401	Pharmaceutical form:tablet Route of administration: oral
753	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	305	398	\N
782	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	45	418	All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
817	2023-01-02 15:22:36.002	2023-01-02 15:22:36.002	4	54	Allegra 180 mg daily x 7 days
833	2023-01-02 15:22:36.009	2023-01-02 15:22:36.009	5	45	1 Levocetirizine 5mg tablet per day before bedtime for 14 days
84	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	5	76	Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).
98	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	5	82	A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
112	2023-01-02 15:22:35.804	2023-01-02 15:22:35.804	8	92	\N
135	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	9	99	All subjects will receive 180 mg fexofenadine
149	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	8	119	10 mg in a capsule
186	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	16	136	Montelukast 5mg
202	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	24	151	Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
238	2023-01-02 15:22:35.852	2023-01-02 15:22:35.852	8	171	Desloratadine 2.5 mg BID
276	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	25	190	\N
295	2023-01-02 15:22:35.874	2023-01-02 15:22:35.874	49	210	Drug identification number : 02369567
301	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	16	245	\N
310	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	29	208	Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
323	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	3	214	\N
350	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	107	233	Tears Naturale II (eyedrop)
366	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	25	239	\N
375	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	5	244	Cetirizine tablet 10 mg
401	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	72	263	One month treatment with both drugs
415	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	4	269	\N
423	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	16	275	Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
437	2023-01-02 15:22:35.91	2023-01-02 15:22:35.91	8	279	\N
461	2023-01-02 15:22:35.914	2023-01-02 15:22:35.914	5	287	Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.
468	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	9	293	\N
503	2023-01-02 15:22:35.925	2023-01-02 15:22:35.925	143	306	\N
523	2023-01-02 15:22:35.928	2023-01-02 15:22:35.928	5	315	\N
529	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	170	320	Children's Claritin Syrup [5 mg of loratadine per 5 mL] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
540	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	183	332	Administered by subcutaneous injection
584	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	9	340	Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
601	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	9	339	Oral placebo for MTX
624	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	57	348	infrared-C irradiation by hot compress with a powered heating eye mask
650	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	239	374	\N
661	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	152	358	\N
681	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	257	362	\N
697	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	29	373	The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
726	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	4	390	Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
758	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	309	398	\N
769	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	44	394	All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
779	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	322	418	All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
793	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	335	406	5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
811	2023-01-02 15:22:35.999	2023-01-02 15:22:35.999	5	51	SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
824	2023-01-02 15:22:36.004	2023-01-02 15:22:36.004	9	49	desloratadine, 5 mg oral tablets, once daily for 15 days
85	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	3	76	Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.
123	2023-01-02 15:22:35.808	2023-01-02 15:22:35.808	24	97	\N
156	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	3	124	5mg po QD
158	2023-01-02 15:22:35.816	2023-01-02 15:22:35.816	5	126	Levocetirizine dihydrochloride 5mg. PO. Single dose.
191	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	8	139	Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
208	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	65	174	levocetirizine 20 mg/day
222	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	72	160	Daily dose of 200 g of mometasone furoate administered as a nasal spray for 15 days.
228	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	9	156	\N
234	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	5	168	\N
243	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	5	173	Eight participants will be administered 4 mg of nedocromil sodium to examine whether this drug can improve their oxyhemoglobin saturation during exercise.
287	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	5	202	\N
306	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	96	205	Empagliflozin is an oral hypoglycemic drug.
320	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	31	213	1 tablet 3 times a day
343	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	5	228	10mg tablets
359	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	4	240	Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of "rescue medication" (desloratadine 5 mg) in case of symptoms for 2 months.
370	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	9	242	\N
384	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	16	248	montelukast 10 mg tablet taken once daily at bed time for 2 weeks
391	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	5	255	Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
477	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	148	296	Midazolam 1 mg
484	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	63	295	Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
499	2023-01-02 15:22:35.923	2023-01-02 15:22:35.923	56	305	cetirizine 10 mg over encapsulated
527	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	169	320	Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).\n\nFor children who were >=2 to <6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.\nFor children who were >= 6 yrs to <12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.
568	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	8	334	1 or 2 330 mg/daily iron sulphate oral tablets
575	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	8	333	Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to <6 years of age and at a dose of 10 mg for children aged 6 to <18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score 4.
596	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	182	340	\N
617	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	56	343	Placebo sublingual tablet
629	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	140	350	Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
638	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	9	357	Rituximab is a chimeric mouse/human monoclonal immunoglobulin gamma-1 (IgG1) antibody which depletes cluster of differentiation antigen 20 (CD20)-positive cells. Rituximab is approved for non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangitis and microscopic polyangitis, and pemphigus vulgaris.
656	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	244	351	\N
678	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	254	362	A single dose is volume matched to Infliximab (250mL) infusion
696	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	189	378	Loratadine tablet 10 mg administered orally as needed for rescue medication.
711	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	145	379	\N
738	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	29	401	Pharmaceutical form:tablet Route of administration: oral
750	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	302	398	Given IV
794	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	44	403	\N
804	2023-01-02 15:22:35.982	2023-01-02 15:22:35.982	338	414	Mometasone furoate nasal spray is a quantitative hand-press spray device, and the content is a white to off-white suspension.\n\nThis product is suitable for the treatment of seasonal or perennial rhinitis in adults, adolescents and children from 3 to 11 years old. For patients who have had moderate to severe seasonal allergic rhinitis symptoms, it is recommended to use this product 2-4 weeks before the start of the pollen season Preventive treatment.
807	2023-01-02 15:22:35.998	2023-01-02 15:22:35.998	4	48	levocetirizine 5 mg daily x 8 days
88	2023-01-02 15:22:35.792	2023-01-02 15:22:35.792	8	72	loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
100	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	5	79	Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
114	2023-01-02 15:22:35.805	2023-01-02 15:22:35.805	41	91	Topical Minoxidil 5% that will be applied once daily.
125	2023-01-02 15:22:35.809	2023-01-02 15:22:35.809	3	104	Pharmaceutical form: Oral drops Route of administration: Oral use
176	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	3	129	5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months
205	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	25	151	\N
216	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	9	157	fexofenadine tablets 60 mg once daily will be taken for six months
270	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	25	186	\N
283	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	9	196	1 x 180 mg
328	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	9	218	Pharmaceutical form:tablet Route of administration: oral
336	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	25	223	\N
344	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	105	231	\N
377	2023-01-02 15:22:35.895	2023-01-02 15:22:35.895	5	250	Drug administration
436	2023-01-02 15:22:35.91	2023-01-02 15:22:35.91	57	279	\N
445	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	34	281	107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to oral famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
473	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	144	293	\N
518	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	99	310	Pharmaceutical form:tablet Route of administration: oral
538	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	44	324	Desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) Ranitidine 5ml (15mg/ml=75 mg) po bid
552	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	145	331	\N
559	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	183	329	Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg of omalizumab upon reconstitution with 1.4 ml sterile water for injection.
570	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	196	342	Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.
594	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	214	340	\N
615	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	5	347	Ascending single oral doses of 120, 240, and 420 mg modified-release tablets
628	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	233	350	\N
636	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	236	354	50mg/ml drug formulation
655	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	44	374	\N
663	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	8	360	MabThera 500 mg/m^2 or 1000 mg administered by IV on Day 1 and Day 15
765	2023-01-02 15:22:35.973	2023-01-02 15:22:35.973	313	420	3 vaginal administrations per day from the day of oocyte retrieval
810	2023-01-02 15:22:35.999	2023-01-02 15:22:35.999	4	51	Zyrtec (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
840	2023-01-02 15:22:36.013	2023-01-02 15:22:36.013	3	34	\N
89	2023-01-02 15:22:35.792	2023-01-02 15:22:35.792	31	72	loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
95	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	34	78	Participants will take placebos to match 10 mg of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
119	2023-01-02 15:22:35.807	2023-01-02 15:22:35.807	9	94	\N
157	2023-01-02 15:22:35.816	2023-01-02 15:22:35.816	4	121	Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
166	2023-01-02 15:22:35.819	2023-01-02 15:22:35.819	8	123	Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
195	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	63	142	Cetirizine tablet; 10 mg o.d.; for 2 weeks and 5 mg b.i.d.; for 2 weeks
206	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	16	147	Matching placebo tablet administered once daily
231	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	4	162	single dose for 7 days, oral, 5 mg
239	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	3	172	1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days
257	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	9	185	\N
277	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	4	187	Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
294	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	3	221	At the end of the HILD assessment participants will be randomized to Levocetirizine Dihydrochloride or placebo. Children will be randomized by an investigational pharmacist to add-on either Levocetirizine dihydrochloride/ Xyzal (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children >11 years per recommended doses) or placebo to their current asthma regimen.
308	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	9	209	Intervention:\n\nThe amount of study lotion (OP2101) used is 11 grams per subject, equivalent to 22 fingertip units (FTU). The lotion is applied to the subject on back and front of the trunk, both hands (palm and back) and both arms. An SOP for handling and application of the lotion ensures the 11 grams covers 54% of the body surface area (BSA) evenly without residue.\n\nComment:\n\nThe treatment is single-dose and single-treatment. The FTU is used to standardize the amount of cream being applied in clinical research. It is also used in clinical practice and hence connects the objectiveness of the trial to the clinical situation.
311	2023-01-02 15:22:35.878	2023-01-02 15:22:35.878	31	208	Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
337	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	24	223	\N
357	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	9	235	Pharmaceutical form:tablet Route of administration: oral
378	2023-01-02 15:22:35.895	2023-01-02 15:22:35.895	9	250	Drug Administration
383	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	9	249	Pharmaceutical form:dry syrup formulation to be suspended in water\n\nRoute of administration: oral
447	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	131	283	This group will be treated with steroid drugs. Oral prednisolone, 1 mg/kg body weight daily in two divided dose for 1 week followed by half mg/kg/day in two divided dose for next one week.
462	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	3	289	HGP0813 + HGP1408
514	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	161	313	CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
545	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	9	325	Placebo: Lactose capsules
573	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	140	333	Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.
578	2023-01-02 15:22:35.941	2023-01-02 15:22:35.941	5	336	ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
588	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	207	340	Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
603	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	221	346	DRV is a protease inhibitor (PI) indicated in the treatment of HIV infection.33 DRV requires coadministration with RTV (100 mg once or twice daily) or COBI (150 mg daily), the latter of which has been coformulated into a fixed-dose tablet with DRV (DRV/c 800/150 mg).
612	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	67	345	participants will receive oral premedication prior to infusion
641	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	159	374	Oral administration
657	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	49	351	25mg dose of Doxepin will be administered one time, by mouth
677	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	255	362	Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.
687	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	67	366	Phosphate buffered saline placebo for injection
725	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	250	390	Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
743	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	292	401	Pharmaceutical form:tablet Route of administration: oral
755	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	307	398	\N
773	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	326	400	Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
801	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	336	411	RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
821	2023-01-02 15:22:36.003	2023-01-02 15:22:36.003	4	46	fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
828	2023-01-02 15:22:36.007	2023-01-02 15:22:36.007	5	14	Clarinex 5 mg daily x 7 days
90	2023-01-02 15:22:35.792	2023-01-02 15:22:35.792	24	86	Desloratadine and pseudoephedrine 5/240 mg
99	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	4	73	administration of Desloratadine 5 mg/day for 4 weeks
129	2023-01-02 15:22:35.81	2023-01-02 15:22:35.81	5	102	The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.\n\nThis group will use Cetrizine 1% gel, which will be prepared at the department of Pharmaceutics, Faculty of Pharmacy, Assiut University in the form of Nano-transferosomes (NTF).
154	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	8	120	\N
163	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	50	127	Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
174	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	13	132	PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days
190	2023-01-02 15:22:35.834	2023-01-02 15:22:35.834	3	133	A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
221	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	57	153	\N
227	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	4	161	Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine
241	2023-01-02 15:22:35.852	2023-01-02 15:22:35.852	4	171	Placebo BID
260	2023-01-02 15:22:35.859	2023-01-02 15:22:35.859	3	183	1 tablet once nightly before visit
279	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	8	195	\N
313	2023-01-02 15:22:35.878	2023-01-02 15:22:35.878	29	219	Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
329	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	13	215	Placebo tablet to be taken orally once a day until stent removal.
338	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	83	227	Oral administration of 250 mg paracetamol
352	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	8	233	Pataday Once Daily Relief Extra Strength (eyedrop)
358	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	8	240	Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of "rescue medication" (Placebo) in case of symptoms for 2 months.
368	2023-01-02 15:22:35.887	2023-01-02 15:22:35.887	110	243	Copaxone injection 20 mg, oral placebo
395	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	3	256	Subjects in two arms, will be enrolled in a classical, randomized, double blind, crossover, placebo controlled trial of Levocetirizine(LCT) with determination of the PD response to LCT as determined by suppression of histamine microvasculature response via HILD.
409	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	5	265	1 drop in one eye at one timepoint
486	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	152	298	oral tablets, 50 mg
508	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	13	314	A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
547	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	34	325	H1 receptor antagonist: 540 mg Fexofenadine Hydrochloride
582	2023-01-02 15:22:35.943	2023-01-02 15:22:35.943	198	341	Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day
595	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	215	340	\N
604	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	222	346	INH is an antimycobacterial agent that can be used alone or in combination with RPT for the treatment of LTBI. Given with Pyridoxine (vitamin B6)
635	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	52	357	Premedication with oral fexofenadine 360 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
664	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	83	360	MK-8808 500 mg/m^2 administered by IV on Day 1 and Day 15 or MK-8808 1000 mg administered by IV at Week 54 and Week 56
679	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	258	362	\N
699	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	216	376	400 mg/m2, 2h infusion, d1, q2w
710	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	144	379	\N
716	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	285	383	Oral placebo Exercise training: Interval-based cycling exercise
731	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	140	391	Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years
746	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	294	401	\N
754	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	270	398	\N
767	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	321	394	All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
787	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	331	403	180 mcg; subcutaneous injection once weekly
813	2023-01-02 15:22:36	2023-01-02 15:22:36	8	56	Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
91	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	25	88	\N
142	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	8	112	\N
153	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	3	118	5 mg tablet once in a day
160	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	3	126	Montelukast sodium 10mg & levocetirizine dihydrochloride 5mg PO. Single dose.
201	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	24	145	Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
209	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	8	148	Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
226	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	4	159	Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)
236	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	5	169	10mg, single dose fed
240	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	81	173	Eight participants will be administered 10 mg of cetirizine HCl to examine whether this drug can improve their oxyhemoglobin saturation during exercise.
254	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	3	197	Pharmaceutical form: Over-encapsulated tablet\nConcentration: 10 mg\nRoute of administration: Oral use
302	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	21	211	a single oral dose of 5 mg
324	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	29	213	1 tablet 3 times a day
332	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	5	226	\N
348	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	5	229	1 drop in each eye at 2 separate times during a 14 day period
374	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	9	247	JMI-001, a combination product of naproxen and fexofenadine
386	2023-01-02 15:22:35.898	2023-01-02 15:22:35.898	5	258	GSK835726 10mg tablet
406	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	5	266	Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).\n\nDigital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
420	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	16	271	loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
453	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	3	283	\N
472	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	85	293	\N
487	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	3	300	Administered SC.
496	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	5	307	daily tablets
524	2023-01-02 15:22:35.928	2023-01-02 15:22:35.928	25	315	\N
526	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	8	320	1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
531	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	177	319	JNJ 56021927 will be administered once daily orally in a dose of 240 mg from Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
541	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	45	324	\N
600	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	165	339	Folic acid 1 mg orally every day beginning at Week -6 until prior to the Week 52 Visit.
616	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	72	343	Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score  4 during the GPS.
649	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	240	374	\N
688	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	260	366	A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
709	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	85	379	\N
717	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	148	382	Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
730	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	240	391	80/4.5 g per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
774	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	131	400	Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
809	2023-01-02 15:22:35.999	2023-01-02 15:22:35.999	5	9	Levocetirizine
814	2023-01-02 15:22:36	2023-01-02 15:22:36	9	57	\N
822	2023-01-02 15:22:36.003	2023-01-02 15:22:36.003	9	46	desloratadine, 5 mg oral tablets, once daily for 15 days
830	2023-01-02 15:22:36.008	2023-01-02 15:22:36.008	4	60	Zyrtec 10 mg daily x 7 days
837	2023-01-02 15:22:36.01	2023-01-02 15:22:36.01	13	59	one tablet, orally
93	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	4	88	\N
104	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	35	84	200  once daily
121	2023-01-02 15:22:35.808	2023-01-02 15:22:35.808	8	97	\N
130	2023-01-02 15:22:35.81	2023-01-02 15:22:35.81	9	106	fexofenadine brand name
139	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	8	108	Intervention is given to study its' effect on vinca alkaloids induced neuropathy
146	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	5	114	Cetirizine oral suspension
173	2023-01-02 15:22:35.82	2023-01-02 15:22:35.82	4	125	Placebo of desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
177	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	3	131	\N
179	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	57	130	\N
187	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	8	136	Montelukast 5mg mixed with Loratadine 5mg, one dose per day
281	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	85	194	Oral tablet.
289	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	8	200	Commercially available pegfilgrastim (Neulasta) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
316	2023-01-02 15:22:35.878	2023-01-02 15:22:35.878	99	219	\N
327	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	5	217	20 mg encapsulated tablets
400	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	8	262	Chewable tablet, oral, single dose
408	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	4	267	20 mg (encapsulated) tablets QD/14 days
413	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	49	269	\N
431	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	16	278	10 mg loratadine tablet given once daily at bedtime for 2 weeks
456	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	45	283	\N
475	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	9	296	the day of phenotyping assay\n\nColchicine : 1.5 mg over 1 hour (1 mg + 0.5 mg 1 hour later)
491	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	105	299	Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
513	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	140	317	In the refractory group (VAS score 7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),
546	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	45	327	\N
564	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	72	330	One sublingual tablet containing 12 units of Amb a 1-U, once daily (QD) for up to 35 weeks.
574	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	190	333	Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to <12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to <18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of 4 despite loratadine and mometasone furoate nasal spray.
580	2023-01-02 15:22:35.942	2023-01-02 15:22:35.942	72	337	Topical
585	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	206	340	Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
614	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	229	344	\N
644	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	5	374	Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
685	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	105	363	Daily 4000 unites vitamin D
703	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	272	376	6 mg/kg BW every 2 weeks
733	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	190	391	200 g per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
739	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	182	401	\N
789	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	330	403	ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.
798	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	45	404	All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
816	2023-01-02 15:22:36.001	2023-01-02 15:22:36.001	3	16	\N
94	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	5	77	Bioequivalence Cetirizine Hydrochloride 10 mg tablet
106	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	3	83	Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
109	2023-01-02 15:22:35.804	2023-01-02 15:22:35.804	25	92	\N
131	2023-01-02 15:22:35.81	2023-01-02 15:22:35.81	9	98	without sodium lauryl sulfate
148	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	3	116	Week 1 to week 5, every day : - the morning : 10 mg of levocetirizine (tablet)\n\nthe evening : 10 mg of levocetirizine(tablet)\n\nWeek 6 to week 10, every day : - the morning : 5 mg of levocetirizine (tablet)\n\nthe evening : placebo tablet
184	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	59	135	\N
194	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	3	141	\N
204	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	8	147	Montelukast 10 mg/loratadine 10 mg tablet administered once daily
213	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	67	149	01 tablet, orally, every 12 hours.
235	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	9	166	180mg, single dose fasting
244	2023-01-02 15:22:35.852	2023-01-02 15:22:35.852	78	171	Oxybutynin 2.5 mg BID
252	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	9	178	\N
259	2023-01-02 15:22:35.858	2023-01-02 15:22:35.858	5	181	1 drop in each eye at 3 separate times during a 21 day period
266	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	4	191	Desloratadine 5 mg tablets
278	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	16	195	\N
288	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	9	203	\N
312	2023-01-02 15:22:35.878	2023-01-02 15:22:35.878	99	208	\N
322	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	16	214	\N
349	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	5	230	1 drop in each eye at 2 separate times during a 14 day period
360	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	5	238	\N
379	2023-01-02 15:22:35.895	2023-01-02 15:22:35.895	114	250	Drug administration
388	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	8	255	Levocetirizine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
396	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	5	264	GSK835726 (10mg) tablet
407	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	72	266	Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).\n\nDigital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
441	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	45	282	\N
451	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	69	283	\N
464	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	140	291	Placebo of cortancyl Oral Tablet 20mg
519	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	8	310	Pharmaceutical form:tablet Route of administration: oral
554	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	9	331	\N
569	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	197	342	Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
592	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	212	340	\N
599	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	216	339	Oral MTX 15 mg weekly
648	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	238	374	\N
701	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	266	392	Patients with HER2 negative metastatic or locally advanced MpBC, will receive a combination of an iNOS inhibitor, nab-paclitaxel and alpelisib . As prophylaxis against deep venous thrombosis and hypertension, patients will receive aspirin (81 mg po daily) and amlodipine (10 mg po Days 0-5 each cycle). Metformin will be initiated at 500 mg once daily starting one week prior to treatment to reduce risk of severe hyperglycemia. Based on tolerability and serial blood sugar assessments, metformin dose will be increased to 500 mg twice daily, followed by 500 mg with breakfast and 1000 mg with dinner, followed by further increase to 1000 mg twice daily if needed. Insulin sensitizers and/or SGLT2i will be used as second anti-diabetic agents, if necessary. For prophylaxis of alpelisib rash, patients will be treated with an anti-histamine (cetirizine 10 mg daily) along with alpelisib.
777	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	45	400	\N
784	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	216	402	pegloticase administered intravenously (IV)
786	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	321	403	0.5 mg once daily; oral
826	2023-01-02 15:22:36.005	2023-01-02 15:22:36.005	4	47	Zyrtec 10 mg daily x 7 days
838	2023-01-02 15:22:36.011	2023-01-02 15:22:36.011	8	52	loratadine 10 mg capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
96	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	5	78	Participants will take 10 milligrams (mg) of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
105	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	3	85	\N
111	2023-01-02 15:22:35.803	2023-01-02 15:22:35.803	3	87	One tablet 5 mg taken orally at night for 28 days
162	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	52	127	\N
217	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	4	150	Every day,per mouth,in the evening, for 14 +- 2 days.
224	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	8	158	6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
237	2023-01-02 15:22:35.852	2023-01-02 15:22:35.852	79	171	Placebo BID
255	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	4	180	\N
258	2023-01-02 15:22:35.859	2023-01-02 15:22:35.859	5	183	5 mg once nightly before visit
297	2023-01-02 15:22:35.874	2023-01-02 15:22:35.874	5	210	Natural product number : 00501190
321	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	5	220	1 drop in each eye at 2 separate times during a 14 day period
333	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	5	222	\N
342	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	9	224	Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
365	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	5	237	A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits
380	2023-01-02 15:22:35.895	2023-01-02 15:22:35.895	5	246	\N
455	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	68	283	\N
463	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	16	289	HCP1102
474	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	145	293	\N
481	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	151	294	continuation of pre-study treatment regimen
506	2023-01-02 15:22:35.925	2023-01-02 15:22:35.925	160	306	Each group administered Fexofenadine 30mg under fasting conditions.
517	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	166	310	Pharmaceutical form:injection Route of administration: subcutaneous
530	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	171	320	\N
537	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	4	324	500 mg Oat flour
556	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	8	329	Placebo to omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg placebo to omalizumab upon reconstitution with 1.4 ml sterile water for injection.
607	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	220	346	RPT is a long-acting rifamycin used in combination with INH in the treatment of LTBI.
626	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	231	349	Standard dose (400 g/daily as 100 g 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
645	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	8	374	\N
658	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	50	351	50 mg dose of Diphenhydramine will be administered one time, by mouth
682	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	205	363	\N
702	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	269	376	400 mg/m2 bolus iv, d1, q2w
740	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	291	401	Pharmaceutical form:solution Route of administration: intravenous
757	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	308	398	\N
831	2023-01-02 15:22:36.009	2023-01-02 15:22:36.009	12	45	1 Cetirizine 10mg tablet per day before bedtime for 14 days.
116	2023-01-02 15:22:35.805	2023-01-02 15:22:35.805	8	93	Take Prapchompoothaweep remedy capsule at 1,000 mg for 3 times a day before meals.
143	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	8	113	Subject will be given 10mg Claritin tablet.
152	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	3	140	5mg daily (oral tablet) for 14 days
159	2023-01-02 15:22:35.816	2023-01-02 15:22:35.816	16	126	Montelukast sodium 10mg. PO. Single dose.
168	2023-01-02 15:22:35.82	2023-01-02 15:22:35.82	54	125	Desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
203	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	8	151	Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
215	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	69	149	\N
246	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	13	175	Placebo
256	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	9	179	\N
261	2023-01-02 15:22:35.859	2023-01-02 15:22:35.859	8	184	\N
290	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	9	201	\N
318	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	4	213	\N
356	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	3	241	Combination therapy compared to mono therapy
373	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	24	260	tablet, BID everyday
404	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	3	266	\N
417	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	118	270	fexofenadine 60 mg daily for 12 weeks
427	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	16	276	cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
432	2023-01-02 15:22:35.905	2023-01-02 15:22:35.905	49	280	Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of ~2 minutes
466	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	5	288	arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
476	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	85	296	Fexofenadine 120 mg
490	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	54	295	Aprepitant (NK1-antagonist): hard capsule (1 x 125 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
502	2023-01-02 15:22:35.925	2023-01-02 15:22:35.925	142	306	During 4~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.
548	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	44	327	Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
567	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	194	334	\N
589	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	211	340	\N
606	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	224	346	\N
613	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	228	344	\N
642	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	57	374	Topical
666	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	217	360	Methylprednisolone 100 mg administered IV before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
704	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	270	376	2400 mg/m2 46-h infusion, d1-2, q2w
737	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	67	401	Pharmaceutical form:tablet Route of administration: oral
752	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	303	398	Given IV
768	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	322	394	All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
842	2023-01-02 15:22:36.014	2023-01-02 15:22:36.014	8	74	Loratadine 10mg/day added to rapamycin for 12 months
117	2023-01-02 15:22:35.806	2023-01-02 15:22:35.806	5	95	The study drug is Xyzal 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).
150	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	8	117	30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
170	2023-01-02 15:22:35.82	2023-01-02 15:22:35.82	55	125	Placebo of aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
185	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	60	135	\N
192	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	3	138	5 mg daily (oral tablet) for 14 days
214	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	4	152	Desloratadine 5 mg once daily
219	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	5	155	Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
229	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	8	164	The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.\n\nThe experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD
249	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	16	176	cetirizine
267	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	4	193	Desloratadine 5 mg tablets
280	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	9	194	Oral tablet.
296	2023-01-02 15:22:35.874	2023-01-02 15:22:35.874	50	210	Drug identification number : 02231603
309	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	4	208	\N
335	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	5	223	\N
405	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	68	266	Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).\n\nDigital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment.
428	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	68	272	Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
434	2023-01-02 15:22:35.905	2023-01-02 15:22:35.905	5	277	Single oral dose of JNJ-39758979 600 mg and Placebo
459	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	68	284	Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
483	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	152	294	\N
492	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	159	299	\N
495	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	9	304	Injection solution SC
501	2023-01-02 15:22:35.925	2023-01-02 15:22:35.925	9	306	Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.
511	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	9	317	125 mg on day 1; 80 mg on day 3; 80 mg on day 5
566	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	195	334	\N
608	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	83	345	mRNA-based biologic
639	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	105	374	Oral administration
676	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	140	362	30 to 60 minutes prior to the start of the infusion\n\nTylenol, 600 to 1000mg by mouth or\nSuppository form
713	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	52	380	Rituximab 500 mg, dissolved in 250 ml NaCl in an infusion bag, covered with non-see-through plastic\n\nadministered iv over a course of max 180 minutes\nat 0 and 4 months (treatment-first arme) OR at 8 and 12 months (placebo-first arm)
718	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	45	383	H1 blockade: oral blockade Exercise training: Interval-based cycling exercise
745	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	166	401	Pharmaceutical form:tablet Route of administration: oral
761	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	188	398	\N
778	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	44	400	\N
797	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	44	404	All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
815	2023-01-02 15:22:36	2023-01-02 15:22:36	5	56	Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
829	2023-01-02 15:22:36.008	2023-01-02 15:22:36.008	5	60	Clarinex 5 mg daily x 7 days
138	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	3	100	\N
161	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	49	127	Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
167	2023-01-02 15:22:35.82	2023-01-02 15:22:35.82	8	125	aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
264	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	68	189	\N
273	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	25	188	\N
284	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	9	199	1 x 180 mg
299	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	4	245	\N
307	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	5	206	Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.
362	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	56	239	Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally
371	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	25	260	\N
394	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	3	292	Encapsulated 20 mg Tablet. Once daily for 28 days
412	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	117	268	Histamine receptor antagonist
421	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	8	275	Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
439	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	5	282	Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy
446	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	72	283	One spray in each nostril once daily for one month
467	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	4	290	2.5 ml (1.25 mg) once daily
482	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	150	294	Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
489	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	8	303	40 mg tab twice daily by mouth for 12 week duration
504	2023-01-02 15:22:35.925	2023-01-02 15:22:35.925	85	306	During 4~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.
515	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	164	310	Pharmaceutical form:tablet Route of administration: oral
525	2023-01-02 15:22:35.928	2023-01-02 15:22:35.928	24	315	\N
532	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	178	319	Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.
534	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	50	352	\N
542	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	44	332	\N
565	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	145	334	This is not an intervention of interest, but it is a selection criterion to define unexplained cough, as suggested by cough guidelines.
581	2023-01-02 15:22:35.943	2023-01-02 15:22:35.943	200	341	\N
622	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	190	343	Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
633	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	45	350	\N
684	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	159	363	\N
692	2023-01-02 15:22:35.959	2023-01-02 15:22:35.959	183	372	For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season.
714	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	16	393	4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
715	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	284	381	NK1 receptor antagonist
721	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	233	386	Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
724	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	50	390	SC Injection
741	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	293	401	\N
759	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	59	398	Given IV
775	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	325	400	Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
802	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	188	411	The placebo for rush immunotherapy will contain the diluents and histamine.
820	2023-01-02 15:22:36.003	2023-01-02 15:22:36.003	4	12	Allegra 180 mg daily x 7 days
836	2023-01-02 15:22:36.01	2023-01-02 15:22:36.01	8	59	loratadine, one 10 mg tablet, orally
841	2023-01-02 15:22:36.014	2023-01-02 15:22:36.014	23	74	Placebo in the same type of capsule than the experimental drug
683	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	259	363	Daily 600 unites vitamin D
707	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	9	379	The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
719	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	233	389	375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.
729	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	238	391	Sublingual immunotherapy once daily for 2 years
776	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	327	400	\N
790	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	333	403	All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.
799	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	307	411	The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
694	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	72	378	MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.
728	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	235	390	Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
748	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	299	396	Participants with AN will undergo three PET scans at two separate time points. The first scan will occur when participants are underweight (but not less than 75% ideal body weight), and the second and third scans will occur 2 to 4 weeks after participants have accomplished weight restoration. Healthy participants will have two PET scans at a single timepoint.
763	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	304	398	\N
785	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	217	402	oral MTX
791	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	322	403	\N
795	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	321	404	ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
800	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	183	411	A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
812	2023-01-02 15:22:35.998	2023-01-02 15:22:35.998	3	48	desloratadine 5 mg daily x 8 days
818	2023-01-02 15:22:36.003	2023-01-02 15:22:36.003	9	12	Clarinex 5 mg daily x 7 days
825	2023-01-02 15:22:36.005	2023-01-02 15:22:36.005	5	47	Clarinex 5 mg daily x 7 days
832	2023-01-02 15:22:36.009	2023-01-02 15:22:36.009	3	45	1 Placebo-Levocetirizine tablet per day before bedtime for 14 days
839	2023-01-02 15:22:36.013	2023-01-02 15:22:36.013	3	30	\N
73	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	9	61	Fexofenadine will be administered to patients.
151	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	5	118	5 mg tablet once in a day
188	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	3	135	\N
196	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	9	144	This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.
207	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	5	174	levocetirizine 10 mg/day + tranexamic acid 2 g/day
247	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	9	175	Fexofenadine 1%
268	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	8	186	Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
282	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	84	194	Oral syrup.
298	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	92	201	\N
367	2023-01-02 15:22:35.887	2023-01-02 15:22:35.887	111	243	\N
376	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	87	247	Naproxen sodium 220mg
392	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	9	259	PF-03654764 single dose 5 mg
399	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	25	261	\N
414	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	50	269	\N
422	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	8	274	montelukast 10 mg tablet orally once daily in the morning for 4 weeks
460	2023-01-02 15:22:35.914	2023-01-02 15:22:35.914	137	287	Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.
469	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	141	293	\N
480	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	119	297	One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.
510	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	54	317	In the refractory group (VAS score 7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)
521	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	45	322	Systemic antihistamine oral drug such as fexofenadine, loratadine and cetirizine.
553	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	143	331	\N
593	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	213	340	\N
598	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	83	339	IV pegloticase 8 mg Q2W
621	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	106	343	Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
627	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	83	350	Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
652	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	241	374	\N
670	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	50	362	Administered at a target dose of 2000mg daily, as tolerated, until study closure
686	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	8	366	Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
706	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	143	379	\N
760	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	306	398	\N
805	2023-01-02 15:22:35.984	2023-01-02 15:22:35.984	183	412	Omalizumab were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
\.


--
-- Data for Name: Location; Type: TABLE DATA; Schema: public; Owner: tim
--

COPY public."Location" (id, "createdAt", "updatedAt", city, country, facility) FROM stdin;
1	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kagoshima	japan	gsk investigational site
2	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bridgewater	united states	sanofi-aventis
3	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gyeunggi-do	korea, republic of	\N
4	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kyeonggi-do	korea, republic of	\N
5	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	\N
6	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nashville	united states	vanderbilt university asthma, sinus, and allergy clinic
7	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	brewer	united states	cancer care of maine
8	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	scarborough	united states	maine center for cancer medicine
9	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	york	united states	york hospital
10	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	glens falls	united states	cr wood cancer center
11	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	united states	mountainview medical center
12	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	burlington	united states	vermont cancer center
13	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	colchester	united states	vermont center for cancer medicine
14	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	brugge	belgium	\N
15	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	brussels	belgium	\N
16	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	liege	belgium	\N
17	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	merksem	belgium	\N
18	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sint-niklaas	belgium	\N
19	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	woluwe-st-lamb	belgium	\N
20	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bernay	france	\N
21	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	besancon	france	\N
22	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hyeres	france	\N
23	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	les milles	france	\N
24	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	marseille	france	\N
25	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montpellier	france	\N
26	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nancy	france	\N
27	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nantes	france	\N
28	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nice	france	\N
29	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nimes	france	\N
30	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	paris	france	\N
31	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	poitiers	france	\N
32	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	quimper	france	\N
33	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint-mande	france	\N
34	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	troyes	france	\N
35	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	valence	france	\N
36	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	villejuif	france	\N
37	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	augsburg	germany	\N
38	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	germany	\N
39	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dresden	germany	\N
40	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dusseldorf	germany	\N
41	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	erlangen	germany	\N
42	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gottingen	germany	\N
43	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hamburg	germany	\N
44	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hannover	germany	\N
45	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	koln	germany	\N
46	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	leipzig	germany	\N
47	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mahlow	germany	\N
48	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mainz	germany	\N
49	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	munchen	germany	\N
50	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	viersen	germany	\N
51	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	caserta	italy	\N
52	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	catania	italy	\N
53	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cesena	italy	\N
54	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	genova	italy	\N
55	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	modena	italy	\N
56	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	palermo	italy	\N
57	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pavia	italy	\N
58	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	roma	italy	\N
59	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	siena	italy	\N
60	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	udine	italy	\N
61	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	verona	italy	\N
62	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	johor bharu	malaysia	\N
63	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kelantan	malaysia	\N
64	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kuala lumpur	malaysia	\N
65	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	negeri sembilan	malaysia	\N
66	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	perak	malaysia	\N
67	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pulau pinang	malaysia	\N
68	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sarawak	malaysia	\N
69	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	brasov	romania	\N
70	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bucharest	romania	\N
71	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dolj	romania	\N
72	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sibiu	romania	\N
73	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cape town	south africa	\N
74	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	durban	south africa	\N
75	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lenasia	south africa	\N
76	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	albacete	spain	\N
77	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	\N
78	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	coruna	spain	\N
79	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	granada	spain	\N
80	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	madrid	spain	\N
81	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	malaga	spain	\N
82	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	murcia (el palmar)	spain	\N
83	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	oviedo	spain	\N
84	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	santiago de compostela	spain	\N
85	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sevila	spain	\N
86	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	valencia	spain	\N
87	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	amersham	united kingdom	\N
88	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cardiff	united kingdom	\N
89	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	irvine	united kingdom	\N
90	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	leicester	united kingdom	\N
91	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	london	united kingdom	\N
92	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nuneaton	united kingdom	\N
93	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	salford	united kingdom	\N
94	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	germany	university of berlin charit, department of dermatology and allergy
95	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	illkirch	france	\N
96	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	\N
97	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sainte-foy quebec	canada	anapharm inc.,
98	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new york	united states	icahn school of medicine at mount sinai
99	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rennes cedex 9	france	research site
100	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seongnam-si	korea, republic of	research site
101	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	research site
102	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	madrid	spain	research site
103	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sevilla	spain	research site
104	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hyderabad	india	vimta labs ltd.,
105	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	neu-ulm	germany	\N
106	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sofia	bulgaria	medical university sofia, department of allergology
107	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hospitalet de llobregat	spain	university hospital of bellvitge
108	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	hospital vall d'hebron
109	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	madrid	spain	hospital la princes
110	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	madrid	spain	hospital puerta de hierro
111	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	santander	spain	hospital marqus de valdecillas
112	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sevilla	spain	hospital virgen del roco
113	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	winston-salem	united states	wake forest university health sciences, department of dermatology
114	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	valinhos	brazil	lal clnica pesquisa e desenvolvimento ltda
115	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	taipei	taiwan	department of dermatology national taiwan university hospital
116	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kingston	canada	\N
117	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chiba	japan	gsk investigational site
118	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tokyo	japan	gsk investigational site
119	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ft. myers	united states	sfbc, ft. myers, inc.,
120	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ahmedabad	india	veeda clinical research pvt. ltd.,
121	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	vienna	austria	allergy center vienna west
122	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	morrisville	united states	aaipharma inc.- aai clinic
123	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	london	canada	london health sciences centre
124	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	balanagar	india	bioserve clinical research private limited
125	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	broadway	united states	sfbc ft myers inc
126	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	winston-salem	united states	comprehensive cancer center of wake forest university
127	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	so paulo	brazil	eurofarma laboratorios s.a
128	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	los angeles	united states	california allergy and asthma medical group
129	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	fukuoka	japan	gsk investigational site
130	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	baltimore	united states	bioanalytical systems, inc.
131	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sainte-foy (quebec)	canada	sfbc anapharm
132	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	baltimore	united states	bioanalytical systems, inc
133	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	atlanta	united states	emory university hospital at wesley woods covid-19 testing facility
134	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	atlanta	united states	emory healthcare network peachtree immediate care covid-19 testing centers
135	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	handok pharmaceuticals co. ltd
136	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	redwood city	united states	stanford health care
137	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	birmingham	united states	\N
138	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	little rock	united states	\N
139	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beverly hills	united states	\N
140	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	crescent city	united states	\N
141	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	huntington beach	united states	\N
142	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mission viejo	united states	\N
143	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san diego	united states	\N
144	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wildomar	united states	\N
145	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	denver	united states	\N
146	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pueblo	united states	\N
147	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	savannah	united states	\N
148	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	stockbridge	united states	\N
149	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	normal	united states	\N
150	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	overlook park	united states	\N
151	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	owensboro	united states	\N
152	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	metarie	united states	\N
153	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	baltimore	united states	\N
154	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	omaha	united states	\N
155	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	papillon	united states	\N
156	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	oklahoma city	united states	\N
157	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	medford	united states	\N
158	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	portland	united states	\N
159	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barnwell	united states	\N
160	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	charleston	united states	\N
161	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dallas	united states	\N
162	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	el paso	united states	\N
163	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new braunfels	united states	\N
164	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	richmond	united states	\N
165	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hot springs	united states	\N
166	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jonesboro	united states	\N
167	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bakersfield	united states	\N
168	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	los angeles	united states	\N
169	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	orange	united states	\N
170	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	roseville	united states	\N
171	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	stockton	united states	\N
172	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	albany	united states	\N
173	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gainesville	united states	\N
174	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bridgeton	united states	\N
175	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	spartanburg	united states	\N
176	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kingsport	united states	\N
177	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	austin	united states	\N
178	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san antonio	united states	\N
179	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sugarland	united states	\N
180	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mount-royal	canada	algorithme (an altascience company)
181	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	louisville	united states	dermresearch, pllc
182	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montreal	canada	mds pharma services
183	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cairo	egypt	al-kasr al-ainy outpatient dermatology clinic
184	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	khlong luang	thailand	thammasat university
185	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	aachen	germany	hno-praxis dr. pasch/prof. schlndorff
186	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	st. laurent	canada	mds pharma services
187	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	assiut	egypt	assiut university
188	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san francisco	united states	ucsf ctsi crc
189	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	portland	united states	providence neurological specialties west
190	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dallas	united states	lexicon investigational site
191	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	edmonton	canada	cross cancer institute
192	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	makati city	philippines	sanofi-aventis administrative office
193	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chicago	united states	university of chicago
194	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bronx	united states	jacobi medical center
195	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ann arbor	united states	the university of michigan
196	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	khlong luang	thailand	faculty of medicine
197	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	scottsdale	united states	\N
198	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	long beach	united states	\N
199	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lilburn	united states	\N
200	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	metairie	united states	\N
201	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	winston-salem	united states	\N
202	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tulsa	united states	\N
203	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	knoxville	united states	\N
204	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	fort worth	united states	\N
205	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	katy	united states	\N
206	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	plano	united states	\N
207	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san angelo	united states	\N
208	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	waco	united states	\N
209	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ahmedabad	india	accutest research lab (i) pvt. ltd.
210	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new brunswick	united states	rutgers cancer institute of new jersey
211	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new brunswick	united states	rwjbarnabas health - robert wood johnson university hospital, new brunswick
212	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	coral gables	united states	aaadrs
213	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	samsung medical center
214	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	napa	united states	st.joseph heritage care
215	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rancho mirage	united states	eisenhower medical center
216	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	santa rosa	united states	st. joseph heritage healthcare
217	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	houston	united states	oncology consultants
218	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	round rock	united states	baylor, scott, & white medical center
219	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	temple	united states	baylor, scott, & white medical center
220	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	waco	united states	baylor, scott, & white medical center
221	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	changsha	china	xiangya hospital central south university
222	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	guangzhou	china	cancer center of sun-yat sen university (ccsysu)
223	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bucheon	korea, republic of	soonchunhyang university bucheon hospital
224	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	north adelaide	australia	\N
225	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	parkville (north melbourne)	australia	\N
226	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bruxelles	belgium	\N
227	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	brno	czech republic	\N
228	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hradec kralove	czech republic	\N
229	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	olomouc	czech republic	\N
230	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ostrava 9	czech republic	\N
231	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	plezen-lochotin	czech republic	\N
232	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	praha 5	czech republic	\N
233	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	praha 8	czech republic	\N
234	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	martigues	france	\N
235	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint-etienne cedex 2	france	\N
236	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tarbes cedex	france	\N
237	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	toulouse cedex 3	france	\N
238	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bayreuth	germany	\N
239	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bielefeld	germany	\N
240	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bochum	germany	\N
241	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wesel	germany	\N
242	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ancona	italy	\N
243	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bari	italy	\N
244	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bologna	italy	\N
245	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	messina	italy	\N
246	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	milano	italy	\N
247	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	napoli	italy	\N
248	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bialystock	poland	\N
249	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gdansk	poland	\N
250	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	karpacz	poland	\N
251	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lodz	poland	\N
252	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lublin	poland	\N
253	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rabka zdroj	poland	\N
254	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	warszawa	poland	\N
255	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wroclaw	poland	\N
256	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bellville	south africa	\N
257	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	clarement	south africa	\N
258	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mowbray	south africa	\N
259	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pietermaritzburg	south africa	\N
260	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sydenham	south africa	\N
261	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	west honeydew	south africa	\N
262	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	westville	south africa	\N
263	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wynberg	south africa	\N
264	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	espluques de llobreqat	spain	\N
265	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dorchester	united kingdom	\N
266	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	enfield	united kingdom	\N
267	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	southampton	united kingdom	\N
268	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	singapore	singapore	pfizer clinical research unit
269	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mississauga	canada	\N
270	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	little rock	united states	gsk investigational site
271	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	albany	united states	gsk investigational site
272	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	columbus	united states	gsk investigational site
273	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lawrenceville	united states	gsk investigational site
274	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chicago	united states	gsk investigational site
275	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	normal	united states	gsk investigational site
276	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	evansville	united states	gsk investigational site
277	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	indianapolis	united states	gsk investigational site
278	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lafayette	united states	gsk investigational site
279	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	south bend	united states	gsk investigational site
280	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	iowa city	united states	gsk investigational site
281	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	louisville	united states	gsk investigational site
282	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	owensboro	united states	gsk investigational site
283	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	metairie	united states	gsk investigational site
284	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sunset	united states	gsk investigational site
285	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	novi	united states	gsk investigational site
286	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ypsilanti	united states	gsk investigational site
287	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	minneapolis	united states	gsk investigational site
288	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	plymouth	united states	gsk investigational site
289	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jackson	united states	gsk investigational site
290	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	columbia	united states	gsk investigational site
291	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rolla	united states	gsk investigational site
292	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	st. louis	united states	gsk investigational site
293	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	warrensburg	united states	gsk investigational site
294	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lincoln	united states	gsk investigational site
295	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	omaha	united states	gsk investigational site
296	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	papillion	united states	gsk investigational site
297	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	canton	united states	gsk investigational site
298	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cincinnati	united states	gsk investigational site
299	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sylvania	united states	gsk investigational site
300	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	oklahoma city	united states	gsk investigational site
301	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pittsburgh	united states	gsk investigational site
302	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	charleston	united states	gsk investigational site
303	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	orangeburg	united states	gsk investigational site
304	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	spartanburg	united states	gsk investigational site
305	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	knoxville	united states	gsk investigational site
306	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	waco	united states	gsk investigational site
307	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	greenfield	united states	gsk investigational site
308	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	milwaukee	united states	gsk investigational site
309	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	west allis	united states	gsk investigational site
310	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	germany	allergie-centrum-charite
311	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	st. louis	united states	washington university school of medicine
312	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	victoria	canada	university of victoria
313	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	taipei	taiwan	tri-service genaral hospital
314	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tucson	united states	\N
315	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sacramento	united states	\N
316	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san francisco	united states	\N
317	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san jose	united states	\N
318	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	colorado springs	united states	\N
319	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	miami	united states	\N
320	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	atlanta	united states	\N
321	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lawrenceville	united states	\N
322	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	louisville	united states	\N
323	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	harvard	united states	\N
324	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	north dartmouth	united states	\N
325	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	novi	united states	\N
326	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	minneapolis	united states	\N
327	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	united states	\N
328	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	skillman	united states	\N
329	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	verona	united states	\N
330	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rochester	united states	\N
331	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	asheville	united states	\N
332	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	charlotte	united states	\N
333	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wilmington	united states	\N
334	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cincinnati	united states	\N
335	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	edmond	united states	\N
336	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pittsburgh	united states	\N
337	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	upland	united states	\N
338	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lincoln	united states	\N
339	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	germantown	united states	\N
340	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	salt lake city	united states	\N
341	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	south burlington	united states	\N
342	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	arlington	united states	\N
343	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	milwaukee	united states	\N
344	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chapel hill	united states	north carolina clinical and translational research center
345	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	secaucus	united states	frontage clinical services
346	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	grenoble	france	chu grenoble-alpes
347	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	khlong luang,	thailand	thammasat university hospital
348	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	campinas	brazil	allergisa pesquisa dermato cosmtica ltda.
349	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tanta	egypt	faculty of pharmacy, tanta university
350	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	germany	department of dermatology, venerology and allergology
351	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	canada	canada	investigational site number
352	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	denver	united states	gsk investigational site
353	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	aventura	united states	gsk investigational site
354	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	miami	united states	gsk investigational site
355	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lenexa	united states	gsk investigational site
356	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	overland park	united states	gsk investigational site
357	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	baltimore	united states	gsk investigational site
358	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bethesda	united states	gsk investigational site
359	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	north dartmouth	united states	gsk investigational site
360	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint louis	united states	gsk investigational site
361	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bellevue	united states	gsk investigational site
362	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	austin	united states	gsk investigational site
363	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dallas	united states	gsk investigational site
364	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kerrville	united states	gsk investigational site
365	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san antonio	united states	gsk investigational site
366	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	south burlington	united states	gsk investigational site
367	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new braunfels	united states	gsk investigational site
368	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	houston	united states	university of texas md anderson cancer center
369	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	peking union medical college hospital traditional chinese medicine department
370	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	germany	allergie-centrum-charit berlin
371	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	andover	united states	ora, inc.
372	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	morgantown	united states	kendle international inc.
373	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	houston	united states	novum pharmaceutical research services
374	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dsseldorf	germany	institut fr atemwegsforschung gmbh
375	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bloomington	united states	1025 e seventh st
376	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	handok
377	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	paramus	united states	tkl research
378	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lodz	poland	department of pediatrics and allergy, medical university of lodz lodz, poland
379	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chengdu	china	department of orl, west china hospital, sichuan hospital
380	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bridgewater	united states	aventis pharmaceuticals inc.
381	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	costa rica	costa rica	sanofi-aventis admnistrative office
382	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	guatemala city	guatemala	sanofi-aventis administrative office
383	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	budapest	hungary	sanofi-aventis hungaria
384	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mexico	mexico	sanofi-aventis administrative office
385	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	warszawa	poland	sanofi-aventis poland
386	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	moscow	russian federation	sanofi-aventis aministrative office
387	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	budapest	hungary	sanofi-aventis administrative office
388	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	warszawa	poland	sanofi-aventis administrative office
389	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	moscow	russian federation	sanofi-aventis administrative office
390	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dundee	united kingdom	ninewells hospital and medical school (tayside nhs trust, university of dundee)
391	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	perth	united kingdom	perth royal infirmary
392	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sorocaba	brazil	clinica de alergia martti antila
393	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	so paulo	brazil	eurofarma laboratrios s.a
394	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	auckland	new zealand	clinical trial site
395	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	fargo	united states	pracs institute, ltd.
396	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	muscle shoals	united states	research site
397	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	anaheim	united states	research site
398	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	fullerton	united states	research site
399	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	santa maria	united states	research site
400	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	santa rosa	united states	research site
401	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	torrance	united states	research site
402	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	whittier	united states	research site
403	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	denver	united states	research site
404	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	golden	united states	research site
405	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	littleton	united states	research site
406	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	norwich	united states	research site
407	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	stamford	united states	research site
408	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	boynton beach	united states	research site
409	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	daytona beach	united states	research site
410	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	fort lauderdale	united states	research site
411	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lakeland	united states	research site
412	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new port richey	united states	research site
413	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	plantation	united states	research site
414	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	stuart	united states	research site
415	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	augusta	united states	research site
416	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	thomasville	united states	research site
417	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	elmhurst	united states	research site
418	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gurnee	united states	research site
419	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mount vernon	united states	research site
420	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	skokie	united states	research site
421	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	urbana	united states	research site
422	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	indianapolis	united states	research site
423	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	south bend	united states	research site
424	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sioux city	united states	research site
425	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	waterloo	united states	research site
426	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hutchinson	united states	research site
427	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lexington	united states	research site
428	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	louisville	united states	research site
429	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mount sterling	united states	research site
430	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	paducah	united states	research site
431	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	alexandria	united states	research site
432	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lafayette	united states	research site
433	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	marrero	united states	research site
434	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	shreveport	united states	research site
435	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cumberland	united states	research site
436	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	randallstown	united states	research site
437	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rockville	united states	research site
438	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	westminster	united states	research site
439	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lowell	united states	research site
440	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	battle creek	united states	research site
441	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	duluth	united states	research site
442	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint cloud	united states	research site
443	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jackson	united states	research site
444	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jefferson city	united states	research site
445	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kansas city	united states	research site
446	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint joseph	united states	research site
447	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint louis	united states	research site
448	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	billings	united states	research site
449	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	omaha	united states	research site
450	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nashua	united states	research site
451	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	denville	united states	research site
452	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	east syracuse	united states	research site
453	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	johnson city	united states	research site
454	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gastonia	united states	research site
455	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hickory	united states	research site
456	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pinehurst	united states	research site
457	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	massillon	united states	research site
458	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	zanesville	united states	research site
459	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bend	united states	research site
460	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bethlehem	united states	research site
461	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	langhorne	united states	research site
462	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	florence	united states	research site
463	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	watertown	united states	research site
464	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bristol	united states	research site
465	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chattanooga	united states	research site
466	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	corpus christi	united states	research site
467	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	plano	united states	research site
468	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ogden	united states	research site
469	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chesapeake	united states	research site
470	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	spokane	united states	research site
471	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	huntington	united states	research site
472	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	janesville	united states	research site
473	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	madison	united states	research site
474	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	racine	united states	research site
475	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wauwatosa	united states	research site
476	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	weston	united states	research site
477	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ban suwayf	egypt	beni-suef hospital
478	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ban suwayf	egypt	faculty of medicine - beni suef hospital
479	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bridgewater	united states	aventis pharmaceutical inc.
480	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kansas city	united states	children's mercy hospital
481	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montral	canada	ciusss de l'est-de-l'le-de-montral
482	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hokkaido	japan	gsk investigational site
483	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kanagawa	japan	gsk investigational site
484	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kumamoto	japan	gsk investigational site
485	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	oita	japan	gsk investigational site
486	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saitama	japan	gsk investigational site
487	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	shizuoka	japan	gsk investigational site
488	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saskatoon	canada	room 346 ellis hall
489	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san antonio	united states	biogenics research chamber
490	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kingston	canada	kingston general hospital
491	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	den helder	netherlands	royal netherlands navy
492	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mansoura	egypt	mansoura university
493	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dhaka	bangladesh	bct ltd.
494	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	smyrna	united states	ucb pharma
495	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	so paulo	brazil	alergoalpha
496	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	campinas	brazil	allergisa
497	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	so paulo	brazil	hospital nipo brasileiro
498	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	andover	united states	ora clinical site network
499	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	so paulo	brazil	ima - instituto de pesquisa clnica e medicina avanada
500	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new york	united states	columbia university irving medical center/nyp
501	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	koganei-shi	japan	investigational site number 392002
502	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	osaka-shi	japan	investigational site number 392003
503	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	shinjuku-ku	japan	investigational site number 392001
504	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hannover	germany	fraunhofer-institute of toxicology and experimental medicine
505	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bad rothenfelde	germany	schchtermann klinik
506	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	vigo	spain	hospital alvaro cunqueiro
507	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	vienna	austria	vienna clinical site
508	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	zurich	switzerland	university hospital zurich, dept. of clinical pharmacology and toxicology
509	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	guang'anmen hospital, china academy of chinese medical sciences
510	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	institute of acupuncture and moxibustion, china academy of chinese medical sciences
511	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	mentougou hospital of tcm
512	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	andover	united states	andover eye associates
513	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	shinjuku-ku	japan	investigational site number 392-001
514	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ontario	canada	novartis investigative site
515	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mount-royal	canada	algorithme pharma inc.
516	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	multiple locations	mexico	many locations
517	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dongjak	korea, republic of	ear, nose and throat, boramae hospital
518	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bloomington	united states	indiana university
519	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	medellin	colombia	medellin
520	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hitachinaka-shi	japan	investigational site number 392012
521	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	isumi-shi	japan	investigational site number 392001
522	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	itoshima-shi	japan	investigational site number 392010
523	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	katsushika-ku	japan	investigational site number 392002
524	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kofu-shi	japan	investigational site number 392006
525	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	komae-shi	japan	investigational site number 392011
526	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	komatsu-shi	japan	investigational site number 392007
527	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	koto-ku	japan	investigational site number 392003
528	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nagano-shi	japan	investigational site number 392013
529	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	okayama-shi	japan	investigational site number 392009
530	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	osaka-shi	japan	investigational site number 392008
767	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	broglie	france	didier cadinot
531	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	setagaya-ku	japan	investigational site number 392004
532	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	setagaya-ku	japan	investigational site number 392005
533	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	fukuoka-shi	japan	sanofi-aventis investigational site number 392015
534	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kanazawa-shi	japan	sanofi-aventis investigational site number 392012
535	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kawaguchi-shi	japan	sanofi-aventis investigational site number 392001
536	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kawasaki-shi	japan	sanofi-aventis investigational site number 392003
537	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kawasaki-shi	japan	sanofi-aventis investigational site number 392004
538	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kita-ku	japan	sanofi-aventis investigational site number 392002
539	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kofu-shi	japan	sanofi-aventis investigational site number 392011
540	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	obu-shi	japan	sanofi-aventis investigational site number 392014
541	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seki-shi	japan	sanofi-aventis investigational site number 392013
542	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	yokohama-shi	japan	sanofi-aventis investigational site number 392005
543	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	yokohama-shi	japan	sanofi-aventis investigational site number 392006
544	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	yokohama-shi	japan	sanofi-aventis investigational site number 392007
545	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	yokohama-shi	japan	sanofi-aventis investigational site number 392008
546	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	yokohama-shi	japan	sanofi-aventis investigational site number 392009
547	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	yokohama-shi	japan	sanofi-aventis investigational site number 392010
548	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hannover	germany	gsk investigational site
549	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	buenos aires	argentina	centre n 101
550	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	buenos aires	argentina	centre n 105
551	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	buenos aires	argentina	centre n 104
552	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	buenos aires	argentina	centre n 103
553	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	buenos aires	argentina	centre n 107
554	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	buenos aires	argentina	centre n 109
555	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	buenos aires	argentina	centre n 108
556	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mar del plata / buenos aires	argentina	centre n 100
557	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rosario - santa fe	argentina	centre n 106
558	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	salta	argentina	centre n 102
559	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	aalst	belgium	centre n 202
560	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	edegem	belgium	centre n 200
561	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gent	belgium	centre n 201
562	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gent	belgium	centre n 204
563	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kortrijk	belgium	centre n 203
564	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lyon	france	centre n 302
565	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	marseille cedex 9	france	centre n 305
566	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nice cedex 3	france	centre n 307
567	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	paris cedex 10	france	centre n 303
568	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	quimper	france	centre n 308
569	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	reims	france	centre n 301
570	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	germany	centre n 411
571	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	germany	centre n 404
572	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	germany	centre n 410
573	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hamburg	germany	centre n 400
574	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hannover	germany	centre n 407
575	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	leipzig	germany	centre n 406
576	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	iwonicz zdroj	poland	centre n 505
577	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	krakow	poland	centre n 507
578	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	krakow	poland	centre n 503
579	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lodz	poland	centre n 504
580	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lublin	poland	centre n 502
581	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	poznan	poland	centre n 506
582	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	warszawa	poland	centre n 501
583	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wroclaw	poland	centre n 500
584	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	brasov	romania	centre n 704
585	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bucharest	romania	centre n 700
586	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bucharest	romania	centre n 701
587	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bucharest	romania	centre n 702
588	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bucharest	romania	centre n 705
589	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bucharest	romania	centre n 706
590	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bucharest	romania	centre n 707
591	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	craiova dolj	romania	centre n 703
592	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	vitoria	spain	centre n 804
593	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	badalona	spain	centre n 802
594	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	leganes	spain	centre n 801
595	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bilbao	spain	centre n 803
596	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	centre n 805
597	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	madrid	spain	centre n 800
598	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	valencia	spain	centre n 806
599	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	leuven	belgium	center for clinical pharmacology
600	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kingston	canada	pfizer investigational site
601	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	richmond	united states	children's hospital of richmond at vcu
602	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kansas city	united states	children's mercy hospital and clinics
603	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hannover	germany	fraunhofer institute for toxicology and experimental medicine
604	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	teaneck	united states	focus pointe global
605	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	qubec	canada	institut universitaire de cardiologie et de pneumologie de qubec
606	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	luodong	taiwan	camillian saint mary's hospital luodong
607	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bad segeberg	germany	segeberger kliniken, herzzentrum
608	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bernau bei berlin	germany	immanuel klinik bernau herzzentrum brandenburg
609	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	halle (saale)	germany	mitteldeutsches herzzentrum universittsklinikum halle (saale)
610	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hamburg	germany	asklepios klinik st. georg
611	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hamburg	germany	universitres herzzentrum hamburg gmbh
768	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	calvisson	france	franois le hingrat
612	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	yonsei university college of medicine, gangnam severance hospital
613	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	oulu	finland	oulu university hospital
614	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bad bevensen	germany	herz- und gefzentrum bad bevensen
615	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hamburg	germany	kath. marienkrankenhaus
616	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hannover	germany	mh hannover
617	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	heilbronn	germany	slk-kliniken heilbronn
618	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	milan	italy	ospedale san raffaele
619	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	eindhoven	netherlands	heartcentre catharina hospital eindhoven
620	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	madrid	spain	hospital universitario la paz
621	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mlaga	spain	hospital universitario virgen de la victoria
622	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	salamanca	spain	hospital universitario de salamanca
623	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chicago	united states	northwestern medical faculty foundation
624	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saskatoon	canada	university of saskatchewan
625	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	taipei	taiwan	national taiwan university (ntuh); ntuh hsin-chu branch; ntuh yun-lin branch; cathay general hospital
626	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	toronto	canada	pharma medica research inc.
627	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dusseldorf	germany	dept. of otorhinolaryngology and head and neck surgery
628	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cincinnati	united states	univ of cincinnati medical center
629	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	philadelphia	united states	einstein medical center
630	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dallas	united states	city doc urgent care center
631	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ottawa	canada	ottawa hospital
632	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	harrow	united kingdom	\N
633	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mississauga	canada	inflamax research
634	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san diego	united states	cosmetic laser dermatology
635	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tansen	nepal	lumbini medical college
636	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jeonju	korea, republic of	chonbuk national university hospital
637	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	colombes	france	hospital louis mourier
638	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	germany	charit - institute for social medicine
639	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	genve	switzerland	centre de recherche clinique, hug, rue gabrielle perret-gentil 4
640	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	paris	france	hpital lariboisire-service de rhumatolologie
641	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ulm	germany	\N
642	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wolfach	germany	\N
643	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mnchen	germany	\N
644	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin-steglitz	germany	\N
645	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	marburg	germany	\N
646	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gttingen	germany	\N
647	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gera	germany	\N
648	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	stadtroda	germany	\N
649	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	boeblingen	germany	dr. erich scholz
650	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	vienna	austria	medical university of vienna allgemeines krankenhaus
651	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dallas	united states	covance dallas
652	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jacksonville	united states	mayo clinic
653	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	aurora	united states	university of colorado
654	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pittsburgh	united states	university of pittsburgh
655	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chandigarh	india	pgimer
656	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bakersfield	united states	kern research, inc-site number:8400016
657	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bellair	united states	palm harbor dermatology-site number:8400024
658	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	miami	united states	university of miami-site number:8400011
659	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	macon	united states	skin care physicians of georgia-site number:8400030
660	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	indianapolis	united states	dawes fretzin clinical research group, llc-site number:8400007
661	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	louisville	united states	ds research-site number:8400031
662	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	baltimore	united states	johns hopkins university-site number:8400020
663	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bellevue	united states	nebraska medical research institute, inc.-site number:8400014
664	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	north charleston	united states	national allergy, asthma & urticaria centers of charleston, pa-site number:8400032
665	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	caba	argentina	investigational site number :0320005
666	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	caba	argentina	investigational site number :0320001
667	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	caba	argentina	investigational site number :0320006
668	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rosario	argentina	investigational site number :0320004
669	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	buenos aires	argentina	investigational site number :0320002
670	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ciudad autonoma buenos aires	argentina	investigational site number :0320003
671	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	calgary	canada	investigational site number :1240001
672	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	london	canada	investigational site number :1240002
673	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	markham	canada	investigational site number :1240003
674	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	toronto	canada	investigational site number :1240006
675	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montreal	canada	investigational site number :1240005
676	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	investigational site number :1560003
677	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chengdu	china	investigational site number :1560004
678	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	guangzhou	china	investigational site number :1560005
679	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hangzhou	china	investigational site number :1560002
680	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	shanghai	china	investigational site number :1560001
681	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	debrecen	hungary	investigational site number :3480005
682	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	szeged	hungary	investigational site number :3480003
683	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	zalaegerszeg	hungary	investigational site number :3480002
684	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	milano	italy	investigational site number :3800003
685	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rozzano	italy	investigational site number :3800002
686	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	firenze	italy	investigational site number :3800005
687	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	roma	italy	investigational site number :3800001
688	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sakai-shi	japan	investigational site number :3920002
689	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tachikawa-shi	japan	investigational site number :3920001
690	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ansan-si	korea, republic of	investigational site number :4100004
691	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	investigational site number :4100005
692	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	busan	korea, republic of	investigational site number :4100003
693	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	investigational site number :4100001
694	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	investigational site number :4100002
695	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wroclaw	poland	investigational site number :6160003
696	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	krakow	poland	investigational site number :6160001
697	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	krakow	poland	investigational site number :6160002
698	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	santullano	spain	investigational site number :7240002
699	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	investigational site number :7240003
700	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	alicante	spain	investigational site number :7240005
701	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	crdoba	spain	investigational site number :7240004
702	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pontevedra	spain	investigational site number :7240001
703	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	austin	united states	clinical investigative site 7905
704	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kerrville	united states	clinical investigative site 7907
705	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new braunfels	united states	clinical investigative site 7903
706	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san antonio	united states	clinical investigative site 7901
707	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san antonio	united states	clinical investigative site 7902
708	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san antonio	united states	clinical investigative site 7904
709	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san antonio	united states	clinical investigative site 7906
710	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	maastricht	netherlands	maastricht university
711	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montreal	canada	algorithme pharma
712	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jeonju	korea, republic of	clinical trial center of chonbuk national university hospital
713	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bridgewater	united states	sanofi-aventis administrative office
714	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	omaha	united states	pfizer investigational site
715	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	roma	italy	campus bio-medico of rome university
716	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	muenster	germany	proinnovera
717	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	investigational site number 724001
718	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chuo ku	japan	eisai trial site 2
719	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	koto-ku	japan	eisai trial site 1
720	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lund	sweden	department of otorhinolaryngology, lund university hospital
721	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	london	united kingdom	gsk investigational site
722	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hamburg	germany	prof. kristian reich, md
723	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	andover	united states	ora, inc
724	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cypress	united states	investigational site number 840003
725	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	stockbridge	united states	investigational site number 840006
726	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	north dartmouth	united states	investigational site number 840007
727	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	plymouth	united states	investigational site number 840010
728	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	omaha	united states	investigational site number 840001
729	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	raleigh	united states	investigational site number 840008
730	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	spartanburg	united states	investigational site number 840002
731	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san antonio	united states	investigational site number 840005
732	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	concord	australia	concord repatriation general hospital
733	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	adelaide	australia	royal adelaide hospital institute of medical and veterinary science
734	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	clayton	australia	monash medical centre
735	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	heidelberg	australia	austin health - austin hospital
736	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nedlands	australia	linear clinical research
737	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	melbourne	australia	the alfred hospital
738	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	waratah	australia	calvary mater new castle
739	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	seoul national university hospital
740	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	asan medical center
741	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	local institution - 201
742	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chisinau	moldova, republic of	\N
743	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sevilla	spain	\N
744	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	aix en provence	france	corinne sion
745	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ales	france	alain faudin
746	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ales	france	philippe piat
747	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ales	france	sylvie chabrol-riviere
748	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	aubevoye	france	daniel feret
749	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	aubord	france	florian komac
750	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	avoine	france	alain giacomino
751	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beaucaire	france	jean deflaux
752	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beauvoisin	france	sbastien convent
753	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beziers	france	catherine brunet-cazot
754	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beziers	france	emmanuel dejoux
755	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beziers	france	gabriel venturini
756	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beziers	france	nicolas breton
757	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beziers	france	robert combet
758	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beziers	france	thierry stefanaggi
759	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bischeim	france	olivier bisch
760	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bischeim	france	sabine grutter
761	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bischeim	france	sophie rosenberg
762	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bompas	france	jacques rambaud
763	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bouillargues	france	chantal martin
764	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	boujan sur libron	france	catherine ayral
765	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bourg achard	france	laurence dages
766	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bretteville l'orgueilleuse	france	dominique edet
769	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	castelnau le lez	france	bernadette chauffaille
770	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	castelnaudary	france	georges binet
771	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	castelnaudary	france	herv vilarem
772	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	clarensac	france	gladys havard
773	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	clarensac	france	marc garcia
774	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	codognan	france	michel amouyal
775	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	codognan	france	nicole ferrier
776	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	colombelles	france	philippe grujard
777	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cournonsec	france	philippe heuze
778	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cournonterrac	france	gregoire martocq
779	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	coursan	france	bruno daubin
780	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	damville	france	jean-baptiste de lemos
781	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dessenheim	france	marcel ruetsch
782	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	equeurdreville hainneville	france	christian daugenet
783	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	evreux	france	grard dugny
784	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	evreux	france	thierry canali
785	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	fecamp	france	frdric renou
786	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	fleury sur orne	france	pascal mabire
787	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gambsheim	france	alain lion
788	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hangenbieten	france	raymond westerfeld
789	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hautot sur mer	france	grard tellier
790	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	herlisheim	france	marc bur
791	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ille sur tet	france	jean pascal sastourne
792	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	laroque des alberes	france	reinhard renner
793	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lasalle	france	christian flaissier
794	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lasalle	france	irne lafont
795	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	le cailar	france	patrick dutilleul
796	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lignan sur orb	france	claude brunaud
797	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lingolsheim	france	jean-philippe richter
798	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	marguerittes	france	stphane bourghol
799	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	maurin	france	maurice gay
800	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	meze	france	patrick olombel
801	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montpellier	france	ccile belin-sauget
802	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montpellier	france	jean franois guillem
803	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montpellier	france	jean roch alea
804	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montpellier	france	marie pascale demoly
805	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montpellier	france	mongin
806	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montpellier	france	thierry autard
807	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montpellier	france	victor bastide
808	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montpellier	france	michel chassagne
809	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montpellier	france	philippe cayron
810	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montpellier	france	jean pierre cano
811	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mulhouse	france	patrick vogt
812	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mundolsheim	france	jean-louis wurtz
813	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nimes	france	nasser gouchene
814	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nimes	france	paul regnier-vigouroux
815	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nimes	france	claude bernat
816	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nimes	france	dominique blot
817	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nimes	france	marie christine bons-gallet
818	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nimes	france	philippe imbert
819	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nmes	france	costa
820	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	obernai	france	georgios markidis
821	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	obernai	france	natacha heitz
822	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	obernai	france	yves-olivier schlecht
823	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ottrott	france	guy birry
824	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pacy sur eure	france	bernard prijac
825	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	perpignan	france	alain guerri
826	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	perpignan	france	chantal malzac
827	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	perpignan	france	grard bourrel
828	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pompignan	france	serge elie
829	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pont de l'arche	france	sonia courtois
830	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pont saint esprit	france	bernard gabbai
831	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rivesaltes	france	genevive durant
832	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rouen	france	baudoin pinson
833	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rouen	france	olivier baissas
834	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rousson	france	dominique genoud
835	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rousson	france	sylvie ollivier
836	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rugles	france	patrick verdavoine
837	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint genis des fontaines	france	catherine mercey
838	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint genis des fontaines	france	yves mercey
839	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint georges d'orques	france	batrice lognos-folco
840	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint sebastien de morsent	france	jean-yves doerr
841	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint siffret	france	martine ferre
842	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sainte anastasie	france	gil meyrand
843	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	salses le chateau	france	jean baptiste thibert
844	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	schilttigheim	france	la aboaf
845	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	schilttigheim	france	monique lescoute
846	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	schilttigheim	france	raymond attuil
847	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sete	france	luc echinard
848	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sommieres	france	laurent tenneze
849	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	charles lousqui
850	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	claire pfrunner-schneider
851	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	claire rolland-jacquemin
852	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	hlne sturchler
853	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	jol etiennez
854	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	judah toledano
855	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	nathan abenhaim
856	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	patrick kormann
857	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	philippe marmor
858	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	roland benedic
859	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	vronique perez
860	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg	france	maxime boumandil
861	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tilly sur seulles	france	herv morel
862	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	trebes	france	bernard clary
863	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	trebes	france	jacques graves
864	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	uchaud	france	christian girard
865	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	uchaud	france	eric liotard
866	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	uzes	france	olivier chaix
867	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	valleraugue	france	franois bayle
868	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ville	france	philippe boisson
869	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	herston	australia	qpharm, pty limited, royal brisbane hospital
870	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	paris	france	fernand widal hospital
871	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	paris	france	lariboisiere hospital
872	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hamilton	canada	mcmaster university
873	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gent	belgium	department of movement and sports sciences, ghent university
874	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	geneva 14	switzerland	university hospitals
875	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	germany	novartis investigative site
876	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bonn	germany	novartis investigative site
877	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dresden	germany	novartis investigative site
878	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	giessen	germany	novartis investigative site
879	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hamburg	germany	novartis investigative site
880	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hannover	germany	novartis investigative site
881	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	koeln	germany	novartis investigative site
882	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	leipzig	germany	novartis investigative site
883	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	luebeck	germany	novartis investigative site
884	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mainz	germany	novartis investigative site
885	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	munich	germany	novartis investigative site
886	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	turin	italy	respiratory pathophysiology clinic, aso san giovanni battista
887	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	singapore	singapore	ubi family clinic & surgery
888	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	singapore	singapore	banyan clinic @ jw private limited
889	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mxico	mexico	hospital infantil de mxico, fedrico gmez
890	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	muenster	germany	proinnovera gmbh
891	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	salt lake city	united states	george e wahlen va medical center
892	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	birmingham	united states	university of alabama
893	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	anchorage	united states	orthopedic physicians alaska
894	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	flagstaff	united states	arizona arthritis and rheumatology research, pllc - flagstaff
895	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	glendale	united states	arizona arthritis and rheumatology research, pllc-west
896	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mesa	united states	arizona arthritis and rheumatology research, pllc-east
897	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	little rock	united states	applied research center of arkansas, inc
898	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	el cajon	united states	triwest research associates
899	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hawthorne	united states	advanced investigative medicine, inc.
900	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	los angeles	united states	axis clinical trials
901	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	poway	united states	acrc studies
902	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	roseville	united states	clinedge sierra rheumatology, inc.
903	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san leandro	united states	east bay rheumatology medical group, inc.
904	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	santa monica	united states	providence st. john's health clinic
905	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tujunga	united states	medvin clinical research
906	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	van nuys	united states	san fernando valley health institute
907	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ventura	united states	ventura clinical trials
908	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	aurora	united states	university of colorado division of rheumatology
909	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	denver	united states	denver arthritis clinic
910	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	deland	united states	avail clinical research
911	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	doral	united states	prohealth research center
912	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	orlando	united states	omega research maitland
913	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pinellas park	united states	dmi research
914	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pompano beach	united states	napa research center
915	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tampa	united states	gcp clinical research
916	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	zephyrhills	united states	florida medical clinic, llc
917	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	meridian	united states	st. luke's clinic - rheumatology
918	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	oxon hill	united states	md medical research
919	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wheaton	united states	the center for rheumatology and bone research
920	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	grand rapids	united states	infusion associates
921	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint clair shores	united states	clinical research institute of michigan, llc
922	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	great falls	united states	benefis hospital
923	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lincoln	united states	physician research collaboration, llc
924	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	santa fe	united states	santa fe rheumatology
925	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	babylon	united states	long island arthritis & osteoporosis care
926	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	orchard park	united states	buffalo rheumatology and medicine
927	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	concord	united states	northeast rheumatology/atrium health
928	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	concord	united states	northeast rheumatology
929	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	greensboro	united states	medication management, llc
930	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hickory	united states	clinedge pmg research of hickory, llc
931	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	salisbury	united states	clinedge pmg research of salisbury, llc
932	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	shelby	united states	shelby clinical research, llc
933	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wilmington	united states	pmg research of wilmington, llc
934	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dayton	united states	premier clinical/stat research
935	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	middleburg heights	united states	paramount medical research & consulting, llc
936	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	perrysburg	united states	clinical research source inc.
937	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	springboro	united states	premier clinical/stat research - springboro
938	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	duncansville	united states	altoona center for clinical research
939	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	greenville	united states	piedmont arthritis clinic
940	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	summerville	united states	articularis healthcare group
941	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jackson	united states	west tennessee research institute
942	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	memphis	united states	ramesh c. gupta, m.d.
943	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	houston	united states	diagnostic and interventional nephrology of houston
944	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	houston	united states	research consultants - frostwood
945	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	houston	united states	research consultants - astoria
946	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san marcos	united states	arthritis clinic of central texas
947	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	waco	united states	arthritis & osteoporosis clinic - waco
948	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	webster	united states	clear lake specialties
949	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bothell	united states	western washington arthritis clinic
950	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	spokane	united states	arthritis northwest
951	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	glendale	united states	rheumatic disease center
952	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bethesda	united states	national institutes of health clinical center
953	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	orange	united states	university of california, irvine
954	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	atlanta	united states	rare disease research
955	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	philadelphia	united states	children's hospital of philadelphia
956	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	houston	united states	university of texas, health science center of houston
957	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ottawa	canada	the ottawa hospital research institute
958	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bron	france	hopital femme mere enfant
959	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	clamart	france	institut de myologie - hopital antoine bclre
960	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	milan	italy	fondazione irccs ca' granda - ospedale maggiore policlinico
961	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	madrid	spain	hospital universitario 12 de octubre
962	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	salford	united kingdom	salford royal nhs foundation trust
963	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	st. paul	united states	pfizer investigational site
964	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bethesda	united states	national institutes of health clinical center, 9000 rockville pike
965	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	palermo	italy	institute of biomedicine and molecular immunology (ibim), national research council
966	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	palermo	italy	institute of biomedicine and molecular immunology, ibim
967	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	los angeles	united states	gsk investigational site
968	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ann arbor	united states	gsk investigational site
969	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	glostrup	denmark	danish multiple sclerosis center, rigshospitalet
970	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	aalborg	denmark	department of neurology, aalborg university hospital
971	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	aarhus	denmark	department of neurology, aarhus university hospital
972	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	esbjerg	denmark	department of neurology, hospital of south west jutland, esbjerg
973	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	herlev	denmark	department of neurology, herlev hospital
974	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hillerd	denmark	department of neurology, nordsjllands hospital i hillerd
975	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	holstebro	denmark	department of neurology, regionshospitalet holstebro
976	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kolding	denmark	department of neurology, kolding hospital
977	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	odense	denmark	department of neurology, odense university hospital
978	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	roskilde	denmark	department of neurology, sjllands universitetshospital, roskilde
979	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	snderborg	denmark	department of neurology, hospital of southern jutland, snderborg
980	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	viborg	denmark	department of neurology, regionshospitalet viborg
981	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cincinnati	united states	cincinnati children's hospital medical center
982	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	herston	australia	nucleus network pty ltd.
983	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	syracuse	united states	suny upstate medical university
984	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tokyo	japan	sanofi administrative office
985	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dresden	germany	medical practice for neurology
986	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wedel	germany	medical practice for neurology
987	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	clifton	united states	obl-nj endovascular & amputation prevention, llc,1429 broad st., clifton, nj
988	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	teaneck	united states	holy name medical center,718 teaneck road
989	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	doha	qatar	hamad medical corporation
990	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new york	united states	rockefeller university
991	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bethesda	united states	national institute of diabetes and digestive and kidney diseases (niddk)
992	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bethesda	united states	national institute of allergy and infectious diseases (niaid)
993	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	birmingham	united states	university of alabama at birmingham
994	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	los angeles	united states	university of california, los angeles
995	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san francisco	united states	university of california, san francisco
996	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new haven	united states	yale university
997	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	atlanta	united states	emory university
998	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	baltimore	united states	university of maryland
999	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	baltimore	united states	johns hopkins university
1000	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ann arbor	united states	university of michigan
1001	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint louis	united states	washington university school of medicine in st. louis
1002	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new york	united states	mount sinai medical center
1003	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cleveland	united states	cleveland clinic
1004	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cleveland	united states	university hospitals of cleveland
1005	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	madison	united states	university of wisconsin
1006	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	winnipeg	canada	university of manitoba
1007	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	toronto	canada	toronto general hospital
1008	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	shiraz	iran, islamic republic of	shiraz university of medical sciences
1009	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tempe	united states	investigational site
1010	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	halifax	canada	maritime neurology
1011	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	beijing tongren hospital
1012	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	milan	italy	ospedale maggiore di milano irccs policlinico dipartimento malattie cardiovascolari e respiratorie
1013	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pathum wan	thailand	chulalongkorn hospital
1014	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	munich	germany	ludwig-maximilians - university of munich
1015	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	gangnam severance hospital.
1016	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	genve	switzerland	hpitaux universitaires de genve
1017	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	germany	charit klinik fr dermatologie, venerologie und allergologie
1018	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	uppsala	sweden	uppsala university hospital
1019	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	centennial	united states	1st allergy & clinical research centers
1020	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	thornton	united states	1st allergy & clinical research centers
1021	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin-mitte	germany	study site 07
1022	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bonn	germany	study site 08
1023	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dresden	germany	study site 06
1024	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dusseldorf	germany	study site 12
1025	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	frankfurt	germany	study site 02
1026	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hamburg	germany	study site 09
1027	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	heidelberg	germany	study site 05
1028	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kiel	germany	study site 03
1029	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	leipzig	germany	study site 11
1030	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lubeck	germany	study site 04
1031	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mainz	germany	study site 14
1032	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	muenster	germany	study site 01
1033	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mnchen	germany	study site 16
1034	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	selters	germany	study site 15
1035	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tbingen	germany	study site 10
1036	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ghent	belgium	department of movement and sports sciences, ghent university, belgium
1037	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dhaka-1000	bangladesh	dhaka medical college hospital
1038	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	genoa	italy	irccs istituto giannina gaslini
1039	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dharn bzr	nepal	b.p. koirala institute of health sciences
1040	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rochester	united states	university of rochester
1041	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tampa	united states	university of south florida
1042	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	alexandria	united states	the neuromedical clinic of central louisiana
1043	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	baltimore	united states	johns hopkins hospital; neurology
1044	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	owosso	united states	memorial healthcare institute for neurosciences and multiple sclerosis
1045	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hickory	united states	neurology associates pa
1046	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dayton	united states	uc health neurology
1047	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	greer	united states	premier neurology
1048	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cordova	united states	neurology clinic pc
1049	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	st leonards	australia	royal north shore hospital; department of neurology
1050	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	north adelaide	australia	the memorial hospital
1051	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	salvador	brazil	clinica amo - assistencia medica em oncologia
1052	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	vitoria	brazil	cedoes - diagnstico e pesquisa
1053	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sao paulo	brazil	hospital santa marcelina; ame - ambulatrio de especialidades mdicas
1054	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	st. john's	canada	memorial university of newfoundland (mun) - faculty of medicine - st. clare's mercy hospital (scm)
1055	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	granby	canada	ciusss de l'estrie-chus/hopital de granby
1056	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	brno	czechia	fakultni nemocnice u sv. anny; neurologicka klinika
1057	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hradec krlov	czechia	charles university, medical faculty, hradec kralove ;department of neurology
1058	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jihlava	czechia	nemocnice jihlava; neu-neurologicke oddeleni
1059	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ostrava-poruba	czechia	fakultni nemocnice ostrava; ms centrum
1060	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pardubice	czechia	pardubicka krajska nemocnice; department of neurology
1061	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	praha 2	czechia	fakultni poliklinika vfn; rs centrum
1062	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	praha 8	czechia	institut neuropsychiatricke pece (inep)
1063	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	praha	czechia	fakultni nemocnice motol; neurologicka klinika
1064	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	teplice	czechia	krajska zdravotni a.s nemocnice teplice o.z.; rs centrum
1065	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	napoli	italy	a. o. u. federico ii; dip neuroscienze, scienze riproduttive ed odontostomatologiche
1066	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	roma	italy	policlinico tor vergata dip. neuroscienze-clinica neurologica-uosd sclerosi multipla
1067	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	roma	italy	azienda ospedaliera sant'andrea; uoc neurologia
1068	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	genova	italy	irccs a.o.u.san martino ist; dinogmi
1069	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	milano	italy	irccs ospedale san raffaele; neurologia neurofisiologia neuroriabilitazione-centro sclerosi multipla
1070	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	montichiari	italy	ospedale civile di montichiari; centro sclerosi multipla
1071	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pozzilli	italy	irccs istituto neurologico neuromed; centro per lo studio e la cura della sclerosi multipla
1072	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	auckland	new zealand	optimal clinical trials
1073	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hastings	new zealand	hawkes bay hospital
1074	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bydgoszcz	poland	neurocentrum bydgoszcz sp. z o.o
1075	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	katowice	poland	care clinic
1076	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lodz	poland	centrum neurologii krzysztof selmaj
1077	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wrocaw	poland	emc instytut medyczny s.a.
1078	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	majadahonda	spain	hospital universitario puerta de hierro majadahonda
1079	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seville	spain	hospital universitario virgen macarena
1080	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	santa cruz de tenerife	spain	complejo hospitalario nuestra seora de la candelaria; servicio de neurologia
1081	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	hospital universitari vall d'hebron
1082	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cordoba	spain	hospital universitario reina sofia; servicio de neurologia
1083	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	malaga	spain	hospital regional universitario de malaga - hospital general; servicio de neurologia
1084	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ankara	turkey	hacettepe university medical faculty; neurology
1085	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	istanbul	turkey	bakirkoy state mental hospital
1086	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	istanbul	turkey	istanbul universitesi - cerrahpasa cerrahpasa tip fakultesi; noroloji anabilim dali
1087	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	izmir	turkey	katip celebi university ataturk training and research hospital; neurology
1088	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kocaeli	turkey	kocaeli university hospital; department of neurology
1089	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	merkez	turkey	kutahya saglik bilimleri universitesi; noroloji
1090	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sleymanpaa	turkey	namik kemal universitesi sagli uygulama ve arastirma hastanesi; noroloji
1091	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	santander	spain	fernando rodrguez
1092	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	xiamen	china	gsk investigational site
1093	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	shenzhen	china	gsk investigational site
1094	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	changsha	china	gsk investigational site
1095	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nanjing	china	gsk investigational site
1096	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	taiyuan	china	gsk investigational site
1097	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wenzhou	china	gsk investigational site
1098	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	gsk investigational site
1099	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chongqing	china	gsk investigational site
1100	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	fuzhou	china	gsk investigational site
1101	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hangzhou	china	gsk investigational site
1102	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	shanghai	china	gsk investigational site
1103	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bern	switzerland	inselspital
1104	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	brugge	belgium	investigational site number 056002
1105	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	brussels	belgium	investigational site number 056001
1106	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dijon	france	investigational site number 250009
1107	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lille cedex	france	investigational site number 250005
1108	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lyon bron	france	investigational site number 250001
1109	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nancy	france	investigational site number 250006
1110	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nantes	france	investigational site number 250010
1111	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nimes	france	investigational site number 250007
1112	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	paris cedex 20	france	investigational site number 250008
1113	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rennes cedex 9	france	investigational site number 250004
1114	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	strasbourg cedex 2	france	investigational site number 250003
1115	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	toulouse	france	investigational site number 250002
1116	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	breda	netherlands	investigational site number 528001
1117	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rotterdam	netherlands	investigational site number 528002
1118	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bilbao	spain	investigational site number 724005
1119	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	madrid	spain	investigational site number 724002
1120	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mlaga	spain	investigational site number 724006
1121	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sevilla	spain	investigational site number 724003
1122	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	valencia	spain	investigational site number 724004
1123	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new york	united states	new york state psychiatric institute
1124	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pittsburgh	united states	national surgical adjuvant breast and bowel project
1125	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	incheon	korea, republic of	gachon university gil medical center
1126	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	palermo	italy	andros day surgery clinic, reproductive medicine unit
1127	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new york	united states	mount sinai school of medicine - seaver autism center for research and treatment
1128	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hong kong	china	queen mary hospital
1129	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hong kong	china	prince of wales hospital
1130	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	frankfurt	germany	klinikum der johann wolfgang goethe universitaet
1131	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hamburg	germany	asklepios klinik st. georg - chirurgisch-traumatologisches zentrum
1132	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hannover	germany	medizinische hochschule hannover
1133	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	leipzig	germany	eugastro gmbh
1134	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	leipzig	germany	universitaetsklinikum leipzig
1135	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	muenchen	germany	klinikum der ludwig-maximilian-universitaet muenchen
1136	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tuebingen	germany	university hospital of tuebingen
1137	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ulm	germany	universitaetsklinikum ulm, klinik fur innere medizin i
1138	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wuerzburg	germany	universitaetsklinikum wuerzburg, medizinische klinik und poliklinik ii
1139	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	busan	korea, republic of	pusan national university hospital
1140	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	severance hospital, yonsei university college of medicine
1141	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	yangsan-si gyeongnam	korea, republic of	pusan national university yangsan hospital
1142	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	louisville	united states	university of louisville hospital
1143	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	puducherry	india	online
1144	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bengbu	china	the first affiliated hospital of bengbu medical college
1145	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hefei	china	the second hospital of anhui medical university
1146	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	beijing shijitan hospital
1147	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	dongfang hospital beijing university of chinese medicine
1148	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wuhan	china	renmin hospital of wuhan university
1149	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	yangzhou	china	northern jiangsu people's hospital
1150	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	changchun	china	the affiliated hospital of changchun university of chinese medicine
1151	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tonghua	china	tonghua central hospital
1152	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	yanji	china	yanbian korea medicine hospital
1153	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	yanji	china	yanbian university hospital(yanbian hospital)
1154	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	qingdao	china	the affiliated hospital of qingdao university
1155	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	yantai	china	yantai yuhuangding hospital
1156	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	zibo	china	zibo central hospital
1157	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	taiyuan	china	first hospital of shanxi medical university
1158	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	taiyuan	china	second hospital of shanxi medical university
1159	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tianjin	china	general hospital of tianjin medical university
1160	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tianjin	china	tianjin people's hospital
1161	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hangzhou	china	zhejiang provincial people's hospital
1162	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	glendale	united states	arizona arthritis & rheumatology -west valley
1163	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mesa	united states	arizona arthritis & rheumatology -east valley
1164	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	spokane	united states	arthritis northwest pllc
1165	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	camperdown	australia	royal prince alfred hospital
1166	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	concord	australia	concord repatriation general hospital, gastroenterology & liver services
1167	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	darlinghurst	australia	st. vincent's hospital sydney
1168	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	westmead	australia	westmead hospital
1169	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	adelaide	australia	royal adelaide hospital
1170	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	clayton	australia	monash health clayton campus
1171	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	fitzroy	australia	st. vincent's hospital melbourne
1172	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	parkville	australia	royal melbourne hospital
1173	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nedlands	australia	linear clinical research ltd.
1174	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pleven	bulgaria	mhat st. pantaleimon ood, department of gastroenterology
1175	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sofia	bulgaria	umhat st. ivan rilski ead, clinic of gastroenterology
1176	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sofia	bulgaria	diagnostic and consultative center - focus 5 - outpatient medical center, eood
1177	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	varna	bulgaria	diagnostic and consultative center mladost-m varna
1178	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hong kong	china	queen mary hospital, department of medicine
1179	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	busan	korea, republic of	inje university busan paik hospital
1180	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	daegu	korea, republic of	kyungpook national university hospital
1181	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	gangnam severance hospital, yonsei university health system
1182	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seoul	korea, republic of	severance hospital, yonsei university health system
1183	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chisinau	moldova, republic of	imsp spitalul clinic de boli infectioase, toma ciorba
1184	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	papatoetoe	new zealand	middlemore clinical trials, middlemore hospital
1185	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dunedin	new zealand	dunedin hospital, gastroenterology research unit
1186	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	auckland	new zealand	auckland clinical studies
1187	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	douliou	taiwan	national taiwan university hospital, yun-lin branch
1188	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	changhua	taiwan	changhua christian hospital
1189	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kaohsiung	taiwan	kaohsiung medical university chung-ho memorial hospital
1190	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bangkok	thailand	king chulalongkorn memorial hospital
1191	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bangkok	thailand	hospital of tropical diseases
1192	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bangkok	thailand	phramongkutklao hospital, division of digestive and liver disease
1193	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chiang mai	thailand	maharaj nakhon chiang mai hospital, gastroenterology division
1194	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	khon kaen	thailand	khon kaen university
1195	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pathumthani	thailand	thammasat university hospital, gastroenterology unit
1196	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	peking union medical college hospital
1197	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	taipei city	taiwan	taipei medical university
1198	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	iowa city	united states	university of iowa
1199	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	omaha	united states	creighton university
1200	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	hongfei lou
1201	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	beijing friendship hospital, cmu
1202	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	beijing shijitan hospital,cmu
1203	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	beijing	china	beijing tongren hospital,cmu
1204	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	guangzhou	china	the third affliation hospital of sun yat-sen university
1205	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wuhan	china	union hospital affiliated to tongji medical college of huazhong university of science and technology
1206	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nanjing	china	jiangsu province hospital
1207	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chiba-city	japan	novartis investigative site
1208	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ichikawa-city	japan	novartis investigative site
1209	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kashiwa-city	japan	novartis investigative site
1210	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	matsudo-city	japan	novartis investigative site
1211	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	urayasu city	japan	novartis investigative site
1212	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kawasaki-city	japan	novartis investigative site
1213	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	yokohama-city	japan	novartis investigative site
1214	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	koshigaya-city	japan	novartis investigative site
1215	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	arakawa-ku	japan	novartis investigative site
1216	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chiyoda-ku	japan	novartis investigative site
1217	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chuo ku	japan	novartis investigative site
1218	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	edogawa-ku	japan	novartis investigative site
1219	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	katsushika-ku	japan	novartis investigative site
1220	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nakano-ku	japan	novartis investigative site
1221	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	setagaya-ku	japan	novartis investigative site
1222	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	shinjuku ku	japan	novartis investigative site
1223	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	shinjuku-ku	japan	novartis investigative site
1224	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	toshima-ku	japan	novartis investigative site
1225	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	birmingham	united states	gsk investigational site
1226	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	walnut creek	united states	gsk investigational site
1227	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	aurora	united states	gsk investigational site
1228	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	washington, d.c.	united states	gsk investigational site
1229	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jacksonville	united states	gsk investigational site
1230	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pinellas park	united states	gsk investigational site
1231	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	worcester	united states	gsk investigational site
1232	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kalamazoo	united states	gsk investigational site
1233	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gulfport	united states	gsk investigational site
1234	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mentor	united states	gsk investigational site
1235	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rapid city	united states	gsk investigational site
1236	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	toronto	canada	gsk investigational site
1237	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bangor	united states	regeneron study site
1238	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	baltimore	united states	regeneron study site
1239	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	plymouth	united states	regeneron study site
1240	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	columbia	united states	regeneron study site
1241	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint louis	united states	regeneron study site
1242	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	missoula	united states	regeneron study site
1243	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	verona	united states	regeneron study site
1244	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	great neck	united states	regeneron study site
1245	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cincinnati	united states	regeneron study site
1246	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	toledo	united states	regeneron study site
1247	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	portland	united states	regeneron study site
1248	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pittsburgh	united states	regeneron study site
1249	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lincoln	united states	regeneron study site
1250	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	greenfield	united states	regeneron study site
1251	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gent	belgium	regeneron study site
1252	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	leuven	belgium	regeneron study site
1253	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kingston	canada	regeneron study site
1254	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	london	canada	regeneron study site
1255	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ottawa	canada	regeneron study site
1256	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	toronto	canada	regeneron study site
1257	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	trois-rivieres	canada	regeneron study site
1258	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	quebec	canada	regeneron study site
1259	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hvidovre	denmark	regeneron study site
1260	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hellerup	denmark	regeneron study site
1261	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	vejle	denmark	regeneron study site
1262	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	heidelberg	germany	regeneron study site
1263	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	stuttgart	germany	regeneron study site
1264	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dreieich	germany	regeneron study site
1265	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	wiesbaden	germany	regeneron study site
1266	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	duisburg	germany	regeneron study site
1267	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dusseldorf	germany	regeneron study site
1268	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dresden	germany	regeneron study site
1269	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	berlin	germany	regeneron study site
1270	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hamburg	germany	regeneron study site
1271	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	vienna	austria	medical university of vienna
1272	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	naples	italy	second university of naples
1273	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sabadell	spain	albada centre socio sanitari parc taul
1274	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	badalona	spain	ballesol badalona
1275	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barber del valls	spain	ballesol barber
1276	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sabadell	spain	residncia allegra
1277	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	residncia poble nou
1278	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	ballesol fabra i puig
1279	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	ballesol almogvers
1280	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	residncia mapfre quavitae
1281	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	residncia amma horta
1282	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	residncia collserola (mutuam)
1283	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	phoenix	united states	banner-university medical center phoenix
1284	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tucson	united states	university of arizona
1285	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	washington	united states	medstar georgetown university hospital
1286	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chicago	united states	northwestern university
1287	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chicago	united states	rush university medical center
1288	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	weymouth	united states	south shore hospital center for wound healing
1289	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	worcester	united states	university of massachusetts medical school
1290	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	columbia	united states	university of missouri
1291	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint louis	united states	mercy
1292	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	manhasset	united states	northwell health system - north shore university hospital
1293	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	mineola	united states	new york university - winthrop hospital
1294	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	columbus	united states	ohio state university medical center
1295	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	philadelphia	united states	university of pennsylvania
1296	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	philadelphia	united states	thomas jefferson university
1297	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pittsburgh	united states	university of pittsburgh medical center
1298	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	birmingham	united states	university of alabama hospital
1299	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chandler	united states	chandler regional medical center
1300	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	phoenix	united states	banner university medical center phoenix
1301	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	phoenix	united states	dignity health - st. joseph's hospital and medical center
1302	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	phoenix	united states	mayo clinic arizona
1303	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tucson	united states	tmc healthcare
1304	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tucson	united states	banner- university medical center tucson
1305	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	carmichael	united states	mercy san juan medical center
1306	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	downey	united states	rancho los amigos national rehabilitation center
1307	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	la jolla	united states	ucsd health la jolla
1308	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	los angeles	united states	cedars-sinai medical center
1309	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	los angeles	united states	ronald reagan ucla medical center
1310	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	los angeles	united states	kaiser permanente los angeles
1311	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	modesto	united states	doctors medical center of modesto
1312	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	ontario	united states	ucla kaiser fontana
1313	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	orange	united states	uc irvine
1314	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pomona	united states	casa colina
1315	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sacramento	united states	uc davis medical center
1316	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san diego	united states	ucsd medical center - hillcrest hospital
1317	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san francisco	united states	ucsf helen diller medical center at parnassus heights
1318	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	santa ana	united states	orange county global medical center
1319	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sylmar	united states	olive view- ucla medical center
1320	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	walnut creek	united states	john muir medical center- walnut creek campus
1321	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	grand junction	united states	st. mary's hospital and medical center
1322	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bridgeport	united states	bridgeport hospital
1323	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hartford	united states	hartford hospital
1324	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new haven	united states	yale-new haven hospital
1325	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	washington	united states	george washington university hospital
1326	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	gainesville	united states	uf health shands hospital
1327	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jacksonville	united states	brooks rehabilitation hospital
1328	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jacksonville	united states	mayo clinic jacksonville
1329	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	miami	united states	jackson memorial hospital
1330	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	miami	united states	university of miami hospital
1331	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	miami	united states	baptist hospital of miami
1332	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sarasota	united states	sarasota memorial hospital
1333	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tampa	united states	tampa general hospital
1334	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	chicago	united states	university of illinois hospital and health sciences system
1335	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	maywood	united states	loyola university medical center
1336	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	peoria	united states	osf saint francis medical center
1337	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	springfield	united states	memorial medical center
1338	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	iowa city	united states	university of iowa hospitals and clinics
1339	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	lexington	united states	university of kentucky albert b. chandler hospital
1340	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	louisville	united states	norton healthcare
1341	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new orleans	united states	ochsner medical center - main campus
1342	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	shreveport	united states	university health shreveport
1343	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	boston	united states	tufts medical center
1344	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	boston	united states	massachusetts general hospital
1345	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	boston	united states	brigham and women's hospital
1346	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	boston	united states	beth israel deaconess medical center
1347	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	springfield	united states	baystate health
1348	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	detroit	united states	detroit receiving hospital
1349	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	detroit	united states	henry ford hospital
1350	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	flint	united states	mclaren flint
1351	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kalamazoo	united states	bronson methodist hospital
1352	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rochester	united states	mayo clinic saint marys campus
1353	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint cloud	united states	saint cloud/centracare health
1354	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	jackson	united states	university of mississippi medical center
1355	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	columbia	united states	boone hospital center
1356	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kansas city	united states	saint luke's hospital of kansas city
1357	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint louis	united states	barnes-jewish hospital
1358	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint louis	united states	ssm health saint louis university hospital
1359	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	springfield	united states	cox medical center
1360	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	omaha	united states	university of nebraska medical center
1361	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	albuquerque	united states	university of new mexico hospital
1362	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bronx	united states	montefiore medical center
1363	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	brooklyn	united states	maimonides medical center
1364	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	brooklyn	united states	nyu langone brooklyn
1365	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	buffalo	united states	buffalo general medical center
1366	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	manhasset	united states	north shore university hospital
1367	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new york	united states	nyu langone -tish hospital medical center
1368	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new york	united states	nyp columbia university medical center
1369	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rochester	united states	strong memorial hospital
1370	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	staten island	united states	staten island university hospital
1371	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	charlotte	united states	carolinas medical center atrium health
1372	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	concord	united states	carolinas rehab northeast
1373	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	greensboro	united states	guilford neurologic associates, inc
1374	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	winston-salem	united states	wake forest university baptist medical center
1375	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cincinnati	united states	christ hospital
1376	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cincinnati	united states	university of cincinnati medical center
1377	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cleveland	united states	uh cleveland medical center
1378	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cleveland	united states	metrohealth medical center
1379	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	columbus	united states	osu wexner medical center
1380	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	toledo	united states	promedica toledo hospital
1381	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	west chester	united states	west chester hospital
1382	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tulsa	united states	st. john health system
1383	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	portland	united states	providence st. vincent medical center
1384	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	portland	united states	oregon health & science university hospital
1385	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bethlehem	united states	st. luke's university hospital bethlehem campus
1386	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	danville	united states	geisinger clinic
1387	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	hershey	united states	penn state milton s. hershey center
1388	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	philadelphia	united states	hospital of the university of pennsylvania
1389	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	philadelphia	united states	temple university hospital
1390	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	pittsburgh	united states	upmc presbyterian hospital
1391	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	columbia	united states	palmetto health richland
1392	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	greenville	united states	greenville memorial hospital
1393	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	memphis	united states	methodist university
1394	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dallas	united states	university of texas southwestern medical center
1395	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dallas	united states	baylor scott & white institute of rehabilitation
1396	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	houston	united states	memorial hermann texas medical center
1397	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	murray	united states	intermountain medical center
1398	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	salt lake city	united states	university of utah healthcare
1399	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	burlington	united states	the university of vermont medical center main campus
1400	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	charlottesville	united states	uva medical center
1401	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	falls church	united states	inova fairfax
1402	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seattle	united states	virginia mason medical center
1403	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	seattle	united states	harborview medical center
1404	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	morgantown	united states	ruby memorial hospital
1405	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	la crosse	united states	gundersen lutheran medical foundation
1406	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	madison	united states	university of wisconsin university hospital
1407	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	duarte	united states	city of hope national medical center
1408	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	la jolla	united states	university of california san diego health (ucsd)
1409	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sacramento	united states	university of california davis (uc davis)
1410	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san francisco	united states	university of california san francisco (ucsf)
1411	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	denver	united states	colorado blood cancer institute (cbci)
1412	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	miami	united states	university of miami
1413	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	tampa	united states	h lee moffitt cancer center
1414	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	atlanta	united states	winship cancer institute of emory university
1415	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kansas city	united states	university of kansas
1416	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	baltimore	united states	university of maryland medical center
1417	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	boston	united states	dana-farber cancer institute
1418	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	rochester	united states	mayo clinic
1419	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	saint louis	united states	washington university school of medicine
1420	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	omaha	united states	university of nebraska
1421	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	new york	united states	memorial sloan kettering cancer center
1422	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	nashville	united states	tristar centennial medical center (scri)
1423	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	dallas	united states	baylor scott & white research institute
1424	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	houston	united states	md anderson cancer center
1425	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	san antonio	united states	tti-methodist (texas transplant institute) (scri)
1426	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	milwaukee	united states	the medical college of wisconsin
1427	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	barcelona	spain	fundacio' hospital universitari vall d'hebron
1428	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	sevilla	spain	hospital universitario virgen del roco
1429	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	valencia	spain	hospital universitario la f
1430	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	cambridge	united kingdom	cambridge university hospitals nhs foundation trust
1431	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	london	united kingdom	university college london hospitals nhs foundation trust
1432	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	london	united kingdom	king's college hospital
1433	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	manchester	united kingdom	manchester royal infirmary hospital
1434	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	glasgow	united kingdom	queen elizabeth university hospital
1435	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	newcastle upon tyne	united kingdom	freeman hospital, the newcastle upon tyne hospitals nhs foundation trust
1436	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	birmingham	united kingdom	university hospitals birmingham nhs foundation trust
1437	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	bristol	united kingdom	university hospitals bristol and weston nhs foundation trust (uhbw)
1438	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	los angeles	united states	university of southern california
1439	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	kansas city	united states	university of kansas medical center
1440	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	charlotte	united states	atrium health f.h. sammy ross trauma center
1441	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	winston-salem	united states	atrium health wake forest baptist
1442	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	portland	united states	oregon health & science university
1443	2023-01-02 15:22:35.562	2023-01-02 15:22:35.562	philadelphia	united states	university of pennsylvania health system
\.


--
-- Data for Name: LocationOnEntries; Type: TABLE DATA; Schema: public; Owner: tim
--

COPY public."LocationOnEntries" (id, "createdAt", "updatedAt", "locationId", "entryId") FROM stdin;
1	2023-01-02 15:22:35.761	2023-01-02 15:22:35.761	6	5
2	2023-01-02 15:22:35.768	2023-01-02 15:22:35.768	1	8
3	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	14	11
4	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	18	11
6	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	16	11
7	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	17	11
5	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	15	11
8	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	19	11
9	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	21	11
10	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	20	11
11	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	22	11
12	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	24	11
13	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	23	11
14	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	26	11
15	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	29	11
16	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	27	11
17	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	31	11
18	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	30	11
19	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	28	11
21	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	32	11
20	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	25	11
22	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	33	11
23	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	35	11
24	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	37	11
25	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	34	11
26	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	41	11
28	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	38	11
29	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	39	11
27	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	36	11
31	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	43	11
32	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	44	11
30	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	40	11
33	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	46	11
35	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	47	11
36	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	45	11
34	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	42	11
37	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	48	11
38	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	49	11
39	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	52	11
40	2023-01-02 15:22:35.775	2023-01-02 15:22:35.775	50	11
41	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	55	11
42	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	51	11
43	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	54	11
44	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	56	11
45	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	58	11
46	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	57	11
47	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	53	11
48	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	61	11
49	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	59	11
50	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	60	11
51	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	63	11
52	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	67	11
53	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	66	11
54	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	65	11
55	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	69	11
56	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	68	11
57	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	72	11
58	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	71	11
59	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	73	11
60	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	64	11
61	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	75	11
62	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	70	11
63	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	78	11
64	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	76	11
65	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	79	11
66	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	82	11
67	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	83	11
68	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	62	11
69	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	85	11
70	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	74	11
71	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	77	11
72	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	86	11
73	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	84	11
74	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	89	11
75	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	91	11
76	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	88	11
77	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	93	11
78	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	90	11
79	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	92	11
80	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	81	11
81	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	94	15
82	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	80	11
83	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	96	19
84	2023-01-02 15:22:35.776	2023-01-02 15:22:35.776	95	19
85	2023-01-02 15:22:35.777	2023-01-02 15:22:35.777	97	21
86	2023-01-02 15:22:35.777	2023-01-02 15:22:35.777	87	11
87	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	98	24
88	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	97	23
89	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	99	26
90	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	100	26
91	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	102	26
92	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	101	26
93	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	102	26
94	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	102	26
95	2023-01-02 15:22:35.778	2023-01-02 15:22:35.778	103	26
96	2023-01-02 15:22:35.781	2023-01-02 15:22:35.781	2	25
97	2023-01-02 15:22:35.782	2023-01-02 15:22:35.782	104	28
98	2023-01-02 15:22:35.783	2023-01-02 15:22:35.783	106	32
99	2023-01-02 15:22:35.782	2023-01-02 15:22:35.782	105	29
100	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	113	31
101	2023-01-02 15:22:35.784	2023-01-02 15:22:35.784	114	35
102	2023-01-02 15:22:35.785	2023-01-02 15:22:35.785	115	36
103	2023-01-02 15:22:35.785	2023-01-02 15:22:35.785	116	39
104	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	118	41
105	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	117	41
106	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	118	41
107	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	118	41
108	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	118	41
109	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	118	41
110	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	118	41
111	2023-01-02 15:22:35.786	2023-01-02 15:22:35.786	119	40
112	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	120	42
113	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	119	43
114	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	104	53
115	2023-01-02 15:22:35.787	2023-01-02 15:22:35.787	120	44
116	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	121	55
117	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	122	58
118	2023-01-02 15:22:35.789	2023-01-02 15:22:35.789	125	64
119	2023-01-02 15:22:35.788	2023-01-02 15:22:35.788	123	61
120	2023-01-02 15:22:35.789	2023-01-02 15:22:35.789	124	62
121	2023-01-02 15:22:35.79	2023-01-02 15:22:35.79	126	81
122	2023-01-02 15:22:35.789	2023-01-02 15:22:35.789	125	66
123	2023-01-02 15:22:35.79	2023-01-02 15:22:35.79	127	69
124	2023-01-02 15:22:35.79	2023-01-02 15:22:35.79	128	70
125	2023-01-02 15:22:35.791	2023-01-02 15:22:35.791	129	76
126	2023-01-02 15:22:35.792	2023-01-02 15:22:35.792	125	86
127	2023-01-02 15:22:35.792	2023-01-02 15:22:35.792	130	77
128	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	131	88
129	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	132	79
130	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	133	78
131	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	134	78
132	2023-01-02 15:22:35.793	2023-01-02 15:22:35.793	122	82
133	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	135	84
134	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	138	83
135	2023-01-02 15:22:35.794	2023-01-02 15:22:35.794	136	80
136	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	137	83
144	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	150	83
143	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	147	83
159	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	161	83
167	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	167	90
176	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	172	90
186	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	164	90
195	2023-01-02 15:22:35.808	2023-01-02 15:22:35.808	186	97
199	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	189	101
214	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	168	140
226	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	203	140
230	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	207	140
233	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	209	118
239	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	215	127
267	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	41	129
280	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	243	129
284	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	258	129
314	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	281	130
325	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	291	130
330	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	295	130
344	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	310	134
358	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	149	138
374	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	158	138
381	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	338	138
394	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	350	150
404	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	357	155
413	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	362	155
424	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	286	155
428	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	362	153
439	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	372	165
455	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	383	179
458	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	385	179
470	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	394	194
476	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	401	200
478	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	399	200
496	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	418	200
497	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	419	200
519	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	441	200
522	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	445	200
539	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	461	200
546	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	463	200
563	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	129	204
564	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	482	204
588	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	118	204
590	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	487	204
600	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	499	213
603	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	500	215
615	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	510	236
617	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	512	230
626	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	518	244
633	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	525	251
644	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	538	249
652	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	535	249
661	2023-01-02 15:22:35.899	2023-01-02 15:22:35.899	553	292
676	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	570	292
683	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	568	292
693	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	588	292
718	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	609	309
733	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	622	273
747	2023-01-02 15:22:35.912	2023-01-02 15:22:35.912	635	283
764	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	648	294
777	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	659	304
778	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	662	304
794	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	677	304
798	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	681	304
814	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	697	304
818	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	701	304
841	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	723	338
855	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	738	321
861	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	743	319
863	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	744	323
880	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	760	323
887	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	766	323
900	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	782	323
905	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	792	323
923	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	803	323
932	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	814	323
944	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	831	323
951	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	827	323
965	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	846	323
971	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	854	323
987	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	867	323
993	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	873	325
995	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	875	329
999	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	881	329
1013	2023-01-02 15:22:35.941	2023-01-02 15:22:35.941	708	336
1021	2023-01-02 15:22:35.946	2023-01-02 15:22:35.946	894	339
1039	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	911	339
1042	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	914	339
1059	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	932	339
1066	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	938	339
1076	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	949	339
1082	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	954	345
1101	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	971	357
1113	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	983	351
1121	2023-01-02 15:22:35.954	2023-01-02 15:22:35.954	992	364
1129	2023-01-02 15:22:35.957	2023-01-02 15:22:35.957	1001	362
1138	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	1009	366
1139	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	1010	369
1154	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1025	381
1159	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1031	381
1167	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1038	389
1170	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1042	390
1175	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1047	390
1190	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1064	390
1193	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1056	390
1212	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1081	390
1215	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1084	390
1223	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1093	388
1242	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1105	401
1257	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1119	401
1270	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1138	394
1271	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1137	394
1281	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1143	400
1288	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	739	418
1298	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1152	410
1320	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1173	403
1330	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1183	403
1342	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1193	403
1379	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1207	412
1395	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1217	412
1397	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1224	412
1407	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	295	413
1414	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	365	413
1426	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1253	417
1428	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1252	417
1444	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1267	417
1445	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1238	417
1455	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1274	419
1464	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1279	419
1474	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1290	423
1483	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1299	422
1499	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1318	422
1507	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1327	422
1521	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1338	422
1532	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1347	422
1544	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1358	422
146	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	144	83
157	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	160	83
138	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	139	83
168	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	141	90
180	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	162	90
185	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	179	90
194	2023-01-02 15:22:35.807	2023-01-02 15:22:35.807	2	94
196	2023-01-02 15:22:35.806	2023-01-02 15:22:35.806	185	95
220	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	204	140
227	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	177	140
241	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	218	127
244	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	217	127
250	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	227	129
274	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	238	129
281	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	248	129
290	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	265	129
297	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	260	129
302	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	271	130
308	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	277	130
323	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	294	130
337	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	301	130
342	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	309	130
351	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	317	138
357	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	145	138
373	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	156	138
376	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	336	138
399	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	282	155
405	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	353	155
416	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	304	155
434	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	369	164
437	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	371	168
449	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	116	197
452	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	386	179
459	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	388	185
468	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	393	189
477	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	400	200
482	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	404	200
494	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	417	200
506	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	429	200
510	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	433	200
526	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	450	200
527	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	455	200
543	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	469	200
547	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	467	200
574	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	483	204
576	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	483	204
587	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	488	245
594	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	493	209
604	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	502	218
605	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	503	218
608	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	504	223
637	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	523	251
643	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	537	249
650	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	544	249
655	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	542	249
657	2023-01-02 15:22:35.898	2023-01-02 15:22:35.898	512	254
664	2023-01-02 15:22:35.899	2023-01-02 15:22:35.899	558	292
681	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	575	292
687	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	578	292
702	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	584	292
710	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	601	257
724	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	613	273
734	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	623	268
739	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	627	312
752	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	640	296
755	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	641	294
763	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	38	294
768	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	650	301
771	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	653	299
775	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	658	304
779	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	661	304
800	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	685	304
801	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	684	304
822	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	704	307
828	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	710	305
832	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	714	314
835	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	717	310
851	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	736	321
867	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	746	323
870	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	752	323
883	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	764	323
886	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	770	323
906	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	790	323
908	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	786	323
929	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	806	323
934	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	819	323
950	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	826	323
963	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	845	323
966	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	851	323
984	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	865	323
985	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	860	323
997	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	880	329
1014	2023-01-02 15:22:35.941	2023-01-02 15:22:35.941	706	336
1025	2023-01-02 15:22:35.946	2023-01-02 15:22:35.946	898	339
1030	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	903	339
1044	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	916	339
1061	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	933	339
1064	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	937	339
1094	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	965	349
1102	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	974	357
1107	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	977	357
1126	2023-01-02 15:22:35.957	2023-01-02 15:22:35.957	999	362
1133	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	1004	362
1151	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1028	381
1162	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1035	381
1164	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1026	381
1171	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	1040	384
1181	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1053	390
1196	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1062	390
1205	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1072	390
1224	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1094	388
1235	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1101	388
1238	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1103	407
1253	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1116	401
1259	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1114	401
1267	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1129	394
1272	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1130	394
1302	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1159	410
1304	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1160	410
1318	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1166	403
1327	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1180	403
1340	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1191	403
1353	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	1131	404
1356	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	1137	404
1370	2023-01-02 15:22:35.982	2023-01-02 15:22:35.982	1201	414
1375	2023-01-02 15:22:35.982	2023-01-02 15:22:35.982	1204	414
1389	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1211	412
1391	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1221	412
1402	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	1230	413
1406	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	1233	413
1420	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1239	417
1429	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1245	417
1443	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1266	417
1446	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1268	417
1459	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1276	419
1473	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1291	423
147	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	148	83
156	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	157	83
169	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	140	90
174	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	174	90
203	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	194	114
208	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	197	140
209	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	165	140
225	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	162	140
229	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	163	140
247	2023-01-02 15:22:35.828	2023-01-02 15:22:35.828	224	129
262	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	38	129
264	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	45	129
276	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	250	129
285	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	256	129
299	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	268	132
309	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	279	130
317	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	285	130
322	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	292	130
334	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	304	130
347	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	209	133
363	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	321	138
366	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	325	138
383	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	341	138
398	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	352	155
407	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	287	155
420	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	363	155
422	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	366	155
441	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	374	172
445	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	377	175
450	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	380	179
483	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	408	200
491	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	415	200
504	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	425	200
515	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	437	200
524	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	449	200
533	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	456	200
541	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	468	200
558	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	479	203
570	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	482	204
571	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	482	204
597	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	496	208
629	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	522	251
651	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	536	249
662	2023-01-02 15:22:35.899	2023-01-02 15:22:35.899	556	292
678	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	573	292
686	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	569	292
699	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	592	292
704	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	579	292
715	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	605	263
720	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	610	309
756	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	645	294
784	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	666	304
792	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	674	304
802	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	689	304
815	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	696	304
821	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	703	307
836	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	718	322
856	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	734	321
869	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	750	323
879	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	761	323
884	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	765	323
903	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	781	323
909	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	788	323
926	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	807	323
936	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	813	323
953	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	834	323
957	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	838	323
973	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	856	323
975	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	861	323
988	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	870	326
996	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	876	329
1004	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	885	329
1006	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	886	334
1009	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	889	335
1010	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	703	336
1020	2023-01-02 15:22:35.946	2023-01-02 15:22:35.946	893	339
1040	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	915	339
1041	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	913	339
1052	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	926	339
1062	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	936	339
1070	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	943	339
1087	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	962	345
1092	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	639	344
1112	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	982	353
1119	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	990	361
1130	2023-01-02 15:22:35.957	2023-01-02 15:22:35.957	998	362
1131	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	1005	362
1145	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	1016	379
1152	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1024	381
1185	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1054	390
1192	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1059	390
1206	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1075	390
1214	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1080	390
1231	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1094	388
1248	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1110	401
1255	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1120	401
1275	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1132	394
1285	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	1125	418
1297	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1154	410
1300	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1156	410
1312	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	893	402
1313	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	949	402
1328	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1182	403
1336	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1185	403
1352	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	1133	404
1377	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1212	412
1381	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1215	412
1394	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1222	412
1409	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	1232	413
1415	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1237	417
1422	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1246	417
1435	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1256	417
1442	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1265	417
1450	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1270	417
1457	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1278	419
1465	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1285	423
1481	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1300	422
1494	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1312	422
1501	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1322	422
1508	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1330	422
1526	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	998	422
1538	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1356	422
1542	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1359	422
1562	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1003	422
1569	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1384	422
1584	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1398	422
1586	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1401	422
1599	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	193	424
1602	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1420	424
1627	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1436	424
1628	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	1439	425
1639	2023-01-02 15:22:35.999	2023-01-02 15:22:35.999	1	9
1652	2023-01-02 15:22:36.014	2023-01-02 15:22:36.014	108	74
145	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	149	83
142	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	146	83
158	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	163	83
163	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	138	90
178	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	159	90
202	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	193	113
207	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	141	140
218	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	202	140
228	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	206	140
238	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	216	127
252	2023-01-02 15:22:35.82	2023-01-02 15:22:35.82	222	125
253	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	231	129
270	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	245	129
272	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	246	129
292	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	261	129
306	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	278	130
318	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	286	130
331	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	293	130
346	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	312	137
349	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	314	138
364	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	173	138
375	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	332	138
384	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	343	138
410	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	360	155
427	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	364	153
429	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	362	153
447	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	2	178
460	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	384	185
461	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	382	185
464	2023-01-02 15:22:35.86	2023-01-02 15:22:35.86	391	183
471	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	395	199
493	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	414	200
495	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	421	200
511	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	436	200
512	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	435	200
531	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	453	200
536	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	459	200
553	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	473	200
554	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	477	198
559	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	480	221
573	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	483	204
578	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	484	204
599	2023-01-02 15:22:35.878	2023-01-02 15:22:35.878	498	212
601	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	371	220
620	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	514	238
621	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	490	239
635	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	532	251
645	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	541	249
653	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	546	249
660	2023-01-02 15:22:35.899	2023-01-02 15:22:35.899	551	292
673	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	571	292
684	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	576	292
695	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	591	292
705	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	598	292
712	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	548	264
716	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	606	266
725	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	616	273
728	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	619	273
741	2023-01-02 15:22:35.905	2023-01-02 15:22:35.905	629	280
762	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	46	294
766	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	599	295
772	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	654	299
780	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	667	304
791	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	673	304
803	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	686	304
813	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	695	304
820	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	702	304
829	2023-01-02 15:22:35.925	2023-01-02 15:22:35.925	711	316
842	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	724	320
850	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	732	321
854	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	735	321
862	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	747	323
878	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	758	323
882	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	763	323
898	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	778	323
904	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	748	323
920	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	798	323
922	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	804	323
940	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	821	323
943	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	825	323
960	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	840	323
961	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	844	323
979	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	863	323
983	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	864	323
992	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	869	352
1007	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	888	328
1017	2023-01-02 15:22:35.942	2023-01-02 15:22:35.942	890	337
1026	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	907	339
1036	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	909	339
1054	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	930	339
1060	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	934	339
1077	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	951	339
1078	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	950	339
1085	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	959	345
1110	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	981	374
1128	2023-01-02 15:22:35.957	2023-01-02 15:22:35.957	1000	362
1135	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	1007	362
1146	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	1017	385
1148	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	1020	393
1177	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1048	390
1183	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1051	390
1202	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1070	390
1207	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1076	390
1218	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1085	390
1227	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1097	388
1233	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1099	388
1241	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1107	401
1250	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1115	401
1273	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1134	394
1289	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1144	410
1292	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1011	410
1308	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1161	410
1319	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1171	403
1325	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1139	403
1339	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1190	403
1347	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	1196	406
1359	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	1125	404
1366	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	1005	411
1369	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	1011	409
1374	2023-01-02 15:22:35.982	2023-01-02 15:22:35.982	1206	414
1384	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1216	412
1398	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	1226	413
1401	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	1229	413
1425	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1248	417
1424	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1249	417
1448	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1260	417
1460	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1277	419
1470	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1292	423
1480	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1303	422
1486	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1306	422
1505	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1326	422
1509	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1328	422
1524	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1340	422
1525	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1342	422
1545	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1362	422
1548	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1367	422
148	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	151	83
140	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	143	83
166	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	166	90
175	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	154	90
187	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	178	90
192	2023-01-02 15:22:35.804	2023-01-02 15:22:35.804	183	91
206	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	191	103
222	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	172	140
223	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	205	140
235	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	211	122
249	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	226	129
255	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	232	129
266	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	49	129
283	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	254	129
287	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	257	129
301	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	74	129
315	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	283	130
321	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	288	130
335	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	305	130
348	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	313	139
350	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	315	138
362	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	326	138
370	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	329	138
377	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	337	138
387	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	344	144
412	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	298	155
415	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	277	155
426	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	303	155
430	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	367	153
451	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	382	179
462	2023-01-02 15:22:35.858	2023-01-02 15:22:35.858	371	181
480	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	403	200
481	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	406	200
501	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	420	200
502	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	423	200
520	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	447	200
523	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	448	200
538	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	444	200
550	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	466	200
555	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	476	200
568	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	483	204
575	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	484	204
596	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	497	208
611	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	506	224
619	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	513	235
636	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	529	251
649	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	547	249
671	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	563	292
677	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	564	292
692	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	585	292
698	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	594	292
713	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	603	261
714	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	604	262
719	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	611	309
731	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	512	265
732	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	618	273
745	2023-01-02 15:22:35.91	2023-01-02 15:22:35.91	633	279
750	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	637	291
753	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	116	297
760	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	38	294
765	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	647	294
773	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	655	302
787	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	669	304
793	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	675	304
807	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	690	304
812	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	682	304
825	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	709	307
830	2023-01-02 15:22:35.925	2023-01-02 15:22:35.925	712	306
864	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	77	319
881	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	762	323
885	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	767	323
901	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	785	323
913	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	791	323
921	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	787	323
924	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	816	323
942	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	823	323
948	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	830	323
959	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	842	323
968	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	847	323
982	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	857	323
998	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	882	329
1000	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	879	329
1035	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	908	339
1037	2023-01-02 15:22:35.946	2023-01-02 15:22:35.946	899	339
1049	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	921	339
1058	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	931	339
1073	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	947	339
1083	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	956	345
1088	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	961	345
1095	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	966	349
1108	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	980	357
1136	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	1006	362
1140	2023-01-02 15:22:35.959	2023-01-02 15:22:35.959	1011	372
1142	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	1013	373
1143	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	1014	376
1149	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	1019	393
1163	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1021	381
1169	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	1038	386
1179	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1044	390
1194	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1063	390
1201	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1071	390
1211	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1082	390
1216	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1087	390
1236	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1102	388
1243	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1106	401
1251	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1117	401
1260	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	1123	396
1266	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1128	394
1282	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1136	394
1293	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1147	410
1311	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1163	402
1323	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1175	403
1331	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1181	403
1351	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	1135	404
1358	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	739	404
1363	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	1138	404
1367	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	1198	411
1373	2023-01-02 15:22:35.982	2023-01-02 15:22:35.982	1203	414
1385	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1209	412
1387	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1210	412
1403	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	1228	413
1418	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1240	417
1436	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1257	417
1439	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1262	417
1453	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1272	421
1469	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1293	423
1471	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1287	423
1488	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1309	422
1489	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1308	422
1506	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1325	422
1514	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1332	422
1527	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1345	422
1531	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1348	422
1550	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1366	422
1552	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1369	422
1566	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1383	422
149	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	152	83
139	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	142	83
172	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	170	90
188	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	156	90
201	2023-01-02 15:22:35.812	2023-01-02 15:22:35.812	192	111
205	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	195	119
215	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	151	140
219	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	160	140
237	2023-01-02 15:22:35.816	2023-01-02 15:22:35.816	213	126
258	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	235	129
269	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	242	129
288	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	259	129
289	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	57	129
305	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	275	130
307	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	274	130
320	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	287	130
324	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	295	130
339	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	306	130
341	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	307	130
345	2023-01-02 15:22:35.833	2023-01-02 15:22:35.833	311	135
352	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	168	138
353	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	318	138
368	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	331	138
378	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	333	138
390	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	346	174
393	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	349	157
397	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	354	155
402	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	358	155
417	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	301	155
419	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	364	155
432	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	365	153
440	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	373	169
443	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	375	173
444	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	376	182
448	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	379	192
454	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	384	179
457	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	380	185
467	2023-01-02 15:22:35.862	2023-01-02 15:22:35.862	392	189
473	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	397	200
490	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	412	200
492	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	413	200
513	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	432	200
525	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	442	200
530	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	454	200
540	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	465	200
548	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	471	200
557	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	475	200
562	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	129	204
567	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	482	204
583	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	486	204
584	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	483	204
592	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	491	211
602	2023-01-02 15:22:35.881	2023-01-02 15:22:35.881	213	214
616	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	371	229
625	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	517	260
628	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	521	251
631	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	520	251
642	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	539	249
646	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	540	249
656	2023-01-02 15:22:35.898	2023-01-02 15:22:35.898	548	258
666	2023-01-02 15:22:35.899	2023-01-02 15:22:35.899	560	292
672	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	561	292
685	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	577	292
694	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	589	292
709	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	600	259
721	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	612	267
727	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	614	273
738	2023-01-02 15:22:35.904	2023-01-02 15:22:35.904	626	286
742	2023-01-02 15:22:35.905	2023-01-02 15:22:35.905	628	280
748	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	636	289
759	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	39	294
782	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	663	304
789	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	672	304
795	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	678	304
810	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	693	304
816	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	698	304
833	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	715	317
837	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	719	322
853	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	739	321
876	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	757	323
888	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	768	323
897	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	775	323
902	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	783	323
919	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	802	323
939	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	817	323
941	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	822	323
958	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	839	323
964	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	849	323
981	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	796	323
986	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	866	323
1016	2023-01-02 15:22:35.941	2023-01-02 15:22:35.941	707	336
1018	2023-01-02 15:22:35.943	2023-01-02 15:22:35.943	655	341
1028	2023-01-02 15:22:35.946	2023-01-02 15:22:35.946	892	339
1038	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	912	339
1051	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	923	339
1055	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	928	339
1074	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	946	339
1084	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	955	345
1086	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	960	345
1097	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	968	350
1114	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	985	358
1116	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	988	375
1120	2023-01-02 15:22:35.954	2023-01-02 15:22:35.954	991	367
1155	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1030	381
1161	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1032	381
1168	2023-01-02 15:22:35.964	2023-01-02 15:22:35.964	1039	387
1178	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1049	390
1197	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1066	390
1199	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1073	390
1217	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1086	390
1226	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1094	388
1228	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1098	388
1239	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1092	388
1274	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1139	394
1284	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	1133	418
1290	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1145	410
1303	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1157	410
1316	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1172	403
1321	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1176	403
1337	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1189	403
1344	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1194	403
1355	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	1134	404
1365	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	1199	411
1371	2023-01-02 15:22:35.982	2023-01-02 15:22:35.982	1202	414
1380	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1208	412
1386	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1220	412
1413	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	1236	413
1417	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1241	417
1431	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1250	417
1438	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1261	417
1461	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1281	419
1472	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1294	423
1484	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1310	422
1492	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1314	422
1503	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1323	422
1513	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1287	422
151	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	156	83
141	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	145	83
160	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	164	83
170	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	168	90
182	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	173	90
184	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	175	90
191	2023-01-02 15:22:35.804	2023-01-02 15:22:35.804	182	92
221	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	161	140
231	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	178	140
236	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	210	122
242	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	220	127
245	2023-01-02 15:22:35.819	2023-01-02 15:22:35.819	221	123
254	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	228	129
265	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	240	129
268	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	244	129
286	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	255	129
296	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	263	129
312	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	280	130
336	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	303	130
340	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	300	130
355	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	316	138
359	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	148	138
371	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	334	138
379	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	339	138
388	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	345	145
403	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	359	155
414	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	300	155
436	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	54	163
438	2023-01-02 15:22:35.851	2023-01-02 15:22:35.851	372	166
453	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	381	179
465	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	389	185
485	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	409	200
488	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	409	200
507	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	431	200
521	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	446	200
535	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	457	200
537	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	460	200
552	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	472	200
556	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	478	198
581	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	486	204
585	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	487	204
606	2023-01-02 15:22:35.882	2023-01-02 15:22:35.882	501	218
607	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	127	225
612	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	508	231
614	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	511	236
632	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	527	251
639	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	528	251
647	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	533	249
659	2023-01-02 15:22:35.899	2023-01-02 15:22:35.899	549	292
670	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	562	292
675	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	565	292
696	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	590	292
697	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	593	292
707	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	596	292
729	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	620	273
737	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	625	270
746	2023-01-02 15:22:35.911	2023-01-02 15:22:35.911	634	282
767	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	649	298
783	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	665	304
785	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	664	304
804	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	687	304
809	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	691	304
824	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	706	307
839	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	721	315
844	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	727	320
857	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	737	321
865	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	745	323
871	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	753	323
889	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	771	323
890	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	772	323
907	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	789	323
910	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	793	323
925	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	808	323
930	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	812	323
945	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	828	323
947	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	829	323
967	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	841	323
974	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	858	323
1012	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	705	336
1019	2023-01-02 15:22:35.944	2023-01-02 15:22:35.944	891	340
1023	2023-01-02 15:22:35.946	2023-01-02 15:22:35.946	895	339
1029	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	902	339
1043	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	917	339
1056	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	925	339
1063	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	935	339
1079	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	952	346
1089	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	958	345
1109	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	972	357
1111	2023-01-02 15:22:35.952	2023-01-02 15:22:35.952	984	355
1115	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	986	358
1127	2023-01-02 15:22:35.957	2023-01-02 15:22:35.957	995	362
1141	2023-01-02 15:22:35.96	2023-01-02 15:22:35.96	1012	371
1166	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1036	383
1172	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1041	390
1176	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1045	390
1187	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1058	390
1191	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1061	390
1208	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1077	390
1229	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1098	388
1247	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1112	401
1254	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	717	401
1258	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1122	401
1277	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	739	394
1278	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1140	394
1283	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	1128	418
1287	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	1140	418
1296	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1151	410
1306	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1149	410
1310	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1164	402
1322	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1174	403
1332	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1187	403
1341	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1167	403
1345	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1186	403
1348	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	1129	404
1357	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	1139	404
1383	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1212	412
1399	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	1225	413
1405	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	357	413
1416	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1243	417
1433	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1256	417
1437	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1259	417
1462	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1282	419
1468	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1289	423
1482	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1298	422
1491	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1311	422
1502	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1321	422
1510	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1331	422
1522	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1142	422
1529	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1343	422
1539	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1351	422
1547	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1364	422
1561	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1378	422
1572	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1387	422
1579	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1395	422
1589	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1404	422
1595	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1408	424
150	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	140	83
165	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	162	83
171	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	169	90
190	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	180	89
193	2023-01-02 15:22:35.805	2023-01-02 15:22:35.805	184	93
212	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	199	140
213	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	147	140
224	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	208	140
234	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	212	124
261	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	237	129
263	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	239	129
277	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	252	129
282	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	249	129
298	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	269	131
303	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	276	130
319	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	289	130
326	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	290	130
338	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	302	130
361	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	323	138
369	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	330	138
386	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	342	138
389	2023-01-02 15:22:35.836	2023-01-02 15:22:35.836	345	151
395	2023-01-02 15:22:35.838	2023-01-02 15:22:35.838	351	154
396	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	270	155
409	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	297	155
418	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	362	155
456	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	381	185
466	2023-01-02 15:22:35.859	2023-01-02 15:22:35.859	390	183
469	2023-01-02 15:22:35.863	2023-01-02 15:22:35.863	114	186
472	2023-01-02 15:22:35.864	2023-01-02 15:22:35.864	395	196
484	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	405	200
489	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	411	200
503	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	426	200
508	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	430	200
518	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	443	200
528	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	452	200
545	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	466	200
549	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	470	200
560	2023-01-02 15:22:35.874	2023-01-02 15:22:35.874	481	210
566	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	482	204
577	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	486	204
586	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	487	204
595	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	494	207
622	2023-01-02 15:22:35.886	2023-01-02 15:22:35.886	515	237
630	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	524	251
634	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	530	251
648	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	543	249
658	2023-01-02 15:22:35.899	2023-01-02 15:22:35.899	550	292
674	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	566	292
679	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	567	292
690	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	587	292
700	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	583	292
717	2023-01-02 15:22:35.901	2023-01-02 15:22:35.901	607	309
744	2023-01-02 15:22:35.905	2023-01-02 15:22:35.905	632	277
761	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	643	294
770	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	652	303
788	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	670	304
796	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	676	304
811	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	694	304
819	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	700	304
827	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	707	307
831	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	713	308
848	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	731	320
849	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	725	320
860	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	741	321
873	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	751	323
877	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	759	323
892	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	774	323
899	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	779	323
915	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	797	323
918	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	801	323
928	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	811	323
937	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	820	323
946	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	833	323
949	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	832	323
970	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	852	323
976	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	848	323
990	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	868	323
994	2023-01-02 15:22:35.938	2023-01-02 15:22:35.938	874	331
1002	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	884	329
1033	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	906	339
1034	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	905	339
1050	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	924	339
1053	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	927	339
1071	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	944	339
1072	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	945	339
1080	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	904	339
1090	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	957	345
1093	2023-01-02 15:22:35.949	2023-01-02 15:22:35.949	964	368
1096	2023-01-02 15:22:35.95	2023-01-02 15:22:35.95	967	350
1103	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	976	357
1105	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	975	357
1118	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	989	370
1132	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	1002	362
1157	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1034	381
1158	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1027	381
1182	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1050	390
1188	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	732	390
1198	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1069	390
1209	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1078	390
1219	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1089	390
1234	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1102	388
1246	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1109	401
1252	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1118	401
1261	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	1124	398
1262	2023-01-02 15:22:35.972	2023-01-02 15:22:35.972	1125	399
1264	2023-01-02 15:22:35.973	2023-01-02 15:22:35.973	1127	395
1268	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1133	394
1301	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1155	410
1315	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1168	403
1329	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1179	403
1334	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1170	403
1350	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	1136	404
1368	2023-01-02 15:22:35.981	2023-01-02 15:22:35.981	1200	408
1372	2023-01-02 15:22:35.982	2023-01-02 15:22:35.982	1205	414
1390	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1219	412
1392	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1210	412
1400	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	274	413
1411	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	1234	413
1419	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1244	417
1434	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1256	417
1440	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1258	417
1452	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1271	416
1466	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1288	423
1477	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1295	423
1485	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1307	422
1497	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1317	422
1511	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1329	422
1519	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1336	422
1534	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1304	422
1536	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1354	422
1555	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1370	422
1559	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1374	422
1568	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1382	422
1580	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1394	422
1596	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1410	424
152	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	153	83
161	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	158	83
183	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	176	90
216	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	200	140
243	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	219	127
246	2023-01-02 15:22:35.821	2023-01-02 15:22:35.821	223	128
256	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	234	129
271	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	247	129
294	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	77	129
310	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	270	130
332	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	298	130
367	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	327	138
385	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	178	138
391	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	347	148
411	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	290	155
433	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	368	158
442	2023-01-02 15:22:35.853	2023-01-02 15:22:35.853	373	170
474	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	398	200
498	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	416	200
516	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	439	200
544	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	462	200
569	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	129	204
623	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	2	242
627	2023-01-02 15:22:35.895	2023-01-02 15:22:35.895	519	250
638	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	531	251
665	2023-01-02 15:22:35.899	2023-01-02 15:22:35.899	559	292
680	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	572	292
701	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	595	292
722	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	608	309
736	2023-01-02 15:22:35.903	2023-01-02 15:22:35.903	624	269
749	2023-01-02 15:22:35.916	2023-01-02 15:22:35.916	638	288
758	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	644	294
774	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	656	304
797	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	679	304
817	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	699	304
845	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	730	320
859	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	213	321
874	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	755	323
893	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	769	323
911	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	794	323
931	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	810	323
956	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	837	323
978	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	855	323
1022	2023-01-02 15:22:35.946	2023-01-02 15:22:35.946	896	339
1045	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	918	339
1065	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	940	339
1099	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	970	357
1117	2023-01-02 15:22:35.953	2023-01-02 15:22:35.953	987	375
1124	2023-01-02 15:22:35.957	2023-01-02 15:22:35.957	994	362
1150	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1022	381
1173	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1046	390
1195	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1065	390
1210	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1079	390
1237	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1102	388
1256	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1121	401
1263	2023-01-02 15:22:35.973	2023-01-02 15:22:35.973	1126	420
1276	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1125	394
1299	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1153	410
1317	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1169	403
1338	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1192	403
1360	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	1140	404
1396	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1223	412
1410	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	1227	413
1427	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1251	417
1449	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1269	417
1458	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1280	419
1478	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1296	423
1479	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1301	422
1495	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1316	422
1496	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1315	422
1515	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	193	422
1517	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1335	422
1535	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1350	422
1543	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1357	422
1556	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1372	422
1560	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1376	422
1574	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1388	422
1583	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1399	422
1604	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1418	424
1616	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1411	424
1632	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	1443	425
1645	2023-01-02 15:22:36.011	2023-01-02 15:22:36.011	8	52
153	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	154	83
179	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	177	90
198	2023-01-02 15:22:35.81	2023-01-02 15:22:35.81	188	98
211	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	138	140
248	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	225	129
260	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	236	129
278	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	251	129
300	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	266	129
316	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	282	130
333	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	299	130
360	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	324	138
382	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	340	138
408	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	361	155
431	2023-01-02 15:22:35.849	2023-01-02 15:22:35.849	365	153
435	2023-01-02 15:22:35.85	2023-01-02 15:22:35.85	370	162
446	2023-01-02 15:22:35.854	2023-01-02 15:22:35.854	378	176
475	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	396	200
500	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	424	200
517	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	440	200
532	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	434	200
551	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	474	200
580	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	486	204
593	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	492	205
598	2023-01-02 15:22:35.877	2023-01-02 15:22:35.877	495	208
641	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	534	249
669	2023-01-02 15:22:35.899	2023-01-02 15:22:35.899	555	292
688	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	582	292
706	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	597	292
726	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	617	273
790	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	671	304
808	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	692	304
840	2023-01-02 15:22:35.929	2023-01-02 15:22:35.929	722	318
868	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	742	319
896	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	780	323
917	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	784	323
938	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	815	323
962	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	843	323
980	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	862	323
1011	2023-01-02 15:22:35.94	2023-01-02 15:22:35.94	704	336
1027	2023-01-02 15:22:35.946	2023-01-02 15:22:35.946	900	339
1047	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	920	339
1068	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	941	339
1091	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	963	347
1106	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	979	357
1134	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	1003	362
1147	2023-01-02 15:22:35.962	2023-01-02 15:22:35.962	1018	380
1153	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1023	381
1174	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1043	390
1189	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1060	390
1213	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1083	390
1222	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1091	391
1240	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1104	401
1265	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1131	394
1280	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1141	394
1294	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1148	410
1307	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1162	402
1326	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1178	403
1354	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	1130	404
1364	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	1197	405
1388	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1218	412
1430	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1255	417
1451	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1269	417
1463	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1283	423
1487	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1305	422
1500	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1319	422
1504	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1324	422
1520	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1339	422
1523	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1341	422
1540	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1361	422
1546	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1363	422
1567	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1380	422
1570	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1385	422
1585	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1400	422
1591	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1406	422
1603	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1417	424
1610	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1425	424
1625	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1437	424
1623	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1433	424
1638	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	1416	425
1643	2023-01-02 15:22:36.008	2023-01-02 15:22:36.008	4	45
154	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	155	83
162	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	137	90
177	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	149	90
189	2023-01-02 15:22:35.803	2023-01-02 15:22:35.803	181	87
232	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	142	140
240	2023-01-02 15:22:35.817	2023-01-02 15:22:35.817	214	127
259	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	233	129
279	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	253	129
295	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	267	129
311	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	273	130
329	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	296	130
365	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	322	138
392	2023-01-02 15:22:35.837	2023-01-02 15:22:35.837	348	149
400	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	355	155
423	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	365	155
463	2023-01-02 15:22:35.855	2023-01-02 15:22:35.855	387	185
479	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	402	200
499	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	422	200
514	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	438	200
534	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	458	200
565	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	482	204
579	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	485	204
609	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	505	224
663	2023-01-02 15:22:35.899	2023-01-02 15:22:35.899	554	292
682	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	574	292
703	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	580	292
711	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	602	256
723	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	615	273
735	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	506	273
743	2023-01-02 15:22:35.905	2023-01-02 15:22:35.905	631	280
757	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	646	294
769	2023-01-02 15:22:35.919	2023-01-02 15:22:35.919	651	300
776	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	657	304
799	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	680	304
838	2023-01-02 15:22:35.927	2023-01-02 15:22:35.927	720	311
846	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	729	320
875	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	756	323
894	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	776	323
914	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	799	323
933	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	818	323
955	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	836	323
977	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	859	323
1005	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	877	329
1008	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	887	328
1024	2023-01-02 15:22:35.946	2023-01-02 15:22:35.946	897	339
1048	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	922	339
1069	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	942	339
1081	2023-01-02 15:22:35.948	2023-01-02 15:22:35.948	953	345
1098	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	969	357
1122	2023-01-02 15:22:35.957	2023-01-02 15:22:35.957	993	362
1184	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1055	390
1200	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1067	390
1220	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1090	390
1230	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1096	388
1245	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1108	401
1279	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1142	397
1295	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1150	410
1314	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1165	403
1335	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1188	403
1382	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1214	412
1404	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	1231	413
1421	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1242	417
1441	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1264	417
1454	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1275	419
1475	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1286	423
1493	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1313	422
1516	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1334	422
1528	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1344	422
1537	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1353	422
1551	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1368	422
1557	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1373	422
1565	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1379	422
1578	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1393	422
1587	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1403	422
1598	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1409	424
1601	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1412	424
1618	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1431	424
1620	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1432	424
1636	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	1296	425
1644	2023-01-02 15:22:36.009	2023-01-02 15:22:36.009	2	50
1647	2023-01-02 15:22:36.011	2023-01-02 15:22:36.011	12	52
155	2023-01-02 15:22:35.796	2023-01-02 15:22:35.796	159	83
164	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	165	90
181	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	161	90
200	2023-01-02 15:22:35.811	2023-01-02 15:22:35.811	190	99
204	2023-01-02 15:22:35.813	2023-01-02 15:22:35.813	196	117
217	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	201	140
257	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	230	129
273	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	58	129
291	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	262	129
304	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	272	130
327	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	292	130
356	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	320	138
380	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	328	138
406	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	291	155
425	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	307	155
487	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	407	200
505	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	427	200
542	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	464	200
561	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	117	204
582	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	118	204
591	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	490	206
610	2023-01-02 15:22:35.883	2023-01-02 15:22:35.883	507	228
640	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	526	251
654	2023-01-02 15:22:35.897	2023-01-02 15:22:35.897	545	249
667	2023-01-02 15:22:35.899	2023-01-02 15:22:35.899	557	292
689	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	586	292
708	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	599	255
730	2023-01-02 15:22:35.902	2023-01-02 15:22:35.902	621	273
781	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	660	304
805	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	683	304
826	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	708	307
834	2023-01-02 15:22:35.926	2023-01-02 15:22:35.926	716	313
847	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	726	320
858	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	740	321
872	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	754	323
895	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	777	323
916	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	800	323
935	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	809	323
954	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	835	323
972	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	853	323
989	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	871	326
1001	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	883	329
1015	2023-01-02 15:22:35.941	2023-01-02 15:22:35.941	709	336
1032	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	910	339
1057	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	929	339
1075	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	948	339
1104	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	978	357
1125	2023-01-02 15:22:35.957	2023-01-02 15:22:35.957	997	362
1137	2023-01-02 15:22:35.958	2023-01-02 15:22:35.958	1008	363
1156	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1029	381
1165	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1037	382
1186	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1057	390
1204	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1074	390
1221	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1088	390
1225	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1095	388
1244	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1111	401
1286	2023-01-02 15:22:35.975	2023-01-02 15:22:35.975	1139	418
1305	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1158	410
1324	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1177	403
1343	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1195	403
1349	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	1132	404
1362	2023-01-02 15:22:35.979	2023-01-02 15:22:35.979	1128	404
1376	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1213	412
1393	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1223	412
1408	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	287	413
1423	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1247	417
1447	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1263	417
1456	2023-01-02 15:22:35.988	2023-01-02 15:22:35.988	1273	419
1476	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1297	423
1498	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1320	422
1518	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1337	422
1533	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1349	422
1541	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1352	422
1553	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	983	422
1573	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1389	422
1575	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1392	422
1590	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1405	422
1600	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1415	424
1608	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1419	424
1633	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	1376	425
1648	2023-01-02 15:22:36.011	2023-01-02 15:22:36.011	7	52
1649	2023-01-02 15:22:36.011	2023-01-02 15:22:36.011	10	52
1657	2023-01-02 15:22:36.014	2023-01-02 15:22:36.014	111	74
1554	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1371	422
1564	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1381	422
1581	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1396	422
1607	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1426	424
1629	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	1442	425
1563	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1377	422
1612	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1416	424
1651	2023-01-02 15:22:36.011	2023-01-02 15:22:36.011	13	52
1571	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1386	422
1594	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1360	422
1614	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1428	424
1631	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	996	425
1656	2023-01-02 15:22:36.014	2023-01-02 15:22:36.014	112	74
1576	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1390	422
1592	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1355	422
1611	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1421	424
1626	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1434	424
1577	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1391	422
1593	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1407	424
1615	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1414	424
1624	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1435	424
1588	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1402	422
1605	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1424	424
1630	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	1441	425
1606	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1423	424
1622	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1422	424
1641	2023-01-02 15:22:36.008	2023-01-02 15:22:36.008	3	45
1653	2023-01-02 15:22:36.014	2023-01-02 15:22:36.014	109	74
1609	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1040	424
1621	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1003	424
1637	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	1297	425
1640	2023-01-02 15:22:36	2023-01-02 15:22:36	2	57
1642	2023-01-02 15:22:36.009	2023-01-02 15:22:36.009	5	45
1650	2023-01-02 15:22:36.011	2023-01-02 15:22:36.011	11	52
1613	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1427	424
1646	2023-01-02 15:22:36.011	2023-01-02 15:22:36.011	9	52
1655	2023-01-02 15:22:36.014	2023-01-02 15:22:36.014	110	74
1617	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1429	424
1634	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	1438	425
1654	2023-01-02 15:22:36.014	2023-01-02 15:22:36.014	107	74
137	2023-01-02 15:22:35.795	2023-01-02 15:22:35.795	141	83
173	2023-01-02 15:22:35.802	2023-01-02 15:22:35.802	171	90
197	2023-01-02 15:22:35.81	2023-01-02 15:22:35.81	187	102
210	2023-01-02 15:22:35.815	2023-01-02 15:22:35.815	198	140
251	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	229	129
275	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	241	129
293	2023-01-02 15:22:35.829	2023-01-02 15:22:35.829	264	129
313	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	284	130
328	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	297	130
343	2023-01-02 15:22:35.832	2023-01-02 15:22:35.832	308	130
354	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	319	138
372	2023-01-02 15:22:35.835	2023-01-02 15:22:35.835	335	138
401	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	356	155
421	2023-01-02 15:22:35.848	2023-01-02 15:22:35.848	306	155
486	2023-01-02 15:22:35.872	2023-01-02 15:22:35.872	410	200
509	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	428	200
529	2023-01-02 15:22:35.873	2023-01-02 15:22:35.873	451	200
572	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	483	204
589	2023-01-02 15:22:35.876	2023-01-02 15:22:35.876	489	206
613	2023-01-02 15:22:35.884	2023-01-02 15:22:35.884	509	236
618	2023-01-02 15:22:35.885	2023-01-02 15:22:35.885	512	233
624	2023-01-02 15:22:35.894	2023-01-02 15:22:35.894	516	252
668	2023-01-02 15:22:35.899	2023-01-02 15:22:35.899	552	292
691	2023-01-02 15:22:35.9	2023-01-02 15:22:35.9	581	292
740	2023-01-02 15:22:35.905	2023-01-02 15:22:35.905	630	280
751	2023-01-02 15:22:35.917	2023-01-02 15:22:35.917	639	293
754	2023-01-02 15:22:35.918	2023-01-02 15:22:35.918	642	294
786	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	668	304
806	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	688	304
823	2023-01-02 15:22:35.922	2023-01-02 15:22:35.922	705	307
843	2023-01-02 15:22:35.93	2023-01-02 15:22:35.93	728	320
852	2023-01-02 15:22:35.931	2023-01-02 15:22:35.931	733	321
866	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	749	323
891	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	773	323
912	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	795	323
927	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	805	323
952	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	824	323
969	2023-01-02 15:22:35.936	2023-01-02 15:22:35.936	850	323
991	2023-01-02 15:22:35.937	2023-01-02 15:22:35.937	872	324
1003	2023-01-02 15:22:35.939	2023-01-02 15:22:35.939	878	329
1031	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	901	339
1046	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	919	339
1067	2023-01-02 15:22:35.947	2023-01-02 15:22:35.947	939	339
1100	2023-01-02 15:22:35.951	2023-01-02 15:22:35.951	973	357
1123	2023-01-02 15:22:35.957	2023-01-02 15:22:35.957	996	362
1144	2023-01-02 15:22:35.961	2023-01-02 15:22:35.961	1015	377
1160	2023-01-02 15:22:35.963	2023-01-02 15:22:35.963	1033	381
1180	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1052	390
1203	2023-01-02 15:22:35.967	2023-01-02 15:22:35.967	1068	390
1232	2023-01-02 15:22:35.968	2023-01-02 15:22:35.968	1100	388
1249	2023-01-02 15:22:35.971	2023-01-02 15:22:35.971	1113	401
1269	2023-01-02 15:22:35.974	2023-01-02 15:22:35.974	1135	394
1291	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	1146	410
1309	2023-01-02 15:22:35.976	2023-01-02 15:22:35.976	910	402
1333	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	739	403
1346	2023-01-02 15:22:35.978	2023-01-02 15:22:35.978	1184	403
1361	2023-01-02 15:22:35.98	2023-01-02 15:22:35.98	1141	404
1378	2023-01-02 15:22:35.983	2023-01-02 15:22:35.983	1212	412
1412	2023-01-02 15:22:35.986	2023-01-02 15:22:35.986	1235	413
1432	2023-01-02 15:22:35.987	2023-01-02 15:22:35.987	1254	417
1467	2023-01-02 15:22:35.989	2023-01-02 15:22:35.989	1284	423
1490	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1302	422
1512	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1333	422
1530	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1346	422
1549	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1365	422
1558	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1375	422
1582	2023-01-02 15:22:35.993	2023-01-02 15:22:35.993	1397	422
1597	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1413	424
1619	2023-01-02 15:22:35.994	2023-01-02 15:22:35.994	1430	424
1635	2023-01-02 15:22:35.995	2023-01-02 15:22:35.995	1440	425
\.


--
-- Data for Name: MeshTerm; Type: TABLE DATA; Schema: public; Owner: tim
--

COPY public."MeshTerm" (id, "createdAt", "updatedAt", term) FROM stdin;
0	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	rhinitis
1	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	rhinitis, allergic
2	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	nasal obstruction
3	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	levocetirizine
4	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	desloratadine
5	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cetirizine
6	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	rhinitis, allergic, perennial
7	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	rhinitis, allergic, seasonal
8	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	loratadine
9	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	fexofenadine
10	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	dermatitis
11	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	eczema
12	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	hydrocortisone
13	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	terfenadine
14	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	urticaria
15	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	chronic urticaria
16	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	montelukast
17	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	pruritus
18	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	malnutrition
19	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	neuromyelitis optica
20	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	carcinoma, non-small-cell lung
21	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	hydroxyzine
22	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	lymphangioleiomyomatosis
23	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	sirolimus
24	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	pseudoephedrine
25	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ephedrine
26	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	hypersensitivity
27	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	dermatitis, atopic
28	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	hematologic neoplasms
29	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	prednisolone
30	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	asthma
31	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	betamethasone
32	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	disease
33	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	covid-19
34	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	famotidine
35	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ciclesonide
36	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	gastroesophageal reflux
37	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	esophagitis, peptic
38	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	alopecia
39	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	alopecia areata
40	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ethanol
41	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	minoxidil
42	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	drug-related side effects and adverse reactions
43	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	multiple sclerosis
44	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	histamine antagonists
45	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	histamine h1 antagonists
46	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	multiple myeloma
47	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	neoplasms, plasma cell
48	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	neoplasms
49	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	diphenhydramine
50	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	promethazine
51	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	paclitaxel
52	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	rituximab
53	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	lung neoplasms
54	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	aprepitant
55	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	fosaprepitant
56	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	fluticasone
57	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	xhance
58	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	colorectal neoplasms
59	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	bevacizumab
60	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	capecitabine
61	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	inflammation
62	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	heat stress disorders
63	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ketotifen
64	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cough
65	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	tranexamic acid
66	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	common cold
67	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ibuprofen
68	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	phenylephrine
69	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	oxymetazoline
70	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	kidney diseases
71	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	diabetic nephropathies
72	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	mometasone furoate
73	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	lymphoma
74	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	aggression
75	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	conjunctivitis
76	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	conjunctivitis, allergic
77	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	rhinorrhea
78	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	mandelic acids
79	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	oxybutynin
80	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	hypoxia
81	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	nedocromil
82	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	skin diseases
83	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	acetaminophen
84	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	mycophenolic acid
85	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	midazolam
86	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	breast neoplasms
87	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	naproxen
88	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	arthritis
89	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	arthritis, rheumatoid
90	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	quinidine
91	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	quinidine gluconate
92	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	dabigatran
93	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	endometrial neoplasms
94	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	head and neck neoplasms
95	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	empagliflozin
96	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	valsartan
97	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	psoriasis
98	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	exanthema
99	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	dexchlorpheniramine
100	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	nephrolithiasis
101	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	kidney calculi
102	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	sulfasalazine
103	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	aortic valve stenosis
104	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	constriction, pathologic
105	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	vitamin d
106	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	olopatadine hydrochloride
107	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	dextrans
108	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ophthalmic solutions
109	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	sclerosis
110	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	glatiramer acetate
111	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	(t,g)-a-l
112	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	rhinitis, vasomotor
113	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	altitude sickness
114	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ebastine
115	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	prostatitis
116	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	pelvic pain
117	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cromolyn sodium
118	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	pregabalin
119	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	azelastine
120	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	keratosis, actinic
121	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	keratosis
122	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ureteral calculi
123	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ureterolithiasis
124	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	colic
125	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	recurrence
126	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	renal colic
127	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	tamsulosin
128	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	otitis
129	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	otitis media
130	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	otitis media with effusion
131	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	anti-bacterial agents
132	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cefpodoxime
133	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	nasal decongestants
134	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	neuralgia
135	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	diabetic neuropathies
136	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	diabetes mellitus, type 2
137	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	gabapentin
138	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	angioedema
139	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	emergencies
140	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	prednisone
141	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	flurbiprofen
142	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	dextromethorphan
143	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	caffeine
144	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	bupropion
145	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	omeprazole
146	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	gout
147	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	arthritis, gouty
148	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	colchicine
149	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	parkinson disease
150	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	pramipexole
151	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ropinirole
152	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	piribedil
153	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cataract
154	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	esophagitis
155	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	eosinophilic esophagitis
156	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	renal insufficiency, chronic
157	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	avitaminosis
158	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	vitamin d deficiency
159	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cholecalciferol
160	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	losartan
161	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	nortriptyline
162	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	calcipotriene
163	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	multiple sclerosis, chronic progressive
164	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	acyclovir
165	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	methylprednisolone
166	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	alemtuzumab
167	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	sinusitis
168	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	triamcinolone
169	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	triamcinolone acetonide
170	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	triamcinolone hexacetonide
171	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	triamcinolone diacetate
172	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	leukemia
173	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	leukemia, myeloid
174	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	leukemia, myeloid, acute
175	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	prostatic neoplasms
176	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	prostatic neoplasms, castration-resistant
177	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	pioglitazone
178	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	rosuvastatin calcium
179	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	depressive disorder
180	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	depressive disorder, major
181	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	peanut hypersensitivity
182	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ranitidine
183	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	omalizumab
184	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	irritable bowel syndrome
185	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	syndrome
186	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	diarrhea
187	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	clemastine
188	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	antibodies, monoclonal
189	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	epinephrine
190	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	albuterol
191	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	bronchial diseases
192	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	laryngeal diseases
193	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	anemia, iron-deficiency
194	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	proton pump inhibitors
195	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	histamine
196	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	loperamide
197	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	antidiarrheals
198	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cyclosporine
199	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	azathioprine
200	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cyclosporins
201	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	lung diseases, obstructive
202	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	pulmonary disease, chronic obstructive
203	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	pulmonary arterial hypertension
204	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	hypertension
205	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	vitamins
206	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	vitamin e
207	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	thioctic acid
208	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	nitroprusside
209	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	phentolamine
210	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cyclo(trp-asp-pro-val-leu)
211	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	norepinephrine
212	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	angiotensin ii
213	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	giapreza
214	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	acetylcholine
215	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	angiotensinogen
216	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	folic acid
217	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	methotrexate
218	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	tuberculosis
219	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	latent tuberculosis
220	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	pyridoxine
221	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	isoniazid
222	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	darunavir
223	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cobicistat
224	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cobicistat mixture with darunavir
225	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	glycogen storage disease
226	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	glycogen storage disease type iii
227	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	antipyretics
228	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ritonavir
229	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ticagrelor
230	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	migraine disorders
231	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	beclomethasone
232	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	pemphigus
233	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ofatumumab
234	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	multiple sclerosis, relapsing-remitting
235	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ocrelizumab
236	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	celecoxib
237	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	azithromycin
238	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	budesonide
239	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	emollients
240	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	formoterol fumarate
241	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	tiotropium bromide
242	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	salmeterol xinafoate
243	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	fluticasone-salmeterol drug combination
244	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	doxepin
245	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	erectile dysfunction
246	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	tadalafil
247	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ischemia
248	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	anaphylaxis
249	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	shock
250	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	dexamethasone
251	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	insulin resistance
252	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	thyroid neoplasms
253	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	thyroid diseases
254	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	methylprednisolone hemisuccinate
255	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	infliximab
256	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	tacrolimus
257	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	thymoglobulin
258	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	antilymphocyte serum
259	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ergocalciferols
260	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	lidocaine
261	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	deoxycholic acid
262	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	mycoses
263	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	aspergillosis
264	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cryptococcosis
265	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	triple negative breast neoplasms
266	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	omega-n-methylarginine
267	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	neoplasm metastasis
268	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	liver neoplasms
269	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	vitamin b complex
270	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	oxaliplatin
271	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	fluorouracil
272	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	panitumumab
273	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	depression
274	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	schizophrenia
275	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	psychotic disorders
276	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	mental disorders
277	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	compulsive personality disorder
278	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	obsessive-compulsive disorder
279	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	mood disorders
280	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	compulsive behavior
281	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	schizophrenia, paranoid
282	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	prurigo
283	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	neurodermatitis
284	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	serlopitant
285	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	histamine h2 antagonists
286	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	nephrotic syndrome
287	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	nephrosis
288	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	sjogren's syndrome
289	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ustekinumab
290	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	rivaroxaban
291	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	methylprednisolone acetate
292	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	prednisolone acetate
293	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	esomeprazole
294	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	prednisolone hemisuccinate
295	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	prednisolone phosphate
296	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	anorexia
297	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	feeding and eating disorders
298	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	anorexia nervosa
299	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	raclopride
300	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	methylphenidate
301	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	colonic neoplasms
302	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	calcium, dietary
303	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	leucovorin
304	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	antineoplastic agents, immunological
305	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	endothelial growth factors
306	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	antibodies
307	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	immunoglobulins
308	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	immunoglobulin g
309	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	calcium
310	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	levoleucovorin
311	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	infertility
312	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cetrorelix
313	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	progesterone
314	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	autistic disorder
315	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	autism spectrum disorder
316	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	oxytocin
317	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	hepatitis a
318	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	hepatitis b
319	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	hepatitis b, chronic
320	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	hepatitis
321	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	tenofovir
322	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	entecavir
323	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	morphine
324	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	antibiotics, antitubercular
325	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	anti-inflammatory agents
326	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	anticoagulants
327	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	coagulants
328	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	pharmaceutical solutions
329	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	hepatitis d
330	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	interferons
331	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	interferon-alpha
332	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	interferon alpha-2
333	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	peginterferon alfa-2a
334	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	cryopyrin-associated periodic syndromes
335	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	tranilast
336	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	immunologic factors
337	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ganglion cysts
338	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	bromides
339	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	diabetes mellitus
340	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	diabetes mellitus, type 1
341	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	resveratrol
342	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	wounds and injuries
343	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	apnea
344	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	sleep apnea syndromes
345	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	sleep apnea, obstructive
346	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	stroke
347	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	ischemic stroke
348	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	precursor cell lymphoblastic leukemia-lymphoma
349	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	leukemia, lymphoid
350	2023-01-02 15:22:35.615	2023-01-02 15:22:35.615	spinal cord injuries
\.


--
-- Data for Name: _prisma_migrations; Type: TABLE DATA; Schema: public; Owner: tim
--

COPY public._prisma_migrations (id, checksum, finished_at, migration_name, logs, rolled_back_at, started_at, applied_steps_count) FROM stdin;
95b8e29b-2c95-40fb-b4fd-fbfe672141b4	1f67e1068b8c71577ac44e3256d8d0632434c156167ecfea4790015c4197cf79	2022-12-29 14:26:18.210456+01	20221229132618_init	\N	\N	2022-12-29 14:26:18.198335+01	1
e27c13b7-f15c-40f1-a698-ab7e70ddaa05	88bddeb7e5e7ba3a66ea030e91758dee16fe72f9ed4321f17c5788d06e745f89	2022-12-29 14:51:04.89575+01	20221229135104_added	\N	\N	2022-12-29 14:51:04.893997+01	1
6eb11518-9aff-4848-af4e-aa118ae5a829	d358c72088c74a9f6e33a5f2c5f78ef6671a9227c05531797cecae0808b56f5f	2023-02-14 17:30:36.38136+01	20230214163036_added_field_to_enum_publication_status	\N	\N	2023-02-14 17:30:36.379463+01	1
9805f10a-ba47-436a-a9f7-8273edcb6638	a575e41d9bcbe7aa904e076cc8448937db78f3c7fdc9eead3cd4cac4edc07089	2022-12-29 15:02:04.294052+01	20221229140204_made	\N	\N	2022-12-29 15:02:04.290311+01	1
373394c6-1f32-4177-b3a6-ceb42e2df22e	1245e9c49707458f2c5d9606389cd8c7bf9787ce6bc2a4c859d359ea270a0876	2022-12-29 15:02:52.32396+01	20221229140252_made_enrollment_optional	\N	\N	2022-12-29 15:02:52.322267+01	1
79fc22a5-6515-480b-8813-1dbfdfbad281	3692bda925071e0756634842f82508a50ac6ddd8e773d1c0e2e92923bd3d7006	2022-12-29 15:03:43.005708+01	20221229140342_made_a_few_more_things_optional	\N	\N	2022-12-29 15:03:43.001381+01	1
98050ec0-8e98-4bb0-ad51-ef63596d41b4	aaeafa27b30b8de54b982e215acc575d70a150b3c607cf8e5f2d70427e8b98b9	2022-12-29 15:04:33.737748+01	20221229140433_made_a_few_more_things_optional	\N	\N	2022-12-29 15:04:33.7362+01	1
e7061fc8-9fc8-4064-b9b2-c7e692d0e7ce	75892653b25fcd4599bce4065dd87aa843240d97cef1b16564ff00515229dc6f	2023-03-19 15:36:22.481996+01	20230319143120_add_drug_name_field	\N	\N	2023-03-19 15:36:22.477672+01	1
106dabc0-7834-4fa5-b8d7-e6b70131d1f8	080fae915f347a0543dadf5383749327234d9ed2b38a3df0f39cabcb70109e8b	2022-12-29 15:05:15.794974+01	20221229140515_made_a_few_more_things_optional	\N	\N	2022-12-29 15:05:15.7913+01	1
848b28ab-518d-46a3-89e3-372ef89d927a	8fca0f1193305fa4e387a684b4f34b2a15635addf7b22430a27f09283e462a00	2022-12-29 15:05:52.520665+01	20221229140552_made_a_few_more_things_optional	\N	\N	2022-12-29 15:05:52.518704+01	1
0afb1b8d-3b00-4a66-a028-39937a76a7cb	e25ca77958c91e19555a1b6e0b87a8a57c6e1e6021206c79a6793f9fb325b53d	2022-12-29 16:33:39.385964+01	20221229153339_added_legacy_fields	\N	\N	2022-12-29 16:33:39.38341+01	1
ae28146e-d7c3-4acd-b778-526bc8df6edc	d067f3bfeeddaf50b33024e9b9f1cb036e59d507d1e90e51f93ea184c22a3532	2022-12-29 16:37:05.772676+01	20221229153705_changed_legacy_import_date_to_date_time_format	\N	\N	2022-12-29 16:37:05.769266+01	1
59418340-6135-48a3-91ec-6f9945430735	d60f3db2c84d31a3de2c92abe4c8e010a6b7ba77220db86d77560bf9df940ee1	2022-12-29 16:52:15.124487+01	20221229155215_change_repurpose_to_default_to_false	\N	\N	2022-12-29 16:52:15.122593+01	1
4653756c-480e-4838-ab12-dbbc4042ca58	b3cb4e943a09c5be44b6150c78ad67a56037fc43ce7c2145597533cb7a8e3a8f	2023-01-02 16:21:04.083121+01	20230102152104_added_reference_citation	\N	\N	2023-01-02 16:21:04.076852+01	1
5186cfbe-627b-450c-90cb-dfcc538daa90	77ba81d0ebf121473a51db1e69daa6b4b5ff728aed7d18b41d033c73c582f993	2023-02-13 20:41:17.50762+01	20230213194117_add_publication	\N	\N	2023-02-13 20:41:17.50313+01	1
\.


--
-- Name: ConditionMeshTermOnEntries_id_seq; Type: SEQUENCE SET; Schema: public; Owner: tim
--

SELECT pg_catalog.setval('public."ConditionMeshTermOnEntries_id_seq"', 795, true);


--
-- Name: Entry_id_seq; Type: SEQUENCE SET; Schema: public; Owner: tim
--

SELECT pg_catalog.setval('public."Entry_id_seq"', 425, true);


--
-- Name: InterventionMeshTermOnEntries_id_seq; Type: SEQUENCE SET; Schema: public; Owner: tim
--

SELECT pg_catalog.setval('public."InterventionMeshTermOnEntries_id_seq"', 842, true);


--
-- Name: LocationOnEntries_id_seq; Type: SEQUENCE SET; Schema: public; Owner: tim
--

SELECT pg_catalog.setval('public."LocationOnEntries_id_seq"', 1657, true);


--
-- Name: Location_id_seq; Type: SEQUENCE SET; Schema: public; Owner: tim
--

SELECT pg_catalog.setval('public."Location_id_seq"', 1, false);


--
-- Name: MeshTerm_id_seq; Type: SEQUENCE SET; Schema: public; Owner: tim
--

SELECT pg_catalog.setval('public."MeshTerm_id_seq"', 1, false);


--
-- Name: ConditionMeshTermOnEntries ConditionMeshTermOnEntries_pkey; Type: CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."ConditionMeshTermOnEntries"
    ADD CONSTRAINT "ConditionMeshTermOnEntries_pkey" PRIMARY KEY (id);


--
-- Name: Entry Entry_pkey; Type: CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."Entry"
    ADD CONSTRAINT "Entry_pkey" PRIMARY KEY (id);


--
-- Name: InterventionMeshTermOnEntries InterventionMeshTermOnEntries_pkey; Type: CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."InterventionMeshTermOnEntries"
    ADD CONSTRAINT "InterventionMeshTermOnEntries_pkey" PRIMARY KEY (id);


--
-- Name: LocationOnEntries LocationOnEntries_pkey; Type: CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."LocationOnEntries"
    ADD CONSTRAINT "LocationOnEntries_pkey" PRIMARY KEY (id);


--
-- Name: Location Location_pkey; Type: CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."Location"
    ADD CONSTRAINT "Location_pkey" PRIMARY KEY (id);


--
-- Name: MeshTerm MeshTerm_pkey; Type: CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."MeshTerm"
    ADD CONSTRAINT "MeshTerm_pkey" PRIMARY KEY (id);


--
-- Name: _prisma_migrations _prisma_migrations_pkey; Type: CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public._prisma_migrations
    ADD CONSTRAINT _prisma_migrations_pkey PRIMARY KEY (id);


--
-- Name: Entry_NCTId_key; Type: INDEX; Schema: public; Owner: tim
--

CREATE UNIQUE INDEX "Entry_NCTId_key" ON public."Entry" USING btree ("NCTId");


--
-- Name: ConditionMeshTermOnEntries ConditionMeshTermOnEntries_entryId_fkey; Type: FK CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."ConditionMeshTermOnEntries"
    ADD CONSTRAINT "ConditionMeshTermOnEntries_entryId_fkey" FOREIGN KEY ("entryId") REFERENCES public."Entry"(id) ON UPDATE CASCADE ON DELETE RESTRICT;


--
-- Name: ConditionMeshTermOnEntries ConditionMeshTermOnEntries_meshId_fkey; Type: FK CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."ConditionMeshTermOnEntries"
    ADD CONSTRAINT "ConditionMeshTermOnEntries_meshId_fkey" FOREIGN KEY ("meshId") REFERENCES public."MeshTerm"(id) ON UPDATE CASCADE ON DELETE RESTRICT;


--
-- Name: InterventionMeshTermOnEntries InterventionMeshTermOnEntries_entryId_fkey; Type: FK CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."InterventionMeshTermOnEntries"
    ADD CONSTRAINT "InterventionMeshTermOnEntries_entryId_fkey" FOREIGN KEY ("entryId") REFERENCES public."Entry"(id) ON UPDATE CASCADE ON DELETE RESTRICT;


--
-- Name: InterventionMeshTermOnEntries InterventionMeshTermOnEntries_meshId_fkey; Type: FK CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."InterventionMeshTermOnEntries"
    ADD CONSTRAINT "InterventionMeshTermOnEntries_meshId_fkey" FOREIGN KEY ("meshId") REFERENCES public."MeshTerm"(id) ON UPDATE CASCADE ON DELETE RESTRICT;


--
-- Name: LocationOnEntries LocationOnEntries_entryId_fkey; Type: FK CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."LocationOnEntries"
    ADD CONSTRAINT "LocationOnEntries_entryId_fkey" FOREIGN KEY ("entryId") REFERENCES public."Entry"(id) ON UPDATE CASCADE ON DELETE RESTRICT;


--
-- Name: LocationOnEntries LocationOnEntries_locationId_fkey; Type: FK CONSTRAINT; Schema: public; Owner: tim
--

ALTER TABLE ONLY public."LocationOnEntries"
    ADD CONSTRAINT "LocationOnEntries_locationId_fkey" FOREIGN KEY ("locationId") REFERENCES public."Location"(id) ON UPDATE CASCADE ON DELETE RESTRICT;


--
-- PostgreSQL database dump complete
--

